<SEC-DOCUMENT>0001193125-23-074011.txt : 20230317
<SEC-HEADER>0001193125-23-074011.hdr.sgml : 20230317
<ACCEPTANCE-DATETIME>20230317165312
ACCESSION NUMBER:		0001193125-23-074011
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20230317
DATE AS OF CHANGE:		20230317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-268607
		FILM NUMBER:		23743453

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d418853d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-268607 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to 28,078,672 Shares of Common Stock </B></P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">This prospectus
relates to the resale from time to time of up to 28,078,672 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of Scilex Holding Company, a Delaware corporation (&#147;Scilex&#148;), by YA II PN, Ltd., a Cayman
Islands exempt limited partnership (the &#147;Selling Securityholder&#148; or &#147;Yorkville&#148;). The shares included in this prospectus consist of shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and
sell to the Selling Securityholder, from time to time after the date of this prospectus, pursuant to a standby equity purchase agreement we entered into with the Selling Securityholder on November&nbsp;17, 2022 (the &#147;Original Purchase
Agreement&#148;), as amended and restated on February&nbsp;8, 2023 (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), in which the Selling Securityholder has committed to purchase from us, at our direction, up to $500,000,000 of our Common
Stock, subject to the terms and conditions specified in the A&amp;R Yorkville Purchase Agreement. As consideration for the Selling Securityholder&#146;s irrevocable commitment to purchase shares of our Common Stock at our election and in our
discretion from time to time after the date of this prospectus and prior to the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the registration statement of which this
prospectus forms a part was initially declared effective by the Securities and Exchange Commission, upon the terms and subject to the satisfaction of the conditions set forth in the A&amp;R Yorkville Purchase Agreement, we have agreed to issue to
the Selling Securityholder 250,000 shares of Common Stock pursuant to the terms of the Original Purchase Agreement (the &#147;Yorkville Commitment Shares&#148;). On February&nbsp;16, 2023, we sold 85,000 shares of our Common Stock pursuant to
advances under the A&amp;R Yorkville Purchase Agreement. See the section of this prospectus titled &#147;<I>Committed Equity Financing</I>&#148; for a description of the A&amp;R Yorkville Purchase Agreement and the section of this prospectus titled
&#147;<I>Selling Securityholder</I>&#148; for additional information regarding the Selling Securityholder. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our registration of the
securities covered by this prospectus does not mean that the Selling Securityholder will offer or sell any of the shares of Common Stock. The Selling Securityholder may offer, sell, or distribute all or a portion of its shares of Common Stock
publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholder pursuant to this prospectus. However, we may receive
up to $500,000,000 in aggregate gross proceeds from sales of our Common Stock to the Selling Securityholder that we may, in our discretion, elect to make, from time to time after the date of this prospectus, pursuant to the A&amp;R Yorkville
Purchase Agreement. We provide more information about how the Selling Securityholder may sell or otherwise dispose of the shares of our Common Stock in the section of this prospectus titled &#147;Plan of Distribution.&#148; We will bear all costs,
expenses and fees in connection with the registration of the shares of Common Stock offered hereby. The Selling Securityholder will bear all commissions and discounts, if any, attributable to its sales of the shares of Common Stock offered hereby.
</P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">The Selling Securityholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the U.S. Securities Act of 1933, as
amended (the &#147;Securities Act&#148;), and any profits on the sales of shares of our Common Stock by the Selling Securityholder and any discounts, commissions or concessions received by the Selling Securityholder are deemed to be underwriting
discounts and commissions under the Securities Act. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol
&#147;SCLX&#148;. On March 16, 2023, the last reported sales price per share of our Common Stock was $7.45. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We are an &#147;emerging growth
company&#148; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future
filings with the Securities and Exchange Commission. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or
supplements as required. You should read this prospectus, together with additional information described under the heading &#147;<I>Where You Can Find More Information</I>&#148;, and any amendments or supplements carefully before you invest in any
of our securities. </P> <P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES
DESCRIBED UNDER THE HEADING &#147;<U><A HREF="#rom418853_11">RISK FACTORS</A></U>&#148; BEGINNING ON PAGE 15 OF THIS PROSPECTUS. </B></P>
<P STYLE="margin-top:5pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:5pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is March 17, 2023 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_1a">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">v</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_2">CERTAIN DEFINED TERMS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">vii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_3">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_4">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_4a">Our Marketed Product and Pipeline</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_5">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_6">Recent Developments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_7">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_8">Summary Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_9">Corporate Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_10">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_11">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_12">Risks Related to our Limited Operating History, Financial Condition and Capital
 Requirements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_13">Risks Related to our Commercial Operations and Product
Development</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_14">Risks Related to our Business and Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_15">Risks Related to our Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_16">Risks Related to Government Regulations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_17">Risks Related to our Relationship with Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_18">Risks Related to this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_19">Risks Related to Ownership of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_20">COMMITTED EQUITY FINANCING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_21">Advances of Common Stock Under the A&amp;R Yorkville Purchase
Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_22">Conditions to Each Yorkville Advance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_23">Termination of the A&amp;R Yorkville Purchase Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_24">No Short-Selling by the Selling Securityholder</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_25">Effect of Sales of our Common Stock under the A&amp;R Yorkville Purchase Agreement
 on our Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_26">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_27">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_28">DETERMINATION OF OFFERING PRICE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_29">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_30">Market Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_31">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_32">Securities Authorized for Issuance under Equity Compensation
Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_33">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_34">Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_35">Business Combination</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_36">Recent Developments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_37">Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our
Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_38">Comparability of Our Results and Our Relationship with
Sorrento</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_39">Sorrento Chapter 11 Filing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_40">Components of Our Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_41">Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_42">Comparison of Years Ended December&nbsp;31, 2022 and 2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_43">Liquidity and Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_44">Critical Accounting Estimates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_45">Recent Accounting Pronouncements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_46"><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet
Arrangements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_47">Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_48">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_49">Emerging Growth Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_50">Smaller Reporting Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_51">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_52">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_53">Our Marketed Product and Pipeline</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_54">Our Strategy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_55">Our Management Team</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_56">Our Product Portfolio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_57">Commercialization and Market Access</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_58">Clinical Development Overview</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_59">Medical Affairs</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_60">Manufacturing and Supply Chain</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_61">Competition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_62">Material Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_63">Intellectual Property</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_64">Government Regulation and Product Approval</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_65">Employees and Human Capital Resources</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_66">Facilities and Properties</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_67">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_68">Our Corporate History</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_69">Website</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_70">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_71">Executive Officers and Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_72">Family Relationships</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_73">Board Composition</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_74">Controlled Company Exemption</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_75">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_76">Role of Board in Risk Oversight Process</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_77">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_78">Board Diversity</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_79">Committees of our Board</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_80">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_81">Compensation Committee Interlocks and Insider Participation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_82">Limitation of Liability and Indemnification of Directors and
Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_83">EXECUTIVE AND DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_84">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_85">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_86">Narrative Disclosure to Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_87">Potential Payments upon Termination or Change in Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_88">Perquisites, Health, Welfare and Retirement Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_89">Pension Benefits and Nonqualified Deferred Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_90">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT> 2022</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_91">Equity-Based Incentive Plans</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_92">Emerging Growth Company Status</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_93">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_94">Director Compensation Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_95">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_96">Certain Relationships of Vickers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_97">Certain Relationships of Legacy Scilex</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_98">PRINCIPAL SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS(continued) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_99">SELLING SECURITYHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_100">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_101">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_102">U.S. Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_103"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_104">Foreign Account Tax Compliance Act</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_105">DESCRIPTION OF OUR SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_106">General</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_107">Authorized and Outstanding Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_108">Our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_109">Our Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_110">Registration Rights</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_111">Anti-Takeover Matters in our Governing Documents and Under Delaware
Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_112">Conflicts of Interest</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_113">Rights of Appraisal and Payment</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_114">Stockholders&#146; Derivative Actions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_115">Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_116">Public Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_117">Transfer Agent and Registrar</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_118">Listing</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_119">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_120">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_121">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom418853_122">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus
supplement and any related free writing prospectus. Neither we nor the Selling Securityholder have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any
related free writing prospectus. We and the Selling Securityholder take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. No dealer, salesperson or other person is
authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This
prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any
related free writing prospectus is accurate only as of the date on the front of the applicable document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents
incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For Investors
Outside the United States</B>: The Selling Securityholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Securityholder
have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into
possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_1a"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> that we filed with the Securities and
Exchange Commission (the &#147;SEC&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by it described in this prospectus. We
will not receive any proceeds from the sale by such Selling Securityholder of the securities offered by it described in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to make any representations other than
those contained in this prospectus or any applicable prospectus supplement, any post-effective amendment or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder take
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where the offer or
sale is not permitted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add
information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional
information to which we refer you in the section of this prospectus titled &#147;<I>Where You Can Find More Information</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;10, 2022, we consummated the previously-announced business combination (the &#147;Business Combination&#148;) pursuant to that certain Agreement and Plan of Merger, dated as of March&nbsp;17, 2022 (as amended, restated or supplemented
from time to time, including by Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated as of September&nbsp;12, 2022) (the &#147;Merger Agreement&#148;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the
&#147;Merger Sub&#148;), and the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination Scilex Holding Company (&#147;Legacy Scilex&#148;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman
Islands Companies Act (as revised) and a domestication under Section&nbsp;388 of the Delaware General Corporation Law, as amended (the &#147;DGCL&#148;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the
State of Delaware (the &#147;Domestication&#148;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148; or the
&#147;Business Combination&#148;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#147;Company,&#148; &#147;Scilex,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#147;Legacy Scilex&#148; refer to the private
Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual
documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those
documents as described below under &#147;<I>Where You Can Find More Information</I>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_1"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#147;forward-looking statements&#148; for purposes of federal securities laws.
Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections of this
prospectus titled &#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>.&#148; In addition, any statements that refer to projections, forecasts or other
characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#147;plan,&#148; &#147;believe,&#148;
&#147;expect,&#148; &#147;anticipate,&#148; &#147;contemplate,&#148; &#147;intend,&#148; &#147;outlook,&#148; &#147;estimate,&#148; &#147;forecast,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;may,&#148;
&#147;might,&#148; &#147;possible,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and other similar words and expressions (including the negative of any of the foregoing), but the absence of
these words does not mean that a statement is not forward-looking. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as
of the date of this prospectus and our management&#146;s current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the
Company and our directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any
subsequent date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual
results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in &#147;<I>Risk Factors,</I>&#148; our
periodic filings with the SEC and the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our public securities&#146; liquidity and trading; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to raise financing in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of any legal proceedings that may be instituted against us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain qualified directors, officers, employees and key personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to compete effectively in a highly competitive market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competition from larger biotechnology companies that have greater resources, technology, relationships and/or
expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to protect and enhance our corporate reputation and brand; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact from future regulatory, judicial and legislative changes in our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to research, discover and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to grow and manage growth profitably; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to execute our business plans and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the continuing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and other similar
disruptions in the future; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors detailed under the section of this prospectus titled &#147;<I>Risk Factors</I>.&#148;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the
assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or
to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or
otherwise, except as may be required under applicable securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_2"></A>CERTAIN DEFINED TERMS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Board</I>&#148; means the board of directors of the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Business Combination</I>&#148; means the merger contemplated by the Merger Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Bylaws</I>&#148; means the Bylaws of Scilex Holding Company, effective as of November&nbsp;10, 2022.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Designations</I>&#148; means the Certificate of Designations of the Company, designating
the series of preferred stock, par value $0.0001 per share, of the Company as &#147;Series A Preferred Stock&#148;. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Certificate of Incorporation</I>&#148; means the Restated Certificate of Incorporation of Scilex Holding
Company, filed with Secretary of State of the State of Delaware on November&nbsp;10, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing</I>&#148; means the closing of the Business Combination. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Closing Date</I>&#148; means date of the Closing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Code</I>&#148; means the Internal Revenue Code of 1986, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Common Stock</I>&#148; means the common stock, par value $0.0001 per share, of Scilex.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Continental</I>&#148; means Continental Stock Transfer&nbsp;&amp; Trust Company, our transfer agent.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Debt Exchange Agreement</I>&#148; means the Contribution and Satisfaction of Indebtedness Agreement,
dated as of September&nbsp;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>DGCL</I>&#148; means the General Corporation Law of the State of Delaware, as amended.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Domestication</I>&#148; means the change of our domicile pursuant to a transfer by way of continuation
of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <FONT STYLE="white-space:nowrap">de-registration</FONT> in the Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Effective Time</I>&#148; means the time at which the Business Combination became effective.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Equity Incentive Plan</I>&#148; means the Scilex Holding Company 2022 Equity Incentive Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>ESPP</I>&#148; means the Scilex Holding Company 2022 Employee Stock Purchase Plan.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Exchange Act</I>&#148; means the Securities Exchange Act of 1934, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>founder shares</I>&#148; means the 3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors
and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into 3,450,000 shares of Common Stock in connection with the Domestication. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Funding Commitment Letter</I>&#148; means that certain letter agreement, dated as of October&nbsp;17,
2022, between Sorrento and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>GAAP</I>&#148; means accounting principles generally accepted in the United States of America.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Initial Shareholders</I>&#148; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the
holders of founder shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IPO</I>&#148; refers to the initial public offering of 13,800,000 Units of Vickers consummated on
January&nbsp;11, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>IRS</I>&#148; means the United States Internal Revenue Service. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Board</I>&#148; means the board of directors of Legacy Scilex. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Common Stock</I>&#148; means the common stock of Legacy Scilex, par value $0.0001 per
share, prior to the Effective Time. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Legacy Scilex Preferred Stock</I>&#148; means the Series A Preferred Stock, par value $0.0001 per share,
of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Maxim</I>&#148; means Maxim Group LLC, the representative of the underwriters in the IPO.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement</I>&#148; means that certain Agreement and Plan of Merger, dated as of March&nbsp;17,
2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Agreement Amendment</I>&#148; means that Amendment No.&nbsp;1 to Agreement and Plan of Merger,
dated as of September&nbsp;12, 2022, by and among us, Merger Sub and Legacy Scilex. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Merger Sub</I>&#148; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned
subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq</I>&#148; means The Nasdaq Stock Market LLC. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Nasdaq Listing Rules</I>&#148; means the rules and listing standards of Nasdaq. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Private Placement Warrants</I>&#148; means the 6,840,000 warrants sold in a private placement to Vickers
Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&nbsp;11, 2021 (of which 2,736,000 were forfeited pursuant to the Sponsor Support Agreement and 3,104,000 were transferred to Sorrento pursuant to the Warrant
Transfer Agreement, in each case in connection with the Business Combination). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shareholders</I>&#148; means the holders of the public shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>public shares</I>&#148; means the Vickers Ordinary Shares which were sold as part of the IPO, whether
they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any
public shares they own). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Public Warrants</I>&#148; means the redeemable warrants that were included in the Units that entitle the
holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>SEC</I>&#148; means the U.S. Securities and Exchange Commission. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Securities Act</I>&#148; means the Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Series A Preferred Stock</I>&#148; means the preferred stock, par value $0.0001 per share, of the
Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento</I>&#148; means Sorrento Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Group</I>&#148; means Sorrento together with its affiliates, subsidiaries, successors and
assigns (other than us and our subsidiaries). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sorrento Trigger Event</I>&#148; means the time that the Sorrento Group first ceases to beneficially own
more than 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsors</I>&#148; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Sponsor Support Agreement</I>&#148; means that certain Sponsor Support Agreement, dated March&nbsp;17,
2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Stockholder Agreement</I>&#148; means the Stockholder Agreement, dated as of September&nbsp;12, 2022,
between Vickers and Sorrento. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">viii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Trust Account</I>&#148; means the Trust Account of Vickers that held the proceeds from Vickers&#146;s
IPO and the private placement of the Private Placement Warrants. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Units</I>&#148; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <FONT
STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without
any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase one share of Common Stock.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers</I>&#148; means Vickers Vantage Corp. I, our predecessor company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Debt Agreement</I>&#148; means that certain Debt Contribution Agreement, dated as of
October&nbsp;17, 2022, by and among Vickers and the Sponsors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Vickers Ordinary Shares</I>&#148; means (i)&nbsp;the ordinary shares, par value $0.0001 per share, of
Vickers prior to the Domestication and (ii)&nbsp;the Common Stock following the Domestication. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<I>Warrant Transfer Agreement</I>&#148; means that certain Warrant Transfer Agreement, dated as of
October&nbsp;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ix </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_3"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a
summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this
prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148;. You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_4"></A>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with
high unmet needs and large market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched
our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in 2023. Our commercial
product, ZTlido<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#147;FDA&#148;) for the relief of
neuropathic pain associated with postherpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription
lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We license the rights to ZTlido from and rely exclusively on Oishi
Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;) pursuant to the Product Development Agreement and Commercial Supply Agreement. We have acquired
two FDA approved <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain products for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults, which we plan to commercialize in the U.S.
in 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate
viscous gel) (&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT
STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain
(&#147;LBP&#148;); and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules)
<FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were
completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;)
with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products
comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark
&#147;GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&#148;. GLOPERBA is an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting
an estimated 8.7&nbsp;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of
pain and can be disabling with tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to
commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. We have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. For more information on Scilex,
please see the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Romeg License and Commercialization Agreement.</I>&#148; On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and
Collegium Pharmaceutical, Inc. the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) and the
commercialization thereof in the United States and Canada. ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM </SUP>is a first-line treatment and the only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with or without aura, in adults. We are planning to commercialize ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in the U.S. in
2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety,
efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of these pipeline product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> (&#147;OTC&#148;) lidocaine patches, of which over 147&nbsp;million and 136&nbsp;million of such patches were sold in the United States in 2021 and 2020,
respectively, according to Symphony Healthcare. We have sold 6,336,032 and 7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc.
(&#147;Semnur&#148;) in March 2019 and are developing <FONT STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <FONT
STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections (&#147;ESI&#148;), which are administered over 12&nbsp;million times annually in the United States. See the section of this prospectus titled &#147;<I>Business &#151; Material
Agreements &#151; Semnur Merger Agreement</I>&#148; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#146;s former equityholders. SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> has been granted
fast track designation by the FDA and, if approved, could become the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over
4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of
<FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT
STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia. There are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable
effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant
unmet needs of the targeted populations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_4a"></A>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization
rights, except with respect to Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our
telephone number is (650) <FONT STYLE="white-space:nowrap">516-4310.</FONT> For additional information about us, please see the sections of this prospectus titled &#147;<I>Business</I>&#148; and &#147;<I>Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations</I>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section of this prospectus titled &#147;<I>Risk Factors</I>&#148; in
this prospectus for a discussion of some of the risks related to the execution of our business strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_5"></A>Business
Combination </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022 (the &#147;Closing Date&#148;), Vickers consummated the previously announced Business
Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger
Agreement, (i)&nbsp;prior to the Closing, Vickers changed its jurisdiction of incorporation by deregistrating as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware
(the &#147;Domestication&#148;) and (ii)&nbsp;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#147;Merger&#148;), with Legacy Scilex as the surviving company in the Merger, and, after giving
effect to such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#146;s shareholders at a meeting held on November&nbsp;9, 2022. In connection with the Business Combination, Vickers changed its
name to &#147;Scilex Holding Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the
Effective Time, (i)&nbsp;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive 0.673498 shares of our Common Stock, (ii)&nbsp;each
share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&nbsp;one share of Series A Preferred Stock and
<FONT STYLE="white-space:nowrap">(b)&nbsp;one-tenth</FONT> of one share of our Common Stock, and (iii)&nbsp;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the
right to receive a comparable option to purchase shares of our Common Stock. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital Market under
the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are governed by
the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&nbsp;6, 2021, between Vickers and Continental (the &#147;Warrant Agreement&#148;). See sections of this prospectus
titled &#147;<I>Description of Our Securities</I>&#148; and &#147;<I>Certain Relationships and Related Party Transactions</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_6">
</A>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>February 2023 Preliminary Unaudited Financial Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, we filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> providing certain preliminary unaudited
financial results for the one month ended February&nbsp;28, 2023, and as of February&nbsp;28, 2023, based on then currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial results. Our
actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our
review of these preliminary financial results for the one month ended February&nbsp;28, 2023, and as of February&nbsp;28, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such
Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> we estimated that: ZTlido gross sales for February 2023 were in the range of $8.6&nbsp;million to $8.8&nbsp;million, compared to $5.1&nbsp;million in February 2022, representing
growth in the range of 68% to 72%; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2023 gross sales were in the range of $16.7&nbsp;million to $17.3&nbsp;million, compared to $10.3&nbsp;million
for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2022, representing growth in the range of 62% to 68%; net sales for February 2023 were in the range of $3.3&nbsp;million to $3.5&nbsp;million,
compared to net sales of $2.0&nbsp;million in February 2022, representing growth in the range of 65% to 75%; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2023 net sales were in the range of
$6.6&nbsp;million to $7.0&nbsp;million, compared to $4.1&nbsp;million for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2022, representing growth in the range of 61% to 70%. Historically, sales
for ZTlido are low during the first quarter of the year due to deductibles with managed healthcare plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elyxyb License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#147;BSDI&#148;) and Collegium Pharmaceutical, Inc.
(&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to
ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) (the &#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated
August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free,
exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Collegium Sellers granted
the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to the
Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties to DRL for sales of the Product in the Territory for all indications and additional amounts if
certain milestones are achieved. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committed Equity Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>B. Riley Purchase Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;8, 2023, we entered into a standby equity purchase agreement (the &#147;B. Riley Purchase Agreement&#148;) with B. Riley Principal Capital II, LLC (&#147;B. Riley&#148;), a Delaware limited liability company. Pursuant to the B. Riley
Purchase Agreement, we have the right to sell to B. Riley up to $500,000,000 of shares of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the B. Riley
Purchase Agreement. Sales of Common Stock to B. Riley under the B. Riley Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to B. Riley under the B. Riley Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to B. Riley&#146;s purchase obligation set forth in the B. Riley Purchase Agreement,
we have the right, but not the obligation, from time to time at our discretion until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the B. Riley Registration Statement (as
defined below) was initially declared effective by the SEC, to direct B. Riley to purchase a specified amount of shares of Common Stock (each such sale, a &#147;B. Riley Advance&#148;) by delivering an irrevocable written notice to B. Riley (each, a
&#147;B. Riley Advance Notice&#148;). Pursuant to the terms of the B. Riley Purchase Agreement, we filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269205)</FONT>
(as it may be amended or supplemented from time to time, the &#147;B. Riley Registration Statement&#148;) related to the B. Riley Purchase Agreement with the SEC on January&nbsp;12, 2023 (following the execution of the B. Riley Purchase Agreement).
The B. Riley Registration Statement was initially declared effective by the SEC on January&nbsp;20, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if
any, that we elect to sell to B. Riley pursuant to a B. Riley Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#147;B. Riley Pricing Period&#148;) beginning at 9:30:01 a.m., New
York City time, on the date of purchase of shares of Common Stock issued and sold to B. Riley pursuant to a B. Riley Advance Notice (such shares, the &#147;B. Riley Advance Shares&#148;) or such later time publicly announced as the official open of
the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such
earlier time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement Time for such
purchase that the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the
applicable B. Riley Advance Notice for such B. Riley Advance (such election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such B. Riley Pricing
Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common
Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AOR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume Maximum&#148; means, with respect to a B.
Riley Advance, if such B. Riley Advance is designated in the B. Riley Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share amount to
be purchased by B. Riley, by (b) 0.10, or (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each
case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each B. Riley Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While
there is no mandatory minimum amount for any B. Riley Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, a B. Riley Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to a B. Riley
Advance, purchase-Type A, such number of shares of Common </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq
Capital Market during the B. Riley Pricing Period for such purchase-Type A, and (ii)&nbsp;with respect to a B. Riley Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the
product of (1) 0.25, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the B. Riley Pricing Period for such purchase-Type B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to B. Riley, from time to time subject
to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, a &#147;B. Riley Additional Advance&#148;) at a purchase price per share equal to 98% of the VWAP during the
Additional Pricing Period (as defined in the B. Riley Purchase Agreement) by delivering an irrevocable written notice to B. Riley (each, a &#147;B. Riley Additional Advance Notice&#148;). The purpose of the B. Riley Additional Advance is to allow us
to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each B. Riley Additional Advance is generally subject to terms and conditions
consistent with those of a B. Riley Advance, except for, among other things, the time period of the pricing period for such B. Riley Additional Advance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that B. Riley could be obligated to pay for the Common Stock we may elect to sell to B. Riley
in any B. Riley Advance or B. Riley Additional Advance. We will control the timing and amount of any sales of Common Stock to B. Riley. Actual sales of shares of our Common Stock to B. Riley under the B. Riley Purchase Agreement will depend on a
variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the B. Riley Purchase Agreement, we may not sell any shares of Common Stock thereunder and B. Riley
shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed
28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the B. Riley Purchase Agreement (the &#147;B. Riley Exchange Cap&#148;), unless (i)&nbsp;we
obtain stockholder approval to issue shares of Common Stock in excess of the B. Riley Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&nbsp;the average price of all applicable sales of shares of Common Stock under the B.
Riley Purchase Agreement equals or exceeds $4.87, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may not issue or sell any shares of Common Stock to B. Riley under the
B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by B. Riley and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule
<FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in B. Riley beneficially owning more than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#147;B. Riley Beneficial Ownership
Limitation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for B. Riley&#146;s commitment to purchase shares of Common Stock at our direction upon the terms and
subject to the conditions set forth in the B. Riley Purchase Agreement, we previously paid B. Riley Principal Investments, LLC, a subsidiary of B. Riley, a structuring fee in the amount of $10,000 and issued 250,000 commitment shares to B. Riley
(the &#147;B. Riley Commitment Shares&#148;). As of March&nbsp;3, 2023, the last date on which we sold shares of Common Stock pursuant to the B. Riley Purchase Agreement (prior to the filing of the registration statement of which this prospectus
forms a part), we have sold 127,241 shares of our Common Stock pursuant to advances thereunder. See the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151;
Recent Developments</I>&#148; for additional information regarding the B. Riley Purchase Agreement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>A&amp;R Yorkville Purchase Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into the Original Purchase Agreement with the Selling Securityholder, which is amended and restated by
the A&amp;R Yorkville Purchase Agreement we entered into with the Selling Securityholder on February&nbsp;8, 2023. The Selling Securityholder is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon satisfaction of the conditions to the Selling Securityholder&#146;s purchase obligations set forth in the A&amp;R Yorkville Purchase
Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to $500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#147;Yorkville Advance&#148;) by
delivering written notice to the Selling Securityholder (each, a &#147;Yorkville Advance Notice&#148;) until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the registration
statement of which this prospectus forms a part was initially declared effective by the SEC (i.e., December&nbsp;9, 2022). In accordance with our obligations under the Original Purchase Agreement, we initially filed the registration statement of
which this prospectus forms a part with the SEC on November&nbsp;30, 2022 to register under the Securities Act the resale by the Selling Securityholder of up to 28,078,672 shares of Common Stock, consisting of an aggregate amount of 250,000
Yorkville Commitment Shares and up to 27,828,672 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to the Selling Securityholder, from time to time under the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Yorkville Advance, a Yorkville Advance may be for a number of shares of Common Stock not to
exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the date of the Yorkville Advance
Notice. The shares of Common Stock, if any, that we elect to sell to the Selling Secuityholder pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period (each, a
&#147;Yorkville Pricing Period&#148;) for such Yorkville Advance, which shall be the period commencing upon receipt by the Selling Securityholder of the Yorkville Advance Notice (or the open of regular trading hours, if later) and ending on 4:00
p.m. on the same day. &#147;VWAP&#148; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that the Selling Securityholder could be obligated to pay for the Common Stock we may elect to
sell to it in a Yorkville Advance. We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock to the Selling Securityholder under the A&amp;R Yorkville Purchase
Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of
funding for our company and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the A&amp;R Yorkville Purchase Agreement, we may not sell any shares
of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of
shares of Common Stock issued thereunder would exceed 28,078,672 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the Original Purchase Agreement (the
&#147;Yorkville Exchange Cap&#148;), unless (i)&nbsp;we obtain stockholder approval to issue shares of Common Stock in excess of the Yorkville Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&nbsp;the average price of all
applicable sales of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds $8.77, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may
not </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issue or sell any shares of Common Stock to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement which, when aggregated with all other shares of Common Stock then
beneficially owned by the Selling Securityholder and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act, and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the Selling
Securityholder beneficially owning more than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#147;Yorkville Beneficial Ownership Limitation&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the A&amp;R Yorkville Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our
Common Stock to the Selling Securityholder. We expect that any proceeds received by us from such sales to the Selling Securityholder will be used for working capital and general corporate purposes, which may include capital expenditures,
commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption
or repurchase of indebtedness or capital stock. The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales of the Common Stock nor enter into any transaction that establishes a net short position in the
Common Stock during the term of the A&amp;R Yorkville Purchase Agreement. The A&amp;R Yorkville Purchase Agreement will automatically terminate on the earliest to occur of (i)&nbsp;the first day of the month following the <FONT
STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the registration statement of which this prospectus forms a part was initially declared effective by the SEC (i.e., December&nbsp;20, 2022) or (ii)&nbsp;the date on which
the Selling Securityholder shall have purchased from us under the A&amp;R Yorkville Purchase Agreement shares of our Common Stock for an aggregate gross purchase price of $500,000,000. We have the right to terminate the A&amp;R Yorkville Purchase
Agreement at no cost or penalty upon five trading days&#146; prior written notice to the Selling Securityholder; provided that there are no outstanding Yorkville Advance Notices and all outstanding amounts owed to the Selling Securityholder have
been paid. We and the Selling Securityholder may also agree to terminate the A&amp;R Yorkville Purchase Agreement by mutual written consent. Neither we nor the Selling Securityholder may assign or transfer our respective rights and obligations under
the A&amp;R Yorkville Purchase Agreement, and no provision of the A&amp;R Yorkville Purchase Agreement may be modified or waived by us or the Selling Securityholder other than by an instrument in writing signed by both parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously paid YA Global II SPV, LLC, a subsidiary of the Selling Securityholder, a structuring fee of $10,000 and issued the Selling
Securityholder 250,000 shares of Common Stock as a commitment fee pursuant to the Original Purchase Agreement (the &#147;Yorkville Commitment Shares&#148;). The A&amp;R Yorkville Purchase Agreement contains customary representations, warranties,
conditions, and indemnification obligations of the parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the
parties to such agreements, and may be subject to limitations agreed upon by the contracting parties. We do not know what the purchase price for our Common Stock will be and therefore cannot be certain as to the number of shares we might issue to
the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. Although the A&amp;R Yorkville Purchase Agreement provides that we may sell up to $500,000,000 of our Common Stock to the Selling Securityholder, only 28,078,672 shares of
our Common Stock are being registered for resale by the Selling Securityholder under the registration statement of which this prospectus forms a part, which represents (i)&nbsp;the 250,000 Yorkville Commitment Shares that we issued to the Selling
Securityholder in connection with the Original Purchase Agreement in consideration of its commitment to purchase shares of Common Stock at our election under the A&amp;R Yorkville Purchase Agreement and (ii)&nbsp;up to 27,828,672 shares of Common
Stock that may be issued to the Selling Securityholder from time to time, if and when we elect to sell shares to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we elect to issue and sell shares to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, we may need to
register for resale under the Securities Act additional shares of our Common Stock in order to receive aggregate gross proceeds equal to the $500,000,000 available to us under the </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
A&amp;R Yorkville Purchase Agreement, depending on market prices for our Common Stock. If all of the 28,078,672 shares offered by the Selling Securityholder for resale under the registration
statement of which this prospectus forms a part were issued and outstanding as of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus forms a part was initially filed with the SEC, without taking into
account the 4.99% Yorkville Beneficial Ownership Limitation or the 19.9% Yorkville Exchange Cap limitation), such shares would have represented approximately 16.6% of the total number of shares of our Common Stock then outstanding and approximately
83.3% of the total number of then-outstanding shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of such date (without giving effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its
equityholders as described elsewhere in this prospectus and assuming we have not otherwise issued any shares to B. Riley pursuant to the B. Riley Purchase Agreement described elsewhere in this prospectus). If we elect to issue and sell more than the
28,078,672 shares offered under this prospectus to the Selling Securityholder, which we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares, which could cause
substantial additional dilution to our stockholders. The number of shares ultimately offered for resale by the Selling Securityholder is dependent upon the number of shares we may elect to sell to the Selling Securityholder under the A&amp;R
Yorkville Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, no Yorkville Advances were requested or completed under the
Original Purchase Agreement. Subsequent to December&nbsp;31, 2022, we sold 85,000 shares of Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds of approximately $0.6&nbsp;million on
February&nbsp;16, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are substantial risks to our stockholders as a result of the sale and issuance of Common Stock to the
Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. These risks include the potential for substantial dilution and significant declines in our stock price. See the section of this prospectus titled &#147;<I>Risk Factors</I>&#148;
for details. Issuances of our Common Stock in this offering will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any
such issuance. Although the number of shares of Common Stock that our existing stockholders own will not decrease as a result of sales, if any, under the A&amp;R Yorkville Purchase Agreement, the shares owned by our existing stockholders will
represent a smaller percentage of our total outstanding shares after any such issuance to the Selling Securityholder. For more detailed information regarding the A&amp;R Yorkville Purchase Agreement, see the section of this prospectus titled
&#147;<I>Committed Equity Financing</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_7"></A>Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth
companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#147;Sarbanes-Oxley Act&#148;), reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with
new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required
to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
<FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will
be subject to the same new or revised accounting standards as other public companies that are not </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing
guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting
requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151; Emerging Growth Company</I>.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth
anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that
is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than
$1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to &#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_8"></A>Summary Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently a single commercial product company that is heavily dependent on the commercial success of
ZTlido and we may be unable to generate sufficient revenue to support our operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant losses since our inception. We anticipate that
we will incur continued losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial
doubt about our ability to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Commercial Operations and Product Development
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw
materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we
may not be able to find an alternative source on commercially reasonable terms, or at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our
future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical
trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and
our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to
our Business and Operations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to retain our key executives, it may delay our development efforts and harm our business,
financial condition and results of operations. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any disruption in our research and development facilities could adversely affect our business, financial
condition and results of operations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Intellectual Property </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT>
from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT
STYLE="white-space:nowrap">SP-103</FONT> would be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of
certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize
GLOPERBA would be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope
of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks
Related to Government Regulations </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we
are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in
significant expense and limit our ability to commercialize such products. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to our Relationship with Sorrento
</I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Certain of our directors and officers may have actual or potential conflicts of interest because of their
positions with Sorrento. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are controlled by Sorrento, whose interests may differ from those of our public shareholders.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Sorrento has recently filed for bankruptcy protection, which may impair our relationship with Sorrento.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks Related to this Offering and Ownership of our Common Stock </I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is not possible to predict the actual number of shares we will sell under the A&amp;R Yorkville Purchase
Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the A&amp;R Yorkville Purchase Agreement with the Selling Securityholder.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The sale and issuance of our Common Stock to the Selling Securityholder will cause dilution to our existing
stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Investors who buy shares of Common Stock at different times will likely pay different prices.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common
Stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If our operations and performance do not meet the expectations of investors or securities analysts, the market
price of our securities may decline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to
emerging growth companies will make our Common Stock less attractive to investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for,
and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_9"></A>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#147;Vickers Vantage Corp. I&#148; on February&nbsp;21, 2020 as a Cayman Islands exempted company for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&nbsp;9, 2022, we changed our jurisdiction of incorporation by
deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&nbsp;9, 2022, we changed our name to &#147;Scilex Holding Company&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <FONT
STYLE="white-space:nowrap">516-4310.</FONT> Our website address is <I>www.scilexholding.com</I>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this
prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You
may obtain any of the documents filed by us with the SEC at no cost from the SEC&#146;s website at <I>http://www.sec.gov</I>. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_10"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </P></TD>
<TD>Scilex Holding Company </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Offered by the Selling Securityholder </P></TD>
<TD>28,078,672 shares of Common Stock, consisting of (i) 250,000 Yorkville Commitment Shares and (ii)&nbsp;up to 27,828,672 shares of Common Stock we may elect, in our discretion, to issue and sell to the Selling Securityholder under the A&amp;R
Yorkville Purchase Agreement from time to time. On February&nbsp;16, 2023, we sold 85,000 shares of our Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </P></TD>
<TD>The Selling Securityholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding Before this Offering(1) </P></TD>
<TD>141,348,856 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding After this Offering </P></TD>
<TD>169,427,528 shares of Common Stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We will not receive any proceeds from the resale of shares of Common Stock included in this prospectus by the Selling Securityholder. However, we may receive up to $500,000,000 in aggregate gross proceeds under the A&amp;R Yorkville Purchase
Agreement from sales of Common Stock that we may elect to make to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement, if any, from time to time in our discretion. We expect to use the net proceeds that we receive under
the A&amp;R Yorkville Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical
trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no
current agreement with respect to any acquisition or strategic transaction. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </P></TD>
<TD>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#147;SCLX&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page 15 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of shares of Common Stock outstanding is based on an aggregate of 141,348,856 shares outstanding as
of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
forms a part was initially filed with the SEC) and assumes that following such date we have not otherwise issued any shares of Common Stock to B. Riley pursuant to the B. Riley Purchase Agreement
(other than the 250,000 shares of Common Stock issued to B. Riley in connection with the signing of such agreement) which is more fully described elsewhere in this prospectus, and excludes: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">744,201 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2017 Scilex
Pharmaceuticals Inc. Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">16,195,178 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock
Option Plan of Legacy Scilex (the &#147;2019 Stock Option Plan&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,003,988 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50
per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14,792,500 shares of Common Stock issuable upon the exercise of stock options outstanding under the Equity
Incentive Plan, which options were issued after November&nbsp;30, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 5,484,166 shares of Common Stock available for future issuance under the Equity Incentive Plan (which
number of shares accounts for the annual increase on January 1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January 1 of each year
beginning on January 1, 2023 and ending on (and including) January 1, 2032, in an amount equal to up to 4% of the total number of shares of our Common Stock outstanding on December 31 of the immediately preceding year nor does such number include
any amendment to such plan that increases the authorized number of shares available under such plan); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 2,875,759 shares of Common Stock available for future issuance under the ESPP (which number includes the
annual increase on January&nbsp;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&nbsp;1 of each year beginning on
January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to up to 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">up to 1,400,000 shares of Common Stock available for future issuance under the Scilex Holding Company 2023
Inducement Plan (the &#147;Inducement Plan&#148;), which was adopted on January&nbsp;17, 2023. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_11"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the
following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section of this prospectus titled &#147;Cautionary Note Regarding Forward-Looking Statements&#148;. If any of these risks
actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks
and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional
risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein.
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_12"></A>Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate
sufficient revenue to support our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is our only product approved for commercial sale and we are entirely
dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in
the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the
medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment
for the relief of neuropathic pain associated with PHN; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability, cost and potential advantages of alternative treatments, including less expensive generic
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of our sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party
payors and government authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of other competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product labeling or any product inserts required by the FDA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of adverse side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing
relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of
products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we
succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a
competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be
successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited operating history and have incurred significant losses since our inception. We
anticipate that we will incur continued losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March
2019, our operations were conducted through Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;), which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired
Semnur, which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential <FONT STYLE="white-space:nowrap">non-opioid</FONT> pain therapy candidates,
undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue to date is attributable to sales of ZTlido, and we expect that sales of
ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and
significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced
by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a
number of factors including our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully complete ongoing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials
and obtain regulatory approvals for our current and future product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify new acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successfully identify new product candidates and advance those product candidates into <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">raise additional funds when needed and on terms acceptable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain experienced management and advisory teams; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support
clinical, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> manufacturing and planned future commercialization efforts and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launch commercial sales of our product candidates, whether alone or in collaboration with others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities
of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party
payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achieve market acceptance of product candidates in the medical community and with third-party payors and
consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $23.4&nbsp;million, $88.4&nbsp;million and $47.5&nbsp;million
for the years ended December&nbsp;31, 2022, 2021 and 2020, respectively. As of December&nbsp;31, 2022, we had an accumulated deficit of approximately $375.9&nbsp;million. For the foreseeable future, we expect to continue to incur significant
expenses related to the commercialization of ZTlido and GLOPERBA and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development of our product candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg dexamethasone sodium phosphate viscous gel) (&#147;SEMDEXA&#148;), <FONT
STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT STYLE="white-space:nowrap">low-dose</FONT>
naltrexone hydrochloride delayed-release capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;).</FONT> We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement
of the Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">SP-103</FONT> and multiple Phase 1 trials for <FONT STYLE="white-space:nowrap">SP-104.</FONT> Consequently, we expect to incur substantial losses for the foreseeable future and may
never become profitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter
unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our
failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as Vickers was a shell company prior to the completion of the Business Combination, we are currently ineligible to use short form
registration statements on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and will not be eligible to file such a registration statement until, among other things, at least 12 calendar months have lapsed since November&nbsp;17, 2022, the date we
filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> disclosing that we ceased to be a shell company. Our inability to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> may significantly impair our ability to raise necessary
capital to run our operations and progress our product development programs. If we seek to access the capital markets through a registered offering during the period of time that we are unable to use Form <FONT STYLE="white-space:nowrap">S-3,</FONT>
we may be required to publicly disclose the proposed offering and the material terms thereof before the offering commences, we may experience delays in the offering process due to SEC review of a Form <FONT STYLE="white-space:nowrap">S-1</FONT>
registration statement and we may incur increased offering and transaction costs and other considerations. Disclosing a public offering prior to the formal commencement of an offering may result in downward pressure on our stock price. If we are
unable to raise capital through a registered offering, we would be required to conduct our equity financing transactions on a private placement basis, which may be subject to pricing, size and other limitations imposed under the Nasdaq Listing
Rules, or seek other sources of capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be required to make milestone payments to the former stockholders of Semnur in connection with our
development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary,
Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0&nbsp;million in contingent
cash consideration based on the achievement of certain milestones. A $40.0&nbsp;million payment will be due upon obtaining the first approval of a new drug application by the FDA (&#147;NDA&#148;) of any Semnur product, which includes SEMDEXA.
Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net sales of a Semnur
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur
product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in cumulative net sales of a Semnur
product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other
aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our
commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs
associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, our cash and cash equivalents were approximately $2.2&nbsp;million and we had an accumulated deficit of
approximately $375.9&nbsp;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our
operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at
all. Any additional fundraising efforts may divert our management from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize
our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we
raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that
may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as
a going concern. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#147;<I>Liquidity and Going Concern</I>&#148; of our consolidated financial statements included
elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our
consolidated financial statements as of and for the year ended December&nbsp;31, 2022, which stated that substantial doubt existed about our ability to continue as a going concern. We have negative working capital and have incurred significant
operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $375.9&nbsp;million as of December&nbsp;31, 2022 and approximately
$352.6&nbsp;million as of December&nbsp;31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain
financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and
expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the
success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be
materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business
activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and
accurately report our financial results or result in a material misstatement of our financial statements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the
audit of our consolidated financial statements for the years ended December&nbsp;31, 2022 and 2021, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or
detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2022 and 2021, the material weakness identified in our internal control
over financial reporting related to ineffective control activities in the areas of revenue, business combination, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
debt and derivative liabilities caused by a lack of sufficient accounting resources with appropriate experience and technical expertise to effectively execute controls over certain judgmental and
technical accounting areas. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance
resource requirements and hiring other personnel with sufficient accounting expertise at Scilex to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any
potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at
Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to
further augment our finance resources, and we cannot be certain that the measures we have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the
possibility that other material weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability
to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading
liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and
financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the
demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange
regulations. Failure to comply with Section&nbsp;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in
the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_13">
</A>Risks Related to our Commercial Operations and Product Development </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We obtain our commercial supply of ZTlido, clinical supply of our product
candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer
to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
rely on a number of sole or single source suppliers and manufacturers, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the commercial supply of ZTlido; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-103;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer and supplier for the clinical supply of <FONT STYLE="white-space:nowrap">SP-104;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturer for the clinical supply of SEMDEXA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, dated as of May&nbsp;11, 2011, by and among Scilex Pharmaceuticals, Inc. (as successor to Stason
Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation (&#147;Itochu&#148;) (as amended, the &#147;Product Development Agreement&#148;), and the </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Commercial Supply Agreement, dated as of February&nbsp;16, 2017, by and among Scilex Pharma and Oishi and Itochu (as amended, the &#147;Commercial Supply Agreement&#148;), we license the rights
to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (collectively, the &#147;Products&#148;). Oishi and Itochu have the right to terminate the Product
Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&nbsp;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to
cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&nbsp;our total net
profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, or
(b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as
agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b) after 30 days of good-faith discussion; and (3)&nbsp;in the event of our
bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have
the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial
Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> depend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&nbsp;17, 2015 (the &#147;Genzyme Supply Agreement&#148;), with Genzyme Corporation
(&#147;Genzyme&#148;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances,
including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2)&nbsp;if our development of SEMDEXA is ceased or we do not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020, or (3)&nbsp;if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#146; notice. We did not file for regulatory
approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause (3), Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement,
effective as of May&nbsp;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative
supplier of sodium hyaluronate on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&nbsp;27, 2017 (as
amended, the &#147;Lifecore Master Services Agreement&#148;), with Lifecore Biomedical, LLC (&#147;Lifecore&#148;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services
Agreement under certain circumstances, including, but not limited to: (1)&nbsp;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&nbsp;if we (a)&nbsp;become insolvent, (b)&nbsp;cease to
function as a going concern, (c)&nbsp;become convicted of or plead guilty to a charge of violating any law relating to either party&#146;s business, or (d)&nbsp;engage in any act which materially impairs goodwill associated with SEMDEXA or
materially impairs the terminating party&#146;s trademark or trade name; (3)&nbsp;if we fail to pay past due invoices upon 30 days&#146; written notice, or (4)&nbsp;if we reject or fail to respond to a major change proposed by Lifecore that does not
change Semnur&#146;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer on commercially reasonable
terms, or at all, may be difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#147;Tulex Master Services Agreement&#148;) and statement
of work with Tulex Pharmaceuticals Inc. (&#147;Tulex&#148;), we depend on Tulex to develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104.</FONT> Tulex has the right to terminate the Tulex Master Services
Agreement under certain circumstances, including, but not limited to: (1)&nbsp;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other
time period expressly stated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in the applicable statement of work) or (2)&nbsp;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy,
reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&nbsp;without cause upon 30 days prior written notice
to Tulex or (b)&nbsp;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an
alternative manufacturer and supplier on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our
third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to
maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at
these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, including
clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other
supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#147;cGMP&#148;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we
would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection and inspections by other health
authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates
are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability
of ZTlido and the development of SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#147;Cardinal Health 105&#148;) as our third-party logistics distribution provider for ZTlido
in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable,
inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2020 and 2021 and the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105
represented all of our net revenue for such periods. As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. Beginning
on April&nbsp;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation (&#147;McKesson&#148;), Cardinal Health 110, LLC (&#147;Cardinal Health 110&#148;) and AmerisourceBergen Corporation
(&#147;AmerisourceBergen&#148;), as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our three large distributors), we expect that our revenue would decline and our
business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics
provider, may negatively impact our sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We discontinued our use of &#147;title model&#148; services provided by Cardinal Health 105,
but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the abovementioned distribution channel would adversely affect our business, financial condition and results of operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example,
under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith
negotiation. As of the date of this prospectus, our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product
Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have
the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on
third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory
requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently
do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (&#147;GCP&#148;)
requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the
potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#147;CROs&#148;), to conduct <FONT
STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over
their actual performance. The third parties with whom we contract for execution of our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials play a significant role in the conduct of these studies and trials and the subsequent
collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our
programs. Although we rely on these third parties to conduct our <FONT STYLE="white-space:nowrap">GCP-compliant</FONT> clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our
investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and
clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our
intellectual property by CROs, which may reduce our trade secret and intellectual property protection, allow our potential competitors to access, and exploit our proprietary technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the
third parties conducting our clinical trials do not adequately perform their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced,
or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be
difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the
applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future enter into collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint ventures, or strategic
alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business,
we may enter into collaborations, additional <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements (such as, for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new
markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements, joint
ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these
opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such
transactions or arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise
sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become,
inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any
agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest,
which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our
collaborators&#146; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements
are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such
rights at a premium. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and
generate additional revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive
clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be
conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with
regulatory authorities on trial design; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying prospective clinical investigators or clinical trial sites that have necessary
qualifications, interest and capacity to perform a requested protocol; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of
which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining approval from one or more institutional review boards (&#147;IRBs&#148;);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment
of additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to the clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in recruiting suitable subjects to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with GCPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites,
including delays by third parties with whom we have contracted to perform certain of those functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in subjects completing participation in a trial or returning for post-treatment <FONT
STYLE="white-space:nowrap">follow-up,</FONT> including, for example, as a result of reluctance to visit medical facilities as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trial sites or subjects dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">key investigators departing their clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lack of adequate funding to continue the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the
resulting data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an
inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other
sponsors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a facility manufacturing our product candidates or any of their components being ordered by the FDA to
temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any changes to our manufacturing process that may be necessary or desired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not
performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or
regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the
IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side
effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In
addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which
may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience
delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and increased knowledge over time. In addition, if we make manufacturing or other changes to our
product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of
<FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary
capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all.
Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential business disruptions and related risks resulting from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2,</FONT></FONT>
was reported to have surfaced in Wuhan, China. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> is the virus that causes <FONT STYLE="white-space:nowrap">COVID-19.</FONT> The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available
liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of <FONT STYLE="white-space:nowrap">COVID-19</FONT> continues to
rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the
United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are monitoring the potential impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, and if
<FONT STYLE="white-space:nowrap">COVID-19</FONT> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to
visit clinical sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators, clinical site staff and potential closure of clinical facilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreases in patients seeking treatment for chronic pain; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including
interruption in global shipping that may affect the transport of clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risk that participants enrolled in our clinical trials will acquire
<FONT STYLE="white-space:nowrap">COVID-19</FONT> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal or state governments, employers and others. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related
to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply
chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of <FONT
STYLE="white-space:nowrap">SP-103</FONT> exclusively from Oishi and Itochu in Japan. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on
our operating results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive
Order 14042, which was signed by President Biden on September&nbsp;9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it
will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be
fully vaccinated against <FONT STYLE="white-space:nowrap">COVID-19,</FONT> subject to disability and religious exemptions, by December&nbsp;8, 2021. Despite the government&#146;s <FONT STYLE="white-space:nowrap">no-action</FONT> position, we
continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are
vaccinated, all of which could negatively affect our business and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of,
<FONT STYLE="white-space:nowrap">COVID-19</FONT> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition,
a recession or market correction resulting from the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially affect our business and the value of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> globally could materially and adversely impact our
operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial
condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain
regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot
commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and
local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical
trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends <FONT
STYLE="white-space:nowrap">non-approval</FONT> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory
authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even
if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation
Strategy (&#147;REMS&#148;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly post-marketing clinical trials. In addition, the
FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with
our product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be delayed or fail in obtaining marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval for indications or patient populations that are not as broad as we intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be subject to changes in the way the products are administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its
distribution in the form of a modified REMS; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be sued and held liable for harm caused to patients; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is
critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <FONT STYLE="white-space:nowrap">follow-up</FONT> periods. If patients are unwilling to participate in our clinical trials
due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed.
We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness
of our product candidates or termination of clinical trials altogether. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that enrolled patients will not complete a clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ability to monitor patients adequately during and after treatment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including
difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the product candidate in
relation to other available products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are
common, but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective
eligibility criteria in place to reduce the placebo effect and the impacts of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> and may experience similar issues with enrollment of our other planned clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our
product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct
some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market
opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product
candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT>
product candidates and determining indications on which to focus in preclinical studies or clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be
inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the
addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may
significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition and our competitors may
discover, develop or commercialize products faster or more successfully than us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries
are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <FONT STYLE="white-space:nowrap">SP-103,</FONT> face and
will likely face competition from prescription and generic topical lidocaine patches, including Lidoderm<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (a branded, prescription 5% lidocaine patch product) (&#147;Lidoderm&#148;) and
generic lidocaine patches manufactured by Mylan N.V., Teva Pharmaceutical Industries Limited (&#147;Teva&#148;) and Par Pharmaceutical, Inc. Additionally, <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various
opioid pain medications, nonsteroidal anti-inflammatory drugs (&#147;NSAIDs&#148;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of acute LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for
the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <FONT STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development.
SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations.
We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and unapproved use of branded and generic injectable steroids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of
certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT STYLE="white-space:nowrap">SP-104,</FONT> will likely face
direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our
competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing
product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more
resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies
or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further
as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing,
acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from
commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <FONT
STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and
commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The third-party payor coverage and reimbursement status of newly approved products is uncertain.
Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market
acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs
(such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ
significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further,
obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use
of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and
reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside of the United States. Assuming that coverage is obtained for a given product, the
resulting reimbursement rates might not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> or <FONT STYLE="white-space:nowrap">co-insurance</FONT> that patients find unacceptably high. Patients, physicians, and other
healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#146; drug formularies for which third-party payors
provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in
their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage
of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined
discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of
reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the
requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the
European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be
reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#147;buy and bill&#148;
basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or
a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement.
<FONT STYLE="white-space:nowrap">J-Codes</FONT> are codes maintained by the Centers for Medicare and Medicaid Services (&#147;CMS&#148;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report
injectable drugs that ordinarily cannot be self-administered. We do not have a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> for any of our product candidates. If our product candidates are approved, we may apply for one but cannot
guarantee that a <FONT STYLE="white-space:nowrap">J-Code</FONT> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <FONT STYLE="white-space:nowrap">J-Code</FONT> is
not available, physicians would need to use a <FONT STYLE="white-space:nowrap">non-specific</FONT> miscellaneous <FONT STYLE="white-space:nowrap">J-Code</FONT> to bill third-party payors for these physician-administered drugs. Because miscellaneous <FONT
STYLE="white-space:nowrap">J-Codes</FONT> may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional
information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment
approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product, ZTlido, we currently have several product candidates
that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater
commercial potential than our current and planned development programs and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates
that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable
market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate
the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we
may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial
technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our
resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that
ultimately do not provide a return on our investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development involves a lengthy and expensive process with an uncertain outcome, and
results of earlier studies and trials may not be predictive of future trial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to
design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical
trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage
clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the
pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials.
As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of
administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization,
such changes carry the risk that they will not achieve their intended objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the
treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for <FONT STYLE="white-space:nowrap">SP-103,</FONT> and multiple Phase 1 trials were initiated in the first quarter of 2022 for
<FONT STYLE="white-space:nowrap">SP-104.</FONT> We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing
approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and
preclinical studies in addition to those we have planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA,
which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to
conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the
commercialization of that product or indication for use. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data
from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> or preliminary data from our clinical
trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient
enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously
published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures
set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim
and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures
must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical
trial is based on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any
information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the <FONT
STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our
product candidates may be harmed, which could harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may fail to
demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex
and expensive <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target
indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety
concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business,
financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential
approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in
any other jurisdiction, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in
any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis regarding safety and efficacy.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However,
the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for
clinical trials and approval may be different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and
validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and
time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory
approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may suffer reputational harm due to failures of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability
to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our
results of operations and financial condition would likely suffer materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido and GLOPERBA may have undesirable properties that could result
in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA
and our product candidates. In the event that ZTlido or GLOPERBA is identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product
or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such
side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving
or maintaining market acceptance of ZTlido or GLOPERBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may
experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is
possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other
adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational
products are tested in large-scale, Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and
prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The
drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of
operations significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in
satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product
candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production
interruptions, including equipment </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our
development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay,
require us to begin new clinical trials at additional expense or terminate clinical trials completely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks
associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <FONT STYLE="white-space:nowrap">scale-up,</FONT> process reproducibility, stability issues,
compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could
result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and
manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or
facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our
manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_14"></A>Risks Related to our Business and Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract,
retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular,
we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and
Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and
GLOPERBA. We do not carry &#147;key person&#148; insurance on any of our executive officers or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key
executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for
qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these
characteristics may be more appealing to qualified candidates than what we have to offer. In addition, regulation or legislation impacting the workforce, such as the proposed rule published by the Federal Trade Commission which would, if issued,
generally prevent employers from entering into <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements with employees and require employers to rescind existing <FONT STYLE="white-space:nowrap">non-compete</FONT> agreements, may lead to
increased uncertainty in hiring and competition for talent. Further, we may experience employee turnover as a result of the ongoing &#147;great resignation&#148; occurring </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as
we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many
academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our
recruitment and retention efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to increase the size of our company and may not effectively manage our growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had approximately 90 full-time employees. We may need to continue to expand our managerial, operational, sales
and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities,
including <FONT STYLE="white-space:nowrap">co-promotion</FONT> activities. Future growth would impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review
process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our
ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and
improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any
increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured
liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry
insurance for all categories of risk that our business may encounter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have
observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be
able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous
waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held
liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may
require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be
required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido and GLOPERBA and clinical
testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is
found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of
product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could
also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if
approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue from product sales; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates or products that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the
market or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against
potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&nbsp;million in the aggregate.
Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that
exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable
cost or in sufficient amounts to protect us against losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any disruption in our research and development facilities could adversely affect our
business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area,
California. Our facilities may be affected by natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to
damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disaster, we may be
forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable
terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without
implementation difficulties, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of
any acquisition, and acquisitions can be costly and dilutive. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and
broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition
of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an
acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately
consummated. Those negotiations could result in diversion of management time and significant <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that
does not materially disrupt existing relationships and that allows us to achieve development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or
may take longer to realize than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses or acquire
intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we
acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business,
financial condition and results of operations could be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>International components of our business expose us to business, legal,
regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The
purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <FONT STYLE="white-space:nowrap">non-compliance.</FONT>
Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#147;FCPA&#148;), as well as export controls laws. Any failure to comply with applicable legal and
regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges,
seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting
business internationally involves a number of risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import
restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing our intellectual property rights and in defending against third-party threats and
intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of
our product candidates, if approved, in various countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost and availability of shipping and other means of product transportation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency exchange rate fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in duties and tariffs, license obligations and other <FONT STYLE="white-space:nowrap">non-tariff</FONT>
barriers to trade; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the imposition of new trade restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complexities associated with managing multiple payor-reimbursement regimes or
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak
of disease, boycotts, curtailment of trade and other business restrictions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and
similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#146; activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively
impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The increasing use of social media platforms presents new risks and challenges.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the
diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates
uncertainty and risk of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their
experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to
defend our business or the public&#146;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate
disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their
activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to
occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business and operations would suffer in the event of a system failure. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have implemented and maintain security measures, our computer systems and those of our CROs and other contractors and consultants are
vulnerable to computer viruses, unauthorized access, cybersecurity attacks, and other security incidents, including as perpetrated by hackers, or as the result of natural disasters, terrorism, war, or telecommunications or electrical failures. While
we have not experienced any such system failure or a security breach to date, if such an event were to occur, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary
information. For example, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loss of clinical trial data from completed, ongoing, or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or
reproduce such data. To the extent that any disruption or security breach were to result in the loss of or damage to our data or applications, or the unauthorized disclosure of confidential or proprietary information, including personal data, we
could incur material legal liability or be the subject of legal claims, suffer damage to our reputation, lose or harm our intellectual property rights, and delay the continued research, development and commercial efforts of ZTlido, GLOPERBA and our
product candidates, if approved. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters or some other matter, that claim could
have a material adverse effect on our business, financial condition, and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a security incident or privacy
violation that leads to the unauthorized acquisition, interruption, modification, loss, theft, corruption, interference, or other unauthorized disclosure of, or prevents access to, personal data, including patient data or other protected health
information, could harm our reputation, compel us to comply with federal or state breach notification laws and foreign equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents, and otherwise
subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and
invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays, or cessations of service or produce
errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are continually evolving and include, but are not limited to, malicious software, ransomware, attempts to gain unauthorized access to data under our
custody or control, and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information, and corruption of data. If we are unable to prevent such cybersecurity attacks
or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, we may suffer loss of reputation, we may be the subject of governmental investigations, legal claims, or litigation, or we may incur financial loss
or other regulatory penalties, each of which may not be covered by our insurance. In addition, these breaches and other unauthorized access to our systems can be difficult to detect, and any delay in identifying any such event may lead to increased
harm of the type described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial
condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and
disruptions in the past several years and especially in 2020 and 2021 due to the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including severely diminished liquidity and credit availability, declines in consumer
confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment,
underemployment or the repeal of certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#147;ACA&#148;), may decrease the demand for healthcare services and
pharmaceuticals. If fewer patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition
and cash flows could be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurances that further deterioration in credit and financial markets and
confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity
and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse
effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations
relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning
corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#147;ESG&#148;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in
some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing
investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors,
particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in
such assessments include, among others, companies&#146; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#146; board of directors in supervising various sustainability
issues. In light of investors&#146; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or
take other actions, to hold us and our Board accountable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapid and ongoing developments and changing expectations
relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we
elect not to or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional
scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services.
A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate
responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our
business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the
market&#146;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over
the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be
harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_15"></A>Risks Related to our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the intellectual property we <FONT STYLE="white-space:nowrap">in-license</FONT> from Oishi and Itochu, and if we lose
the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <FONT STYLE="white-space:nowrap">SP-103</FONT> would be harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product
Development Agreement, we have been granted an exclusive, worldwide license (except </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to Japan) under current and future intellectual property rights relating to ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> lidocaine tape products and the lidocaine in
such products, including, among other things: (1)&nbsp;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2)&nbsp;all <FONT STYLE="white-space:nowrap">know-how,</FONT> work
product, trade secrets, inventions, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3)&nbsp;copyrightable works, copyrights and applications, registrations and
renewals, (4)&nbsp;logos, trademarks, service marks, and all applications and registrations relating thereto, (5)&nbsp;other proprietary rights, (6)&nbsp;abbreviated new drug applications or other applications to market, and (7)&nbsp;any regulatory
exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <FONT STYLE="white-space:nowrap">SP-103</FONT> depends on the effectiveness and continuation of the Product Development Agreement. If we lose the
right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> as well as new product candidates based on the licensed intellectual
property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various development, regulatory and/or commercial diligence
obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1)&nbsp;if we are in material breach of the agreement and the
breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&nbsp;if, at any time during the term of the Product Development Agreement, the market conditions are such
that (a)&nbsp;our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more
consecutive quarters, or (b)&nbsp;the economic viability of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed
detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b) after 30 days of good-faith discussion; and
(3)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, Scilex&#146;s net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net
sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product
Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating
to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property rights from
Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently entered into the Romeg Agreement for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> of certain intellectual property
rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations
of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA.&#148; Under the Romeg Agreement, among other things, Romeg granted us
(1)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein to (a)&nbsp;commercialize the pharmaceutical product comprising liquid formulations of colchicine
for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the &#147;Territory&#148;), (b) develop other products comprising the Initial Licensed Product as an
active pharmaceutical ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and (c)&nbsp;manufacture Licensed Products anywhere in the world, solely for commercialization in
the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial
Licensed Product solely in the Territory. The license to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <FONT
STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&nbsp;1, 2027 and, thereafter, is
<FONT STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&nbsp;expiration of the last to expire
of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products
depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the
licensed intellectual property would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement imposes various development, regulatory and/or commercial diligence
obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&nbsp;in the event we are in material breach of the Romeg Agreement, unless we have
cured any such breach within 60 days after any notice thereof was provided; (b)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite
quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&nbsp;immediately, if we challenge the licensed
patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&nbsp;by written notice to us if sales of Licensed Products do not commence or continue within specified
periods agreed to by the parties; or (e)&nbsp;in the event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our
failure to timely pay milestone payments, we will be required upon Romeg&#146;s request to transfer all licensed intellectual property rights, including those relating to GLOPERBA and the Licensed Products, to Romeg or its designee, within thirty
days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing
arrangements on acceptable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves
complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial or other obligations under the license agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property rights of the
licensor that are not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense intellectual property rights to third parties under collaborative development
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual
property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into
additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide
the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of
certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to
successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not
sufficiently broad, we may not be able to compete effectively in our markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks,
trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United
States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or <FONT STYLE="white-space:nowrap">in-licensing</FONT> patent
applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost or in a timely manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the
potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and
even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful
opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory
approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent
application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These
risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Patent and Trademark Office (&#147;PTO&#148;) and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <FONT STYLE="white-space:nowrap">non-compliance</FONT> with which can result in abandonment or lapse of a patent or patent
application, and partial or complete loss of patent rights in the relevant jurisdiction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise
may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made
significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope
of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S.
courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other parties may have designed around our claims or developed technologies that may be related or competitive to
our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could
dominate our patent position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the
practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">because patent applications in the United States and most other countries are confidential for a period of time
after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the
first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&nbsp;16, 2013. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all
necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects
of our research and development output before it is too late to obtain patent protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <FONT
STYLE="white-space:nowrap">in-license</FONT> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido,
GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a
materially adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary rights to product components and
processes and brands for our development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties related to ZTlido,
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> may require the use of additional proprietary
rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights. In addition, our product candidates may require
specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or
<FONT STYLE="white-space:nowrap">in-license</FONT> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product
candidates. Even if we are able to obtain a license to such proprietary rights, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be
required to expend significant time and resources to develop or license replacement technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or
collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated
trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not
be provided. Therefore, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations,
which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under
those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent
applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce
licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses
terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or
control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot currently
determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we
use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have
greater resources than we do, may also be pursuing strategies to license or acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If
we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or
at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required
third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an
interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being
unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be
necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business.
Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties
may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners,
licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of our product candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary
rights of other parties, we could face adverse consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a
proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation
is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one
of our current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may
be currently pending third-party patent applications which may later result in issued patents that our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties
making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more
of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our
intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability.
Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual
property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">result in costly litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cause development delays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally
invalid or not infringed in a court of law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be
possible on a cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which
may include treble damages if we are found to have been willfully infringing such intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to pay the attorney&#146;s fees and costs of litigation to the party whose intellectual property
rights we may be found to be infringing; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable
terms, or at all. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or
methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a
showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#146;s time and attention in pursuing
these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the
validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <FONT
STYLE="white-space:nowrap">non-infringing</FONT> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our
product candidates to market and be precluded from manufacturing or selling our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have
not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">some patent applications in the United States may be maintained in secrecy until the patents are issued;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States and elsewhere can be pending for many years before issuance, or
unintentionally abandoned patents or applications can be revived; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pending patent applications that have been published can, subject to certain limitations, be later amended in a
manner that could cover our technologies, our product candidates or the use of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification of third-party patent rights that may be relevant to our technology is difficult because patent
searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patent applications in the United States are typically not published until 18 months after the priority date; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publications in the scientific literature often lag behind actual discoveries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the
patent&#146;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to
market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending patent application will issue
with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours,
and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S.
and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such
technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of
these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have
similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of
our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay
developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#146;s intellectual property unless that party grants us or our strategic partners&#146; or licensees&#146; rights
to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement
claims, which could severely harm our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or
enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may
infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of
our management and key personnel. For example, on June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#147;Apotex&#148;) in the U.S. District Court for the Southern District
of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section of this prospectus titled &#147;<I>Business &#151; Legal Proceedings</I>&#148; for additional information regarding such proceedings. Any claims we
assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent
infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a
risk that, even if the validity of such patents is upheld, the court will construe the patent&#146;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent
claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude
third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may
determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of
such trademarks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity
and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for years before they are concluded. Even if we ultimately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the
proceedings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued
patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best
interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <FONT STYLE="white-space:nowrap">non-litigious</FONT> action or
solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our
intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without
strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the
market and for commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is subject to change over time. In the
United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major
pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to
management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property
rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition
and results of operations may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#147;ZTlido,&#148;
&#147;SCILEX&#148; and &#147;RESPONSIBLE BY DESIGN,&#148; and we have filed trademark applications for the marks &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We also have trademark registrations for ZTlido in the
UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party trademark registration for ZTlido and
filed an invalidation proceeding &#151; Invalidation of TM Registration No.&nbsp;36299669 &#147;ZTlido&#148; in Class&nbsp;5 in the name of
<FONT STYLE="font-family:pmingliu; font-size:9pt">&#31206;&#30343;&#23798;&#24646;&#39423;&#21830;&#36031;&#26377;&#38480;&#20844;&#21496;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt"> (Qinhuangdao Hengjun Trading Co., Ltd.) (the
&#147;China ZTlido Trademark Invalidation Proceeding&#148;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or
determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors
or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement,
dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to
trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby
impairing our ability to protect our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our
success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing
biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#147;AIA&#148;), which was passed in September 2011, resulted in significant changes to the U.S. patent system.
An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned from a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> to a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same
invention. Under a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally
will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering
an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but
circumstances could prevent us from promptly filing patent applications on our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by
the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before
March&nbsp;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding
sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first
challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs
surrounding the prosecution of our or our licensors&#146; patent applications and the enforcement or defense of our or our licensors&#146; issued patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <I>inter partes </I>review or other proceedings challenging our or our
licensors&#146; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent
rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent
rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent
protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with
regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and
regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently
indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and
other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are
allowed during </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. For example, in Europe, a new unitary patent system takes effect June&nbsp;1, 2023,
which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent
which will be subject to the jurisdiction of the Unitary Patent Court (&#147;UPC&#148;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation
of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single <FONT
STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.
Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to
maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various
foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting
in partial or complete loss of patent rights in the relevant jurisdiction. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely
file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to
properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have
an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees may not adequately
prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how</FONT> and our inventions for which patents may be unobtainable or
difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential
information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our
confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and
confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become
known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our
<FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets, a competitor&#146;s discovery of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations.
Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is expensive, time-consuming and unpredictable, and the enforceability of confidentiality
agreements may vary from jurisdiction to jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or
other proprietary information is disclosed, the value of our trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and other proprietary rights would be significantly impaired and our business and competitive position would suffer.
Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> patented inventions or other proprietary information, including rights to sublicense
and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> or other proprietary information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their
current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our
employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try
to ensure that our employees, consultants and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these individuals or we have used or
disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect
inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us
from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A
loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who
may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached,
and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have
preexisting or competing obligations to a third party. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our position as a relatively small company may cause us to be at a significant disadvantage
in defending our intellectual property rights and in defending against infringement claims by third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation relating
to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property
rights and in defending against claims that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including
new procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to
which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages,
enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical
industries, including PTO administrative proceedings, such as <I>inter partes </I>reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and
foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the
risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may
be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product
candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition,
third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or
any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license
under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly,
if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent
may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case,
such a license may not be available on commercially reasonable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive
or other equitable relief, which could effectively block our ability to further commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and
attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates,
which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of
litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of
operations significantly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or
our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is
common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were
previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees
or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation
could result in substantial costs and be a distraction to our management team and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual
property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries.
Filing, prosecuting and defending patents on ZTlido and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same
extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our
inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products
to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our product candidates, if approved, in jurisdictions where we do not have
any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian patent applications. Recent
Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of
treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign
jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and
could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant
licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to
grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe
patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other
advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary
information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure
of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in
2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information
that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to
enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of
misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a
competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect
our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or
all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual
property rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and
time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United
States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in
the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that
technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive
position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent
protection or to protect our trade secret information may be jeopardized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our reliance on third parties may require us to share our trade secrets,
which increases the possibility that our trade secrets will be misappropriated or disclosed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to
help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements
with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements
or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <FONT STYLE="white-space:nowrap">know-how</FONT> and
trade secrets, a competitor&#146;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data
potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our
agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights and regulatory exclusivity rights do not necessarily address
all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain
because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors
may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are
not covered by the claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to make the inventions covered by the
issued patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We or our licensors or strategic partners might not have been the first to file patent applications covering
certain of our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our pending patent applications may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not develop additional proprietary technologies that are patentable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial
condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent
applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current
or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as
to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may
be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business,
financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly
uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in
the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or
pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly
uncertain. Our pending and future patent applications may not result in patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive
technologies and products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other
countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. For example, the complexity and uncertainty
of European patent laws have also increased in recent years. In Europe, a new unitary patent system takes effect June&nbsp;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system.
Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. As the UPC is a new court system, there is no precedent for the
court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain
under the jurisdiction of the UPC will be potentially vulnerable to a single <FONT STYLE="white-space:nowrap">UPC-based</FONT> revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We
cannot predict with certainty the long-term effects of any potential changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party <FONT
STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <I>inter partes </I>review, post-grant review or interference proceedings challenging our patent rights or
the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such
submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our
inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not
conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed <FONT
STYLE="white-space:nowrap">non-provisional</FONT> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent application. The scope of patent protection
may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_16"></A>Risks Related to Government Regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain
regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain marketing approval from the FDA for a product candidate is unpredictable but typically takes many years following
the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount
of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to
support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our
future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny approval of a product candidate for many reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with the design or implementation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to such authorities&#146; satisfaction that a product candidate is safe and
effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative or ambiguous results from our clinical trials may not meet the level of statistical significance
required for approval by the FDA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree with our interpretation of data from preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may not agree that the data collected from clinical trials of our product candidates are acceptable or
sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers
with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data
insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete
the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial
condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may
grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that
product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than
an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be
successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our
business, financial condition and results of operations will be substantially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the FDA does not conclude that certain of our product
candidates satisfy the requirements for the Section&nbsp;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&nbsp;505(b)(2) are not as we expect, the approval pathway for those product candidates
will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> we may
seek FDA approval through the Section&nbsp;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&nbsp;505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#147;FDCA&#148;). Section&nbsp;505(b)(2) permits the filing of an NDA where
at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&nbsp;505(b)(2) allows an NDA we submit to the FDA to
rely in part on data in the public domain or the FDA&#146;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially decreasing the amount
of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&nbsp;505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide
additional data and information and meet additional standards for regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the
Section&nbsp;505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&nbsp;505(b)(2) NDAs are
subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section&nbsp;505(b)(2) NDA. These requirements may give rise to patent litigation against
us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose
additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if
successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In
addition, even if we are able to utilize the Section&nbsp;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any approved product candidate will be subject to ongoing and continued regulatory review, which may
result in significant expense and limit our ability to commercialize such products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will
remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and
other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must
also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA
review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as
continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our
third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investigation or additional study obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">communications to prescribers or patients about specific information or issues; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning or untitled letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or
suspension or revocation of product license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and
generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant
expense, lost revenues and damage to our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146; policies may change, and
additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or
government regulations may also alter the competitive landscape, potentially to our disadvantage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in
which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed OTC and without FDA approval, require approval and compete
inappropriately with ZTlido. In December 2018, we filed a citizen&#146;s petition asking the FDA to clarify its requirements and take enforcement action against such products. The FDA has not responded with a decision or action. The FDA has
generally held the position that requests for enforcement action via citizen petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to our December 2018 petition. Furthermore, we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our
intellectual property. In February 2021, we filed a complaint against such manufacturers to seek an award of damages and the entry of injective relief enjoining further dissemination of such false and deceptive advertisement. In addition, on
March&nbsp;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES Act&#148;) was signed into law, which included statutory provisions reforming FDA&#146;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA
considers a drug to be generally recognized as safe and effective (&#147;GRASE&#148;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the
OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">notice-and-comment</FONT></FONT> rulemaking, which was
lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period
for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this
may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> and compete
with ZTlido. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive
actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes
through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the
FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of
operations may be negatively affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A fast track product designation, breakthrough therapy designation or other designation to facilitate
product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening
condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for
the treatment of sciatica and <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. Even though SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103</FONT> have received fast track designation, we may not experience a faster
process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA.
Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the
FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A
breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most
efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and
accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead
determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA
procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica, the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the
time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If approved, our products candidates regulated as biologics may face competition from
biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition
and Innovation Act of 2009 (the &#147;BPCIA&#148;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#147;PHSA&#148;) for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the
reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#147;BLA&#148;) for the competing product
submitted under section 351(a) of the PHSA containing the competing sponsor&#146;s own <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and
potency of the other company&#146;s biological product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#147;first
licensure&#148;. Not every licensure of a biological product is considered a &#147;first licensure&#148; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also
been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional generic substitution for <FONT
STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing
our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and
services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of
other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical
activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020,
the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on
July&nbsp;10, 2020, the FDA announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a <FONT
STYLE="white-space:nowrap">COVID-19</FONT> variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign
surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a
prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the
ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties,
private litigation or adverse publicity and could negatively affect our operating results and business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators
are subject to federal, state and foreign data protection laws and regulations. In the United States, such laws may include, but are not limited to, U.S. state personal data breach notification laws, state health information privacy laws, and
federal and state consumer protection laws, including Section&nbsp;5 of the FTC Act, each of which govern the collection, use, disclosure and protection of health-related and other personal information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as such terms are defined in HIPAA), we may
have access to very sensitive data regarding patients who participate in, or whose tissue samples or other biospecimens are used in, our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens and
litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to HIPAA and other privacy, data security and consumer protection laws.
Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a Covered Entity in a manner that is not authorized by HIPAA, and we may be
subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the
scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, U.S. states are constantly adopting new laws or amending existing laws relating to data privacy and security and consumer
protection, which requires our frequent attention. For example, the CCPA creates new individual privacy rights for California consumers and places increased privacy and security obligations on entities handling personal data of consumers or
households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#146; data collection, use and sharing practices, provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of
certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of security incidents. The CCPA has been amended by the CPRA, which largely took effect on January&nbsp;1,
2023. The CPRA also created a new state agency (the CPPA) vested with authority to implement and enforce the CCPA. New implementing regulations are expected to be introduced by the CPPA. Virginia also recently enacted a similar state privacy law,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Virginia Consumer Data Privacy Act (the &#147;VDCPA&#148;), and Colorado, Connecticut and Utah also have similar laws in place. New legislation enacted in various other states will continue
to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international, or
other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, VDCPA, and other similar state privacy laws and general consumer protection authorities are potentially
significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to so comply. Privacy laws and regulations are constantly evolving and there are a number of legislative
proposals at both the state and federal levels that could impose new obligations or limitations in areas affecting our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC
also sets expectations for failing to take appropriate steps to keep consumers&#146; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information
(such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&nbsp;5(a) of the FTC Act. The FTC expects a company&#146;s data security measures to be reasonable and appropriate in light of the sensitivity
and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that
merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#146; personal information. Any failure to honor promises, such
as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to
enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including the GDPR, may also apply to health-related and other personal information obtained outside of
the United States. The GDPR imposes several data protection requirements in the EU, as well as fines for violations that can reach up to the greater of &#128;20&nbsp;million or 4% of annual global revenue. The regulation imposes numerous
requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used,
the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information,
including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such
processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries in the EEA. Further, the UK&#146;s departure from the EU (Brexit)
has led and could also lead to further legislative and regulatory changes and may increase our compliance costs. Presently, the processing of personal data of UK data subjects is governed by the UK GDPR, which authorizes similar fines to the EEA
GDPR and potentially divergent enforcement actions for certain violations. On June&nbsp;28, 2021, the European Commission adopted an adequacy decision for the UK, allowing for the relatively free exchange of personal information between the EU and
the UK, however the European Commission may suspend such adequacy decision if it considers that the UK no longer provides for an adequate level of data protection. Other jurisdictions outside the EEA are similarly introducing or enhancing privacy
and data security laws, rules, and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require
us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are
or will be in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individual privacy rights, failed to comply with data protection laws, or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend against and could result in adverse publicity that could harm our business,
financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business involves the use of hazardous materials and we and third-parties with whom we contract
must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and
development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are
subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#146;
facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in
costly <FONT STYLE="white-space:nowrap">clean-up</FONT> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety
procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do
not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or
contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of
certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our
research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future
compliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper
activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial
partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide
true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with
laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees,
independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or
sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient
organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our
current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and
patient privacy regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made
under a federal healthcare program, such as the Medicare and Medicaid programs &#151; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a
violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent
claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals,
improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses (i.e., uses not expressly approved by the FDA in a drug&#146;s label);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting
to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment
for health care benefits, items or services &#151; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and
transmission of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to
physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical
devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing
metrics to government agencies, including CMS and Department of Veterans Affairs (&#147;VA&#148;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare
programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and
may potentially limit a drug manufacturer&#146;s ability to offer certain marketplace discounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate
complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer
protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s
voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug
manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and
entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future research and development of our product candidates outside the United States, and any future
sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or
the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.
Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we
may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries
or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and
curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is
found not to be in compliance with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect
our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA and other regulatory agencies actively enforce the laws and regulations
prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <FONT
STYLE="white-space:nowrap">off-label</FONT> uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in <FONT STYLE="white-space:nowrap">pre-approval</FONT> promotion prior to the approval of
such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription
products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved
labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label, if the physicians believe in
their professional medical judgment it could be used in such manner. However, if we are found to have promoted our product for any <FONT STYLE="white-space:nowrap">off-label</FONT> uses, the federal government could levy civil, criminal and/or
administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us
under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would
materially adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare reform measures could hinder or prevent our
product candidates&#146; commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and
regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare
reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of
healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted
at the end of 2017 includes provisions that, effective January&nbsp;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the <FONT STYLE="white-space:nowrap">so-called</FONT>
&#147;individual mandate.&#148; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our
business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA
remain possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In
August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&nbsp;1, 2020, through May&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for
1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration
will be 2.25% for the first half of the year, and 3% in the second half of the year. The American </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the
government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in
healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce
the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#147;<I>If we fail to comply with our reporting and
payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and
fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects</I>.&#148; While any proposed measures may require authorization through additional legislation to become effective,
Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the
future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or
additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented
regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of
operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other
healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand
for ZTlido, GLOPERBA and our product candidates, if approved, or put pressure on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable
to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations
and future prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to
interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter
was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase
costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could
negatively affect financial results. CMS issued a final regulation, which became effective on April&nbsp;1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to
increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has
taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to
participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&nbsp;1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether they participate
in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting
in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or
<FONT STYLE="white-space:nowrap">single-use</FONT> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be
subject to civil monetary penalties of 125&nbsp;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to
increase faster than the pace of inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Resources and Services Administration (&#147;HRSA&#148;) issued a final regulation
regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&nbsp;1, 2019. Implementation of this
regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes them to 340B covered
entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&nbsp;13, 2021, HRSA newly established an
administrative dispute resolution (&#147;ADR&#148;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate
discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result
in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results
of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a manufacturer (i)&nbsp;is found to have knowingly submitted any false price or
product information to the government, (ii)&nbsp;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&nbsp;fails to submit the required price data on a timely basis, or (iv)&nbsp;is found to have knowingly and
intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case
federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#146;s covered outpatient drugs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could
be applied if a manufacturer fails to provide these discounts in the amount of 125&nbsp;percent of the discount that was due. Furthermore, Congress could enact a Medicare Part D inflation rebate, under which manufacturers would owe additional
rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact
additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. In addition, Congress could enact a drug price negotiation program under which the prices for
certain high Medicare spend single source drugs would be capped by reference to the <FONT STYLE="white-space:nowrap">non-federal</FONT> average manufacturer price. This or any other legislative change could impact the market conditions for our
products. We expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency and other policies to address
drug pricing concerns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or
contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification
requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary
disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement
action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may
adversely impact our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product
candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for
confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an
alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in
an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new
trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to the
U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we
conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or
other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations
and relationships </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future
regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including
the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on
our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties,
disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_17"></A>Risks Related to our Relationship with Sorrento </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Jaisim Shah, Dr.&nbsp;Henry Ji, Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr.&nbsp;David Lemus and Mr.&nbsp;Tommy Thompson serve on our Board. Mr.&nbsp;Jaisim Shah and Dr.&nbsp;Henry Ji, who are our executive officers, are also members of the board of directors
of Sorrento (and in the case of Dr.&nbsp;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&nbsp;Dorman Followwill, Ms.&nbsp;Laura&nbsp;J. Hamill,
<FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee, Mr.&nbsp;David Lemus and Mr.&nbsp;Tommy Thompson are &#147;independent directors&#148; within the meaning of applicable regulatory and stock exchange requirements in the United States,
both Mr.&nbsp;David Lemus and Mr.&nbsp;Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&nbsp;Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and
continues to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr.&nbsp;Henry Ji. Further, <FONT STYLE="white-space:nowrap">Dr.&nbsp;Tien-Li</FONT> Lee is the founder, the Chief Executive Officer and a director of Aardvark,
which has been involved in an asset purchase transaction with Sorrento in connection with Sorrento&#146;s acquisition of Aardvark&#146;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of
Sorrento&#146;s investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#146;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#146;s ownership interest as of
December&nbsp;31, 2021. Also as part of such investment, Dr.&nbsp;Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other
Sorrento equity awards. These individuals&#146; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#146;
total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different
implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements
governing the transition services and the relationship thereafter between the companies. Potential conflicts of interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent
conflicts, we may be precluded from pursuing certain growth initiatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento currently performs or supports many of our important corporate functions. Our financial
statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a stand-alone public company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of replicating and replacing certain functions, systems and infrastructure to which we no longer have the
same access after the Business Combination. We are also making investments and hiring additional employees to operate without the same access to Sorrento&#146;s existing operational and administrative infrastructure. These initiatives are costly to
implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these
services on an allocation basis. As a result, our consolidated financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer
a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for
agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total
costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and
an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to
replace these services or enter into appropriate third-party agreements on terms and conditions, including costs, comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements
terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own
adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically
received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of this informal support will diminish or cease following the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, Sorrento controls approximately 52.1% of our voting power (including shares of our Series A Preferred Stock
held by Sorrento but excluding shares issuable upon exercise of warrants to purchase shares of our Common Stock), which means that, based on its percentage of voting power, Sorrento controls the vote of all matters submitted to a vote of our
stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate decisions. In particular, for so long as Sorrento continues to own a majority of the outstanding shares of our capital stock
entitled to vote generally in the election of directors, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any unsolicited acquisition of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated Registration Rights Agreement entered into in connection with the Business Combination (the
&#147;Registration Rights Agreement&#148;) and our Certificate of Incorporation, Sorrento has certain rights, and the ability to take certain actions, that are not otherwise available to all of our stockholders. For example, the Registration Rights
Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a registration statement or request that their shares of our Common Stock be covered by a registration statement that we are otherwise filing. See the
section of this prospectus titled &#147;<I>Description of Our Securities &#151; Registration Rights</I>&#148; for additional information regarding these rights. We have filed a registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> which was initially declared effective by the SEC on
December&nbsp;27, 2022, in order to satisfy these obligations. In addition, until such time as Sorrento first ceases to own greater than 50% of the outstanding voting power of the outstanding shares of our capital stock entitled to vote generally in
the election of directors, the Certificate of Incorporation effectively provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend the Certificate of
Incorporation (subject to approval of our Board) and amend our Bylaws. The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock
repurchase programs, declare dividends and make other decisions. See the section of this prospectus titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Matters in our Governing Documents and Under Delaware Law</I>&#148; for additional
information regarding Sorrento&#146;s ability to take such actions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when Sorrento ceases to control a majority of the total voting
power of Scilex, for so long as Sorrento continues to own a significant percentage of our Common Stock and for so long as the Sorrento Group owns any shares of Series A Preferred Stock, Sorrento will still be able to significantly influence the
composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the
significant ownership position held by Sorrento, our classified board structure and the rights granted to Sorrento under the Stockholder Agreement, new investors may not be able to effect a change in our business or management. The concentration of
ownership and availability of the foregoing rights could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of the Company and ultimately might affect the market price of our Common
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that
may not be in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or
incur new or refinance existing indebtedness. Additionally, Sorrento&#146;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change
in control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry
generally. In the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses
that directly or indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its
affiliates and any person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Sorrento and its
affiliates (each an &#147;Identified Person&#148;) will have any duty to refrain from (i)&nbsp;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are
deemed to be competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business activities or
lines of business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same
or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be
complementary to our business and, as a result, those acquisition opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance
its investment, even though such transactions might involve risks to our stockholders or may not prove beneficial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&nbsp;30, 2022, Sorrento announced that its board of directors
authorized Sorrento to dividend to Sorrento equityholders of record as of January&nbsp;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento. Subsequent to such dividend Sorrento continues to hold approximately
53.3% of our voting power, including shares of our Series A Preferred Stock and shares issuable upon exercise of warrants to purchase shares of our Common Stock, which shares have the rights, preferences and privileges described below, and Sorrento
would still have significant rights that are not otherwise available to holders of our Common Stock. See the risk factor below titled &#147;<I>Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not
held by, and are preferential to, the rights of holders of our Common Stock.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento has recently filed for bankruptcy protection, which
may impair our relationship with Sorrento. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary,
Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the
Company is not a debtor in Sorrento&#146;s voluntary Chapter 11 filing. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million receivable from Sorrento, which was fully reserved. Sorrento&#146;s filing for bankruptcy protection may impair
our relationship with Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not held by,
and are preferential to, the rights of holders of our Common Stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is issued only to Sorrento and is
not convertible into shares of our Common Stock. The holders of Series A Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including
the right to receive, in the event of a change of control, liquidation dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our
Common Stock. The preference amount is $10.00 per share (subject to adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate,
on a deemed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-common</FONT></FONT></FONT> stock basis, in such dividend with the holders of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock have certain voting rights over our corporate actions including, among others, any change to the
shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, for so long as the Sorrento Group beneficially owns any shares of Series A Preferred
Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder Designee&#148; and collectively, the
&#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board
in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably necessary, and not otherwise
prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for
any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have agreed to ensure that our
Board complies with all applicable requirements of the stock exchange, including independence requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we are prohibited from taking certain actions
without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of our Board, the incurrence of certain amounts of indebtedness and the payment of dividends
on our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on the terms of the Series A Preferred Stock, see the section of this prospectus titled
&#147;<I>Description of Our Securities &#151; Our Preferred Stock</I>&#148; and the section of this prospectus titled &#147;<I>Certain Relationships and Related Party Transactions &#151; Certain Relationships of Vickers &#151; Stockholder Agreement
with Sorrento.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of
directors of public companies headquartered in California. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, California enacted Senator Bill 826 (&#147;SB
826&#148;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on
its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&nbsp;13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding
that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September&nbsp;16, 2022, the appellate court ruled to temporarily
stay enforcement of the trial court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB 826, pending a further order of the appellate court. On December&nbsp;1,
2022, the appellate court vacated the temporary stay order and on February&nbsp;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of
California to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on September&nbsp;30, 2020, California enacted Assembly Bill 979 (&#147;AB 979&#148;), which generally requires public companies
with principal executive offices in California to include specified numbers of directors from &#147;underrepresented communities&#148;. A director from an &#147;underrepresented community&#148; means a director who self-identifies as Black, African
American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December&nbsp;31, 2021, each public company with principal executive offices in California was required
to have at least one director from an underrepresented community. By December&nbsp;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities,
and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&nbsp;1, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down
AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&nbsp;6, 2022, a notice of appeal was filed. On September&nbsp;16, 2022, the appellate court ruled to temporarily stay enforcement of the
trial court&#146;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB 979, pending a further order of the appellate court. On December&nbsp;1, 2022, the appellate
court vacated the temporary stay order and on February&nbsp;3, 2023, a record on appeal was filed and such appeal is currently pending. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and
report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB 979 will continue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq
Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_18"></A>Risks Related to this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It is not possible to predict the actual number of shares we will sell under the A&amp;R Yorkville Purchase Agreement to the Selling Securityholder, or
the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the A&amp;R Yorkville Purchase Agreement with the Selling Securityholder. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into the Original Purchase Agreement with the Selling Securityholder, as amended and restated by the
A&amp;R Yorkville Purchase Agreement dated February&nbsp;8, 2023, pursuant to which the Selling Securityholder has committed to purchase up to $500,000,000 of our Common Stock, subject to certain limitations and conditions set forth in the A&amp;R
Yorkville Purchase Agreement. The shares of our Common Stock that may be issued under the A&amp;R Yorkville Purchase Agreement may be sold by us to the Selling Securityholder at our discretion from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of any sales of our shares of Common Stock to the Selling Securityholder under
the A&amp;R Yorkville Purchase Agreement. Sales of our Common Stock, if any, to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately
decide to sell to the Selling Securityholder all, some or none of the shares of our Common Stock that may be available for us to sell to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Common Stock that we may elect to sell to the
Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock prior to each Yorkville Advance made pursuant to the A&amp;R Yorkville Purchase Agreement, if any, it is not
possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, the purchase price per
share that the Selling Securityholder will pay for shares purchased from us under the A&amp;R Yorkville Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Securityholder under the A&amp;R
Yorkville Purchase Agreement, if any. As of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus forms a part was initially filed with the SEC), there were 141,348,856 shares of our Common Stock outstanding,
of which 5,622,266 shares were held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates</FONT> (in each case without giving effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders as described
elsewhere in this prospectus and assuming we have not otherwise issued any shares to B. Riley pursuant to the B. Riley Purchase Agreement described elsewhere in this prospectus). If all of the 28,078,672 shares offered for resale by the Selling
Securityholder under the registration statement that includes this prospectus were issued and outstanding as of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus forms a part was initially filed with the
SEC), such shares would have represented approximately 16.6% of the total number of shares of our Common Stock then outstanding and approximately 83.3% of the total number of then-outstanding shares held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates</FONT> (without giving effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders as described elsewhere in this prospectus and assuming we have
not otherwise issued any shares to B. Riley pursuant to the B. Riley Purchase Agreement described elsewhere in this prospectus). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, although the A&amp;R Yorkville Purchase Agreement provides that we may sell up to an aggregate of $500,000,000 of our Common Stock
to the Selling Securityholder, only 28,078,672 shares of our Common Stock (including the aggregate amount of 250,000 Yorkville Commitment Shares issued to the Selling Securityholder pursuant to the Original Purchase Agreement) are being registered
for resale under the registration statement of which this prospectus forms a part. If we elect to sell to the Selling Securityholder all of the 28,078,672 shares of Common Stock being registered for resale under this prospectus, depending on the
market price of our Common Stock prior to each Yorkville Advance made pursuant to the A&amp;R Yorkville Purchase Agreement, the actual gross proceeds from the sale of all such shares may be substantially less than the $500,000,000 available to us
under the A&amp;R Yorkville Purchase Agreement, which could materially adversely affect our liquidity. On February&nbsp;16, 2023, we sold 85,000 shares of our Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder under the
A&amp;R Yorkville Purchase Agreement more than the 28,078,672 shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the A&amp;R Yorkville Purchase Agreement, we must file
with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Securityholder of any such additional shares of our Common Stock we wish to sell from time to time under the A&amp;R Yorkville
Purchase Agreement, which the SEC must declare effective. Additionally, we would need to obtain stockholder approval to issue shares of Common Stock in excess of the Yorkville Exchange Cap under the A&amp;R Yorkville Purchase Agreement in accordance
with applicable Nasdaq Listing Rules, unless the average price of all applicable sales of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of
the Nasdaq Listing Rules), in which case the Yorkville Exchange Cap limitation would not apply to issuances and sales of Common Stock under the A&amp;R Yorkville Purchase Agreement. Any issuance and sale by us under the A&amp;R Yorkville Purchase
Agreement of shares of Common Stock in addition to the 28,078,672 shares of Common Stock being registered for resale by the Selling Securityholder under the registration statement of which this prospectus forms a part could cause additional dilution
to our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Common Stock under the A&amp;R Yorkville Purchase Agreement
if such issuance would breach our obligations under the rules or regulations of Nasdaq. In addition, the Selling Securityholder will not be required to purchase any shares of our Common Stock if such sale would result in the Selling
Securityholder&#146;s beneficial ownership exceeding 4.99% of the then-outstanding voting power or number of shares of Common Stock. Our inability to access a part or all of the amount available under the A&amp;R Yorkville Purchase Agreement, in the
absence of any other financing sources, could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sale and issuance of our Common Stock to the
Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to
fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Securityholder under the A&amp;R Yorkville Purchase
Agreement will fluctuate based on the price of our Common Stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Common Stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Securityholder, the Selling Securityholder may resell all, some, or none of those shares at its
discretion, subject to the terms of the A&amp;R Yorkville Purchase Agreement. Therefore, sales to the Selling Securityholder by us could result in substantial dilution to the interests of other holders of our Common Stock. Additionally, the sale of
a substantial number of shares of our Common Stock to the Selling Securityholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors who buy shares of Common Stock at different times will likely pay different prices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, we control the timing and amount of any sales of Common Stock to the Selling
Securityholder. If and when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement, the Selling Securityholder may resell all, some, or none of such shares in its discretion
and at different prices, subject to the terms of the A&amp;R Yorkville Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those
shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling
Securityholder in this offering as a result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the
Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, or if investors expect that we will do so, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a
desirable time and price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock
to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Common Stock to the Selling
Securityholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those
net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not
yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_19"></A>Risks Related to Ownership of our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at
prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements regarding results of any clinical trials relating to our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse regulatory decisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not
limited to clinical trial requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and
our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical
trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our dependence on third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of the introduction of new products by our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions and trends in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements concerning product development results or intellectual property rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future issuances of common stock or other securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we
may provide to the public; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet or exceed the estimates and projections of the investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall performance of the equity markets and other factors that may be unrelated to our operating performance or
the operating performance of our competitors, including changes in market valuations of similar companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by the Company or by any securities analysts who might cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fluctuation of the market values of any of our potential strategic investments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuances of debt or equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with our contractual obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our Common Stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trading volume of our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about the Company or its industry or positive or negative recommendations or
withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to effectively integrate the operations of Semnur; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our relationship with Sorrento; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of natural or <FONT STYLE="white-space:nowrap">man-made</FONT> catastrophic events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effects of public health crises, pandemics and epidemics, such as the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could
result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past,
stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#146; stock. Such litigation, if instituted against the Company, could cause
us to incur substantial costs and divert management&#146;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#147;<I>Risk
Factors</I>&#148;, could have a dramatic and material adverse impact on the market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have not paid cash dividends in
the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid cash dividends on our Common Stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable
future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including
Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#146;s ability to receive a return
on such stockholder&#146;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the perception of future sales, of a substantial number of shares of our Common Stock
may cause the price of our Common Stock to decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell,
substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Except as described below and unless otherwise waived by
the Company and the applicable parties to the Registration Rights Agreement, Sorrento and certain directors and equityholders of Vickers, including the Sponsors, are currently subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions
that restrict their ability to transfer certain of their shares of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. In
connection with the Closing of the Business Combination, the Company, the Sponsors and Sorrento agreed to waive compliance with the <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions under the Registration Rights Agreement and any other
applicable agreement that restricted the transfer of our Common Stock solely with respect to 1.5&nbsp;million shares of our Common Stock held by the Sponsors as of such Closing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described elsewhere in this prospectus, on December&nbsp;30, 2022, Sorrento announced that its board of directors authorized Sorrento to
dividend to Sorrento equityholders of record as of January&nbsp;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that were held by Sorrento. Such shares are subject to a <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction and
may not be sold, pledged or otherwise transferred until May&nbsp;11, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the restrictions on resale end, the market price of shares
of our Common Stock could drop significantly if the holders of these shares of Common Stock sell them or are perceived by the market as intending to sell them. These factors could also make it more difficult for us to raise additional funds through
future offerings of our shares of Common Stock or other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our operating results may fluctuate significantly. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be
affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in the level of expenses related to our development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the addition or termination of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any intellectual property infringement lawsuit in which we may become involved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product
candidates, and the level of underlying demand for such products and purchasing patterns; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or
receive under these arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors
or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our
stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and
reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts
of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading
price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock
price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to
decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to
ZTlido or our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity
incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock.
The issuance of additional equity securities, whether pursuant to the B. Riley Purchase Agreement, the A&amp;R Yorkville Purchase Agreement (pursuant to each of which we may also sell up to $500&nbsp;million of shares of our Common Stock, or an
aggregate of $1.0&nbsp;billion, as more fully described elsewhere in this prospectus) or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&nbsp;9, 2022, we are authorized to grant equity awards to our
employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&nbsp;9, 2022, we are authorized to sell shares to our employees. Further, pursuant to the Inducement Plan, which was adopted on
January&nbsp;17, 2023, we are authorized to grant equity awards to individuals as a material inducement to join the Company. A total of 20,276,666, 2,875,759 and 1,400,000 shares of our Common Stock have been reserved for issuance under the Equity
Incentive Plan, the ESPP and the Inducement Plan, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&nbsp;1, 2023. As a
result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and
Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering such securities and certain of our other securities. We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> which was initially declared effective by the SEC on December&nbsp;27, 2022, in order to satisfy these obligations. The registration of these securities will permit the public sale of such
securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the
market price of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have
to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be
significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal
stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over our management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially own, in the aggregate,
approximately 56.7% of our outstanding voting stock (which percentage gives effect to the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders). This concentration of voting power may make it less likely that
any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders may desire. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. See &#147;<I>Risk Factors &#151; We
are controlled by Sorrento, whose interests may differ from those of our public shareholders</I>&#148; above for additional information regarding Sorrento&#146;s influence and control in the Company. See &#147;<I>Principal Securityholders</I>&#148;
for information regarding the ownership of our outstanding Common Stock by our directors, executive officers, and current beneficial owners of 5% or more of our voting securities and their respective affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have in the past and may in the future be subject to short selling strategies that may drive down the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short sellers have in the past and may attempt in the future to drive down the market price of our common stock. Short selling is the practice
of selling securities that the seller does not own but may have borrowed with the intention of buying identical securities back at a later date. The short seller hopes to profit from a decline in the value of the securities between the time the
securities are borrowed and the time they are replaced. As it is in the short seller&#146;s best interests for the price of the stock to decline, many short sellers (sometime known as &#147;disclosed shorts&#148;) publish, or arrange for the
publication of, negative opinions regarding the relevant issuer and its business prospects to create negative market momentum. Although traditionally these disclosed shorts were limited in their ability to access mainstream business media or to
otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (&#147;blogging&#148;) have allowed many disclosed shorts to publicly attack a
company&#146;s credibility, strategy and veracity by means of <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;research reports&#148; that mimic the type of investment analysis performed by large Wall Street firms and independent research
analysts. These short attacks have, in the past, led to selling of shares in the market. Further, these short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S. and they
are not subject to certification requirements imposed by the SEC. Accordingly, the opinions they express may be based on distortions, omissions or fabrications. Companies that are subject to unfavorable allegations, even if untrue, may have to
expend a significant amount of resources to investigate such allegations and/or defend themselves, including shareholder suits against the company that may be prompted by such allegations. We may in the future be the subject of shareholder suits
that we believe were prompted by allegations made by short sellers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss and tax credit carryforwards may be
subject to limitation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#146;s stock, by value, over a
three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a
corporate reorganization in the past, some ownership changes as a result of the Business Combination and may experience some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we
earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased
future tax liability for the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and JOBS Act of 2017 (the &#147;TCJA&#148;), as amended by the CARES Act, includes
changes to U.S. federal tax rates and the rules governing net operating loss (&#147;NOL&#148;) carryforwards. The TCJA, as modified by the CARES Act, limits a taxpayer&#146;s ability to utilize NOL carryforwards to 80% of taxable income (as
calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December&nbsp;31, 2020. In addition, NOLs arising in tax years ending after December&nbsp;31, 2017 and before January&nbsp;1, 2021
may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&nbsp;31, 2020 may not be carried back. NOLs arising in tax years beginning after December&nbsp;31,
2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January&nbsp;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&nbsp;1, 2018 will continue to
have a <FONT STYLE="white-space:nowrap">two-year</FONT> carryback and <FONT STYLE="white-space:nowrap">20-year</FONT> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is
expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our estimates or judgments relating to our critical accounting policies are based on assumptions
that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual
circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of
our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of
our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws and the DGCL contains provisions that could make it more difficult for a third party to acquire
the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established
and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for a classified board of directors with staggered three-year terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power
of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors (the &#147;Sorrento Trigger Event&#148;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66
2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the
direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in
part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a
single class; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for elections to the Board and for proposing matters that
can be acted upon by stockholders at stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL generally prohibits a Delaware
corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We have expressly elected not to be
governed by Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section&nbsp;203 of the DGCL, except that the restrictions
on business combinations of Section&nbsp;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions
could discourage, delay or prevent a transaction involving a change in control of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they
desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace
current members of our management team. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the
Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also delay or impede a merger, tender
offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For information regarding
these and other provisions, see the section of this prospectus titled &#147;<I>Description of Our Securities.</I>&#148; In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial
markets, including negative impacts on the price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Certificate of Incorporation designates the Court of Chancery of the
State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit
our stockholders&#146; ability to obtain a favorable judicial forum for disputes with the Company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of
Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state
court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted
by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees
or stockholders to us or our stockholders; (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of
Incorporation or the Bylaws; (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&nbsp;any action or proceeding asserting a claim against us or
any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&nbsp;any action asserting an &#147;internal corporate claim,&#148; as
that term is defined in Section&nbsp;115 of the DGCL; <I>provided that</I>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts
have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an
alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The
Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation
described above. See the section of this prospectus titled &#147;<I>Description of Our Securities &#151; Anti-Takeover Measures in our Governing Documents and Under Delaware Law &#151; Exclusive Forum</I>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and
officers. The enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In
addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with
resolving such challenge. While we currently </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these
specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and
could have an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and we cannot be
certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take
advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of
the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and
stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive
as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an
emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or
(c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to equal or exceed $700&nbsp;million as of the last business
day of the second fiscal quarter of such year, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that
are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could
significantly affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a controlled company within the meaning of the Nasdaq
Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power of our outstanding shares of Common Stock. As a result, we are a
&#147;controlled company&#148; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an
individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within one year of the date of the listing of their common stock:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a board that is composed of a majority of &#147;independent directors&#148; as defined
under the Nasdaq Listing Rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have a compensation committee that is composed entirely of independent directors or have a
written charter addressing the committee&#146;s purpose and responsibilities; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are not required to have director nominations be made, or recommended to the full board of directors, by its
independent directors or by a nominating and corporate governance committee that is composed </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a
controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to be a &#147;controlled company&#148; in the future, we will be required to comply with the Nasdaq listing standards, which may
require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and
administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance
initiatives. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and
these expenses may increase even more after we are no longer an &#147;emerging growth company.&#148; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act (the &#147;Dodd-Frank Act&#148;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we
expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and
regulations to make it more difficult and more expensive for the Company to obtain directors&#146; and officers&#146; liability insurance and we may be required to incur substantial costs to maintain sufficient coverage. We cannot predict or
estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board
committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect that we will need to implement an enterprise resource planning (&#147;ERP&#148;) system. An ERP system is intended to
combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to
complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect
our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and
diversion of management attention. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with
SEC rules that implement Section&nbsp;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth
company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will
be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants
and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating
effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal
control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or
deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#147;<I>Risk Factors &#151; We have identified a material weakness in our internal control over financial reporting. Any material weakness
may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements.</I>&#148; above for additional information regarding a previously identified material weakness. These
reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for
public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a
result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to
disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#146;s time
and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their
application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to meet Nasdaq&#146;s continued listing requirements could result in a delisting of our Common Stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#146;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid
price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#146;s ability to sell or purchase our Common Stock when a
stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or
improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive U.S. federal income tax reform could adversely affect the Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In
recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA,
which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a
&#147;worldwide&#148; system of taxation to a modified territorial system. On March&nbsp;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S.
economy in light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&nbsp;16, 2022,
President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <FONT
STYLE="white-space:nowrap">buy-backs,</FONT> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; under the law or for taking price
increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential
tax consequences of investing in our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Warrants are exercisable for our Common Stock, which would increase the number of shares
eligible for future resale in the public market and result in dilution to our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding warrants to purchase an
aggregate of 11,003,988 shares of our Common Stock are exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised,
additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the
public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as
such, the Warrants may expire worthless. See below risk factor, &#147;<I>The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the
then-outstanding Warrants approve of such amendment</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Warrants may never be in the money, they may expire worthless and the terms of
the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, the exercise price for our Warrants is $11.50 per share of Common Stock. On March 10, 2023, the closing
price of our Common Stock on the Nasdaq Capital Market was $7.27. If the price of our shares of Common Stock remains below $11.50 per share, which is the exercise price of our Warrants, we believe our warrantholders will be unlikely to cash exercise
their Warrants, resulting in little or no cash proceeds to us. There is no guarantee that our Warrants will be in the money prior to their expiration and, as such, our Warrants may expire worthless. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Warrants were issued in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The
Warrant Agreement provides that the terms of the Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the
then-outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the
then-outstanding Warrants approve of such amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other
things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a Warrant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may redeem any unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the Warrants worthless.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a
price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like)
on each of the 20 trading days within any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">30-trading-day</FONT></FONT> period commencing after the Warrants become exercisable and ending on the third trading day prior to the date on
which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.
Redemption of the outstanding Warrants could force the holders thereof to: (i)&nbsp;exercise such Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii)&nbsp;sell such Warrants at the
then-current market price when a holder might otherwise wish to hold such Warrants; or (iii)&nbsp;accept the nominal redemption price that, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the
market value of such Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the Warrants at any time after they become exercisable and prior
to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants (1)&nbsp;may be less than the value the holders would have received if
they had exercised their Warrants at a later time where the underlying share price is higher and (2)&nbsp;may not compensate the holders for the value of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_20"></A>COMMITTED EQUITY FINANCING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into the Original Purchase Agreement with the Selling Securityholder, which is amended and restated by
the A&amp;R Yorkville Purchase Agreement dated February&nbsp;8, 2023. Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to $500,000,000 of shares of our Common
Stock, subject to certain limitations and conditions set forth in the A&amp;R Yorkville Purchase Agreement, from time to time during the term of the A&amp;R Yorkville Purchase Agreement. Sales of Common Stock to the Selling Securityholder under the
A&amp;R Yorkville Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. In accordance with our
obligations under the A&amp;R Yorkville Purchase Agreement, we initially filed the registration statement of which this prospectus forms a part with the SEC on November&nbsp;30, 2022 to register under the Securities Act the resale by the Selling
Securityholder of up to 28,078,672 shares of Common Stock, consisting of an aggregate amount of 250,000 Yorkville Commitment Shares and up to 27,828,672 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to the
Selling Securityholder, from time to time under the A&amp;R Yorkville Purchase Agreement. On February&nbsp;16, 2023, we sold 85,000 shares of our Common Stock pursuant to advances under the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock
to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common
Stock, and determinations by us as to the appropriate sources of funding for our company and its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the
A&amp;R Yorkville Purchase Agreement, we may not sell any shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after
giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed 28,078,672 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and
outstanding as of the date of the Original Purchase Agreement, unless (i)&nbsp;we obtain stockholder approval to issue shares of Common Stock in excess of the Yorkville Exchange Cap in accordance with the applicable Nasdaq Listing Rules or
(ii)&nbsp;the average price of all applicable sales of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement equals or exceeds $8.77, which represents the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq
Listing Rules). Moreover, we may not issue or sell any shares of Common Stock to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the
Selling Securityholder and its affiliates (as calculated pursuant to Section&nbsp;13(d) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated thereunder), would result in the Selling Securityholder beneficially
owning shares of Common Stock in excess of the 4.99% Yorkville Beneficial Ownership Limitation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder
may assign or transfer any of our respective rights and obligations under the A&amp;R Yorkville Purchase Agreement, and no provision of the A&amp;R Yorkville Purchase Agreement may be modified or waived by the parties other than by an instrument in
writing signed by both parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds from sales, if any, under the A&amp;R Yorkville Purchase Agreement, will depend on the
frequency and prices at which we sell shares of Common Stock to the Selling Securityholder. To the extent we sell shares under the A&amp;R Yorkville Purchase Agreement, we currently plan to use any proceeds therefrom for working capital and general
corporate purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments,
business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously paid YA Global II SPV, LLC, a subsidiary of the Selling Securityholder, a
structuring fee of $10,000 and issued the Selling Securityholder 250,000 Yorkville Commitment Shares as a commitment fee pursuant to the Original Purchase Agreement. The A&amp;R Yorkville Purchase Agreement contains customary representations,
warranties, conditions, and indemnification obligations of the parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit
of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_21"></A>Advances of
Common Stock Under the A&amp;R Yorkville Purchase Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the right, but not the obligation, from time to time at our
discretion, until the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the registration statement of which this prospectus forms a part was initially declared effective by the SEC
(i.e., on December&nbsp;9, 2020), to direct the Selling Securityholder to purchase up to a specified maximum amount of shares of Common Stock as set forth in the A&amp;R Yorkville Purchase Agreement by delivering written notice to the Selling
Securityholder (each, a &#147;Yorkville Advance Notice&#148;) on any trading day (each, a &#147;Yorkville Advance Notice Date&#148;), so long as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares be issued under any single Yorkville Advance does not exceed 200% of the average of the
daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the Yorkville Advance Notice Date, unless otherwise agreed by the
parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable Yorkville Pricing Period (as defined below) for all prior Yorkville Advances has been completed
and all shares of Common Stock subject to all prior Yorkville Advances have been received by the Selling Securityholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to a Yorkville Advance will be purchased at a
price equal to 98% of the VWAP (as defined below) during the applicable pricing period (each, a &#147;Yorkville Pricing Period&#148;) for such Yorkville Advance, which shall be the period commencing upon receipt by the Selling Securityholder of the
Yorkville Advance Notice (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. &#147;VWAP&#148; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital Market for
such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_22"></A>Conditions to Each Yorkville Advance
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#146;s obligation to accept Yorkville Advance Notices that are timely delivered by us under the A&amp;R
Yorkville Purchase Agreement and to purchase shares of our Common Stock in Yorkville Advances under the A&amp;R Yorkville Purchase Agreement are subject to the satisfaction, at the applicable Yorkville Advance Notice Date, of the conditions
precedent thereto set forth in the A&amp;R Yorkville Purchase Agreement, all of which are entirely outside of the Selling Securityholder&#146;s control, which conditions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy in all material respects of our representations and warranties included in the A&amp;R Yorkville
Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there being an effective registration statement pursuant to which the Selling Securityholder is permitted to
utilize the prospectus thereunder to resell all of the Common Stock that we shall issue and sell to the Selling Securityholder (the &#147;Yorkville Advance Shares&#148;) pursuant to such Yorkville Advance Notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sale and issuance of such Yorkville Advance Shares being legally permitted by all laws and regulations to
which we are subject; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no Material Outside Event (as such term is defined in the A&amp;R Yorkville Purchase Agreement) shall have
occurred and be continuing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">us having performed, satisfied, and complied in all material respects with all covenants, agreements, and
conditions required by the A&amp;R Yorkville Purchase Agreement to be performed, satisfied, or complied with by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no statute, rule, regulation, executive order, decree, ruling, or injunction having been enacted, entered,
promulgated, or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially, and adversely affects any of the transactions contemplated by the A&amp;R Yorkville Purchase Agreement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Common Stock being quoted for trading on Nasdaq and us having not received any written notice that is then
still pending threatening the continued quotation of the Common Stock on Nasdaq. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_23"></A>Termination of the
A&amp;R Yorkville Purchase Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the A&amp;R Yorkville Purchase Agreement, the A&amp;R
Yorkville Purchase Agreement will terminate automatically on the earliest to occur of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the first day of the month following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date
on which the registration statement of which this prospectus forms a part was initially declared effective by the SEC (i.e., December&nbsp;9, 2022); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the Selling Securityholder shall have purchased shares of Common Stock under the A&amp;R
Yorkville Purchase Agreement for an aggregate gross purchase price equal to $500,000,000. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have the right to
terminate the A&amp;R Yorkville Purchase Agreement at any time, at no cost or penalty, upon five trading days&#146; prior written notice to the Selling Securityholder; <I>provided</I> that there are no outstanding Yorkville Advance Notices under
which we are yet to issue Common Stock. We and the Selling Securityholder may also terminate the A&amp;R Yorkville Purchase Agreement at any time by mutual written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_24"></A>No Short-Selling by the Selling Securityholder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales during the term of the A&amp;R Yorkville
Purchase Agreement and will not enter into any transaction that establishes a net short position with respect to the Common Stock, provided that nothing shall restrict the Selling Securityholder from selling a number of shares of Common Stock that
it is obligated to purchase under a pending Yorkville Advance Notice but has not yet received from us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_25"></A>Effect of Sales of
our Common Stock under the A&amp;R Yorkville Purchase Agreement on our Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Common Stock that may be issued or
sold by us to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement that are being registered under the Securities Act for resale by the Selling Securityholder in this offering are expected to be freely tradable. The shares of
Common Stock being registered for resale in this offering may be issued and sold by us to the Selling Securityholder from time to time at our discretion over the term of the A&amp;R Yorkville Purchase Agreement. The resale by the Selling
Securityholder of a significant amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales of
our Common Stock, if any, to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all,
some, or none of the shares of our Common Stock that may be available for us to sell to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement,
the Selling Securityholder may resell all, some, or none of such shares in its discretion and at different prices subject to the terms of the A&amp;R Yorkville Purchase Agreement. As a result, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of
dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of future
sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the A&amp;R Yorkville
Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the
future at a desirable time and price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of
Common Stock that we may elect to sell to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock during the Yorkville Pricing Period, as of the date of this
prospectus we cannot reliably predict the number of shares of Common Stock that we will sell to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, the actual purchase price per share to be paid by the Selling Securityholder
for those shares, or the actual gross proceeds to be raised by us from those sales, if any. As of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus forms a part was initially filed with the SEC), there
were 141,348,856 shares of our Common Stock outstanding, of which 5,622,266 shares were held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates</FONT> (in each case without giving effect to the dividend of 76,000,000 shares of our Common Stock
by Sorrento to certain of its equityholders as described elsewhere in this prospectus and assuming we have not otherwise issued any shares to B. Riley pursuant to the B. Riley Purchase Agreement described elsewhere in this prospectus). If all of the
28,078,672 shares offered for resale by the Selling Securityholder under the registration statement that includes this prospectus were issued and outstanding as of November&nbsp;30, 2022, such shares would have represented approximately 16.6% of the
total number of shares of our Common Stock then outstanding and approximately 83.3% of the total number of then-outstanding shares held <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates</FONT> (without giving effect to the dividend of
76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders as described elsewhere in this prospectus and assuming we have not otherwise issued any shares to B. Riley pursuant to the B. Riley Purchase Agreement described
elsewhere in this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the A&amp;R Yorkville Purchase Agreement provides that we may, in our discretion, from time to
time after the date of this prospectus and during the term of the A&amp;R Yorkville Purchase Agreement, direct the Selling Securityholder to purchase shares of our Common Stock from us in one or more Yorkville Advances under the A&amp;R Yorkville
Purchase Agreement, for a maximum aggregate purchase price of up to $500,000,000, only 28,078,672 shares of Common Stock (250,000 of which represent the aggregate amount of Yorkville Commitment Shares we issued to the Selling Securityholder pursuant
to the Original Purchase Agreement as payment for the Selling Securityholder&#146;s commitment to purchase shares of our Common Stock under the A&amp;R Yorkville Purchase Agreement) are being registered for resale under the registration statement
that includes this prospectus. Assuming all of such 28,078,672 shares were sold to the Selling Securityholder at the maximum 98% discount to the per share price of $8.77 (which represents the lower of the official closing price of our Common Stock
on Nasdaq on November&nbsp;16, 2022, the trading day immediately preceding the date of the Original Purchase Agreement, and the average official closing price of our Common Stock on Nasdaq for the five consecutive trading days ending on
November&nbsp;16, 2022, the trading day immediately preceding the date of the Original Purchase Agreement), such number of shares would be insufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling
Securityholder equal to the Selling Securityholder&#146;s $500,000,000 total aggregate purchase commitment under the A&amp;R Yorkville Purchase Agreement. While the market price of our Common Stock may fluctuate from time to time after the date of
this prospectus and, as a result, the actual purchase price to be paid by the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement for shares of our Common Stock, if any, may also fluctuate, in order for us to receive the full
amount of the Selling Securityholder&#146;s commitment under the A&amp;R Yorkville Purchase Agreement, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that
includes this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder more shares
than are being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the A&amp;R Yorkville Purchase Agreement, we must first (i)&nbsp;to the extent necessary, obtain stockholder approval
prior to issuing shares of the Common Stock in excess of the Yorkville Exchange Cap in accordance with applicable Nasdaq Listing Rules, and (ii)&nbsp;file with the SEC one or more additional registration statements to register under the Securities
Act the resale by the Selling Securityholder of any such additional shares of our Common Stock, which the SEC must declare effective, in each case, before we may elect to sell any additional shares of our Common Stock to the Selling Securityholder
under the A&amp;R Yorkville Purchase Agreement. The number of shares of our Common Stock ultimately offered for resale by the Selling Securityholder depends upon the number of shares of Common Stock, if any, we ultimately sell to the Selling
Securityholder under the A&amp;R Yorkville Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of shares of our Common Stock to the Selling
Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement would not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders would be diluted. Although
the number of shares of our Common Stock that our existing stockholders own would not decrease as a result of sales, if any, under the A&amp;R Yorkville Purchase Agreement, the shares of our Common Stock owned by our existing stockholders would
represent a smaller percentage of our total outstanding shares of our Common Stock after any such issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets
forth the amount of gross proceeds we would receive from the Selling Securityholder from our sale of shares of Common Stock to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement at varying purchase prices: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Assumed</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Average</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Purchase</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Registered</B><br><B>Shares to be<BR>Issued if</B><br><B>Full Purchase<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of<BR>Outstanding<BR>Shares</B><br><B>After Giving<BR>Effect to</B><br><B>the Issuance to<BR>the</B><br><B>Selling<BR>Securityholder<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross Proceeds</B><br><B>from
the</B><br><B>Sale&nbsp;of&nbsp;Shares&nbsp;to&nbsp;the<BR>Selling</B><br><B>Securityholder<BR>Under&nbsp;the&nbsp;A&amp;R&nbsp;Yorkville<BR>Purchase</B><br><B>Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.88</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,666,666.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46.93</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.64 <SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,758,620.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43.21</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,996.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.43</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,995.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,333,333.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.09</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,428,571.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,997.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30.66</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,000,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.77 <SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,012,542.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.74</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">499,999,993.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include the aggregate amount of 250,000 Yorkville Commitment Shares that we issued to the Selling
Securityholder as consideration for its commitment to purchase shares of Common Stock under the A&amp;R Yorkville Purchase Agreement. The number of shares of Common Stock offered by this prospectus may not cover all the shares we ultimately sell to
the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement, depending on the purchase price per share. We have included in this column only those shares being offered for resale by the Selling Securityholder under this prospectus
(excluding the 250,000 Yorkville Commitment Shares), without regard for the Yorkville Beneficial Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future
stock performance. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The denominator is based on 141,348,856 shares outstanding as of November&nbsp;30, 2022 (which denominator
includes the aggregate amount of 250,000 Yorkville Commitment Shares we issued to the Selling Securityholder), adjusted to include the issuance of the number of shares set forth in the second column that we would have sold to the Selling
Securityholder, assuming the average purchase price in the first column. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
The numerator is based on the number of shares of Common Stock set forth in the second column. As this information speaks as of November&nbsp;30, 2022 (the date on which the registration
statement of which this prospectus forms a part was initially filed with the SEC) and is intended to reflect only the impact of this offering assuming the sale of all shares being offered for resale under this prospectus, it does not take into
account any shares of Common Stock actually sold by us to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement or to B. Riley under the B. Riley Purchase Agreement following such date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the closing price of the Common Stock on Nasdaq on November&nbsp;29, 2022, the trading day prior to
the initial filing of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the average Nasdaq Official Closing Price for the five trading days immediately preceding the date
of the Original Purchase Agreement on November&nbsp;16, 2022, the trading day prior to execution of the Original Purchase Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_26"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from
third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this
prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the
information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#147;<I>Risk
Factors</I>&#148;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_27"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Common Stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the Selling
Securityholder for its own account. We will not receive any of the direct proceeds from these sales. However, we may receive up to $500,000,000 aggregate gross proceeds from any sales we make to the Selling Securityholder pursuant to the A&amp;R
Yorkville Purchase Agreement. The net proceeds from sales, if any, under the A&amp;R Yorkville Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this
prospectus. See the section of this prospectus titled &#147;<I>Plan of Distribution</I>&#148; elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the net proceeds that we receive under the A&amp;R Yorkville Purchase Agreement for working capital and general corporate
purposes, which may include capital expenditures, commercialization expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business
combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of
the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these
proceeds. Pending our use of the net proceeds as described above, we intend to invest the net proceeds pursuant to the A&amp;R Yorkville Purchase Agreement in interest-bearing instruments. Our expected use of the net proceeds from this offering
represents our current intentions based upon our present plans and business condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is difficult to predict our liquidity
requirements, we anticipate that we will continue to incur net losses into the foreseeable future as we support our commercialization activities, clinical development to expand approved indications, continue our development of, and seek regulatory
approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the consolidated
financial statements are issued. See Note 2 titled &#147;<I>Liquidity and Going Concern</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to
those uses, for any net proceeds we receive. The costs and timing of development activities, particularly conducting clinical trials and preclinical studies, are highly uncertain, subject to substantial risks and can often change. Due to the many
variables inherent to the development of our drug candidates, we cannot currently predict the stage of development we expect the net proceeds of this offering to achieve for our clinical trials, preclinical studies and drug candidates. Accordingly,
we will retain broad discretion over the use of these proceeds. For example, if we identify opportunities that we believe are in the best interests of our stockholders, we may use a portion of the net proceeds from this offering to acquire, invest
in or license complementary products, technologies or businesses, although we have no current understandings, agreements or commitments to do so. In addition, the amounts and timing of our actual expenditures will depend upon numerous factors,
including the results of our research and development efforts, the timing and success of preclinical studies, our ongoing clinical trials or clinical trials we may commence in the future and the timing of regulatory submissions. Depending on the
outcome of these activities and other unforeseen events, our plans and priorities may change and we may apply the net proceeds of this offering toward different uses and in different proportions than we currently anticipate. Pending our use of the
net proceeds as described above, we intend to invest the net proceeds from this offering in interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_28"></A>DETERMINATION OF OFFERING PRICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Securityholder under this
prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_29"></A>MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_30"></A>Market Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW,&#148; respectively.
Prior to the consummation of the Business Combination, Vickers&#146;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#147;VCKA,&#148; &#147;VCKAU&#148; and &#147;VCKAW,&#148; respectively. At the Effective Time,
without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase
one share of Common Stock. As of March&nbsp;6, 2023, there were 313 holders of record of our Common Stock and two holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners
holding shares through nominee names. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_31"></A>Dividend Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if
any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our
business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other
obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or
our subsidiaries incur. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_32"></A>Securities Authorized for Issuance under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Equity Incentive Plan and the ESPP were the only compensation plans under which securities of the Company
were authorized for future grants. Each of the&nbsp;Equity Incentive Plan and the ESPP were approved by our stockholders. In March 2019, the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;), which was
adopted by the board of directors and stockholders of Scilex Pharma on June&nbsp;26, 2017, as amended and restated on July&nbsp;5, 2018, terminated in connection with a corporate reorganization that was effected in March 2019. However, the Scilex
Pharma 2017 Plan continues to govern awards outstanding thereunder. Additionally, the 2019 Stock Option Plan, which was adopted by the board of directors and stockholders of Legacy Scilex on May&nbsp;28, 2019 and June&nbsp;24, 2019, respectively, as
amended on December&nbsp;21, 2020, terminated at the Closing of the Business Combination. However, the 2019 Stock Option Plan continues to govern awards outstanding thereunder. On January&nbsp;17, 2023, the Compensation Committee adopted the
Inducement Plan. The Inducement Plan has not been approved by our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information as of December&nbsp;31, 2022 with respect to the
Company&#146;s existing and predecessor plans, excluding the Inducement Plan which was adopted after December&nbsp;31, 2022. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(a)<BR>Number of<BR>Securities&nbsp;to&nbsp;be&nbsp;Issued<BR>Upon Exercise of<BR>Outstanding Options,<BR>Warrants and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b)<BR>Weighted-<BR>Average<BR>Exercise<BR>Price of<BR>Outstanding<BR>Options,<BR>Warrants<BR>and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(c)<BR>Number of<BR>Securities<BR>Remaining<BR>Available for<BR>Future Issuance<BR>Under
Equity<BR>Compensation<BR>Plans&nbsp;(Excluding<BR>Securities<BR>Reflected in<BR>Column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by
stockholders<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,084,983</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,084,983</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the following plans: the Equity Incentive Plan, the ESPP, the Scilex Pharma 2017 Plan and the 2019
Stock Option Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount is based on the weighted-average exercise price of vested and unvested stock options outstanding under
the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, a total of 14,622,712 shares of our Common Stock were reserved for future
issuance pursuant to the Equity Incentive Plan, which number excludes (x) 16,195,178 shares subject to outstanding awards granted under the 2019 Stock Option Plan reflected in column (a)&nbsp;above that, following the effective date of the Equity
Incentive Plan return to the Equity Incentive Plan under the circumstances described therein and (y)&nbsp;the 5,653,954 shares that were added to the Equity Incentive Plan as a result of the automatic annual increase on January&nbsp;1, 2023. The
Equity Incentive Plan provides that the number of shares of our Common Stock reserved and available for issuance under the Equity Incentive Plan will automatically increase on January&nbsp;1 of each year for a period of ten years, beginning on
January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (A) 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year,
(B)&nbsp;7,311,356 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (C)&nbsp;such number of shares of our Common Stock determined by our Board or our
Compensation Committee prior to January&nbsp;1 of a given year. All of the foregoing share numbers are subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. Shares subject to awards granted under
the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the
number of shares available for issuance under the Equity Incentive Plan. Shares of our Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the
number of shares available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of our Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the
number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or
condition required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or
repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. The Company no longer makes grants under the Scilex Pharma 2017 Plan or the 2019 Stock Option Plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, a total of 1,462,271 shares of our Common Stock have been reserved for issuance
pursuant to the ESPP, which number excludes the 1,413,488 shares that were added to the ESPP as a result of the automatic annual increase on January&nbsp;1, 2023. The ESPP provides that the number of shares of our Common Stock reserved and available
for issuance under the ESPP will automatically increase on January&nbsp;1 of each year for a period of up to ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (A) 1%
of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar year; (B) 1,827,839 shares of our Common Stock (subject to the adjustment for recapitalizations, stock splits, stock dividends
and similar transactions); and (C)&nbsp;such number of shares of our Common Stock determined by our Board or our Compensation Committee prior to January&nbsp;1 of a given year, provided however, that our Board may act prior to January&nbsp;1 of a
given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (A)&nbsp;to (C) above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_33"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations
should be read together with the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve
risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and
elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#147;Risk Factors&#148; and &#147;Cautionary Note Regarding Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_34"></A>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are an innovative revenue-generating company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. We believe that our innovative <FONT
STYLE="white-space:nowrap">non-opioid</FONT> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#146; lives. We target indications with high unmet needs and large
market opportunities with <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product
in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve
pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period. We market ZTlido through a dedicated sales force of <FONT STYLE="white-space:nowrap">60-70</FONT> sales representatives, targeting 10,000 primary care physicians, pain specialists,
neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (&#147;SEMDEXA&#148;)
(10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica,
<FONT STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of acute LBP, and
<FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules), a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release
naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. SEMDEXA has been granted fast track designation
by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> alternative to <FONT STYLE="white-space:nowrap">off-label</FONT> ESIs, which are administered over 12&nbsp;million times annually in the United
States. <FONT STYLE="white-space:nowrap">Top-line</FONT> results from the completed Phase 3 study have been received in November 2021 and reflected achievement of primary and secondary endpoints. <FONT STYLE="white-space:nowrap">SP-103</FONT> has
also been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP.
<FONT STYLE="white-space:nowrap">SP-103</FONT> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold higher than any lidocaine topical product that we are aware of, either approved or in development. We are
examining <FONT STYLE="white-space:nowrap">SP-103</FONT> as a treatment for acute LBP, a condition with high unmet need which, as of 2019, affected over 22&nbsp;million patients in the United States. According to the CDC in 2020, LBP was the most
common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of <FONT STYLE="white-space:nowrap">SP-103</FONT> in acute LBP in the second quarter of our fiscal year 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We obtain
our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased
and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April&nbsp;2, 2022, we announced the expansion of our direct distribution network to national and regional
wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our
inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. We acquired Semnur and its lead product candidate, SEMDEXA, in
the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development
of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <FONT STYLE="white-space:nowrap">SP-103.</FONT> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our
product, ZTlido, and the development of our product candidates. For the years ended December&nbsp;31, 2022, 2021, and 2020, we had a net loss of $23.4&nbsp;million and $88.4&nbsp;million, and $47.5&nbsp;million respectively. As of December&nbsp;31,
2022, we had an accumulated deficit of approximately $375.9&nbsp;million. As of December&nbsp;31, 2022, we had cash and cash equivalents of approximately $2.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of
ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> (acquired from
Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a
combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at
all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_35"></A>Business Combination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, we consummated the previously announced Business Combination pursuant to the Agreement and Plan of Merger, dated as
of March&nbsp;17, 2022 (as amended by Amendment No.&nbsp;1 to Agreement and Plan of Merger, dated September&nbsp;12, 2022, together, the &#147;Merger Agreement&#148;), by and among Vickers, Vantage Merger Sub Inc. (&#147;Merger Sub&#148;), a wholly
owned subsidiary of Vickers and Legacy Scilex. Pursuant to the terms of the Merger Agreement, a business combination (herein referred to as the &#147;Business Combination&#148; or &#147;reverse recapitalization&#148; for accounting purposes) between
Vickers and Legacy Scilex was effected through the merger of Merger Sub with and into Legacy Scilex with Legacy Scilex surviving the merger as Vickers&#146;s wholly owned subsidiary. In connection with the Business Combination, Vickers changed its
name from Vickers Vantage Corp. I to Scilex Holding Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the Business Combination, New Scilex (as defined below)
received net proceeds of approximately $3.4&nbsp;million. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;), and Sorrento, totaling $290.6&nbsp;million,
was converted into equity interests in New Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Contribution and Satisfaction of Indebtedness Agreement, dated as of September&nbsp;12, 2022, by and
among Sorrento, Legacy Scilex and Scilex Pharma (the &#147;Debt Exchange Agreement&#148;) (see Note 12 titled &#147;<I>Related Party Transactions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional
information). The Company operates as &#147;Scilex Holding Company&#148; and was listed on the Nasdaq Capital Market under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022. Scilex Holding Company following the completion of the
Business Combination is sometimes referred to herein as &#147;New Scilex&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization in accordance with
U.S. GAAP. Under this method of accounting, Vickers was treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination was treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers,
accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_36">
</A>Recent Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>February 2023 Preliminary Unaudited Financial Results </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2023, we filed a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> providing certain preliminary unaudited
financial results for the one month ended February&nbsp;28, 2023, and as of February&nbsp;28, 2023, based on then currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial results. Our
actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our
review of these preliminary financial results for the one month ended February&nbsp;28, 2023, and as of February&nbsp;28, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such
Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> we estimated that: ZTlido gross sales for February 2023 were in the range of $8.6&nbsp;million to $8.8&nbsp;million, compared to $5.1&nbsp;million in February 2022, representing
growth in the range of 68% to 72%; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2023 gross sales were in the range of $16.7&nbsp;million to $17.3&nbsp;million, compared to $10.3&nbsp;million
for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2022, representing growth in the range of 62% to 68%; net sales for February 2023 were in the range of $3.3&nbsp;million to $3.5&nbsp;million,
compared to net sales of $2.0&nbsp;million in February 2022, representing growth in the range of 65% to 75%; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2023 net sales were in the range of
$6.6&nbsp;million to $7.0&nbsp;million, compared to $4.1&nbsp;million for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-date</FONT></FONT> February 2022, representing growth in the range of 61% to 70%. Historically, sales
for ZTlido are low during the first quarter of the year due to deductibles with managed healthcare plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elyxyb License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. (&#147;BSDI&#148;) and Collegium Pharmaceutical, Inc.
(&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to
ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) (the &#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the Company assumed various rights and obligations under that certain asset purchase agreement, dated
August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free,
exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the Product in the Territory. Additionally, under the Purchase Agreement, the Collegium Sellers granted
the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to exploit the Product in the Territory. No cash consideration was or will be payable to the
Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties to DRL for sales of the Product in the Territory for all indications and additional amounts if
certain milestones are achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2023, we entered into the B. Riley Purchase Agreement with a wholly-owned subsidiary of B. Riley Principal Investments, LLC
(&#147;B. Riley&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we have the right, but not the obligation, to sell to B. Riley up to
$500,000,000 of shares of Common Stock, from time to time at our sole and absolute discretion (each such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale, a &#147;B. Riley Advance&#148;) at any time during the 36 months following the date on which the B. Riley Registration Statement (as defined below) was initially declared effective by the
SEC, subject to the terms of the B. Riley Purchase Agreement. To request a B. Riley Advance, we would submit an advance notice to B. Riley (each, a &#147;B. Riley Advance Notice&#148;) specifying the number of shares we intend to sell to B. Riley.
The registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-269205)</FONT> related to the B. Riley Purchase Agreement was initially filed with the SEC on January&nbsp;12, 2023
and was initially declared effective by the SEC on January&nbsp;20, 2023 (as it may be amended or supplemented from time to time, the &#147;B. Riley Registration Statement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to B. Riley pursuant to a B. Riley Advance will be purchased at a price equal to 98%
of the VWAP (as defined below) during the period (such period, the &#147;B. Riley Pricing Period&#148;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of shares of Common Stock (the &#147;B. Riley Advance Shares&#148;) or
such later time publicly announced as the official open of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date (the &#147;Purchase Commencement Time&#148;) and ending at the earliest of (i) 3:59 p.m., New York City
Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#147;regular&#148;) trading session on Nasdaq on such purchase date, (ii)&nbsp;immediately at such time following the Purchase Commencement
Time for such purchase that the total number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&nbsp;if we so elect in the applicable
B. Riley Advance Notice for such B. Riley Advance (such election, a &#147;Limit Order Discontinue Election&#148;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such B. Riley Pricing Period is less
than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#147;VWAP&#148; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on the
Nasdaq Capital Market for such period as reported by Bloomberg through its &#147;AOR&#148; function, subject to certain exceptions, qualifications and limitations. &#147;Advance Share Volume Maximum&#148; means, with respect to a B. Riley Advance,
if such B. Riley Advance is designated in the B. Riley Advance Notice as a (i)&nbsp;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share amount to be purchased by
B. Riley, by (b) 0.10, or (ii)&nbsp;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&nbsp;the B. Riley Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to
certain adjustments). We may also specify a certain minimum acceptable price per share in each B. Riley Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no
mandatory minimum amount for any B. Riley Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, a B. Riley Advance may be for a number of shares of Common Stock not to exceed (i)&nbsp;with respect to a B. Riley Advance,
purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&nbsp;the product of (1) 0.10, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital
Market during the B. Riley Pricing Period for such purchase-Type A, and (ii)&nbsp;with respect to a B. Riley Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&nbsp;the product of
(1) 0.25, multiplied by (2)&nbsp;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the B. Riley Pricing Period for such purchase-Type B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to B. Riley, from time to time subject
to certain limitations, at our sole and absolute discretion an additional B. Riley Advance Notice (each, a &#147;B. Riley Additional Advance&#148;). To request an additional purchase, we would submit an additional B. Riley Advance Notice to B. Riley
specifying the number of shares we intend to sell to B. Riley. The purpose of the B. Riley Additional Advance is to allow us to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the
terms of the B. Riley Purchase Agreement. Each B. Riley Additional Advance is generally subject to terms and conditions consistent with those of a B. Riley Advance, except for, among other things, the time period of the pricing period for such B.
Riley Additional Advance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also specify a certain minimum acceptable price per share in each B. Riley Advance or B. Riley
Additional Advance. In no event is B. Riley obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable Nasdaq Listing Rules, in no event will we issue to B. Riley shares that, in the aggregate, would exceed the 19.9% B. Riley Exchange Cap, unless we have received stockholder approval
for such issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Riley&#146;s obligation to purchase
shares of Common Stock pursuant to the B. Riley Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the B. Riley Commitment Shares and the shares to be
issued pursuant to any B. Riley Advance or B. Riley Additional Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for B. Riley&#146;s commitment to purchase shares of Common Stock
at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued to B. Riley 250,000 shares of Common Stock. Subsequent to the execution of the B. Riley Purchase Agreement on January&nbsp;8, 2023
and through March&nbsp;3, 2023, the last date on which we sold shares of Common Stock thereunder (prior to the filing of the registration statement of which this prospectus forms a part), the Company sold an aggregate of 127,241 shares of Common
Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $1.0&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Yorkville Purchase
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;17, 2022, we entered into that certain Standby Equity Purchase Agreement (the &#147;Original Purchase
Agreement&#148;) with YA II, PN LTD (&#147;Yorkville&#148; or the &#147;Selling Securityholder&#148;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. On February&nbsp;8, 2023, we entered into
an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), amending, restating and superseding the Original Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to Yorkville up to $500,000,000 of
shares of Common Stock, from time to time at our sole and absolute discretion (each such sale, a &#147;Yorkville Advance&#148;) by delivering written notice to Yorkville (each, a &#147;Yorkville Advance Notice&#148;) until the first day of the month
following the <FONT STYLE="white-space:nowrap">36-month</FONT> anniversary of the date on which the registreation statement of which this prospectus forms a part was initially declared effective by the SEC (i.e., December&nbsp;9, 2022). In
accordance with our obligations under the Original Purchase Agreement, we initially filed the registration statement of which this prospectus forms a part with the SEC on November&nbsp;30, 2022 to register under the Securities Act the resale by
Yorkville of up to 28,078,672 shares of Common Stock, consisting of an aggregate amount of 250,000 Yorkville Commitment Shares and up to 27,828,672 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to Yorkville,
from time to time under the A&amp;R Yorkville Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock purchased pursuant to a Yorkville Advance
will be purchased at a price equal to 98% of the VWAP (as defined below) during the applicable pricing period (each, a &#147;Yorkville Pricing Period&#148;) for such Yorkville Advance, which shall be the period commencing upon receipt by Yorkville
of the Yorkville Advance Notice (or the open of regular trading hours, if later) and ending on 4:00 p.m. on the same day. &#147;VWAP&#148; means, for a specified period, the volume weighted average price of the Common Stock on the Nasdaq Capital
Market for such period as reported by Bloomberg L.P. through its &#147;AQR&#148; function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Yorkville Advance may be for a number of
shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the
date of the Yorkville Advance Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville&#146;s purchase of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement
would be subject to certain limitations, including that Yorkville may not purchase shares that would result in it (together with its affiliates) owning more than 4.99% of the outstanding voting power or number of shares of Common Stock after such
purchase or that would result in it owning more than 19.9% of the Company&#146;s aggregate amount of Common Stock issued and outstanding as of the date of the Original Purchase Agreement (the &#147;Yorkville
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Exchange Cap&#148;). The Yorkville Exchange Cap will not apply under certain circumstances, including if the average price of all applicable sales of Common Stock under the A&amp;R Yorkville
Purchase Agreement equals or exceeds a certain minimum price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously paid Yorkville a structuring fee of $10,000 and issued
250,000 shares of Common Stock to Yorkville as a commitment fee pursuant to the Original Purchase Agreement (the &#147;Yorkville Commitment Shares&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville&#146;s obligation to purchase shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement is subject to a number of
conditions, including that a registration statement be filed with the SEC registering the resale of the Yorkville Commitment Shares and the shares to be issued pursuant to any Yorkville Advance under the Securities Act, and that such registration
statement is declared effective by the SEC. Pursuant to the terms of the Original Purchase Agreement, the Company previously filed the registration statement of which this prospectus forms a part with the SEC on November&nbsp;30, 2022, which was
initially declared effective by the SEC on December&nbsp;9, 2022. During the year ended December&nbsp;31, 2022, no Yorkville Advances were requested or completed under the A&amp;R Yorkville Purchase Agreement. Subsequent to December&nbsp;31, 2022,
the Company sold 85,000 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for aggregate net proceeds to the Company of approximately $0.6&nbsp;million on February&nbsp;16, 2023. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_37"></A>Impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are closely monitoring the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and its potential impact on our business. In an effort
to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee
travel restrictions. The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with
confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of
actions taken in the United States and other countries to contain and treat the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_38"></A>Comparability of Our Results and
Our Relationship with Sorrento </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our consolidated
financial statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. In particular, certain legal, finance, human resources and
other functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup. We expect that Sorrento may continue to provide us with some of the services related to these functions on a transitional basis in exchange for
agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs
related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an
enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_39"></A>Sorrento
Chapter 11 Filing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals,
Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in
Sorrento&#146;s voluntary Chapter 11 filing. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved. The Company will
evaluate the collectability of this receivable on a quarterly basis going forward.<B><I> </I></B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_40"></A>Components of Our Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists
solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales adjustments for government and commercial rebates,
chargebacks, wholesaler and distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for
our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Costs and Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost
of Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists of the cost of purchasing ZTlido from our manufacturing partners, inventory write-downs related to
expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory, cost of shipments, and royalty payments to our manufacturers. We expect the cost of revenue to fluctuate with related sales revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and
development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in
research and development functions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to outside consultants. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that
are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly,
we expect to incur significant research and development expenses in connection with our Phase 3 clinical trial for SEMDEXA, our ongoing Phase 2 clinical trials for <FONT STYLE="white-space:nowrap">SP-103,</FONT> and initiation of Phase 2 trials for <FONT
STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs,
including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent,
accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies
to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and
listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our
administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Amortization Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the
estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss on Derivative Liability
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability consists of the changes to fair value of derivative liabilities between reporting periods relating
to certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 7 titled &#147;Debt&#148; and Note 12 titled &#147;Related Party Transactions&#148; to our consolidated financial statements
appearing elsewhere in this prospectus for a description of the Scilex Pharma Notes. Gain on derivative liability also included the remeasurement of the warrant derivative liability. See Note 4 titled &#147;<I>Fair Value Measurements</I>&#148; to
our consolidated financial statements appearing elsewhere in the prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss on Debt Extinguishment, Net </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment rights,
which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December&nbsp;31, 2021, by a gain on debt extinguishment as a result
of the forgiveness of the loan in the amount of $1.6&nbsp;million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#147;PPP Loan&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense
consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Loss (gain) on Foreign Currency Exchange </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu Chemical Frontier
Corporation (&#147;Itochu&#148;), a manufacturer and supplier of lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_41"></A>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&nbsp;31, 2022 and 2021 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands, except for per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating costs and expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other (income) expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Loss) gain on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other (income) expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial information and discussions pertaining to the year ended December&nbsp;31, 2020, refer to the
initial filing of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> of which this prospectus forms a part, which was initially filed on November&nbsp;30,
2022 and initially declared effective by the SEC on December&nbsp;9, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_42"></A>Comparison of Years Ended December&nbsp;31, 2022
and 2021 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue
for the years ended December&nbsp;31, 2022 and 2021 was $38.0&nbsp;million and $31.3&nbsp;million, respectively. The increase of $6.7&nbsp;million was driven by the increased volume of gross product sales of ZTlido by approximately 50% offset by
increase in rebates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost of Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&nbsp;31, 2022 and 2021 was $10.8&nbsp;million and $3.6&nbsp;million, respectively, and relates to
product sales. The increase of $7.2&nbsp;million was primarily due to an approximately 50% increase in gross revenue for the years ended December&nbsp;31, 2022 compared to the year ended December&nbsp;31, 2021, royalty expense of $4.5&nbsp;million
beginning in the second quarter of 2022, and the sale of $0.5&nbsp;million of fully reserved inventory in May 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expenses
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&nbsp;31, 2022 and 2021 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase<BR>(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-102</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,464</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-102</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-103</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-103</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SP-104</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">SP-104</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GLOPERBA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total GLOPERBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2022 and 2021 were $9.1&nbsp;million
and $9.2&nbsp;million, respectively. The $0.1&nbsp;million decrease was primarily attributed to the phasing out of the Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> trial in 2022, and was partially offset by the clinical trial costs of
Phase 2 <FONT STYLE="white-space:nowrap">SP-103</FONT> in 2022, the Phase 1 <FONT STYLE="white-space:nowrap">SP-104</FONT> study in the first two quarters of 2022, and the development costs for GLOPERBA in the last quarter of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Selling, General and Administrative Expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&nbsp;31, 2022 and 2021 were $64.9million and $50.6&nbsp;million,
respectively. The increase of approximately $14.3&nbsp;million was primarily due to a $7.5&nbsp;million increase in legal expenses related to the ZTlido patent infringement in which the Company was the plaintiff, $1.1&nbsp;million increase in travel
and entertainment expenses, $3.1&nbsp;million increase in consulting expenses, $2.1&nbsp;million increase in insurance expense related to a directors and officers (D&amp;O) insurance policy incurred after the Business Combination, $0.6&nbsp;million
increase in personnel expense, and a $1.8&nbsp;million increase related to a related party receivable reserve, offset by a $0.4&nbsp;million decrease in contracted services, $1.2&nbsp;million decrease in marketing expense, and a $0.3&nbsp;million
decrease in other expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intangible Amortization Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the years ended December&nbsp;31, 2022 and 2021 was $3.9&nbsp;million and $3.7&nbsp;million,
respectively. The increase of $0.2&nbsp;million is related to the amortization of acquired licenses for the exclusive license of GLOPERBA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss
on Derivative Liability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&nbsp;31, 2022 and 2021 was $(8.3) million and
$0.3&nbsp;million, respectively. The gain and loss recognized during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to
revised sales forecasts and the derivative warrant liability associated with the Private Warrants assumed in the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(Gain) Loss on
Debt Extinguishment, Net </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net for the years ended December&nbsp;31, 2022 and 2021 was $(28.6)
million and $12.5&nbsp;million, respectively. The gain and loss incurred during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to Scilex Pharma&#146;s repurchase of the Scilex Pharma Notes of $20.0&nbsp;million and
$41.4&nbsp;million in February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7&nbsp;million in September 2022 (see Note 7 titled &#147;<I>Debt</I>&#148; to our consolidated financial statements included elsewhere in
this prospectus for additional information) and $20.0&nbsp;million in each of February 2021 and April 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&nbsp;31, 2022 and 2021 was $9.6&nbsp;million and $11.8&nbsp;million, respectively. The decrease
recognized during the years ended December&nbsp;31, 2022 and 2021, respectively, was attributed to the payment of Scilex Pharma Notes in September 2022 and the conversion of related party notes payable with Sorrento that was outstanding as of the
closing of the Business Combination into shares of Preferred Stock and Common Stock pursuant to the Debt Exchange Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Tax Expense
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense for the years ended December&nbsp;31, 2022 and 2021 was $4&nbsp;thousand and $5&nbsp;thousand, respectively. The
lower income tax expense during the year ended December&nbsp;
31, 2022 was primarily due to an increase in share-based compensation tax benefits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_43"></A>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had cash and cash equivalents of approximately $2.2&nbsp;million. In connection with the completion of the
Business Combination, we received approximately $3.4&nbsp;million from the balance of the Vickers&#146;s Trust Account (the &#147;Trust Account&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020
revolving credit facility. We also have deferred consideration related to the GLOPERBA license acquired in 2022. The following table summarizes the aggregate indebtedness of these issuances as of December&nbsp;31, 2022 and December&nbsp;31, 2021 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes with Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Revolving Credit Facility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Scilex Pharma Notes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the irrevocable standby letter of credit, issued by
Sorrento to Scilex Pharma (the &#147;Letter of Credit&#148;), as required under the terms of the Indenture (as defined below) as a result of actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes (as defined below)
through December&nbsp;31, 2021 being less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT>
amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $10.0&nbsp;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount
equal to $20.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No.&nbsp;4 with
U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Agent&#148;), and the beneficial owners of those certain senior secured
notes due 2026 issued by Scilex Pharma in September 2018 (the &#147;Scilex Pharma Notes&#148;) listed on the signature pages thereto (the &#147;Holders&#148;), which amended that certain Indenture, dated September&nbsp;7, 2018, by and among Scilex
Pharma, Sorrento, the Trustee and the Agent, as amended (the &#147;Indenture&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amendment to the Indenture
(1)&nbsp;on June&nbsp;3, 2022, Scilex Pharma repurchased $41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof, (2)&nbsp;the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for
$41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex Pharma Notes, (3)&nbsp;the minimum cash
requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&nbsp;the maximum aggregate principal amount of that certain intercompany promissory note issued by
Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August
2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million. On September&nbsp;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As
of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&nbsp;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&nbsp;million as the
holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&nbsp;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. See Note 7 titled &#147;<I>Debt</I>&#148; to our consolidated financial
statements elsewhere in this prospectus for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarterly principal payments, based on a percentage of projected net
sales of ZTlido, optional and contingently accelerated repurchases, and the Early Paydown Provision under the Scilex Pharma Notes since January&nbsp;1, 2021 are as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Three Months Ended,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Principal<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2021*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2022*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments since January&nbsp;1, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">151,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes repurchase or Early Paydown Provision during the period (see Note 7 titled &#147;<I>Debt</I>&#148; to
our consolidated financial statements elsewhere in this prospectus). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Deferred Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $3.7&nbsp;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of
consideration transferred for the GLOPERBA license (see Note 3 titled &#147;<I>Acquisitions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred consideration minimum royalty
payments begin the first full quarter following June&nbsp;14, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other contractual obligations include the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Royalties </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex Pharma is a
party to the Product Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex
Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December&nbsp;31, 2022, Scilex Pharma made royalty payments in the amount of $2.3&nbsp;million. As of
December&nbsp;31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Scilex Pharma is in a net profit position, as defined in the Product
Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may seek to raise additional funds through equity offerings, debt
financings, collaborations, government contracts or other strategic transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingent Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $280.0&nbsp;million, $13.0&nbsp;million, and $23.0&nbsp;million in aggregate contingent consideration obligations in connection with
the SEMDEXA, GLOPERBA, and <FONT STYLE="white-space:nowrap">SP-104</FONT> acquisitions (see Note 3 titled &#147;<I>Acquisitions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information),
respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the
achievement of certain amounts of net sales (see Note 3 titled &#147;<I>Acquisitions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Standby Equity Purchase Agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;8, 2023, we entered into the A&amp;R Yorkville Purchase Agreement with Yorkville, whereby we have the right, but not the obligation, to sell to Yorkville up to $500.0&nbsp;million of shares of Common Stock at our request during the 36
months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed
with the SEC in connection with the Original Purchase Agreement was initially declared effective by the SEC on December&nbsp;9, 2022 and we are now able to offer and sell shares of our Common Stock under that agreement, subject to the limitations
set forth therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2023, we entered into the B. Riley Purchase Agreement with B. Riley, whereby we have the right, but
not the obligation, to sell to B. Riley up to $500.0&nbsp;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable
pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the B. Riley Purchase Agreement was initially declared effective by the SEC on January&nbsp;20,
2023 and we are now able to offer and sell shares of our Common Stock under that agreement, subject to the limitations set forth therein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Future
Liquidity Needs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may
use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the degree of success we experience in commercializing ZTlido and GLOPERBA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates,
SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current
or future collaboration or license agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is
adopted by the physician community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to expand our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing products and product candidates and other market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and types of future products we develop and commercialize; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any product liability or other lawsuits related to our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses needed to attract, hire and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need to implement additional internal systems and infrastructure, including financial and reporting systems;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending
intellectual property-related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent and scope of our general and administrative expenses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA and other product candidates not materialize at the anticipated rate contemplated in our business plan,
we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise
additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the A&amp;R Yorkville Purchase Agreement and the
B. Riley Purchase Agreement. The registration statements filed with the SEC in connection with the Original Purchase Agreement and the B. Riley Purchase Agreement were initially declared effective by the SEC on December&nbsp;9, 2022 and
January&nbsp;20, 2023, respectively, and we are now able to offer and sell shares of our Common Stock under both agreements (subject to the limitations set forth therein), which will provide us with an additional source of liquidity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue generating products, Yorkville Advances under the A&amp;R Yorkville Purchase Agreement and B.
Riley Advances and B. Riley Additional Advances under the B. Riley Purchase Agreement, we will receive up to an aggregate of approximately $126.5&nbsp;million from the exercise of the Warrants (at an exercise price of $11.50 per share of Common
Stock), assuming the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds will depend on the market
price of our Common Stock. If the price of our Common Stock falls and remains below $11.50 per share, we believe warrant holders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities held by Sorrento and the Sponsors that were previously registered for resale on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268603)</FONT> filed with the SEC on November&nbsp;30, 2022, which was initially declared effective by the SEC on December&nbsp;27, 2022 represent a
significant percentage of our outstanding Common Stock. As the restrictions on resale end, the Sponsors and Sorrento (who holds 66,476,412 shares of our Common Stock representing approximately 44% of the shares of our Common Stock outstanding as of
March&nbsp;6, 2023 (assuming the full exercise of all outstanding Warrants held by Sorrento and the Sponsors)) are able to sell all of the shares of our Common Stock and any Warrants registered for resale thereunder for so long as such registration
statement is available for use. The sale, or indication of an intention to sell, substantial amounts of our Common Stock or Warrants could result in a significant decline in the public trading price of our securities
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and impair our ability to raise capital through the sale of additional equity securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the
units were issued in Vickers&#146;s IPO, the Sponsors and Sorrento may have an incentive to sell because they will still profit on sales due to the lower price at which they purchased their shares compared to the public stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all,
or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by
issuing equity or convertible debt securities, including pursuant to the A&amp;R Yorkville Purchase Agreement and the B. Riley Purchase Agreement, it could result in dilution to our existing stockholders or increased fixed payment obligations. In
addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would
restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our
product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts
or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not
limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <FONT STYLE="white-space:nowrap">SP-102,</FONT>
<FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide
us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate
that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our
corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled
&#147;<I>Liquidity and Going Concern</I>&#148; to our consolidated financial statements included elsewhere in this prospectus for additional information. Net proceeds from the Trust Account in connection with the Business Combination, together with
our existing cash and cash equivalents and proceeds from any Yorkville Advances made under the A&amp;R Yorkville Purchase Agreement or any B. Riley Advances or B. Riley Additional Advances made under the B. Riley Purchase Agreement, may be
insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through
equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used for) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For financial information and discussions pertaining to the year ended December&nbsp;31, 2020, refer to the
initial filing of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> of which this prospectus forms a part, which was initially filed with the SEC on
November&nbsp;30, 2022 and initially declared effective by the SEC on December&nbsp;9, 2022. <B><I> </I></B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Operating Activities
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, net cash used for operating activities was approximately $21.3&nbsp;million, primarily from
our net loss of $23.4&nbsp;million, other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of $43.6&nbsp;million related to depreciation and amortization, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT>
operating lease cost, <FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on
derivative liabilities and offset by changes in operating assets and liabilities that provided $45.7million of cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2021, net cash used for operating activities was approximately $28.7&nbsp;million, primarily from our net loss of $88.4&nbsp;million offset by other <FONT STYLE="white-space:nowrap">non-cash</FONT> reconciling items of
$46.1&nbsp;million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, <FONT STYLE="white-space:nowrap">non-cash</FONT> operating lease cost,
<FONT STYLE="white-space:nowrap">non-cash</FONT> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss on debt extinguishment, and a loss on derivative liabilities,
and by changes in operating assets and liabilities that provided $13.6&nbsp;million of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2022, net cash used for investing activities was approximately $2.1&nbsp;million attributed to cash paid
for the acquisition of GLOPERBA licenses from Romeg and $7.0&nbsp;thousand attributed to cash paid for property and equipment purchases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, no cash was used for investing activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash Flows from Financing Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
the year ended December&nbsp;31, 2022, net cash provided by financing activities was approximately $21.2&nbsp;million and is primarily related to $51.9&nbsp;million in proceeds from related party payables, $62.5&nbsp;million in proceeds from related
party note payables, $9.9&nbsp;million in proceeds from the CNH Revolving loan, $96.0&nbsp;thousand in proceeds from the exercise of stock options, and $3.4&nbsp;million in proceeds from the Business Combination, offset by $18.8&nbsp;million
repayment on CNH Revolving Loan, $84.8&nbsp;million repayment of the Scilex Pharma Notes, and $2.9&nbsp;million on transaction costs payment related to the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2021, net cash provided by financing activities was
approximately $28.2&nbsp;million and was primarily related to $47.9&nbsp;million in proceeds from related party payables, $47.8&nbsp;million in proceeds from the CNH Revolving Loan, $14.7&nbsp;million in proceeds from related party note payable with
Sorrento, and offset by $48.8&nbsp;million repayment of the CNH Revolving Loan and $33.4&nbsp;
million repayment of the Scilex Pharma Notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_44"></A>Critical Accounting Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#146;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial
statements which are prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and
expenses during the reporting period. We continually evaluate our estimates and judgments and base them on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as
circumstances change and additional information becomes known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the following accounting policies and estimates are most
critical to aid in understanding and evaluating our reported financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with
our customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the
consideration we expect to receive from the customers in exchange for those products. In accordance with FASB ASC Topic 606 &#147;<I>Revenue from Contracts with Customers</I>&#148;<I>, </I>this process involves identifying the contract with a
customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been
satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is
separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.
We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our performance obligations with respect to sales of ZTlido are satisfied at a certain point in time, and we consider control to have
transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the
customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time. Invoicing typically occurs upon shipment and the length of time between
invoicing and the date on which payment is due is not significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established
for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount
approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates and Chargebacks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid
drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to
and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare
providers. Both types of rebates vary over time. We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates
on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and chargebacks are recorded as accrued rebates and fees under current liabilities within the Company&#146;s consolidated balance
sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prompt Payment Discounts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
provide our customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based
on actual gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers
and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a
reduction of revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We currently estimate our
product returns using historical trends and product return rates typically experienced in the industry and record this estimate as a reduction of revenue in the period the related product revenue is recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive
<FONT STYLE="white-space:nowrap">co-</FONT> payment assistance. We accrue for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by third-party
administrators. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative Liability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each
balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities included embedded derivatives that were identified and required bifurcation from the Scilex Pharma Notes and separate
accounting as a single compound derivative. Certain of these embedded features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Scilex
Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities associated with the Scilex Pharma Notes as of December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At closing of the Business Combination, the Company assumed a derivative warrant liability
of $2.5&nbsp;million related to Private Warrants (See Note 8 titled &#147;<I>Stockholder&#146;s Equity</I>&#148;<I> </I>to our consolidated financial statements included elsewhere in this prospectus for additional information). The warrant liability
associated with the Private Warrants was valued using the Black-Scholes option pricing model, which is considered to be Level&nbsp;3 fair value measurement. The primary unobservable input utilized in determining the fair value of the warrant is the
expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are publicly available as well as the implied volatility of the Public Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock-Based Compensation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for
stock-based compensation in accordance with FASB ASC Topic 718 &#147;<I>Compensation &#150; Stock Compensation</I>&#148;, which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions,
stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#146;s requisite service period (generally the vesting
period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. We account for forfeitures as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company determines the expected life
assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the Company determines an estimate
of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of
stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legacy Scilex Common Stock Valuation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of the Business Combination, the estimated fair value of the Legacy Scilex Common Stock was determined by the board of
directors of Legacy Scilex (the &#147;Legacy Scilex Board&#148;), considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective
factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the
Legacy Scilex Common Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#147;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity
Securities Issued as Compensation.&#148; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent
third-party valuation firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the
potential value of a strategic merger or sale at different time points, given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our historical operating and financial performance as well as our estimates of future financial performance,
including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The status of research and development efforts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our stage of development and commercialization and our business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Industry information such as market trends and macro-economic events; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Valuations of comparable companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Additional objective and subjective factors relating to our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our valuations did not always coincide with the dates of our stock option grants. In determining the exercise prices of the stock
options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#146;s assessment of additional objective and subjective factors we believed
were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying the valuations represented management&#146;s best estimate, which involved inherent uncertainties and the
application of management&#146;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#146;s stock-based compensation expense could have been
materially different. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since a public trading market for our Common Stock has been established in connection with the closing of the
Business Combination, it is no longer necessary for our Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will
be determined based on the quoted market price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_45"></A>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 1 titled &#147;<I>Nature of Operations and Basis of Presentation</I>&#148; of the notes to our consolidated financial statements
included elsewhere in this prospectus for a discussion of recent accounting pronouncements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_46"></A><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have, during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements, as defined under applicable SEC rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_47"></A>Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions, see the section of this prospectus titled &#147;<I>Certain Relationships and Related Party
Transactions</I>&#148; and Note 12 titled &#147;<I>Related Party Transactions</I>&#148; to our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_48"></A>Quantitative and Qualitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest Rate Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market
risk is confined to our cash and cash equivalents. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an
immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration Risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to April&nbsp;2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of
our net revenue. On April&nbsp;2, 2022, we announced the expansion of our direct </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. Additionally, during the
year ended December&nbsp;31, 2022, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit exposure by setting
credit limits, and have not experienced any credit losses for the year ended December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_49"></A>Emerging Growth
Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An &#147;emerging growth company&#148; as defined in the JOBS Act is eligible to take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth companies
but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our
business could significantly affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of
evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain
exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board
requiring mandatory audit firm rotation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and
registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will qualify and will remain as an emerging growth company
until the earlier of (i)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1.235&nbsp;billion, or (c)&nbsp;in which we are
deemed to be a large accelerated filer, which means the market value of our common equity of that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> equals or exceeds $700&nbsp;million as of the last business day of our most recently
completed second fiscal quarter; and (ii)&nbsp;the date on which we have issued more than $1.00&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. References herein to
&#147;emerging growth company&#148; have the meaning associated with it in the JOBS Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_50"></A>Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two
years of audited financial statements. We expect that we will not be a smaller reporting company to the extent we remain a majority-owned subsidiary of Sorrento. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_51"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_52"></A>The Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing
<FONT STYLE="white-space:nowrap">non-opioid</FONT> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with
<FONT STYLE="white-space:nowrap">non-opioid</FONT> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are
developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in 2023. Our commercial product, ZTlido<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the &#147;FDA&#148;) for the relief of neuropathic pain associated
with postherpetic neuralgia (&#147;PHN&#148;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing
significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We license the rights to ZTlido from and rely exclusively on Oishi Koseido Co., Ltd. (&#147;Oishi&#148;)
and Itochu Chemical Frontier Corporation (&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;) pursuant to the Product Development Agreement and Commercial Supply Agreement. We have acquired two FDA approved <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain products for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults, which we plan to commercialize in the U.S. in 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <FONT STYLE="white-space:nowrap">(i)&nbsp;SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel)
(&#147;SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>&#148;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <FONT
STYLE="white-space:nowrap">(ii)&nbsp;SP-103</FONT> (lidocaine topical system) 5.4%, <FONT STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain
(&#147;LBP&#148;); and <FONT STYLE="white-space:nowrap">(iii)&nbsp;SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules)
<FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose</FONT> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were
completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;)
with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&nbsp;the right to manufacture, promote, market, distribute and sell pharmaceutical products
comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&nbsp;an exclusive, transferable license to use the trademark
&#147;GLOPERBA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>&#148;. GLOPERBA is an <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting
an estimated 8.7&nbsp;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of
pain and can be disabling with tenderness, warmth and swelling. <FONT STYLE="white-space:nowrap">Non-steroidal</FONT> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S.
is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. We
have a direct distribution network to national and regional wholesalers and pharmacies throughout the U.S. states. For more information on Scilex, please see the sections of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151;
Romeg License and Commercialization Agreement.</I>&#148; On February&nbsp;12, 2023, we acquired from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. the rights to certain patents, trademarks, regulatory approvals, data,
contracts, and other rights related to ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> (celecoxib oral solution) and the commercialization thereof in the United States and Canada. ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM
</SUP>is a first-line treatment and the only <FONT STYLE="white-space:nowrap">FDA-approved,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> oral solution for the acute treatment of migraine, with
or without aura, in adults. We are planning to commercialize ELYXYB<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> in the U.S. in 2023. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established
mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic
Act for each of these pipeline product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently
available prescription and OTC lidocaine patches, of which over 147&nbsp;million and 136&nbsp;million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and
7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <FONT STYLE="white-space:nowrap">SP-102</FONT> from Semnur Pharmaceuticals, Inc. (&#147;Semnur&#148;) in March 2019 and are developing <FONT
STYLE="white-space:nowrap">SP-102</FONT> to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <FONT STYLE="white-space:nowrap">off-label</FONT> epidural steroid injections
(&#147;ESI&#148;), which are administered over 12&nbsp;million times annually in the United States. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Semnur Merger Agreement</I>&#148; for a description of
our acquisition of Semnur and our ongoing obligations to Semnur&#146;s former equityholders. SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP> has been granted fast track designation by the FDA and, if approved, could become the only <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it was estimated that over 4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. <FONT
STYLE="white-space:nowrap">SP-103</FONT> has also been granted fast track designation by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP.
We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> as a novel delayed-release formulation of <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet
medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia. There are no <FONT STYLE="white-space:nowrap">low-dose</FONT>
formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently
approved product and future product candidates, if approved, could uniquely address what we believe are the significant unmet needs of the targeted populations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_53"></A>Our Marketed Product and Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization
rights, except with respect to Japan for ZTlido and <FONT STYLE="white-space:nowrap">SP-103.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g11q22.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_54"></A>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Maximize the commercial potential of ZTlido.</B> We have assembled an integrated commercial organization using
a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <FONT STYLE="white-space:nowrap">60-70&nbsp;people,</FONT> targeting over 10,000
primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-patient</FONT></FONT> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating
contracts and have already achieved significant uptake by adding ZTlido to key formularies such as CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United
Healthcare Commercial, Optum Rx Select Commercial, Anthem Blue Cross Blue Shield (&#147;BCBS&#148;), BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North
Dakota. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Commercialize and successfully <FONT STYLE="white-space:nowrap">re-launch</FONT> GLOPERBA</B><SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP><B> for gout in the U.S.</B>: We will utilize our current commercial infrastructure comprised of our sales, marketing, and managed health care functions to promote GLOPERBA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> for gout to approximately 3,000 healthcare providers (&#147;HCPs&#148;) in the U.S. market. We anticipate a good degree of overlap between the current HCPs that we target and HCPs who prescribe
colchicine for gout, allowing for efficient dual promotion of Gloperba and ZTlido. The principal elements of the GLOPERBA strategy are as follows: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Educate the market on the need for and value of simplified and precise colchicine dose adjustments to allow
individualized, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">patient-by-patient</FONT></FONT> therapy. Scilex will leverage its <FONT STYLE="white-space:nowrap">in-person</FONT> sales forces, medical affairs teams, and
omni-channel HCP engagement campaigns to drive awareness of GLOPERBA&#146;s features and benefits. In addition, target providers, rheumatologists and primary care physicians treating various comorbidities, will be provided with tools to help them
identify and prescribe GLOPERBA to appropriate patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase access to GLOPERBA for subsets of patients in prophylactic treatment of gout, specifically those with
comorbidities and GI intolerance. Our managed healthcare account executives will negotiate contracts with key payer and pharmacy customers to achieve uptake of key formularies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of
sciatica.</B> We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <FONT STYLE="white-space:nowrap">off-label.</FONT> Many of these products contain potentially
neurotoxic preservatives and particulates, and are administered over 12&nbsp;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry
warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents
and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <FONT STYLE="white-space:nowrap">6-month</FONT> data analysis was completed in February 2022
and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy
designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We intend to submit a request to the FDA for a type D meeting in
order to clarify the expectations regarding the size of the safety database needed for a NDA given that at this time no safety concerns </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
have been identified during the course of clinical development, and to agree on acceptance of SP-102 Phase 3 trial data as pivotal evidence of efficacy to support product registration. We have
extensive clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102.</FONT> We expect to
present the robust data collected over the course of our multi-year clinical development program to the FDA as part of a New Drug Application (&#147;NDA&#148;). We also presented the pivotal Phase 3 trial results at the American Society of
Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the first approved topical
treatment in patients with acute LBP.</B> We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior
adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <FONT STYLE="white-space:nowrap">SP-103</FONT> is designed to use ZTlido&#146;s delivery and adhesion technology to deliver a dose
of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation
by the FDA and, if approved, could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pursue clinical development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of
fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects.</B> We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride delayed-release capsules are routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic pain conditions such as complex regional
pain. <FONT STYLE="white-space:nowrap">SP-104</FONT> addresses the shortcomings of using the high-dose commercial products and pharmacy-compounded products by delivering a <FONT STYLE="white-space:nowrap">low-dose</FONT> of naltrexone hydrochloride
(approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues
associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <FONT STYLE="white-space:nowrap">SP-104</FONT> has completed two
Phase 1 studies to characterize the pharmacokinetics and safety of the product, and we expect to commence Phase 2 studies in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our product portfolio by developing or acquiring <FONT STYLE="white-space:nowrap">non-opioid</FONT>
assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure.</B> We are continuously evaluating opportunities to leverage our research and development experience to develop <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire <FONT
STYLE="white-space:nowrap">non-opioid</FONT> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, we intend
to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage our management team&#146;s experience to further develop and commercialize its current and future
product portfolio.</B> Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd. (&#147;Teva&#148;), Novartis Pharmaceuticals,
Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully
commercializing products. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative <FONT STYLE="white-space:nowrap">non-opioid</FONT> product
portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#146; lives. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_55">
</A>Our Management Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific,
business and leadership expertise in pharmaceutical industry, in addition to strong transactional and business development track records. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with
strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 60 years of global biopharmaceutical and biotechnology experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jaism Shah has over 30 years of industry success in leading product development&nbsp;&amp; commercializing innovative therapies and creating
companies with documented success in development and commercialization of some of today&#146;s most recognized pharmaceutical brands. He is a seasoned life science executive and board director with extensive accomplishments at Bristol-Myers Squibb,
Roche, PDL Biopharma, Sorrento, Pfizer/Upjohn, Scilex, and <FONT STYLE="white-space:nowrap">start-ups</FONT> such as Elevation and Semnur Pharmaceuticals. Mr.&nbsp;Shah has been Chief Executive Officer and President of Semnur Pharmaceuticals
(acquired by Scilex Pharmaceuticals) since its inception in 2013. He has served as Chief Executive Officer and President of Legacy Scilex and Scilex Pharmaceuticals since March 2019 and of Scilex since November 2022. Mr.&nbsp;Shah also serves on the
board of directors of Sorrento Therapeutics Inc. and Scilex. Most recently, Mr.&nbsp;Shah served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, business strategy, mergers and acquisitions, and business
development. He led the sale of Elevation to Sunovion Pharmaceuticals in 2012. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as Chief Business Officer and also held the position of senior vice president of marketing and medical
affairs. During this time, he completed numerous licensing/partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka, and Biogen Idec. His leadership in marketing and portfolio management including leading the
commercial enterprise helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000, Mr.&nbsp;Shah received the &#147;Presidents Award&#148; for
completing one of the most significant collaborations in the company&#146;s history. Prior to working with Bristol-Myers Squibb, Mr.&nbsp;Shah led international marketing for oncology and virology and was global business leader for corporate
alliances at Roche from 1991 to 1997 with Genentech and IDEC, and prepared products for worldwide launch and <FONT STYLE="white-space:nowrap">pre-launch</FONT> at F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG in Switzerland. He has
played a key role in the formulation of long-range plans and <FONT STYLE="white-space:nowrap">pre-launch</FONT> and launch strategies for such brands as Abilify<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Pegasys<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, and Rituxan/MabThera<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, each of which have generated well over $1&nbsp;billion in sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Henry Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento
Therapeutics, Inc.&#146;s (&#147;Sorrento&#148; and, together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries), the &#147;Sorrento Group&#148;) intellectual property. Our Chief Financial Officer,
Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes
a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport,
Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <FONT STYLE="white-space:nowrap">non-opioid</FONT> and <FONT
STYLE="white-space:nowrap">non-addictive</FONT> treatments to provide safe, effective and durable relief of multiple pain conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design
and deliver effective first-class pain management therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_56"></A>Our Product Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product,
ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved
adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. We launched ZTlido in October 2018 with an integrated commercial organization
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated
sales growth and increased market uptake. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prescription Lidocaine Patch Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of
neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by
the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5&nbsp;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in
patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, there were more than 147&nbsp;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of
this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system,
ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the
FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have
been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-to-drug</FONT></FONT> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on
monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in
only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <FONT STYLE="white-space:nowrap">off-label</FONT> treatments, including nonsteroidal anti-inflammatory drugs (&#147;NSAIDS&#148;) and opioids.
These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as
respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <FONT STYLE="white-space:nowrap">12-month</FONT> period ending in
April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and
patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal medications that are designed to achieve systemic
drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area
surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure
and minimal systemic side effects reported </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in clinical trials, we believe a topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those
with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can
improve patient compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain
patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#147;FAERS&#148;). Because the drug is incorporated in
the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance
issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#147;TDSs&#148;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA
issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#146;s past experience with regulatory agencies, shows the FDA&#146;s interest and the importance of adhesion
performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the
targeted adhesion performance with an overall benign dermal safety profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following figure depicts data derived from FAERS as of
December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that
limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers
3&plusmn; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#146;s pliability can be
compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining
adhesion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a
bioavailability of 3 &plusmn; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, as captured in a bolded warning on
the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of
these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting
that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal
marketing status. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#147;Mylan&#148;), while providing bioequivalent delivery
of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key
advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key Advantages of ZTlido vs. Lidoderm and Associated
Generics </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Drug-in-adhesive</FONT></FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Source: A Scilex-sponsored
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> comparative adhesion study
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(SCI-LIDO-ADH-003)</FONT></FONT></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint
associated with other currently marketed topical lidocaine products. ZTlido uses an advanced <FONT STYLE="white-space:nowrap">hot-melt</FONT> technology, which uses premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various
excipients and lidocaine, followed by current Good Manufacturing Practices (&#147;cGMP&#148;) compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (a branded, prescription 5% lidocaine patch product) (&#147;Lidoderm&#148;) and Mylan&#146;s generic lidocaine patch at 12 hours after application. In a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> study of 44 subjects, ZTlido showed statistically significant adhesion at <FONT STYLE="white-space:nowrap">all-time</FONT> points compared to Lidoderm. Further, ZTlido maintained greater than 90%
mean adhesion over the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#146;s generic lidocaine patch.
In this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <FONT STYLE="white-space:nowrap">12-hour</FONT> administration
period, while Mylan&#146;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile
without creating dermal sensitization and maintaining a benign irritation profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of
ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#146;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol
where adhesion could not be enhanced (i.e., no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product
to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#146;s NDA approval. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from
the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido
lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation
has not been evaluated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to
Lidoderm and Teva&#146;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material
allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#146;s generic lidocaine patch
is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4 sessions of <FONT
STYLE="white-space:nowrap">30-minutes</FONT> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period.
Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is
supported by an adhesion or pharmacokinetic study showing that, while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no
clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (e.g., heating pad or blanket), the <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of
value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a
perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and
generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product
under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management,
marketing and managed care capabilities. We market ZTlido through a dedicated <FONT STYLE="white-space:nowrap">65-person</FONT> sales force, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians
who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key
formularies, including CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial, Anthem BCBS, BCBS Louisiana and
Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing
efforts, have driven, and will continue to drive, accelerated sales growth and increased market uptake. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several
investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used
corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sciatica Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve
root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning low back pain
(&#147;LBP&#148;) combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like
numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <FONT STYLE="white-space:nowrap">one-third</FONT> of these cases will develop symptoms lasting over a year. According to a
report by Decision Resources Group, it was estimated that over 4.8&nbsp;million patients would suffer from sciatica in the United States in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from
2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and
therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple
specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with
severe adverse events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and <FONT STYLE="white-space:nowrap">non-invasive</FONT>
treatment options. Surgical intervention options include vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc
replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For
these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&nbsp;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy,
traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&nbsp;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants; and (iii)&nbsp;injectable pharmaceutical
therapies such as <FONT STYLE="white-space:nowrap">off-label</FONT> use of ESIs or nerve blocks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are
one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#146;s pain is inadequately controlled with oral pain medications, topical
systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or
betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <FONT STYLE="white-space:nowrap">non-particulate</FONT> steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer
with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles
present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage:
(1)&nbsp;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&nbsp;several particulate steroids have an immediate and massive effect on
microvascular perfusion because of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe
permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <FONT
STYLE="white-space:nowrap">off-label</FONT> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is
to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of
fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health
care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT
STYLE="white-space:nowrap">SP-102</FONT> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <FONT
STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe for delivery
via an epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> allows for the use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates.
The product is also formulated without the use of preservatives and packaged in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> syringe, so as to confer greater physician convenience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there
are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks
of serious neurologic complications. Unlike currently-used steroids, <FONT STYLE="white-space:nowrap">SP-102</FONT> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic
complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <FONT STYLE="white-space:nowrap">SP-102</FONT> may substantially
reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <FONT STYLE="white-space:nowrap">SP-102,</FONT> which uses a biocompatible,
biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe
<FONT STYLE="white-space:nowrap">SP-102,</FONT> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, <FONT STYLE="white-space:nowrap">SP-102</FONT> could become the first <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESI
product. We believe an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> therapy for the treatment of sciatica could potentially benefit from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-market</FONT></FONT>
advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <FONT STYLE="white-space:nowrap">SP-102</FONT> benefits from our substantial
intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <FONT
STYLE="white-space:nowrap">SP-102.</FONT> Our complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile viscous product candidates are also key to our competitive edge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating data on <FONT STYLE="white-space:nowrap">SP-102</FONT> from a pivotal Phase 3 Corticosteroid Lumbar Epidural
Analgesia (&#147;CLEAR&#148;) trial, which was designed to evaluate the safety and efficacy in the proposed indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary
objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> compared to an intramuscular
injection of placebo over four weeks. A full <FONT STYLE="white-space:nowrap">6-months</FONT> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and
secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program
leading to market approval. We intend to submit a request to the FDA for a type D meeting in order to clarify the expectations regarding the size of the safety database needed for a NDA given that at this time no safety concerns have been identified
during the course of clinical development, and to agree on acceptance of SP-102 Phase 3 trial data as pivotal evidence of efficacy to support product registration. We also presented the pivotal Phase 3 trial results at the American Society of
Interventional Pain Physicians annual meeting in Las Vegas, Nevada in May 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results
reflect achievement of primary and secondary endpoints, are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), demonstrated a rapid onset of pain relief, measured by Numeric
Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17), with a <FONT
STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT>
(SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation.
By contrast, <FONT STYLE="white-space:nowrap">off-label</FONT> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and
estimating quality of life, showed a 28% improvement at 4 weeks on <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) compared to baseline (minimal clinically meaningful improvement <FONT
STYLE="white-space:nowrap">8%-12%)15.</FONT> The LS Mean (SEM) difference as compared to placebo was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49), with a <FONT STYLE="white-space:nowrap">p-value</FONT> &lt; 0.001. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There were no adverse events (&#147;AEs&#148;) of special interest reported, such as paraplegia, hematoma, or
infection at the injection site, which events are associated with the <FONT STYLE="white-space:nowrap">off-label</FONT> use of <FONT STYLE="white-space:nowrap">non-approved</FONT> injectable steroid preparations. Of the 354 patients receiving at
least a single injection of <FONT STYLE="white-space:nowrap">SP-102,</FONT> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#147;TEAEs&#148;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%)
patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patient experiencing AEs related to early withdrawal. Of the 47 patients only
receiving a single placebo injection (and no repeat injection of <FONT STYLE="white-space:nowrap">SP-102),</FONT> there were 14 (29.8%) patients experiencing TEAEs with (i)&nbsp;two (4.3%) patients experiencing treatment-related AEs, (ii)&nbsp;two
(4.3%) patients experiencing medication-related AEs, (iii)&nbsp;one (2.1%) patient experiencing procedure-related AEs, (iv)&nbsp;one (2.1%) patient experiencing serious AEs, (v)&nbsp;one (2.1%) patient experiencing AEs related to early withdrawal,
and (vi)&nbsp;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <FONT STYLE="white-space:nowrap">(SP-102:</FONT> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <FONT STYLE="white-space:nowrap">(SP-102:</FONT> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <FONT
STYLE="white-space:nowrap">(SP-102:</FONT> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <FONT STYLE="white-space:nowrap">(SP-102:</FONT> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also
established the safety of repeat injections, as patients who experienced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> radicular pain between 4 and 23 weeks were allowed to receive open-label
additional <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Phase 3 <FONT STYLE="white-space:nowrap">SP-102</FONT> C.L.E.A.R Trial &#151; Primary
Endpoint </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a05.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to be a triple-strength, <FONT STYLE="white-space:nowrap">non-aqueous</FONT>
lidocaine topical system for the treatment of acute LBP. <FONT STYLE="white-space:nowrap">SP-103</FONT> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release
liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acute LBP Market Overview
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute LBP addresses a high unmet need and creates large market opportunities. LBP affects about
70% of people in resource-rich countries at some point in their lives. Acute LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a
high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
duration over time. Americans spent approximately $134.5&nbsp;billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of
Institute for Health Metrics and Evaluation at the University of Washington. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Current Treatment Landscape and Limitations of Existing Treatments
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had
lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18 - 44, 45 - 64, and
75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <FONT STYLE="white-space:nowrap">65-74</FONT> years.
Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas
others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or
possible osteoporosis), major or progressive motor or sensory deficit, <FONT STYLE="white-space:nowrap">new-onset</FONT> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic
to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of
benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our
Solution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength <FONT STYLE="white-space:nowrap">SP-103</FONT> is an investigational,
<FONT STYLE="white-space:nowrap">non-aqueous</FONT> lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that <FONT STYLE="white-space:nowrap">SP-103</FONT> could become the lidocaine topical
product for acute LBP indications. All current uses of topical lidocaine products for LBP are <FONT STYLE="white-space:nowrap">off-label.</FONT> This program builds on the learnings from ZTlido because both products share the same adhesive drug
delivery formulation and manufacturing technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-103</FONT> to deliver a dose of
lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture <FONT STYLE="white-space:nowrap">SP-103</FONT> to have a drug load of
108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers
threefold the level of drug of Lidoderm and associated generics by extrapolation. <FONT STYLE="white-space:nowrap">SP-103</FONT> has been granted fast track designation by the FDA and, if approved, could become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> lidocaine topical product for the treatment of acute LBP. We believe <FONT STYLE="white-space:nowrap">SP-103,</FONT> if successfully developed and approved, may be able to address the limitations of
prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds.
<FONT STYLE="white-space:nowrap">SP-103</FONT> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single
topical system. This level of dosage for <FONT STYLE="white-space:nowrap">SP-103</FONT> is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a <FONT STYLE="white-space:nowrap">24-</FONT>
hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug
product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not
increase drug delivery to a localized area under the topical system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute LBP market presents an attractive commercial opportunity due to the
large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical <FONT STYLE="white-space:nowrap">non-opioid</FONT> product targeting this segment of the pain population
represents a commercially attractive strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend initially to evaluate <FONT STYLE="white-space:nowrap">SP-103</FONT> in a Phase
2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period</FONT> cross-over, multicenter study of
<FONT STYLE="white-space:nowrap">SP-103</FONT> and placebo in subjects with acute LBP. The study consists of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where all subjects receive
active treatment. Responders to treatment then will be randomized to blinded Treatment A, consisting of 30 days treatment with <FONT STYLE="white-space:nowrap">SP-103</FONT> or Treatment B, consisting of 30 days treatment with placebo patch with no
lidocaine. We initiated the Phase 2 trial in the second quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104</FONT> for the treatment of fibromyalgia.
<FONT STYLE="white-space:nowrap">Low-dose</FONT> naltrexone hydrochloride <FONT STYLE="white-space:nowrap">delayed-release</FONT> capsules are routinely used <FONT STYLE="white-space:nowrap">off-label</FONT> to treat fibromyalgia and other chronic
pain conditions such as complex regional pain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fibromyalgia Market Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&nbsp;million people in the United States and an estimated 3% to 6% of the world population. While it is
most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary
care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&nbsp;billion to $14&nbsp;billion each year and the condition accounts for a loss
of 1% to 2% of the national overall productivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Potential Complications of Fibromyalgia </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> list of complications of fibromyalgia: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extreme allodynia with high levels of distress; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">opioid or alcohol dependence; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marked functional impairment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">severe depression and anxiety; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obesity and physical deconditioning; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">metabolic syndrome. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no
apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia are detailed in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran,
have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new
treatments with higher efficacy are needed to improve management of fibromyalgia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Solution </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-104</FONT> has key clinical data supporting its use in fibromyalgia. There are investigational trials that
support use and development of <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia. Currently there are no <FONT STYLE="white-space:nowrap">low-dose</FONT> formulations (i.e., less than 5&nbsp;mg) available. Physicians currently use the
commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level
of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This approach can lead to errors in dosing and challenges with titration. The commercial
products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria,
insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">SP-104</FONT> uses delayed burst release technology
that bypasses the stomach and releases the drug in the gut (upper intestine). When taking <FONT STYLE="white-space:nowrap">SP-</FONT> 104 at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid
conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#146;s
potential to elicit compensatory response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to develop <FONT STYLE="white-space:nowrap">SP-104</FONT> for fibromyalgia.
Phase 1 studies are designed to characterize the pharmacokinetic and safety profile of <FONT STYLE="white-space:nowrap">SP-104,</FONT> and Scilex intends to initiate a Phase 2 study in 2023. If successful, we believe
<FONT STYLE="white-space:nowrap">SP-104</FONT> can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_57"></A>Commercialization and Market Access </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales&nbsp;&amp; Marketing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our current marketed product, ZTlido, and our two other <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products, GLOPERBA and ELYXYB, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical
lidocaine product market, where we believe we have the only actively promoted product. Our dedicated <FONT STYLE="white-space:nowrap">65-person</FONT> sales force has broad experience in pain management and is exclusively focused on promoting
ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN
patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could benefit from SEMDEXA and <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved. Our sales representatives typically have over 10
years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, ZTlido had gained approximately 11.4% market share of the lidocaine patch prescription market across the
territories we cover in the United States. The total prescriptions of ZTlido for the year ended December&nbsp;31, 2022 grew by more than 50.4% over the year ended December&nbsp;31, 2021, according to Symphony Healthcare&#146;s national prescription
data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing
team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT>
administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is
supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics
team is conducting market research to support the launch of <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> if any of these candidates is approved. We
believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <FONT
STYLE="white-space:nowrap">non-opioid</FONT> pain management therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Market Access </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor
sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#146; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in
establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&nbsp;million of the over 300&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lives, with the remaining 25&nbsp;million to be considered in the future. Currently, ZTlido is covered for over 200&nbsp;million lives in the United States and coverage continues to improve. As
of January 2023, we have secured coverage for ZTlido on CVS Caremark/Aetna Commercial, Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and most Medicare plans), United Healthcare Commercial, Optum Rx Select Commercial,
Anthem BCBS, BCBS Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Elixir Commercial and Medicaid in California, Florida, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers
in all books of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Formulary Coverage &#151; Over 90% of Lives Covered or In Negotiation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with
commercial insurance or those paying <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket.</FONT></FONT> With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido
prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_58"></A>Clinical Development Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of
neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times
and settings. Based on these studies, we concluded that ZTlido: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">demonstrated bioequivalence to Lidoderm in study
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PK-002A;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period in study <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-001;</FONT></FONT></FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">showed superior adhesion to Lidoderm and Mylan&#146;s generic lidocaine patch in studies <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-AHD-002</FONT></FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-003;</FONT></FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was not meaningfully impacted by heat or exercise in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-HEX-001;</FONT></FONT></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">was able to be used under showering and bathing conditions in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-004;</FONT></FONT></FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">did not show clinically meaningful dermal irritation in study <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-DERM-001.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido Study Details </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Bioequivalence Study &#151;
</I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PK-002A</FONT></FONT></FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose pharmacokinetic (&#147;PK&#148;) study between ZTlido and Lidoderm designed as a <FONT
STYLE="white-space:nowrap">two-way</FONT> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other
product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that
ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#146;s analgesic effects for
ZTlido&#146;s approval. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean Lidocaine Plasma Concentration Time Profiles &#151; Semilog Scale </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pivotal Adhesion Study &#151; </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-ADH-001</FONT></FONT></FONT><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period,
single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period of the product. The study also investigated
whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <FONT
STYLE="white-space:nowrap">12-hour</FONT> administration period, over 90% of the subjects (49 out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Maintained Greater Than 90% Adhesion Over the
<FONT STYLE="white-space:nowrap">12-Hour</FONT> Time Period </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the
product label. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion Study versus Lidoderm &#151; </I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-002</FONT></FONT></FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to
evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application.
ZTlido maintained a mean percent adhesion performance greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while Lidoderm fell below 90% mean adhesion within three hours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a11.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Head-to-Head</FONT></FONT> Adhesion
Study versus Mylan&#146;s Generic &#151; </I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-003</FONT></FONT></FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <FONT STYLE="white-space:nowrap">two-period,</FONT> single-application adhesion performance study
in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The
purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> formulation. We selected Mylan&#146;s generic lidocaine patch as a comparator
because it has similar product characteristics, including a <FONT STYLE="white-space:nowrap">non-aqueous</FONT> polymer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> system allowing for a thinner
patch and a lower drug load as compared to Lidoderm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance
compared to Mylan&#146;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period, while the generic product had a mean adhesion score of only 80%
immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated
Superior Adhesion Compared to Mylan&#146;s Generic Lidocaine Patch </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PK and Adhesion Study under Exercise and Heat Conditions &#151; </I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-HEX-001</FONT></FONT></FONT><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label,
randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under
normal conditions, respectively. The three treatment periods were as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In
this treatment period, subjects were instructed to perform exercise for 30 minutes on a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of
the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment
period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment
period, topical systems were applied to the <FONT STYLE="white-space:nowrap">mid-lower</FONT> back and worn for 12 hours. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an
effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the
subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but
the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e.,
immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a14.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dermal Sensitization and Irritation Study &#151; </I><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">SCI-LIDO-DERM-001</FONT></FONT><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human
clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the
overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a <FONT STYLE="white-space:nowrap">7-point</FONT> scale where a score of 0&nbsp;indicated no irritation and a score of 7 was considered a strong reaction
spreading beyond the application site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal
safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible
erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Photoallergy and Phototoxicity
Studies</I> &#151; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOT0-001</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002</FONT></FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">6-week</FONT> randomized study,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-001,</FONT></FONT> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we
observed that ZTlido was not photoallergenic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <FONT STYLE="white-space:nowrap">4-day,</FONT> randomized study, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-PHOTO-002,</FONT></FONT> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy
volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-Approval Studies for ZTlido </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Water Stress Study (Shower and Swimming) &#151;
</I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SCI-LIDO-ADH-004</FONT></FONT></FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed
to two separate water stress conditions of (1)&nbsp;showering (10&nbsp;minutes) and (2)&nbsp;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no
further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the
associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the
<FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investigator-Sponsored Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal
tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a Phase 3 pivotal study of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The Corticosteroid Lumbar
Epidural Analgesia for Radiculopathy (&#147;CLEAR&#148;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of
<FONT STYLE="white-space:nowrap">SP-102</FONT> to placebo. We announced final results from this study in March 2022. We also presented the pivotal Phase 3 trial results at the American Society of Interventional Pain Physicians annual meeting in Las
Vegas, Nevada in May 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Trial Highlights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> has been evaluated in a number of preclinical studies and clinical trials as a potential
treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Repeat injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> showed continued pain reduction with no
unexpected adverse events based on preliminary results from the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-102-03</FONT></FONT> study; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended local activity with epidural administration in
the <FONT STYLE="white-space:nowrap">ES-1504</FONT> study; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">SP-102</FONT> showed an extended residence time and tolerability in the
1014-1512 and the 1014-2847, preclinical studies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The introduction of <FONT STYLE="white-space:nowrap">SP-102</FONT> into blood vessels did not result in
neurological complications in the UPD003-IS21 preclinical toxicology study. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA)
Study Details Phase 3 Pivotal Clinical Trial &#151; CLEAR </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a pivotal, randomized, double-blind,
placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate
the safety of administering <FONT STYLE="white-space:nowrap">SP-102</FONT> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <FONT STYLE="white-space:nowrap">SP-102</FONT> to investigate the
safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <FONT STYLE="white-space:nowrap">SP-102.</FONT> The
schematic of this Phase 3 trial is demonstrated in the flowchart below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic
effect of <FONT STYLE="white-space:nowrap">SP-102</FONT> on average leg pain, measured using the Numeric Pain Rating Scale (&#147;NPRS&#148;) following a single transforaminal injection. These results were compared to an intra-muscular injection of
placebo over a four-week period. The secondary objectives of this study include (i)&nbsp;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&nbsp;characterization of the change of the subject&#146;s
radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&nbsp;evaluation of the safety of a single and
repeat <FONT STYLE="white-space:nowrap">SP-102</FONT> injections. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schematic of CLEAR &#151;
<FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) Phase 3 Pivotal Trial </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a15.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study
in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the
affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <FONT STYLE="white-space:nowrap">-1.08</FONT> (0.17) compared to placebo with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The two key secondary endpoints assessing Oswestry Disability Index (&#147;ODI&#148;) and Time to open label
repeat injection have been demonstrated for <FONT STYLE="white-space:nowrap">SP-102.</FONT> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <FONT STYLE="white-space:nowrap">-6.28</FONT> (1.49) with a <FONT
STYLE="white-space:nowrap">p-value</FONT> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI)
0.49 (0.36, 0.65), with a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.001. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Repeat Dose Study &#151; </I><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-102-03</FONT></FONT><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT
STYLE="white-space:nowrap">single-arm,</FONT> pharmacodynamics (&#147;PD&#148;) and safety study of repeat epidural injections of <FONT STYLE="white-space:nowrap">SP-102</FONT> in patients with sciatica. We conducted this study to characterize
repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <FONT STYLE="white-space:nowrap">SP-102</FONT> epidural injections 4 to 8 weeks
after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <FONT
STYLE="white-space:nowrap">28-day</FONT> observation period for both treatments. Based on a preliminary review of the results, <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and there were no new unexpected
adverse events observed. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g418853g00a16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1 Trial of <FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) Compared to Reference Listed Drug &#151; </I><FONT
STYLE="white-space:nowrap">ES-1504</FONT><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <FONT STYLE="white-space:nowrap">single-arm,</FONT> <FONT
STYLE="white-space:nowrap">two-period,</FONT> fixed sequential-dose study to evaluate the PK, PD and safety of <FONT STYLE="white-space:nowrap">SP-102</FONT> when administered by epidural injection. <FONT STYLE="white-space:nowrap">SP-102</FONT> was
compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <FONT STYLE="white-space:nowrap">SP-102</FONT> followed by the
intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between <FONT
STYLE="white-space:nowrap">SP-102</FONT> and the Reference Listed Drug. The Tmax observed with the administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> was four hours, compared to 15 minutes observed with intravenous dexamethasone. The
PD parameters and safety results of both products were similar, and <FONT STYLE="white-space:nowrap">SP-102</FONT> did not prolong cortisol suppression time. <FONT STYLE="white-space:nowrap">SP-102</FONT> also maintained analgesic effects throughout
a <FONT STYLE="white-space:nowrap">one-month</FONT> observation period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar,
whether administered as <FONT STYLE="white-space:nowrap">SP-102</FONT> or injected intravenously, with a mean AUCinf of 0.916 &micro;g*h/mL (observed with <FONT STYLE="white-space:nowrap">SP-102)</FONT> compared to 0.943 &micro;g*h/mL (observed with
intravenously-administered dexamethasone). Notably, there was a <FONT STYLE="white-space:nowrap">16-</FONT> fold increase in the time to maximum serum concentration (&#147;Tmax&#148;) following epidural injection of
<FONT STYLE="white-space:nowrap">SP-102.</FONT> The median Tmax was 4.00&nbsp;hours for <FONT STYLE="white-space:nowrap">SP-102</FONT> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back
and leg pain during the <FONT STYLE="white-space:nowrap">one-month</FONT> observation period following a single epidural injection of <FONT STYLE="white-space:nowrap">SP-102.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural
injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as
the safety profile, were similar between the two treatments. <FONT STYLE="white-space:nowrap">SP-102</FONT> injections were generally well-tolerated and did not result in new unexpected side effects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Toxicology Studies</I> &#151; Study Nos. 1014-1512 and 1014-2847 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <FONT STYLE="white-space:nowrap">non-rodent</FONT> animal species to assess <FONT
STYLE="white-space:nowrap">SP-102</FONT> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended
residence time of the viscous gel formulation of <FONT STYLE="white-space:nowrap">SP-102</FONT> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with
administration of dexamethasone sodium phosphate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preclinical Toxicology Study &#151; </I>UPD003-IS21<I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels
providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of <FONT
STYLE="white-space:nowrap">SP-102</FONT> was injected over <FONT STYLE="white-space:nowrap">1-2</FONT> minutes into the vertebral artery of large animal species. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-</FONT> and post-dose angiography showed no remarkable changes and all animals survived for approximately
24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hydrodynamic Study &#151; </I><FONT STYLE="white-space:nowrap">SP-PC002</FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <FONT STYLE="white-space:nowrap">SP-102</FONT> in <FONT STYLE="white-space:nowrap">non-rodent</FONT>
animal species, which showed that epidural administration of <FONT STYLE="white-space:nowrap">SP-102</FONT> demonstrated an increased local residence half-life and a decreased flow from the injection site. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Intravascular Injection Study &#151; </I><FONT STYLE="white-space:nowrap">SEM-005</FONT><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> into the vertebral
artery of <FONT STYLE="white-space:nowrap">non-rodent</FONT> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <FONT STYLE="white-space:nowrap">SP-102</FONT> following a <FONT
STYLE="white-space:nowrap">24-hour</FONT> survival period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> is an investigational, <FONT STYLE="white-space:nowrap">non-aqueous</FONT> lidocaine topical
system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <FONT STYLE="white-space:nowrap">SP-103</FONT> will build on the learnings from ZTlido because both products share the same adhesive drug delivery
formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <FONT STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. A Phase 1 study was completed that demonstrated
bioequivalent pharmacokinetics between the administration of a single <FONT STYLE="white-space:nowrap">SP-103</FONT> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of <FONT
STYLE="white-space:nowrap">SP-103</FONT> (i.e., 1, 2 or 3 patches) over a <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. Adhesion performance was assessed and found to be comparable between
<FONT STYLE="white-space:nowrap">SP-103</FONT> and ZTlido. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, we plan to evaluate
<FONT STYLE="white-space:nowrap">SP-103</FONT> in the following studies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-103-02</FONT></FONT> is a Phase 2 study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <FONT STYLE="white-space:nowrap">two-period,</FONT> cross-over, multicenter study of <FONT
STYLE="white-space:nowrap">SP-103</FONT> versus placebo. The study is expected to consist of a <FONT STYLE="white-space:nowrap">7-day</FONT> open-label <FONT STYLE="white-space:nowrap">run-in</FONT> period where all subjects receive active
treatment. Responders to treatment will then be randomized to receive blinded treatment of either <FONT STYLE="white-space:nowrap">SP-103</FONT> or placebo. This study will inform on the pivotal Phase 3 study design to support market approval.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to a pivotal Phase 3 program, we intend to perform a <FONT STYLE="white-space:nowrap">3-day</FONT> PK
study of <FONT STYLE="white-space:nowrap">SP-103,</FONT> an adhesion performance study of <FONT STYLE="white-space:nowrap">SP-103</FONT> and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of <FONT
STYLE="white-space:nowrap">SP-103</FONT> to support the NDA submission. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 trial of <FONT
STYLE="white-space:nowrap">SP-103</FONT> was initiated in the second quarter of 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5mg, <FONT
STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release capsules) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been
completed for <FONT STYLE="white-space:nowrap">SP-104</FONT> at investigative sites in New Zealand: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-01</FONT></FONT> is a food effect and
bridging pharmacokinetic study comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment,
randomized study to characterize the PK and safety and tolerability of <FONT STYLE="white-space:nowrap">SP-104</FONT> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK
and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The
study also serves as a &#147;pharmaceutical bridge&#148; between <FONT STYLE="white-space:nowrap">SP-104</FONT> and the commercial reference listed drug (the &#147;RLD&#148;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual
Section&nbsp;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <FONT STYLE="white-space:nowrap">SP-104</FONT> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#146;s findings of safety for
the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficacy of
<FONT STYLE="white-space:nowrap">SP-104</FONT> in the treatment of fibromyalgia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SP-104-02</FONT></FONT> is a Phase 1 study of <FONT
STYLE="white-space:nowrap">SP-104</FONT> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <FONT STYLE="white-space:nowrap">two-period,</FONT>
<FONT STYLE="white-space:nowrap">two-treatment</FONT> crossover study to evaluate the safety of <FONT STYLE="white-space:nowrap">SP-104,</FONT> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the
hypothesis that, when taken at night, the delayed release of 4.5&nbsp;mg&nbsp;Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52)
cross-over trial in healthy volunteers comparing <FONT STYLE="white-space:nowrap">SP-104</FONT> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#147;compared drug&#148;), there were no
serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of <FONT STYLE="white-space:nowrap">SP-104,</FONT> there
were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one treatment-related TEAE within 72 hours after first administration of <FONT
STYLE="white-space:nowrap">SP-104.</FONT> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <FONT STYLE="white-space:nowrap">SP-104.</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT>
administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of
<FONT STYLE="white-space:nowrap">SP-140</FONT> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <FONT STYLE="white-space:nowrap">SP-104</FONT> (n=9; 12
events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea <FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=0; the compared drug: n=3) and
headache <FONT STYLE="white-space:nowrap">(SP-104:</FONT> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as
their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New
Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3,
randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#147;adequate and well-controlled&#148; study to establish the efficacy of <FONT STYLE="white-space:nowrap">SP-104</FONT> in
the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <FONT STYLE="white-space:nowrap">SP-104</FONT> or as an additional Phase 3 study may be required. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_59"></A>Medical Affairs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <FONT STYLE="white-space:nowrap">in-house</FONT> medical expertise, health economics and third-party payor
support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical
Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our
sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works
with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_60">
</A>Manufacturing and Supply Chain </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage
and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our
Quality System, Standard Operating Procedures and contract manufacturing organizations (&#147;CMOs&#148;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality
and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">drug-in-adhesive</FONT></FONT> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) in Japan. We have exclusive worldwide rights to
Oishi&#146;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and <FONT STYLE="white-space:nowrap">hot-melt</FONT> mixing of various excipients and lidocaine, followed by
cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#147;<I>Business</I> <I>&#151;</I> <I>Material
Agreements</I> <I>&#151;</I> <I>Itochu and Oishi Product Development Agreement</I>&#148; and &#147;Business &#151; Material Agreements &#151; Itochu and Oishi Commercial Supply Agreement&#148; for additional information regarding the manufacturing
and supply chain of ZTlido. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive
third-party logistics distribution provider, Cardinal Health 105, LLC (&#147;Cardinal Health 105&#148;), ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on
the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson Corporation (&#147;McKesson&#148;), Cardinal Health 110, LLC (&#147;Cardinal Health 110&#148;) and
AmerisourceBergen Corporation (&#147;AmerisourceBergen&#148;). Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as well as independent pharmacies. In addition
to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory
control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&nbsp;31, 2020, 2021, and first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all
of our net revenue for such periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution
network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies from the second quarter of 2022.
In April 2022, we discontinued our use of &#147;title model&#148; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-102</FONT> (SEMDEXA) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product
containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <FONT STYLE="white-space:nowrap">pre-filled</FONT> glass syringe with a 2 mL deliverable volume. <FONT STYLE="white-space:nowrap">SP-102</FONT> also contains sodium
hyaluronate, which is a novel, biocompatible, <FONT STYLE="white-space:nowrap">viscosity-enhancing</FONT> excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <FONT
STYLE="white-space:nowrap">SP-102</FONT> from the manufacturer and supplier. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102</FONT> is
manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of <FONT STYLE="white-space:nowrap">SP-102.</FONT> In March 2022, we announced final results of the Phase 3
clinical trial, satisfying the primary efficacy and key secondary efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production
of <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#147;Sanofi&#148;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage
Sanofi for commercial supply of dexamethasone sodium phosphate for <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved. See the section of this prospectus titled &#147;<I>Business</I> <I>&#151;</I> <I>Material Agreements</I> <I>&#151;</I>
<I>Genzyme Supply Agreement</I>&#148; and &#147;<I>Business</I> <I></I>&#151; <I>Material Agreements</I> <I>&#151;</I> <I>Lifecore Master Services Agreement</I>&#148; for additional information regarding the manufacturing and supply of the
proprietary excipient and contact manufacturing of <FONT STYLE="white-space:nowrap">SP-102</FONT> product, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-103</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-103</FONT> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi,
using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <FONT STYLE="white-space:nowrap">SP-103</FONT> manufacturing protocols in a supplemental new drug application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SP-104</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SP-104,</FONT> a novel <FONT STYLE="white-space:nowrap">low-dose,</FONT> naltrexone
hydrochloride delayed release formulation for treating fibromyalgia. <FONT STYLE="white-space:nowrap">SP-104</FONT> is 4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed release capsule product in clinical
development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex Pharmaceuticals Inc. (&#147;Tulex&#148;), located in Cranbury, NJ. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_61"></A>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain
management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily
available capital, and established research and development organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <FONT
STYLE="white-space:nowrap">SP-103,</FONT> if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par
Pharmaceutical, Inc. Additionally, <FONT STYLE="white-space:nowrap">SP-103,</FONT> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval
for the treatment of acute LBP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, has the potential to become the first <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> epidural steroid product for the treatment of sciatica. While there are currently no <FONT STYLE="white-space:nowrap">FDA-approved</FONT> ESIs indicated for the treatment of sciatica, we are aware of
certain <FONT STYLE="white-space:nowrap">non-steroid</FONT> product candidates in development. <FONT STYLE="white-space:nowrap">SP-102,</FONT> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants,
anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <FONT STYLE="white-space:nowrap">off-label</FONT> and unapproved use of
branded and generic injectable steroids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the
treatment of fibromyalgia, we are aware of certain <FONT STYLE="white-space:nowrap">non-opioid</FONT> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <FONT
STYLE="white-space:nowrap">SP-104,</FONT> will likely face direct competition from these candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will
become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as
well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing
product candidates and launching, marketing and selling product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and
pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their
products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of
capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any
product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and
later enter the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel
compounds or to <FONT STYLE="white-space:nowrap">in-license</FONT> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or
discovering, developing and commercializing medicines before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido, <FONT
STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103</FONT> and <FONT STYLE="white-space:nowrap">SP-104</FONT> are likely to be their efficacy, durability, safety, price and the availability of reimbursement from
government and other <FONT STYLE="white-space:nowrap">third-party</FONT> payors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_62"></A>Material Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#147;Oishi&#148;) and Itochu Chemical Frontier Corporation
(&#147;Itochu,&#148; and together with Oishi, the &#147;Developers&#148;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&nbsp;source and provide the active
pharmaceutical ingredient for the Products for manufacturing, (2)&nbsp;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&nbsp;conduct product development activities necessary to support the filing of
applications for regulatory approvals for the Products and (4)&nbsp;conduct manufacturing <FONT STYLE="white-space:nowrap">scale-up</FONT> activities and preclinical studies for the Products. We are responsible for, among other things,
(a)&nbsp;conducting all pivotal human clinical trials for the Products, (b)&nbsp;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and
(c)&nbsp;commercially launching the Products. We maintain the ultimate responsibility and <FONT STYLE="white-space:nowrap">decision-making</FONT> control with regard to the marketing and pricing of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the
active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue
patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable,
worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#146; development obligations under the
Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters
after the commercial launch equals a negative amount (a &#147;Net Loss&#148;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with accounting
principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). Under the Product Development Agreement, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
if our total net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> are equal to or less than five percent of our net sales of ZTlido and
<FONT STYLE="white-space:nowrap">SP-103</FONT> for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus,
our net profits for ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement.
As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee
to the Developers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&nbsp;2, 2028, which is the 10th
anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless we or the Developers terminate it upon <FONT
STYLE="white-space:nowrap">six-month</FONT> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&nbsp;the other party is in material breach of the agreement and the breach is not curable, or if the
breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&nbsp;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of
efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&nbsp;the market conditions are such that (a)&nbsp;our total net profits of the Products are equal to or less than five percent
of our net sales of the Products for a period of four or more consecutive quarters, or (b)&nbsp;the Products&#146; economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances
deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&nbsp;and (b) after 30 days of good-faith discussion; (4)&nbsp;the parties fail to reach
mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&nbsp;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product
Development Agreement if (i)&nbsp;any of the pivotal human clinical trials for any of the Products fail, or (ii)&nbsp;the FDA issues a &#147;Refusal to File&#148; for any of the Products&#146; regulatory approval application and, after reasonable
consultation with the Developers, we believe that it is commercially unreasonable to <FONT STYLE="white-space:nowrap">re-file.</FONT> The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any
of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any
third-party liabilities arising out of (1)&nbsp;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&nbsp;any failure by either of us to comply with all applicable laws, or (3)&nbsp;our
respective negligence or willful misconduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and
its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;16, 2017, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) entered into the Commercial Supply Agreement with
Itochu and Oishi (the &#147;Commercial Suply Agreement&#148;). Pursuant to the Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development
Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by
us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido
placebo samples, in each case subject to certain minimum order </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quantities. We are required to provide a <FONT STYLE="white-space:nowrap">12-month</FONT> rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis.
Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the years ended December&nbsp;31, 2022, 2021 and 2020, we
purchased inventory in the amount of $6.7&nbsp;million, $5.7&nbsp;million, and $0.8&nbsp;million, respectively, under the Itochu and Oishi Commercial Supply Agreement. The significant increase in inventory purchased in fiscal year 2021 was largely
due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement.
Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&nbsp;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving
written notice specifying the nature of the breach, or (2)&nbsp;in the event of any of the parties&#146; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any
representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product
Development Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its
amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genzyme Supply Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;17, 2015, through our wholly owned subsidiary, Semnur, we entered into that certain exclusive Supply Agreement (the &#147;Genzyme Supply Agreement&#148;) with Genzyme Corporation (&#147;Genzyme&#148;), an affiliate of Sanofi-Aventis
U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium hyaluronate in
specified territories, including the United States and all countries of the European Union (&#147;EU&#148;), exclusively from Genzyme. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply,
the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&nbsp;1, provided that in no case will the price be increased by
more than 5% each year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will remain in effect
until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as
set forth therein, and for additional <FONT STYLE="white-space:nowrap">two-year</FONT> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may
terminate the Genzyme Supply Agreement if (1)&nbsp;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&nbsp;if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by
January&nbsp;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#146; notice. We did not
file for regulatory approval for SEMDEXA by January&nbsp;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#146;s right terminate the Genzyme Supply Agreement if it decides to discontinue
manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&nbsp;31, 2024. Although we are currently in the process of
identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain
exceptions, to indemnify each other against any third-party liabilities arising out of (1)&nbsp;any material breach of our respective representations, warranties and obligations thereunder, or (2)&nbsp;our respective gross negligence or willful
misconduct. In addition, we have agreed to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization
of sodium hyaluronate by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an
exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lifecore Master Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;27, 2017, through our wholly owned subsidiary, Semnur, we entered into that certain Master Services Agreement (as amended, the
&#147;Lifecore Master Services Agreement&#148;), with Lifecore Biomedical, LLC (&#147;Lifecore&#148;). Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for
SEMDEXA as set forth in each separate statement of work (each a &#147;Lifecore Statement of Work&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a
Lifecore Statement of Work on January&nbsp;27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1)&nbsp;project management support, (2)&nbsp;development services, (3)&nbsp;clinical trial materials, and (4)&nbsp;stability
studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#146;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive,
worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expired on December&nbsp;31, 2022, and we are currently negotiating a new agreement with Lifecore. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as
exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Semnur Merger Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#147;Semnur Merger Agreement&#148;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#147;Sigma Merger
Sub&#148;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#147;Semnur Equityholders&#146; Representative&#148;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub
merged with and into Semnur (the &#147;Semnur Merger&#148;), with Semnur surviving as Legacy Scilex&#146;s wholly owned subsidiary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex
in exchange for one share of common stock of Legacy Scilex (&#147;Legacy Scilex Common Stock&#148;), par value $0.0001 per share (the &#147;Contribution&#148;). As a result of the Contribution, and prior to the consummation of the Semnur Merger,
Scilex Pharma became a wholly owned subsidiary of Legacy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#146;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly
owned subsidiaries of Legacy Scilex. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#146;s capital
stock (the &#147;Semnur Equityholders&#148;) and options to purchase Semnur&#146;s common stock, upfront consideration with a value of $70.0&nbsp;million. The upfront consideration was comprised of the following: (i)&nbsp;a cash payment of
approximately $15.0&nbsp;million, and (ii) $55.0&nbsp;million in shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#147;Stock Consideration&#148;). A portion of the cash
consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#146; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to Semnur Equityholders were
placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been released per the terms of the escrow agreement. The Semnur
Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in
Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#146;s issued and outstanding capital stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur
Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0&nbsp;million in aggregate contingent cash consideration based on the achievement of certain
milestones, comprised of a $40.0&nbsp;million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur
products, as follows: (i)&nbsp;a $20.0&nbsp;million payment upon the achievement of $100.0&nbsp;million in cumulative net sales of a Semnur product, (ii)&nbsp;a $20.0&nbsp;million payment upon the achievement of $250.0&nbsp;million in cumulative net
sales of a Semnur product, (iii)&nbsp;a $50.0&nbsp;million payment upon the achievement of $500.0&nbsp;million in cumulative net sales of a Semnur product, and (iv)&nbsp;a $150.0&nbsp;million payment upon the achievement of $750.0&nbsp;million in
cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#146;s first bona fide equity financing with one or more third-party financing sources on an arms&#146; length basis with gross proceeds to Legacy Scilex of at
least $40.0&nbsp;million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&nbsp;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger
Agreement, and (ii)&nbsp;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur
optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights
Agreement with Legacy Scilex (as amended, the &#147;Exchange Agreement&#148;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger,
100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital
stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the <FONT STYLE="white-space:nowrap">60-day</FONT> period commencing the date that was the 18 month
anniversary of the closing of the Semnur Merger (the &#147;Share Exchange&#148;), the Stock Consideration for shares of Sorrento&#146;s common stock with a value of $55.0&nbsp;million based on a price per share of Sorrento&#146;s common stock equal
to the greater of (a)&nbsp;the <FONT STYLE="white-space:nowrap">30-day</FONT> trailing volume weighted average price of one share of Sorrento&#146;s common stock as reported on Nasdaq as of the consummation of the Share Exchange and (b) $5.55
(subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#147;Exchange Price&#148;). Pursuant to an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#146; Representative on September&nbsp;28, 2020, on October&nbsp;9, 2020, Sorrento paid
$55.0&nbsp;million in cash to the Semnur Equityholders in lieu of issuing $55.0&nbsp;million of shares of Sorrento&#146;s common stock at the Exchange Price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as
exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aardvark Asset Purchase Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark
Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights,
for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex
Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Sorrento. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to
<FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), pursuant to which Sorrento sold, conveyed,
assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights
thereto) and Legacy Scilex assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within
60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus, none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the
founder, chief executive officer and a member of the board of directors of Aardvark. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of
the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of
all of their respective terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tulex Master Services Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex acquired the Tulex
Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of <FONT STYLE="white-space:nowrap">SP-104</FONT> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master
services agreement (the &#147;Tulex Master Services Agreement&#148;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&nbsp;15, 2022 and will remain in effect until five years after the effective date, unless terminated early
by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&nbsp;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such
breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&nbsp;in the event of the other party&#146;s insolvency, bankruptcy, reorganization,
liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or
any Tulex Statement of Work (1)&nbsp;without cause upon 30 days prior written notice to Tulex or (2)&nbsp;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex
Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the
Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&nbsp;such party&#146;s
breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&nbsp;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex
Master Services Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as
an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor LP Assignment Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2013, through Semnur, we entered into an Assignment Agreement (the &#147;Assignment Agreement&#148;) with Shah Investor LP
(&#147;Shah Investor&#148;). Mahendra Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain
intellectual property related to pharmaceutical compositions of corticosteroids (the &#147;Assigned IP&#148;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the low-single digits to Shah Investor based on
the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#147;Royalty Product&#148;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The
royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the first Royalty
Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents contained in the Assigned IP. As of the date of this prospectus, no royalty payments have been
made as we have not yet commercialized any applicable products and therefore such payments have not been triggered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignment Agreement will remain in effect on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis until royalties are no longer due on any Royalty Product. Either party may
terminate the Assignment Agreement upon sixty days&#146; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable,
unless such assertion is eliminated and the effect of such assertion cured within such sixty day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of
the material terms of the Assignment Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Romeg License and Commercialization Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&nbsp;14, 2022, we entered into a License and Commercialization Agreement (the &#147;Romeg Agreement&#148;) with RxOmeg
Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1)&nbsp;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and
(2)&nbsp;an exclusive, transferable license to use the trademark &#147;GLOPERBA&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things,
Romeg granted us (1)&nbsp;a transferable license, with the right to sublicense, under the patents and <FONT STYLE="white-space:nowrap">know-how</FONT> specified therein to (a)&nbsp;commercialize the pharmaceutical product comprising liquid
formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148;) in the United States (including its territories) (the &#147;Territory&#148;), (b) develop other products comprising the
Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#147;Licensed Products&#148;) and commercialize any such products and (c)&nbsp;manufacture Licensed Products anywhere in the world,
solely for commercialization in the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark &#147;GLOPERBA&#148; and logos, designs, translations, and modifications thereof in connection with the
commercialization of the Initial Licensed Product solely in the Territory. The license to <FONT STYLE="white-space:nowrap">know-how</FONT> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the
royalty term, but is otherwise <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&nbsp;1, 2027 and, thereafter, is <FONT
STYLE="white-space:nowrap">co-exclusive</FONT> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&nbsp;expiration of the last to expire of the
patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the date of the Romeg Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&nbsp;an
<FONT STYLE="white-space:nowrap">up-front</FONT> payment of $2.0&nbsp;million, (2)&nbsp;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&nbsp;million and (3)&nbsp;certain
royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&nbsp;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product
from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&nbsp;at any time, without cause, upon written notice to Romeg, which termination
will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&nbsp;million shall be paid to Romeg depending on when during the 10&nbsp;year period following the date of the agreement any such termination
notice set forth in the immediately preceding clause (2)&nbsp;has been provided. Romeg may terminate the Romeg Agreement (a)&nbsp;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties
or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period;
(b)&nbsp;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
office or assist any third party to conduct any of these activities; or (c)&nbsp;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed
to by the parties. In addition, either party may terminate the Romeg Agreement (1)&nbsp;in the event the other party materially breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was
provided or (2)&nbsp;in the event the other party (a)&nbsp;files in any court or agency a petition in bankruptcy or insolvency, (b)&nbsp;is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has
not been stayed or dismissed within 90 days after its filing, or (c)&nbsp;makes an assignment of substantially all of its assets for the benefit of its creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain
exceptions, to indemnify Romeg against any loss arising out of the manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the
license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the
registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_63"></A>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <FONT
STYLE="white-space:nowrap">know-how,</FONT> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other
methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the
development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We
also rely on trade secret protection of our confidential information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our novel adhesion and delivery technology, platforms and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing
date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We
cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of December&nbsp;31, 2022 contains approximately sixteen issued and unexpired
U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada,
China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South&nbsp;Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <FONT STYLE="white-space:nowrap">SP-103,</FONT> our patents and patent applications cover compositions and methods
of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With
respect to <FONT STYLE="white-space:nowrap">SP-104,</FONT> our pending Patent Cooperation Treaty application is WO&nbsp;2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst
formulations of <FONT STYLE="white-space:nowrap">low-dose</FONT> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have six issued U.S. patents and
two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
10,765,749, 10,765,640 and 11,278,623 all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate
to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No.&nbsp;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. We believe that we have certain <FONT
STYLE="white-space:nowrap">know-how</FONT> and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However,
trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve
the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trademarks, Trade Secrets and Other Proprietary Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for
the marks &#147;SCILEX,&#148; &#147;ZTlido&#148; and &#147;RESPONSIBLE BY DESIGN.&#148; We also own pending trademark applications for &#147;SEMNUR PHARMACEUTICALS&#148; and &#147;SEMDEXA&#148; in the United States. We also license the GLOPERBA
trademark as discussed in relation to the Romeg Agreement described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of
our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> we rely on trade secret protection and confidentiality
agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship
with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#146;s relationship with
us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors.
Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <FONT STYLE="white-space:nowrap">know-how</FONT> for sterile
viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_64"></A>Government Regulation and Product Approval </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively
regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and
reporting, marketing and export and import of products such as those we are marketing and developing. <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104</FONT> and
any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally
marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial
resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and
local statutes and regulations. The process of obtaining regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to
comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as inspection
scrutiny, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, refusals of government contracts, or reimbursements, restitution, disgorgement of profits or civil or criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory
Practices (&#147;GLPs&#148;) or other applicable regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an Investigational New Drug Application (&#147;IND&#148;), which must become effective
before human clinical trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (&#147;IRB&#148;) covering each clinical site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the laws and regulations
pertaining to the conduct of human clinical trials, collectively referred to as Good Clinical Practice (&#147;GCP&#148;) requirements to establish the safety and efficacy of the proposed drug for its intended use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an NDA or other marketing application (collectively, an &#147;NDA&#148;), for a proposed
new drug, including its specific formulation and labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is
produced to assess compliance with the FDA&#146;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the
NDA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical
testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate.
The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available
clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the
effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA,
unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time period. In such a case, the IND
sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <FONT
STYLE="white-space:nowrap">non-compliance,</FONT> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend
or terminate such trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target
disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the
FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the
FDA&#146;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and
rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that
must be provided to and signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are
required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 1.</I></B> The drug is initially introduced into healthy human subjects and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently
toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 2.</I></B> The drug is evaluated in a limited patient population to identify possible adverse effects
and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Phase 3.</I></B> The drug is administered to an expanded patient population in adequate and well-controlled
clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of
the product. Generally, at least two adequate and <FONT STYLE="white-space:nowrap">well-controlled</FONT> Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a
single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used
to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA,
and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that
suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase 1, Phase 2 and Phase 3 clinical trials may not yield positive results,
or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are
being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has
been associated with unexpected serious harm to study subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to
meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice,
and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they
believe will support approval of the new drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and
must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Review and Approval Processes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA
may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process
and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to
the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the
NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#146;s identity, strength,
quality and purity. Under the Prescription Drug User Fee Act (&#147;PDUFA&#148;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a standard, original NDA for a new molecular entity to
review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after the application is submitted. The FDA
conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information
rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory
committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an
advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (&#147;REMS&#148;) is necessary to assure the
safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or
dispensing of products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be
manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within required specifications. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the
submission and often will request additional testing or information. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial
marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response
Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical
trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are
submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the
approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications,
warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#146;s safety and effectiveness
and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development
and Review Programs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to
expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are
eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes
available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees
to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA
programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy
exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority
review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or
conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than
irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or
lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">well-controlled</FONT> post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <FONT
STYLE="white-space:nowrap">pre-use</FONT> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the
standards for approval but may expedite the development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act
established a category of drugs referred to as &#147;breakthrough therapies&#148; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#147;breakthrough therapy&#148;
if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA
interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as
breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st
Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is
intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The
benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval
based on surrogate or intermediate endpoints. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral
radicular pain and have applied for breakthrough therapy designation for the treatment of lumbosacral radicular pain based on the <FONT STYLE="white-space:nowrap">top-line</FONT> results obtained from the pivotal Phase 3 trial, which results reflect
achievement of primary and secondary endpoints. We intend to submit a request to the FDA for a type D meeting in order to clarify the expectations regarding the size of the safety database needed for a NDA given that at this time no safety concerns
have been identified during the course of clinical development, and to agree on acceptance of SP-102 Phase 3 trial data as pivotal evidence of efficacy to support product registration. We have also obtained fast track designation for <FONT
STYLE="white-space:nowrap">SP-103</FONT> for the treatment of acute LBP. We may seek additional designations for SEMDEXA, <FONT STYLE="white-space:nowrap">SP-103</FONT> or our other product candidates. Even if a product qualifies for one or more of
these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may
result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional
labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state
agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a
condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by
the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or
commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#146;s approved labeling, which is known as <FONT
STYLE="white-space:nowrap">&#147;off-label</FONT> use,&#148; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have
negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications,
withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hatch-Waxman Amendments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first
being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product,
but some of the data are not owned by or licensed to the applicant. Section&nbsp;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application
(&#147;ANDA&#148;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown
to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be
substituted by pharmacists under prescriptions written for the branded reference drug. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains
full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference.
This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be
submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&nbsp;no patent
information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&nbsp;such patent has expired; (3)&nbsp;the date on which such patent expires; or (4)&nbsp;such patent
is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the
reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30&nbsp;months from the receipt of the notice of the Paragraph IV Certification, the
expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#146;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <FONT
STYLE="white-space:nowrap">30-month</FONT> stay. Thus, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#146;s or patent
owner&#146;s decision to initiate patent litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman
Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the
holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the
holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or
bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation
that required the new clinical data, but generally allows the approval for <FONT STYLE="white-space:nowrap">non-protected</FONT> characteristics and labeling. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making
the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or
condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such
approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug
supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used <FONT
STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug
within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-Party Payor Coverage, Pricing and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate
reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United
States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication, and which can change over
time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to
purchasers, private health plans or government healthcare programs, in order for the company&#146;s products to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary
or cost-effective. A payor&#146;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#146;s determination to provide coverage for a
product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available
to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of
pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of
managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid
healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in
jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. See the discussion below under
&#147;<I>U.S. Healthcare Reform&#148;</I>, and regarding the Inflation Reduction Act for further information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and
reimbursement schemes exist in other countries. In the European Economic Area (&#147;EEA&#148;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of
pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some countries in the EEA operate positive and negative list systems
under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the
completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits.
The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border
imports from <FONT STYLE="white-space:nowrap">low-priced</FONT> markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow
favorable reimbursement and pricing arrangements for any of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party
payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major
legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2020 (the &#147;ACA&#148;) was enacted, which is intended to broaden access to
health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry
and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, (1)&nbsp;subjected therapeutic biologics to potential competition by
lower-cost biosimilars by creating a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products, (2)&nbsp;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&nbsp;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in
Medicaid managed care organizations, (4)&nbsp;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare
programs, (5)&nbsp;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated
prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D, (6)&nbsp;expanded eligibility criteria for Medicaid
programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially
increasing manufacturers&#146; Medicaid rebate liability, (7)&nbsp;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&nbsp;created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9)&nbsp;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to
lower Medicare and Medicaid spending, potentially including prescription drug spending. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial,
Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the
ACA has been signed into law. The TCJA included a provision that repealed, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain individuals who fail to
maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#147;individual mandate&#148;. Further, the Bipartisan Budget Act of 2018 (the &#147;BBA&#148;), among other things, amended the ACA, effective
January&nbsp;1, 2019, to increase from 50% to 70% the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to
close the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole&#148;. On June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety
because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that
initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that
limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage
through Medicaid or the ACA. In addition, on August&nbsp;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA
marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#147;donut hole&#148; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or other efforts, if any, to modify or
invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and
services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce
healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with
the exception of a temporary suspension from May&nbsp;1, 2020, through May&nbsp;31, 2022, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows
the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second
half of the year. Moreover, on January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and
cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the
ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve
research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drug products. On May&nbsp;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of
integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#146;s prescription drug benefit. Similarly, since
2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&nbsp;16, 2022, President Biden signed into law the Inflation Reduction Act
of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and
Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug
manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#147;maximum fair price&#148; under the law or for taking price
increases that exceed inflation. The legislation also caps Medicare beneficiaries&#146; annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> drug expenses at $2,000. The second provision imposes a
requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to
limit price increases. The new rebate applies to drugs covered by Medicare under Part B or Part D. The rebate obligation applies if the average sales price (for Part B) or average manufacturers price (for Part D) of a single source drug or biologic
increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The
base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is
subject to a penalty of 125% of the original rebate amount. The provision for Part D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part B takes effect in 2023. At the state level, legislatures are increasingly
passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and
governmental authorities in reference pricing systems and publication of discounts and list prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare
reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the United&nbsp;States Department of Justice and individual United
States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and
abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us.
Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in
pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback
Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the
referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#147;remuneration&#148; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted
to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market
value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to
induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback
Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government
may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary
penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as
claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any
third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False
Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false
statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to
bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has
increased </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and
not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the
federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price,
improper promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses (i.e., uses not expressly approved by the FDA in a drug&#146;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities
relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases,
among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending
such claims, as well as any sanctions imposed, could adversely affect our financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under
the U.S. federal Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (&#147;HIPAA&#148;) impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a
scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health
care benefits, items or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security
regulation promulgated by both the U.S. federal government and the U.S. states in which we conduct our business. For example, under HIPAA, the U.S. Department of Health and Human Services imposes upon &#147;covered entities&#148; (broadly,
healthcare providers, health plans and healthcare clearinghouses) and their respective &#147;business associates&#148; (individuals or entities that create, receive, maintain or transmit protected health information on behalf of a covered entity)
privacy obligations; requirements to implement appropriate administrative, physical and technical safeguards to ensure the confidentiality, integrity, and security of electronic protected health information; and breach response notification
obligations. We are not subject to HIPAA, as we are neither a covered entity nor business associate. The Federal Trade Commission (the &#147;FTC&#148;) also requires companies to take appropriate steps to keep consumers&#146; personal information
secure and to make accurate statements regarding how they secure personal information under their custody or control, such as in a privacy notice. The FTC also expects a company&#146;s data security measures to be reasonable and appropriate in light
of the sensitivity and volume of personal information it holds, the size and complexity of its business, and the cost of available tools to improve data security and reduce vulnerabilities. Individually identifiable health information, which we
process, is considered sensitive data that merits stronger safeguards. Violations of the foregoing FTC requirements may constitute unfair or deceptive acts or practices under Section&nbsp;5(a) of the Federal Trade Commission Act (the &#147;FTC
Act&#148;). While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce public privacy statements as it interprets them. Further, events that we cannot fully control, such as data breaches, may also
result in civil penalties, FTC enforcement or enforcement by U.S. state attorneys general or other regulators. . Various U.S. states have implemented privacy laws and regulations that regulate the use and disclosure of health information and other
personal information. For example, the California Consumer Privacy Act and its implementing regulations (the &#147;CCPA&#148;), established a privacy framework for covered businesses by, among other items, expanding the definition of personal
information, establishing new data privacy rights for consumers that are resident in the State of California, imposing rules on the collection of personal information from minors, and creating a statutory damages framework for violations of the
CCPA, including for failure to implement reasonable security procedures and practices to prevent data breaches. Penalties for violations of the CCPA include civil penalties and may result in related legal claims. The California Privacy Rights Act
(&#147;CPRA&#148;), most provisions of which became operative on January&nbsp;1, 2023, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (the
&#147;CPPA&#148;). Similarly, the Virginia Consumer Data Protection Act took effect on January&nbsp;1, 2023; the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Colorado Privacy Act will take effect on July&nbsp;1, 2023; the Utah Consumer Privacy Act will take effect on December&nbsp;31, 2023; and the Connecticut Data Privacy Act will take effect on
July&nbsp;1, 2023. The foregoing U.S. state privacy laws impose many similar obligations as the CCPA on our processing of personal information. Other U.S. states are considering similar privacy legislation, and industry organizations regularly adopt
and advocate for new standards in these areas. The uncertainty, ambiguity, complexity, and potential inconsistency surrounding the implementation and interpretation of the CCPA and other enacted or forthcoming U.S. state privacy laws exemplify the
vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the
event of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with such laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local,
state, provincial, and national data protection standards, impose additional compliance requirements, and generate additional risks of enforcement for <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Such laws may also restrict the access,
use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and
hackers, or to remediate issues caused by such breaches. Compliance with these laws is challenging, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an
increasing and substantial cost in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs,
devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers
of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions
require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&nbsp;1, 2022, these reporting obligations are extended to include transfers of
value made to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these
laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports
with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain
physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing
administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the Foreign Corrupt Practices Act
(&#147;FCPA&#148;). If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus
Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also
be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and
wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some
states also impose requirements on manufacturers and distributors to establish the pedigree </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the
distribution chain. Many of our current as well as possible future activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and
reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at www.ClinicalTrials.gov. We are subject to various environmental, health and safety regulations, including those
governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be
subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension
of production, denial or withdrawal of <FONT STYLE="white-space:nowrap">pre-marketing</FONT> product approvals, private &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter
into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> and the curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for
instance, applicable <FONT STYLE="white-space:nowrap">post-marketing</FONT> requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value
to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Hatch-Waxman Exclusivity</I>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain
applications of other companies seeking to reference another company&#146;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing
exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is
the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&nbsp;505(b)(2) NDA submitted by another
company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of
patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing
NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an
existing drug. This <FONT STYLE="white-space:nowrap">three-year</FONT> exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active
agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and
adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Pediatric Exclusivity</I>. Pediatric
exclusivity is another type of regulatory market exclusivity in the United&nbsp;States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This <FONT STYLE="white-space:nowrap">six-month</FONT>
exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Europe/Rest of World Government Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior
to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#147;CTA&#148;) must be submitted
to each country&#146;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#147;Clinical Trials
Directive&#148;) and the related national implementing provisions of the relevant individual EEA country&#146;s requirements, the clinical trial described in that CTA may proceed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#147;Clinical Trials Regulation&#148;) was adopted. The Clinical
Trials Regulation entered into force on January&nbsp;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the prior Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to
start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&nbsp;31, 2022. The transition period for the trials ongoing at the moment of
applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&nbsp;31, 2023 can continue to be conducted under the
Clinical Trials Directive until January&nbsp;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of
the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single
entry point, the &#147;EU portal&#148;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications
for clinical trials, which is divided into two parts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin
America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each
jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can
be commercialized only after obtaining a Marketing Authorization (&#147;MA&#148;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. There is a &#147;centralized&#148; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#147;EMA&#148;). If the EMA
issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;centralized&#148; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal
products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#147;centralized&#148; procedure is optional for products
containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#147;decentralized&#148; procedure allowing companies to file identical applications to several EEA countries simultaneously
for product candidates that have not yet been authorized in any EEA country and a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;mutual recognition&#148; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities
in other EEA countries. Under the &#147;decentralized&#148; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference
Member State (&#147;RMS&#148;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA
or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after
the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds
in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded
products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile
additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#147;HTA&#148;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures
in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal
product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The
extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA
across the EEA, will apply from January&nbsp;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in
the EEA could be negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also
governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#146; codes of professional conduct. Failure to comply with these
requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the
advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that
promotional materials and advertising in relation to medicinal products comply with the product&#146;s Summary of Product Characteristics (&#147;SmPC&#148;), as approved by the competent authorities in connection with a marketing authorization
approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <FONT STYLE="white-space:nowrap">off-label</FONT>
and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals.
Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited
by, data privacy and security regulations in the EEA, Switzerland, or the United Kingdom (&#147;UK&#148;), where the legislative and regulatory landscape continues to evolve. There has been increased regulator attention to privacy and data security
issues that could potentially affect our business, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including through legislation such as the EEA General Data Protection Regulation (&#147;EEA GDPR&#148;) and UK General Data Protection Regulation (&#147;UK GDPR,&#148; and together, the
&#147;GDPR&#148;), which each imposes strict obligations on the processing of personal data, including the transfer of personal data from the EEA, Switzerland, or UK to third countries that the European Commission has determined does not ensure an
adequate level of protection, such as the United States. If we violate the GDPR, we may face significant penalties of up to EUR&nbsp;10,000,000 or 2% of our total worldwide annual, or for more serious violations, up to EUR 20,000,000 or 4% of our
total worldwide annual turnover. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The GDPR and other EEA and UK data privacy and security regulations generally restrict the transfer of
personal data from the EEA, United Kingdom and Switzerland, to the United States and certain other third countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary
safeguards on which companies may rely to import or export personal data from had been the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield and <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield frameworks administered
by the U.S. Department of Commerce. However, the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#147;CJEU&#148;) in a case known as &#147;<I>Schrems
II</I>.&#148; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#147;FDPIC&#148;) announced that the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield does not provide adequate safeguards
for the purposes of personal data transfers from Switzerland to third countries that are deemed as not providing adequate protection, including the United States. While the FDPIC does not have authority to invalidate the <FONT
STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield regime, the FDPIC&#146;s announcement casts doubt on the viability of the <FONT STYLE="white-space:nowrap">Swiss-U.S.</FONT> Privacy Shield as a compliance mechanism for <FONT
STYLE="white-space:nowrap">Swiss-U.S.</FONT> data transfers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CJEU&#146;s decision in <I>Schrems II</I> also raised questions about
whether one of the primary alternatives to the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, namely the European Commission&#146;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the
United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in <I>Schrems II</I>, it made clear that reliance
on the Standard Contractual Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights
of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or
applicable European law, the decision in <I>Schrems II</I> and subsequent draft guidance from the European Data Protection Board (the &#147;EDPB&#148;) would require the parties to that transfer to implement certain supplementary technical,
organizational and/or contractual measures to rely on the Standard Contractual Clauses as a lawful &#147;transfer mechanism.&#148; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures
appears to conclude that any combination of such measures may not be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#147;in the clear&#148; to recipients in countries where
the power granted to public authorities to access the transferred data goes beyond that which is &#147;necessary and proportionate in a democratic society&#148; &#151; which may, following the CJEU&#146;s conclusions in <I>Schrems II</I> on relevant
powers of United States public authorities and commentary in draft EDPB guidance, include the United States in certain circumstances (<I>e.g</I>., where Section&nbsp;702 of the US Foreign Intelligence Surveillance Act applies). Further, the UK
Information Commissioner&#146;s Office (&#147;ICO&#148;) has provided for separate international data transfer mechanisms for restricted transfers of data from the UK: an international data transfer agreement (the UK equivalent of the EU Standard
Contractual Clauses) (&#147;IDTA&#148;) and an international data transfer addendum (which amends the EU Standard Contractual Clauses for purposes of international data transfers from the UK to countries without an essentially equivalent data
protection framework) (the &#147;Addendum&#148;). Both the IDTA and the Addendum came into force in March 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to
implement a valid solution to transfer personal data from the EEA to the United States or other countries that have not been deemed to provide an essentially equivalent level of data protection, we may face increased exposure to regulatory action,
substantial fines, or injunction orders to stop processing personal data from EEA, Swiss, or UK residents. Any inability to import personal data to the United States may also </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrict our clinical trials activities in the EU; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies
subject to EU data privacy and security laws; and require us to increase our data processing capabilities in the EU and the UK at significant expense. Additionally, other countries outside of the EU have enacted or are considering enacting similar
cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in the EEA, Switzerland, and the UK
will likely also arise in other jurisdictions that adopt laws similar to the GDPR or regulatory frameworks of equivalent complexity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions or criminal
prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_65"></A>Employees and Human Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, we had approximately 90 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our
workforce, seven employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and 13 were primarily engaged in general management and administration. None of our employees are represented by labor
unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on
identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve
our human capital management strategies and find ways to foster engagement and growth within our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total
rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward
selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the
success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and
professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#146; lives. The success of our business is fundamentally connected to the
well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, which included
implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_66"></A>Facilities and Properties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office
space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate
space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_67"></A>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S.
LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding
their respective OTC patch products (the &#147;Sanofi-Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements
of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently
scheduled for trial to begin on July&nbsp;24, 2023. We cannot make any predictions about the outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Former
Employee Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former
President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with
us, breach of fiduciary duty, and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement (the &#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction
enjoining Mr.&nbsp;Mack from further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax from tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT>
agreement. The case was tried from September&nbsp;12, 2022 to September&nbsp;14, 2022. Post-trial briefing and closing arguments have been concluded and the case is under submission to the Court. We cannot make any predictions about the outcome in
this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ZTlido Patent Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together,
&#147;Apotex&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;ZTlido Patent Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;). The ZTlido
Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#146;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the
ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Apotex&#146;s ANDA be no earlier than the expiration of
the asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such further and other relief as the court may deem appropriate. Apotex is subject to a <FONT STYLE="white-space:nowrap">30-month</FONT> stay
preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&nbsp;11, 2024. Trial in the ZTlido Patent Litigation has not yet been scheduled. We cannot make any predictions about the final
outcome of this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_68"></A>Our Corporate History </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&nbsp;18, 2019,
Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex
Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#147;Contribution&#148;). Pursuant to the Contribution and Loan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5&nbsp;million in the form of a note payable, which loan was used to fund the acquisition of Semnur.
Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#146;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur
equity, and Sorrento, for limited purposes (as amended, the &#147;Semnur Merger Agreement&#148;). Pursuant to the Semnur Merger Agreement, Sigma Merger Sub, Inc. merged with and into Semnur (such transaction, the &#147;Semnur Merger&#148;), with
Semnur surviving the Semnur Merger as Legacy Scilex&#146;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. Prior to the Contribution and
the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we are eligible for exemptions from
various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the
Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_69"></A>Website </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is <I>www.scilexholding.com</I>. We do not incorporate the information on, or accessible through, our website into this
prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_70"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and
executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_71"></A>Executive Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of March&nbsp;1, 2023. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer, President and Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Chairperson and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth A. Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors</I>:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP
STYLE="font-size:75%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Jaisim
Shah</I></B>. Mr.&nbsp;Shah has served as our Chief Executive Officer and President and a member of our Board since November&nbsp;10, 2022. Mr.&nbsp;Shah has also served as Legacy Scilex&#146;s President, Chief Executive Officer and a board member
since March 2019. He has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the
Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Legacy Scilex in March 2019. Mr.&nbsp;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to Semnur,
Mr.&nbsp;Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., a publicly traded company, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&nbsp;Shah led a successful sale of Elevation to
Sunovion Pharmaceuticals Inc. in September 2012. Prior to Elevation, Mr.&nbsp;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to Zelos, Mr.&nbsp;Shah was the Senior Vice President and
Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&nbsp;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic
transactions with pharmaceutical and biotech companies. Prior to PDL, Mr.&nbsp;Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the &#147;President&#146;s Award&#148; for completing one of the
most significant collaborations in the company&#146;s history. Previously, Mr.&nbsp;Shah was at F. <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche AG in international marketing and was global business leader for corporate alliances with
Genentech, Inc. and IDEC Corporation. Mr.&nbsp;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since September 2013.
Mr.&nbsp;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&nbsp;Shah&#146;s extensive operational, executive and business development experience qualifies him to serve on our
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Henry Ji, Ph.D</I></B>. Dr.&nbsp;Ji has served as our Executive Chairperson and a member of our Board since
November&nbsp;10, 2022. Prior to that, he served as Legacy Scilex&#146;s Executive Chairperson and a board member from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
March 2019 to November 2022. Dr.&nbsp;Ji has served on the board of directors of Scilex Pharma since November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016
to March 2019. He <FONT STYLE="white-space:nowrap">co-founded</FONT> and has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since January 2006, served as its Chief Scientific Officer from November 2008 to September
2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief Executive Officer and President since September 2012 and as Chairman of its board of directors since
August 2017. In 2002, Dr.&nbsp;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr.&nbsp;Ji served
as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and
nanotechnology. During his tenure at CombiMatrix, Dr.&nbsp;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr.&nbsp;Ji served as Director of Business Development, and in 2001 as Vice
President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr.&nbsp;Ji <FONT STYLE="white-space:nowrap">co-founded</FONT>
Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr.&nbsp;Ji previously served as a director of Celularity Inc. from June 2017 to
July 2021. Dr.&nbsp;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#146;s intellectual property. Dr.&nbsp;Ji has a Ph.D. in Animal Physiology from the University of
Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&nbsp;Ji has demonstrated significant leadership skills as President and Chief Executive Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene
Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on our Board. We believe that Dr.&nbsp;Ji&#146;s extensive knowledge of the industry in which we operate allows him to bring to our Board a
broad understanding of the operational and strategic issues we face. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Elizabeth A. Czerepak</I></B>. Ms.&nbsp;Czerepak has served as
our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary since November&nbsp;10, 2022. Prior to that, she served on the Legacy Scilex Board from September 2019 to October 2020 and on the board of directors of
Sorrento from October 2021 to May 2022. Ms.&nbsp;Czerepak has over 35 years of experience in big pharma, biotechnology and venture capital. Since September 2020, she has served as the Chief Financial Officer of BeyondSpring Inc., a global
biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. From May 2018 to January 2020, Ms.&nbsp;Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a
technology-focused lipid nanoparticle delivery company, From 2015 to 2018 she served as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015,
she served as the Chief Financial Officer and the Chief Business Officer of Isarna Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014,
Ms.&nbsp;Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a
Managing Director at JPMorgan Chase&nbsp;&amp; Co. and Bear, Stearns&nbsp;&amp; Co., a General Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63).
Since February 2020, Ms.&nbsp;Czerepak has served as a director and chair of the audit committee of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms.&nbsp;Czerepak previously served on the board
of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. She holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020, Ms.&nbsp;Czerepak
earned a Corporate Director Certificate from Harvard Business School. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Dorman Followwill</I></B>. Mr.&nbsp;Followwill has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served
as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
since October 2017 and as its lead independent director since August 2020. Mr.&nbsp;Followwill was Senior Partner of Transformational Health at Frost&nbsp;&amp; Sullivan, a business consulting
firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles at Frost&nbsp;&amp; Sullivan, including Partner
on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost&nbsp;&amp; Sullivan to help found the
Consulting practice in January 1988. Mr.&nbsp;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry
sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&nbsp;Followwill&#146;s extensive knowledge and understanding of the healthcare
and life sciences industries qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Laura J. Hamill</I></B>. Ms.&nbsp;Hamill has served as a member of
our Board since November&nbsp;10, 2022. Prior to that, she served as a director of Legacy Scilex from April 2022 to November 2022 and has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial operational
roles in a variety of executive leadership positions. Since <FONT STYLE="white-space:nowrap">mid-2019,</FONT> Ms.&nbsp;Hamill has served as the founder and a consultant at Hamill Advisory Group, LLC. From September 2018 to July 2019, Ms.&nbsp;Hamill
served as the Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a research-based biopharmaceutical company, where she was responsible for leading the company&#146;s global commercial strategic direction and
delivering annual revenue of $20&nbsp;billion. Prior to joining Gilead, Ms.&nbsp;Hamill held a number of U.S. and international executive positions at Amgen Corporation, a biotechnology company focused on discovering and delivering innovative human
therapeutics, from July 2000 to August 2018, most recently as Senior Vice President, U.S. Commercial Operations. During her time at Amgen, Ms.&nbsp;Hamill established the company&#146;s intercontinental region and managed the company&#146;s
international marketing and business operations while living abroad in Switzerland for three years. She also served as a member of the company&#146;s corporate governance team, such as business development, global commercial operations, the Amgen
Foundation and chair for the company&#146;s Senior Women&#146;s Leadership Council. In addition, Ms.&nbsp;Hamill previously held a variety of executive roles in the biopharmaceutical industry, including positions at Klemtner Inc. and F. <FONT
STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG. Ms.&nbsp;Hamill has served on the board of directors of a number of public companies, including AnaptysBio, Inc. since September 2019, <FONT STYLE="white-space:nowrap">Y-mAbs</FONT>
Therapeutics, Inc. since April 2020, Pardes Biosciences, Inc. since August 2021 and BB Biotech AG since March 2022. She previously served as a director at Acceleron Pharma Inc. (acquired by Merck) from September 2020 to December 2021.
Ms.&nbsp;Hamill holds a B.A. in business administration from the University of Arizona. We believe that Ms.&nbsp;Hamill is qualified to serve on our Board because of her extensive leadership experience in the biopharmaceutical industry and her
global commercial operations and strategic planning expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D</I></B>.
Dr.&nbsp;Lee has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served as a director of Legacy Scilex from March 2019 to November 2022 and as a director of Scilex Pharma since November 2018. Dr.&nbsp;Lee has over 20
years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. He is the founder and has served as the Chief Executive Officer of Aardvark
Therapeutics, Inc. since March 2017. Prior to that, Dr.&nbsp;Lee joined NantKwest, Inc., a publicly-traded immunotherapy company in 2014 and served as its Chief Strategy Officer until March 2017. His experience includes therapeutics for immunology,
cardiovascular, oncology, neurology, and infectious disease indications. Dr.&nbsp;Lee is also an inventor or <FONT STYLE="white-space:nowrap">co-inventor</FONT> of multiple biomedical and biotechnology innovations, licensed or assigned to several
companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc., Sorrento and Aardvark Therapeutics, Inc. Dr.&nbsp;Lee earned his M.D. degree from the University of California, San Diego and his B.A.
degree from the University of California, Berkeley in Molecular Biology. We believe that Dr.&nbsp;Lee is qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional
background in the field of biotechnology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>David Lemus</I></B>. Mr.&nbsp;Lemus has served as a member of our Board since
November&nbsp;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
October 2017. Mr.&nbsp;Lemus has served as Chief Executive Officer of IronShore Pharmaceuticals Inc. since January 2020 as well as the founder and Chief Executive Officer of LEMAX LLC since 2017.
He also currently serves as a <FONT STYLE="white-space:nowrap">non-executive</FONT> board member of Silence Therapeutics, plc and BioHealth Innovation, Inc. and served previously on several other boards of public and private companies as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director. He served from November 2017 to September 2018 as the Chief Operating Officer and Chief Financial Officer of Proteros biosciences GmbH. Previously, from January 2016 to May 2017, he served as
Interim Chief Financial Officer and Chief Operating Officer of Medigene AG. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he served as Chief Executive Officer from January 2013 to July 2015, as Chief Operating Officer from March 2012 to
December 2012, and as V.P. Finance from July 2011 to February 2012. Mr.&nbsp;Lemus previously served as Chief Financial Officer and Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his role at MorphoSys AG, he held various
positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division) at F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche AG, Group Treasurer of Lindt&nbsp;&amp; Spruengli
AG and Treasury Consultant for Electrolux AB. Mr.&nbsp;Lemus received a M.S. from the Massachusetts Institute of Technology Sloan School of Management in 1988 and a B.S. in Accounting from the University of Maryland in 1984. Mr.&nbsp;Lemus is also a
certified public accountant licensed in the State of Maryland. We believe that Mr.&nbsp;Lemus&#146; extensive accounting and financial background and business experience in the life sciences industry qualify him to serve on our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tommy Thompson</I></B>. Mr.&nbsp;Thompson has served as a member of our Board since November&nbsp;10, 2022. Prior to that, he served on
the Legacy Scilex Board from July 2022 to November 2022. Mr.&nbsp;Thompson currently serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. From July 2020 to March 2022, Mr.&nbsp;Thompson served as University of Wisconsin
System President. From 2005 to 2012, Mr.&nbsp;Thompson was a partner in the law firm of Akin Gump Strauss Hauer&nbsp;&amp; Feld LLP in Washington, D.C, and as an Adjunct Senior Advisor from 2017 to 2020. February 2005 to January 2011,
Mr.&nbsp;Thompson served as President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions. Prior to entering the private sector in 2005, Mr.&nbsp;Thompson enjoyed a long and distinguished career in public
service. From February 2001 to January 2005, Mr.&nbsp;Thompson served as the former Secretary of the U.S. Department of Health&nbsp;&amp; Human Services, where he served as the nation&#146;s leading advocate for the health and welfare of all
Americans. Prior to that, Mr.&nbsp;Thompson served four terms as Governor of Wisconsin from January 1987 to February 2001, where he was best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform,
and for his work toward expanding health care access across all segments of society. Mr.&nbsp;Thompson currently serves as Chairman of the board of directors of Physicians Realty Trust (NYSE: DOC) and of TherapeuticsMD, Inc. and also serves as a
member of the board of directors of United Therapeutics Corporation (Nasdaq: UTHR). He previously served on the boards of directors of various other companies, including Logistics Health, Inc. Health Solutions, a health care consulting company, C.
R. Bard, Inc. (NYSE: BCR), Centene Corporation (NYSE: CNC), Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.) (Nasdaq: PSTV), CareView Communications, Inc. (OTCQB: CRVW), Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) (Nasdaq: VYNT),
and Pure Bioscience, Inc. (Nasdaq: PURE). Mr.&nbsp;Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison. We believe that Mr.&nbsp;Thompson is qualified to serve on our Board because of his experience in public service,
particularly his services and knowledge related to the health care industry as a whole, and extensive board experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_72"></A>Family Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_73"></A>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of seven members. Dr.&nbsp;Ji serves as
Executive Chairperson of our Board. The primary responsibilities of our Board are to provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <I>ad hoc </I>basis as required.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Certificate of Incorporation and the Bylaws, our Board
is divided into three classes with staggered three-year terms, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;I directors are Dorman Followwill, David Lemus, and Tommy Thompson, and their term will expire at
the annual meeting of stockholders to be held in 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;II directors are <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. and Laura J. Hamill and
their term will expire at the annual meeting of stockholders to be held in 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Class&nbsp;III directors are Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting
of stockholders to be held in 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, the successors to directors whose terms
will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our
Board; <I>provided </I>that, at any time the Sorrento Group beneficially owns, in the aggregate, at least 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, the
stockholders may also fix the number of directors by resolutions adopted by the stockholders, in each case, subject to certain rights of any holders of our preferred stock to elect directors. Any increase or decrease in the number of directors will
be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. No decrease in the number of directors constituting our Board will shorten
the term of any incumbent director. Our directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the
election of such directors; <I>provided, however</I>, that, from and after the Sorrento Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting
power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to
applicable law and the Certificate of Incorporation and subject to the rights of the holders of any series of our preferred stock (including pursuant to the Stockholder Agreement), any vacancy on our Board may be filled by our Board or our
stockholders; <I>provided, however</I>, that from and after the Sorrento Trigger Event, any such vacancy shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office
until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#146;s earlier death,
resignation, retirement, removal or disqualification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_74"></A>Controlled Company Exemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power for the election of directors. As a result, we are a &#147;controlled company&#148; within the
meaning of the Nasdaq Listing Rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power is held by an
individual, group or another company is a &#147;controlled company&#148; and may elect not to comply with certain corporate governance standards, including, but not limited to, the requirements (i)&nbsp;that a majority of its board of directors
consist of independent directors, (ii)&nbsp;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities and
(iii)&nbsp;that director nominees must be selected or recommended for the board&#146;s selection, either by independent directors constituting a majority of the board&#146;s independent directors in a vote in which only independent directors
participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#146;s purpose and responsibilities. While we do not presently intend to rely on these
exemptions, we may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the
corporate governance requirements of Nasdaq. If we cease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be a &#147;controlled company&#148; and our shares of Common Stock continue to be listed on Nasdaq, we will be required to comply with these standards and, depending on our Board&#146;s
independence determination with respect to its then-current directors, we may be required to add additional directors to our Board in order to achieve such compliance within the applicable transition periods. See the section of this prospectus
titled &#147;<I>Risk Factors &#151; We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have
the same protection afforded to stockholders of companies that are subject to such governance requirements.</I>&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_75"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#146;s criteria for &#147;independence.&#148; As a
&#147;controlled company&#148;, we are largely exempted from such requirements. Our Board has determined that each of the directors on our Board, other than Dr.&nbsp;Ji and Mr.&nbsp;Shah (as a result of their positions as our Executive Chairperson
and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and our Board consists of a majority of &#147;independent directors&#148; as defined under the rules of
the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_76"></A>Role of Board in Risk Oversight Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a
culture that incorporates risk management into its corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational (including
cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks we face. Throughout the year, senior management reviews
these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive
management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#146;s risk oversight process builds upon management&#146;s risk assessment and mitigation processes, which include reviews of
long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal,
regulatory, cybersecurity, strategic and reputational risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_77"></A>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of
our Board. Our Board is chaired by Dr.&nbsp;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically
review its leadership structure and may make such changes in the future as it deems appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_78"></A>Board Diversity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#146;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge,
experience, skills and expertise that are likely to enhance our ability, as well as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as personal and professional integrity, ethics and values;
experience in corporate management, such as serving as an officer or former officer of a publicly-held company; and experience as a board member or executive officer of another publicly-held company. In addition, our Board may consider diversity in
identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective, including, but not limited to,
with respect to age, gender, race, place of residence and specialized experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_79"></A>Committees of our Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an audit committee, compensation committee and nominating and corporate governance committee. Our Board has adopted a charter for
each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each committee are available on the investor relations portion of our website. The composition and responsibilities
of each of the committees of our Board are as set forth below. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit
committee consists of David Lemus, Laura J. Hamill and Dorman Followwill, with David Lemus serving as the chairperson of the committee. Each of the members of the audit committee satisfies the independence requirements under the applicable Nasdaq
Listing Rules and SEC rules. Each member of the audit committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the audit committee are included in a written charter. The audit committee assists our Board in fulfilling our
Board&#146;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit
function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this
purpose, the audit committee performs several functions. The audit committee&#146;s responsibilities include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered
public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public
accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between the Company, or persons in financial oversight roles with the Company, and such independent registered public
accounting firm or their affiliates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving engagements of the independent registered public accounting firm, prior to commencement
of the engagement, and the scope of and plans for the audit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing with management and the independent registered public accounting firm any fraud that includes
management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding
accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the results of management&#146;s efforts to monitor compliance with our programs and policies designed
to ensure compliance with laws and rules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing our programs, policies and procedures related to our information technology systems, including
information asset security and data protection; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management and the independent registered public accounting firm the results of the
annual audit and the independent registered public accounting firm&#146;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the audit committee by the
independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#146;s review of our quarterly financial information prior to public disclosure and our
disclosures in our periodic reports filed with the SEC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert
within the meaning of SEC regulations and each of David Lemus, Laura J. Hamill and Dorman Followwill meet the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management
periodically meet separately with the audit committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews, discusses and assesses its own performance and
composition at least annually. The audit committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its
consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the audit committee complies with all applicable requirements of the
Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
compensation committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill, with <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D. serving as the chairperson of the committee. <FONT
STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee is a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The compensation committee acts on behalf of
our Board to fulfill our Board&#146;s responsibilities in overseeing our compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to our executive officers and
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. The responsibilities of the compensation committee are included in its written charter. The compensation committee&#146;s responsibilities include, among others: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding)
our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval)
the compensation and terms of employment of our executive officers and other members of senior management; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of
employment agreements, severance agreements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and other compensatory arrangements for our executive officers and other members of senior
management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conducting periodic reviews of the base compensation levels of all of our employees generally;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the type and amount of compensation to be paid or awarded to <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation
rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such
plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive
risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#147;emerging growth company,&#148; as defined in the JOBS Act, the responsibilities of the compensation
committee will also include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive
compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive
compensation to be included in our annual meeting proxy statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board
that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> registration statements and our annual meeting proxy statements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the compensation committee may form, and delegate authority to, subcommittees as appropriate. The compensation committee
reviews, discusses and assesses its own performance and composition at least annually. The compensation committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommends any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the compensation
committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and
Laura J. Hamill, with Dorman Followwill serving as the chairperson of the committee. <FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing
Rules. The responsibilities of the nominating and corporate governance committee are included in its written charter. The nominating and corporate governance committee acts on behalf of our Board to fulfill our Board&#146;s responsibilities in
overseeing all aspects of our nominating and corporate governance functions. The responsibilities of the nominating and corporate governance committee include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations to our Board regarding corporate governance issues; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria
approved by our Board); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the minimum qualifications for service on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating incumbent directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instituting and overseeing director orientation and director continuing education programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">serving as a focal point for communication between candidates,
<FONT STYLE="white-space:nowrap">non-committee</FONT> directors and our management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making other recommendations to our Board regarding matters relating to the directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing succession plans for our Chief Executive Officer and our other executive officers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and overseeing matters of corporate responsibility and sustainability, including potential <FONT
STYLE="white-space:nowrap">long-and</FONT> short-term trends and impacts to our business of environmental, social and governance issues, and our public reporting on these topics; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering any recommendations for nominees and proposals submitted by stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee periodically reviews, discusses and assesses the performance of our Board and the committees
of our Board. In fulfilling this responsibility, the nominating and corporate governance committee seeks input from senior management, our Board and others. In assessing our Board, the nominating and corporate governance committee evaluates the
overall composition of our Board, our Board&#146;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The nominating and corporate governance committee reviews, discusses and
assesses its own performance and composition at least annually. The nominating and corporate governance committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter,
and recommends any proposed changes to our Board for its consideration and approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the nominating
and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_80"></A>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, on November&nbsp;10, 2022, our Board approved and adopted a written code of business conduct
and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of
business conduct and ethics is posted on our website at <I>www.scilexholding.com</I>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an
inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_81"></A>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is currently, or has been at any time in the past year, one of our officers or employees.
Other than Dr.&nbsp;Ji and Mr.&nbsp;Shah, none of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers
serving as a member of our Board or compensation committee. Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the compensation of Dr.&nbsp;Ji and Mr.&nbsp;Shah. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_82"></A>Limitation of Liability and Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the
fullest extent permitted by the DGCL. Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of our directors, unlawful payments of dividends or unlawful stock repurchases or redemptions in
violation of the DGCL; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director or officer derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors or officers, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;), and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition,
the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final
disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer,
employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or
loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These
agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually
and reasonably incurred by the directors and executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We also
maintain directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the
Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus
is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their
employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of
Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers,
even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers
pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification
is against public policy and is therefore unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our
directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_83"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_84"></A>Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vickers Executive Officers and Director Compensation Prior to Completion of the Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing of the Business Combination, none of Vickers&#146;s executive officers or directors received any cash compensation for
services rendered to Vickers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex and Current Executive Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain,
incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives
with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information
disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#146;s named executive officers in 2022. As an &#147;emerging growth company&#148; as
defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or the compensation committee of our Board (the &#147;Compensation Committee&#148;), with input from our Executive Chairperson and
Chief Executive Officer, historically determined the compensation for Scilex&#146;s named executive officers. Our named executive officers for the year ended December&nbsp;31, 2022, were Jaisim Shah, our Chief Executive Officer and President, Henry
Ji, our Executive Chairperson and Elizabeth Czerepak, our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_85">
</A>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to
Scilex&#146;s named executive officers for the fiscal years ended December&nbsp;31, 2022 and December&nbsp;31, 2021: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman"><B>Principal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:7.5pt; font-family:Times New Roman; "><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Qualified</FONT><BR>Deferred<BR>Compensation<BR>Earnings ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Jaisim Shah</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,435<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">785,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B></B><I>Chief&nbsp;Executive&nbsp;Officer,&nbsp;President and Director</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">579,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">290,509<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,600<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">881,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Henry Ji, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><I>Executive Chairperson</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Elizabeth Czerepak</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B></B><I>Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</I><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">172,917</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B></B>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50,000<B></B></TD>
<TD NOWRAP VALIGN="top"><B><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">222,917</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include for 2022 the amount of any bonuses that may be awarded to our named executive officers as our
Compensation Committee has not, as of the date of the filing of this prospectus, yet determined bonus amounts, if any, that may be awarded our named executive officers for 2022. If any such bonus amounts are determined, we will, in accordance with
the SEC rules and regulations, file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or otherwise disclose the 2022 bonus amounts within four business days after our Compensation Committee has assessed 2022 performance and
determined any bonus awards for 2022 for our named executive officers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents matching contributions made to Mr.&nbsp;Shah under the Company&#146;s 401(k) plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents discretionary bonus amount awarded to Mr.&nbsp;Shah by the board of directors of Legacy Scilex.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents a signing bonus awarded to Ms.&nbsp;Czerepak in connection with her becoming our Executive Vice
President, Chief Business Officer, Chief Financial Officer and Secretary. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_86"></A>Narrative Disclosure to Summary
Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Arrangements with Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with each of Mr.&nbsp;Shah and Ms.&nbsp;Czerepak. The material terms of the offer letters are described
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&nbsp;Shah (the &#147;Shah Offer Letter&#148;), dated April&nbsp;19, 2019, pursuant to which
Mr.&nbsp;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&nbsp;Shah&#146;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November&nbsp;11,
2022 (but became effective as of March&nbsp;17, 2022). Mr.&nbsp;Shah&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Mr.&nbsp;Shah may terminate the terms and conditions of the employment
relationship at any time, with or without cause and with or without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2019, Scilex issued to Mr.&nbsp;Shah an
option to purchase 8,126,836 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month thereafter,
subject to Mr.&nbsp;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. On December&nbsp;21, 2020, Scilex issued to Mr.&nbsp;Shah an additional option to purchase 1,626,497 shares of
Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on December&nbsp;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&nbsp;Shah providing
continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise prices for Mr.&nbsp;Shah&#146;s options reflect the application of the Exchange Ratio in the Business
Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Mr.&nbsp;Shah&#146;s continuous service terminates due to an involuntary termination of employment without
&#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ji Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not
entered into an offer letter or employment agreement in connection with Dr.&nbsp;Ji&#146;s service as our Executive Chairperson. On November&nbsp;11, 2022, our Compensation Committee approved Dr.&nbsp;Ji&#146;s annual base salary of $792,000 and
bonus of $554,400, effective as of March&nbsp;17, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;20, 2019, Scilex issued to Dr.&nbsp;Ji, in connection with his
service as a director, an option to purchase 2,031,708 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&nbsp;18, 2020, and 1/48th of the total amount of the shares vested and shall
vest each month thereafter, subject to Dr.&nbsp;Ji providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Dr.&nbsp;Ji&#146;s option reflects
the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Dr.&nbsp;Ji&#146;s continuous service terminates due to
an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13&nbsp;months after the effective time of
such Change in Control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Czerepak Offer Letter and Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Ms.&nbsp;Czerepak (the &#147;Czerepak Offer Letter&#148;), dated April&nbsp;27, 2022, pursuant to
which Ms.&nbsp;Czerepak serves as our Executive Vice President, Chief Business Officer, and Chief Financial Officer. Under the Czerepak Offer Letter, Ms.&nbsp;Czerepak&#146;s annual base salary is $300,000 and she was awarded a $50,000 signing
bonus. Following the closing of the Business Combination and Scilex&#146;s filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8,</FONT> subject to the Board&#146;s approval, Scilex shall grant Ms.&nbsp;Czerepak an
incentive stock option to purchase 350,000 shares of Common Stock, which shall vest over a four year period, whereby 1/4th of the shares subject to the option shall vest on the date that is one year after the vesting commencement date and an
additional 1/48th of the shares subject to the option shall vest on the same date of each month thereafter, subject to Ms.&nbsp;Czerepak providing continuous service (as defined in the equity incentive plan pursuant to which the option will be
granted) on each such vesting date, inclusive. In addition, all of the shares subject to the option will vest upon the occurrence of a change in control (as defined in the Equity Incentive Plan) that occurs prior to the termination of her continuous
service. Ms.&nbsp;Czerepak&#146;s employment with Scilex is <FONT STYLE="white-space:nowrap">at-will,</FONT> and either Scilex or Ms.&nbsp;Czerepak may terminate the terms and conditions of the employment relationship at any time, with or without
cause and with or without notice. However, if Scilex terminates Ms.&nbsp;Czerepak&#146;s employment other than for cause or Ms.&nbsp;Czerepak resigns from her employment with Scilex for good reason (each, as defined in the Czerepak Offer Letter),
subject to Ms.&nbsp;Czerepak&#146;s execution and delivery of a release of claims in a form prescribed by Scilex, and so long as Ms.&nbsp;Czerepak has not been offered a full-time position at Sorrento with a base salary and annual bonus potential of
not less than the combined base salary and target bonus she received from both Scilex and Sorrento, if any, as of immediately prior to the termination of her employment, Scilex will continue to pay Ms.&nbsp;Czerepak her base salary for a period of
twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;14, 2019, Scilex issued to Ms.&nbsp;Czerepak, in connection with her service as a director, an option to
purchase 404,098 shares of Common Stock, with an exercise price equal to $1.73 per share, whereby 1/48th of the shares vested on October&nbsp;23, 2019, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject
to Ms.&nbsp;Czerepak providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Ms.&nbsp;Czerepak&#146;s option reflects the application of the
Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Ms.&nbsp;Czerepak&#146;s continuous service terminates due to an involuntary
termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in
Control. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Arrangements with Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our Compensation Committee to review and
advise on our compensation practices, on November&nbsp;11, 2022, our Compensation Committee approved the following base salaries and target bonuses (on terms and conditions determined by our Board) of our executive officers, effective as of
March&nbsp;17, 2022. No bonuses were awarded to our named executive officers for 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target<BR>Bonus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 792,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 300,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing of the Company&#146;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> with respect to the 2022 Equity Incentive Plan, our Board approved the following stock option grants thereunder, subject to the continued service of the individuals: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,700,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_87"></A>Potential Payments upon Termination or Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, Scilex did not have any arrangement with any of its named executive officers providing for
potential payments, compensation or other benefits upon termination or the occurrence of a change of control, other than the severance provision for Ms.&nbsp;Czerepak and the accelerated vesting provisions pursuant to previously granted options as
described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_88"></A>Perquisites, Health, Welfare and Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical,
vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the
premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best
interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_89"></A>Pension Benefits and Nonqualified Deferred Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. We made matching contributions to the 401(k) plan totaling $0.3&nbsp;million for each of the years ended December&nbsp;31,
2022 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Shah participates in our <FONT STYLE="white-space:nowrap">tax-qualified</FONT> Section&nbsp;401(k) plan and we
provide a 4% matching contribution up to an annual compensation limit ($305,000 in 2022). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not provide any other pension plan for
our employees, and none of Scilex&#146;s named executive officers participated in a nonqualified deferred compensation plan during the year ended December&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_90"></A>Outstanding Equity Awards at Fiscal
<FONT STYLE="white-space:nowrap">Year-End</FONT> 2022 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity
awards held by each of Scilex&#146;s named executive officers as of December&nbsp;31, 2022. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in
accordance with the terms of the Merger Agreement and the 2019 Stock Option Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>Option Awards<SUP STYLE="font-size:75%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>per<BR>Share($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/6/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/18/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,618,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2020</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">813,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/20/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/18/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,904,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/20/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/23/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on
November&nbsp;10, 2022, outstanding equity awards were adjusted as follows: (i)&nbsp;each option to purchase Legacy Scilex common stock that was outstanding as of immediately prior to the Effective Time was converted into the right to receive an
option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#147;Option&#148;) except that (x)&nbsp;such Option relates to that
whole number of shares of our Common Stock (rounded down to the nearest whole share) equal to the number of Legacy Scilex common stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1, and (y)&nbsp;the exercise price per share
for each such share of our Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the
share numbers outstanding and exercise prices as of December&nbsp;31, 2022, in each case after giving effect to the Exchange Ratio. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option was granted under the 2019 Stock Option Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each option vested as to 1/4th of the shares subject to the option on the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of
an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as
defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary
commencing on October&nbsp;23, 2019, subject to full acceleration in the event of an involuntary termination of employment without &#147;cause&#148; or due to a voluntary termination of employment with &#147;good reason&#148; (each, as defined in
the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_91">
</A>Equity-Based Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Scilex Pharma originally adopted and its stockholders approved the 2017 Scilex Pharmaceuticals Inc. Equity Incentive
Plan (the &#147;Scilex Pharma 2017 Plan&#148;) on June&nbsp;26, 2017. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma 2017 Plan, as amended and restated, provided that Scilex Pharma could grant incentive stock options, <FONT
STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock awards, stock unit awards, stock appreciation rights and other stock awards. The only form of equity award granted under the Scilex Pharma 2017 Plan was options to purchase shares
of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the corporate reorganization that was effected in March 2019, the
maximum number of shares of common stock of Scilex Pharma that could be issued under the Scilex Pharma 2017 Plan was 24,000,000, of which 18,099,000 remained available for future grants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no
additional awards were granted under the Scilex Pharma 2017 Plan. Each option to purchase shares of common stock of Scilex Pharma outstanding and unexercised immediately prior to the Contribution was cancelled and substituted for an option to
purchase the equivalent number of shares of Legacy Scilex Common Stock. Each new option was subject to the same terms and conditions as were in effect immediately prior to the Contribution. No stock options of Scilex Pharma were outstanding
following the reorganization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;6, 2023, options to purchase 744,201 shares of our Common Stock were outstanding pursuant
to options previously granted under the Scilex Pharma 2017 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148;) on May&nbsp;28,
2019. The 2019 Stock Option Plan was approved by Legacy Scilex&#146;s stockholders on June&nbsp;24, 2019. Upon adoption, 30,000,000 shares of Legacy Scilex Common Stock were authorized for issuance under the 2019 Stock Option Plan. The Legacy Scilex
Board and Legacy Scilex&#146;s stockholders approved an amendment to the 2019 Stock Option Plan on December&nbsp;21, 2020 to increase the number of shares authorized thereunder by 15,000,000 shares. As of March&nbsp;6, 2023, options to purchase
16,195,178 shares of our Common Stock were outstanding under the 2019 Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Stock Option Plan has terminated at the
Closing, and no further awards has been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the 2019 Stock Option Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Under the 2019 Stock Option Plan, an aggregate of 30,000,000 shares of Legacy Scilex Common Stock were initially
reserved for future issuance, which number was increased to 45,000,000 in December 2020. The authorized shares are subject to adjustment in the event of a change that occurs with respect to the common stock without the receipt of consideration by
Scilex, including a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination
of shares, exchange of shares, recapitalization, reincorporation, reorganization, change in corporate structure, or similar equity restructuring transaction. Additionally, shares issued pursuant to awards under the 2019 Stock Option Plan that are
repurchased or that are forfeited, as well as shares reacquired as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2019
Stock Option Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards</I>. The 2019 Stock Option Plan provided for the granting of (1)&nbsp;incentive stock options
intended to qualify as incentive stock options under the Code, (2)&nbsp;nonstatutory stock options that do not qualify as an incentive stock option, (3)&nbsp;stock appreciation rights, (4)&nbsp;restricted stock awards, (5)&nbsp;restricted stock unit
awards and (6)&nbsp;other stock awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Incentive stock options could only be granted to Legacy Scilex&#146;s
employees or employees of its affiliates, and stock awards other than incentive stock options may be granted to employees, directors and consultants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options and Stock Appreciation Rights</I>. The Legacy Scilex Board determined the
exercise price for stock options and stock appreciation rights, provided that the exercise price generally could not be less than 100% of the fair market value of Legacy Scilex Common Stock on the date of grant, subject to certain exceptions
relating to the assumption or substitution of options or stock appreciation rights in connection with a corporate transaction in a manner consistent with Section&nbsp;409A or, if applicable, Section&nbsp;424(a) of the Code. Unless an award agreement
provides otherwise, the termination date shall be: (1)&nbsp;the earlier of 18 months or upon the expiration of the option or stock appreciation right, if termination is due to death; (2)&nbsp;the earlier of 12 months or upon the expiration of the
option or stock appreciation right, if termination is due to disability; or (3)&nbsp;three months, if termination is due to reasons other than for death, disability or cause. If the termination of service is due to cause, the stock option or stock
appreciation right will terminate immediately upon such termination of service, and the participant will be prohibited from exercising the option or stock appreciation right. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock and Restricted Stock Unit Awards</I>. Each restricted stock and restricted stock unit award agreement is in the form and
contains such terms and conditions as the Legacy Scilex Board deemed appropriate. Unless otherwise provided in the award agreement, the Legacy Scilex Board held certificates or, if not certificated, other indicia representing the restricted shares.
If a recipient&#146;s service terminates, Legacy Scilex could receive through a forfeiture condition or a repurchase right, any or all of the shares of common stock held by the recipient as of the date of termination. Restricted stock units not yet
vested shall be forfeited upon termination of the recipient&#146;s employment unless otherwise set forth in the award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability</I>. Stock options or stock appreciation rights are generally not transferable except by will or by the laws of descent and
distribution or as otherwise provided under the 2019 Stock Option Plan. Restricted stock awards could be transferable by the participant only upon such terms and conditions as are set forth in the restricted stock award agreement, as the Legacy
Scilex Board determines in its sole discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The 2019 Stock Option Plan is administered by our Board, although
our Board may delegate the administration of the 2019 Stock Option Plan to a committee. The administrator has full power to determine, among other things: (1)&nbsp;who will be granted awards; (2)&nbsp;when and how each award will be granted;
(3)&nbsp;what type of award will be granted; (4)&nbsp;the provisions of each award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or shares of common stock under the award; (5)&nbsp;the
number of shares of common stock subject to an award; and (6)&nbsp;the fair market value applicable to an award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in
Control/Corporate Transactions</I>. The 2019 Stock Option Plan provides that in the event of a change in control transaction (as defined in the 2019 Stock Option Plan), a stock award may be subject to additional acceleration of vesting and
exercisability as may be provided in the stock award agreement for such stock award or as may be provided in any other written agreement between us or our affiliate and the participant, but in the absence of such provision, no such acceleration will
occur. In addition, the 2019 Stock Option Plan provides that in the event of a corporate transaction (as defined in the 2019 Stock Option Plan), our Board has the discretion to take a number of actions with respect to awards contingent upon the
closing of the transaction, including arranging for the assumption or substitution of awards, arranging for the assignment of repurchase rights in respect of awards, accelerating the vesting of awards, canceling awards or making payments in respect
of awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our Board generally has the authority to amend awards, subject to the award recipient&#146;s consent if the
amendment is not favorable to the participant, except in connection with a capitalization adjustments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Equity Incentive
Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the Equity Incentive Plan. On
November&nbsp;9, 2022, our stockholders approved the Equity Incentive Plan. The Equity Incentive Plan became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Equity Incentive Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be
given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of incentive stock options (&#147;ISOs&#148;) within the meaning of Section&nbsp;422
of the Code, to our employees and our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options (&#147;NSOs&#148;), stock appreciation rights, restricted stock awards, restricted stock unit awards,
performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#146; employees and consultants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum
number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&nbsp;an additional number of shares of Common Stock equal to the
number of shares subject to outstanding awards granted under the 2019 Stock Option Plan, that, following the effective date of the Equity Incentive Plan, (a)&nbsp;are not issued because the award or any portion of the award expires or otherwise
terminates without all of the shares covered by the award having been issued, (b)&nbsp;are not issued because the award or any portion thereof is settled in cash, (c)&nbsp;are forfeited back to or repurchased by us because of the failure to meet a
contingency or condition required for the vesting of such shares, (d)&nbsp;are withheld or reacquired to satisfy the exercise, strike or purchase price or (e)&nbsp;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the
number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will automatically increase on January&nbsp;1 of each year for a period of ten years, beginning on January&nbsp;1, 2023 and ending on (and
including) January&nbsp;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock (subject to
adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (3)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given
year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause (i)&nbsp;was increased to 20,276,666 based on the foregoing provisions. Notwithstanding anything to the contrary in the foregoing
sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan was initially 14,622,712 shares, which amount was to increase commencing on January&nbsp;1, 2023 and
ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 7,311,356 shares of Common Stock (subject to
adjustment for recapitalizations, stock splits, stock dividends and similar transactions), and (iii)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given
year. On January&nbsp;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause (i)&nbsp;regarding ISOs was increased to 20,276,666 based on the foregoing provisions. All of the foregoing share numbers are
subject to adjustment as necessary to implement any changes in our capital structure (as described below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that
will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash
will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common Stock withheld under an award to satisfy the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan.
With respect to a stock appreciation right, only shares of Common Stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any
shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&nbsp;to satisfy the
exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance
under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, administers the Equity Incentive Plan. Our Board, or a duly authorized committee of our
Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by
applicable law, the terms of such awards; and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board,
will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award;
the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common
Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive
Plan, (i)&nbsp;our Board will not, without stockholder approval, (a)&nbsp;reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&nbsp;at any time when the
exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our Common Stock, cancel and <FONT STYLE="white-space:nowrap">re-grant</FONT> or exchange such option or stock appreciation right for a
new award with a lower (or no) purchase price or for cash, and (ii)&nbsp;a participant&#146;s rights under any award will not be materially adversely impaired by any amendment without the participant&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an
NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except the exercise price of a stock option generally will not be less than 100% (or 110% in the case of ISOs granted
to a person who owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the
date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be determined by our Board. The terms and conditions of separate options need not be identical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a
shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#146;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship
with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
three&nbsp;months following the cessation of service. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain
period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates
ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An
optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#146;s stock option agreement or other written agreement between an
optionholder and us, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period:
(i)&nbsp;the exercise of the optionholder&#146;s option would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares of Common Stock issued
upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional
extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of
extensions. However, in no event may an option be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase
of Common Stock issued upon the exercise of a stock option will be determined by our Board and may include (i)&nbsp;cash or check, bank draft or money order payable to us; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;subject to certain
conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option if it is an NSO; or (v)&nbsp;other legal consideration acceptable to our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of
descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Limitations on ISOs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair
market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed
$100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting
power or that of any of our parent or subsidiary corporations unless (i)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the term of the ISO does not
exceed five years from the date of grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our
Board. A restricted stock unit award represents a participant&#146;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have
voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in
consideration for a participant&#146;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or
the issuance of any shares of Common Stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration
determined by our Board and set forth in the restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting
of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement
between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock
awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form
of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited
with respect to shares subject to a restricted stock award, as determined by our Board and specified in the applicable restricted stock award agreement. If a participant&#146;s service relationship with us ends for any reason, we may receive any or
all of the shares of Common Stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock
appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will
determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive
Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in
any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine
the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death,
the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#146;s service relationship with us or any of our affiliates ceases due to death, or a
participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#146;s
service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination
for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate
applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other
than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&nbsp;the exercise of the participant&#146;s stock appreciation right would be prohibited solely because the issuance of shares upon
such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the
calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such
extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards
may be structured so that the stock or cash will be issued or paid only following the achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that
are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance
goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the
performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a
performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles; (iv)&nbsp;to
exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting principles;
(vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such
divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our Common Stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based
compensation and the award of bonuses under our bonus plans; (x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and
(xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to
define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the
performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such
awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the
persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service
as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees
paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a <FONT STYLE="white-space:nowrap">non-employee</FONT>
director is first appointed or elected to our Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our
Board will appropriately and proportionately adjust (i)&nbsp;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity
Incentive Plan; (ii)&nbsp;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&nbsp;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding
awards granted under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#146;s award agreement or other written
agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any
surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving
or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&nbsp;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective
time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of
performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate
transaction) as our board of directors determines (or, if our board of directors does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised
(if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and
(ii)&nbsp;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us
with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event
an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such
form as may be determined by our Board, equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the award, over (ii)&nbsp;any per share exercise price payable by such
holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#147;corporate transaction&#148; generally will be the consummation, in a single transaction or
in a series of related transactions, of (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our board of directors, of the consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at
least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving
corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly
provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of
a restricted stock award and similar awards, after the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in
compliance with the provisions herein, the terms of our trading policy and applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to
adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt,
to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited
to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or
Termination </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the
time during which an award grant under the Equity Incentive Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our
Board will have the authority to amend, suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. Certain
material amendments will also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is
suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Federal Income Tax Consequences Associated with the Equity Incentive Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a general summary under current law of the material federal income tax consequences to participants in the Equity Incentive
Plan. This summary deals with the general tax principles that apply and is provided only for general information. Some kinds of taxes, such as state, local and foreign income taxes and federal employment taxes, are not discussed. Tax laws are
complex and subject to change and may vary depending on individual circumstances and from locality to locality. The summary does not discuss all aspects of income taxation that may be relevant in light of a holder&#146;s personal investment
circumstances. This summarized tax information is not tax advice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Nonstatutory Stock Options</I>. For federal income tax purposes, if
an optionee is granted an NSO under the Equity Incentive Plan, the optionee will not have taxable income on the grant of the option, nor will we be entitled to any deduction. Generally, upon exercise of NSOs, the optionee will recognize ordinary
income, and we will be entitled to a deduction, in an amount equal to the excess of the fair market value of a share of our Common Stock over the option exercise price on the date each such option is exercised. The optionee&#146;s basis for the
stock for purposes of determining gain or loss on subsequent disposition of such shares generally will be the fair market value of our Common Stock on the date the optionee exercises such option. Any subsequent gain or loss will be generally taxable
as capital gains or losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Incentive Stock Options</I>. There is no taxable income to an optionee when an optionee is granted an ISO
or when that option is exercised. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an &#147;item of adjustment&#148; for the optionee for purposes of the alternative minimum
tax. Gain realized by the optionee on the sale of an ISO is taxable at capital gains rates, and no tax deduction is available to us, unless the optionee disposes of the shares within (a)&nbsp;two years after the date of grant of the option or
(b)&nbsp;within one year of the date the shares were transferred to the optionee. If the shares acquired </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon exercise of the ISO are sold or otherwise disposed of before the end of the <FONT STYLE="white-space:nowrap">two-year</FONT> and <FONT STYLE="white-space:nowrap">one-year</FONT> periods
specified above, the excess of the fair market value of a share of our Common Stock over the option exercise price on the date of the option&#146;s exercise will be taxed at ordinary income rates (or, if less, the gain on the sale), and we will be
entitled to a deduction to the extent the optionee must recognize ordinary income. If such a sale or disposition takes place in the year in which the optionee exercises the option, the income the optionee recognizes upon sale or disposition of the
shares will not be considered an item of adjustment for alternative minimum tax purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An ISO exercised more than three months after
an optionee terminates employment, for reasons other than death or disability, will be taxed as an NSO, and the optionee will recognize ordinary income on the exercise. We will be entitled to a tax deduction equal to the ordinary income, if any,
realized by the optionee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I><B><I>. </I></B>An individual to whom restricted stock is issued generally will not
recognize taxable income upon such issuance, and we generally will not then be entitled to a deduction, unless an election is made by the participant under Section&nbsp;83(b) of the Code (&#147;Section&nbsp;83(b)&#148;). However, when restrictions
on shares of restricted stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the individual generally will recognize ordinary income, and we generally will be entitled to a deduction for an amount equal to the
excess of the fair market value of the shares at the date such restrictions lapse over the purchase price. If a timely election is made under Section&nbsp;83(b) with respect to restricted stock, the participant generally will recognize ordinary
income on the date of the issuance equal to the excess, if any, of the fair market value of the shares at that date over the purchase price of such shares, and we will be entitled to a deduction for the same amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. A participant will not be taxed upon the grant of a stock appreciation right. Upon the exercise of the stock
appreciation right, the participant will recognize ordinary income equal to the amount of cash or the fair market value of the stock received upon exercise. At the time of exercise, we will be eligible for a tax deduction as a compensation expense
equal to the amount that the participant recognizes as ordinary income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards and Other Stock Awards</I>. The participant
will have ordinary income upon receipt of stock or cash payable under performance awards, dividend equivalents, restricted stock units and stock payments. We will be eligible for a tax deduction as a compensation expense equal to the amount of
ordinary income recognized by the participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Section</I><I></I><I>&nbsp;162(m) of the Code</I>. Section&nbsp;162(m) of the Code
generally limits to $1.0&nbsp;million the amount of compensation that we may deduct in any calendar year for certain current and former executive officers. For grants under the Equity Incentive Plan, we will not be able to take a deduction for any
compensation in excess of $1.0&nbsp;million that is paid to a covered officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Requirements of Section</I><I></I><I>&nbsp;409A of the
Code</I>. Certain awards under the Equity Incentive Plan may be considered &#147;nonqualified deferred compensation&#148; for purposes of Section&nbsp;409A of the Code (&#147;Section&nbsp;409A&#148;), which imposes certain requirements on
compensation that is deemed under Section&nbsp;409A to involve nonqualified deferred compensation. Among other things, the requirements relate to the timing of elections to defer, the timing of distributions and prohibitions on the acceleration of
distributions. Failure to comply with these requirements (or an exception from such requirements) may result in the immediate taxation of all amounts deferred under the nonqualified deferred compensation plan for the taxable year and all preceding
taxable years, by or for any participant with respect to whom the failure relates, the imposition of an additional 20% income tax on the participant for the amounts required to be included in gross income and the possible imposition of penalty
interest on the unpaid tax. Generally, Section 409A does not apply to incentive awards that are paid at the time the award vests. Likewise, Section&nbsp;409A typically does not apply to restricted stock. Section&nbsp;409A may, however, apply to
incentive awards the payment of which is delayed beyond the calendar year in which the award vests. Treasury regulations generally provide that the type of awards provided under the Equity Incentive Plan will not be considered nonqualified deferred
compensation. However, to the extent that Section&nbsp;409A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applies to an award issued under the Equity Incentive Plan, the Equity Incentive Plan and all such awards will, to the extent practicable, be construed in accordance with Section&nbsp;409A. Under
the Equity Incentive Plan, the administrator has the discretion to grant or to unilaterally modify any award issued under the Equity Incentive Plan in a manner that conforms with the requirements of Section&nbsp;409A with respect to deferred
compensation or voids any participant election to the extent it would violate Section&nbsp;409A. The administrator also has sole discretion to interpret the requirements of the Code, including Section&nbsp;409A, for purposes of the Equity Incentive
Plan and all awards issued under the Equity Incentive Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&nbsp;9, 2022, our stockholders
approved the ESPP. The ESPP became effective on November&nbsp;9, 2022, the day immediately preceding the date on which the Closing occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to
provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our Common Stock in a
manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code (the &#147;423 Component&#148;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&nbsp;423 of the Code. We
intend (but make no undertaking or representation to maintain) the 423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&nbsp;423(b) of the Code. The other component will permit the grant of purchase rights
that do not qualify for such favorable tax treatment (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or
employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the 423 Component. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share Reserve </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum
number of shares of our Common Stock that may be issued under the ESPP will not exceed 1,462,271 shares of our Common Stock. On January&nbsp;1, 2023, the maximum number of shares of our Common Stock that may be issued under the ESPP was increased to
2,875,759 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common Stock that will be reserved for issuance will automatically increase on January&nbsp;1 of each year for a period of up to ten years,
commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar
year; (ii) 1,827,839 shares of our Common Stock; and (iii)&nbsp;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&nbsp;1 of a given year, provided however, that our Board
may act prior to January&nbsp;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&nbsp;to (iii) above.
For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to
satisfy the purchases of our Common Stock under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right
granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased under such purchase right will again become available for issuance under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased
by us on the open market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board.
All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate
some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation.
Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the 423 Component or
the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and
revoke rules and regulations for the ESPP&#146;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it
deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the 423 Component; and to adopt such rules,
procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be
final, binding and conclusive on all persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Offerings </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase
periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the 423 Component, will comply with the
requirements of Section&nbsp;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed 27 months
beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than
one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&nbsp;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&nbsp;a
purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or
a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the
discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock
on the first day of that offering, then (i)&nbsp;that offering will terminate immediately as of that first trading day, and (ii)&nbsp;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the
first trading day of such new purchase period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or
related corporations as designated by our Board) on the first day of an offering if such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed
two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements with respect to the 423 Component: (i)&nbsp;being customarily employed by us, or any of our related corporations or affiliates, for more than 20 hours per week and more than five
months per calendar year; or (ii)&nbsp;such other criteria as our Board may determine consistent with Section&nbsp;423 of the Code with respect to the 423 Component. Our Board may provide that each person who, during the course of an offering, first
becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the
purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such
employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related corporation) determined in accordance with the rules of Section&nbsp;424(d)
of the Code. As specified by Section&nbsp;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other rights granted under all employee stock purchase plans of ours or any of our
related corporations, do not permit such eligible employee&#146;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which, when aggregated, exceeds $25,000 (based on the fair market value per share of
such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our
related corporation, who are highly compensated employees, as within the meaning of Section&nbsp;423(b)(4)(D) of the Code, or a subset of such highly compensated employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation
of such eligible employee is not advisable or practical for any reason. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase Rights; Purchase Price </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to
purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed 15% of such employee&#146;s earnings (as defined by our Board) during
the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will
establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to
10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&nbsp;a maximum number of shares of our Common Stock that may be purchased
by any participant on any purchase date during an offering, (ii)&nbsp;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&nbsp;a maximum aggregate number of shares of our
Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum
aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#146;s accumulated contributions,
will be made in as nearly a uniform manner as will be practicable and equitable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock
acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date
of purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Participation; Withdrawal; Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by
completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by
our Board. Each participant&#146;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a
third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior
offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her
contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire
transfer prior to a purchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by
delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#146;s purchase right in that offering will immediately terminate and we will
distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#146;s purchase right in that offering shall then terminate. A participant&#146;s withdrawal from that offering will
have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the
participant either (i)&nbsp;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&nbsp;is otherwise no longer eligible to participate. We will distribute the
individual&#146;s accumulated but unused contributions as soon as practicable to such individual. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our
Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such
designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the 423 Component to an offering under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component, the exercise of the participant&#146;s purchase right will be qualified under the 423 Component only to the extent such exercise complies with Section&nbsp;423 of the Code. If a participant
transfers from an offering under the <FONT STYLE="white-space:nowrap">Non-423</FONT> Component to an Offering under the 423 Component, the exercise of the purchase right will remain <FONT STYLE="white-space:nowrap">non-qualified</FONT> under the <FONT
STYLE="white-space:nowrap">Non-423</FONT> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the 423 Component and between offerings under the 423 Component and offerings under the
<FONT STYLE="white-space:nowrap">Non-423</FONT> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purchase of Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase
date, each participant&#146;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price
specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#146;s account after the purchase of shares on the final purchase date of an offering, then such remaining
amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be
exercised to any extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material
compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such
compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except
that the purchase date will in no event be more than 27 months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in
material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the
payment of interest is otherwise required by applicable law). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the
rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#146;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our
transfer agent). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization,
recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar
transaction, our Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the ESPP; (ii)&nbsp;the class(es) and maximum number of securities by which the share reserve is to increase
automatically each year; (iii)&nbsp;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&nbsp;the class(es) and number of securities that are subject to purchase limits
under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate
Transactions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to
purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume,
continue, or substitute for such purchase rights, then (i)&nbsp;the participants&#146; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such
other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&nbsp;our Board, in its discretion, may terminate
outstanding offerings, cancel the outstanding purchase rights and refund the participants&#146; accumulated contributions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
ESPP, a &#147;corporate transaction&#148; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&nbsp;a sale or other disposition of all or substantially all, as determined by our Board, of the
consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or
(iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue
of the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#146;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a
participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Withholding </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to
fulfill any withholding obligation for taxes arising out of or in relation to a participant&#146;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by
(i)&nbsp;withholding from the participant&#146;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&nbsp;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP,
either through a voluntary sale or a mandatory sale arranged by us; or (iii)&nbsp;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment, Suspension or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any
outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such purchase
rights were granted, (ii)&nbsp;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to
obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or
listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2023
Inducement Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2023, the Compensation Committee of our Board adopted the Inducement Plan and it became
effective on the date of its adoption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Inducement Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Purpose of the Inducement Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
purpose of the Inducement Plan is to advance our interests by providing a material inducement for individuals to join us as employees and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our
Common Stock through the granting of awards under the Inducement Plan.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Awards and Eligibility </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Inducement Plan provides for the grant of NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other
forms of awards. We intend to grant awards pursuant to the Inducement Plan only to persons to whom we may issue shares of our Common Stock without stockholder approval under Section&nbsp;5635 of the Nasdaq Listing Rules. The Inducement Plan provides
that awards may be granted to a natural person to whom we or one of our subsidiaries makes an offer of employment, provided that (i)&nbsp;such person was not previously an employee or us or one of our affiliates, or the person is returning to
employment with us or one of our subsidiaries following a bona-fide period of <FONT STYLE="white-space:nowrap">non-employment;</FONT> and (ii)&nbsp;the grant of an award under the Inducement Plan is a material inducement to the person&#146;s
decision to enter into employment with us or one of our subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An aggregate of 1,400,000 shares of our Common Stock have been reserved for issuance pursuant to awards granted under the Inducement Plan,
subject to adjustment as necessary to implement any changes in our capital structure (as described below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Inducement Plan that expire or
terminate without being exercised in full will not reduce the number of shares available for issuance under the Inducement Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the
Inducement Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under
the Inducement Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Inducement
Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&nbsp;to
satisfy the exercise, strike or purchase price of an award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for
issuance under the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Plan Administration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will delegate administration of the Inducement Plan to a duly authorized committee of our Board (the &#147;Committee&#148;) and to
the extent required by applicable law, including the Nasdaq Listing Rules, each member of such Committee will be an &#147;independent director&#148;, as defined in Section&nbsp;5605(a)(2) of the Nasdaq Listing Rules. Under the Inducement Plan, the
Committee will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to
an award; the number of shares of Common Stock or cash equivalent subject to each award; and the fair market value applicable to an award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, (i)&nbsp;the Committee will not, without stockholder approval, reduce the exercise or strike price of an option or
stock appreciation right (other than in connection with a capitalization adjustment), and (ii)&nbsp;a participant&#146;s rights under any award will not be materially adversely impaired by any amendment without the participant&#146;s written
consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by the Committee and each option will be an NSO. The Committee will determine the
exercise price for stock options, within the terms and conditions of the Inducement Plan, except the exercise price of a stock option will generally not be less than 100% of the fair market value of our Common Stock on the date of grant. Options
granted under the Inducement Plan will vest at the rate specified in the stock option agreement as will be determined by the Committee. The terms and conditions of separate options need not be identical. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years or a shorter period specified in the applicable award agreement. Unless the
terms of an optionholder&#146;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than
disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to
death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#146;s
service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options
generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#146;s stock option
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement or other written agreement between an optionholder and us, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause
and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&nbsp;the exercise of the optionholder&#146;s option would be prohibited solely because the issuance of shares of common stock upon such exercise
would violate applicable law, or (ii)&nbsp;the immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the
calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such
extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the Committee and
may include (i)&nbsp;cash or check, bank draft or money order payable to us; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder;
(iv)&nbsp;a net exercise of the option; or (v)&nbsp;other legal consideration acceptable to the Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the Committee provides
otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of the Committee or a duly authorized officer, an option may be transferred pursuant to a
domestic relations order. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Unit Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Inducement Plan, each restricted stock unit award will have such terms and conditions as determined by the
Committee. A restricted stock unit award represents a participant&#146;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not
have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be
granted in consideration for a participant&#146;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit
award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. The Committee may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be
acceptable to the Committee and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by the
Committee and set forth in the restricted stock unit award agreement. At the time of grant, the Committee may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the
award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us
and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#146;s continuous service ends for any reason. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock
awards will be granted under restricted stock award agreements adopted by the Committee. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other
form of legal consideration that may be acceptable to the Committee and permissible under applicable law. The Committee will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid
or credited with respect to shares subject to a restricted stock award, as determined by the Committee and specified in the applicable restricted stock award agreement. If a participant&#146;s service relationship with us ends for any reason, we may
receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by the Committee and denominated in shares of
Common Stock equivalents. The terms of separate stock appreciation rights need not be identical. The Committee will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair
market value of our Common Stock on the date of grant. A stock appreciation right granted under the Inducement Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the Committee. Stock appreciation
rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by the Committee and specified in the stock appreciation right agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will determine the term of stock appreciation rights granted under the Inducement Plan, up to a maximum of ten years. If a
participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following
the cessation of service. If a participant&#146;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally
exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#146;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any
vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right
may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the
participant and us, if a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period:
(i)&nbsp;the exercise of the participant&#146;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&nbsp;the immediate sale of any shares issued upon such
exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the
exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no
event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Stock Awards </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock,
either alone or in addition to other awards. The Committee will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock
award (or cash equivalent) and all other terms and conditions of such awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Changes to Capital Structure </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, the
Committee will appropriately and proportionately adjust (i)&nbsp;the class(es) and maximum number of shares subject to the Inducement Plan; and (ii)&nbsp;the class(es) and number of shares and exercise price, strike price, or purchase price, if
applicable, of all outstanding awards granted under the Inducement Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporate Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#146;s award agreement or other written
agreement with us or one of our affiliates or unless otherwise expressly provided by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Committee at the time of grant, any awards outstanding under the Inducement Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation
(or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its
parent company) does not assume, continue or substitute for such awards, then (i)&nbsp;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate
transaction, or current participants, the vesting (and exercisability, if applicable) of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless
provided otherwise in the applicable award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as the
Committee determines (or, if the Committee does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the
effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such awards that are held
by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not
terminate and may continue to be exercised notwithstanding the corporate transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not
exercised prior to the effective time of a corporate transaction, the Committee may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by
the Committee, equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the award, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. As a
condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Inducement Plan governing a corporate transaction involving us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Inducement Plan, a &#147;corporate transaction&#148; generally will be the consummation, in a single transaction or in a series of
related transactions, of (i)&nbsp;a sale or other disposition of all or substantially all, as determined by the Committee, of the consolidated assets of us and our subsidiaries; (ii)&nbsp;a sale or other disposition of at least 50% of our
outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but
the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transferability </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly
provided in the Inducement Plan or the form of award agreement, awards granted under the Inducement Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a
restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in
compliance with the provisions herein, the terms of our trading policy and applicable law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clawback/Recovery </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Inducement Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt
pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the
extent applicable and permissible under applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an award agreement as the Committee determines necessary or appropriate, including but not
limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment or Termination </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Committee may accelerate the time at which an award granted under the Inducement Plan may first be exercised or the time during which an
award grant under the Inducement Plan or any part thereof will vest, notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. The Committee will have the
authority to amend, suspend, or terminate the Inducement Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#146;s written consent. No awards may be granted under
the Inducement Plan while it is suspended or after it is terminated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_92"></A>Emerging Growth Company Status </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain
requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the
median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_93"></A>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2022, our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received the following
compensation: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Name<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid&nbsp;in<BR>Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Ji, our Executive Chairperson, and Mr.&nbsp;Shah, our Chief Executive Officer and President, are not
included in this table, as each of them was an employee of ours and therefore receives no compensation for his service as a director. Dr.&nbsp;Ji&#146;s and Mr.&nbsp;Shah&#146;s compensation as named executive officers are included in the section
above titled &#147;&#151; <I>Summary Compensation Table</I>&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2022, Dr.&nbsp;Lee held options to purchase an aggregate of 427,670 shares of our
Common Stock (which number of options gives effect to the Exchange Ratio) and none of Mr.&nbsp;Followwill, Ms.&nbsp;Hamill, Mr.&nbsp;Lemus and Mr.&nbsp;Thompson held any options or other equity awards to acquire shares of our Common Stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Between January&nbsp;1, 2022 through April&nbsp;24, 2022, the fees earned by Dr.&nbsp;Lee were pursuant to a
consulting agreement dated October&nbsp;27, 2020, as amended on March&nbsp;17, 2021. Between April&nbsp;25, 2022 through December&nbsp;31, 2022, the fees earned by Dr.&nbsp;Lee were for his service as a member of our board of directors.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_94"></A>Director Compensation Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined the following compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Annual Cash Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 82,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 37,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance
Committee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Equity Compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, <FONT STYLE="white-space:nowrap">pro-rated</FONT> for any partial months of service. The equity compensation paid to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the
annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#146;s attendance at Board and committee
meetings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_95"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2020 and any currently proposed transactions to which Vickers or Legacy
Scilex was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of Vickers&#146;s or Legacy Scilex&#146;s directors, executive officers or, to Vickers&#146;s or Legacy Scilex&#146;s knowledge,
beneficial owners of more than 5% of Vickers&#146;s or Legacy Scilex&#146;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are
described under the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_96"></A>Certain
Relationships of Vickers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Founder Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of the Sponsors for an aggregate
purchase price of $25,000. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. On October&nbsp;8, 2020, Vickers effected a share capitalization of 0.2 shares for each share
outstanding, on December&nbsp;7, 2020, the Sponsors forfeited 1,437,500 Vickers Ordinary Shares, which were cancelled by Vickers, and on January&nbsp;6, 2021, Vickers effected a share capitalization of 0.2 shares for each share outstanding,
resulting in 3,450,000 Vickers Ordinary Shares issued and outstanding. All share and <FONT STYLE="white-space:nowrap">per-share</FONT> amounts have been retroactively restated to reflect the share transactions. The founder shares included an
aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#146; over-allotment option is exercised, so that the number of founder shares will equal, on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis, approximately 20% of the issued and outstanding Vickers Ordinary Shares after the IPO. As a result of the underwriters&#146; election to partially exercise their over-allotment option, no
founder shares are currently subject to forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or
sell any of their founder shares until six months after the consummation of the Business Combination or earlier if we consummates a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders
having the right to exchange their Vickers Ordinary Shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Promissory Note </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2020, Vickers issued an unsecured promissory note (the &#147;Promissory Note&#148;) to an affiliate of the Sponsors, pursuant
to which Vickers may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable on the earlier of (i)&nbsp;December&nbsp;31, 2020 or (ii)&nbsp;the
completion of the IPO. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the IPO on January&nbsp;14, 2021. Borrowings under the Promissory Note are no longer available to Vickers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Loans </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
December&nbsp;20, 2021, the Sponsors loaned Vickers an aggregate of $500,000 for working capital purposes. On January10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account, to provide Vickers with an additional three
months to consummate an initial business combination pursuant to Vickers&#146;s Amended and Restated Memorandum and Articles of Association (&#147;Vickers&#146;s Charter&#148;). On January&nbsp;27, 2022, the Sponsors loaned Vickers an additional
aggregate principal amount of $500,000 for working capital purposes. On April&nbsp;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account to provide Vickers with an additional three months to consummate an initial
business combination pursuant to Vickers&#146;s Charter. On June&nbsp;30, 2022, Vickers&#146;s shareholders approved an amendment (the &#147;Extension Amendment&#148;) to its amended and restated memorandum and articles of association to extend the
deadline by which it must complete an initial business combination from July&nbsp;11, 2022 to January&nbsp;11, 2023. Each extension </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was made on a monthly basis and was conditioned on the deposit into the Trust Account of a payment equal to $0.0333 per public share outstanding. In connection with the shareholder vote on the
Extension Amendment, Vickers was required to provide its shareholders with the right to redeem their public shares. Holders of 4,073,605 public shares elected to redeem their shares at a per share redemption price of $10.27 thereby reducing the
amount in the Trust Account by an aggregate of approximately $41.8&nbsp;million. On July&nbsp;8, 2022, the Sponsors deposited an aggregate of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an
initial business combination pursuant to Vickers&#146;s Charter. After the redemption of the 4,073,605 public shares, there were 9,726,395 public shares remaining. On each of August&nbsp;11, 2022, September&nbsp;9, 2022 and October&nbsp;10, 2022,
the Sponsors deposited an additional payment of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#146;s Charter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Sponsors and Vickers entered into the Vickers Debt Agreement, which provides that, effective as of immediately
prior to the Effective Time, all of the issued and outstanding loans made by the Sponsors to Vickers prior to such Effective Time shall be contributed by the Sponsors to Vickers in exchange for a number of shares of our Common Stock determined by
dividing the aggregate amount of such indebtedness by $10.00. As of immediately prior to the Effective Time, the outstanding indebtedness was $5.3&nbsp;million, which resulted in the issuance of an additional 533,057 shares of our Common Stock to
the Sponsors, in accordance with the Vickers Debt Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advances from Related Party </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced Vickers an aggregate of $30,000 to fund expenses in connection with the IPO. The advances
are <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and payable upon demand. As of June&nbsp;30, 2022 and December&nbsp;31, 2021, there were no advances outstanding. The outstanding amount of $30,000 as of December&nbsp;31, 2020 was
repaid on February&nbsp;26, 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Administrative Service Fee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the registration statement of the IPO through the acquisition of a target business, the Sponsors have
provided Vickers with office space and certain office and secretarial services at no cost. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any
finder&#146;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to the Sponsors, officers and directors, or any of their affiliates, prior to, or in connection with any services rendered in order to
effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable
business combinations. Our audit committee will review on a quarterly basis all payments that were made to the Sponsors, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be
reimbursed. There is no cap or ceiling on the reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by such persons in connection with activities on our behalf. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder Designee&#148; and
collectively, the &#147;Stockholder Designees&#148;), regardless of whether </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in
order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&nbsp;we are required to take all actions reasonably necessary, and not otherwise
prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties have agreed that our Board will
continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also have the right to designate a replacement director for any Stockholder Designee that has been
removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Stockholder Agreement also provides that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&nbsp;amend, alter, modify or repeal (whether by merger, consolidation, by operation of
law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&nbsp;take any action that would
have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&nbsp;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the
respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&nbsp;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our
subsidiaries; (v)&nbsp;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed
or available amounts) or (B)&nbsp;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of
$10,000,000 (with &#147;principal amount&#148; for purposes of this definition to include undrawn committed or available amounts); (vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture
or corporate reorganization by the Company or any of our subsidiaries; (vii)&nbsp;declare or pay any dividend or distribution on our Common Stock, other Junior Security or Parity Security; or (viii)&nbsp;purchase, redeem or otherwise acquire for
consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&nbsp;a reclassification of any Junior Security for or into other Junior Securities, (B)&nbsp;a
reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&nbsp;a reclassification of any Parity Security into a Junior Security, (D)&nbsp;the exchange or conversion of
any Junior Security for or into another Junior Security, (E)&nbsp;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&nbsp;the exchange or conversion of any
Parity Security for or into any Junior Security or (G)&nbsp;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement will terminate and be of no further force and effect upon the earlier of (i)&nbsp;mutual written agreement of the
parties thereto and (ii)&nbsp;the date upon which Sorrento (together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) ceases to own any shares of Series A Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrant Transfer Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer
Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders had redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&nbsp;17, 2022, then in addition to the
forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors would transfer to Sorrento, and Sorrento would acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as
equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar
transaction, or any share dividend or distribution paid in shares) as determined in accordance with the following schedule: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Redemptions</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Private<BR>Placement<BR>Warrants&nbsp;to&nbsp;be<BR>Transferred to<BR>Sorrento</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Private<BR>Placement<BR>Warrants&nbsp;to&nbsp;be<BR>Retained by<BR>Sponsors</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Private<BR>Placement<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90% or greater</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85% to 89.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,504,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75% to 84.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% to 74.99%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,440,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Below 50%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,840,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the public shareholders redeemed an aggregate of 8,576,838
Vickers Ordinary Shares, which redeemed shares, together with the shares redeemed in connection with the Extension Proposal, represented an aggregate of 91.67% of the public Vickers Ordinary Shares outstanding as of March&nbsp;17, 2022. Accordingly,
the Sponsors transferred 3,104,000 Private Placement Warrants to Sorrento pursuant to the Warrant Transfer Agreement and forfeited 2,736,000 Private Placement Warrants pursuant to the Sponsor Support Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_97"></A>Certain Relationships of Legacy Scilex </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Reorganization </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Legacy Scilex completed a corporate reorganization. In connection with the corporate reorganization, the existing stockholders of Scilex Pharma exchanged their shares for the same number of newly issued shares of Legacy Scilex
Common Stock, pursuant to a Contribution and Loan Agreement. As a result, Scilex Pharma and Semnur became Legacy Scilex&#146;s wholly owned subsidiaries. In connection with the reorganization, each option issued by Scilex Pharma to acquire shares of
common stock granted under the Scilex Pharma 2017 Plan was cancelled and substituted for an option to purchase an equivalent number of shares of Legacy Scilex Common Stock. See the section of this prospectus titled &#147;<I>Business &#151; Our
Corporate History</I>&#148; for further information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Relationship with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the Closing of the Business
Combination, Sorrento continues to beneficially own a significant percentage of our outstanding Common Stock. In connection with the Business Combination, Legacy Scilex and Sorrento entered into certain agreements that relate to Legacy Scilex&#146;s
relationship with Sorrento prior to the Business Combination and provides a framework for our ongoing relationship with Sorrento. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;1, 2017, Scilex Pharma entered into a transition services agreement with Sorrento. Pursuant to this transition services agreement, Sorrento agreed to provide, directly or indirectly, certain administrative, financial, legal, tax,
insurance, facility, information technology and other services to Scilex Pharma. In addition to the services provided under this transition services agreement, Sorrento retains insurance coverage on behalf of Scilex Pharma. For the years ended
December&nbsp;31, 2021 and 2020, the total cost of services and insurance, including an agreed-upon markup, provided to Scilex Pharma was $4.0&nbsp;million and $2.3&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Itochu and Oishi Product Development Agreement and Commercial Supply Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to the Product Development Agreement with Oishi and Itochu, who are responsible for supplying ZTlido and <FONT
STYLE="white-space:nowrap">SP-103</FONT> for development and commercialization purposes. We are also a party to the Itochu and Oishi Commercial Supply Agreement, pursuant to which Itochu agreed to purchase Products (as defined in the Itochu and
Oishi Commercial Supply Agreement) from Oishi and handle the shipping of the Products. As of December&nbsp;31, 2020, Itochu held approximately 14.7% of Legacy Scilex&#146;s outstanding capital stock, representing a noncontrolling interest. Itochu
ceased to be a shareholder of Legacy Scilex on January&nbsp;13, 2021. Its Managing Executive Officer, Kenji Hakoda, served on the Legacy Scilex Board from March 2019 to October 2020. During the years ended December&nbsp;31, 2021 and 2020, pursuant
to the aforementioned Product Development Agreement and the Itochu and Oishi Commercial Supply Agreement, Legacy Scilex purchased inventory from Itochu in the amount of $5.7&nbsp;million and $1.0&nbsp;million, respectively, on terms Legacy Scilex
considers to be arms&#146; length between the parties. See the sections of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Itochu and Oishi Product Development Agreement</I>&#148; and &#147;<I>Business &#151; Material
Agreements &#151; Itochu and Oishi Commercial Supply Agreement</I>&#148; for additional information regarding such agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indenture and Letter
of Credit </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;7, 2018, Scilex Pharma entered into the Purchase Agreements with the Purchasers and Sorrento, which is
a beneficial owner of more than 5% of Legacy Scilex&#146;s capital stock. Pursuant to the Purchase Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Purchasers the Scilex Pharma Notes for an aggregate
purchase price of $140.0&nbsp;million. The Scilex Pharma Notes are governed by the Indenture with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as the Trustee and Collateral Agent, and Sorrento, as
guarantor. The Indenture provides that the holders of the Scilex Pharma Notes will be entitled to receive quarterly payments in an amount equal to a fixed percentage, ranging from 15% to 25%, of the net sales of ZTlido for the prior fiscal quarter
on each February&nbsp;15, May&nbsp;15, August&nbsp;15 and November 15. As security for the Scilex Pharma Notes, Scilex Pharma has granted to the Collateral Agent, for the benefit of the Purchasers, a continuing security interest in and lien on
Scilex Pharma&#146;s right, title, and interest in and to ZTlido and all property and assets of Scilex Pharma that are necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive
of Japan). Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture. Pursuant to the
terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (as amended, the &#147;Letter of Credit&#148;) which provides that, in the event that (1)&nbsp;Scilex Pharma does not hold at least $29.0&nbsp;million
in unrestricted cash (inclusive of cash equivalents in the collateral account) as of any calendar month ending March&nbsp;31, 2020 through and including the month ending March&nbsp;31, 2021 or at least $35.0&nbsp;million in unrestricted cash
(inclusive of cash equivalents in the collateral account) at the end of any calendar month after March&nbsp;31, 2021, (2) actual cumulative net sales of ZTlido from September&nbsp;7, 2018 through December&nbsp;31, 2021 are less than a specified
sales threshold for such period, or (3)&nbsp;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, are less than a specified sales threshold for such calendar
year, Scilex Pharma, as beneficiary of the Letter of Credit, will draw, and Sorrento will pay to Scilex Pharma, $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. The Letter of Credit will
terminate upon the earliest to occur of: (a)&nbsp;the repayment of the Scilex Pharma Notes in full, (b)&nbsp;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&nbsp;the
consummation of an initial public offering on a major international stock exchange by us that satisfies certain valuation thresholds, and (d)&nbsp;the replacement of the Letter of Credit with another letter of credit in form and substance, including
as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, the parties entered into a Consent Under and Amendment No.&nbsp;3 to Indenture and Letter of Credit
(&#147;Amendment No.&nbsp;3&#148;), which amended: (i)&nbsp;the Indenture, and (ii)&nbsp;the Letter of Credit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;14, 2020, and in connection with Amendment No.&nbsp;3, the aggregate
$45.0&nbsp;million in restricted funds held in previously established reserve and collateral accounts were released and Scilex Pharma utilized such funds to repurchase an aggregate of $45.0&nbsp;million in principal amount of the Scilex Pharma
Notes. Scilex Pharma also repurchased an aggregate of $20.0&nbsp;million in principal amount of the Scilex Pharma Notes on December&nbsp;16, 2020. Pursuant to the foregoing repurchases, the aggregate principal amount of the Scilex Pharma Notes was
reduced by an aggregate of $65.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further related to Amendment No.&nbsp;3, the Purchasers also consented to Scilex Pharma
incurring up to $10.0&nbsp;million of indebtedness in connection with an accounts receivable revolving loan facility with another lender and the incurrence of liens and the pledge of collateral to such lender in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the
Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento
paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan. Per the terms of the Amendment No.&nbsp;3, in February 2022, Scilex Pharma repurchased Scilex Pharma Notes in an
aggregate amount equal to $20.0&nbsp;million at a purchase price in cash equal to 100% of the principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective
February&nbsp;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $28.0&nbsp;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through
December&nbsp;31, 2021 did not equal or exceed a $481.0&nbsp;million sales threshold for such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and
Scilex Pharma, entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (&#147;Amendment No.&nbsp;4&#148;) with the Trustee, Collateral Agent, and the Purchasers, which amended the Indenture. Pursuant to Amendment No.&nbsp;4, (1) on
June&nbsp;3, 2022, Scilex Pharma repurchased approximately $41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof (the &#147;Repurchase&#148;), (2) the Purchasers agreed
that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase
the Purchasers will forgive and discharge $28.0&nbsp;million of the aggregate principal amount of the Scilex Pharma Notes, and (3)&nbsp;the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash
equivalents at the end of each calendar month. Scilex Pharma funded the Repurchase with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022.
We paid off all the amounts outstanding under the Scilex Pharma Notes as of immediately prior to the Closing of the Business Combination, which payment was funded by Sorrento and treated as intercompany debt in exchange for Series A Preferred Stock
pursuant to the terms of the Debt Exchange Agreement described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;28, 2022, we repurchased the remaining
outstanding principal balance of the Scilex Pharma Notes with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $34.0&nbsp;million received from Sorrento. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Oaktree Guaranty </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
November&nbsp;7, 2018, Sorrento and certain of its domestic subsidiaries entered into a Term Loan Agreement, as amended on May&nbsp;3, 2019 and December&nbsp;6, 2019 (as amended, the &#147;Oaktree Loan Agreement&#148;) with certain funds and
accounts managed by Oaktree Capital Management, L.P. and Oaktree Fund Administration, LLC, as administrative and collateral agent, for an initial term loan of $100.0&nbsp;million and a delayed draw term loan of $20.0&nbsp;million that was provided
to Sorrento on May&nbsp;3, 2019. On April&nbsp;12, 2019, Legacy Scilex and Semnur entered into a Joinder Agreement to the Oaktree Loan Agreement whereby each entity became a guarantor under the Oaktree Loan Agreement and pledged all of their
respective assets (other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than equity of Scilex Pharma) as collateral for the loans made to Sorrento under the Oaktree Loan Agreement. All obligations owed under the Oaktree Loan Agreement were paid off in full on
June&nbsp;12, 2020 and both Legacy Scilex and Semnur ceased to be a guarantor under the Oaktree Loan Agreement as of such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercompany
Promissory Note and Sale of Shares to Sorrento </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento an intercompany
promissory note in the amount of approximately $21.7&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). On October&nbsp;22, 2018, Sorrento purchased from Legacy Scilex 24,117,608
shares of Legacy Scilex Common Stock in exchange for the cancellation of $21.7&nbsp;million of indebtedness under the Intercompany Note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&nbsp;million and
$10.3&nbsp;million, respectively, under the Intercompany Note. As of December&nbsp;31, 2021 and 2020, the outstanding principal balance under the Intercompany Note was approximately $23.5&nbsp;million and $15.4&nbsp;million, respectively. In
connection with Amendment No.&nbsp;4 to the Indenture, the maximum aggregate principal amount of the Intercompany Note was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. As of immediately prior to the Closing of the Business
Combination, the outstanding principal balance under the Intercompany Note was $23.5&nbsp;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in
exchange for preferred stock as more fully described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Note Payable to Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;18, 2019, Legacy Scilex entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million. Legacy
Scilex may borrow up to an aggregate of $20.0&nbsp;million of principal amount under the note payable. The note payable is interest bearing at the lesser of (i) 10% simple interest per annum, and (ii)&nbsp;the maximum interest rate permitted under
law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note payable as of December&nbsp;31, 2021 and
2020 was $19.6&nbsp;million and $13.0&nbsp;million, respectively. Accrued interest of $3.9&nbsp;million and $2.6&nbsp;million was recognized under related party payable in Legacy Scilex&#146;s consolidated balance sheet as of December&nbsp;31, 2021
and 2020, respectively. During the six months ended June&nbsp;30, 2022 and 2021, Sorrento made advances to Legacy Scilex in the amount of $27.5&nbsp;million and $0, respectively, under the note payable. The outstanding principal balance of the note
payable on June&nbsp;30, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and $19.6&nbsp;million, respectively, which was recorded under the current related party note payable in Legacy Scilex&#146;s consolidated balance sheets. As of
June&nbsp;30, 2022 and December&nbsp;31, 2021, Legacy Scilex had ending balances resulting from the accrued interest on the note payable of $5.6&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under the related party payable in
Legacy Scilex&#146;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur and to finance Legacy Scilex&#146;s operations. As of immediately prior to the Closing of the Business Combination,
the outstanding principal balance under the note payable was $54.3&nbsp;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for
preferred stock as more fully described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Exchange Agreement and Related Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement with
Sorrento (the &#147;Debt Exchange Agreement&#148;), pursuant to which (i)&nbsp;Sorrento shall contribute to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy
Scilex and Scilex Pharma that remain outstanding as of immediately prior to the Closing of the Business Combination (the &#147;Aggregate Outstanding Amount&#148; or &#147;Outstanding Indebtedness&#148;), including with respect to the Scilex Pharma
Notes, the Intercompany Note, and the other notes payable to Sorrento described above, in exchange for the issuance by Legacy Scilex to Sorrento of preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock of Legacy Scilex, (ii)&nbsp;Legacy Scilex shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of
capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the Closing of the Business
Combination, Sorrento has elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of Legacy Scilex Preferred Stock (subject to adjustment for
recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt Contribution&#148;) that is equal to (i)&nbsp;the Aggregate Outstanding Amount plus the amount equal to
10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, Sorrento and Legacy Scilex entered into the Funding Commitment Letter. Pursuant to the terms of the Funding
Commitment Letter, upon the written request of Legacy Scilex (which request Legacy Scilex shall make to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net
tangible assets as of immediately following the Effective Time) (the &#147;Net Tangible Assets Condition&#148;), Sorrento shall fund one or more loans to Legacy Scilex in the amount set forth in such written request (a &#147;Loan Request&#148;),
provided, that any amounts funded by Sorrento in respect of any Loan Request shall be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount
thereunder. The Funding Commitment Letter also provides that in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&nbsp;an amount that, when taken together
with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. As consideration for the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant
Transfer Agreement, which is more fully described elsewhere in this prospectus. No Loan Requests were made under the Funding Commitment Letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Debt Contribution, Legacy Scilex filed, with the Secretary of State of the State of Delaware, (i)&nbsp;a Certificate of Amendment
to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of Legacy Scilex from 20,000,000 to 45,000,000 and (ii)&nbsp;a certificate of designation setting forth the designations, powers,
rights and preferences and qualifications, limitations and restrictions of the Exchange Shares. Following the issuance thereof to Sorrento and in connection with the Closing of the Business Combination, such shares were converted into the right to
receive (i)&nbsp;one share of Series A Preferred Stock and <FONT STYLE="white-space:nowrap">(ii)&nbsp;one-tenth</FONT> of one share of our Common Stock, which shares of Series A Preferred Stock shall then have the rights set forth in the Certificate
of Designations. Sorrento is entitled to the rights set forth in the Stockholder Agreement as a result of Sorrento&#146;s ownership thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the Closing of the Business Combination, the Outstanding Indebtedness (including amounts related to the transfer of
certain liabilities to Sorrento and repayment of Scilex Pharma Notes) was $290,570,964, which was contributed by Sorrento, in accordance with the Debt Exchange Agreement, in exchange for 29,057,097 shares of Legacy Scilex Preferred Stock, which were
in turn converted into the right to receive 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shah Investor
LP Assignment Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex, through Semnur, is a party to the Assignment Agreement with Shah Investor LP, pursuant to
which Shah Investor LP assigned Legacy Scilex certain intellectual property and Legacy Scilex agreed to pay Shah Investor LP a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on the quarterly net
sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing such intellectual property, which would include SEMDEXA. Mahendra Shah, Ph.D., who served on the Legacy Scilex Board
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from March 2019 to October 2020, is the managing partner of Shah Investor LP. See the section of this prospectus titled &#147;<I>Business &#151; Material Agreements &#151; Shah Investor LP
Assignment Agreement</I>&#148; for additional information regarding the Assignment Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisition of
<FONT STYLE="white-space:nowrap">SP-104</FONT> Assets from Sorrento </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase
agreement (the &#147;Aardvark Asset Purchase Agreement&#148;) with Aardvark Therapeutics, Inc. (&#147;Aardvark&#148;), pursuant to which, among other things, Sorrento acquired Aardvark&#146;s Delayed Burst Release Low Dose Naltrexone <FONT
STYLE="white-space:nowrap">(DBR-LDN)</FONT> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT>
Assets&#148;), which includes a Statement of Work dated November&nbsp;18, 2020 (the &#147;Tulex Statement of Work&#148;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <FONT
STYLE="white-space:nowrap">SP-104.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development
efforts related to <FONT STYLE="white-space:nowrap">SP-104</FONT> and on May&nbsp;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement, pursuant to which Sorrento sold, conveyed, assigned and
transferred to Legacy Scilex all of its rights, title and interest in and to the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and
Legacy Scilex assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition, Legacy Scilex issued a promissory note in the aggregate
principal amount of $5,000,000 to Sorrento (the &#147;Promissory Note&#148;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and
(b)&nbsp;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#147;Consideration Shares&#148;) or any combination thereof, at Legacy Scilex&#146;s sole discretion,
and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento,
within 60 days of the issuance of such Consideration Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is
obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy
Scilex&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#147;Commercial
Product&#148;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to
reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of
the date of this prospectus none of the foregoing payments have been triggered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the
SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the
board of directors of Aardvark. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Guaranty of Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;8, 2019, Legacy Scilex entered into a new office lease for approximately 6,000 square feet for its executive offices in Palo
Alto, California, as amended on September&nbsp;15, 2019. The term of the lease commenced on September&nbsp;15, 2019 and will expire on November&nbsp;30, 2024. We will be obligated to pay an average of approximately $0.5&nbsp;million in annual rent
over the term of the lease. In connection with the lease, on August&nbsp;8, 2019, Sorrento executed a Guaranty of Lease, guaranteeing the performance of our obligations under the lease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intercompany Receivable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During
the month of December 2022, we paid $1.8 million of invoices on behalf of Sorrento for legal fees incurred by Sorrento, which was fully reserved in our financial statements for the year ended December 31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officer and Director Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Executive and Director Compensation</I>&#148; for information regarding the
compensation of our executive officers and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into offer letter agreements with our named executive officers, other than Dr.&nbsp;Ji, that, among other things, provide for
certain compensatory and change in control benefits, as well as severance benefits. For a description of such agreements, see the section of this prospectus titled &#147;<I>Executive and Director Compensation &#151; Arrangements with Executive
Officers.</I>&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation of Liability and Indemnification of Officers and Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#147;<I>Management &#151; Limitation of Liability and Indemnification of Directors and
Officers</I>&#148; for information regarding our arrangements to provide indemnification to our officers and directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combination
Related Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Vickers, Legacy Scilex and Sorrento entered into a
Company Stockholder Support Agreement, pursuant to which Sorrento agreed to vote all Legacy Scilex Common Stock beneficially owned by it, including any additional shares of Legacy Scilex it acquires ownership of or the power to vote, in favor of the
Business Combination and related transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, in connection with the closing of the Business Combination,
Scilex, Sorrento, the Sponsors, and Vickers&#146;s former directors Pei Wei Woo, Suneel Kaji and Steve Myint, entered into the Registration Rights Agreement, whereby, subject to certain exceptions, the parties agreed, among other things, not to
transfer any of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&nbsp;one hundred eighty (180)&nbsp;days
from the date of the Registration Rights Agreement or (ii)&nbsp;the date on which we complete a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange
their shares of our Common Stock for cash, securities or other property. The Registration Rights Agreement governs the registration of certain shares of our Common Stock for resale and includes certain customary demand and &#147;piggy-back&#148;
registration rights with respect to shares of our Common Stock held by the parties thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Person Transaction Policy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval
or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related
person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their
respective immediate family members and any entity owned or controlled by such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been
identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation,
our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or
ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are
comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and,
to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors
have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of
our Board, will take into account the relevant available facts and circumstances including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit
committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other
independent body of our Board, determines in the good faith exercise of our discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_98"></A>PRINCIPAL SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of March&nbsp;6, 2023 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person or &#147;group&#148; known to be the beneficial owner of more than 5% of our outstanding Common
Stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our current executive officers and directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a
security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently
exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated
as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is
based on 145,811,298 shares of such common stock outstanding as of March&nbsp;6, 2023. Voting power is based on 145,811,298 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of March&nbsp;6, 2023. Shares of
Series A Preferred Stock are held solely by Sorrento. <B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information
available to us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Common</B><br><B>Shares</B><br><B>Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of</B><br><B>Total</B><br><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%&nbsp;of</B><br><B>Total</B><br><B>Vote</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors and Executive Officers Jaisim
Shah<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,294,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,197,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Tien-Li</FONT> Lee, M.D.<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Directors and Executive Officers as a Group (8 individuals)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,383,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Beneficial Owners</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,476,412</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise indicated, the business address of each of the following individuals is 4955 Directors Place,
San Diego, CA 92121. None of the following individuals own shares of Series A Preferred Stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 9,181,876 shares subject to options exercisable within 60 days of March&nbsp;6, 2023 and 112,633
shares held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 2,594,208 shares subject to options exercisable within 60 days of March&nbsp;6, 2023 and 603,298
shares held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 383,880 shares subject to options exercisable within 60 days of March&nbsp;6, 2023.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 443,295 shares subject to options exercisable within 60 days of March&nbsp;6, 2023 and 1,409 shares
held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents 15,625 shares subject to options exercisable within 60 days of March&nbsp;6, 2023 and 300 shares
held directly. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents (a) 61,985,795 shares held following completion of Sorrento&#146;s previously announced dividend on
January&nbsp;19, 2023 of shares of our Common Stock then held by Sorrento (of which 2,259,058 shares are being held in abeyance for the benefit of certain holders of warrants to purchase shares of common stock of Sorrento who may be entitled to
receive shares of Common Stock pursuant to the terms of the applicable warrants as a result of the previously declared dividend of shares of Common Stock by Sorrento), (b) 3,104,000 shares subject to Private Placement Warrants and (c) 1,386,617
shares subject to Public Warrants exercisable within 60 days of March&nbsp;6, 2023. &#147;Public Warrants&#148; means the redeemable warrants that were included in the Units that entitle the holder of each whole warrant to purchase one Vickers
Ordinary Share at a price of $11.50 per share. &#147;Units&#148; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant upon the consummation
of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities,
comprised of one share of Common Stock and <FONT STYLE="white-space:nowrap">one-half</FONT> of one warrant to purchase one share of Common Stock. The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, CA 92121.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">238 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_99"></A>SELLING SECURITYHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by the Selling Securityholder of up to 28,078,672 shares of Common Stock that have been and may
be issued by us to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. For additional information regarding the shares of Common Stock included in this prospectus, see the section of this prospectus titled &#147;<I>Committed
Equity Financing</I>&#148; above. We are registering the shares of Common Stock included in this prospectus pursuant to the provisions of the A&amp;R Yorkville Purchase Agreement we entered into with the Selling Securityholder on February&nbsp;8,
2023 in order to permit the Selling Securityholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the A&amp;R Yorkville Purchase Agreement, and as set forth in the section of
this prospectus titled &#147;Plan of Distribution&#148; in this prospectus, the Selling Securityholder has not had any material relationship with us within the past three years. As used in this prospectus, the terms &#147;Selling
Securityholder&#148; and &#147;Yorkville&#148; mean YA II PN, Ltd., a Cayman Islands exempt limited partnership, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling
Securityholder&#146;s interest in the Common Stock other than through a public sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the
Selling Securityholder and the shares of Common Stock that may be resold by the Selling Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects
holdings as of November&nbsp;30, 2022 (the date on which the registration statement of which this prospectus forms a part was initially filed with the SEC). The number of shares in the column titled &#147;Maximum Number of Shares of Common Stock to
be Offered Pursuant to this Prospectus&#148; represents all of the shares of Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some, all, or none of the shares being
offered for resale in this offering. We do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Securityholder and any other stockholder, broker,
dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated by the SEC under the
Exchange Act, and includes shares of our Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of our Common Stock beneficially owned by the Selling Securityholder
prior to the offering shown in the table below is based on an aggregate of 145,811,298 shares of our Common Stock outstanding on March&nbsp;6, 2023. Because the purchase price to be paid by the Selling Securityholder for shares of Common Stock, if
any, that we may elect to sell to the Selling Securityholder in one or more Yorkville Advances from time to time under the A&amp;R Yorkville Purchase Agreement will be determined on the applicable Yorkville Advance Notice Dates for such Yorkville
Advances, the actual number of shares of Common Stock that we may sell to the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement may be fewer than the number of shares being offered for resale under this prospectus. The fourth
column in the table below assumes the resale by the Selling Securityholder of all of the shares of Common Stock being offered for resale pursuant to this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based
on the information furnished to us, that the Selling Securityholder has sole voting and investment power with respect to all shares of Common Stock that it beneficially owns, subject to applicable community property laws. Except as otherwise
described below, based on the information provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or an affiliate of a broker-dealer. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Securityholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares</B><br><B>of&nbsp;Common</B><br><B>Stock&nbsp;Beneficially</B><br><B>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>Number of</B><br><B>Shares of</B><br><B>Common</B><br><B>Stock Being</B><br><B>Offered<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares of
Common</B><br><B>Stock</B><br><B>Beneficially&nbsp;Owned</B><br><B>After&nbsp;the&nbsp;Offered</B><br><B>Shares&nbsp;of&nbsp;Common</B><br><B>Stock Are</B><br><B>Sold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">YA II PN, Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,078,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">239 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the Yorkville Commitment Shares we issued to the Selling Securityholder in consideration for
entering into the A&amp;R Yorkville Purchase Agreement with us. In accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the future
offering all of the remaining shares that the Selling Securityholder may be required to purchase under the A&amp;R Yorkville Purchase Agreement, because the issuance of such shares is at our discretion and is subject to conditions contained in the
A&amp;R Yorkville Purchase Agreement, the satisfaction of which are entirely outside of the Selling Securityholder&#146;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the
Yorkville Advances of Common Stock under the A&amp;R Yorkville Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the A&amp;R Yorkville Purchase Agreement. Also, the A&amp;R Yorkville Purchase Agreement
prohibits us from issuing and selling any shares of our Common Stock to the Selling Securityholder to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by the Selling Securityholder, would
cause the Selling Securityholder&#146;s beneficial ownership of our Common Stock to exceed the 4.99% Yorkville Beneficial Ownership Limitation. The A&amp;R Yorkville Purchase Agreement also prohibits us from issuing or selling shares of our Common
Stock under the A&amp;R Yorkville Purchase Agreement in excess of the 19.9% Yorkville Exchange Cap, unless we obtain stockholder approval to do so or all applicable sales of shares of Common Stock under the A&amp;R Yorkville Purchase Agreement equal
or exceed the &#147;Minimum Price&#148; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the 250,000 Yorkville Commitment Shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all shares being offered pursuant to this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">YA II PN, Ltd. is a fund managed by Yorkville Advisors Global, LP (&#147;Yorkville LP&#148;). Yorkville
Advisors Global II, LLC (&#147;Yorkville LLC&#148;) is the General Partner of Yorkville LP. All investment decisions for YA II PN, Ltd. are made by Yorkville LLC&#146;s President and Managing Member, Mr.&nbsp;Mark Angelo. The business address of YA
II PN, Ltd. is 1012 Springfield Avenue, Mountainside, NJ 07092. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">240 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_100"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock offered by this prospectus are being offered by the Selling Securityholder. The shares may be sold or distributed
from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market
prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. We may receive up to $500,000,000 aggregate gross proceeds under the
A&amp;R Yorkville Purchase Agreement from any sales we make to the Selling Securityholder pursuant to the A&amp;R Yorkville Purchase Agreement. The net proceeds from sales, if any, under the A&amp;R Yorkville Purchase Agreement, will depend on the
frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of
the shares of our Common Stock offered by this prospectus could be effected in one or more of the following methods: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokers&#146; transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions involving cross or block trades; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through brokers, dealers, or underwriters who may act solely as agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;at the market&#148; into an existing market for our Common Stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in other ways not involving market makers or established business markets, including direct sales to purchasers
or sales effected through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in privately negotiated transactions; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of the foregoing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed
brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#146;s registration or qualification requirement is available and
complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities
Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if
any, of our Common Stock that it may acquire from us pursuant to the A&amp;R Yorkville Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then-current market price. Such registered
broker-dealer may, in some circumstances (for instance if such registered broker-dealer&#146;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#146; or sellers&#146; commissions), be
considered to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act. The Selling Securityholder has informed us that each such broker-dealer may receive commissions from the Selling Securityholder for executing such
sales for the Selling Securityholder and, if so, such commissions will not exceed customary brokerage commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers,
underwriters, or agents participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers
may act as agent, of the shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be
less than or in excess of customary commissions. Neither we nor the Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling
Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">241 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other
stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which
this prospectus forms a part to amend, supplement, or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this
prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters, or agents that participate in the distribution of such shares by the Selling
Securityholder, and any other related information required to be disclosed under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to
the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Securityholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for its irrevocable commitment to purchase our Common Stock under the A&amp;R Yorkville Purchase Agreement, we issued to the
Selling Securityholder 250,000 shares of our Common Stock as Yorkville Commitment Shares in connection with the execution of the Original Purchase Agreement. In addition, we have paid an affiliate of the Selling Securityholder a structuring fee of
$10,000 in connection with the structuring of the transactions by the Selling Securityholder under the A&amp;R Yorkville Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify the Selling Securityholder and certain other persons against certain liabilities in connection with the
offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act, or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. The Selling Securityholder
has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by the Selling Securityholder specifically for use in this prospectus or, if such indemnity is unavailable, to
contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that, in
the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has represented to us that at no time prior to the date of the A&amp;R Yorkville Purchase Agreement has the Selling
Securityholder or any entity managed or controlled by the Selling Securityholder engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any short sale or any
transaction that establishes a net short position with respect to our Common Stock. The Selling Securityholder has agreed that, during the term of the A&amp;R Yorkville Purchase Agreement, none of the Selling Securityholder, its officers, its sole
member, or any entity managed or controlled by the Selling Securityholder will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain
exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or
purchase, any security that is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of
that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will
terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Securityholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">242 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_101"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the purchase, ownership and
disposition of our Common Stock. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect
on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences
relating to the purchase, ownership and disposition of our Common Stock. In addition, this discussion does not address all aspects of U.S. federal income tax consequences to particular holders nor does it take into account the individual facts and
circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal
3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S. state
and local, or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S. federal income tax consequences to a holder of the
purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our Common Stock as &#147;capital assets&#148; within the meaning of
Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders in light of their individual circumstances, including holders
subject to special treatment under the U.S. tax laws, such as, for example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks or other financial institutions, underwriters, or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities who elect to apply a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts and regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, qualified retirement plans, individual
retirement accounts, or other <FONT STYLE="white-space:nowrap">tax-</FONT> deferred accounts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expatriates or former long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subchapter S corporations, partnerships or other pass-through entities or investors in such entities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities, commodities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grantor trusts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. persons whose &#147;functional currency&#148; is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or
through a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan or otherwise as compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our Common Stock as a position in a &#147;straddle,&#148; as part of a &#147;synthetic
security&#148; or &#147;hedge,&#148; as part of a &#147;conversion transaction,&#148; or other integrated investment or risk reduction transaction; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">243 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to
which there are one or more United States shareholders within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.367(b)-3(b)(1)(ii);</FONT> or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#147;U.S. Holder&#148; means a beneficial owner of our Common Stock that is, for U.S. federal income tax
purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is
created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (i)&nbsp;if a court within the United States is able to exercise primary supervision over the
administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for
U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; means a
beneficial owner of our Common Stock, that is neither a U.S. Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes,
holds our Common Stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such
partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the ownership and disposition of our Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE
OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT
AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM
OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_102">
</A>U.S. Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to
U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income
tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in our Common
Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#147;<I>U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of
Common Stock</I>&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">244 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for
the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period
requirements are met, dividends we pay to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder will generally constitute &#147;qualified dividends&#148; that will be subject to tax at the preferential tax rate accorded to long-term
capital gains. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#147;investment income&#148; pursuant to Section&nbsp;163(d)(4) of
the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a
dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would
have taxable income equal to the entire dividend amount, and <FONT STYLE="white-space:nowrap">non-corporate</FONT> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified
dividend income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including
on a redemption that is treated as a sale or exchange under Section&nbsp;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#146;s holding period for the Common Stock so
disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&nbsp;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&nbsp;the U.S.
Holder&#146;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#146;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#146;s acquisition cost for such Common Stock, less any prior distributions treated
as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders are generally eligible for reduced rates of tax. If the
U.S. Holder&#146;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax
rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_103"></A><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
general, any distributions (including constructive distributions) we make to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as
determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s
conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate
of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> as applicable). Special certification and other requirements apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that are pass-through entities rather than corporations or
individuals. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its shares of our Common Stock and, to the
extent such distribution exceeds the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#147;<I><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</I>&#148; below. In addition, if we determine that we are likely to be classified as a &#147;United States real property
holding </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">245 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation&#148; (see &#147;<I><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders-Gain on </I><I>Sale, Exchange or Other Taxable Disposition of Common Stock</I>&#148; below), we will
withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (or if a tax treaty applies are
attributable to a U.S. permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder) will generally not be subject to U.S. withholding tax, provided such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <FONT STYLE="white-space:nowrap">W-8ECI).</FONT> Instead, such dividends generally will be
subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a corporation, dividends that are
effectively connected income may also be subject to a &#147;branch profits tax&#148; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax in respect of
gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the conduct of a trade or business by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is an individual who is present in the United States
for 183 days or more in the taxable year of disposition and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are or have been a &#147;United States real property holding corporation&#148; for U.S. federal income tax
purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder held our Common Stock and, in the case where shares of our Common Stock
are regularly traded on an established securities market, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period
preceding the disposition or such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established
securities market for this purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally
applicable U.S. federal income tax rates as if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder were a U.S. resident. Any gains described in the first bullet point above of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is
a foreign corporation may also be subject to an additional &#147;branch profits tax&#148; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income
tax. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder and applicable exceptions are not
available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock from such holder may be
required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are urged to consult their tax advisors regarding the application of these rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_104"></A>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to
as the &#147;Foreign Account Tax Compliance Act&#148; or &#147;FATCA&#148;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds
from a sale or disposition of, securities which are held by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">246 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or through certain foreign financial institution (including investment funds), unless any such institution (a)&nbsp;enters into, and complies with, an agreement with the IRS to report, on an
annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities that are wholly or partially owned by
U.S. persons and to withhold on certain payments, or (b)&nbsp;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such
information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our Common Stock are held will affect the
determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that
is a <FONT STYLE="white-space:nowrap">non-financial</FONT> <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either
(i)&nbsp;certifies to the applicable withholding agent that such entity does not have any &#147;substantial United States owners&#148; or (ii)&nbsp;provides certain information regarding the entity&#146;s &#147;substantial United States
owners,&#148; which will in turn be provided to the U.S. Department of Treasury. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and
administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common
Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult
their tax advisors regarding the possible implications of FATCA on their investment in our Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup
Withholding. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale
or other disposition of our shares of Common Stock. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting
and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup
withholding is not an additional tax. The amount of any backup withholding from a payment to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A
GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">247 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_105"></A>DESCRIPTION OF OUR SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_106"></A>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of the
Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of
Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_107"></A>Authorized and Outstanding Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii)
45,000,000 shares of preferred stock, $0.0001 par value per share (the &#147;Preferred Stock&#148;), of which 29,057,097 shares have been designated as Series A Preferred Stock. As of March&nbsp;6, 2023, there were 141,811,298 shares of Common Stock
and 29,057,097 shares of Series A Preferred Stock issued and outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_108"></A>Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders
of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our
capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be
declared and paid to stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on
which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected
classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders
at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to
vote thereon, except that our directors will be elected by a plurality of the votes cast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Right to Receive Liquidation Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in
all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No
Preemptive or Similar Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no
redemption or sinking fund provisions applicable to our Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">248 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and <FONT STYLE="white-space:nowrap">Non-Assessable</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_109"></A>Our Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of
preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the
qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders.
The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our
outstanding stock entitled to vote thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that
could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred
Stock issued to Sorrento in connection with the Closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Number and Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed
the Certificate of Designations, designating 29,057,097 shares of our preferred stock as &#147;Series A Preferred Stock&#148;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant
to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock
shall rank (i)&nbsp;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock
as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Junior Securities&#148;); and (ii)&nbsp;on parity with each class or series of our capital stock, created
specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company (&#147;Parity Securities&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividend Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the
Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are
paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date
for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">249 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, whether
voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to
receive an amount per share of Series A Preferred Stock equal to the greater of (i)&nbsp;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the
Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&nbsp;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion and Redemption Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by
the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-converted-to-</FONT></FONT></FONT> Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number
of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set
forth in the Certificate of Designation (a &#147;Deemed Conversion&#148;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&nbsp;stated value by (ii) $10.00 (subject to anti-dilution
adjustments). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Other Preferred Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will
be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be
entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a
majority of the outstanding shares of Series A Preferred Stock (a)&nbsp;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms
of the Certificate of Designations; (b)&nbsp;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon
liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up</FONT> of the Company, or increase the authorized amount of any such other class or series; or (c)&nbsp;amend the Certificate of Incorporation or the Certificate of Designations
in any manner that adversely affects the holders of Series A Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Agreement with Sorrento </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns
any shares of New Scilex Series A Preferred Stock, among other things, (i)&nbsp;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#147;Stockholder
Designee&#148; and collectively, the &#147;Stockholder Designees&#148;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu
of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">250 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board, or the size of the Board and (ii)&nbsp;we will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to
be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the
right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange,
including independence requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we will be prohibited from taking certain actions
without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends
on our Common Stock. For more information on the Stockholder Agreement, see the section of this prospectus titled &#147;<I>Certain Relationships and Related Party Transactions &#151; Certain Relationships of Vickers &#151; Stockholder Agreement with
Sorrento</I>.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_110"></A>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our
stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective
registration statement under the Securities Act covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of
these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in
the public market may have an adverse effect on the market price of our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_111"></A>Anti-Takeover Matters in our Governing
Documents and Under Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all
of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids.
These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to
acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Capital Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval,
subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and
unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term
(except that the term of our current Class&nbsp;I directors shall expire at the first annual meeting of stockholders following the Closing of the Business Combination and the term of our current Class&nbsp;II
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">251 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors shall expire at the second annual meeting of stockholders following the Closing of the Business Combination), with one class being elected each year by the stockholders. This system of
electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the
directors. See the section of this prospectus titled &#147;<I>Management</I>&#148; for more information on the classified board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board; provided that, at any time prior to a Sorrento Trigger Event, the stockholders may also fix the number of
directors by resolution adopted by the stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors; Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be
removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of such directors; provided, however, that, from and
after the Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock
entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the
death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided,
however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority
of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes
in our management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we will opt out of Section&nbsp;203 of the DGCL until the occurrence of a Sorrento Trigger
Event, at which time we shall immediately and automatically become governed by Section&nbsp;203 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL
prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless
the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#147;interested stockholder&#148; is a person who,
together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock. Generally, a &#147;business combination&#148; includes a
merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our
Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&nbsp;203 of the DGCL will not apply to
Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">252 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially
owned by them. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative
voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Stockholder Meetings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board,
our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairperson of our Board at the
request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in
the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Nominations and Stockholder Proposals </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as
directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#147;properly brought&#148; before a meeting, a stockholder will have to comply with advance notice requirements
and provide us with certain information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#146;s notice must be delivered to our secretary at our
principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#146;s annual meeting (in the case of the first annual
meeting of stockholders held after January&nbsp;1, 2023, the date of the preceding year&#146;s annual meeting of the stockholders shall be deemed to be June&nbsp;30, 2022); provided, however, that, if the date of the annual meeting is advanced more
than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#146;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier
than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date
of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#146;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by
resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In
addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations
are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to influence or obtain control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;228 of the DGCL and the terms of the Certificate of Incorporation, any action required or permitted to be taken by our
stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">253 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taken at any annual or special meeting of our stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is
signed by or on behalf of the holders of record of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and
voted, is delivered to us in accordance with the DGCL, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Certificate of Incorporation or Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a
corporation&#146;s certificate of incorporation or bylaws, unless a corporation&#146;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at
least 66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of
Incorporation: Article V (Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article VIII (Corporate Opportunities and Competition), Article IX
(Exclusive Forum), Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the
circumvention of the provisions set forth in any of such Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our
Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative
vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing
changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate
of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter
jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the
fullest extent permitted by law, be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Company, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or
former directors, officers, employees or stockholders to us or our stockholders, (iii)&nbsp;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of
the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&nbsp;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&nbsp;any action or proceeding
asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&nbsp;any action asserting an
&#147;internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">254 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate claim,&#148; as that term is defined in Section&nbsp;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim
for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent
in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action
arising under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application
of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#146;
certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and
regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such
action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in
shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation
of Liability and Indemnification of Directors and Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that
limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as
directors, except liability for the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of their duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal
liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our
request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#147;Covered Person&#148;) and who is or was a party to,
is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#146;s actions
in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other
enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income
Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#146; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">255 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&nbsp;advance costs, fees or expenses (including attorneys&#146; fees) incurred by a Covered Person defending
or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&nbsp;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer,
employee or agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture,
trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the
Bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as
determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to
advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors
and executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the
indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors may, through their relationships with their employers, be
insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and
indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of
derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#146;s investment may be adversely affected to the extent we pay the costs of
settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been
informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_112"></A>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the
corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&nbsp;engaging in a
corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&nbsp;otherwise investing in or providing
services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to
offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us
or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified
Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_113"></A>Rights of Appraisal and Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the
Company. Pursuant to Section&nbsp;262 of the DGCL, stockholders who properly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">256 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of
Chancery. However, appraisal rights are not available in all circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_114"></A>Stockholders&#146; Derivative Actions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#146;s name to procure a judgment in its favor, also known as a
derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_115"></A>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a
warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_116"></A>Public Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to
adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently
to all of the warrants, provided that we will provide at least 20 days&#146; prior written notice to registered holders of the warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance
of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the
Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration
statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from
registration is not available, holders will not be able to exercise their warrants on a cashless basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five
years from the consummation of the Business Combination (i.e., November&nbsp;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at any time while the warrants are exercisable, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon not less than 30 days&#146; prior written notice of redemption to each warrantholder, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <FONT
STYLE="white-space:nowrap">sub-divisions,</FONT> share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day
prior to the date on which notice of redemption is given, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of
the Public Warrants, and a current prospectus relating thereto, available throughout the <FONT STYLE="white-space:nowrap">30-day</FONT> redemption. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">257 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise
of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised prior to
the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#146;s warrant upon surrender of such warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to
the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption
call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call
the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#147;cashless basis.&#148; In such event, each holder would pay the exercise price by
surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&nbsp;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise
price of the warrants and the fair market value by (y)&nbsp;the fair market value. The &#147;fair market value&#148; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on
the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior
to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#147;cashless
basis&#148; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in
this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the
Public Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under a warrant agreement (the &#147;Warrant Agreement&#148;) between
Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written
consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any change that adversely affects the interests of the registered holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances
including in the event of (i)&nbsp;a stock dividend or split up, (ii)&nbsp;a consolidation, combination, reverse stock split or reclassification of the Common Stock, (iii)&nbsp;extraordinary dividend or (iv)&nbsp;reclassification or reorganization
of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise
of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by
a fraction (x)&nbsp;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&nbsp;the denominator of which will be the number of shares of Common
Stock so purchasable immediately thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the
expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">258 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or
privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to
one vote for each share of Common Stock held of record on all matters to be voted on by stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no
Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to
be exempt under the securities laws of the state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus
relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock
issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is
not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have
no value, the market for the warrants may be limited and the warrants may expire worthless. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a
restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#146;s affiliates) would
beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving effect to such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares
will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be
issued to the warrantholder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Private Placement Warrants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even
if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#146;s option, and will not be redeemable by us, in each case so long as they are
still held by the initial purchasers or their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not
purport to be complete and is qualified in its entirety by reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_117"></A>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#146;s address is 1 State Street, 30th Floor, New
York, New York 10004. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="rom418853_118"></A>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#147;SCLX&#148; and &#147;SCLXW&#148; respectively. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">259 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_119"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_120"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&nbsp;31, 2022 and 2021, and for each of the three years in the
period ended December&nbsp;31, 2022, appearing in this prospectus, have been audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph
describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such
report given on the authority of such firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_121"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> including exhibits, under the
Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer
to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those
documents&#146; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#146;s website at<I> http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current
reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is
not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">260 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom418853_122"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:
42)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_2">Consolidated Balance Sheets as of December&nbsp;31, 2022 and
2021</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_3">Consolidated Statements of Operations for the Years Ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_4">Consolidated Statements of Stockholders&#146; Equity / (Deficit) for the Years
 Ended December&nbsp;31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2022, 2021 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin418853_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex
Holding Company </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&nbsp;31, 2022 and 2021, the related
consolidated statements of operations, stockholders&#146; equity/(deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2022, and the related notes (collectively referred to as the &#147;consolidated financial
statements&#148;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2022 and 2021, and the results of its operations and its cash flows for
each of the three years in the period ended December&nbsp;31, 2022, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Company&#146;s Ability to Continue as a Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company
will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has negative working capital, has suffered losses from operations, has recurring negative cash flows from operations, and has stated that substantial
doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 2. The consolidated financial
statements do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test
basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;7, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_2"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF DECEMBER&nbsp;31, 2022 AND 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for par value and share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>ASSETS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY/(DEFICIT)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued rebates and fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,842</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term portion of deferred consideration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">301,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments and contingencies (See Note 10)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; equity/(deficit):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 45,000,000 shares authorized; 29,057,097 and 0 issued and
outstanding at December&nbsp;31, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 740,000,000 shares authorized; 141,348,856 and 132,858,484 shares
issued and outstanding at December&nbsp;31, 2022 and December&nbsp;31, 2021, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">412,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(375,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity/(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#146; equity/(deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_3"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except for net loss per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,034</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating costs and expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating costs and expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other (income) expense:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other (income) expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before income taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,572</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_4"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY / (DEFICIT) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;Legacy&nbsp;Common&nbsp;Stock&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(216,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(90,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Retroactive application of the recapitalization due to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2019, after the effect of Business Combination</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,009</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Cancellation of shares held in escrow related to Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Adjustment to shares issued in Semnur Acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(352,550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(223,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> license transfer from Sorrento, net of
discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Aardvark <FONT STYLE="white-space:nowrap">SP-104</FONT> discount amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued pursuant to the terms of the Debt Exchange Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued as a result of the Business Combination, net of transaction activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Shares issued to Yorkville pursuant to Yorkville Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Balance, December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">412,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(375,914</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_5"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEARS ENDED DECEMBER&nbsp;31, 2022, 2021, AND 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,779</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Amortization of debt issuance costs and debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt
discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">(Gain) loss on derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,310</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Forfeitures of Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(598</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Inventory</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Prepaid expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,629</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,379</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,066</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrued rebates and fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used for operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,664</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,461</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition consideration paid in cash for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,060</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash used for investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs paid related to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment of principal on the Scilex Pharma Notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58,927</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Repayment on other loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from other loans</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from stock options exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Proceeds from related party note payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Net change in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(501</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash and cash equivalents at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosures:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and
financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Related party debt converted to equity pursuant to Debt Exchange Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Deferred consideration for Romeg intangible asset acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> consideration in Semnur acquisition</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other loan forgiveness</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Promissory Note issued to Sorrento in exchange for the
<FONT STYLE="white-space:nowrap">SP-104</FONT> license, net of discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Fair value adjustment to derivative liability in troubled debt restructuring</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Acquisition of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of shares to Yorkville pursuant to Yorkville Purchase Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-cash</FONT> distribution to Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accrual for transaction costs related to the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Transaction costs obligation assumed by Sorrento</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes to audited consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin418853_6"></A>SCILEX HOLDING COMPANY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of Operations and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Organization and Principal Activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scilex Holding
Company (&#147;Scilex&#148; and together with its wholly owned subsidiaries, the &#147;Company&#148;) is the successor entity to Vickers Vantage Corp. I (&#147;Vickers&#148;). Vickers was formed on February&nbsp;21, 2020 as a Cayman Islands exempted
company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Scilex was originally formed in 2019 and is a majority-owned
subsidiary of Sorrento Therapeutics, Inc. (&#147;Sorrento&#148;). Scilex has two wholly owned subsidiaries, Scilex Pharmaceuticals Inc. (&#147;Scilex Pharma&#148;) and Semnur Pharmaceuticals, Inc. (&#147;Semnur&#148;). The Company is a commercial
biopharmaceutical company focused on acquiring, developing and commercializing <FONT STYLE="white-space:nowrap">non-opioid</FONT> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in
October 2018, ZTlido (lidocaine topical system) 1.8% (&#147;ZTlido&#148;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing
significantly improved adhesion and continuous pain relief throughout the <FONT STYLE="white-space:nowrap">12-hour</FONT> administration period. The Company <FONT STYLE="white-space:nowrap">in-licensed</FONT> the exclusive right to commercialize
GLOPERBA (colchicine USP) oral solution, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The
Company is currently developing three product candidates, <FONT STYLE="white-space:nowrap">SP-102</FONT> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural
injections to treat lumbosacral radicular pain, or sciatica <FONT STYLE="white-space:nowrap">(&#147;SP-102&#148;</FONT> or &#147;SEMDEXA&#148;), <FONT STYLE="white-space:nowrap">SP-103</FONT> (lidocaine topical system) 5.4% <FONT
STYLE="white-space:nowrap">(&#147;SP-103&#148;),</FONT> for the treatment of acute low back pain, and <FONT STYLE="white-space:nowrap">SP-104</FONT> (4.5 mg, <FONT STYLE="white-space:nowrap">low-dose</FONT> naltrexone hydrochloride delayed-release
capsules) <FONT STYLE="white-space:nowrap">(&#147;SP-104&#148;),</FONT> a novel formulation for the treatment of fibromyalgia. Since inception, the Company has devoted substantially all of its efforts to the development of <FONT
STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> <FONT STYLE="white-space:nowrap">SP-104,</FONT> and the commercialization of ZTlido. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Business Combination</B><I> </I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;17, 2022, Scilex entered into an Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Vickers and Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#147;Vickers Merger Sub&#148;). Pursuant to the terms of
the Merger Agreement, Vickers Merger Sub merged with and into Scilex, Inc. (f/k/a Scilex Holding Company and now a wholly owned subsidiary of Scilex) (&#147;Legacy Scilex&#148;), with Legacy Scilex surviving the merger and becoming a wholly-owned
subsidiary of Vickers (collectively, the &#147;Business Combination&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, Vickers consummated the Business Combination
pursuant to the terms of the Merger Agreement. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, Scilex received net proceeds of approximately $3.4&nbsp;million. Additionally, all
existing related party indebtedness between Legacy Scilex and Sorrento totaling $290.6&nbsp;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt
Exchange Agreement (see Note 12). The Company, as the successor entity of Vickers, will operate as &#147;Scilex Holding Company&#148; and was listed on the Nasdaq Capital Market under the new ticker symbol &#147;SCLX&#148; on November&nbsp;11, 2022.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the closing of the Business Combination, 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock (&#147;Legacy Scilex Common Stock&#148;) and
Legacy Scilex stock options, respectively, were converted to 133,060,534 shares of Common Stock (&#147;Common Stock&#148;) as part of the consideration using the 0.673498:1 ratio of the Company Common Stock to Legacy Scilex Common Stock (the
&#147;Common Stock Exchange Ratio&#148;) and 16,939,436 shares of Common Stock were reserved for Legacy Scilex optionholders. Pursuant to the terms of the Debt Exchange Agreement (see Note 12), $290.6&nbsp;million was converted to 29,057,097 shares
of Preferred Stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;Preferred Stock&#148;) and 2,905,710 shares of Common Stock. In addition, pursuant to the terms of the debt agreement entered between the Vickers Venture Fund VI Pte Ltd, Vickers Venture
Fund VI (Plan) Pte Ltd (&#147;Sponsors&#148;) and Vickers (&#147;Vickers Debt Agreement&#148;), the aggregate amount of loans that the Sponsors funded Vickers to finance the transaction costs (&#147;Working Capital Loans&#148;) at the closing of the
Business Combination of $5,330,557 was converted to 533,057 shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse
recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers was treated as the &#147;acquired&#148; company for accounting purposes and the Business Combination was treated as the equivalent of the Company issuing stock
for the net assets of Vickers, accompanied by a recapitalization. Upon the closing of the Business Combination, the net assets of Vickers were recorded at historical cost, with no goodwill or other intangible assets recorded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s legal, accounting and other fees directly attributable to the Business Combination were initially capitalized within prepaid expenses and
other current assets on the consolidated balance sheets, of which $9.1&nbsp;million has been offset against the equity proceeds in the Business Combination and $0.4&nbsp;million was attributed to the liability-classified Private Warrants and, as
such, were expensed upon the closing of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#147;U.S. GAAP&#148;) and include all adjustments necessary for the fair presentation of the Company&#146;s financial position for the periods presented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements include the accounts of the Company as well as its wholly owned subsidiaries. All intercompany balances and
transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these
estimates are reasonable; however, actual results may differ from these estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes
its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any
losses on such accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and
liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Quoted prices for similar instruments that are directly or indirectly observable in the
marketplace. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Significant unobservable inputs which are supported by little or no market activity and that are
financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to
the fair value measurement. The Company&#146;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of
different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of
the instruments could realize in a current market exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and 2021, the carrying amount of cash equivalents approximates
their fair value based upon quoted market prices. Certain of the Company&#146;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or
short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounts receivable are presented net of allowances for expected credit losses and prompt payment discounts. Accounts receivable consists of trade receivables
from product sales to customers, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts
receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by
reducing the allowance for expected credit losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inventory </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines inventory cost on a <FONT STYLE="white-space:nowrap">first-in,</FONT> <FONT STYLE="white-space:nowrap">first-out</FONT> basis. The
Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow- moving. The Company reserves for excess and obsolete inventory based upon historical
experience, sales trends, and specific categories of inventory and expiration dates for <FONT STYLE="white-space:nowrap">on-hand</FONT> inventory. Inventory costs resulting from these adjustments are recognized as cost of sales in the period in
which they are incurred. When future commercialization is considered probable and the future economic benefit is expected to be realized, based on management&#146;s judgment, the Company capitalizes <FONT STYLE="white-space:nowrap">pre-launch</FONT>
inventory costs prior to regulatory approval. As of December&nbsp;31, 2022 and 2021, the Company&#146;s inventory was primarily comprised of finished goods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and
equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold
improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Acquisitions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for business
combinations using the acquisition method of accounting, which requires that assets acquired, including <FONT STYLE="white-space:nowrap">in-process</FONT> research and development (&#147;IPR&amp;D&#148;) projects and liabilities assumed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be recorded at their fair values as of the acquisition date on the Company`s consolidated balance sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as
goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the
measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When the Company determines net assets acquired do not meet the definition of a business combination under the acquisition method of accounting, the
transaction is accounted for as an acquisition of assets and, therefore, no goodwill is recorded and contingent consideration such as payments upon achievement of various developmental, regulatory and commercial milestones generally is not
recognized at the acquisition date. In an asset acquisition, <FONT STYLE="white-space:nowrap">up-front</FONT> payments allocated to IPR&amp;D projects at the acquisition date and subsequent milestone payments are charged to expense in the Company`s
consolidated statements of operations unless there is an alternative future use. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has acquired and may continue to acquire the rights to
develop and commercialize new product candidates. Intangible assets acquired in a business combination that are used for IPR&amp;D activities are considered indefinite-lived until the completion or abandonment of the associated research and
development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently
as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Goodwill and Other Long-Lived
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for
impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has one reporting unit. During its goodwill impairment review, the Company may assess qualitative factors
to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market
considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than
its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to
perform the quantitative goodwill impairment test. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates its long-lived and intangible assets with definite lives, such as property and
equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <FONT STYLE="white-space:nowrap">non-generic</FONT> and generic
competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is
measured by comparison of the assets&#146; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an
impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contingent Consideration
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of contingent consideration liabilities assumed in business combinations is recorded as part of the purchase price consideration of
the acquisition, and is determined using a discounted cash flow model or Monte&nbsp;Carlo simulation model. The significant inputs of such models are not observable in the market, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain financial metric growth rates, volatility rates, projections associated with applicable milestones, discount rates and the related probabilities and payment structure in the contingent
consideration arrangement. Fair value adjustments to contingent consideration liabilities are recorded through operating expenses in the consolidated statement of operations. Other than contingent consideration that is accounted for in accordance
with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 480, <I>Distinguishing Liabilities from Equity,</I> and Topic 815, <I>Derivatives and Hedging</I>, contingent consideration
arrangements assumed in an asset acquisition will be measured and accrued when such contingency is resolved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public Warrants and Private Placement
Warrants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of the Business Combination, the Company assumed public and private placement warrants (&#147;Public Warrants&#148; and
&#147;Private Warrants&#148;) that were issued by Vickers in connection with its initial public offering (declared effective by the Securities and Exchange Commission (&#147;SEC&#148;) on January&nbsp;11, 2021) whereby holders of the public and
private placement warrants are entitled to acquire ordinary shares of Vickers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Public Warrants were accounted
for as equity per FASB ASC Subtopic <FONT STYLE="white-space:nowrap">No.&nbsp;815-40,</FONT> <I>Contracts on an Entity&#146;s Own Equity</I>. Warrants classified as equity are recorded at their issuance cost and are not subject to remeasurement at
each subsequent balance sheet date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Business Combination, the Private Warrants were accounted for as liabilities per ASC Subtopic <FONT
STYLE="white-space:nowrap">815-40.</FONT> The Private Warrants are not considered indexed to the Company&#146;s stock per ASC Subtopic <FONT STYLE="white-space:nowrap">815-40</FONT> as the fair value calculation applicable upon a cashless exercise
of a Private Warrant changes based upon the holder of the instrument, which is not an input to a valuation model for a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fixed-for-fixed</FONT></FONT> option contract. Therefore,
Private Warrants are recognized as derivative liabilities at their estimated fair value on November&nbsp;10, 2022, the date of the closing of the Business Combination, and are revalued at each subsequent balance sheet date, with fair value changes
recognized in the statement of operations. The Company estimates the value of these warrants using a Black-Scholes option pricing formula. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future
net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Derivative Liabilities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derivative liabilities are
recorded on the Company&#146;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting
periods recorded as other income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research
and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, license fees and other external costs. Nonrefundable advance payments for goods and
services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with FASB ASC Topic 730, <I>Research and
Development.</I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions
of the FASB ASC Topic 740, <I>Income Taxes</I>,<I> </I>addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Subtopic <FONT STYLE="white-space:nowrap">740-10,</FONT> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be
sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the
related financial amounts, using currently enacted tax rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has deferred tax assets, which are subject to periodic recoverability
assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&nbsp;31, 2022 and 2021, the Company maintained a full valuation allowance
against its deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company determines if an arrangement is a lease at inception. Operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> (&#147;ROU&#148;) assets and liabilities are recognized at the commencement
date based on the present value of lease payments over the lease term. As the Company&#146;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining
the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#146;s lease terms may include options to extend or terminate the lease when it is reasonably
certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s revenue is
generated from product sales within the United States. The Company does not incur significant direct costs to obtain contracts with its customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#146;s performance obligation with respect to sales of ZTlido is satisfied at a
point in time, when control is transferred upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been
transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing
and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&nbsp;31, 2022 and 2021 were not material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenues from product sales are recorded net of reserves established for commercial and government rebates, fees and chargebacks, wholesaler and distributor
fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#146;s customer
contract, customary industry practices and current government regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rebates and Chargebacks </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug
rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access
to and position on that provider&#146;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with
commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
claims. The Company monitors the sales trends and adjusts for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. Reserves for rebates and
chargebacks are now separately presented as accrued rebates and fees under current liabilities within the Company&#146;s consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prompt Payment Discounts </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provides its
customers with prompt payment discounts which may result in adjustments to the price that is invoiced for the product transferred, in the case that payments are made within a defined period. The prompt payment discount reserve is based on actual
gross sales and contractual discount rates. Reserves for prompt payment discounts are included in accounts receivable, net on the consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Service Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company compensates its customer and
others in the distribution chain for wholesaler and distribution services. The Company has determined such services received to date are not distinct from the Company&#146;s sale of products to the customer and, therefore, these payments have been
recorded as a reduction of revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Product Returns </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company
may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer
and record this estimate as a reduction of revenue in the period the related product revenue is recognized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Payment</FONT> Assistance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <FONT STYLE="white-space:nowrap">co-payment</FONT>
assistance. The Company accrues for <FONT STYLE="white-space:nowrap">co-payment</FONT> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Customer Concentration Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to
April&nbsp;2, 2022, sales to the Company&#146;s sole distributor represented 100% of net revenue. On April&nbsp;2, 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The
distributor continued to provide traditional third-party logistics functions for the Company. The Company had four customers during the year ended December&nbsp;31, 2022, which individually generated 10% or more of the Company&#146;s total revenue.
These customers accounted for 83% of the Company&#146;s revenue for the year ended December&nbsp;31, 2022, individually ranging between 19% to 24%. As of December&nbsp;31, 2022, these customers represented 90% of the Company&#146;s outstanding
accounts receivable, individually ranging between 24% to 36%. Additionally, during the fiscal years ended December&nbsp;31, 2022 and 2021, the Company purchased inventory from its sole supplier, Itochu. This exposes the Company to concentration of
customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the years ended December&nbsp;31, 2022, 2021, and 2020.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
accounts for stock-based compensation in accordance with FASB ASC Topic 718, <I>Compensation&#151;Stock Compensation</I> which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions,
stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#146;s requisite service period (generally the vesting
period of the equity grant) or <FONT STYLE="white-space:nowrap">non-employee&#146;s</FONT> vesting period. The Company accounts for forfeitures as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, the Company
determines the expected life assumption for options issued using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period since the Company does not have historic exercise behavior. Then the
Company determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as variables in the Black-Scholes option
pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments are identified as
components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assessing performance. The Company has determined that its
chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily
in the development of <FONT STYLE="white-space:nowrap">non-opioid</FONT> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates
its business as a single reportable segment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the <FONT STYLE="white-space:nowrap">two-class</FONT>
method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the <FONT STYLE="white-space:nowrap">two-class</FONT> method, basic net loss per share attributable to common stockholders is computed by dividing the
net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially
dilutive impact of stock options and warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company has reported losses for all periods presented, all potentially dilutive securities are
antidilutive and accordingly, basic net loss per share equals diluted net loss per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <FONT STYLE="white-space:nowrap">2021-08,</FONT> <I>Business Combinations (Topic 805): Accounting for Contract Assets and
Contract Liabilities from Contracts with Customers</I>, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU
<FONT STYLE="white-space:nowrap">2021-08</FONT> is effective for fiscal years beginning after December&nbsp;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial
statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Liquidity and Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management
has assessed the Company&#146;s ability to continue as a going concern for at least one year after the date the financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, Scilex acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note&nbsp;3). The Company anticipates the cash needed for the development of Semnur&#146;s primary product candidate in development, <FONT
STYLE="white-space:nowrap">SP-102,</FONT> as well in the development of <FONT STYLE="white-space:nowrap">SP-103,</FONT> will be in excess of the Company&#146;s cash available </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and
commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). <FONT STYLE="white-space:nowrap">SP-104</FONT> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be
responsible for funding all development and commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into a license and commercialization
agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs
related to the commercial launch and marketing of GLOPERBA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2022, Scilex and Scilex Pharma entered into a Debt Exchange Agreement
(see Note 12) with Sorrento, pursuant to which all related party indebtedness that remained outstanding as of immediately prior to the closing of the Business Combination was converted into equity interests in the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown Provision (see Note 7) to fully extinguish the Scilex Pharma Notes (see Note 7). In August 2022 and
September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $41.4&nbsp;million. Pursuant to Amendment No.&nbsp;4 (see Note 7), a principal balance of $28.0&nbsp;million was forgiven by the Scilex Pharma
Note Purchasers (see Note 7) upon the Company&#146;s exercise of the Early Paydown Provision. The Company funded the principal payments with <FONT STYLE="white-space:nowrap">cash-on</FONT> hand and $34.0&nbsp;million received from Sorrento on
September&nbsp;28, 2022 (see Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company&#146;s negative working capital was $15.2&nbsp;million, including cash
and cash equivalents of approximately $2.2&nbsp;million. During the year ended December&nbsp;31, 2022, the Company had operating losses of $50.6&nbsp;million and cash flows used for operations of $21.3&nbsp;million. The Company had an accumulated
deficit of approximately $375.9&nbsp;million as of December&nbsp;31, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has plans to obtain additional resources to fund its currently
planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic
transactions. The Company entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. (&#147;Yorkville&#148;) on November&nbsp;17, 2022 (as amended and restated on February&nbsp;8, 2023), and a Standby Equity Purchase Agreement with B.
Riley Principal Capital II, LLC (&#147;B. Riley&#148;) on January&nbsp;8, 2023 whereby the Company has the right, but not the obligation, to sell to Yorkville and B. Riley up to $500.0&nbsp;million each of shares of its Common Stock at its request
any time during the 36 months following the date on which the registration statement related to each such purchase agreement has been declared effected by the SEC, subject to certain conditions (see Note 8 and Note 14). The Company&#146;s plans are
also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#146;s marketing of ZTlido. Should the Company&#146;s sales of
ZTlido not materialize at the expected rate contemplated in the Company&#146;s business plan, due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other factors, the Company believes that there are a number of ongoing and
potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical
development programs for <FONT STYLE="white-space:nowrap">SP-102,</FONT> <FONT STYLE="white-space:nowrap">SP-103,</FONT> and <FONT STYLE="white-space:nowrap">SP-104,</FONT> and other discretionary costs. Although the Company believes such plans, if
executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#146;s control. As such, management cannot conclude that such plans will be effectively
implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#146;s
ability to continue as a going concern for one year after the date the financial statements are issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Acquisitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">SP-104</FONT> Acquisition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#147;Bill of Sale&#148;), with Sorrento. Pursuant
to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#146;s Delayed Burst Release Low Dose Naltrexone
<FONT STYLE="white-space:nowrap">(&#147;DBR-LDN&#148;)</FONT> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Assets&#148;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#147;Aardvark&#148;) in April 2021 pursuant to an asset purchase agreement (the
&#147;Aardvark Asset Purchase Agreement&#148;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the
<FONT STYLE="white-space:nowrap">&#147;SP-104</FONT> Acquisition&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the <FONT STYLE="white-space:nowrap">SP-104</FONT>
Acquisition, the Company issued a promissory note in the aggregate principal amount of $5.0&nbsp;million to Sorrento (the &#147;2022 Promissory Note&#148;). Upon issuance of the note, the Company recorded a related party note payable of
$4.1&nbsp;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The 2022 Promissory Note matures seven years from the date of issuance and bears interest at
the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company&#146;s common stock or any combination thereof, at the
Company&#146;s sole discretion, and may be prepaid in whole or in part at any time without penalty. On November&nbsp;10, 2022, the 2022 Promissory Note was converted to equity, pursuant to the terms of the Debt Exchange Agreement (See Note 12). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new
drug application for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (which amount may be paid in shares of the Company&#146;s common stock or cash, in the Company&#146;s sole discretion) (the &#147;Development Milestone Payment&#148;) and
(ii) $20,000,000, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (the &#147;Sales Milestone Payment&#148;). The Company will also pay Aardvark
certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, <FONT
STYLE="white-space:nowrap">SP-104</FONT> Assets. The Sales Milestone Payment and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic 815, <I>Derivatives and Hedging</I>, and will not be
recognized until the contingencies are realized in accordance with the Company&#146;s accounting policy for contingent consideration in an asset acquisition. The Development Milestone Payment represents a liability within the scope of ASC Topic 480,
<I>Distinguishing Liabilities from Equity</I>, which will be measured at fair value each reporting period. As of December&nbsp;31, 2022, the contingent consideration of $0.2&nbsp;million associated with Development Milestones Payment was recognized
under other long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GLOPERBA License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into a license agreement (the &#147;Romeg License Agreement&#148;) with RxOmeg Therapeutics, LLC (a/k/a Romeg
Therapeutics, Inc.) (&#147;Romeg&#148;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (1)&nbsp;a transferable license, with the right to sublicense, under the patents and
<FONT STYLE="white-space:nowrap">know-how</FONT> specified therein (with such license to <FONT STYLE="white-space:nowrap">know-how</FONT> being exclusive for the limited purposes specified therein) to (i)&nbsp;commercialize the pharmaceutical
product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#147;Initial Licensed Product&#148; or &#147;GLOPERBA&#148;) in the United States of America (including its territories) (the
&#147;Territory&#148;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#147;Licensed Products&#148;) and commercialize any such products and (iii)&nbsp;manufacture Licensed Products
anywhere in the world, solely for commercialization in the Territory; and (2)&nbsp;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection
with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the United States in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg License Agreement, the Company paid Romeg an <FONT
STYLE="white-space:nowrap">up-front</FONT> license fee of $2.0&nbsp;million, and has agreed to pay Romeg (a)&nbsp;upon the Company&#146;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to
$13.0&nbsp;million, (b)&nbsp;certain royalties in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digit to <FONT STYLE="white-space:nowrap">low-double</FONT> digit percentages based on annual net sales of the Licensed Product by the Company
during the applicable royalty term under the Romeg License Agreement, and (c)&nbsp;minimum quarterly royalty payments totaling $7.1&nbsp;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending
on the later of (i)&nbsp;expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii)&nbsp;the tenth anniversary of the effective date of the Romeg License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is
the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $5.7&nbsp;million, which is comprised of the upfront license fee of $2.0&nbsp;million and a deferred
consideration of $3.7&nbsp;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent sales milestones and sale volume-based future royalties were determined to meet a scope exception
for derivative under ASC Topic 815, and will not be recognized until the contingencies are realized. No contingent consideration was recognized as a liability or included in the fair value of the assets as of December&nbsp;31, 2022. The Company
determined the useful life of the intangible asset to be 15 years, which approximates the life of the licensed patents covering the Initial Licensed Product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Fair Value Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents
the Company&#146;s financial assets and liabilities that are measured at fair value (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs&nbsp;(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value measurements at December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs&nbsp;(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs&nbsp;(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market
accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Derivative liabilities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recorded a gain of
$8.3&nbsp;million, loss of $0.3&nbsp;million, and gain of $0.8&nbsp;million on derivative liabilities for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively, which was attributed to compound derivative liabilities associated with
the Scilex Pharma Notes (see Note 7) and Private Warrants. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $30.4&nbsp;million immediately after entry into Amendment No.&nbsp;4 (see Note 7) associated
with the Scilex Pharma Notes on June&nbsp;2, 2022. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including
consideration of the terms of Amendment No.&nbsp;4. Significant Level&nbsp;3 assumptions used in the measurement included a 6.1% risk adjusted net sales forecast and an effective debt yield of 21.5%. The Scilex Pharma Notes were fully extinguished
in September 2022 (see Note 7) and, as such, there were no remaining loan derivative liabilities associated with the Scilex Pharma Notes as of December&nbsp;31, 2022. At the closing of the Business Combination, the Company assumed a derivative
warrant liability of $2.5&nbsp;million related to Private Warrants (See Note 8). The fair value of derivative warrant liability related to Private Warrants was $1.2&nbsp;million as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the year
ended December&nbsp;31, 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loan derivative liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Re-measurement</FONT> of fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Warrant liability acquired as part of the Business Combination</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeiture of Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value measurement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,710</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Warrant Liability Measurement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The derivative warrant liability was valued using the Black-Scholes option pricing model, which is considered to be Level&nbsp;3 fair value measurement. The
primary unobservable input utilized in determining the fair value of the warrant is the expected volatility of the Common Stock. The expected volatility assumption is based on historical volatilities of comparable companies whose share prices are
publicly available as well as the implied volatility of the Public Warrants. A summary of the inputs used in valuing the derivative warrant liabilities is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>November&nbsp;10,<BR>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity Value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Call option value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contingent Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Development Milestone Payment represents a liability under the scope of ASC Topic 480, <I>Distinguishing Liabilities from Equity</I>, as it pertains to a
potential contractual obligation to settle a fixed value in a variable number of shares of Common Stock. Upon the achievement of FDA approval for a new drug application for <FONT STYLE="white-space:nowrap">SP-104,</FONT> the Company will transfer
$3.0&nbsp;million in cash or shares of Common Stock, at the discretion of the Company. The fair value of the contingent consideration liability associated with Development Milestone Payment was estimated using a probability-weighted discounted cash
flow method. Significant Level&nbsp;3 assumptions included the likelihood of receiving FDA approval for <FONT STYLE="white-space:nowrap">SP-104,</FONT> expected timing for receipt of FDA approval for <FONT STYLE="white-space:nowrap">SP-104,</FONT>
and a discount rate of 10.0%. As of December&nbsp;31, 2022, the fair value of contingent consideration related to the Development Milestone Payment was $0.2&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no transfers between fair value measurement levels during the years ended December&nbsp;31, 2022, 2021, and 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment, Net </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment
consisted of the following as of December&nbsp;31, 2022 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computers&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense for each of the years ended December&nbsp;31, 2022, 2021, and 2020 was $40&nbsp;thousand,
$39&nbsp;thousand, and $40&nbsp;thousand, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Goodwill and Intangible Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022 and December&nbsp;31, 2021, the Company had recorded goodwill of $13.5&nbsp;million. The Company performed a qualitative test for
goodwill impairment during the fourth quarter of 2022. Based upon the results of the qualitative testing, the Company concluded that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the fair value of the Company&#146;s
goodwill was in excess of the carrying value and therefore performing the first step of the <FONT STYLE="white-space:nowrap">two-step</FONT> impairment test was unnecessary. The conclusion has not changed as of December&nbsp;31, 2022 and no goodwill
impairment was recognized for the years ended December&nbsp;31, 2022 and 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s intangible assets, excluding goodwill, are composed of
patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. A summary of the
Company&#146;s identifiable intangible assets as of December&nbsp;31, 2022 and December&nbsp;31, 2021 is as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;carrying&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,&nbsp;net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;carrying&nbsp;amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>amortization</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intangibles,&nbsp;net</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patent rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assembled workforce</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">38,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from
Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $5.7&nbsp;million was assigned to acquired licenses with an amortization period of approximately 15
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the weighted average remaining life for identifiable intangible assets was 10.4 years. Aggregate amortization
expense was $3.9&nbsp;million, $3.7&nbsp;million, and $3.7&nbsp;million for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively. Patent rights and acquired technology are amortized over a
<FONT STYLE="white-space:nowrap">15-year</FONT> period. Assembled workforce is amortized over a <FONT STYLE="white-space:nowrap">5-year</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimated future amortization expense related to intangible assets at December&nbsp;31, 2022 is as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Debt </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2018 Purchase Agreements and Indenture </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#147;2018 Purchase Agreements&#148;) with certain investors (collectively, the &#147;Scilex Pharma Note Purchasers&#148;). Pursuant to the 2018 Purchase
Agreements, on September&nbsp;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due 2026 in an aggregate principal amount of $224.0&nbsp;million (the &#147;Scilex Pharma
Notes&#148;) for an aggregate purchase price of $140.0&nbsp;million (the &#147;Offering&#148;). The Scilex Pharma Notes were governed by an indenture (as amended, the &#147;Indenture&#148;) with Scilex Pharma, as issuer, U.S. Bank National
Association, a national banking association, as trustee (the &#147;Trustee&#148;) and collateral agent (the &#147;Collateral Agent&#148;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally
guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#147;Guarantee&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal amount of the Scilex Pharma Notes increased by $28.0&nbsp;million on February&nbsp;15, 2022 as a result of actual cumulative net sales of ZTlido
from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 not equal or exceeding $481.0&nbsp;million. As a result, the Company recorded the increase of $28.0&nbsp;million in principal and
<FONT STYLE="white-space:nowrap">non-operating</FONT> expense at December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;14, 2022, Scilex Pharma issued to
Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&nbsp;31, 2021 were less than a specified
sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan and Scilex Pharma became
subject to a minimum cash requirement of $10.0&nbsp;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $20.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&nbsp;4 to Indenture (the &#147;Amendment No.&nbsp;4&#148;)
with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment No.&nbsp;4, (1) on June&nbsp;3, 2022, Scilex Pharma repurchased approximately
$41.4&nbsp;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&nbsp;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the
Scilex Pharma Notes at any time on or before September&nbsp;30, 2022 for $41.4&nbsp;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&nbsp;million
of the aggregate principal amount of the Scilex Pharma Notes (the &#147;Early Paydown Provision&#148;), (3) the minimum cash requirement under the Indenture was reduced to $5.0&nbsp;million in aggregate unrestricted cash equivalents at the end of
each calendar month, and (4)&nbsp;the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October&nbsp;5, 2018 was increased from up to $25.0&nbsp;million to up to $50.0&nbsp;million. The Company funded
the repurchase with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $15.0&nbsp;million received from Sorrento on June&nbsp;2, 2022. The Company concluded that the Amendment No.&nbsp;4 was a troubled
debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&nbsp;4, and accordingly, no gain
was recognized in the quarter ended June&nbsp;30, 2022. Due to a decrease of $30.4&nbsp;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&nbsp;4, the carrying value of the Scilex Notes was increased by
$30.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and
September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&nbsp;million and $39.7&nbsp;million, respectively. Pursuant to Amendment No.&nbsp;4, $28.0&nbsp;million of principal amount on the Scilex
Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The Company funded the repurchase with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cash-on-hand</FONT></FONT> and $34.0&nbsp;million received from Sorrento on September&nbsp;28, 2022. The Company recorded a gain on debt extinguishment of $28.6&nbsp;million as a
result of the extinguishment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Borrowings of the Scilex Notes consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;December&nbsp;31,&nbsp;2021&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">133,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unamortized debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,228</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carrying value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Estimated fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">115,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made principal payments of $106.0&nbsp;million, $45.9&nbsp;million, and $69.8&nbsp;million during the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. The amount of debt discount and debt issuance costs included in interest expense for the years ended December&nbsp;31, 2022, 2021, and 2020 was approximately $3.1&nbsp;million, $7.9&nbsp;million
and $10.7&nbsp;million, respectively. The Company recorded a gain on debt extinguishment of $28.6&nbsp;million, a loss on debt extinguishment of $12.5&nbsp;million, and no gain/loss on debt extinguishment in connection with its repayments of
principal made during the years ended December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Related Party Notes Payable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 12). On March&nbsp;18, 2019, the Company entered into a note payable with
Sorrento (see Note 12). On February&nbsp;14, 2022, Sorrento paid to Scilex Pharma $35.0&nbsp;million in a single <FONT STYLE="white-space:nowrap">lump-sum</FONT> amount as a subordinated loan (see Note 12). On May&nbsp;12, 2022, the Company issued
Sorrento a promissory note of $5.0&nbsp;million in exchange for the <FONT STYLE="white-space:nowrap">SP-104</FONT> Assets (see Note 3). On November&nbsp;10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento
was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 12). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2020 Revolving Credit Facility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#147;Credit Agreement&#148;) with CNH Finance Fund I, L.P. (&#147;CNH&#148;) which provides Scilex Pharma with the ability to incur indebtedness under an
accounts receivable revolving loan facility in an aggregate amount of $10.0&nbsp;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement,
interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be due and payable in full on January&nbsp;1, 2024; unless the
Credit Agreement is earlier terminated. As of December&nbsp;31, 2021, the outstanding balance was $8.8&nbsp;million. On February&nbsp;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective March&nbsp;18, 2022.
Upon termination, all principal balances and interest accrued were settled. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated statement of stockholders&#146; equity has been retroactively adjusted for all periods to reflect the Business Combination and reverse
recapitalization described in Note 1. The balances as of December&nbsp;31, 2022 and 2021 from the consolidated financial statements of the Company as of that date, share activity (Preferred Stock, Common Stock, and additional <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital)</FONT></FONT> and per share amounts were retroactively adjusted, where applicable, using the Common Stock Exchange Ratio. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination, pursuant to the terms of the Amended and Restated Certificate of Incorporation, the Company authorized
740,000,000 shares of Common Stock with a par value of $0.0001. As of December&nbsp;31, 2022 and December&nbsp;31, 2021, there were 141,348,856 shares issued and 132,858,484 of Common Stock outstanding, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, all previously issued and outstanding shares of Legacy Scilex Common Stock and Legacy Scilex stock
options were converted into shares of Common Stock pursuant to the Common Stock Exchange Ratio. The Company has retroactively adjusted shares issued and outstanding prior to November&nbsp;10, 2022 to give effect to the Common Stock Exchange Ratio to
determine the number of shares of Common Stock into which they were converted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of the Common Stock are entitled to one vote for each share of the Common Stock held at all meetings of stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common stockholders are entitled to
receive dividends whenever funds are legally available and when declared by the Company&#146;s board of directors. No dividends have been declared as of December&nbsp;31, 2022.The Stockholder Agreement, dated as of September&nbsp;12, 2022, between
Vickers and Sorrento (the &#147;Stockholder Agreement&#148;), provides that the Company will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, the payment of dividends on shares of
the Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject
to the rights of the holders of Preferred Stock, in the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of Common Stock are entitled to share equally in the assets available for distribution after
payment of all creditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the
closing of the Business Combination, $290.6&nbsp;million of all existing related party indebtedness between Scilex, Scilex Pharma, and Sorrento were cancelled in exchange for the issuance of preferred shares of Scilex (&#147;Series A Preferred
Shares&#148; or &#147;Series A Preferred Stock&#148;). In connection with the closing of the Business Combination, all issued Scilex Series A Preferred Shares were cancelled and converted into the right to receive 1) one share of domesticated parent
preferred shares (&#147;New Scilex Preferred Stock&#148; or &#147;Preferred Stock&#148;) par value of $0.0001 per share, and 2) <FONT STYLE="white-space:nowrap">one-tenth</FONT> of one domesticated parent common stock (&#147;New Scilex Common
Stock&#148; or &#147;Common Stock&#148; and such transaction including cancellation of all the existing related party indebtedness in exchange for Preferred Stock and Common Stock, the &#147;Conversion&#148; or &#147;Contribution&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Conversion, Legacy Scilex filed a Second Amended Certificate of Incorporation (defined below) to increase the authorized number of shares to
45,000,000 shares and a Certificate of Designation (&#147;Certificate of Designation&#148;) to designate the rights, preferences, and privileges of Scilex Series A Preferred Shares. In connection with the closing of the Business Combination, the
Company filed the Certificate of Designation and issued 29,057,097 shares of the Series A Preferred Stock to Sorrento. As of December&nbsp;31, 2022, there were 29,057,097 shares of Preferred Stock outstanding. There were no Preferred Stock
outstanding at December&nbsp;31, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Board of Directors have authority to issue such shares of Preferred Stock in one or more
series, to establish, from time to time the number of shares to be included in each such series, and to fix the dividend, voting, and other rights, preferences, and privileges of the shares. Other than the Series A Preferred Stock issued
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to Sorrento in connection with the closing of the Business Combination, there are no other Preferred Stock outstanding and the Company has no current plans to issue any other shares of preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of shares of
Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Preferred Stock
will be entitled to one vote for each share of Common Stock that such share of Preferred Stock would otherwise be convertible into pursuant to a deemed conversion on the record date for the determination of the stockholders entitled to vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Stockholder Agreement, holders of Series A Preferred Stock have the right to designate each director to be nominated, elected or appointed to
the Board of Directors of the Company. The Series A Preferred Stock also has certain protective provisions, such as requiring a written consent of the holders of Series A Preferred Stock to change or amend their rights, powers, privileges,
limitations and restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of the Preferred Stock are not entitled to dividends unless the Company pays dividends to holders of the Common Stock and shall be entitled to receive,
when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of the Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of
Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the rights of the
holders of parity shares (if any), in the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> holders of Preferred Stock rank senior to the Common Stock and are entitled to share equally in the assets
available for distribution after payment of all creditors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Assumed Public Warrants and Private Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, holders of the Public Warrants and Private Warrants are entitled to acquire Common Stock of the
Company. The warrants are exercisable on the later of (a)&nbsp;the completion of a Business Combination and (b) 12 months from the closing of Vickers&#146;s Initial Public Offering. The warrants will expire five years after the completion of the
Business Combination or earlier upon redemption or liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant entitles the holder to purchase one share of Common Stock for $11.50 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending three business days before the Company sends the notice of redemption to the warrant holders, the Company may redeem all the Public Warrants at a price of $0.01 per warrant upon not less
than 30 days&#146; prior written notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, the Company will have the option to require all holders
that wish to exercise the Public Warrants to do so on a cashless basis. The Company will not be required to net cash settle the warrants. As of December&nbsp;31, 2022, there are 6,899,988 Public Warrants outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the closing of the Business Combination, 3,104,000 Private Warrants were transferred to Sorrento pursuant to the Warrant Transfer Agreement
between Vickers, the Sponsors, Sorrento and Maxim Group, LLC where Sorrento acquired all rights, title and interests to such Private Warrants (&#147;Warrant Transfer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement&#148;). As of December&nbsp;31, 2022, there are 4,104,000 Private Warrants outstanding, of which 3,104,000 Private Warrants are held by Sorrento and 1,000,000 Private Warrants are held
by Sponsors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legacy Scilex Common Stock and Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex had the authority to issue 200,000,000 shares of common stock, par value $0.0001 per share and 20,000,000
shares of preferred stock, par value $0.0001 per share per the Certificate of Incorporation dated February&nbsp;27, 2019. The Certificate of Incorporation was amended and restated on March&nbsp;4, 2019 (&#147;First Amended Certificate of
Incorporation&#148;), in which Legacy Scilex had the authority to issue 350,000,000 shares of common stock, par value $0.0001 per share and 20,000,000 shares of preferred stock, par value $0.0001 per share. The First Amended and Restated Certificate
of Incorporation was amended and restated on November&nbsp;10, 2022 (&#147;Second Amended Certificate of Incorporation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the Second
Amended Certificate of Incorporation, Legacy Scilex had the authority to issue 785,000,000 shares, consisting of 740,000,000 shares of common stock and 45,000,000 shares of preferred stock. Immediately prior to the Conversion, there were 197,566,338
shares of Legacy Scilex Common Stock outstanding and 29,057,097 shares of Series A Preferred Stock, par value $0.0001 per share, of Legacy Scilex outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Yorkville Standby Equity Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
November&nbsp;17, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#147;Yorkville Purchase Agreement&#148;) with Yorkville, whereby the Company has the right, but not the obligation, to sell to Yorkville up to
$500.0&nbsp;million of shares of its Common Stock at its request any time during the 36 months following the execution of the Yorkville Purchase Agreement, subject to certain conditions. Pursuant to the Yorkville Purchase Agreement, the shares of
Common Stock, if any, that the Company elects to sell to Yorkville pursuant to a sale of Common Stock (each such sale, a &#147;Yorkville Advance&#148;) will be purchased at a price equal to 98% of the lowest daily volume weighted average price of
the Common Stock for any trading day (&#147;VWAP&#148;) during the two consecutive trading days commencing on the date of delivery of a written purchase notice to Yorkville (each, a &#147;Yorkville Advance Notice&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#146;s commitment to purchase shares of Common Stock at the Company&#146;s direction upon the terms and subject to the
conditions set forth in the Yorkville Purchase Agreement, upon execution of the Yorkville Purchase Agreement, the Company issued 250,000 shares of Common Stock to Yorkville and paid $10.0&nbsp;thousand in structuring fees. The registration statement
on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268607)</FONT> related to the Yorkville Purchase Agreement was filed with the SEC on November&nbsp;30, 2022 and was declared effective by the SEC
on December&nbsp;9, 2022. As of December&nbsp;31, 2022, there were no shares sold to Yorkville under the Yorkville Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Refer to Note 14
&#147;Subsequent Event&#148; below for a subsequent event related to the Yorkville Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Stock Incentive and Employee Benefit Plans
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated statements of stockholders&#146; equity / (deficit) have been retroactively adjusted for all periods to reflect the Business
Combination and reverse recapitalization described in Note 1. The balances as of December&nbsp;31, 2022, 2021, 2020 from the consolidated financial statements of the Company as of that date, share activity (stock options) and per share amounts were
retroactively adjusted, where applicable, using the Common Stock Exchange Ratio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#147;Scilex Pharma 2017 Plan&#148;). The Scilex Pharma
2017 Plan reserved 24.0&nbsp;million shares of Scilex Pharma common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each
month thereafter. The Scilex Pharma 2017 Plan was amended and restated on July&nbsp;5, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March
2019, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#146;s common stock outstanding and unexercised immediately prior to reorganization was cancelled and substituted for that number of options to acquire
Legacy Scilex Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2019 Stock Option Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#147;2019 Stock Option Plan&#148; or &#147;Prior
Plan&#148;) on May&nbsp;28, 2019. The 2019 Stock Option Plan was approved by the Company&#146;s stockholders on June&nbsp;7, 2019. As of December&nbsp;31, 2019, 30.0&nbsp;million shares of Scilex Common Stock of the Company were reserved for
issuance pursuant to the 2019 Stock Option Plan. Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares
on each monthly anniversary thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the consummation of the Business Combination, the 2019 Stock Option Plan was terminated and no further
awards were granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted under the terms of the Equity Incentive Plan (defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors of the Company adopted the Scilex Holding Company 2022 Equity Incentive Plan (the &#147;Equity Incentive Plan&#148;) on October&nbsp;17,
2022. The 2022 Equity Incentive Plan was approved by the stockholders and became effective on November&nbsp;9, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of common shares
for which incentive stock options (&#147;ISOs&#148;) may be granted under the Equity Incentive Plan is not to exceed 14,622,712 shares plus a number of shares of Common Stock equal to the number of shares subject to outstanding stock awards granted
under the Prior Plan (&#147;Returning Shares&#148;), if any, as such shares become available from time to time, which the amount will be increased commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an amount
equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&nbsp;31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii)&nbsp;such number of shares of the Common Stock determined by the
Board or the compensation committee of the Board prior to January&nbsp;1 of a given year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, there were no options to purchase
shares of Common Stock outstanding under the Equity Incentive Plan and options to purchase 16,939,436 shares of the Common Stock were outstanding under previous plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total stock-based compensation recorded within operating expenses was $5.3&nbsp;million, $5.8&nbsp;million, and $5.4&nbsp;million for the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total unrecognized compensation costs related to unvested employee and <FONT
STYLE="white-space:nowrap">non-employee</FONT> stock option grants as of December&nbsp;31, 2022 was $2.7&nbsp;million and the weighted average period over which these grants are expected to vest is 1.4 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2022 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;17, 2022, the Board adopted the Scilex Holding Company 2022 Employee Stock Purchase Plan (the &#147;ESPP&#148;). The ESPP was approved by the
stockholders and became effective on November&nbsp;9, 2022. The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum
efforts toward the success of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase the
Common Stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Internal Revenue Code of 1986 (&#147;Code&#148;) (the &#147;423 Component&#148;) and accordingly, it will be construed in a manner that is consistent
with the requirements of Section&nbsp;423 of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <FONT STYLE="white-space:nowrap">&#147;Non-423</FONT> Component&#148;) in
order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by
the Board, it will operate and be administered in the same manner as the 423 Component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board administers the ESPP and will have the authority to
determine how and when purchase rights are granted and the provisions of each offering. Initially, the total number of shares of the Common Stock that may be issued under the ESPP will not exceed 1,462,271 shares of the Common Stock. The number of
shares of the Common Stock that will be reserved for issuance will automatically increase on January&nbsp;1 of each year for a period of up to ten years, commencing on January&nbsp;1, 2023 and ending on (and including) January&nbsp;1, 2032, in an
amount equal to the lesser of (i) 1% of the total number of shares of the Common Stock outstanding on December&nbsp;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of the Common Stock; and (iii)&nbsp;such number of shares of the
Common Stock determined by the Board or the compensation committee of the Board prior to January&nbsp;1 of a given year, provided however, that the Board may act prior to January&nbsp;1 of a given calendar year to provide that there will be no
increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&nbsp;to (iii) above. As of December&nbsp;31, 2022, there were no shares outstanding under the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Valuation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company calculates the fair
value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the
expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The assumptions used in the Black-Scholes option-pricing method related to options issued to employees and
nonemployees for the year ended 2020 is set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted&#151;average grant date fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected stock-price volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.53</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value per share of common stock on date of grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected dividend yield</I>. The Company bases the expected dividend yield assumption on the fact that the Company has
never paid cash dividends and has no present intention to pay cash dividends on the Company&#146;s common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected stock-price volatility</I>.
The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting
the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-free interest rate</I>. The Company bases the risk-free interest rate assumption on the U.S.
Treasury&#146;s rates for U.S. Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> bonds with maturities similar to those of the expected term of the award being valued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected term of options</I>. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company
does not have historic exercise behavior, the Company determines the expected term assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary
vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents a summary of the options outstanding at December&nbsp;31, 2022, 2021, and 2020 and changes during the years then
ended (in thousands, other than weighted-average exercise price): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>average</B><br><B>exercise&nbsp;price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited/Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,827</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Benefit Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are
voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $0.3&nbsp;million for each of the years ended
December&nbsp;31, 2022, 2021, and 2020, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Product Development Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2013,
Scilex Pharma became a party to a product development agreement (as amended, the &#147;Product Development Agreement&#148;) with two parties (the &#147;Developers&#148;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#147;Itochu&#148;),
pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> (the &#147;Products&#148;), for Scilex Pharma. The Developers initially developed, and have
intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for
sourcing and supplying lidocaine for development and commercialization purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Product Development Agreement, Scilex Pharma is required
to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During the year ended December&nbsp;31, 2022, Scilex </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma made royalty payments in the amount of $2.3&nbsp;million. As of December&nbsp;31, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.2&nbsp;million. Net profits are
defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the
sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The
Product Development Agreement will continue in full force and effect until October&nbsp;2, 2028, the date that is ten years from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for
subsequent successive <FONT STYLE="white-space:nowrap">one-year</FONT> renewal periods unless Scilex Pharma or the Developers terminate it upon <FONT STYLE="white-space:nowrap">6-month</FONT> written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#147;Supply Agreement&#148;) with the two Developers to
provide commercial supply of ZTlido and <FONT STYLE="white-space:nowrap">SP-103</FONT> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement
provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Distribution Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2015,
Scilex Pharma entered into an Exclusive Distribution Agreement (the &#147;Distribution Agreement&#148;) to appoint an exclusive third-party logistics distribution provider (the &#147;Distributor&#148;) and as an authorized distributor of record of
ZTlido in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a 3% annual adjustment. The Distribution Agreement has an initial term of three years following the first shipment of <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of
the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#146;s negligence or willful misconduct. Pursuant to
the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#146;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was
sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between 1% to 2% which was recorded as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gross-to-net</FONT></FONT> sales
adjustment. As the Company continues to expand the commercialization of ZTlido, it has expanded its direct distribution network to national and regional distributors and pharmacies since the beginning of April 2022. The Company currently holds all
necessary wholesaler licenses and commenced selling directly to the main distributor customers as well as pharmacies in April 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales
Operations Services </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and
detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#147;Project Agreement&#148;). In connection with the detailing services, the Project Agreement provides that the vendor will
provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each
of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales
representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor continued to provide sales operations services, fleet management services and sample </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accountability services. The work order was in effect until June&nbsp;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order
with 90 days&#146; notice. Scilex Pharma paid an implementation fee of $59.0&nbsp;thousand and will pay fixed monthly fees of $63.7&nbsp;thousand to $65.8&nbsp;thousand for ongoing services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized an expense of $0.9&nbsp;million, $1.9&nbsp;million, and $10.5&nbsp;million within selling, general and administrative expenses for
services performed for the years ended December&nbsp;31, 2022, 2021, and 2020, respectively, including implementation fees, fixed monthly fees and pass-through costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the normal course of business, the
Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the
aggregate, are deemed to be material to the Company&#146;s financial condition or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time the Company may become
involved in various legal proceedings, including those that may arise in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sanofi-Aventis U.S. LLC and Hisamitsu
America, Inc. Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California
against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by
those companies regarding their respective OTC patch products (the &#147;Sanofi-Aventis&nbsp;&amp; Hisamitsu Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false
or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly the Company&#146;s claims, but which motions the court has largely rejected. Discovery
is proceeding. The case is currently scheduled for trial to begin on July&nbsp;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Former Employee Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2021, the
Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#147;Virpax&#148;), a company now headed by Mr.&nbsp;Mack, alleging, among other things, breach by
Mr.&nbsp;Mack of his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement with the Company, breach of fiduciary duty, and tortious interference by Virpax with that <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement (the
&#147;Former Employee Litigation&#148;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&nbsp;Mack from further violating his <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement and enjoining Virpax from
tortiously interfering with Mr.&nbsp;Mack&#146;s <FONT STYLE="white-space:nowrap">non-compete</FONT> agreement. The case was tried from September&nbsp;12, 2022 to September&nbsp;14, 2022. Post-trial briefing and closing arguments have been concluded
and the case is under submission to the Court. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ZTlido
Patent Litigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc.
(together, &#147;Apotex&#148;) in the U.S. District Court for the Southern District of Florida (the &#147;ZTlido Patent Litigation&#148;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#147;ZTlido Patents&#148;).
The ZTlido Patent Litigation was initiated following the submission by Apotex, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Apotex&#146;s ANDA seeks approval to market a generic
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief,
an order that the effective date of any FDA approval of Apotex&#146;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&nbsp;10, 2031, and such further and other relief as
the court may deem appropriate. Apotex is subject to a <FONT STYLE="white-space:nowrap">30-month</FONT> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&nbsp;11, 2024.
Trial in the ZTlido Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases
administrative and research and development facilities under various <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of
December&nbsp;31, 2022, the Company&#146;s leases have remaining lease terms of approximately 1.6 to 1.9 years. The term of the Company&#146;s leases does not include extension options that were not reasonably certain to be exercised from its lease
terms, ranging from 3 to 5 years. Many of the Company&#146;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the
measurement of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income
is recognized on a straight-line basis and is immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Company&#146;s leases do not provide an implicit rate, the Company uses its incremental
borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&nbsp;31, 2022, the Company has no
finance leases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods
presented. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Supplemental quantitative information related to leases includes the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash paid for amounts included in the measurement of lease liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows from operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(654</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ROU assets obtained in exchange for new operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term in years&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate&#151;operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company entered into a new <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease
agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is 26 months and the Company does not expect to exercise the extension option at the end of the
lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Approximate future minimum lease payments under operating leases were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year Ended December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current portion of lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Income Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total
loss before income taxes for the years ended December&nbsp;31, 2022, 2021 and 2020 did not include a foreign component. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the provision
expense (benefit) were as follows for the years ended December&nbsp;31, 2022, 2021, and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current income tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax expense (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,981</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,970</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,851</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,247</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,453</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total income tax benefit from continuing operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and
liabilities for financial reporting purposes and the amounts used for income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#146;s net deferred tax liabilities and related valuation allowance are as
follows as of December&nbsp;31, 2022 and 2021 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2022&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt related interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expense and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,543</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#146;s provision for income taxes
are as follows for the years ended December&nbsp;31, 2022, 2021, and 2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debt discount and interest limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(806</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition related charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prior year <FONT STYLE="white-space:nowrap">true-up</FONT> and carryback</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,968</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State, net of federal tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,545</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,164</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax credits and incentives</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the
amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the deferred tax assets, the Company maintains
a valuation allowance of $67.5&nbsp;million against its deferred tax assets as of December&nbsp;31, 2022. Realization of the deferred tax assets will be primarily dependent upon the Company&#146;s ability to generate sufficient taxable income prior
to the expiration of its net operating losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the Company had $205.6&nbsp;million and $106.9&nbsp;million of federal and
state net operating loss carryforwards, respectively. The net operating loss carryforwards begin to expire in 2035 and 2034 for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
federal and state, respectively. The Company also had federal research and development income tax credits of $2.0&nbsp;million which will begin to expire in 2035. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Internal Revenue Code Section&nbsp;382 rules apply to limit a corporation&#146;s ability to utilize existing net operating loss and tax credit carryforwards
once the corporation experiences an ownership change as defined in Section&nbsp;382. For the years ended December&nbsp;31, 2022 and 2021, there was no impact of such limitations on the Company&#146;s income tax provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in U.S. federal and state tax jurisdictions. All of the Company&#146;s tax years will remain open for three years for
examination by the federal and state tax authorities from the date of utilizations of net operating loss. There are no active tax compliance audits as of December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending amount of unrecognized tax expense (benefits) is as follows for the years ended December&nbsp;31, 2022, 2021, and
2020 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease related to prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase related to current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31, 2022, 2021, and 2020, $0.4&nbsp;million, $0.4&nbsp;million and $0.4&nbsp;million, respectively, of the
Company&#146;s total unrecognized tax benefits, if recognized, would impact the effective tax rate, however given the full valuation allowance in the jurisdiction in which the unrecognized tax benefits relate to, the impact on the effective tax rate
would be nil. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s policy is to recognize interest and penalties related to income tax matters in income tax expense. No interest or
penalties have been recognized as of and for the periods ended December&nbsp;31, 2022, 2021, and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company believes that no material amount of
the liabilities for uncertain tax positions are expected to reverse within 12 months of December&nbsp;31, 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Related Party Transactions
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, approximately 14.7% of the outstanding capital stock of the Company was held by Itochu. On January&nbsp;13, 2021,
34,889,868 shares of Legacy Scilex representing all outstanding capital stock of Legacy Scilex held by Itochu were acquired by <FONT STYLE="white-space:nowrap">non-related</FONT> minority shareholders. Thus, Itochu is not a shareholder subsequent to
January&nbsp;13, 2021. During the years ended December&nbsp;31, 2022, 2021, and 2020 the Company purchased approximately $6.7&nbsp;million, $5.7&nbsp;million, and $1.0&nbsp;million respectively, of inventory from Itochu, a previous minority
shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#146;s statement of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Semnur is party to an Assignment Agreement, dated August&nbsp;6, 2013 (the &#147;Assignment Agreement&#148;), with Shah Investor LP (&#147;Shah
Investor&#148;). Mahendra Shah, Ph.D., who has served on the Company&#146;s board of directors since March 2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to
Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the <FONT STYLE="white-space:nowrap">low-single</FONT> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection
developed using such intellectual property, which would include <FONT STYLE="white-space:nowrap">SP-102.</FONT> Through December&nbsp;31, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2017, a Transition Services Agreement (&#147;TSA&#148;) was executed between Scilex
Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#146;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to
the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the years ended December&nbsp;31, 2022, 2021, and 2020 the total cost of services and insurance, including an agreed-upon markup, provided to
the Company and recognized in general and administrative expenses was $3.8&nbsp;million, $4.0&nbsp;million, and $2.3&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
March&nbsp;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $16.5&nbsp;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) 10% simple interest per annum, and
(b)&nbsp;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the years ended
December&nbsp;31, 2022, 2021, and 2020 Sorrento made advances to the Company in the amount of $27.5&nbsp;million, $6.6&nbsp;million, and $13.7&nbsp;million respectively, under the note payable. All outstanding related party indebtedness immediately
prior to the closing of the Business Combination was converted to equity pursuant to the Debt Exchange Agreement (defined below) and therefore the last day the debt outstanding was November&nbsp;10, 2022 (see Note 12). The outstanding principal
balance of the note on November&nbsp;10, 2022 and December&nbsp;31, 2021 was $47.1&nbsp;million and $19.6&nbsp;million, respectively, which was recorded under the current related party note payable in the Company&#146;s consolidated balance sheets.
As of November&nbsp;10, 2022 and December&nbsp;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $7.2&nbsp;million and $3.9&nbsp;million, respectively, which was recorded under related party payable
in the Company&#146;s consolidated balance sheets. The proceeds from the note payable were used to finance the operations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $21.7&nbsp;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#147;Intercompany Note&#148;). Scilex Pharma may
borrow up to an aggregate of $25.0&nbsp;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) 10% simple interest per annum, and (b)&nbsp;the maximum interest rate permitted under law. All
outstanding principal amounts and accrued interest was due upon maturity on August&nbsp;31, 2026. On October&nbsp;22, 2018, Sorrento purchased from the Legacy Scilex 24,117,608 shares of the Legacy Scilex Common Stock in exchange for the repayment
of $21.7&nbsp;million of indebtedness under this promissory note. During the years ended December&nbsp;31, 2022, 2021, and 2020, Sorrento made advances to Scilex Pharma in the amount of $0, $8.1&nbsp;million, and $10.3&nbsp;million respectively,
under the promissory note. As of November&nbsp;10, 2022 and December&nbsp;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $5.1&nbsp;million and $3.1&nbsp;million, respectively, which was recorded
under related party payable in the Company&#146;s consolidated balance sheets. As of November&nbsp;10, 2022 and December&nbsp;31, 2021, Scilex Pharma&#146;s outstanding principal balance under the promissory note was $23.5&nbsp;million, which was
recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company received $35.0&nbsp;million in February 2022 to fund the payment of Scilex Pharma Notes as described in Note 7. The $35.0&nbsp;million received in February 2022 was due no earlier than February 2030 and was recorded under the <FONT
STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets as of November&nbsp;10, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional funding received from Sorrento was due on demand and recorded under the related party payable in the Company&#146;s consolidated balance sheets. As
of November&nbsp;10, 2022, related party payables due to Sorrento included $61.7&nbsp;million to cover working capital requirements, $100.0&nbsp;million for repurchases of Scilex Pharma Notes, and $18.2&nbsp;million for litigation fees (see Note 7).
As of December&nbsp;31, 2021, related party payables due to Sorrento consisted of $35.7&nbsp;million to cover working capital requirements, $51.0&nbsp;million for repurchases of Scilex Pharma Notes, and $6.0&nbsp;million to pay litigation fees. As
of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million related party receivable from Sorrento related to certain invoices paid on behalf of Sorrento, which was fully reserved (see Note 14). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the
Bill of Sale, the Company assumed all of Sorrento&#146;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note
matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&nbsp;the maximum interest rate permitted under law. As of November&nbsp;10, 2022, the outstanding
balance, net of discount, under the 2022 Promissory Note was $4.2&nbsp;million, which was recorded under the <FONT STYLE="white-space:nowrap">non-current</FONT> related party note payable in the Company&#146;s consolidated balance sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Debt Exchange Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;12,
2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#147;Debt Exchange Agreement&#148;) with Sorrento, pursuant to which (i)&nbsp;Sorrento shall contribute to the Company all amounts
(including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company that remain outstanding as of immediately prior to the closing of the Business Combination (the &#147;Aggregate Outstanding
Amount&#148; or &#147;Outstanding Indebtedness&#148;), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $27.5&nbsp;million for certain amounts
previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 7), in exchange for the issuance by the Company to Sorrento of Preferred Stock of the Company, (ii)&nbsp;the Company shall contribute
to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&nbsp;upon the occurrence of the events described in clauses (i)&nbsp;and (ii), the
Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective
as of immediately prior to, and contingent upon, the closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to the Company in exchange for the issuance by the Company to Sorrento of that number of shares of
preferred stock, par value $0.0001 per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#147;Exchange Shares&#148; and such transaction, the &#147;Debt
Contribution&#148;) that is equal to (i)&nbsp;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event would the
Aggregate Outstanding Amount exceed $ 310,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2022, all existing related party indebtedness between Scilex, Scilex Pharma, and
Sorrento totaling $290.6&nbsp;million was converted into equity interests in the Company in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement. This amount was converted to
29,057,097 shares of Scilex Preferred Stock and 2,905,710 shares of the Company&#146;s Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, <I>Earnings Per Share</I>. The Company has two classes of shares, which
are referred to as Common Stock and Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share attributable to common stockholders is presented in conformity
with the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for participating securities. Net loss per share has been retrospectively adjusted for all periods presented prior to the Business Combination. The retroactive adjustment is
based on the same number of weighted average shares outstanding in each historical period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2022, 2021, and 2020,
basic loss per share is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method. The <FONT STYLE="white-space:nowrap">two-class</FONT> method is an earnings allocation formula that determines earnings per share for each class of
common stock and participating securities according to dividends or dividend equivalents and participation rights in undistributed earnings. Preferred Stock is not contractually required to share in net losses of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the reconciliation of basic and diluted loss per share for the years ended
December&nbsp;31, 2022, 2021, and 2020 (in thousands except per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to Scilex</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,364</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(88,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,519</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for Diluted Loss per Share&#151;Adjusted for Dilutive Securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and Diluted Loss Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share
because their effect would have been anti-dilutive for the periods presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,939,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,967,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,746,432</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,899,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Private Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition and disclosure purposes in the audited consolidated financial statements as of December&nbsp;31,
2022. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>B. Riley Standby Equity Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;8, 2023, the Company entered into a Standby Equity Purchase Agreement (the &#147;B. Riley Purchase Agreement&#148;) with B. Riley, whereby the Company shall have the right, but not the obligation, to sell to B. Riley up to
$500.0&nbsp;million of its shares of the Company&#146;s Common Stock at the Company&#146;s request any time during the 36 months following the execution of the B. Riley Purchase Agreement, subject to certain conditions. The Company expects to use
the net proceeds received from this for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for B. Riley&#146;s commitment to purchase
shares of Common Stock at the Company&#146;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued 250,000 shares of Common Stock to B. Riley in connection with the execution of the
B. Riley Purchase Agreement on January&nbsp;12, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the execution of the B. Riley Purchase Agreement, the Company sold an aggregate of
127,241 shares of Common Stock pursuant to the B. Riley Purchase Agreement for aggregate net proceeds to the Company of approximately $1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scilex Holding Company 2023 Inducement Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;17, 2023, the Compensation Committee of the Board of Directors (the &#147;Compensation Committee&#148;) of the Company adopted the Scilex Holding Company 2023 Inducement Plan (the &#147;Plan&#148;). The Plan will serve to advance the
interests of the Company by providing a material inducement for the best available individuals to join the Company as employees by affording such individuals an opportunity to acquire a proprietary interest in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company. The Plan provides for the grant of equity-based awards in the form of <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, stock appreciation rights, restricted
stock, restricted stock units, and other awards (as set forth under the Plan) solely to prospective employees of the Company or an affiliate of the Company provided that certain criteria are met. The initial maximum number of shares available for
grant under the Plan is 1,400,000 shares of the Company&#146;s Common Stock (subject to adjustment for recapitalizations, stock splits, reorganizations and similar transactions). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to the Yorkville Purchase Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
February&nbsp;8, 2023, the Company entered into an Amended and Restated Standby Equity Purchase Agreement with Yorkville (the &#147;A&amp;R Yorkville Purchase Agreement&#148;), amending, restating and superseding the Yorkville Purchase Agreement
dated November&nbsp;17, 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the A&amp;R Yorkville Purchase Agreement, the shares of Common Stock, if any, that the Company elects to sell
to Yorkville pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily volume weighted average price of the Common Stock for any trading day on the date of delivery of a written purchase notice to Yorkville. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to December&nbsp;31, 2022, the Company sold an aggregate of 85,000 shares of Common Stock pursuant to the A&amp;R Yorkville Purchase Agreement for
aggregate net proceeds to the Company of approximately $0.6&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Elyxyb License </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2023, the Company acquired from BioDelivery Sciences International, Inc. (&#147;BSDI&#148;) and Collegium Pharmaceutical, Inc.
(&#147;Collegium&#148;, and together with BDSI, the &#147;Collegium Sellers&#148;) the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to ELYXYB (celecoxib oral solution) (the
&#147;Product&#148;) and its commercialization in the United States and Canada (the &#147;Territory&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for the acquisition, the
Company assumed various rights and obligations under that certain asset purchase agreement, dated August&nbsp;3, 2021 (the &#147;DRL APA&#148;), between BDSI and Dr.&nbsp;Reddy&#146;s Laboratories Limited, a company incorporated under the laws of
India (&#147;DRL&#148;), including a license from DRL including an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> and patents of DRL related to the Product and necessary or used to exploit the
Product in the Territory. Additionally, under the Purchase Agreement, the Seller granted the Company an irrevocable, royalty-free, exclusive license to <FONT STYLE="white-space:nowrap">know-how</FONT> related to the Product and necessary or used to
exploit the Product in the Territory. No cash consideration was or will be payable to Collegium Sellers for such acquisition; however, the obligations under the DRL APA that were assumed by the Company include obligations to pay royalties for sales
of the Product in the Territory for all indications and additional amounts if certain milestones are achieved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sorrento Chapter 11 filing
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2023, Sorrento, together with its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary
proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas. While the Company is majority-owned by Sorrento, the Company is not a debtor in Sorrento&#146;s voluntary
Chapter 11 filing and management does not expect this will impact the Company and will continue to operate its business as usual. As of December&nbsp;31, 2022, the Company had a $1.8&nbsp;million receivable from Sorrento, which was fully reserved.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g418853g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1KH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &LR^:& X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $T1E97!A
M:R!086YE97)S96QV86T .$))300E       03VU_L"E!NVXS#Z"992D'2CA"
M24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $Y   "<P    8 9P P
M #  80 P #$    !                          $              G,
M  $Y                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $Y     %)G:'1L;VYG   "<P    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M70#_ $[J#AXR1_[L*.5F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'!?I_4#5T4B\3;Z]#DS.E()+L9"KV$MEE44QDX$2/W2&4K/%[U':7M>4=+<
MW!-<.BYX2.#69I%I[1-BX/X-ZM5C-WOZ$1+F]'T$MR4)S=U1<W2I5XN1XI^:
MZP.F3AH!MD-ZS_*G\]O/^^]@-4>XF<T[*FO?'Z^;[3ZA7J[M0.AS][>/])-8
M_>*GE3^>WG_?>P&J/<3'94U[X_7S?:?4*=J!T.?O;Q_I)K'[Q4\J?SV\_P"^
M]@-4>XF.RIKWQ^OF^T^H4[4#H<_>WC_236/WBIY4_GMY_P!][ :H]Q,=E37O
MC]?-]I]0IVH'0Y^]O'^DFL?O%3RI_/;S_OO8#5'N)CLJ:]\?KYOM/J%.U Z'
M/WMX_P!)-8_>*LQMC\_^7<'PNXU[4BMPNVE]O>P]U0EKL 4_7JJDO%U5]!HP
M#4\>O4E8EH$>F\<%*JP8-5W':=+M5<2D$NXW+A U>QHS35U:O"D3Y]QO;$N1
MTE;B7FHBXXCH+:H991Q86H9;;0I6>[*L#'#=+=#=P*W#AXX5-'S-$,O:<T[I
MG0<^S6TWO4J$PI=XC7!RY/)DMWE$UXR5L-$HDR7FVMC#*&P5 X<^5/Y[>?\
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M7OC]?-]I]0IVH'0Y^]O'^DFL?O%3RI_/;S_OO8#5'N)CLJ:]\?KYOM/J%.U
MZ'/WMX_TDUC]XJ^F;N=.V=@[OXBZSV7M*Q*6J[S[V]I2TXK'1$4=XG#W^S0T
M<46,%'Q<8CWM&,&C4!;LDA5!$%5A47.HJ?TOP=7>XWS25LN5TD&7-?5.#KY:
M99*PS<);#?Y-AMIH;+3:$=R@9V<JRHDGY1=$]HS37!_PU:KTKI"V)L]@MT?3
MJX5O1*FS$L*G:;M,Z41(N,F7+7QLJ0\\0X^L(*RAL);"4CYF>ZG_ ,_;?_\
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MOI3A%T_K2[7JVV!Q<QFRQX#[ER2E2(DHSERT!$8.(0XL,F(K:>"2RX%I+2U
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M$K.17.5XL[SKJ:3NS4*4@XWPI&13QXLM&NSL5I.;1KQ#+,6;]9X((RZZ<>L
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M4K[)>Y)?S"]-_P#U'9W^*=RSV/P2?Z"6?_YW+^U9U?#7HT/]HO7'_P#+I/\
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MHAP=?R???[6KS7P1?Z[.B<_G)P=_]E(K7YG/:]*5<[6>WKMJ1Q-NJ6\9LUK
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MAQ ^2(\6-TRZEEEO"4(4$C<!64FW?]G;P]_K8Y%_VE6LVJ\?ZN]'?RMJ/_\
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MJ>23YZ^9J/\ I.U7[YX[$FO/$[7.=K]<IVY_0Z>74GZ)ZP]A4\DGSU\S4?\
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M[-.&G=2N+ER[+&GMW)I41NTKF1Q'6^T Y)8:;>VLLJ< 5C#_ ,DGSU\S4?\
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M<#^KL=?JK1S8'[ C=NS7%50KMX4%3JN4ORBS@&O:&>)M@.HBU @H"ITI"J!
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M\[D>DKB:IU\O54913")>HJ$79R<0S;1LG'ND3@HW=L7S1))PW<MU2E4243.
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M4A*\*P=DJ 5C!-6\M#SD62W'6&WUL.H965% 0ZI"@VHK2E2DA*B#M)2HIQD
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MM?9R,RB0DB]:P4,W<N548MD1!3)\/P_+X:EDIQYT!.*0ZTUHW3TPM7H&.JT
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M,4IBE,4IBE,4IBE,4IBE>AHU6>NFS-N &7=+I-T2F,!2BJL<J9 ,8?B* F,
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M4#CMG)^(D!?M&ZK=,[^G29T#E5;D*"SN2;R1&JQBF!--P+=NH)VW6ZY%A!$
M,80Z:,EUM:9C:=E)$:&XG94G!4RZX5L#?O*$R!@)SN0H!.ZI8%NFQQ%?=;=(
MC7R*EU)2XK+;,5R*I]O*=I3?'.)2'"G!0-LE(!Q'VBE67C:K 0TZLW=+3D6_
MF^_XP&2*L@)S(&=*2JD@9)%E$MEEBM4^]R]?M5U3&!14W3,P[&1)MH:D'B(L
ME,AY+C?$\B4.R9"EEQ86O$=#;+0 [G !4XHA62D(NS;]YN4ZWMNH3;ID:WB/
M*,A2(P3QB6$Q$QPM;\QY#:GU\8<%#: -AL 6[L+Y&4GYR2;D[-O(R\D^0)T
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ME.<)$=E;"$Y45*4"E94HK*E%0!R ,5-#L4>(XP]Q[[[K#SKP6Z&$[2G(S40
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MUCV<50R7B;5!4(!!,4E;@E.@%#'(4P"14Q1*)R'()@$0*<ABF$#%$ B'I"B
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M2;3<E\BHRR5"'(7W<)U>"KI=:TC:<?9=++KJ0VL2:1<T6,JTE<GLRR36? G
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M@#(JA++&Q\I/*^,!X(+!#U!>/D$&:ST2I1S>.2>MC%:$55;J"9@Y;@/000Z
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M'I'(E+H."EP':&XA0.V?S=W+M$ X[^[=R5=!ZRA(2';6$H*P$AR($H4!AP
MX20!A8P#@=UN%=3J#L0K@5S'2J[LZ .3D.V=K.B(])@ZZY#)F63 .H;I[0
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M  KSIJ74ERU1<W+E<7<D_DXT9O*8T*.DG8CQF\X0A(.]7Y[BLK<)42:R?VQ
M3MKU9LNK5==%K9K+0+E 5URX<*-&[>=F*[)1T0NN[2(JJV11D'+=15PDDHHB
M0IE"$.8H%'(U@!N(/@(K5_Q-XV\]M76"=#>>SVNQ->/M37RH,J 79<JZBV$T
MW1UNVUBG F7K:)J^!6C/8[6<G$1<.DR2$0)F[P$DP;PWYY<C'?QR_(!^#4Q*
M3R#?G)SO\/P_JW5B?7^ /=$G-+K;%[>Z]1/%6IP5<>:[8;=E+I$WU&(WU.;'
M!I)W62IL?-UM$*9+-ZX+V*;*/G7>!6;I51@H1)*(J&1X,C)(')\6>7D\&/EK
MKM'<[^;%HTO)5V-94^A6FQ;QV#>Y"D0O(*X+T:MQ-JAD8NHSE4F$*BQF6Z]$
M=-B38U=R15&:EEW*Y9-B4Q"EAC_'\;N3_P!C.^@4!G=G/)X>7E)\/?\ CY,8
M%4";[G/S?G:Y>D&5:H]+MEMW[JS8,6_A>14\_K5:JFN'-79.G,<Q>Z["P1\_
M=(R!<RMR/#3D>\E9.1<L$)!K'J& 6#OW_%^/V[_A&,TR-V!R'/P]_O\ [-WQ
M\F_Z42@(%* _R@4 '_X]'Q__ .Y&I:_<4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE:'MR=Q.=;%WA?]Z4OE7*:WF=F["V;?;O5AU,>R5"VC;$"M:3!
MVA@VVK5GLFQJ$;+7RL6I1G(1)]E4J[.JT]3KJ<4P>Y C/AQN_5^.]]=3!6.]
MX?ESWS^K]?AW7*X[]R5E=%[$0V0YY16&9FC.+25V>H4!YK]Q'0-F@IZ,2IM)
M>NMFW52IU"M2,PUD*Q"JI3J<<SA(N-44=+MTI1)\N?Q^/ES0J!QN&['S <GX
M[VZL?]]]QIVU:F-$;43?M%L;*A;-EIZMQ]VT],H6!W7=AV-I*7U7=5VC=ULU
M]UHL&;0J<778N'U<,D=94'\J?I*)6/#O_9\>/P?AH%$9/?P/"<X(Y=_@S_=B
MI]=.XSW.SMH9!ES#>(&9Z\I5!DO&;3LO:FPNZGK@E 0V-6$$MYP"U<V?75 <
M3NJ+4]=V/\&[A^_;+,;:=R9Z$,9QDG=GY<GD^+X*CM8Y$@?K^#]G]_AJ><8^
MY*3/'??NLMTR7)%MLQGK-&9".B9K3[^.N:PS=7L59=0[._*;BFV$33 /.)V,
ME:3HKMSXSEF)(9SLYL6K"('R_P"')^/\ (%6>]CY?Q\G@&[XMSN1J6F*4Q2L
M Y->MQ=BL8%W%H]FL>TOWZS*5O)&\@R=-W[O_(WB!&Y1;N$#J&2=H")CI+)F
M(!PZHB.!6IH.*_RR"DI><7LJ? 4%%+C92H=X@+.1RA0Y<5W^,Q<IEMMA.C->
M/(3:(\5#\2P*<COM.,,D/L.*</&-N!(6RO 2IM05L[]W<TM-=:D9E4V]QU>=
MY&.9,7=]6."AC',H0ZI$^R3%5(QA[-9,B:P (@8YNL;I@EQE/%8F6[+24I"N
MF#M'9*,*)).%80$DIV=I)4% Y&)'K/<72^1H_A*9X_&UQ.GDIV0$[*DI4H*5
ML+P"I"U*1D9"00,<R6Z#260<)[DX]$51%OTF+L!?H63;2#B1114)_P!&"0'<
MG1,5,J8J( 0#F,H':#+EG9*1-@ %M#9_RC)/%Q7XB5')QM<6^5$ !/&(0L)!
MV]N"K)-6A;:M%\)!0KC2!UNHRA3S++*UI4 %%9XE+@*BK965;.$80.EQ:(%R
MWC4%-S<? &,+'D16)L!8BJI(Y!N@B5P !V*HF%N"RB@I=J*JAQ(H0@)D3G6Z
MTM:7#,MP4E2E$A\]UM+>7@@D@;)?7@I 5C<5$$YF;L\YI<I2=%<(V):I*UH5
MIQ!2A4IUQQPM'\] '&;"4[12$)3D$[15Q<V2OO!CQ<;DX]J&C7!5T!'8"P=?
M\11-1-8"@!3E6*J;KG "K$$"F152$.G),LDMDS8!V$N(.9)[M+B @I4001@#
M(*-E62=^#BIFK3<61*#>C.$9*9390L#3;9V>[2M"FR02"A2!LI)+9&0M"A7C
M>2]:=F#HW-Q_;HE?QC])NCL%0R:1HE 6[5 #N"+KJ)"GT=J9=55P<Q0'M@'I
MR;C&N,0YT] _)O*>2GI@;(4KB^Y/?*1Q8 R=K!.5'=BNS N3*5 Z*X175+C2
MHJW%Z<2%J3,67'G,-\6VE>T3LA"$M)!QQ9JKFN4.IV15=T<?#D3  -T7SJF4
M,4RA05.;L?QEBM1;LBG, ]#5BT3$!%,QCRE32DI0J=!*0TVR<2 "4ML2&-K.
M"-M:9"UK5LG+@2<8!2;'J#,25*1HGA'2I2BH9T\2$Y*%["1M;FR\EQ\I&"79
M#ZL]TD)[9NSTM^[358[<T&BU S-19H\V"FL@N=F90R95$$VQ4NJIVAC.3% H
MKK"*Q2(#\63..,N.J69EO"2YQ@;Z8RG:*7$GP$)/&;6R#N6-L'*B*E@6>^1V
M5(D:0X0UNE+S:'6-.+0MM+P0%*2XI97M)V &P<AM'<$N#?7!Y<X1W))2?X8N
M.S=1)M'M"H-[ZJ5OV,<X[X2*)3@HH/:&_%6 5>J8GQ% H_'D%.-J4XKIZW@N
M)2DX?[R6'&!CO[TN%1SG*@D\F09FK#-:C&+UF<)+B2[)>*W-/)+FW);#:SE.
MRD;( *,(!!SDD5XEI^JO9V&FWNX]!]>&<]^$;L]B&13<.2"DH0YP<(.DT>LL
M@B*G>Z:9.H!@!(P 0H1*V"XMSIRWI*F7VALOYP7DOC:[LDX"WBHI!"=Q(2%*
M43<(MEU8M\Z QHSA"V9S894Z_IK;4VUO0I*2VMI2R&EK"2XI2BK!*P=I1RTU
M,W8(Z]K:;&7@[$U(W>@C-5YZ24AGP#*/C'.Q?E33*X(DH)T%1 A>HX253Z!$
MG2.7B;(CM[*T.)PK"VU;2%=VK.RH<N#D'X017(]7K><U'<UR(4ZW/*<9*X5R
MCF+-8/2K "7XZE*+:EI <0"H[3:T*Y%5<3LT_P!&3YI?JRXK6Z=FG^C)\TOU
M8I3LT_T9/FE^K%*=FG^C)\TOU8I3LT_T9/FE^K%*=FG^C)\TOU8I3LT_T9/F
ME^K%*=FG^C)\TOU8I3LT_P!&3YI?JQ2G9I_HR?-+]6*4[-/]&3YI?JQ2G9I_
MHR?-+]6*4[-/]&3YI?JQ2G9I_HR?-+]6*4[-/]&3YI?JQ2G9I_HR?-+]6*4[
M-/\ 1D^:7ZL4IV:?Z,GS2_5BE.S3_1D^:7ZL4IV:?Z,GS2_5BE.S3_1D^:7Z
ML4IV:?Z,GS2_5BE.S3_1D^:7ZL4IV:?Z,GS2_5BE.S3_ $9/FE^K%*=FG^C)
M\TOU8I3LT_T9/FE^K%*=FG^C)\TOU8I3LT_T9/FE^K%*=FG^C)\TOU8I3LT_
MT9/FE^K%*=FG^C)\TOU8I3LT_P!&3YI?JQ2G9I_F$^:7ZL4KGBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE88\\@Y&JZ$48\69"R1&
MUY6]T:);RU5;PZTI&5Q_,E0L;\RT[5KI&1[)JP,*KV37K,MWBB45BMCB'0*H
MC&=_)O\ V5JRY*[K[K7J&V\>M,:WUO==Y!!H5AUN?<59U"]7K-@EVE=FIURL
MC>(>9CF3V(<2)8NM6.$4U]5%7#TQG$>\:D,1#(;]WZ\?&/#\&?C^ XJ8;.?C
MSC)Y.7?\>[DSR'OYJYNQMG]U3NG$]F_KE3DZ%R2BN2^OFR8TS681L?8M0.M3
M1U[G&$Q7;@XN9VM=;7R2<ZWL=D9/V;U4\0=9FI!/5%$4H_J_7^/QNJ&$@G?D
M8R/CW;MW+^/!FK8L^27=8Z)H;?&SG>D=HW7;=MVC7IS36J9#3;:X,M?4.9J\
ME,+4M=C6Y:@SBS*-5;1D1,3[I[9)*,L[UPB=LHU*5%&!./Q^OX?DJ.$[M^1O
M)\/>P,?'^KXJ[;[SD[JMK;B7,[2G>+<C+[HBU(^REKU=T5:W4 TK9*8UL=@@
M+'&J;#).1*D;)&=PP6YEX6(5RW4*XK2/9])V_P"7X/C^/P?@U [.=Q./UG]6
M[YOK$*TOW1/NGVXZ/1;E5=!QD^A,,]AN+*DCH;8;(\+8(A^Y805 G :7693K
M<RSC4HZS(31U92)MQYHM?)XO#&.94X9^#'[>7>-_Q'Y>6HE('?P3R9/Q? ,#
ME&_')R5>B*Y3=UQB:G?']FXX0MDGT*FLM4T:_IVZ17@Z<[?3SXT@I&KW>3<W
M S2,OM]CDZHS7@G<G(ZQ?+(2Z0OEV<<.=WA)'R#^_P#5RTPCPG=X>_\ +CP_
MW][?7%7D5W6JS5[938NFV52<CK"W+468C-(W 99M>(6N-):%D"LK!:RD?GGY
M 7,4TJJT>DLB]'L"2;X42BNW^#Y/QN_74"!NP>4_,/AW#?R_C?6Z#3\E:9C5
M>O)2\&>'N3^G5]U:32%9=4Q]X?6C6YY4'55>NW[J!7*]%8JD:N\<';F 2]H(
M= !&I:N-BE?-YM7_ +4-D?T]N']X9'.;2O\ .9'_ !WO_P!%5],-)?Z*Z9_F
M_9O[.C5&"0,ZJ) 2AI503H"Y("<<[.)VX=("X*!41$40$! 50#J ("'6^(<I
M%M8SE"QA(4<I(PDY(4=VX8!W\FX^"LHJXV] RJ?#2 OBB52F  Y^CR5CN]X[
MC\[?R5X@9/!2*N#1R*!U^]2+ @J*1G/1T][E4 G4,OT?'V("*G1\?5R !)2
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M7(;JGBI(AA."8%,Q=%-US'!,I.@4@'KBH($ O\HG$"@'6'HR 2I1 "223@
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MBT8-Q(ST0S;V:280]=77D&R:$Y*2B2B\:PBE14[-\Z?HHJJM$6QE#N$TS'2
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M^OP[!!BK79J6"*EW]DB7#R1;I++3+I4!;MI$Q06.$0S* .4$4%3K$?$(J B
M#TS-3^)::"4$NQMHL+*L K6M\E;A VMI"'1Q>,[)4Z,X4")IW!O<9TIZ0+G
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M>,?".;L4DE;]XU]W UN-<=+.@RA4R2=G=HG, ^,"*9E0:5=(0*)X\%"/;"J
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M6,6FJN1B15-L+KJ,0*[5(194IW#DJJZ_7$5U%1Z!"=3[JG%O*4"XZXIU9V4
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M]Y!GZ2:2]NT\J]P'\^P?1OMGW%QV5=!^/#S7>/9].U.X?O(,_2327MVGE7N
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M<O30#[+\8.)2)O?=3\&XF^UZ!B]CLI:I!08!9](US8$:Y!I<)B>[RE$'M@/
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MM57S]R) ^/LFC1!9PN;^0B29SC\0#E=B-(DA\L,K=$9A<E\H&>*CMJ0A;R_
MA*G$))[Q4!WZLYMPA6UE,B?)9B,K?8C)=>6$(5(E.I8CL@GE6\\M#;:>52E
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M2=M:7)C@24\:1D6-':"@K$>/8]/Q7)<%%N#*&(K:Y-OBLH;1$#>0IZ,PPVA
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MH\<&C"+3SE^NH=J*!!DU%%3@#CX[\"^R5SK2E-PEJ@2H[-Q@-(=E"/)TY.7
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M&!EXR;C^^';/OZ(?M9)GWVP<JLG[7OIFJLAWPR>(+-':'7[5LY1506*15,Y
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MIT0N):DM-21QVK+J'F9+;T9U(B%3'&1PXK7-0<%VFM227I5P,[C9$M$QU*3
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MC\\*B#J2=JO%RHE/NA0Y4BJ+&*F4ZAS 0"@8YA 3#BD<&*D(2CJT%;*0-I4
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)E,4IBE,4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g418853g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[22"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )&:^DQ@X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $T1E97!A
M:R!086YE97)S96QV86T .$))300E       03VU_L"E!NVXS#Z"992D'2CA"
M24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              &4   "90    8 9P P
M #  80 P #,    !                          $              F4
M  &4                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  &4     %)G:'1L;VYG   "90    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MY]6WTG2[8YOOW^G]/V>HC7B@R/8ZNRWJ&"YQ:W(K+@-Q >WC][E1/4\ <WL
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MZ;$E/__1[3J1R/MEOHM8?<)WDCLWC:#^:@--^Z$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MP[_6XX5+<\=Q2MAMI_+<)_W23XJ-O_/O??5XXDXV;+^5:DW9N=_[;5M8:-&
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MN?Y=8S)"E'O)!4U*E@[,+B[$7Y6'@!EK6"L,A)4!0-ETO5A:[FM8R2^OI\.
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MH*3]^(.!FR4E<U14$G*QRBJK$$*<LU#;=A2(1QB1/6E$IF4@J$P9BP!8@N
M7\6L-IOQ?)8&5U=?>4UC"LZ>SB)DP9\!Q#\66TL)*7F7NI+BD'?V4RGW\GCG
M4 +>[\N6YCTY<SXB'#.1<6L/'780X '@\=W/W?22$D)]]SL?L?;[>=O?B"4A
M-F4#=S;I:_U@,Y)&8T#-XBKQ[*E;GSO_ &#CF4NK9C4TOO2-18/M$'Z\ZQ1=
M%<'1E4F,_9S;+(*'$,<J&%):7<91E$WY905QD+0M,9F18.,B5)4E09BI>6$]
M0!X[</+,\E* "H)*[Z I!&FIJ=O.//XEC1P^0F>MV7.3*2 DGO*0M:7+&C(<
MTU:K@0@,Z[C%*I^SUC&/Z>H1(K:]N8[D$6=3RITXN$1XDI3<9WOM+"VW&G6@
MI:6@XV.D$JW&"FDVHU+/RN0U"'_<1YYX[*DD_P 2D2AF2D$K=)*BQ +7%26!
MR@5T>W#YJ-$[&=:5L/4_$WIM/$EV-K%9MF%R(4."F,J3(*%)0E,9EN3'=><*
MEJ1ZAL;=*@1(P$TMIN2 0+#0[O?E$CM1PI+YYLET@N"M8J":B@SN!9)'UA R
M'G"T6JJY,J#J3A<R9(JOG-;">O6(B;""N0(C+ZI;B2S$C*E'L*DN=38<'0I2
M-]Q<<.FO5P.@]G_.M(R5VJX7E>7-E**FRC.IDNS9CE 3753,];5DW =:L,S^
MTD4-+D]#-OX577VEG35UDQ92JQ$]IMUD/&,"V6%H<'0]U?O"4J0DI4%<8S\*
MJ2D*+U+5 %A76E]:-6.W \8P^.F*ERU2RI" I00O,>\:-H1ZOY1+#[[K: L+
M'E)4=U=(Z?(*DD)4-PKI !&VQ)^VW'(CO+(JPOR ?U>FG(QZTQ24H<4+7YGS
M#;%NO/0%?.O*JJ#725?8NJ-E6C=E(@C'(TY,CYW$<6/E=FTXB,5MQWT%3LA>
MQ0VTQ(V5U)X]+^$2I"<H<N7(<DEJ!W T]>C?*3>T!PZIIG60I(2SY2231@DJ
M>AY,*,3$HW/-=B-'AMQ8.7./2,\IL6CWDS"%6W;DHG6-8_90(2WFX[KL=F8W
M"G" \J.XEP-I[A!25*R_@U> IU8$EF)Y;;7CJ/:7!B1G[IF!()0ZG<FQ&6S
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ME*XZ^RX4(/; W'N?ANT1 6ETE1)1E+D $%%?E+O;2/Z6_0*7QZ9@^VXX?/\
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M-&EY3?5E!$ER!$9DV<EJ(PN0K92&0ZZM*>MS_-H3ON5+ 'D@&\O#&8^4%5K
MF]!MS/0$Z"-9F+ER6,PA+O4G:NS>!N_GYJK:BS"H5-A2X=S3SV5ICNQG&WXT
MN(\A3;B.XE1;<!(<0ZDD;=("@">+JD+D$!JEW%K6OH18V=^D9IQ$C&H54%(
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M;72XXO;9)5U$@>\?P>)%PJ^W+]G;[165Q+ARR G&RU,ZBTR6:!)))K4!G+,
M 26JUJ-J/ALQ]J-#S+'Y;[SB4(CQKNN?D/!:"6O3MMR5+6MQSP$@>4_DCA_!
M8EO[]W(LWAZ-72)_FG#/BJE#&22L90$B;*)=0! 8*>KTWL.7I_4O!V''8\O-
ML8B/1RL/MN9!5-OLNH<4VXP\TY+"VW&EA3:D*2"E22%#<<0,%B31IA<WR^(T
M+ @W/*D3-XGPQ /_ %V2D@U!FR@S%B#WRS&C7>E:QYD9]A,/M2I.94<=$]LN
MQEOW-8VB0RD]!=C+,E*74!22E3B"4A0*=]QMQ'\'B9BRA(72X +V<4 H?3I'
M.KBO"Y0$V9CI*$K#@F=* (L[E0%2+U\&)C$DY]I_8P [(RC&EUSSKD=QY^UK
M507B@;OQU.+E%E;JFU#J;))V.Q2!OQTIP.,D,0%I*6.KUL;4T>NE;QF>,\$Q
M0#8[#S)9)2%?%E$%20Y2^=CE!?HU&,(<>9I W"G>AL,'%>&FW;)$:32JAI;W
M#3;DYMMWL!H+V:0IY.W5L/?8\048LDDE3EJEW)Z_GSTC-2^" %0FX9F!40N3
M86*F5TJ?R8\19.CLR<R(]C@\VRW0F,AJ11NSUJ;; :;C%MU3QZ604AM!^EO<
M !/%RG&)'=4L"M7+7+.6!N*>EC&,M7 EG*9N$4IZ *DDZ6#GR87YQ;<N-&&'
MWF7[? FRPY(3T2+"DZFU+:29R"A;^[9^KH=;V2%[D.!2O/#X6./>!F.JI(O4
M@!RSU(B4K[.I64?$P0*5$9<\FA !9L^CVHW.AC-DV>E%;WJYVQPF"H,1$*@2
M)%(RXI+'5*C-O1G70"SV' Y$0ML@!06WL.(,C'+#%4U0)%2["K,Y%]#1Z#QZ
M%8G@DAP,1AI2Q3YY:2 !F%,S!].@(+TC+F9%IM.BUTR=D6+/PB^#62YMA4N1
ME28P>83Z)UU\M^LCK?0'>TH.(4D>0H)X@2L8@E(,P$=TL>NK5=@S787>+'%\
M)G(0I>*D*0:I*ILK*[%V=3$@+J'+4?>"+>::+A6#<*YQ)ZG;[+MJW'F5+M:C
MYC(*6W;%*751D^I=CO*"Y W=)*R5GSQ52,63WBLG1W?<@4#4H:ZD':+2\3PF
M6"96)DI ()*%R\J<Q 2Y!(J4@!W+O<B,:GEZ42Q,KZJ;A<Y+R%R)]?#=I'@Z
MVA2E]V1&:<4AYE@K<)6ZA0;ZE'<>>++EXH,Y6U-34@ ARST:CW;5S%</B>%+
M7-*,5(4H+F*41,ED]XYE$LHEP2Y-@7H (3'+G1Z<_'1,N<"E&%U,1&WIE"XE
MIE"D*4S&_?%3;0<6EMII&PV"4].XXMDQ02""MS<.3<:AB*6CF5B."SYWPYN)
MPLT!1"0I<H@LJWS<VYO32%.98:35\UYJ?9X9 GH;Z7VI4JGC3@E0Z4)=#CJ'
M"A:0$[.;A2? W'CB!_&LPF36ZGTI3P\(E2N!)40N;A4J11E&4" +?W4T '@&
MA23E6 TT.,Q^T6.5,-]D*A(^95D.+(C[@AR$D/H;6R5_2M37TDGW]^,UR<0O
MY@HEW-[@UT\VCIEX_AN& $K&2I22'24KE)20:.D9CL0XK79WSV,QQ%V,]..6
M4$JOC.MM/R$6]>N+&6\@NMLO/(D=M#BD;;(6L*( V&WCC-$C$%TLHOHQLY/^
MVU;1TC&8&6/C?QTONEPL3)18JTHIA0VKZQR0^))3<O6IV5<M4_.=<L>PN7C&
MH:9V/Q&76;-.33C,I-H<I4!QQ5='[D-C=YY03L73[ [?-<<X<I:T*F=P@@YB
MDG5"G+"@;UZ@1^T_I3^I9[.CB6$P&/4J7Q*4)6*DR)TI*9TM"<04(F9LV?*M
M2E!FNQK;IU77VC:T0I"KS )<_LUH$H3\=7,>G(9;;:6ETN]]<@)2.VI:E.MC
MZ4%)\'Z>5A<6$(;XC9$L6+,D7( =B>FP-2_XGB^(\(F8G$3%XO#YE3YJB%39
M3C/,42#WG=RQ#7$*+V2:317;)AR[PEEV8I4>WCO3J1E^1VI*8\E-DE;H,A]A
MY1ZDR4K(5NE0\['48?&FQF$&U[L[@M=0UZ"\<_\ '\'0_P#UK#H-0H?$E AE
M,0>\]%7&@<M:*62](H[+(L)&#PXTU*IS"93M(VW,0IE+*ID1+C@0]'5'5VU/
MI"DJ;)!5Y/%PK'EA\2::6*U48E02?'SL\93QP(57,P@S'.,RI7>HE.8!2ZC*
M&Y$/>L7(62:8PA\Q@Y#B45I26*]5BQ8U#+90MMU;%=ZD/;**(K;KS<52R$-L
MDH;"$':JT8N8X)6Q>CV(#DAA0O4'4L82,5PB6,TO%R$ 91F3,E $$+RI<+(%
M :6 #U:'+7Z@XI8AWT&5T<\LM*==3&N*]Y3#2"0_(D=N2KML-'_\56R4^RB.
M.96"Q()?/2Q H=6=K^C"\=\KBO#)H[N-DJ(!*FFRBR0]2R@PW-@!UBPWJ;@D
ME;;+&<8VZ\ZK9MF/D-0XZXYN 6FD)EE:B/LE*2=N)&!Q-'SM4N0WA:WW?8Q"
MN*\,!88Z0[AOZTJH)#?WFKFVMASH[J=@Z5J:_;;%T+2X&G$+OZMMQHI<+;G6
ME4H$.(<!0I.VX(((WXM_"S_]A%]*TKM9N5=(?S;A=0<=(20*_P!25169FJO<
M-6K^$9<K4'$("FFY^744-<EH.LIE6]>PMQHCP^R')*"IE7]1P I.X\DG@,+/
M+C*JM- :[4%?.!XIPY/S8V2DD. J9*%#8CO6(L:CK&,=1\-#*)!S/'@VM2FF
MW?G=;Z9QYL)+K"'3)"%/-(4A:T!74GKW5L"#Q7^!Q)/]^S-7;;UU+EFO8<5X
M7?\ C9)22S_%E7 !(HMGJY#NQ! W$:CX8Y%DS6,SQ^1&BI07W4W5<XTP@J*4
MF0M,HI;+SG[ILK("E$)&Y\<!@<3F (74BXH10G2S&L4/%^%Y%+_C9)2E*B3\
M:2P U->6L5BZCX39N"/"RN@G.O,J6W%AW$"1,<0D?O5)8:DK4M*4D@[ ^1L?
M!\:'!STTR-4OH'MM7>WW$5E\9X3-0,N+DS%*"F"9DM6;NO0!;ONSWV$:6<^D
MO1G47E6U2Q7,M5\<P[';)&.,W&1Q)\&V>J7HN78Q/:'RV+(6^XZ[,8CP6W$(
M*VH[SJSNI.X\_&X&9,D8A*G ,J:Y9Q5"ZG5Q1O"E:_6=CNT>$X;Q?!8[#XQ+
MX3%R)X$J;*?-)G2)@&8J-"R!3<$.08E_3VYT:AZ=:9TTC),,OVJS"<6B0K*S
MD4K\J55?(:Q"7RW/<+\5$I#8<6R0/I6 H%)VXZN%X7$2L"A,I2@E,H)=)(K\
M) +:B^Y85V,>'VR[2\*XEVCQN+GXO#"?BL?B)RPM<KXG]3&3YA!)4 5$JS**
M159-XE24_I5#8CKD3\)@Q+&.VMAQZ12)39P$]"XZVNZX$28R%A '1U-M=* C
M8[;=,HXW^HDJFK/> +D9;!^3)!%;B[B/*FG@R):9B9^&EIFI!4<\EIB5 E0)
M*G(4W2A!8@QCQKG21I@3H5IA+34-Q3;;[,RE;C1G'PZ%-!UMT)8?E-)=7TA:
M2L()Z2$J/$E&+=LRRY%7+.W32,$8G@?S"?A0 6)"I5"I-0!G !4$FYJS@!B8
MO1)FD4I<I$"7A$S9@/34P7Z=Y9CM!2B_,0RZ>IIK=2^XZ"E)/42"">(",:"E
ME+#&C$[]#MN-XN)G %NTW"J*0ZN]*4R0+_/I5SIYF+ N]'I7=91<X-)-AV0Z
MRF?2K,_ST1FWD"0HR'$* ;:0L**3L$>?'%_A\1'_ &DYP5!W);4AM!2]'UBG
MQNSRN[\;"G,$EL\IS5DA@MR7H!>HO>/<*YT@H9_?B6V"U5BPE316Q,I(DV.2
MDEQM\I>;6A16"D@^5;;*W4-^(5+QZTD+7-4C4',Q<O6G/DWF(O+Q' I,Q*I<
M_"HF!V5GDA22'I\]P"7H^^\/"7GV)0"A,_+J.#UM(>1ZJWKHZG6G?\V^SW9"
M>XPH?PN)"DDD;$[[<8?PTZV0^1_$=QXC@$WQLD4!#S)0<*%".];H^X>,->HV
M'(C":K-<<$4NAE4E-[6&,'0AM;K"7?4]LR6FELO*;)ZDH=ZB %#<G"SU'*$*
M<FGEI0T+>;VBJ^)<-0@S/YA*RBC_ !)1#C*"'S$.'!-R 7J],EG4/#Y#,EZ/
MEV/2FH2$OR7&+NN6(T=2@E#LI8DE+:%J*6TK64I*E)2#U* X'!XCN@I6*L"Q
M#LSOW2#^'NQ,6E\4X;,!*<;)+!U'XDHM5G++H-'+5(BPUJ9A$N0S'B9KC<B1
M)[:8<=B]J7G9#SJ@VAEMIN6M;CBUD)0A(*BL@ >.!PF(&8E!9+7!#"Q)+.?'
M<>%?YIPTK0D8Z2ZC0"9*+TT&=SS&]N0O4C"6Y#D9S-\<;?8=7'?8=O:IMUEQ
MO_.-O-JE!:'D.@-K0H!20K8^_A_#3C4(5KH>NVPIR>+?S+AH+?Q\EP"X^)*8
M%P[]ZC!^A<;129J#AT-Q;-EF5%$6A*7%1WKBN8D)#FZVE*;<D!7:=;6VIM7@
M*&Q22"-R<+/)HDC4&P(J:4>U-SIK%)W$>&RDYEX^4D I<&;*30@,Y*GJ2&>X
M:M8A#F0RO'<BT-SVNIK:@OIE]03:RJK6K>J=CV4YP-)#"%NR@R7(RU-*='<W
M;2OJ)!4#QT2,+-SLJ66#UJ&VN&.C>ND>;Q?B6!."697$$)*P4H*5RG?, Z>\
MQ4D&M:/O&HLG.]0[?3[3.CP.DETKNG[F-_.7YUECWR5B1%J'8TA,]4>4\TU!
M;GI0L*):6KQLK?<<>OA\++2L&8!1)>BG4VIO46%7;U^3FXZ9-P*1(Q\R6,.N
M45J"\.<RG9U]X)RDUK1R7WB&L.3K_7V6I-_37?ILNS-W#';">C(:*3?3S"1*
M-VU0!EX[,)?:CB"%-J4BK+J22K=0[58?"T"D(9S1B1IHVQ(<N]-F'ER<;Q!1
MF"5QF<5KRDY5X8JN_P#3 4#0 NSD"E S332:A<P3CMY^UFH;";&/APCT$+%<
MAQQRLMK:4RVR^B4JQ>]5!R6#(2X6PA*VG5N.;(!"=L%X/!=W+)0XF,04J!8"
M^@(YV/E'=A^,8^3,,R9QB9B ,,H(DF9AB"L$ *4$G-\1-<P <'H'@ZZS;FC@
MH9,G(Y2<\KM/LCIC/1=8RBP-Z[E%=+IDJ>?6VZFPE5*)3<[I;#*TMM[(!V)Z
MI>!P609I,M[@LJV6A:VSBC&K,(\'&\<X\N?-$G$8A! *0RY8RJ,S,W>NP! H
M^EHD7$=0>;Y2=&W<CRVHQ^A5E>1R<OFY)91%R[N@D6%?-I.Z[&=:8=KFJJ3.
MBMR&E]"5,,]95N..69@L*5+"9:' 478T8D#H^S$6>]/5X=Q7C)3AOX_'3)$A
M\P6LR@J<HE"TB9F(S)(*D@AJ)4!5X6=7M-:S5SF?I<IL;6/7Z84^#5C%YF-?
M,QMR/:Y-69)#R6NI3;KF^JJS+=K(C!E1DJDJ8CKC "/)?4E+E*$D!(!420);
M*)*7#T #D)()&[@&L>OBCA,1/5./$2@)"<RTS) 0%920ZBK^]0+:V+,DF&SD
M=GS+YO-U/H:C,9\O'WLRPRWQEN'D5$BP@XY4ZCJ8RUB*NM?=;CUB,476S$NK
M)5)8;27NAP]*LYN#P^5"UH22H@%@H.2"3<#D6J7  O'EJG\0Q,W$2)7&<0$)
M"IX"5X8Y!+7E85+( (K4,D5#0WM;E:Q9IC%Y'3E2\CO*K6?#KC#JJ%D6/.P(
MN*XK9&<SD%/(]1WOF+\5"FI;*BH*F!GQL"%;HP6#*0?@R_EU"G"NZ/J3JU(X
ME8OB4N>M*^/XAA.04I3,PQ3D25NR@JQ2E)(H5$UK?HMH;J-(:TTQ9.K65TU9
MJ!&@N1LGAV5[4F4B=&>=0MZ44RDD/RX[3;[WT)2'E. !(&W'AX_!A:\N'0 D
M$*!0"Y%0S-:Q8]&>/T'A7%</*DH3BN))5,'<69LV2%*6.\H* 515W#72S")K
MGYSA]<F-Z[+*& F6RF1&7*MZ]I<EAX M/M!V2GK94"$A2 4GJ W)X\Y/#YQT
M60Q%00*-2WDS UTCVL3Q;ATM"3,QTI&8)*7FR@X()!!*JUVH:\X\HU"P1$,R
MW,PQL14N^F7-1=UH92[MU=GNKE]'<2GZNC?< GV WXNG!STJ+I54,Q# =-/S
MO&9XKPSX0F#'2 ';-\:47(#D456]+OSO%8N<XA;-31 RFBL&X;:GI?IK>KDJ
M8C(4DE]X-2' VWO]/4[TI.Y!43Q=.&G)4/Z;N>;.1J1^-]P8F7Q' 8A"FQ\I
M64.HI7*4  1<I462]"2PJUXYE81E][0.:X8W28DY'L]0,PRF?26==<XXVV[#
MG5\V)"D1NW+=><D.RE,=EA3*VPIY1+1\#CZ7^"E*3*SA+(#J%34@$: 6>Y^A
MCXJ1CI:9W$)2.(J/Q52S*7FDY@5.DRT#,]%,0[DNR=#$,6O]-MSE&D$VZL:'
MHP&TQJTKJ]5]1,TE+*:P;(ZJS?MF$O-/_-D91.KHDA("6%0B%AHJ3N+?P$D5
MR(#/3*2U'- ^@>GU>/EL3CL;_$RE2^-3 E&4A.;#959<J'6,P))41G!*6+U:
ML2A7YCS0M(KH62ZB)IJN5F5>;MYN_P =.:UT-K&E-6#L-J4XB.[BC^6MN+:9
M=0'36%*ENAI2UHK_  6%?O2T*.3,"4G*S$L0*N0- X 85,>O+XCC4RTIF<;G
M)/QN\Z\,)Q+Y"!5S+!-!9^\X2(L:DY)S$33JDMN]EVV(WEG6.X J7=XTBLD2
M\7SEV)9QH+7>#+<"5B4?YB1WG73804%WM/!Q LG"8-P!*EDL"IPHLXH38:BY
M!N="V>,QF-^$J8.,XA*)JU&6L+PX2?AJ[R4$JJE("DG+J +W9%)J;SF-1]4T
M0,G2^R6,A&*6&1W](J+7E>4.MX^&G8#H,66K&%/NQT/$(<DQXZ 3L=ZS<#AB
MQ^'+#.Y -7R[.3U.I-&=_&PG%>-HF30GCF)7+6D(4I:\,THD$I6#F "CE4E+
MD.'8%GB<=<$9?J?RTXAARK2JSW5-^[PB=8?*W:>PE0/DMU$M+.QG0)<H*=[%
M9#>7.;;(+Z@HE*6@YM@C#_#F*RI^'+8#,7 65:)I4/0.VHJX$?9_Q,O%X%$J
M9Q(SL0Q45(5)5-"4DEU)2HAPD#,0*W(#0W;Z+J!I@]IOC&C6H")E!&ENS,O?
M>O,9KJV4]:6C+MR'J]$E7:=;9EO")$BN!AA2%(9*GCT\="),I:5'$)!JR,P/
MRZD4<@WV>E(^=Q,W$8>9*1P_C,Q*0EYJ4S<,0J8H?W9EZ"C"J;W-$7 I&MU#
M(AXUFVH<V/3N1]195I =OZ*=(EV\FP>53UURF8\V\BC?J7V3![24.(4I27AU
M ;S_  F#()$I&@)*5 $>9W/GH(2L3Q&64IF<;Q  SJ*%3<,5?+0+2HAAL?[G
M)V,2#R4VV>Z;U4S%-4IQQO#6*> [B:K6[I?1NROF=FNT13/"2E#U>M#\=S<*
M5T*'3OL-N/+Q_#T%:1AI24@)(4$O18+BI<VIS)CW^!<0."*DXWBJURYP2N3\
M>9)0D@$IS2R"G,"206<7<BD=#4:A84J.N8<QQPQXSGIW)8O*PLH??(0PEU;<
MHH2XL))0A2DD[D@;#SY/\!/<C(MR"10A@!6XT:MF+[Q]NGBW#3*)_CI)HEU?
M&E>(^>[>#>(%6=0,+DJ>]/F>/R"RVZ\\&+FM7Z:*UL%S%],E70RVI;*5.*V0
ME3@W.YXA7#\1F'=6 0PH2Y-M*&['5C&:.*<.4%K_ (Z4H(402)LID@$$YB%4
M#:GD':+L/4/$K&5'A0,PQN3*DK+;$>->5;LB2Z5;EMEI,I;KBD(4A1"$D$^!
ML3Q8X:;+#F669RX.UZ-=CY$D"-9?$>&8HY)/$9)43E"4KE+)H*?.0')  YB\
M/V$%);<"GE/_ +U1"U_Q $ ].X ! .^Q&_C^[C&NH9J:]=>O.FL=:9?PPV8K
MS,IR1K0,!06ZUK$(\R6/1,KTBS*CG":F+)KXQ#D!\QI29#<Q#T=V/(20II45
MUE#SA\ HW'GR.-I4P2R"=_Q]?%[:O'+C)*ITE:!JDCT5R-GO];1P\U'Y8M,M
M8<[O=1,S?S6?D>1(C-W$F%F%A#CK17T]=2,N,,LD-I2MFN1W D J<ZU _5Y]
M?#<4E2DU- QM0VYZD%F_S\%C.R^+QD]9#JS&[ESWE-7*[-;0@.[1F9!RRZ>Y
M7A&%8!;R,O<QG!W9KM%&AY78HEM+DI;0H/R_XRDAI/4E1(&Y5OY/'6>-R"IP
MU6>VCO3-;:C"L<N*_3A>+P(.(Q:Y)3,7EEA<L"J0<P"D/5F)#_*&-XI7<LFF
M]5I?D.D<5S+VL-RFX@7-M#.76+EB]9UJP8KT*?X7'$?PIY ("DJ'N3XJ>,R0
M78.UZ?=5=WT+M&^ _3$(P,V5_,EY%G.I'Q)&512$A)8H<D/L?K%G3+EBTSTC
MRA>687(S2/>B#/K/\IRZSL(ZH$]KLS%)9=44,J#6X0M(!WW(\[<9+XU*4JP<
M#U%-55=@.9(BF!_3=&'"LO$EI4F;-(9<D$!5&?*^NQO>$.CY0-(,<RZNS>L.
M;)NJV^:R""ZO-;1Z,S/;D&2VY*C*44&&A\E:XX!!/V\<5'&91%!]P>C*_8MR
M$=*?TYDI4%#B"P004D*DN"""&9+49W+;$UB]G'*)I+J%F&1YKE#N</WF3S)M
ME<SHN86<2'(GS#^\<BQD$):9<3LD!(2>G;[\:IXU)"<K!G)#!RW@O;D*:4CB
MG?IG+GXI<Y?$5J6MBI17)J0D@DG+RU-BU0T.'+^6?3O/*'!L8R&5F"ZK3ZG?
MJ\;BQ,JL6WF6'EJ<Z7Y2=BXG<CI2HGH2 D>$C:W\ZDN6 J02^4U'_F;6W[QO
MB?TQ0N6A*N(K*9:2E SR>ZDJS$!T.Q45$E]34.7MM\L^G3>DR-&"]F!P567(
MS40F\LLOF7[0-L)C&:W8D]U,$,H[,EE2NE10L!.W&*^,R<Y( )HVM+LQ5:H/
MC6+2/TXEHP*,/_,EY!,6O)GDMF4K*5-E?,S 4=O0TNY:M.-)+VRO,'DYHS/N
M*"WQN<).664]I%):%QN>XQW2H172DEEDI'6&$-;;;>(_G$DTR@BC6OFYD5=J
MEJ@Z4BF%_3J4B82CB2TDI5+<+D@E,Q"D+!&5N^DY3R)L7= PCE$THT]RW'LW
MQIS,XU]C%LU:5$F3FEI,@LO,;KBKL(RU%+T1CJ'0PH'I<W_'#^<R6L&H0? \
M^A/(-<4HK],T)QRYLOB*T+SRU(4E<FA0A+$'+2H>YYG2,'*N3'1W+LGOLMNO
MVV?M\EMIMS;N)RVZ99D3K"4N7*?;8:D(;;9>?<6ZRE*$A+:T#;??=_.I-,J6
MHP(-*>(VT_,6Q7Z8H6ZE\14HJ)4HE4DJ*B7*B<CN222>OA=U<Y9-.+O J6//
M?R]R-IWAEQ7XNVG*;=A3".Y8V7;EK97U3-I3ZU#U:R0CI0-D)2!T<%QLK%\3
MF)4'=0N*'N6OJ_[M6/GNW/Z?RN'=EL+B#Q"82F0L)/Q90*&Q) 9DA3 DJ8N^
MI:VF?PP=(*OFJR7-]&]7,BS"PP'#J=G,:2BKLJFUJ(M](L&ZR98/JBK[SRI#
M7;2>IP@D'< ^>/L.TAE8/#2URT(S*H>ZY(!O2@;6K4H'C\@_2C@2>-8[$X7%
M\4Q.)P^&(F(E)G2@F5-F) *R!_NH*@NHUW'>S&?AC\N&'8YG>)T+>=-5FI-+
M$I,F1.S>YF2508DU%DW\NE//ERL=[Z-O4,E*UH/1[ \?G@XD" X2PLSNU*FN
MO/E']*S.P'#Q+FH^-,_J)"5@S$V"B6'= K5R]0:PFX#\+7EKTTS*@SW&/Z0$
M9'B]C\PJEV>=W=C7HD.1%1$M2X3KZFY##C+A4I*@4]S97YXL>(BK)H6H'>G,
MEN=1'-A_T[X9*6)DN;,)2O. 9H+Y2[,0-@:5( #;HMW\)/E9O[VVOK)C4E=A
M;S'K&8MG4*\9#TR5,:G.NQXR)(0EH.)#+R$C9<=/;(V]^A/&U(2E(2APU"Y+
M -5S<Z;;D14_IMPI<]:S-F K4M>83Q\RE$O\E D:-L8=>J'PQ.7/5[,+#.\P
M.>&]M&J.),?J,TN:: (U#6HJ88;BQGT-M.^E::9?6E(+@&ZR5;GB!QM20PEI
M*6HY%2Y:NS$UOT,:XO\ 3KAN*6J9-G3"M1'=3- H$L6HS*8$;/0-2+EG\,?E
MTM=.<*TNFHSS]EL$N[;(<>[6<W+,^+9WC_J;)=C:(D!ZPC+?"#&CNE2$=*
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MBA9@]+E]K1CC_P!/.&XF4H39TTN909,[+E$L)"0[$MW0Y=@>IA,F?"RY:++
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MG_:GR'KO%R<U%5&Q @4XM04%*)"R"H'[E(V!/\AXXCX<NO<36IH-/=K10)2
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MEI&_0VE.Y).P W)]R?R?/N>(.4T)'1[?B(  =@ ]VUZQY$9@**@RV%$$%02
M=B23Y]_))/\ ,\'3NGTB,J026#FY:L5+#)&Q:01^J0?T_P /OP5\I;;T/[1+
M#8>46%1V02D-( \>  /U^WZ\8N7?6##8>0A/EE:5Q0TLH0XXM*T).P5LGP%
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MVRTR"EIM+84HJ(0  5$ $G;[D >?TXAR;EXA*4I#)  =V&_L1$^N)/\ 1EF
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M0Y!CR\BA5#6-1*IB5-8:BM2(SUHR_P"E<=2TN*_/0X%-]\J6I,M:B#WD@W+
M._\ M#TT)ZF,9^(E?S' 8<)S&8LI !":_!4HDER_>N"0*'I$=_%0UXU-T>S7
ME4K-/K]JD@YSJ(FKR=M=9 E.3XCECC#/:CNV+;@CK[,AU"C[@+5[$DGXKM!C
M58=>5"BGXF4* IFK+9G(>O)B2:58_P!)?HEV=D\8X9VSFXB0F:,+@L"9:B3F
ME%6(Q*5J"D D.AW*2]B*L8VBSOD<P/6=VUR+.<WU.M'<IQC**2- 3DY]+C3.
MH=5\LR(X\/0*[ CP%%NO0$]EIH*0VD(Z=OH\'\B"Y+I222=2+/Z<^AC\%XB
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M8AB_(QJ4]K;I-5:(Z9X,K$WXN+YJN9AVG.-L6K#T!-E5Y!C%E3RK$3H4(/\
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M]1;E'ZO+1-2E*)JBN: RUJS.5 7.;,I__$38:%@\]2OA;:@YS>S+S&-8] ,
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MB:7YN+LYTQF&.8VS5U-V\MV'DU/ DWBH%J*?&4"HL$]#]DOI*162.Z2/P68
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M%C<>%@$@*'D D;['@P-P#X"$'99)22TWN@I*#T)W24A024^/I*0M83MML%*
M_B.YAL/(0BA88(Z2RT4]M3726T$=I>W6WMT[=M6PZD?PJV&X.W$VM3]K1! -
MP#U /NP\HN=*?P/[AP@PV'D(KPB8.$(.$(.$(3UH2#W.G<E1"ST@]83_  @^
M-U ;GP3L/.W%I9=.57,C?G?4WYU>,U#*K,DAR ^Y8?0>ACCG\3;02;K%F7+5
M:0M3-.\$.(9\+)^)G%^U5R<D9^:8VX:G&OW8<ESG%0GE=ITE!<<8Z@"@ ?#=
MK94Q9DB60C*;@Y"0%2[D$.*%S4@4%(_H'](>U".!R.)2S@E3AB$GXA1A535$
M_"GY>ZF<@9G+@,:U8DN9DPCX>FFTBTU<R36BP@ZRNZI9;/R:IBM)SK%ZS!(%
MLS![L*BA_P!*&35D"]=<K8+SFH&)UF$9.MV'$=3,;5%84CZ+AX6E"!G4S)!"
M5*": FP-06<$BAJ](_"N)A,S%8B:492J?-4' "AFF$Y2+A@P(%OE=A#LL>1/
M22AKKI[2:N5AF37F'6> V.39==ZC:L5EEAF;9.;K/H][AN0:JT]5F62Y>X0M
MK(LD:LK&MEK5+1(MW6S2/=\Q)EJ*D/+42Y*.Z;-=)!)95*O5A>.>42L!*B5C
M0+.87)J"X H"3E%@3JV9DOPZN57,9>+V.08AG1G8CCFG&)U:,;UJUEPR"U4Z
M<73F08++5083J!14_P PH\B?>O6Y@B!^/:+=MFG$3%+D'4I!J?H#]B>7(;7B
M/VU_>EOK%FG^&AR<4+-LQ5:;9%7IR#%[/#KV='UAU=3/NJBZA.U4MFSE#/U/
M3K%BJ?>J6[64MV6FL>D04/&,\M!94[ ^ _$/#:_NX:_K$IZF\H>A6K.+X%A&
M<4.82:+3*,N-A3=#JQJIAMA$CN4*\:_RJWP7.Z3([THJ''6NNYL99##CB5*V
M6Z%F&PYVKZ6MY1!2G4"^@_'H="VHB(7?AG<GKL-^!*P+-)[3\VIFR6K;7+7F
MU>6[2U,>GB 29NI+Q<:A5L9AF&PM:X[2TD)2 2.##8>GT;J\2PV'E[?[5AS0
M^03EFB2LOD5V(YK&_;FEN:#(XC.M.L8B2:?('4/7=?75[FH!@8T](DMB2M^B
M:AK<<4IWNE2MR"4_[4CP'XTB&&PYT'EUATX#R8:!::Y[2:EXECN70,VH:UVF
MA6D[5W5G(E2JEYB/%576=5=YS.JKF-"CQV$P/FL:8(10I4=*2>)B6#V&_/W:
ML;A<(F**]C_(_P"'$&Q;:$8:_P"%:@%?YI2OI3N3X/L/8G]#X)\'BJ10A56.
MM=!O$&QZ&-%OB%:>*U6Y3M5,%:RC%\+=N(V.H5DN:VGR/&XB869XU/=-C8$+
M8AQ;$QTQ&WW&UMLS'67PVZXG;C@QZ'E3DLD$A;UROFHQ=@Q)=R0*$T:/L^Q.
M(_A^+82<H+6E,^2IT2_B$&64S0H!(^)G"4*2D2PI:RL('S!TM/+)1Y[I[HBQ
M<Y'8/R\2TLDZ:Y:K'I4Z!"U#T^SO$:O'LNIWIF/V5#:4$C(5U#%Q291CUW6K
MQN9#<%6ZQ"MIG>RX?*82LH"3D2.Z"0:I!4:W+&KA.G=H8\KMO,$_C6.FH4M*
MU8V:<V5*)A09T]:I:E2R@A.95/B$*"AWR% QA4/P_-(<4D8Q38:PFLTZJ\RQ
M?4/(L1R6YSW4R_O\QT\:KH&!2ZK+,XU'LX^)TE/6UT9FSHZ_'5(M/2P6'I9,
M5+Q]!:2X!)(U!+@BH((=J_?6\?.X>3*EI*TRT!:GS3<B0M68 NM:1F4Z@Y<F
MM=7*G<_#=Y1[_,$YQ+P3,6;\7\G(VET6M>LU#40[*?;Q+^7&;Q:CU#@8PS E
M7\*+?3*YNL]!+MH[4^1&=D--K =VB7 %F<?>C /[ILSWT>[T&VMR:AM+UA-U
M<^'=HKF])GKF$QFM/L]S03'7<LF3]0LLI*6192&';:35X2QJ=BD2FEWR6&A?
M6^,7.,75F4AQZW2X$K1*1F4"JM14A]R+GK<M<FCQ50H2"06H:CF68BH-''[0
MEX/\-W0VDJZ1_/$9'G>=5-')QN5FU9FFKF&/R,?L&'F5TD-L:D9%;/545M]T
M5[&19;E<VI<6IRNN(3G1QME279*10UIJ16H VHP^T8=[^Y1-6+U:PW)?<UM0
MZC8'1OEOQ'1_*G;VGFVT]3..56%8E%NI5I;'%,-J5./,T$*WR&\N\HM7'9"U
M29EE<6$D//'<-I41M+ 5 %ALXY<V9MN51!(&8$ "N@K71]C8QM3Q$=$'"$'"
M$'"$4V'X']PX0@V'X']W"$44A"P0I*5 ^"%)!!'X(((/]O$%*3=(/4 PB@:;
M224MH!*BLD(2"5J 25'8?Q%( *O<@ $[#B810LM*5UEILKZ>CK*$E70%=01U
M$;](5]73OMU>=M_/!AM$,-A &FA[--C=14=D)&ZE$%2O _B) )/N2 2>(8;"
M)BG88ZBOLM=9 !5VT=1 4I0!5T[D!2E* )_B4H^Y)X,-A$,-A'KMHW!Z$;@]
M0/2-PK8IZ@=O!Z24[CSL2/8GB8EAM'H)2-M@!TCI&P'A)VW _ \#P/'@?@<(
M17A"#A"#A"#A"#A"$^R:?=CN(BOHBR5-/-QY#D5R:AA]QLI9><BH=8]0PVO9
M3S*G6@X@=(>9)#B88;#RA'-S2[X;>D6-4&7P-65G5+*\PR6PR%W,8<[43!I]
M&VYD<S(Z6KQ"*G5W,9.$N5=C+7)B66*7E*AV2>_\MA.)0D0$IV \ P\A^3>(
M8,Q#MRJ=^A)U_P PY<F^'KHJ_!G56"TK6+0<QIL<P[4BNR&VU!SQC)M/\=O)
MV3L4<*#9:CMT-%D;M[,DVCF:/5UC:R),F0M;A>===7+"E -+ 4M5@=*[G6(R
M@.P&IL-;MU^\+><?#TY7-3,PG9QE.,:@#(;.OI:N4O'-;]<\(K#$HL:LL2J5
M0J'$<\HJ*)-JZ.PD1X[L2,IR.A3BFE(#[I?J9<M39D(44OE)2DD/<@D%COOK
M%@Z78D.SL2':SCE#:;^&/R:0*V?75^FF455?=P<8CWOR[636RO58HQ5BDAT-
MG(5"SETV60PH^+XXR),W>4[#KX3#SSJ8C0;T!4!0D#D6?5V!Y[-%,B'?*'N[
M?=JG=R27.D3!KSR<:#<R@H(^KV/Y=>MXS6W-# :Q_5?4_"6?E&55\&BOX%K'
MPG+L=:NX=K4PX2)J;M%AZA,5U"TI2X^EZK"[:W;9HTS*8@*4!J H@5Y [O7K
M$35_PR.3JNGQ[1&G672IT.W:O&I=[K;K==%5M"EUKT2T>-OJ1*4]/C/T4"=Z
MS=4ASI<0M92Z0HP&@JVGNT587:O,5]?;4 A85\.[E4;CW$-C"LQCP\BK*RHM
MV(FM&L:&C5TEY*R.G@0&QJ X(;$6ZGRIB&(YC-(C3'(J4]H=H"E)8Y4N.0]*
M4L/&+A<QFSK;09E, "6H[>3<ZQ*FF?*=HEHYF\O47 J#*JW+;2G72V]G:ZE:
MHY>U:P5R52CZVHR#+[>JF2VWUK[%C,BN3XC1+<9U#:ECB7-:G2FC#WS\(S8.
M[#=V<O38/XOX4C9R,D)2M*4! !&P20I*MQOU=12'"H_UPX5*!\ [<0 !8 /=
M@SQ:,GB80<(0<(0<(1$6N/\ R9YC_P!B/?\ OV>$478=?L8Y3M>SG_M7/\>)
M-_!/T$91=XB$'"$'"$'"$'"$'"$'"$'"$'"$'"$8-Y4JR&BM*5#[,1VSK9M>
MU(=#BTM%YI2"ZZ@?3VTEWSOLDI\G?SQU<+Q@D8U56*2 :FY0&_N %SY<XX,=
MP[^=<+XK@F<@(2UQ_IE=0$+YTR\K&&;R/\C>I?)#E.1ZG0+>NU2<S?&ZK'12
M5<&S8DUKCDEFR]8LLPG&GFTI^CN=>P(/GWW^FXUQ1.+P^1151F#T+*)-7-'Z
M.-*O'Y)^EWZ?S.R6-QV(S25#&,LB6"HH"9+!*GD24I420X!(YU:.J-7JSJ5.
MA7K\G2^WBO5\9*JUI3-NDSGDR.A0 ^7D$* .W2=R#[_GXX%PXL>GV_)C]P0K
M,D*H'=QLQ]WB_ANJ^H][?P:NYTSM*.'(=4'[&0Q<%A#(:4IP;K@A(6'-D@DC
MP0/'CB8G7W2]?M"58:QZL-3Y<6#I59OL1YO9CRS%N B2SWBA;H!K]M@CZAY*
M0#PKX?7G>VEKQ/LQD9)JUJC56KD*LTMM;*'Z6JE,R66;A8$I^.ER7&64P/(:
M<)24^ -CU#;SP\"7Y>/H+^Q"%:UU1U!@8EB]S%T\LK&WNITR-:4S4:W3(KF8
M_7V7%;0>M*%!.W6>D+(W"E>2(_-.C>I.FPB']_2H][M"97:MZE2:._L9&F5L
MQ85:*<5\!4:XZI_JI3B'RE)@$KV0-MT[[[ GP/"H)'U%N1WZ7WB85<%U1U$O
M;*3!O=-[2BC,5LF6)LB-;J0]*0DJ8C([D  +6=D] \[G;;?B??OT@[_7SAM,
MZS:L*EI87I-;*:=D,,(D>FN4(1U2NPX^X! '2@1O\HV\ ;[^PW*$+^::J:C4
M-].J:+3>TN($1MER/9LQK=UF4E8W=2E:8"DJ4@D@'JW!'OPJ_3H7YN"P]?"(
M<?YH?(QZR?5#4.E@X_,J-/+2Y?M*UN191$1;@*A2G%@+85TP5=)0V=R/I.X)
MV&W"#L:T&[Z[16!J9J!(Q.\O9.GEE'N*^Q;AUM,J-;]R9#<">Y*Z#"!66R3]
M80?MY XT2S'3H0Y'7DW(,;:QBK.A8,P'*XL% ,1H#W?-R=#2G,KG;TWR#F+R
M30VVR_$-0<;EZ;9>WDE3'QO%+G)43Y2)M7*:9NO30VU4S"D0%_O'E/)"2HA.
MQ&_S7&)(GE(4*)8&@+D%-@07VJ=K.8_<_P!.^+<"X;+F?&4A2IK*:8<,\LY%
MI+*7,=BIC\J;EN\'CH%3:NZII14UZ])+@Q4OL1%R%Q;A*D0$MI2)&QK]T*V\
MC8@)]AML!QZ^"0 E(TRI9V:RA1QHP.@ZB/QOB2@<3B%H(*5SYI#:I*R7!%33
MK?5Q"Q>:M:FU]M:U\#2BRGQ*^RLFF)S<:W4U.ALM]4%]I7R\I*Y75TN*"OK'
M@[C?CMFH&AVV-@+"@I5XY\/6[.]&+%B7&CTJ7-C4"S+66ZG:@4D7&5TNG-E<
M.W509-FVF+;I%7/4$J4P^! ^E1)42%@;^Y^YXSKY:Z/T_>MM##W[](3#JQJ0
MC''K,:7VIL6[2-6M5YAVQ=7!57I=<?Z?EW41W"3OMMOMOU$;B?#0'S]CSB'M
M45M]O3SA2PO4O4&]%V+G3JRHFX57,E5H?B6RS+F,*"8C!*X "S(;&R@"5$#;
M97@%[]W@#X\_9UTO#?J]8=59=E6PYFDUC'@2'^W*E&+;!+*5K'6237A(2G?K
M._@[>3]^$3!.UBU4C6%A#8TEM'XD";,8:E)C6ZD266'>W#=9(K]NAUK98"3L
MH?<CA[][_:$.#+]3,_I7:IBDTXLKE,JN8GRULQK=(B2G0"['6E,'9*TE1&Q&
MX5Y_'$'4"[4V_$(3'=6]3FZ"#:M:86KMO+LID5VJ[%NI;$9EI@M25(]!U)2H
MJ4#N G?J(.^_$^_#V17\P]_F+E9JUJ7/I+J?)TOM8<J B*W$B.-7 7++DA*9
M#J 8 44-I)/4/8)]QYX@NQZ'DU/?K6T5462H[))]"T9^&ZH:AY!?Q*NYTWLJ
M&L=B/JE6LAFU0VPZC_,?6[!2WTK( /4>GSN=QOO:74 E5=+"OE]NCQ4J_I!5
MS0&[527W+N.=/.-..;L9IKUR_P"HND^7:=YAB]'DK6/Q9.0XU17.4SH"JS+<
M;R-A$.JB0X[E@EZ1 8CH+028X>4E"FR2>/,QQ40L,X((+.X<DU<M>Q-G(%Q'
MU78^8A.)DK5,RS$+S2T9@ 5!,JB4T5\I6:$.$ U2F)CP'.=0,*P3"</JM+K:
MQJ\:PW'*NMER:RWCSI<6MQNHC,^KJW8"W*MSI92@QU/.!GI#82.A*3IPY) 3
MW11+.W>((00:Z,S,:4 $>9VJF!?%)JD$*$R=,4H,"Q.(Q(6P!9@:G,27))<Q
M,>2ZE:@5-;C#]7I]963]K6)EVT81;=Q57+2H+0VH""KH5O\ 5]02KS[>QX[I
MJ'"C0L35GJ*[V>VS<X\G,R98-R$#2Y !&A<:N*'Q,)C&K>I+V,S;E6EEJ;.-
M8Q(T6I=BVX>?CKC;O2P#7!6R5;D+  '@[^..?WT]/=(T->@=O4ZGWS,*6'ZH
M:@WLBR9N--K*G:@U;\J'ZB+;!4R6A!4B.AUR -NM6R $^2/ &WCB4.XL?2FN
MNS_B(4:*(T<V\!0./=X;\#5_55ZSA0YFE%DQ&?EAI^:(=NI,5LNA)<V%=L!V
M]U$#8>/QQT5U#]:VJ;%NM]XP=F(VVY,01^;WCW:ZOZI5]M.CPM*;*;$8E2$Q
MI28=N"MA)';>V%> 2XGJ4?L>GR/P^_YZ\M?Q$I)<"S%C0.^KDZD7-_&'-F&I
MNH%([5&DT^L[AJPKHDZ9VXUNM4*4L NQ24P5=/2"H$;#90WZ0?>/=HVA%_I>
MU+...7*-,;95BNV?AHJ%1[@/-PTPXJVY*D^AZ@''5*2%$=))(!)*CQ'+6]J7
MMU_RVD/?OWMXYN/:K:DV,#(Y=CIM9PEU%;'DU\-<6W#UC.>DM,N1FUF "L--
M../%*=U=#9/MP'NGUY^VAX/[O"=0ZPZHV=U30;/2NWK(4^9#B6$U<:Y*845^
M2TV]*(] -NVT5**MTE/D]7Y5?Z4^\(LVFK^K$.VM($32RUF1X<^;"8G(C7!:
M>CM2 BOD-I$ @]U!#CJAN%-[D^!XF$*F7:K:F4=P*^FTVL[: W$KWC,:BW"P
MZ](9"Y+*5B 05LOGLG8[@@CQ["-/Q7RZ=/"'7WO&/(U=U,;QVNN(^F=H[:SI
MUA%DU2H]N%P&F$1C'>=3Z$*2EU2E=/4G8^=M]SQ-:C7U!Y]-8BF][5I^']85
M\?U0U%M:3))MAIW80;"F89<KHCL6V;^9OJ/[QMHF"GK[8W.R0H_IMXXBK^Z>
MZQ,(N.ZNZFVUQ!B66EMM70I#;G=DK8N0 XEIQ9"28  /6E"0?;ZC[;\3]-_M
M3I[JQ_/;[QA(UHU7^8(85I+;EIV0VP7!%N4H;2)09>="OE^VS<<]W<GS[_??
MB*_@6]^7TA&9D&KVJ%5:642OTLMK"#'<<3#EM1KEP/,!GJ"]Q 4"HND@$_9.
MP]B.)K['[PA:RC4[42FJL4FTVG-C=S;:L;EW,-MJVZJM\%"?3K"(.Z'%)<4K
MI6E*CT;[*"=S'OWS\_I"$Z/JWJ0YC]I9O:7VS<Z-:QH<"L,>X#KT-Z-)<?E$
M^@"EAIYEEK<^ 7@? .W$[N^C>/U^E;T,1LS$:G\>/.%#$-4M1+Z98,7FG%G1
ML0Z.?81WG8UOM+FQE,)BP4;P$[N2%N=0V\E*%)V4#MP]V/L:W\WN>W/Z;\]/
M.&W6ZRZJR;*"P_I1<1V'WH+4M]<:YZ6@\Z4S%]*H'2E++8"TGV23[^>%??3?
MRJUM(EQO[]@^47+G6#5:OM;")#TKM;")'EOM0I#<:Y"78J2E++Q4*\]94"2?
M)_A]_N(KOZ>]/7R*%[+-4-0Z).-_*-.[.Z58U:9MNVQ&MSZ"2I:$JC*4F">E
MQ*5$])*3L"=M@.)A[$)W]+NIW[-KMCI7:_,Q:&+'KNS;]Q4((ZQ)6GY?U$=8
MZ 2/O[^>(+\AU'HSCEKX0^FGO6%C$]3<_O&<A>N-.;.G7653DRO;=BVJC8S5
M;I]&R%P!]0"0LA&Y(/GQYX5Y'T^Y\?O:#C>U^4-JGUAU0L+6N@3M*+:'#F3(
M[,R6J)<[1HZD.>H<(,#Z$IZ6CXV'U'R-^)((T\Z1#O:O2+-AK%JJQ,EQX^DE
MG(CLO.L1G4PK<(6DR4--;'Y=TJ;7'W<<2/!Z4D[[<(GV84<CU9U(JKH0(.E5
MK.B-N0BJ>PQ<+0IF7Z9M]Q*A7^78S;DI*E;]24( '@<!T/[>L1Y5^MO'00H6
M&IVH==A^,7,736PG7MLY8+LJAN':H<JC&G/1(W<0F 5),JN2PZG=*#TES9*D
MJZE*Z0VVWYT9NKFT8-;JOJ5(IKR<]I;8QI5<[$%?#<B6RES!,]298:2:_P#_
M "ZF&>OI\;OIW&Q.\5ZUKIS_  (E_?VC*PO4_4?(KQN!?:>6%)6&%/D*FO1;
M9L(>CQ77&(_4J"GI6Z^EM+8"@K<_3]0 XF(>W/V_3\PW6M9M4O6!C^B.W+:Y
MC,=#ZH-QLVEUQMJ0\2*_P@,J+OC8;K43[D\(GW]H4,DU;U-K+>5 @Z5VEG$A
MOMHBS&XMNMMYEQ *WDCY>H++(W\@$I(]^$/?C"U>:H:B5-#BTZNTYL[6RMH1
MD6T-J);)56/!U2.PXE, D*4V$N#J .WV^_"(>O+=]=H3(VKNI:Z"PLG=+K9,
MZ-+2S%KS'N.Y):4D.*<'^0;[)42@^=AT[?IP]\HEXK2:M:G6;EP)^EUK5F)0
M3K2'W&;E0DV,8QD08"3Z$#N2>Y)46P"5!I.XV!/"$5QS6#4JVR&HKK33*SJZ
MZ=*<CR9CK,UE,9@'8.*3)897N1]?6$E.WCJW! BK^#D-H;'P8GIX1#C<1LXV
M% *2K<I20$$[E13TI/U$^Y"B1O[D#SYWXF)B)M<?^3/,?^Q'O_?L\(HNPZ_8
MQRG:]G/_ &KG^/$F_@GZ",HN\1"#A"#A"#A"#A"#A"#A"#A"#A"#A"$'.)#\
M3#,D?C/.L/-XU;.-NL.+:=:6(DE06AQLI6A74E)"DD$%(.^X''?P&4B9Q)86
ME*@5/WDA0<2VL0=&CQNT>,7A. <37)F*D3<J/ZDE2I:W8@$K0H*=J%S9Q:-0
MO@AZFZB9CKGJY6YAGV:Y76P,%JW85?DF4WE[!ANBY2WW(L2TGRH\=TM?1ULH
M0KH^C?I\<?<=J,/)EX-!1)E2U$!BF6E)!=KA+Z5K81_.OZ%<:Q^/XKQE&*QV
M,Q0E+ELG$8J=/2'D@LE,V8L  TH!<F/J$:;;+:#T(\ [;I3X^HGQX\>?/^OW
MX_-P& &PC^JW!J&8V:T7>A'@]"=P20>D>"K^(CQX)^Y^_P!^)A!TI\?2GQN1
MX'@GW(\>-_O^>$( A ]DI'D'PD#R!L#X'N!X!^P\<(0!"!MLA(Z=PG9('2#[
M@;#QO]]O?[\(13MH'LA V" /I'@-G=L>WL@DE _JD[C;A"/12DC8I!&^^Q (
MW_.WY_7A"*="//TI\^_TCSXV\^/QX_EXX0@"4I 2E*4I'L   -_?8 ;#A"#H
M1_H)]]_X1[[;;^WOMXW]]N$(39W2$(*?!*E#QL/;;;V \>_^'YXF6D@*<OW>
MOUYOY"( >;)! (*BX-OE)MK5OK'"SXO>99YBV=\G<;#\HRVABVFJ3D:X1BMQ
M=54>0P+#%D):M6JJ5':E,A#SR0U*2X@)==2$@+5O\/VC3/3,1DFS$ *![BUI
M#?TS4!@;BVCL3:/Z:_0*3PG$X+MG_'<.P.,5+P. ,E6,PN&Q"I2E8C&)4J4J
M<A1E%0"4K4AB0FM!7MQ6RFH6/P+"=*;:89J([TN3*=0RP&Q%0M<R0^^H!AGZ
M2I94I(W))!(\_5R2?A2R]2A+L>5[[O:CDM'\Y8X#^+Q0 ##$S@ &8?U%,E(%
M"::4%H0V=1L$>B4<Z-F>*2*W(9@J:&4QD%0N):SDDA,:MD)E%%E."D]/I82G
M74^W1[;]:'*7-;U-2]>O/ES!8QYZR$D,6KI2E--G-+7M4PI5^7XI:FU3"R2C
ML#56\:CM1$MJV6(5R5)ZJB1V)"E0IRB?,&4$SME']V=VP(S)W$:0]BA'D]*1
ML>K?I&X/3T]0\>X3XW]]O'MQ+C<>8_>$1PQFN+"Z_9U>3T!O4S&X8IE6]<FT
M;?=C^K:CJA^J4^9DB$S)L([!8"_2(*PA*4[\82U%V)=JC9K7=G-2QL]+L,P2
MX'/4U%1>M^6]!J(?Y0@)VZ$D#=03TC;?[D#;8$_GCHB%$YBQ.END)S-A#D/O
MQ&)$=3\13*9;+#K3C\1]SZF&GF$E1;*VQN I(\>1XX>_.-B"&=ZNU+@:[^D*
MCJ$#J(2@$IW)*1YVW(*B!N=CY_(^W",B3G9RSBC](26Y]<Y,DQ8TV&_/AI0N
M5%;D,%^$7@ @OM)5WV^\$@)+@V/C;<#;C!SN?6-=Q3?>P-B'\>EQ";#R/&[.
MTL*6!?TTVVJ T+2KA64&5957?4"ANPBMR79#*7E$! =8; ]T['?B4FH&RMSY
M-;7UB%?W&C '1A0'P<M;>'(^E(;\)&W2#L /)2#T_IN-AM^-AM[<;IN.H^L9
M+^04>U-Z&.<_Q1[G(<<Y)=8;;%[:\I<@BP\2]#:8Y,FUUS#]1G.+L/HC6%>Z
MS,8#[*RR]VG4=UE9;<!0>GCP^-%:,)B64K-\*:H%)(*60HW!HQ 8TN#4M'Z'
M^FTN2KM#PLSY<J9*3C,&5HG)2M"P,1A\R3+6"E3HS Y@V0J!8/&S_+O*F3-$
M=(Y%F])E3I.F6&2Y3\Y3CTMV6]0TX7(DN/*4Z[(*NI:W'5*<4HE1<)._&_!"
MJ9PN3,4HJ(2E*B2<Q:3+)=5SR<QY';=<@]L^-HE2Y<N4.)8[X<I"4)EH!Q\\
M94)#)0D$E("0$IL (D27E&.5EL*JSOJ6#8?+9-DN#-M(<.4JN@?OI,X1'9"9
M2(D1M!<?D*28R&^HN*2GR.Y!)"PY([QJ7U \-N="PCYA-9TX#,0A"J44S3
MXT "F<, *ABT6J[4/ ;J361:O,L6LI-S$E3JN'!R&GE/SXL+<2I,5,>8I<IB
M*$D/+B)6TUL0Z1Y'%8EVM??P]UZ6AVL2(LZ)ZF/):DQW>H-R(KS3K+J 2%EI
M22H ((*5>0>H;^-M^)?76W2VWE MI]_7K>F]X;EME6.X^ME.0Y#242GF94AD
M7%C#@=]J$R7Y*XXES(XD-U\8=Z8ZGJ2VGRM2=]^#G_<?,^G[M @4<:, VC7M
M8_2E&$+<&;%L&HTR(_&EQY;0>CR&5I<CRV%H2X)49YE;S;D=YE2%L%"U(Z3]
M!V/EF/\ N/F??^8AAM&6J3&CR8S#K[+:I;G;C,NNLM..K2E2BAEI9#CQ2D*5
MTI!( *MMDD@3X?C;F.1L  #$^'7G^/"%%QMM25=2$GJV*CML204[$J&RO'2G
M[_U0/8#@Y.II6^WXB(295E B.1XTJ7'C2)TE<>"S)?88<G/--K>4F*RXM"Y"
MT--K<6A&ZNTA1V(&W!R6J?,TI4Z\[5Y:1+>_?/\ RU81;O*L>H'JZ)=WU33R
M[J6(%.S93X=7*MIPZE+@US$V0AR8X64N+2VPES^'?8!&X.QOO7</S=B7]F()
M8$["OMJ:#<DZO#@CJ"UJ4#[%*"=]E]26SNAY!_A<2E6_4G^(>YZ=AQL+>E7>
MF_,6._TR47^QK?NOT%J&QU>,Y"4@I   'L-AL/OX'V\^?Y^??B8A).85-7?R
MBYVV]R>VC=1W)Z$[D^/).WD_2/)\^!^!PC:*]"-MNA.P\@=(V!_.VVW"$4[:
M/I^A'T_P_2/I_P"KX\?V;<(1ZZ4GW2D^2?8>Y]S_ #/W_/"$4"$)&P0D#;;8
M) &Q]QL!['\<(10-M@[A" 3MN0E()VWV\[?;<[?C<[>_"$5*$';="3L"!ND>
M 2"0/'@$@$C\@<(0%"#[I2=M@-T@[ $$#R/L0"/P0#PA!T(W)Z$[G?<](W._
MON=O.^PW_.W"$ 0@;;(2-AL-D@; >P'CP/TX0@#:!OLA W.YV2!N3[D[#W/"
M$'0@D$H3N/8](W'\CMXX0@Z$?Z*?O_5'W]_M]]AO_+A"$JYL(%/!D6=C-B5<
M"(TX_-GS76H\2/'0D%QR3(>6VRRT$C93KJPE ^XXHNPW?T:OVA#63G>'*<HV
MVLLQ@_M(TMW'TB[JUFX#39=4:Q)EGYDCL]:E.P^X&DIW=/24[YN=SZZ'VT3H
MY%S3PNS'[-L7B_59=B][$:G4F04=M"=FR:V._5VU?,CN38R^R_7ID1WW65RF
M'>XB0PA?=;)2EU'U#BR3N2>I%?-J;UV<&*J( #EG<<[>>V\.5PI25$;@I27%
MI0"IPN$ [I\$K*?W2$I!'TK"?.R0().Y\]W:S:-XZ1=(<BU]?.M#?3H=H:5;
MFN(V%DJE@95C,R]3+G1G:J';P)4Y%A6B.JTB^E1+7)]1%:F5ZID=#75#[[*G
M1^_;WNDN[E["_E31Z=8NI.K4 8GD0&40U@_TTAU=*5)<6ZHC;I6M'6A;: VH
MJ(0D)2>EP[!SNE1V\)"4D@WC!;,7=J'9[%J/?Q_'FMFQ):I3$:3'DK@R/33$
MLO-NKCRE(2ZXP^A"E%I:6W$ )7L2V4^-AQG-)S)T+%P*:I:@M^7Z15&M22]7
M+^]>@:%)QM/T](2CI"@D@ $ CRE(VZ1U?<\7-CTC2$6-95\M^2Q$EQ'GH;R8
MLMN/):E.QG5H+B6Y+;*U*9=4V"I*5E!Z-_MOQS)4Y54W%";L/7J"? Q)ZOK:
MQU]BAI&!4Y-CEQ*LZ^HO:BUG4[G9M(578P)DRL605)1/C,2)#\9Q6_5VWDM+
MV\]!'GCI2<P!I7WO[O$0Z&4)*2I80I:E)6H['W"1T$I5_"H)V]@-OY\3"+X2
MD>P ^_@ >=MM_P"[Q_+QPA%>$(B+7'_DSS'_ +$>_P#?L\(HNPZ_8QRG:]G/
M_:N?X\2;^"?H(RB[Q$(.$(.$(.$(.$(.$(.$(.$(.$(.$(;N?M]>"90E!4ET
MXW:]*4IZUN?Y'*V"1LHCV\ #<[>W'I=GO_J<S_Q#;26'NP;KYO'@=JL.9G9W
MBBJU0FVC CEMOK=VCGY\%:SB8;JQKQD^1-3*^FHM*F+.TL%1I)6W$BW'J'D%
ME+2?4.".VI;344N2#].^V_C[GM62<)) M5[.:O0T8:Z=!'\U_H#ARCBO'55<
MS)1!% PE,<P(!.P(#^4?21I'S#Z?ZPXTUD^+*R&HIU*1'AKS>DG8?+FMJ07$
MSH$6\]*N=!;0I"U2&"X@H6CJ7YX_,TG, ;./=G]ZQ_7390S&E/?MFB6F,MH7
MDN)1D-+(5%8=5,::MJXJ81U?0^_T2E=H*'GRKI'Y&PXF)A%N<\QRHC*G/W$>
M:A2HR6*^KGQ9<J6F2XD-OQH:'TNOH22"767%(4D'Z3]GOW[^[P2W[T'G"\WD
M])]:5WU4TXR\S&EH?L(;+T::^VV]$A/,.OA3,A;*TDLJ 6I7VWZMD3[]M&:Y
M>5"'8<9ZWKF'[)*G8$5Z=%:<L4=(4KT@4^%R$,)Z2IQCJ2H>1ON>$(U8G<Z6
MBM;JVYHU86M]$R]>;P]/TRYM#81L15DEUAV0YE4-M9(M*:[T#U'AMNZ])#W;
M9G(<9*@K=(:%KZ;:_M;\1#U9J5KS^WCK&SZ\CIVURTJNJEA<-+"Y27[*('6&
MI"26536U/I,5+B5)4RM02'@4E.X(X1,(#><T[EE;1')_I6:EZ"DV4I;$.MF>
MN;*X[%=8.O*CSW%!386V VL%70@K.QXCG>S,WOU_=[Z^_>T6<MU-PO"Z7(\C
MR/*:J'58I52;O('F+"/(D5L&N0IQ]QR"PMV24I01U;M@D[;@$[<3#]Z^_>\)
MNCNLF Z[X'1ZD:9W@R#$K]ATUMFEIV.7TLO%MUQ*'0DD!0/DCV/V&X"$29.2
M VWTG?ZE'W_EM_:=_P#=Q*%.%#_E+_YVO!/^M)_\2O\ VF.+/Q5]:\FTHS+E
M3KL=:QUR/EVI2*ZS-W10+J2(Z[+'8KCD)4UAY5>]U3E_OV2VKJCMD*^E)'Q?
M:+&JEK0$90%%(=24*< H#=X%JZAC36K?TI^@O!)'$<#VV7.3,4K#X# J2$3I
M\K*9F(Q68_T5RPLD"F?,$N" ',;4:IZ9:K9Q@>HT"-:Y+C.!Y)A]]&M*N&ZO
M.<NLI$V"E53-PNAIV4O,Q5*40G'W)R;%2E!+;6YX^CE E*33Y4OY LVS\A:C
M1_/.- 3B<2E[8B<!K035>98:ZW(CF2UR?\P]70.3,FP*RO;;5&HR2FTJQ[$\
M?CUU-H!FTS)\(?Q'-;BO@N.5NG;U?0T$ZXLIL%U4KYA+F5;JP_(>@K[T?*&&
MGE6ICRIA[WBVFU//TIH[3QF?+!JCRPN:F9YRUX7D^HTNUUIQ'/K7%<C2Y>1[
M_*\IV-SE=9414Q9.0TN*M6K-=(=ENIGU-_9VEX\Y*K,13$<Y LO5F\MSZ6(\
MGJ^\;%\W&HW-QCF6Z#JT/P7.+'ONUEIJ"U5U+-OA"XDRWJ(5GBUU*92[+CV<
M.-+?MF)REQ63%KI0CF2[O',!9UVMU>['2CWH:5>'EKS^A_S'*FZQ7FF>U6L]
M196CO,@SJ2_DV$98WGU5HH)S5=;T&)ZDP[:OKI=>PIJ;5P9N14M3!D26O7V$
M%T("GXD)E]%D!3V(J7+D68CQ&M@QN=< #4UO=[%Q6O71O(-&W.&ZE?$BR3(M
M57,T@9I@F.*QFHF85!K-*,DM;8DU5%*DIKI#%=)K8^2+FHLXLVGD/R'HX>^I
M"&DAWCL%MZ=7-K]"[T\"QA8TWISMN!72W-M(M6.H?/IT90BHP75ZGCOW&-S%
M7L;36+/R9*G,<<4S7P0RVRSD5>K($MMWLSJ#]!#>=;DA*F=N(;W[]FG*.N87
M=P&HS/3FS%[=1>)'Y6]3^=Z;K_&IM=L;U>3AEB<@BSS-TS<A8+3O1Z. [7/P
M\R8*6NB1:>KCQVU)>[FPV43L>%6-[:>'AM>.4_,!S #AJ7UJ?J;F&AE&4<RN
M%&5!TQQ[4&[U>F:ZY!/U3ML7Q]>0TS.'L6L-RGKK*-V)5HW46>.2^[C[L!0B
MMS8,EI]Q+JPV>;?4[>;?AXV'3_'KUY:\M/8>B?.;A626^M&C6/:X1-2K+*]=
MQ>#(\&75/W%5;Y!76^&HNPII<FRB-T\NUGX\IMN8N+/CLT\;=241#9+N!JZ;
M;ZZ/Z^$0H442:-:VA)+^7+K'1GDPR/G3R?45IKF L\YBXM6Z4XY,*K33FWQ;
M&+K,Y]E<Q;6(B?D4&JMDV]77M5TAU!BI;D$J4E@(4E9[$@,2_>(\@:O1N7VC
M"9_I)JU@^GRD5J::_:)L^)!GMWIER?:KYWCR:KYK4QL37&9OJZ+<U:C89GC$
M"4U.K9R'8KW2P^XZP'4;-N]+B"A: 1\_QI13A<402D_"G V5_:HV-'< C5GC
M]%_3?#HQ?'^%R%I*Q,QN#2>\I*D_$G2);A22%C,)BDD @U2=!#BQN'JMF>D^
MCEWC5K';J9.E>,R<JQNI?8QNYO'YN/5*R*&X4W+JZ]AI*B&F^IAMM:T'K;2D
MD;\"61PN6Y?,AV*6J9$H/2A<#0B^L>+VSP2I';GC,H+ ER>(8](2ZE',GB>(
M/>*AG[@! S$D_-F4"(T#@:)ZMQN8W6_(]0L0U8RG#LYI\OK<K=B8XWD;E9I;
M(QJ!787CNC^60%39<G+S=1I,#)\:@,A4B')LK.S4([K!'9+!_JEK!5C<N!T=
MO\TCYJ3W<5BRUY<RI'=+S$AM*D"CU^D..KY(\G-=I;J7355]3ZHX329UBN.U
MC,&NQZM@X B1:2\>:R*-5QXXK<ILJJ6S!F-Q&429DV0?6!UR.DI??Q]^GF8M
M]J >_?2)MQW.^:@\EUM9SM+,RP_6N%8V&/XMC6'4+0OXT#U+<>KOUT$]<R6B
M"Q(+IL%%,N7.KT"T;:2F2$(1/2N]!O1M==&CGOK'5\X>K]CA4C5O135?(7Z/
M!,QK8M=CVF:+2@<E9!@5E53+.QFK3\X9N)F1%AEJN#"&2T6WDL]OH<X=.9^^
ML1"[I[E_Q(L2Q;2G!</Q'5"CQ/%;;':J[R+-=*<C3:,5+,:N4SCRL?H*JRF.
M4$1KUT61==(9:4AHRY<=*2G@:\N0MZN8GW[]U,; 6V>\\,;(:V%CV(ZI9C.3
M-U+B0,AR'3(UM*X^,<KSAEG'?M(T&=B\6'8+M(<.<_WX5Q, <4X8RB V?Q:(
MKX6_:(GL=4OB25=GBLU%1K[8XI&D7TYMJ-I"9>2W,&#(Q1<2HS>OC-%JCD2E
MN9E'@R8[W7/K*^NLNF-ZAM#SK?\ <Z^O4GQ==J=>=F]T:-Y-=;C,8.LL#+9F
M-Y?>QW>7&_7IQC]!6J=R)G55RP=-I$H($U(BL99(QY.]<)C;[B"U)0PVXM?:
M6W^^D2P:XZ:N].N]+>3\E];](N='F'A8#9:C4', C4'!-.-0Y<2;2Z<2&Z>;
MD&.:S5%IAUBS8NQ&_D693M/HCR*UY!A2)"VI\*1%?$UAAT!?H_1KF_OJ8JNH
M.S"QK2YJ/'TC::%F?Q*F<_R>HR)&?1,?DZKZ<4>/)QW3*YLU#3N5F+$>]R:R
MO5UJ<=@(=T^FSY^1%NSD2JR_KH+'IV ]V#L@7+$[N:NQ-1I9]VUK3!5*.SUK
M>[5%GVZZQW4K&Y$5N(R[(D3^W&:8=F2.D//.!IXN.N$=L%PJ2WU)0RGHZQL2
MGJ(V4S%P 7M^="6Z^L60.\.C_;ZPR-9-7,6T/P"XU%S9J]=QO'VF'[:30T\V
M[D0(;\AJ,Y82(5>ER0*^%W1(L98041(K;K[NS:#QG&T1SA/,[IGG>9V&)X_)
MR"7#8Q"GSUO,)5)+@:?V..WR4HA3JK-I#B*F8XX^GTSL!#B)$9\]*D)7OPA$
MPU^>8;;7UIC-=E5--O:B%&FVE9$G1I$RO@2T*5&E26FI"NS'6G<MR%@(6 %
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MFRI8*DRG4SWI(Z$R(["NTPH$;'U9">CSL>H?<^&OGZ>Z]>4(0?Z5]2!)+/\
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MZ>_%Q'GK!\-/(>7[>,+>1:@YO4-4*ZO3FRN'[BH^8V"6Y22*::4@BI>'3X=
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MEL;(6:X+M5ZH!U40)44V"1MOTE02/YD_;B80H8YJ%G-LW=O6NG%E2N5=>EZ
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M S;7+5NHRG-LCR2)6Z?5;L*)9V\F8W#2+I" $,$*0T4H!1] )4D>^W'VW:O
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M@E2\B\2@J)GXQ9_T)Z'909+I4QJD/=PZ$9C5:0:U\YLN%R^ZZ1K?4_4&JO\
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MTFW8AYUE"2EK*(F$Q\6:1C]*_%E45NN0Q$F,.-A]T,DJ$8<G(JX !>I-P=Z
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M5%R45$)#(\DJ40/!'CC5%O'\0BU16<"ZK8]I5SX=E E@KCRZ]Y+\)Q"3V_\
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M@BX0'8N$FM%JJ[(W"%-!@)<VZN[V]@6RZ0@Z*+MT'@XM]ZD_6.>0D3 &L34
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MB2\!MJESF DPL>IXD273=J\AY&K2^1\U6(U^Z_\ *TT[;:UUZF3;[]+B=P7
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M4JNE'#:K'T&.BQG*I:LIB**$RT+6'$)4!Y_:,E6"FNP>6JK&P3-<N-=6(-*
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M:EX;65_%3RG4:OS73>7H7EFC\1&EUQD<O5DZCF!'H+B%&?E5=IC[AI,;=O\
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M/SF,<F6&GU6SF,G'C/9M9\N$*6*F-%E,QD2E*3,;Z#T\/R?J?*(J-SSIZ/\
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M6N'/W7JI-K45E957T3%K611W$NCF]9%FU37<9V"^7$M>F;;2MM"VRE1W0P
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M7T>'V<:-80Z:@F1Y+C%I"L&ZZL6W+5*:0['GLK0DA:)#2TA"DD$A \D!/$@
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MIEN(JID!J4_+C(D1$+"2$0VP6E=/2=R3]AVKPP&%12A!#M_S4-#J&I>SG?\
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M5*LZ>$?2K@SV8CK"K".X.Y):5^X/$W>=[$LSC^ZU6N["K:%XZ4+8 &Z4MX@
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M]BWILU*6M3?SM&>U/W]VB3VO97_75_@.*1LCY1X_4Q%FM_\ R79E_P!CN_\
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MW#W'+*6I4Q854%18$%BRB&?9V8:[BL6G=T!0N14LY%#LX<$7OM'.6SYO^8G
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M4=0E$@$)  JZ0+!B*!H\;MS)ER.V7;"5+*2A&-[0"4<Q45 <5Q<M "RI:EN
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M0*^5=RYS]?6OS6VZZN@GUT^1)" RS%BGOONK2VULXH#CCG%G4*6TZ/IH"S@
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M.R$+*_*!QT<$IPR6$A@4(60'UDRQX$9@]6(#"X$>-VTPJD=M^.2E%2E(XEQ
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M9[ANF^+:C4&2Y-GE%D>38Q$HYR)C<VMQ:3#B7)<=0%=$B-+GLMJ9="% !P[
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MZSCY75N-R'(HB2G))QVRKI4*;*882],4L;@?'I5G2%;A]?O'[TK+F)15-&#
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M@"DGV4#XW\$>Q]C_ "/Y]N$( 00"""#[$$;';WV/"$4ZD@[%2=]NK;<;]/\
MI;;^WZ^W"$)DI:"&^VM+A2M94$$*(W'C<))V!^V_]_%P.ZIZ V.Y#EAO%#6=
M*3J%$D'0%"F)V'/F&C@1\9V)-=SKDO<@Q9;X.JZ2\N.VZZAH"UQ(_66TJ2@#
MP-ST[^-AQ^;=J4?U4&H<I[Q-" 98)<>-; OR?^J?^'9&#1@>W"L3B</))P&
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MULH'=)^QUEM,E$ NH%5+?W#>E@UP:!W#1BMY?$1+F I5\*0HI.9(RK1F202
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M64J0FO5TN.I<0=E@$];8Z22.#O"%"9K%IW7TE;DLO(3%IKQ4M-5,7!NWTRS
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M!WX @"_F=NL1"9'T=TO8D-3HN)5*7XCW<;6VB0XIN0AP.A82G<E2%@$CIV\
MD?EW;OO=1;U/M^D/?OW]2]96D.FLR2[+G8M5NRW9#DJ3(Z7D*+SXZRX=U=.X
M2GSOMM[$#B0Q+ @EZ5<OR_:%@YH-]*7A3L],L!NC$=L\=KI3M=$1$A%8<7V8
MJ"E;+)(]DA24*2D;D[ C?B6ZTI<^O[Q#C<>8C!&DNG:J]-/^R56*U$I4OTY;
M?2%S"E4<O )._4IE""3L01L?8[F&'HVY8Z/?\0!!L1%^'I3@4!B=%@8O6LL6
M<1,2R8[$@(E-,K0^TDN$ D(=;0L?])( ._C@WXN?8B8L1-(=-ZB3$GQ,0J(L
MNK6S.BS$H>5V)$5Y#Z%I!W3U)6@*&_G;?9)VVX4%26&Y);U,(LRM'M,)DJ18
M2L5J79LI3\B1)+;Y*I$YSO.R% J">DJ45*<)Z1YW 4#Q RFQ%1H?P=M8&EZ=
M>5_*,FRTMT[MY"Y=EC-;)G]+">HMOJ4@1FRPP%;'9(" 0GJ2"I(W!5Y/%C9S
M9[Z ]?=]HAP[ A^H?W3TCPK2;3=ZM8J7,4K370WG'XL9:7TH1(>!:>=\'P5)
M;1YV((Z=O!&]73N-G>OG>)C*A:8X'7P["! QVMCP;1E+-BP&'TI?2T=P2LCR
M$[>^R=@/?B0VA?Q=K?CSA&- TCTRJY+4^NQ>I:EQ$GL/=+G[CZ%-K5OU*"=T
M.*220/"O'V/!O?N_C",4:-Z9!8D(Q.F#JEH<0^EI[;OH?#I<"@K8]2U>""1N
M=Q]^# <AS)^YA&3+TBTTLI$J3-Q:K>?D*_?NAMSJ6E.R$]1\IV) VVV"B" 3
ML0([MWO_ ,WAO",ZPTOP6XB5T&SQRMDL4C!B5B'0I2&(ZU-K*4[$$;EM.XW(
M]QL-]A-#0$>!KM4W\]:WA[O[WC$:TKTS,%^&QBU*:N;)3+DH'=2VN3';>9#Z
MOJZ?W:''D;]0'4H[G?;I!M*\W?UB'&XBY4:9Z=T+DB538]3PUR(DB!*=:4XZ
M7H4@GNL$=73TK>8;W(W)4TI"3UC@Z0+@"UPS&C>-1!P=0?V_$)C.C^EL9]E]
MC%:9B7&5%=0X0\%)<W6ZI12I>Z3TH4HD@  '?I WX,">=+$^%'@X%R!XQDR-
M'],YTJ3)E8G6/29+BWGUAEY2E+*PE"E@$[ D=0.W2=B02E)VDAKN/$Z^_#2#
M@V(/C"E9Z6X)<^A3:XS62E5D9,6&5M.D-14*"DM)5XW V'T]15[_ &X08!^=
MXL'233I4%58,0JC7N2#*[!0^@"04])=(VW22G=(\[<06U+>-]-;^+Q,7H&FF
M#4+<\5>,UL--A!7!FM,I=4J7'W"@V4K]PE1*B4>V_P!AN"!2+$>;TMKZ;:0A
M.BZ/Z;09<>9#Q6KCRF'VW&WB'">LMDJZ0%$)4=S_ !'8D'[>##I_W;?W;>/G
MO#[18=T<TPE./..8G5*>E]3CKI9>([BG4O%2B5=(W4VCW(W"DGSU#<Z3KZMS
MW_Q:%N495AI+IS:3A/GXI52I3KS0?D*;=W;;CL?N@H[H2!U1V4J"@""4_=2>
M)=.X&MQJ1SYO]:/#;F>?OWX1>?TPP&94UM).QRJ>JZM+JH,)\/-"*N:OU,@-
M)W&_><3NH;;@M%/NE24'%*]*]>?6#<O?L>D>6-*M-X\:7$CXK4LPK#MB:RRS
M(6'C!4ZA'5MMT%HONH)\;E:@=RG8 U6.Q-7II4^_.$>Z?2W3Z@G"UI,;JX,S
MLN--/H#P5V'D*8>02K<)#B7 .GI4I6WX'B,R'^8/_P"(:\GA"?\ T.:9%SNL
M8K4&2TIEU#A:=*PXEQ3J7!Y]G%*44D;A0!Z2=E$2W7S/L\_6$9<W2;3NSDO2
MYV(5C\QU92[(#+^_2TD%OJ /D'V "?)WVW\\&Z^!;T#0C/FZ:X39P*^KL,9K
M)-94=:*Z,\V\!'03U$(0/*@I1)W_ +/L>##]W+^=X181I=@<>HE42<;J6*>:
M^U+>A]#I0XXT1^\5U%*D]*.D>-@D>5; \3_F\(I4:8:>T<[YE28S5PIJVW6D
MO(2\-V7=T+(.ZATNH'C?8* \$@$\0WBQ?=J?B(<"Y \8I6Z3Z>5MC$MJK%JF
M/,AO.R8\E#;H=9??4I:EMDGP"HE>YW4>HGV(/$M[<^_QI$N-XDEL$)Z5%1*3
ML2H ;[@'Z2 -TC?8;^1ML?(X0B*];_\ DNS+_L=W_P :.$4/S>"?_>(Y01_X
M#_)G_P LQPC*+_"$'"$'"$'"$'"$'"$'"$'"$'"$'"$-W4$I."Y,GJ"E?LS;
M (!W/48<L $?D[@ >2=QX\CCW.SJ$IQZIA(#D7(%D,7IR>\?*]LDK'9SBJY0
M45E"2P=SW"D,$L2S4K2O2-"_@/+5_P (#5[JV2%:?U2D[[CJ2N]2&U#SLKJ4
M" 1X/G;SQ]KVPG(7@I:4J!*0]% _W%R&)I:K?:/YL_X=58M?%N.F?+6D!4K*
MZ9@_[%3_ #$C:T?5WW&O&[K:2>H]*E *^@;K\?\ 1!!5^ 0>/RZ/[%MRCT%(
M/LXV=QU?Q#VWVW_EOX_GPA%[N(3T)*T J&R1U#ZNG8';SYV) _F0/N.$(HEU
MI1Z4N(42E*P H$E*RH(4!OY"BA02?OTG;V/"$67'64=U2WFD):27'"I8 ;1L
MI74LGP!TI4=R?8$^P/%"L D5IT_,(.MOR>ZWX4$'ZO92EEM*?;W+@* /NH%/
MOXX9QL?3\PBXA]E6R4NMJ(0%[)6D_224A7O_  E25 '[D$?;BXJ =X1Z[S6P
M/<1L=R#U#8[ D_?[ $_V<(14.MD!06@I4=DD*&Q.Y3L#]SU I_GX]^$(KUIW
MVZD[[$[;CV'N?[/]A_!X0A,FA*DM]00 5J_A&QVV'D[_ ']B/MOQ9#Y5W\=G
M+MRNT4! FR2EG"RS-_M.U?WCB1\5]S1U&8<I*=6:[4.QGJU/;3B"<'NJ6E@1
M;46N.AJ1D:+RGNUV-<A3C1>]*V $$)V!4E0^&[2$!:7"C;*4JR@%Y>Z9CT!#
M@W<@&Q_H[]!IG:(87MN.%KR(_@,!_$/)QLU*D_Q&,2!_0Q.'"2&S*<ET I3D
M?.-D\YYZZW1')=6:#47!H==A>D>F-/G]/=4>9)OLIR9"I,/'X]$O#'<7QN%
MES[2PKTTC5?E^2RI2YC/SR'B:%L]7TDC$G(@,0R$@NX<Y=G#M0D,_)H_!^)@
MC%X@J(*C.G%3!@ZII*B I2S?5U$&I-0TH:?\Y> V^@6(:_ZHW&$::4&89!$Q
M5#=7EL[,Z^)D-M<KI,9QZ9=_(,6<@Y"Y;H75V=,<==>8M JN67%H45=HGYA5
MW!:K.'!W-W :O,->/,D@*VNQ#T-WH+$@$7 #;1GIY_.416+W^7IUMQ%6/8BJ
MB1<6 ?D%F*<FD6$2N"*](,N7TR*FR97VF5]EV!-:3TNQW&TU]^]&_9HGWIH!
MX>%]#>K?L^?[EZIKC%%SLXJ8^!9IBE5D6.YLZNX1!MIM_)DO8E45L(T@<D3)
MM'3W]S*::=+C4&N@2%-*:L0L/?-N?OQB-?9'G^\*^H_/OROZ7UEI87NH\28J
M!AS6H,>LIH=A8S[C&I 1_P 94C[:?26H0A:5NQX;RU,H(*^E/DZ9A8$UJ[D:
M-4O?H"- (S*M1:[$C<==@U'J3$;:B_$<T7QJ/C$_"<@Q?-ZN3DV.4V<OOWUA
M0S\*I,A0$1[B'7-8WD!O)<:0MN++@ID1E,OJ+3LEHC8BHZ L=2X;9C;=U'7E
M$.JG/<,37<O4^(#TC?W$LGH,TQ^CRK%[*%:8_D59&M:2W@*26IT.2D*;?3Y4
MA;;B3LE0*MR2 1X/&D:P[5#=*AOMNDC< $C<'SLH%)V_!!!^X(X@T!.P,(@?
M7'/[S2[2W*]1<;H*[*9^+5ILA2W.1O8W$F,!X-S@+]&*YI)B2FF25Q8R<?3#
M<>Z&G7V&E%Q/,<01I0D AJ_^ZIY :ZM5^_MG]\X@CF;YKK#EWT+IM8(6GL#*
M7[GY6':>TRYS%\=J1;14J6_<9-68OF-C C!Y3$*+)@8C;P9<AQIN6Q5MN%:9
M1B"5H# 9E"I!=BH"SFI>AJ_BT571*B!_::$Z 'D1Z1"6,?$,NYVH67X+F&@=
MK@596XUC5QB&37V81U5&63\CJZJPLD6$N;25N.8_C](BZ_RFYAW5].<@UMM/
M=QBO#L:*NY/_ %H!KK=PY4/ZC/O?H;Z6A!?#DL/E=@S,4./,W'+1X>_Q$[?3
M6PY*M2[+/'\BO=.9==A4B6]IM;TL?(I\%678K-JI-!<28$RJ/H+1<>64-L1'
M)D!D!N5$[@E\>=VA(1@YI(5\JU$#N_*)I=)4%&H#BMS\S.!]_P#INB8OM#PE
M,LH2?X[ Y2L*F)0I6(PR0\M"Y9(+CO*=("2$@*+BY;ZPZG:/Z$:-Y)I'I'A&
M>8<C M,JR<SG^L-WI[DD5W(58SBF-X_10\>TCU;B99?S7K!EEU$F=C=<F4M"
M9-G"86N0U?@\X'AB&!RB6A57+-*ET+*8EP'5X!(:/,[9R9G_ $XXU+F9<PXC
MCD%:<R02KB>);*@I"DI95'=09++4""8TM_B*7U!D*ZAW1.(_,S=^WIM$"-4'
M50\_R"ESW$]-K6%ETAW#B=/("<LRF,:ZRJJS/4V%"Q*LPS!Z#&5I+Q16M:6+
M$G51L0+$D"A-A5]#2/F$2!_$8I+-\)$U0=2B>Y, ;*1Y6OU!V4H><K2NOTCQ
M?5S5RZK=+&<AR*VPV9 L["=:PXN<T-K)HKBFK+ENO@?-(KCU8^[7N+I*SU*=
MW$H:45;='2WLC=HKLY8$L/JUC[,4LN?_ )1*_%++-9VN.'HQJIG0:^=/#LO=
MN99MNO5W:;0'G7FI++#[K0:8>#J&'"@*"% !^]-M^6GG$[?M7Z'UJ;5A)E<^
MV@E/D@A91FE'0XM*J(-AC&6S)%HL9,N=&38.^CA?)8Z&XL:J<:D291D*0UU=
M3G;"2> WT&MP^WG=_6(_?W[$9>=\_/*Y@G>CVNI,>;91\@Q#'%5M376,F>EW
M.9;$>DE]KJ0%4KBW4F5;DJB,LI=5NLH+:K(+*#@L]Z5Z/MS]8JOY5;L-6U'C
MY5UB-]0/B):)X->8"W1WF-9CA]OJ K3_ %!R=&2VD.3I[(=H)-[66GR=W')T
M?(H$WTC[#TI>20FV4!+Z9DOM>E;Z"7\F'33V[O<D4C$%JN>8%/ 6UU-&JT="
MZ"\K,AK:R[IYS%E4W$6/95<^*4B-+A3&>]&>94"0\TZTH+0M)(4//VWXCWSK
M[>F\73<'=P-;-J#0M2P84K#CXB-83[5Q3-=,>0'%%EA3O0RA:WG WLM3; ;(
M6)#B4E#"TA9:>4ASMNA!;7G-_P!-3<OJ/+K<:0CD;8_$7U!HTX_*L.6U#+%K
MK?)P+)ZFMSC+CE.G6+^GE/P,MSVCD:.5AK[V^@1';2LQV+87.-SZWO6HU#,E
MA-!)QE*U:Y%.;,1J21KKR%8HM3 7)W>@9F^[/2G*.A>C^JU)JY6SK>F?J@BM
MLWX?RZ)=PK2VC-E"S&?OJYJ#&<H9DJ/NZS"0XXM3*BMPE!5QU+^16U" #SN0
MWA0@/1J1C+.9:=P]RG8OH.E#U$/#4BQS6FPVYL=/\>I\FRZ,PE=/49'DCN'T
M3[_6GJ7:Y$QC^4RJR$RWUN/OP\?MI80D^GANN;#CGCK8L;6W!U!T/C',^N^(
M;GT!BFE9]H%CM5#@/6DS4JQQ#5V;ET7&\48R#]E*RZP21D.E6&66?2K6\ZP]
M#M!@_8A,"5$G.GH;7*5 $D[5^N](CR]_XTWJ8GS0SG&9U"3F$G43"6=+J_&L
M33J;7SV\R=RN-,TZEO2F(E_<KD45/)H;-*(BG9^/Q#:U]>I11\YF@K4G3XB:
M<^GYB- =]-1U&D.VBY\N4_*)*(5+K9B$V3(J9]V$*>?CK-;40/F\N7U.*2V0
MU 2F8F.@)<?BDO- M@DU4H$"]_>\3M7>UQ_F&E8_$)Y:GL0KL^Q;4"BRK#G,
MND8GD^21WY-;58C'K8KDFYMK5J7$D=^/6O.0HDEIM*%A^RAI4ZDN(ZZ/]S]/
M?T@"!>S5\_!NKGRI#[:YS^6F528Q?,ZH4GR3,LBL,/QR<8UA'+F0U3S+,^E=
M0NOC.55DT\_'6B).+;[G6R$()=2>)26/6F^H8^%]7MK$*9K[;[;W%0Q/.@$1
M'5_$;Y?\ZT[?RS2G)ZW)LRM\0S'*,-T]RN;.PZ;DAQ"-?N*KI=FFAR--"W;,
MX[8RJ5YRIEFR26G6&G6U. WS%B2+BC_X8L[VJ[/2N6:CN0X)V!Y@E]!0]&H\
M2+IQS58MJQR\VNNNF57(SV\JL*A7]OIQC<Z=96T7,[+#:O*T8&Q,G0HUBJ>E
M-U$;AKB4<94B'/9>C4KSLN*RJBU @G5Z.^H(N"X&[,*LQ> -2J]+/J:4<.".
M]:SD1K9#^(/F-=9: Q,FT'K_ )'JK&RAK.\BQ34#+<EJ]+I^-/,5RL?G)O\
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M>5V2\HN&KF:FQF?NTQ([[,&$AJ#!C(:9CH693ZNIQ3LIQ2=SJ6T>U7W_ !!
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M$GP?8;;_ &_4;?G[;['B(C,G?V8H7VD[=2PG< ^=P #[$DCZ1Y'D[ ;^>()
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MLR5H#AQ5KL.;/:<NV&DH82LN]A(9+G@AU320VIU'TH/;=4DN-A24J"%)"P%
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MN0EI<VI.H<[$@&U(_2_TK_I]I^!(2E:LO$< 1E )6V*P9R5(3F.1TDJ3WGJ
M2]S-LPU9TGT9Y7[_  6^CC#:QS1S'M0GZFCIK&LFXG=+Q?'Y#LE-N7;BJJ&$
M375U/[.+-NF6IMV?(77H?C*MP%(_EB$A04$I[I!(#B3)"2S4# D#7QCP^VI6
MOMIVQF*099_C^/S"A1"BB9_-,3W5*#@E+D%F!(Z$S'JWS8TND.IVF&F<W3S4
MS(I6I-LJ$+W&,>7*IZ_OT-[8($J49""T^V:Q+K[(27F&5AUU*$^3WH()G"Y
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ML\RHJ+J?AN3S,EK$TB:J7,R!Z;D\.'2095+8J@M.2$R)$N5!ZI*+\00J8/Z
MS'P%.Y8G+9B/ A["/,PZP2<RF8#0F[N'%Q1GYQA8YSO<UV$:5XU5:8Z%6%[+
M@WVFF%7N6Y;HUK?5)BXZWI%C[#+.7Q5XK+R.\N9^:JM:B5?T-:^S#6R7[!^-
M#=:E.= 0J[-I?K^*/R(I6,GN&%]K,7 ^U1K5A2-IK77?5'*[=B?DL>PJ=0<!
MUKTSJ--F:;&,UQ"MNJ'4&X<@YGB+CF7UE'-S53&)+[&06[=4[4U+J$V)G-V
M3'#*LT8TLS6UH*EXAZOM1^M=JU-=Z]8[3\:QO!Q!=BUVIUA'D;G^(#Q]SL?_
M -7&80=:>L(#N" D;#<$GQ_;X_V\04*V?RA'KC:$4/@'^1X0O&*XH=#GU$;(
M5N0/*?!W(&Q\CW&P/G[<9H!$T*9TFCN-5 V=[159 27+!C7P/7UC0#XCVG.:
M:M\HNJ.!Z?4DC(LONFL39K*QF7$A/2/0YCC5I,4F9-G5\1DLP([TD=R='6YV
M^U'47U(0?,X]+5-P<],L%2\JRPH&*9B=6%R!X@#G^A_ICC<-@NTG"L1B9PE8
M>7C,',FS%!1"4R\1(F+40E*ED)EH4LY0JVNK_P!,]",$N<#Y?[3433V@M-1=
M---<*32RK6*U/LL.L324?S.+4RERIZ8ST6=":*S'D+C..M(6EXH <3?@,I<O
MADH*3E8("JAP/@2B4L2XZB_6D?/=L<5A\3VS[53I$WXDK%\3XVN0L)($V5/X
MGBE2E,0DA*P0>\ 4N":A@XL\Y2.7S5O,JC4'5#1O!LTSC'##&/Y+D%4U:65>
MFM[P@>F>6I@1NV9DEQEAM/2PZHN)>ZNDGO0"%+9ZYM;VU:EA04'2/ E9D8<R
MK'XA60"[C(E(-$AF 8A[:$6<V8\M.BN>9CBFHV8Z68CE.>8-'2QB.47%;'E6
MV/);6A;;55(?#QB--/MM/L)(="$H[?3[@QD.U2U:<[_YIXB'V]>OOZ1F7_+[
MI5E:Z7]IM.\3O?V<R09E1JM*B),77Y87$.'(X[CR%.,7"0@(3(0LMI 2 V T
MV!*$J"@68 Z[/4,-&H/9BI *2-2"*4/T\+O;01"W,5R2X3S$V+$Z^O<@QT2S
M4QLOAT"*5ZOSJEI;%NRKZ?)8MW760?CM2&]B8:HCO:44)> '3Q6;+4L@I'4N
M*>9#MM]#&>0T\07TKIUY:ZPZ;7DEY7KJ/0LVN@>F5A^SM,]CE4N1C%?WH5%)
M0XF75QU,",6X4M;CCK\8J<:4MU1Z/8\;([J=E>!8T>K5<6-]XDRP:::D_MIX
M/MR>MURR:&9%AV):?7NE&&6N$X%+B3\-Q>54,/4V,38;2V8TVD@O%UJ)+99<
M6RAULMK;2M12H'8G":A:U!@2+ 4;1^56]F+?#EL V^Y <UZ>#ORB/Z_D4Y4:
MNO:J(7+[I?'JTY UE9C,8O7- 7T*%&JX%DH)0GOS6ZF'%@.R'B5.-1(J'.M"
M2D:@*$LIU=F&SFY>M/ ^$$RT)4X #6)S=.9ZTKOK&1:\C_*U<WUME4O0;3A.
M37-Y"RF;D+.-US5P_E518.V55D3\I Z%SX-HMJU@N=DJCRV4/[]20E50E1!#
M-:_OG772)4B6K3Z@:V:O)RWE:6])-):?22@1C],N5-[UG:7=Q=6+X>MKZ]MY
MUG-M+FT<0E++DF6[-;0RAEII,6"S&@((CP8[?%D@BC>+WO\ M8#GM&:)007!
M>KZ_[6]!3[F)?XO&L6W4E2=@-SN/P/\ 'BJOE/O6$,S-\%QK4/&+3$,SH*W)
M<;N&DL65+;,)E5\UI+B7$HDQRM =0EQ"5]!4D$I&YXR"5;'Q'YI"(RR/EJT;
MS#3>!I'DNE^'6NFU4VAFNP:54PE8TPPTZIQIM-;V#&2$O..R$H++B@XLK6\M
M1WXG*K;U'O??K8"?\^=].G*D(KO*/R^.:7)T85H]A+NE<>:Q.BZ?OTT5W&69
MT12#'F-UCJE-..,J'>CJ=<2EIQ"5(:0-TED.Q\_&VO+:T/MR'KOXAH=[&@6E
M;>+MX.K3S$_V0;QIW$!0&K875'%G'E.JH40BE+3,)Y9[DJ.VD,/=2D%&QWX9
M5;?2 \/%_M[VA&R#EPT^M--J[3''ZA."4F.FJDX6]AS<6G>P6SI9'?J9V+M(
M;<8B&&M;N\)Q#E>_'6]#E,28TJ0TN,BBU#3IXCI];B!_;][#\Q NEWPZ.7/3
M_3RQP:_T^QO4YW(;=619=D^:X[C\G(LJMV;5VV@2;=R) B,O.PO4.0X*4+91
M&0"X5+<=<7Q.56@^FE[N/R*P#:[Z:C7E3[QL'A_+=HQIZC-%8/I;AV,2-1%1
M?VV=J:EEA66LU4-FIJ6<B4RN.JQ$*D;;JXK;ZG Q%:0TEWMH"51D5MZO3PU:
MW.^\'T?RIRJP<^-8BZEY!^4;&8T2-C'+;I)2LQ\<L<0*&,0JT.*Q2VKDU5G0
M]Q*5*;@3:UYZ(_&0K]^EM"%R0T5I<N@*2;!FN6)N/L_C%%)2M@H6((ZC?D=8
M<<[DQY8[&GQ"HFZ"Z;R*W D2?V.A.XS5*.-JFEAZ4NJ26BB*Z_)80Y(Z75A]
M:4J<<4!QI$@!'RZ69^5GZ"\*6D7*YI=HME,_(L"QF/CR11OX[05$%P-4&-4]
ME91[N[@8_5(2EBN%M=1HUE926QW;*2TA<D)].UU/'P]^^47,Q:P H4%1:^MM
MWOJPC9-A*D#HZ>E*1]R"5*)W*O'V_N^VPX16,CBBP2S#?[0C#ELK>[(3OLEP
MJ6-U $!)VW"5HW(5ML#U#?SL#L>*9%;?3\P\6B![#EDT,N)FHTZUTFPN9,U<
MB,U^ILB13Q77,Y@Q$+:C,9"ZH*<G(#)"$I?+B4))"1N2>**EJ+4/F!?Q<>5+
MZ0]^V;PBQFW*[H7J3@='ICGNE&'Y3@6-(4WCF*6U7$>IJ(MQG8D?Y?&0VV([
M;49:VFW6_P!ZE#O;Z0"HB\M!3?0G[TT^G-VH5Z'WI]!#DK]#=+ZS3I>D5=@%
M# TO<I;#'DX,W!B#'VZ:T2Z9D%,,I6&&EK>D MMK6G=]3@45*(3=8)9JM?2+
MI+/H_C].OI&1>:,:<Y+3S:"]P+&;&JL,8&%3(,BKAO07L66TMI= J*XCM.4B
M(S@B&(M 2\RA;+C?;65&N55'\W#C;G1K>&L54<S^W%/#<G2I$,#.>63#LJT[
MQO3K'C,TT@8"VP=-;+ T0JZ9@$J'%771'\>C/-.U9CHK9$F$JKL(,JM>AK5!
MD1GHA<0Z7)1,(*O[7RL] 36UW]- 8QRG06>[5N/H!XU%XB# /AT\M.%Z65.F
M%WI7A6>PZ^Z:O+*XR+&:,VN37+4V5,;O[=5=$KF$VP3,<CN.,(1'V074, .E
MD73+EH^4$:O4[T:VHV%ZVB,BA5GK:E!3G76)QI>631+',*RS3BETBPJJP3/9
M4R;FN*UU1$8J,FFV<=N-82;B(TF.U8KDM,L,R7)'[R2T@]T**4 PL%65A8$?
M?\Q= (=Z MMY4;5KZU$,N/R+\J455HJ+R]Z6,.7L!%5<NIQ>L0J=7(KV*WTC
MRO3K?7#,6+&9$0OI3V&DH2M'D<4*%&X)Y$@^->>C]0Y<WA0D<EW+2^U3%>AN
MFH5C.-2L1Q[MXS$9=I\;F,.L3:*N5'4PJ/5RT.N-N1$.I0IIQ:%DE14655FL
M7OR]V_Q"D)5=]&-1]#IT,.?1SENTYT2EVTG!L?CT[5A&AU,"OBI9CU6.XW6
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M0)VZDA2D [;_ %+ *$^/](CSX]P1PA%0XD]/A?U>!NVX/LI7G= V\(/OMO\
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MMC5:0.PX5I&5J)FKZK2*ADNS)I?=AE'E2X[_ $MI)*MSOT-'[;$>>/B$! 2
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MNM"A%6;^T5;1_P#)UC^=^*!\3BD@-EQ$X7=OZI<.Y4]&<D[WA4M-&I=K93[
M:E9_ ]?)?FI@Q+;MPV$N]+:&DL%E*P@'?N?3LWNHJ"=QOJH7K?J+VVK6PJ.6
MGG2TD$ZN;D &KTO<$DAR*Z0JY)I8]>-8^T,\RZL%#6"K<76RDM?,2$E1EW.Y
M'<44CJ*E #8[E7U))TS)K6G-ZNW6NX_$5R'9MW()-S?T:GU;&.D$Q5&]2G4?
M.T]ZT-C\R%O_ ,8(03OZ<.>GV*1^ 0G<G^V<Z7-:="*> _9](C(JP#ESLSFE
M*O9A6K:ZPH8WI)*QTV*OVZRZU]=62("?F4Q"U1UN*^F0TH*4.[_6!(&VPWZ3
MN.)%+4Z>^D;1@U&C=C4V4"P7J1G]BF%(5)5&FW27$/\ 5Y+"P&=BD>=P?H_'
MGSPK<ER[_MX#Q^D0S6ITA/FZ)3)4B7(_I/SZ,J3+FR!#8M^F$PF:[W0AMH,D
MI3'_ ($A7@)_A/CBA6D7._\ :3[O7?E$Q>F:.3I[K+XU/U$BH3%1%(B7:4('
M9&Q>)+( *]O)W"O(\>!Q9*@0Z3SUZ]>D&W'OV?6*N:.6#D&LA?TDY\R("%I]
M8S:J3*E%YS<>H=5'"0E*?)ZE'SLD;DCB;:P:/</1:P@Q9T;^DC/)0F0F88?>
MN$E^/V)'J.^T2R.EQ>W;\'8>Y\<00[]&'MV^D54.ZK1P=-QZQ?Q_1^70V<"S
M7J)G5PF"EXK@VENEZ/)[AZRW)3V=EM  I6-]U)) XF6M"2$$G-I0[@-0;CF^
MM(P,M10D/1(!)9(=DD:=7L6V,:'_ ! :.[T:Y5=3M0ZO)K;,9^/#"G4XWG4:
M/?8O8(;S3&X?:NJM9[DJM"70\E25-IZ$AE3B5J3QX_%OZ>'GK40'E3 E+!0)
MRS,N8.0ST.8$%B":Q^G?II,!XOP_!Y'7.Q>'1+F"8J4L39L["RD(EK2D9%E2
M0D3!.049\XHE1&Q.C>GDK,],<!RL9_E50G*=-\0F2Z_&;%J%15TM['Z=Q<2L
MK&URF8L-M*M@VEU+A;^D$+!">O@Y">&RW(*EA*LK!DA4E &4I)  (+)HS@
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M"ZW_ *6^YV\ G^WV_A'W5_"/N>$(H7F_](GR!ND%0W)VVW ()'NK;^%(*CL
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MHA3%M-1II#TM 1#E//LMQI'AB0MUL-+65IWNBH#5\/?NL-2'<B_N_G$BUEE
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M6FP'BT(CF[^$;6V]%/C#5^+#R:1)CM-7<'2JHATRJ.)A'[#1XMAC*,M>;G9
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M?3F*]8G-2AO:]33371V^T/2.W'B1&6&Q%9CQD)1Z>.EMI@,H5VDM,H2&R@,
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MO;<?;CO2L*20'<*<TV#1\UE+YTCNJ26(VHJNMOH1&:);!Z=E@A8!!&VPW07
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MC>Q!D>3]?4#]BGVX-ZTA">CETMT2VWOZ1;XQT2PZ&.](V2PB4F4AH?Y1YZE
M(43[)'C@;'2$9UYR_P!I=6DZR&?7D 2W''$QXS[Z&VRMD-C;9_;8=.^P^Y^W
MGB-]"?'\:"$*V4:)6.1UF-5:,SMJY%#7(KWY$9Y]#UCY0M;[Z@^"5A32 -]R
M>I7G;A]&]_OX<X0F1] ;1G'[*G7J!?.2)]I&GHG%^1W8[$:/*CB(@]_?MNF0
MEU9_TFD^">)A[]^D*.':&S\5G3I;N<75N)E-.JTMS'7UHC.REQU(F-)5(.SK
M094A)&Q"5J]M_$5Z?77]M]80W:_ERM8<^!*7J-D#S4)Z.\6EOR"AT,R1*+12
M9!V25H0C??\ @)'G[J\F^U?LWK",BVY>K:SM+*R;U!O(8G3%RDQV77^TT'2@
MK0D!\;) 1LD>P!.WZS"%[+-$)N2?(@SFUY5BF@)A*,.0^@RUI*5>I?W?/6M1
M3TD$>Q_'"$)!T"MOV=70_M_?%;UF;!R>I][U&Q;+?8"DO@]L;A6WL2 =M^(#
MZMX>D(6<5T4L,=9R%E[-;BS-U5JK6793KZS!ZB3ZED%\E+I!*21L=@/L3Q,(
M;E-R[VM3;5UDK42_EHKY3,H1GGGU-/=A#@0VM)D;=!+JPK<>0$^^W"$>)W+I
M;3)LJ4WJ-?QD2I#CBF4.O]*6G9*92D)VD>/J3VQ^$_?SPB!8/M&;DF@%I?6Q
MLF<]O*U#IAE<6._(#;:HBXCI6D"1Y+ZH32%I]NEQS\G=TB85;/0^?8XECF,H
MS:XAKI'+!U^Q8<?3(GKGSESCWU"1NKTZUJ;:))V0K;V'A[OU]_>D(3X&@=C#
MJ;RK7GEZ\JW<AJ;EK?D%V$(0D@=D^HW'?$G]YML3V4;\(1E87H98XG=HN9&<
M7ET&X<Z*(<U]Y;"U2HSD=#VRGU!*V@X5)\;A6Q^W"$-]'+C;)F"2=2,A4CU;
M,A3"G7BE;3#J7T->'P %*"D*_P"CM^O OZU?W>$9F0\OMI>W$FS1GU[7M2WF
MY!AL2'PTPXTD )0!( *7"!U;#P-_SMPA"Q>Z'3[FEQ>G1FUQ ./0C%=E1G7T
M.V"BZIT.OD/[J6-R@$_U>$/?OW]X3FM ;-%%.IE9]?%<N8Q+3,,B07F@SLGM
M(/J-PA21U$>W43X_"$>ZC0*=6&X[V<W\[YG36%.@ORGR8QL%L%<YO=_Z7FDQ
MD! !W'6O8^>(O[UA!CF@MM07M1<.Y_>V2*V2IY<20\\69"5*Z^AQ"GR"G<])
M'W2.%7T;I7S?[0C9!I!0D[^ZE%1\D_8#[DCSMOXV]_;?SQ,(BK7!0&F&9)/N
M:9U0_&P=;'^*AQ#@:Q0_-X)_]PCE*RA24**M@E( 6M2@AM!:9:;(4XLI0%+6
MDAM()*MO8<3X'J 37P'^7H\9L!=21U4!O^(O+04 =7@G;9.R@K<@$) (&YV(
M.Z=TG?PH^>(?>G6E*UKH6,5)#@."2'H7'0D4<:AX"G9*E*4E/2 2#U;^?ML$
MGS^F_!QN(L$D_DV@2A:@HI0HA#?=4=MMD @%1WV.PWW/CVX@J',]*_>+?#4*
MEAX_MZQ[[1Z5+2I*FTIZU.)"^@ J"4_44#^(GQMN/R1Q&<793=(Q5,2CYGWL
M\>>A6ZAMY3N=MB>H)\**2 4J"3X5L=TD$$ \62<X< ZW#6]MUB$S4+^5]+@B
M_6/)Z0I*>M)ZQNE0/T_RW(!W!\$;>_Z>>)7W 2JPV]Z:QHQNQ\ 3]'B@(/D'
M<;D;_P CL?\ 6.*H4%I"@[%[AC0M]H@%]QUO!Q:)@X0@X0AL:@+3^Q.4)/C;
M&;1)41](*HLE()/GQ]7O]O?;VX]3@2U2L>5+(^&HTRFK9&J*:OK:Y,?,]LI1
MF]F>)IRF8,@[DL%:Z@_VI<OKTK'-OX.4&WO<[YCZ?&H4>WO9^B,B!5UTN>W6
MPW)5E9.166I,YYB4NO1+<= #XC.AOH4H-* &_P!7VIQ:<3A4B231[AN0<6H+
M@LW1B/YI_P"'/!B3Q;CS8;$22%R 5XB29-Y1# S "IP&[MJ/'0/).0#FCI-,
M=*'-),UML8U)?OH\S7"*YJ'5F;9U%?#1$QVJQ[*Y&.JJW*S%PVZH0I-(79C;
MZ=GD*;2KC\P 6 RVS_W-9]0-& (+G9Z1_84U*E3%*<&NA=V#;-&([R'\V&11
M])[')8D>5G&+9SJ3;VN67FMJLAAT=):5LV%@4QO'UXXU#NGX,I<6?+B)3$4T
MM(0V^KH2.-!+F*#AF)!OJU?344Y4C/(H[#QKZ0Z]..4CGAI-1,&NLLO&5X#4
MS,FDWF(LZT6DMIN;'QFMB4TY]Y5,VY:TMQET*5?/T:%,&FCSQ"3(E!O<R92Z
MN!6I).W^?2-+ /ILW34^+TM5K1$UOR)?$#R>-#O/VSJ,0S2A=U/5A4VOU9LK
MAK"1F-10.0T16Y%4U&M$HLX%W4QC/:>76PKAJ82ZJ&$*CX2]&-@:C2[UZ#H+
M5B07WK7E[Y<^L/!WDWY]9V(:04N3V-7J(,6N=.+Z959%JZB(YC,S#-<Z?4+(
M"^_6XZW79LWD&*UD"JH'WHL.3C*ZIILNRU2%.<;!"F#M87-_K$C2OC;QI$[\
MQW*_S?ZF9'S-6^F&5NX0UE\310Z2N#4M*X$AFBFK.K]&JF?IEQ,5FY%5"+"K
M[IPST&9&5,],VEWI$Y%:M^*4_%(1KAD_)O\ $7N*&R9HLDCXU>O4.A-3<Y(C
M56AEYIG+.!PLL9R1%G._9%NFK94:9DD-^+-=@R6;*/3!CL,JE]2=10#D (R*
M"2=B3K7K[](D5_EFY[I67:C6MB_#D45UC6/UF/5]9K.80L<@Q^/3O,9-;I>Q
MM\5KD^1'GQ;Z% 2Q'EI#;D3L,2U-!6[[^OYKY5B @\AL*6UMM2)RY.>7/G-T
MWUUU+S;F"SYK*<.RBEAHQRNJ\JASL=JI)9KU&OC8\Y4-VT<5BFYD9F<[:NMR
MD+2Z64=12)VVN1[.W2&15:!]"]^7*.K80H  )   &P(V&PVV'MX'\A_+@:DG
M<Q.0\O?A".MM^*2RM#1AE2UAT*)?*EGJ<!0 $@(40$^=R-]_/DW 04DNK.Q)
M##+3G]M-XU,_$KQ*0)<O*I*$).8OW4L7!IIX.=Q''_XG>I&DF#9?RQQ=5-'6
M-4)=[J(B-BMA)L37_LI/%KCR$63" $^L=3(7 6&4J!*&!YV]_BNTF,P4M2$S
M)<U:B0*)+ YD@BA(J20^CO'[_P#HOV?XKQKA_:?^$XBC!C 8?#SY_>ELH35X
MCX905H)[IEDD) ):^W7VGEL&HK%@=H+K(CB6-TE;33S+805)"B>VWN M>Y2
M"2?!X^JDK29<L &J$D W (</5Z UC\*QJ%2\5B4J.8IGSDE5LQ0LA2N3FL+*
MGFU>RM^E'</Z(_TS_P!'P=^-XX&S$D<K^^49/"-8.$(.$(.$(.$(.$(.$(HK
MV/\ (_X<(1BN*Z&5+]MF5@';?ZMB1X^_M_;[<0FI/_B'T$56627>Q%.AC0_X
M@N585AG*AJC?Z@X8C4##Z]&-LVV&.S!!%I&D9UB\*&#)2E;@:@V#[,UI"$*4
MYV@A*2H@'R^**"</BE$.$RIQ4 U@"::EF( H[\C'V?8C#8C%<4P<C"J$N=,Q
M,E$E2WR_%44H0"IB$]Y25%1=@D#41L+H=/J['1_2^QIJENC@R\#P^9"ITK[J
M*F#*QRJDLU:5[]+SD.,$(6X-PDH\%2N-^%+"\!)6&8RD) OE/PD%E'Q#MJ>4
M>9VLDXN5V@XCA)Q"I\C&X@35$@H4J5C)\I10S=W,"A#@!F4&<1,3$MI3G:^L
M*0=U%22$G8-> H^Y)=3L/&^RA]O/5+20YI=0]0?H8^?,Q)7\-CF2GO:@$4->
MMMX4 Z@D ;[G].-(M%SA"#A"#A"#A"#A"#A"#A"#A"**/2"=B=OL/)]]N$(M
M*>2E(4$J4"=OI \>=B3NH  ??[_@'A"/(E-$ _6 >H>4*'E/\2=B-]Q^@(.Q
MV)XDAO;_ $BH4"6'X^L7$NH6=DDG<;@_97\C]R/N-O'$1:+G"$'"$'"$'"$'
M"$'"$'"$'"$'"$6G'FVO+AZ4[@=1VV!) 2#Y]U$@#8'SPB0":"IKZ5BSZQD;
M;A8)4$].R20LA2@A0"CTJ( VW\?4GSY\($$7UL=VU'+G:,A*PKP-P0 2DC8C
M?['[;_G8G;A$1[X0@X0@X0@X0@X0@X0@X0@X0@X0@X0@X0B)-<4[Z89D1MO\
MD? /WW[K*_?\;(5_A]^,EOG3U2/-0_<;^L06RJWT\C]VCAIK=E>88K3X])PV
MRD0YEIE=/5OQ&H59+781Y[O3_DXM&7(Q=C=U#CH[K92E25=1\;^[@),J8!G:
MG-(  RO4TU\:UK'P_&<=BI*UF3FIFMGLZ[M7:[5&EH\S-76L&=PZAS)-M=7.
M4R68OS-+,".(DN;-3&CQYC<5Y+#+R%/-A2FDN-A!^DJZ GCHQ7!Q/FA<E:0G
M($FH^8$FP2:U'4;1Y."[1SY$M29Z5E1F*(=*WRD) =R" 5 LP-RVL8T_F-PZ
MJ?K85A774:;:WLRCBP"RV].4Y#+:5RGVF9#G:945$I<4KRD A ]AS_R)?^__
M .X>7R?MS9H]B5VH- 4/6G=6>?\ O\WIXO"[F&M&.X;D$7&9,2SESG(K=HMY
MI"7F&FYBW8=;$6M+R5N)E3$=)0VTX6D[J>+1V''3*X5*E)"9K*5F.J:@VKE!
MWNU !K'+B.UDQ,W(E*PG*".ZO4LU%T'6F^IB+86HVIMGHO>Y^Y:1JJV7D#$>
MJ;131)3U53(MA!DQ%H4\\T^EXJZDO+2%,)"O!/@Z?R[#O9/F-;>&G.O4<*NT
MTV99"P[GY5AO_O>K'S%[1)[V>RL3'S#(9]AD3-I(IX,9IB!11&JY,Z+&7+>$
MA#,5];:G'RM/2M2@D$%((''',PTJ7/*4LP"2&:[5IU9GI:^O7A^T$P2PHRU,
MZKI4"6+5)5K6EKCE"II[K!BNI\S(XF.,S-L;FNUSC\MA;3:W8[A87VW%K<;=
MZ5IZ5$+3N0=D[>.,<7)0$FQH.6S;\R[:EK1])P[C\K$$)4@NY!(!%LU#W[!@
M ;#:\2GN2!NM"R!L5(*"G^0+:EI\>QV43OOOL?''E@ !A:OU_,>W,F)FJ*TA
MDD!A:P8ZG5X.)BD'"$'"$8EY*KJVALYUK',V#&JI\R;%Z0H2(K32UKC[$@*Z
MT,N#;<>X&^QW&_"E+7CU(#G*L =#+<T]O:.*:N1P[!\8QO$F5@UA"DI6Q2E(
MDY#19E@#.'++9V-S"9R><R?*]J1'U?B<LV 2-,=1\3TJ7<V>22\;HVTN1(3:
MVXRBPF;,5,Z+-OK0U(;0%!16%#<CCWN.RL1)D%2UDI8D)RD$ FEKL7KXT,?E
M_P"G':#LMQW$<2D]GL,C#XB6I(GS$&4RU&5W2,DR80U !4"MVB4,>^(M68AC
M5&YFF$:C9K>NV;.,VCM5 Q"%%K;*-B<;(I]RA F0)!JI\5_O;K"I33O6TEE2
M GCXJ6O. I5R'+[FEJG3QWC]BE(F29:)4XO-0G*LUJH5>PNP)<!^M84(WQ<=
M#;3(,BQG%L!U6RB?C-E3TKKT&C:8KIES;R&(:*WYM8/Q:M"H\AX-[2)K2E*0
M>TE?@<=J+/H?+PIKR>U](O"OS?<UNINE&;:05>-1YV$XS88O?ZIZE9%+I\>R
MU;&,8TNI]5AB:N5/BS8LV>IU^*Y:U;CQ:E+;V0EL%P0HD$E^FNSCE4%]]KQB
MHU-6Z/=O0M3ZM6'OI'\0#&=4]2J31^LTHU(K\W><LF<@9M6Z-$7'/EL.@M'U
MV3L>VDEQ#E5D]%9QUQ1+;7$GM!3B7PZRB H]T7.I=Z$V-VTYC:)"RVM+UYW>
M^PVZ0W[OXG>C%?J%KYIG Q?.+JYT#KW)N0V#<6+4TMP[ M\9I;&LJ[6P=C1D
MSXMGEE3%BPE*#U@1)#20I"0YBJ:L*(8MF8,]G(#TZ%@UC4F- :#IJ!;G1OQ3
ME%+WXHFC6,X59ZA9'A^H-%B,?!,4SRJMK*LA1U7T?)T8UV*JGKS+5/DSX,W*
M8,">/3H#4AF: 5EA)77XTRM".KBQVTT)-[@/$O:AO[Z<[\GUD*]Y]L J-&](
MM7XV$:@69UI1.<QS!V:Z/799"510IEAD#%C'M'H+#4JMBULY\Q#)+DMII*XB
M70K8=:22E)-RD$]2(1'VAO,KJ?S"<TN65V*.*I>7S%=.L S&M1/HJ)Z3GZ]2
MJ2?;U[S-DJ8;^F<BLQ6$-1GXS33RH<T=M"4M=V?=N=OW\;1&M^3<]/Q'3UO_
M #:/^HG_  'Z#_ ?R'$Q,>^$(2IGE+8).W6O[_S/W_EQ,LDA9-Q3I2WYB"2F
M;):KJ^J"?K''?XF=!H)=9;RMNZV9=F.,6D'45:\.:Q:)5RD7ERBPQY;;%R;!
MAPM02^FO'5$2VX$%WV*1O\OQW"X)1>>I25 (*2D)(*NX^9ZNU0P#T>/W/]%N
M)<=PTCM>CA<J1-0K!8$8@3S.20G^)Q298E?"9)*E*5FST L7,/\ N\AYHZ[7
MIK1.EU=5&H-085?J3I]EAP+!Y3V'Z>TTF1 RG#WXCU2A^WLWU3:Y5;<VOJWE
M]+ZE-MEOZ_8DV0WRY0QHY&5GTOL*='I^-<3),^>319FS0H)L%9W4SFSEZO3G
M0Y&"?%.T9SS]K&\8PO5&YBX/F!Q"UR%RA8KJ%^(P[;09&7OVTIQBNC5 LJ25
M 5'==;<$R1#82UTO%:.X%P.>_P!N7T#1YLI3YGHP#WHSC7I]J-'4^/(;DM-O
M-*W2XA*P/&X"P"-]O'W]P2/UXF-8O\(0<(0<(0<(0<(0<(117L?Y'_#A",1_
M?TW@;GI.P]]STJV'@@^3^H_GP3\W_F'T3&<SY3K_ (,:)?$+K]-[+E0U,AZM
MW>0X[I\N#C*<@ML4CQ9-^V&\LQUZM37,2F'4+><N4PTK ZEMM=;C:'5A#1\O
MBP2<)BLY(2),X$AB2R%!@]J.=6(<O:/N_P!/5SQQOAQP\N7,FC$X8ROB%00E
M6>5E6HI(+9PA*@Q)2H@%)((@;.=9]0-"T<M;NF]P]E6A]MH#D5MF-$_0TSF2
MUV+8=18%$K-2Z"06C)DW-,SE$:RO,6'312JFNM5LLQ)#04[MP02SPY(224!(
M,LD$%DRI67,;.7.8"F8%A2/)[2+Q$SMKQ).*"$SEXK&'$(E50F<>*3<^11&;
M)WR$9W44!)42;(O+Y\0JMET6E./:@6F3:GY9F+N.3,JU&J,>Q>AQNAKL_P ^
MR#$]/C,JH"ZU?IY<ND3"7(@5DR0EQU#LIY'<ZF^R543!7NE57NQ Y;_O>/",
MM!Q6* ([B)JDAQ_;- H QH/ QU_8^OH<3Y0H)4A7V6E2>I*D_<@I(.Y V^_%
MHSC-X0@X0@X0@X0@X0@X0@X0@X0BV[_ ??[>QV^_YXI,)"217EN#3GU\(LGY
MA]ZZ1KAS4WVH>*:&YSDNE]U'H\RHZUFPIU2JR#:09DAF9'WK9[,^/*::A6"%
M*B2);3/J8C;BGXRT/(2KCF5,F"HS #J[\N8T&OI$*;K=RU"&VT;W< <]\+Y]
MLDK,TR63GC^0SKBGQ;$J>=R]U./8U"O*W4^U?,1Q4&^FMT\RPJ;MAIVRIO66
M2(RXH\NI4.UQI+FS%+ 4"U6+,+/XEQ>GBX?!)[SLW(#ELQ.GL1T\T2U;QO6_
M3S&-1\5;F,5&0Q9#J8E@QV9L";&?=B3X,E(6M >BRF'6%J9<>86ILEIYQ!"C
MT1L_OS_!B7^$(.$(.$(.$(.$(.$(.$(.$(.$(1K=MYYAQMB2N(\MI]+4AM#+
MJF75,*2T]VGT.-.EE:DNI;<:=:6I*4NMK02.$63?V_@:-YCQM'$<<XVNN,9+
MAN Y[FCV/O)UWR*EC9Q$P[&Y$+5#3#'J'+;BWK7VY=8Y I<GIGZ2$E:J<14+
M@3&WEE+A"0C6<  DE@2IM*4%&'F[#PCHORO<UF(\R#V7PJ'&LHQ6QQ%FDF.0
M\C:@)398]DB),O'KV"[6S)D9;5BPTZM;:E-/LJ3T+: "248>_.-NN$(.$(.$
M(.$(.$(.$(.$(.$(.$(.$(.$(B;6\[:7YB3[?)GR?S_&VGQ_WQ[_ &W^_%5!
MV.K@>O[^D0H$T%M>GE''G(<(Q3,XK,?**2!<BO?[\(3FEO)9EM1PAMQHH=94
MRI#Z4K#@*CL=^GQL=9<Z;+JD@'D2/"WWCBF</P\Y_BH!) J DN6J[C4D^!?5
MAB?T6::=R%U893.HJW _7JD1O4+;D,NB1%=5WUNJZVGTI5U=P_3X \>=_P"8
MXY-$+1E:RE3+VT(T]?.//G=GL!,7G"6H!\J!9R3\AKXOJ^]YS373YUQM;F*U
M3BF9JK-MU<8)<%FZ$=R6VIA;#C1!0G=HNK;<"4@I'G>/YCQ+_O$5<_-,OH2-
MWV)ZB\2GL]P]-Y==&"+?^BG-FH!UA5M<-PZ]LX-U<X]66%O 0MAFPD0XZGD,
M'J6EIG]ULVT'CW>TX7BE8W0XG<\:)XAB5#^JH%5B05$$ =VY>AN[?<YS.SO#
M"O,99)"0Q*)1-S6J''@?I%(>&8;"QY_%X]#7LT$KO>II414+@.&0X[(<6EMT
MK0AQ4@H<*NV3U%1'L.)..F[UIN+?^8TY5C>7P'@R6>2K7_LY-/\ [==_.+"<
M#P=NKAU#6-UJ($*0)C,-UA+S(E!#F[B0R(H3U.!E1W0K8 C=72.,%8B:N8I:
ME$NS5.B6W]?$@QM.X/P=4D2Y<F8%58F7) #D'0&MQ0-][M+B&+8T_.D8[20J
M=VRE"3+<B---%Q1V*_+;:7O*O.Q?/MX(\<4G3IDQ+)-6:I(#4H&>_AISCGP7
M",'AIF90.5Z!(0=% N"@5.:K7J^D.5Q76HJ*BK?[DN*/CP-RXMQ9.VWNL@>R
M0  !SRTJ2@!9!4Y=GU42*G8&/8F_"SM)"A+8,% !3MWG":?,[-HVL>.-(S@X
M0@X0AN:@C;!LF)]CC%N-OYPI?G8^!YW\_?<_CCV>S<M"^)+>A!%V ?X=_'<^
M$?,?J L87LGB58Q3R,7+_H(PZ@N: %F6KXB%E(22NH9^[6\<]?@H45#D.K6M
MV.Y'7MY!27VE\>IMJ>6TN7"F5TN]2PN-(C)?;1V5=:DK+B3_ ! '<'C[7MC)
MEC"( "02Y=.5KO0V\*5]/YE_X=Y,GAW&.-_!1BC\4R5DKE,@D(R)9:<ME7!>
MEKU[WN?#VY'?3-H=Y;M+TM>J5-Z'*&,PAB68*:TR"A:O!]&A$53@W'04[!?4
M./R:7)"DC*6#.Q+&A8=T U?F&TC^RUS,RC,F* 4HYB%$ ^()>C,=ND++?([R
M=0Y:;.-R^:9M27)E1+;,7&HC?5-HRAVLD.*;#+*7(3B$RDO/H;676PI+A7MO
MUIEJ2"[ "Y?\W=KA[U.V84A1HM&_S#32Y.MK^#Q*>;<O^B6I.05>5YKIYB64
MY%1T=EC%7<7,!F?(B4%RVVW84H$A:TF#,9Z>J(Z%MN'H7TIV\T4S9G84+O0V
MWI84K6&5)?OIH2"RJBS$FYJQ#V?81"M%I#RIZ$:GZ3PL2T;H,7SC(F\PQC!,
MEQW&F66JR&N&_D&45T^Y:+;D%NT5!CM2D+0Y*GOQ8C,AL-0VW>*IRJL0];J!
M=G?9[AP.A&I*E!(=4V4*FGQ$YG%Q5G-&H3?0N(D+)>3SECS2]R_)\DT2T\NK
MS4%N"WFEQ)HH7J<K;K;&ONX*KQUEI)GA%O65\E14L%T5\53BED$"Y0A[![D<
M[6/^-(D,PJ""'<,S>%&;TBT.3+E@0U,CIT/TY<C6.*M8//C*Q^$N-)Q)A3+C
M-"6'&G6&H*'H%:XVVVV%M=@;.+Z$[LDL4*0*]:]#X]8"MBDBU;>)K] PYM#@
MMN5_0:^P#&=*;C2W#;+3K"RA>+8L[3QS64+K((876M-I#E>['"G&^Y'>07&5
MJ;?"RHK,T#6#4'X'E$AE.'%"07M2A!N^](6L(T TATZRW(<\PC L4Q;-,KJZ
M:FR6^HH @S;NLH(S<2F@2TLN#:)4,-]BLCDK$1I3J0I7></$VBH*2K*"E_I8
M%ST\FKM$WAU  !)W  /C;V&WL/ _D.$6BO>1^O\ =PA&#, <2E+:22"H^1XW
M.Q^VY_(^W]N_%DEGYBS.YZ=/2)2!\26LJ2$H4Y<L:@BUM1>.._Q/N73/=<LO
MY8+C#9F*Q8VG&H3U[D"LAOD4+Z(+<G'9:UU;;D25\P?0W"=#C2"CI4IOZO)4
MGX;M%A<9.F(,K$89"<U1,GE!#9 :$-1(]O']%_HAQK@?!L/VIE<0P^,G8CB6
M#PLO!?PF%&*25R9N*61.(4DRP<R0EDDN"3E'>CH9#TKT>L\TQG5JQQ3&9VI=
M#CS>/5V9*80JUAU\D=Q^%%=2HN=J1(0TI( '=Z2?I/A7TTM<F6F5FFRR,J0X
M6D@G(U*@W9JUJ0&C\,XI@L5_$XE:I$T),^>L)*%Y@GXA)<!-,KC/_M(J6J6'
M)Y2^4SHR)#FBNF[8RZ\7F%^PU1QXL:VODVBK5S(+&(WV._*1;%$AP/!M\R''
MD;]*@H](Q,A\OQ$ @$L5)J'J;[EM "&CSL/P[%S'*)*V4H =R8V922I*1W*E
M21F3HSEVC:87-9 CL!MR.AI3;';5ZB/V]G D-H24NDG8%/U([C8'@.'8D:F9
M*'_:2VT.=+'G?D]=(TE8#%3G"),QPY(,N8] 2;(+&C,6+M2HC*3D-6OJV?'T
M@*5N6PD((6I*BYU]OZFVUN!/7U]M))0#XXJ9\D7FR_\ UII1W-=J]*Q8\-Q@
M('PE5H&"G?N@C+ES=U2@@G+E"B [$&/+&1U4A"5HD(Z5!13N['W^@E+@*4O*
M*>V0>M2PE \;*.XW@XB0"09TH,6_U$5W;O6&IL(SQ&"Q.&F"7,DS"HV*9<PI
ML""Y0 Q!!&\41DM0M12F3NL+[80 %*6X1NE"$H4HJ4H>4@#R/[.)^-)I_5EU
MH.^F^U[\KWI&DSAV,E("UR5!)&;,Q8!V))(  !N=-;&/2\CJ6R0Y*2VH(#G0
MX4(6&RKI"RA:TJ2"KZ=E +!!"DCBWQ)?_>2S1W"TD;;[TBJ>'XM8=,E:DN1F
M2E2DN*D!24D$@5H32L5=R&K8[??D-LAT?NB\['9#GY[8=>0I>WY0DI/]4GB/
MC2O^]E_^M/YB4</Q<QQ+E+F%-Q+1,F$:UR(4$L*D*((U$43D56H*V>\M^'-R
MV @[ A)7W.VI1"D_2A:B.H;@>=H^/)9_BRZ/3.DFG0Q)X=BP0#*+J;+13J!U
M RYFH:LU#R<&05:T%:'^M!22%IZ5(/V\K2HH;)4>D!U394KPG?B#B).4J^(@
MA(<G,FU[D@:&[5\('AV+"@@RB%'0@@C6Q *F'>.4*85BTB]K9+*0R_UD[[!"
M2XHD @@(9[B_!(!5T] _TMO/%I,Z5,(4B8@@E_G2* !]=(QQ> Q6&23-DK 2
M:D)4;A1#,'J 6^T:.?$'P.XUOY5]2M+\,FT",GR%C&$UPN;2/7U2$U^68_<.
M2),Y3<GM!4.*XN,L1GT*>Z$NI0@+6GQ^+XB49&(DB;+*YB)B0/B2V=8*$N2H
M&A4 6!+.3'V_Z=YL-QC!8V?A\0,-(G2IDQ29,U2LDA4K$30@!)26E2U'O*2'
M !4"7$A:7\OVGSV,:'91F>%XA:ZEZ;Z44F&TN3ICI??IH=MB\&JR:MIY[P6X
MJKM&B@N--GMS51VB4M@)V[N$2S)X=*1F2IY:"I2.\D/*ENRGI8.:!BX%@/"[
M5XJ1B.UO%L=+*A*G8[&_!^)E3-^&OB&(6E*D62XT+E/,ERY4<JW+VU?8AD:=
M(,!8M\!"6<*GHHX;+]"E$^9:M,URDMA,>*Q9V$NRCL(24MS5F0@I62>.Z6 1
M,;_F<N]*9@^@(T]8^94%2YRIA4EIKBJG4<ZBJNF[@?>FQZ"A"^I)2$E8VV4%
M;(" E*4I\A(\'^$_R'GA%W&X\Q&1WD?A7\]A_OW_ -7")BO>1^O]W"(<;CS$
M'>1^O]W"#C<><'>1^O\ =PB8"^@>?/\ =_O(X0@[S?\ I ?S(!_N)X1#C<><
M'?;W'DG?\;'_ &^?[-_UX1,'>1^O]W"$>''$J20"=]Q]N((!O$@MZ^L,3433
MS"M5L4L<(U QRKRO%;4QE6%)=1DRZ^6N'(;EQE/L*V2LL2&6WFS_ %7$!0\@
M<1E2]MO3WJ\07:G-NL1SD'+1HAEE;;4^2Z8X7;UEW6T]3:1IE+&=<G5M 4_)
MH4M\(0J2U5)!3!6ZGK9&Z02#OQ8)EI'=2QWM[^O-J1F$$%R0U?6E??YB5L/Q
M+',$I:O&,4I:_'\<HXHKZ>HJV1'A0(#:0&HT2,VE#4:.A6ZDL(24I42H'=1X
M1=QN/,0[N\C\G^[A!QN/.*]YK_G$?RZT[_RVW]_TX0S)_P!P\Q'GO)_"MO;?
M8;?X\'&\38.2!I<0=]'X5_</]_"(<;CS$'>3^%?W#_?PB00;$;W$>@\U]UI2
M?PI24G^XGA$$@7('4@13O-_8[_J-B/[P>$2X-B\'>1^O]W"$'>1X]_/Z?_/_
M  X0C"F,QYK:V7NA3+J%MN)*@"IIQ/0XW]P4.HZD.)/\23MP@% 5</I4>=[^
M<01CO+-H3BT.+7T6EF%5D*%D=KE\2-%J&0F)E%[&EP[>Z84-DIF6,:;)9ENM
MMMJ?;>4%J( W1I,F!02+ :EJ[>G,PZ-*=$]*-%(]U&TQP/&L);R.:FSOCC]:
MU"<MK%*.TF1-<; 6^IIE*&FBX5*2@>^Y/",01NGFS#[Q+A>1_P!(_P!G^\CA
M$N-QYB*=]K_2X0<;CS$5[R/^D/YC_<3P@X-B#!WD?K_=PB8.\W]U '\$@'^X
MD<(AP+D#Q@[S?G8[[?C8_P"W;A!P;$&#O(^YV_GL/]O"!(%R!U@[S?\ I#^]
M/^_A!QN/,1Y,A ( "U;CW0 H?R)"O!X4W Y$@'U,05 %@"7U <="=#%>^C\+
M'Z;#?^[?WXMEH^9.]X9O^57E'M"PX.H CSMLH;'[?J?SQ7Q!Z%_44B07T(ZA
MHBC6\*<TQS!IM#CCBZA;:$-M..J6MUYOI"4MI420&E%0VW VVW)VX@_<?41,
M<IDM/M]85&DI4I:EE*X[K2T]6WTJ0^EI6XV\E(4@[[!9(($PCUL[_P#H[_\
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MDI4OCZOCF.3CY 0#WDZ[.:AP5[5 &AM'Y9V X?ANRN*FS\6,'ATSC+*?BSI
M^(H,>\@%"TJ2*]X(8L'K"_,Y**W*;#(<ATVYQ]!IM/4Z6TU5;547,XO[/8=/
M1718=I<6SU+<+O%8Y9VL)VP:A2LHAH18O.S/I?Z4H^'E<*Q.=TE926"6*B_3
MN -U %W-X_;\1VA[.8U*\2<;ATE0$R:$3L&F7+!)2]9Q*4DVJ2]G#1=TBY4L
MBD74FIH^<+E0?GVE/DT>12Z=9K:RY]W7R[FON(E/8-2\SLK5_%ZV-&F0G6([
MK*FXTUX^I<W)'1B.%8L)K\4=7)J[$,@OT;2HO')A>-=ERMD<1PZG=TIQ.")H
MQ403-&G07K$]X#I%H#@=KA-C?<TW+!*L*F9E</4N@>S3%7Z(T3F02LCPG%,6
M:NLL=LH6.8#DDI+<>FF/=^3!)B.RVY!,I0\&Q*I$LJ$SY$L22RB 14B70'0J
M %*D$D1G_P!(NS*<1-".*X:DPND8K!@I#A@WQM&8@.1L7>,C2+3-?+WJIC5K
MJ'S1<I-5'A:E6>J.18E#N*3!3 K<HPJ5C#L?%L;5?P(D:%8*<:O6%3&Y;:9C
M[I0N0@!;E)/!YX4%)$PT.7*"74,KO_3<;@D)3X5&F([0=G)9[_$L-+4&.5>*
MP:&!!()!G5#&H#D4+ %QUVL^9+0'':#'[[(-8=,*'',DBK?QJ^NL]Q"JJ+Z'
M&0@2)E18S;>-#FPV%+2VY(CK[(404;MJ0HZJX9BW6\N8Z2ZJ*H7I_:02S425
M$. 6) C<=H>!)DR%_P RP81-0%2E*Q.&"5H *2I),P!@4J2] X(%H]5',KH!
M<U-[?4NL>EUI28NU$>R:X@Z@8=+J\>:L X8"[BQC7;L* B;V7A#6^^E$HLN>
MG6X "1X9B@0"A9*G 8+)(Y@(=(-V6$TZ%ID]H>!S0I2.(8,I0V=2<5A<J"HL
MD*4)Q27((#$@D4,>L:YD] ,MF2*[$=9-+LBL&8\BQD0*C/L2L9B848'U<PQH
M=PZ^W#8Z>IR0\VAM*1NI?$+X9BDA),N9I\H4IJ4=DD<BUCM>$CM%P&:9J9?$
ML&HH5,*A_%X4?(1G-9H%-26#5%&,(*>;3E;,CML\P6C"I2GPP&DZHX&I:GW'
MA';;2PF_,E:URE)92D-J47%I3MN>+'A>+(8RUBCLRG8Z.$L[59W](Q1VF[/&
M<4CB>"*BK*W\7A')*F#)^-FO<MUTA7O^9SEVQ2RETV5ZW:2XU<UZ4*GU-]J-
MA=59Q Z.IM3\&;>,R4!T>6SVSU @CP=^('#<30"23H#D5ZN@-_Y@(T7VCX$A
M2DKXC@D*2>\E6*PH4.H^-4]'BY=\RO+_ (S#J;')=8M,<=K[^&FQHIU_GF(T
MT2YKE*"$3ZR397,9F9#<60EN0RM3:RI)22% F?Y9B:_TG9G9*BQ.E$[5+..;
MTB%=H^!I""KB&#0)B<TLJQ.%2%IKWDDSA0L0':NC5CU%YE] )M%99+!UBTTF
MXQ32VH%QD4+/,1?HZNPD)0XQ"G6J+DP69+R%A;31>)6GZANG8DCAN+=@E9)=
M@RR6<APR" VN8@[BH$2KM'P,(,W^/P9EI(2I8Q.&*4J(H"?C5*JD-F%ZAHX)
M_&)U;TZU7O>6*GTYU=P[)*QW,K=K))N!:@TMI-HJR9-QB')G3I&.V\IVJC,,
M*DOJD36 PEEMQ74%)*3^>]J."8Z8N6$KG(25 3"\UTYEH% F7<!ZEZTJ"X_J
M;_AW[2=@_C\0F<3Q_#YLU*1,PJ%XOA>6:M$G%94D8C$)/>F)2DE)>MTF\PXG
MR;?#SB3<6LFN<_U%Y&>II3<3_A'X,ZW/GQ EUF*J(N3UJ*G-TNM*3W/! 25;
M[>NCL9Q'X:%!>+(R @_U&HEP0!(=C4AJU#AH^!XO_P 079:9B\5+'#OT^ 1/
MFRTO,PQ7W9C$J;BC%7=#B@)UM#EU$Y0OA^Y%F^9WN1\XJJ/(+;);&TR.F7S%
M8%6)K+AZR;L)=:*MR6B3 :;F@,F EHI2%%"B%$@6/8WB1.8+Q*7+A(^*P!8G
M_P#APS4-6(&@H_E83]?NRV#2)2\%V"490$M:ITS#?%*D!276%<5!*RY)(L00
M[!XE/77ECY+<[K=)&=1.:>5C4/%=.8V.XF\G7+$:L9'B<5ILF\4;1Z5\Y<4G
MH*+..9#FZ^HG;=7'8KLSQ*8 E)Q*<J0@M\09E.23WI1#E[T3:J:1RR/UFX!@
M?B+F8?L2H8B8N>CXRL.D)EE*981+R\1EO*=)_P!QSE3E5A'HY2N01.E+F()Y
MN=\*&H[-R[DW]/V"A+>70J2UB1\>=OE3 T4N4\JPL16A?0IB"\^/I;/5@KL=
MQ)89\4265\LW,P#4_HT!![R3W@IM.\-C^N79Z8L31ANPN5'],M,D?#*EE*QF
M/\S;,#*(07&9)6H,00'_ ,O/+/R582[J%(TJYI9>=NY!A4ZBRL0-<L0R9JFQ
MMY6T^X:%%(0S6KB*/2_/;*E(V(V(VW?]$.)(+J.+.<94E0FU400P_H=U1_M"
M@SLY>D98K]8^S_&)B<1*PO8D_!4)ZSAU8=0R(RJ4%_\ S&:1+(1_45F&5(-0
M(BC">3WX>]#F.,7%#SF?.;N%=09=72GF*P2P;N+2)TB-$$9N5UOK4H +92"5
MJ.PW._#_ *'<32+XP@5(::;-6DA2C<V!(#5J'UF_KEV=Q2#A$X7L&Y3E!$R1
MF&9RX2.)J((O346>,/*N3WX>EGE]_<6W.0_76MAD5E96E7_PB\%A^@M56;CT
MZ#Z!4I,F,W$FN*C&'VNEE:0WY4#MJ.R'$RG-FQ8+@A/]44JQK)  >K7>]8UP
MWZ_]EN"X7^1XC!?I\O$J'PQ-Q$W#?Q.<!2: \40LJ!F)).0$%@0XB9.8'EBY
M+LZN<-F:E<T$C"YE3A]31TT5&N.)X[\YQ^,EM,.W]+(D-)F*D)2E3M@P'6W0
M2I2@"3Q1/93B4PT.+2 DN2)@<@58&0!4"M7.A>.3!?K%P'LO,G8K&R.P\Y&.
MSHEC%S961)G@2D?#S<1E$!*AW&S@DT)HS&F\IW(+)TKQO%9/-N8^&P,FO[.K
MR3^G[!&/57DN/'8LX#UTN8EN;Z!IN,X(H6LL!]LC<+ #_H=Q)BD'%N YI,<N
M!0'^'[P?2A=R0*&-?_CCV?S?&&%["Y<OP@DS) 0% E15_P#5" LA56)[H&A:
M+F(\J'(/4Z?ZG4=-S;FVQK)(U-'S"V&O6#RU8^W72FY%>XW8-25_*?5R$I;*
MT*(D=13L?(XJ>QO$F4@JQ9*@P83&+@W_ *#):_>;D#6!_77LZ&F_PO8("6ZB
M?B8=O'_YH'85<%[A[&'1RY<KO)#I[JC0Y3IAS5'.<Q9KYL6GQQ>N^$Y1ZV-T
M!4EYNDAOO2'E,H/EPAM8 6?&Q(OA^R?$L( 5?Q2P "<R9IE_*!WOZ(*@"'=(
M( (J\5Q?ZS\ XUA52$8;L0%3F2A>&7AS/S,3_3 XFM68NW]P!N&#'GESD<M/
M)CIKR]ZA9SHYS6OYSGM([0KQ[$WN8#'<F?D2+;),?8M&T45=9&Q<$2LLI<]3
M"$J$&'#=*U!; 0OR.(]C.)J$V;\3$O+S3.]\7+E09BB[23J" +*!!>M/L^PW
MZT=DYD]/#)^%[$(P^-_ZK.Q&'G8(8J2G$_ D%4@+XCD$U(?(I25!,Q0>6M(,
M=J-$^9OE[QC1S1^BR_7?26GR2OT\P)BPJKC4W"H-Y72E8S3NNUUG4S[]F9&G
ML'K:D(="EM/=(1W>HGCZ?@W!L:C 2D@3E?T&42)C9OAR\U3+LVX*@ Y:D?D/
M;SM+V61VFXB9'$\ A$S'SU2$_P 9@"HR/XK$I061B" 5)1_:&<LEXV&O>8_E
M_P =ATTO)-8=,:2%?1'+*@F6^=XE!CW$!EL*<G5LF1<)9EQD)(ZGF%J3U;@$
M[';OD\,Q;3!+EK6*A=%4"B!JD$Z59A3-I'S\_M%P%*91G<2P:,P2J65XK"@*
M&4EP\T\PQ9R" "QA-:YI^6M=7)O4:Z:0KHX4EF%+NAJ7@BZF+,DH<=BQ'[!&
M0*BM2I++$A]AA;H<6S'?7T@-GBW\KQ=LJB2+,NVMT,&M6^CTC)/:?@!#CB6!
MR@A.;^+PA#GY0XGER0Z@ YR@DM:%:EYEN7_)E3&<;UGTIR%ZN@.6<^/1:B87
M;.P:UD=3T^9Z&]?1%B,H!6Z_(6VVA *E* '%1PW% C^G, =@2E;/LP1F8_\
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M$N 031@"*UA1I>9/E\R5NT=Q_6;2F\320!:W2JG4+"[%-/5;[&TLUQ+QYN#
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MW\KQ9(_ID@BA(4Q (_Y'!+NRF4QM$CM-P #_ .I8$-0@XK"N"W_]8NVX)!-
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MXF192'YC;[,M#[3[:DK0 &VVW&&WD)2DA+HV"0!U&W\TQ3'ON2&<F99B"/\
M4];FKZ1RRNP'9R5B/CC"K"@K,%":Z@0K," 4!-"Y;<M:D.W4/D Y7-4\FFYG
MG6EU'DN4V+33,ZXLURG);[3&P93W&W$!'92-D;(/L/(\;0.*8H, H,-'F?\
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MVBV(0+&GGLV%7)9<LUN1)#.Q3(0%OI3W^L @G<> 23[<2KC>.*6$XN7TW_\
M,=.75XY</V#[.2)_QAPC  @@@B3+)#)(!"3*858L#1J%XM7/PU^4&^O)N26>
MBN*R;JSG2K.PG.2+(ORYTN6N;(<<=*RKID2'%./)  )(3L4CC-/&<>@,F8&
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..4H=V.5W-SW0D>CQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g418853g00a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a04.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1A04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#2^898X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $T1E97!A
M:R!086YE97)S96QV86T .$))300E       03VU_L"E!NVXS#Z"992D'2CA"
M24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $:   "9     8 9P P
M #  80 P #0    !                          $              F0
M  $:                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $:     %)G:'1L;VYG   "9     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MAVL#V^BUV][F5/9ZU[;K/ZBKC/W5@'J%P=ZH<U_V<B!M>XM+1]*MSGM]CO\
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MIM(@DN_.=]-OT-ZD,/J/N#LXEK@X "MH()(<T[P=WM^@KNUO@$MC? )6K@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $, D8# 1$
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MLJ[=Q-P=MH$MYJK;<1;>J5:G26THIDBF7%Y:Y%F0)K8=BO--)@/)D)4\A<<
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MO-0-NJ50*E5I$EURZ:C$I=NT^&PER=5YTY/68C1TNH;;#P8)6XV2D@IY>8$
M'79AJKC4$SD,&PD7.P\HG6)C5;6)Q;*%*C4S_P#*"1$$NO87Y#N'F+J]V]NG
M;E7@"3,J::,ZEV:AR)6NC3)[2(3[D9UYV))4A?0#C:BIU.4)3A>0DC%G8.N
M(DF?P@&8$QJ8FUK$[66&AQ;"N!SU&@SH]P81>-+<CN!OXWOW<VVEY,9=R4E+
M[B4N-LKGP>J6758:=*4.*40Z1]P6$E#B5HP22=83@<:XES"[(!ID&HU()OIM
M$:V,+;=Q/APRM%6G)B?ZAUN# )T-K\^Y3WKNI$8R6Y%8@,+BM*>D!Z9%0J.R
ME(4M^1SI28S+:/NBG'$<N%#OC&K?<L4='.D;AH(.UXM()F_T$'&[B&&:2"]@
MBY&8:<R"9 ]%AU>W=M^A5*UZ>N:*D[==?CT""BDKC3$QWEPW9[DJ2IHK4B,(
MZ4GF*4E20EU">FXDZR,X?BBTDEQRP22T"QDWGT[H[U@?Q3#M>QO6-)J. :&N
M#C:,QM)OF $Q,2+&5EWNQHB6Y#KMP4IMJ&H-SGESXB&X:EJ]!#RW.1#3RL@
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M@^ @DC7Q,1J1KO=3>^VMK9=MTJJ3IDZX+NGKI]M6Q1HK4^NUE]AHR9BHT;E
M\GB1FG77WE%"$-H6>?FY1JF%PU9S*CJW;#+R1ECM$0<H O(O$V$Q-\6,QK:=
M:E2IORNJ$PUH:20UN8GMSK$:R9MN!D=M;GTRLPZBY/$NW95',%BJQ[B9137(
MDB>VM]IM+CF(TA?3* 4,NJ)( 'I$#5WX=[B!3!&8&([7=-[B\[V-CS66GBF-
M:36>);\4PW=VD1<B+:VWNKR]?MMQGDL2[EH[+R4-+*7)T*.I[K=D*#+KBG R
MX.[*@H=122A*CW&L;<%BV',\N<V(@M &8FT$7L)MO:QO&-W%L"#EZVD#?6H
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M!0.RD@D:P5L+B&-D$QI,-F\1<R(,ZV.XFZV,/Q#"5JO59F%UM'R="XRT .!
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M%-SW6AP#8(&6T7!+KG9QVF(V':Q?1[I'BL+@Z;0?Z;G5"<\.&9K1!AA@2"0
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MU1:)<_G.IQH<^.PW,9EUNAK?B/O5%]*U(80A:<86G.>+X8.!+66%CN+Z_&2
M!:PN3Z8Z'1'CQPU0==5%7LEPSCJZC02(,49!:8(+BX3(RS$=><*NTE_[?/\
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M2TV0?$%"2#Z)1W&/P"4_(2/7JJOKK=0##(P0TV"$I0,(2/10>9*>P\$J[@>
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M3*_N30?-%Z;\SZDEJO6C6:<B+:-'IL2'[DIAE,0DT]N9):ZLN2B.MR470_\
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M\BP#E*V%^EG(0E:'?35G]QA)'I=LX]?<1$.#M8BWG[_E6+2^FYMA,B^\@-
M[IOXA<&7GPB6)>]<W2KR[OJ<=G=&?:]R.,1VHK[%%N.U5I<I-;8+WW22$.H1
MU(3I;C*Y2DN(R==;#X_J + D6N28L =)F>Z=Y&J\?C>C#,=5K%SZC>M([+.;
M2729U@DVT(M,+9^UFRU&VGL:[;=I%X2I%QW?7;@N^N7=.AQG)"KCKZ%=6J-4
MOF;A-"(W"S%I[+JFDH0"EQ:B5FN(QO75S6RPTM8-;=D $<S(M>-#(U73P' W
M8+ #"2XD.J5,WXIJ/<\.\1,@F8N1$+E.]_L>MO7O"N5^;NO4&;FO/;NE;75^
MO0K8HL<5&F4"2EV!,12D23&C5%++33"GU.*:6TCP0M12G>I=(?NT 0(OJ=3>
M#W"2/&0-PO*<2^SZEQ$O<]U0%S0PA@: 0T,;8G0]GO)U-Y*V;0MD61<.T%L7
M"[5:LG9.EB71MRPQ3Z7%KZ?(#3G;>E4:,ZM]I+"4,R'BTI49UUEMQ07ZL53B
M76N?B!_U9=8SJ(L=1&^^W<MK#=%^K^Y8$YW#A\-94,2X-<US:;@" 0'6L+S-
M[+"JUP&TVMQ;^@+WHN9BG;A;J5;=2M1H%+I<5E50K,%<1ZCJ+;SADQ4,*:!3
M);+CJH[2UHRD 2WCPHD69 ;E$ZQH-!$6'L2HQ703KA4+JM<=95-9UVY7.[=X
M&I&8B= )@PL7J?V.:@3*91J5'WEJ]*@4ZP:5M[$:;MVD2'7*72JV:W%?7U'P
M"^[+/3=4$)"^Z2!DC60\?;4:1E$N.8F=9 !-QZ: Q,S8:K?LZ =3>:M8]72:
MP AOPM+G-!CXA+S?4@"QA=A[A;04C<3;V+M],NQFG--QHC#E151HM14M^$VE
MMM]/E!2S398*"I+[,AIULK*4*QG/.J8H/<7 :DG:P^(1O BXOK&P"]..#N%*
MG3>XS3;L!VC!$G6#X1-B=PI.Y>Q=B[IV!0[&N*KSW7;372)UN7()"9-<I]:H
M;;8A5A<J0T67IDA;*')33B@'0I2'#RDG5<'Q0-=F;EETAP)U L--P!/KJLF,
MX2S%TFL?,-@M(@D&-;C<6O;0:::)J/!/9]VR]QZUN/>]0O2N[C60U9$N9&I4
M2@PJ?2HZ'2W4(M&A+FQG*TVXI*W)[Q2):V4MAE:5],[K^,0YAEIAP+03R,QX
M'8[^)D\&MT2I5Q5:]S\U=G52PY")!&<6@O(L9D7YPK55>""@3[1V]M*EW^W;
M:]OJ[[H7:I1[-HD%5RU-% >MN*Y5V&5^2F?YH<07GVGER)90A;O(#C6?_71)
ML!( -M-S%])U!)M$"UM!WV?M-&E38][.K?GD,8'/(;U<U+DDANAT.8FTE4=H
M< -C6Q5MO*U+O%-S5"P;>?M.6JX;7HDZ!7J.*EYZBN.T]X+8I]5I4\-J14("
MG%)[\Z4K45ZA_'I:187FVEI'C&AG4'P"G#_9]1HU&57.JN+&QVP'#+8M[, 9
MFQ!C63&H*R&;P74:?M1NWM6O="HF%N[>CEYU*L"CTIR13([\VG295&IL9+J&
M7FG&J<B.)4@K?2E:N[BDH P.XVS.UW9EH<!WYHF8\+:02=;A;[.AY;0KX?K7
MEM=]-[B0VP838<G$W, @V'(K9NR/#M3MF+HN>XZ'N#4:A2[M3 DUJWI,*)'B
MR*_3J6Q2#5XLP%+K7EL.,WY=%80M"G4A7.E7?6OB^+-Q%,-AH(>""+=D&]R.
M[321S71X1T:/#*SZC*E0M-)X>QT1F@PZ1!L+1 UN=UB5R<-=3K'$#4]^;<WI
M>MBMS;+38<6FBS:5684*AJJ,2:I3"Y4EB3(G+F,,K:>)=2DI7AI1(4C-2XBV
MG0#2&N;9Q!D M G7747'*TC1:O\ H1K\2?BVUB*I:6-R#X!+0-9!($ 3RFSA
M(U]7N!FE7M5957N3=NN5F9/L&/9;\EZATYN4N;"N%%U0[B:)6F0B;#J#D9],
M7!86RD-. @D'(.D+<U@RT@ @V;)Y>@MIM "T:G0EM>L[-5JDY.T!!.8/,F7"
MX!(T,F+*JB\$E/3+K59>W;J<NY:K>,"_Z/75T&E):H=PTZD*HDF<( 4VQ4(D
MR(IQ4E$A]EIB0H%+H4 A5O\ < @ 9; B\D1/Z&0>ZUEA;T";UQ>ZI5+R[.7
M@ .:#'B3'<0;B\+)K-X,;+VVK>V]=V_ONMV]4+&M6J6?5$^1PYC-TT6NUGS[
M/DU"._TO(Y7G>:](CS(Q#C*'^EY-(0EI>J_ZT*X>'-!B"V#;:T6-\LFVLC<
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MV\4(]8*1XCV$@?$2/7HB=%G\4U^@CUGY/6?G.H(!U /BID\SZJ06FBM666B
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MB/\ ^L>T17>1][/_ , O^C:^H_,=$7-^^ERW79^Q+US67744&LT.%;$Q<AR
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MMRZ>VVV.=UYSS?(A-LH:0"M0=J*P0%<Q &K'A6"J"65J4D2&N+))<.S<&US
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M3W[FYFVJX[^AG YC[EAK@WZMH(,6,D"=KF=#&AG6DOAM^QX5<-2$[?U>B+E
M=)<3;O=FUEDJ&><EVUZ>6R>;F*5@*2>R@""!?_7Z\W>+G03I?8B_>==-(6 ]
M!>!EQ_\ #M!-P!E G80&SX\M-()P<\+'"'SXM[<[>.R_*7&&F/)*GNO2$-^5
MOJCQ0VJKTM+24K=3R)4G" $A1*6R%':'&7[-V&I!!\.7F8[]5@J?975<,U/%
M8UC'"6AE=Q :3( #J@ AM@ (Y#E2C9*P::XANV..'>.VE*9ZD9JL5JJR6W$"
MHKI 4GSU2H^4^<4*C *.5<H6!T2'"/$Z;KO8PS\79&P_[;$#0^BTZGV><5I
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M&/.?E,X ]$ (",8]'.2>55Z(XVYPG%_NYV)PQ?%M(ZX;QO$#2ZZ5'I;1'_\
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MXH<V"$Y(2-619QHBQVY/O:)_&$7^D&B*_->]/Y2OUZ(K#<GWC_UB%_6DJ_\
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M:)NW,V\P8,F)G9XET9P^.8[%<->VK2<"XTFDES 0##&EX<X'*26P"!! +5W
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M7,"&MR3=W:D?*+FVO\U.I5DT1-$31$T1-$31$T1-$31$T1-$4M385XGL3DX
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MH$9A!YS*Y2INXN\/"Q/B43=5JH;C;4I<$>G;CP6')59HC*E%#$:Z(Z3S%IA
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M.UIJ#->0"?,[1<&9L.Y#ZZ?3]-%] :>08K6 D8'*H)2$X6.RP0D!/,%9YB
M3DCMC6<Z^GTMY<N2*LU"+GGBT_XKG$?_ ,QNZO\ W%KNH=H? _1%LK:S_-GM
M[_H3:W_8D+4HL\T1-$31$T1>5(2K(4 01@@^!'L(\#HH(!,G7Q*E*C,+[J;!
M[@^*AC (& "   2 !V^+5#382"1)&AD_NKYG92V>R1!$"#>>7/?7;1>DL-)!
M 0,$Y()41GP[9)Q^;&#W'?5]! TY>*QAH&@^9_=6NM4:E5J"Y JL"/4(CPZ:
MXTMKRB.X% CE=95E"T'P4%)4".Q!UH\0P6&XAAG8;%4FUZ)<QYIN) +F&6GL
MN:;$SK'<8"V<)B:V"KC$8:H^C5 (SL,.RN^( WB=_1<37OP<4B)67[QV.N6K
M[,WBIP2W7*!)DR[8FRDE2B9EN2WI$!"'%<@6W&CM,E/-EK.%#QV+Z/\ W0%_
M"Q]U< 2W)-03!-NL<\[-B1$- G9>KP_2 XF&\3!QK'&"UY#'%LQVLH8TV+K@
METF0,Q"L<3?G?#91U<3?JSGZW;S"T,LW_8\14N&\A1!5-J%#:;7.CDI"E.J:
M5TDK.$H [:YV'XMQS@U7/Q2I4Q&&=_2IMZJF(<'3F_ILD]D1<M&]BNE4X/P7
MC#3_ *46T,0&E[V/J/+=!V6%[AE#7'X8>8).:RZOL#>*QMS(":E9MU4^L,^A
MU([*VQ*94H'+<B,X&GX[B2E04AQ!4%#E]6O9</Z2<-QXRM<&U/[7.+38F20Z
M-8M'+O7DN(='^(X!TU6O%/=P:'4]CV7MFT$'8F8U6U&W>9:AU22 ,I ! )!.
M,CMD8]1\>W;!SW!&H>'--A=IB+;:R>9VM*XYDGX2S+$FY#I[SW<C:;W4.J2X
M4!WTAXC ^+';_P"V/B]ERQV4F#!%B@J,TM,\S,?I//EWJH;)(.5<QYCW\,=A
MVUC8'@'.9O;2P@:D:E6,;"/FIFKJ$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$6.W)][1/XPB_P!(-$5^:]Z?RE?KT16*XTA4!SG"RV%,\Z4(0HJ!= /OB#G!
M]7;\^L534>])-YM%O&47!M<MR2CC0H%41 N[R%BETU45YB.^FWE)\AJ D$+Z
MJ8W5:*6VGLH*ONN"<D:S,T/>+DDVG;2W@-8B HB_J->^WC^DE?0V.<LH.2H$
M'"CRY4G)Y3Z/;N,'4'PCN_RI4[1%Q[Q(?YVN!?\ Z6%U_P#@QXN=$78"/>)_
M)3^H:(O6B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HBQE_\ ;0C^(_\ ZQ[1%<YF?)7TXYNHTI*!G!"A&6HJ4?4E
M("59P<$?'JKC#7'N/OW?DB^4O$==<NL;I;=46J6G<M/HUBHM26[<,)J*JGU=
MNH3J:PEF<_.A/(?I@?*2]%@K7)4LH?6A(0DG'AC_ %-A8:?,P#8QRCU"'W$?
M/^+KZCIJT*G0H;DV9&@,.>1,H7+EH8:7)E!+#$%EQ\,]=]]S"F0E(4X5)Y4$
M'MG=$F^IL=)GND^DRB(N*E.5-RCMUBFN51D*4[3D3&53([:5%(==C\W5/88+
M12"?\J.RAJ$6G.+ D\+/$:3D$[&;J>)R?VBUWOD>T=_B\#J':'P/T1;-VL_S
M9[>_Z$VM_P!B0M2BSS1$T1-$31$T1-$31% @>OU=_FU!( OH?/WHH,Q;522A
M)5GT1@D@Y []_9\1U66=WI_"I#_[OF>4<O>NJME2@1YC"F)<9B7'=*PXTXA+
MH*5)/[E0QW./'([=QC6OB,'@\=3-+$,8YLRV0T7((,2-3)V/-9:6)Q6%J-JT
M7.#A8EA((;KM!(FW*_>N/=P^$.Q;AJCMS6)4JCM;>ZU%]NN6?-7#+DE.%)<J
M%/:*(TMM1]%Q"T94@J&2.X\+Q+H14;4.)X>]U$FX#,Q; MM2.H<=#I-@O:</
MZ;5&L^[8]M/&4S&852UM4#D.T6N @?$T\K:K XVZ?$EL0I47=ZTD[J6;$)*+
M^L)HHKK$-'^4?JMKG!=4TVM"GGF%J*BAPHR3G6MA^,<2X)GI<3!=GR]2\E^C
M)-0@O#=>L9((, #F%MU,!PCC':X<XT:KIS4GM:!/X0UH<71#'$]6>0/)=-[9
M[[;9[LQDS[/N:#4%GE;?@.+,"JPY"DI)8F4Z9TI3;R,8*>F0E0(SC7I.&])Z
M&,.0/:9$ $@.OM=\$CNC31>?XCT6QW#SUU3#U0P3%1K'.IEH)N2&#+$7#OGJ
MMVMN$$)2HK<)R4J=;0>^/!L>^'B KU^&>VO3L>*C0]NA[Y_4K@N-XMV>SZ;W
MN)Y%5J%\Z<X((."",8(\1\?CX^O5U5>]$31$T1-$31$T1-$31$T1-$31$T1-
M$31%CMR?>T3^,(O](-$5^:]Z?RE?KT18Y=//YL>#0 =68Z$*4/1YU26TMA7M
M3S'TA[#\>L3]1X?O[]E2+'?R,%?."!2=W:!Q7T&;N!4+<GHKM:>8I*V&$/5!
M-MQJ54'6&(4A5'=53X\;E0JHEFIH==D);6&T\H.J9G#\1%B#VCIW\["]U'I[
MO[E3;\XO;BI6[E8IMJUJDHLZC;1[BSJ+;3T9Q^;5;QM>N6M2&ZI6NS=3BT[G
MJLMNB1:=*:5.8@O39#R52'&6\S28!U)._G<S,Z*#OKH/YC2_TD+H78:_KVJ=
MY7[M]>5T2+Q>MBAV=<\&Y1!ID%99NR!(>DTM;5)C0X,E$61%>5 <$=3S4$L"
M4[(EAZ0[(,^7[ _JI]^_>RU)OGN]:%P<3?!MMA -<-U6]Q-WK-GLR:!5XE("
M6^#/BS9ZK-QO-(I<A7/.82AJ,\IU76ZS8YX7H2B^BC:@IMM0((4A*@0"D$%(
M((2>Z0<^![CPT1>]$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31%CK@!N8Y .*#V^+_#'O#1%6SN\>8D]TF')RG.
M/N+*00?W)Y5K&1X G0Q!G3>=([T7)&Y,/<.I5S;YJ':ELHLNE,V_*7=JK?:O
M*Z:4^@1^HW3:<_ABCM+1R#SN4R5,Y4I#:"D%4  7&L 2+&/$1/?S!-D\X]Z+
M4?&5!W#J%6VYF,VQ/J]ET'<W;"=2_-E>I\*+,K2JZTI]ZOTE2Q,PQ'4>G(+?
MFYML)#P2D8,D^NT^'KZ(L4LBG54[OTN,NG34;K-<0.X%:O*K/1I#CIL65!2:
M#$D5>..G+H<:D&GPZ9$#RH$:>R^IAI#W4)@SW>!Y^-_HH^7N8W]Z+<?';>NZ
M-O\ #]OO2;-V?FWS;L[8/=7SO=$6\+4H4>@]2S*XU*6[3*Q5H=5FJB0BJ4E=
M/CN+2M)4D\^%"4)]Z#U]_2>M=KAC;7;X!(3BRK8]$+*PG_$L+T0LDE8'@%$D
MJ'?)SHI6=Z(FB)HB:(FB)HB:(FD ZB44,#V#YAJ('(>@1.5)\4@_F&F5MCE$
MBX,"QYCDBE>3Q\\W09YOPNDC/?L>_+GN.VKYG 0'. Y28Y\^:IU;)G(R>>43
M?6\;JEF18DCD:>CQW2H' =9;6GE1@D>FD]L#L!GN!VUH8G"X.NYC:^$PM=SL
MV7KL/1JD1EG*:C3$PT$B\ <EL4ZE:G-2E5J4\ER65',NZ1)@CS[I7).[7"SM
M3>DR9>-,8D;?WS%0J2U?=DR$V_6H[C0ZW6G/PVTQZE&;+94['J+;Z2CF (22
M#Y#I!T992P]7$8$#!/RN>'X5HH92 3/].FTG2;&9 B-O5\%Z58MU6GA\4YW$
M:,M:ZCBGOQ <P$-#&-J/>),P#ERP8(A?(Z9Q@[L[1[_4Z!5=R)NYMH6/(DV[
M/*&O)/=33U+*5S9"6I*(LBL0'G,)DK;:B^@DMA#I<4K\_P!;[0>DO1SI!0X<
M:W$<=A7M94<Y];%5J<'%]2:<'%4FMAK"8-,P'"3L/T/@?LVZ.=)^C6)XK3HX
M'AN*#WL#&TJ%-[:HP;<0'D,PU4D!]0-+:=6DPAI;EU)^K%I<;FTE9?C0+GEW
M'8E3?CQW4L773)-*AX?0%-<E463 ?#B3S)6A]15D!1.1K[SP?[0,-C,+1J8K
M#.H/--A.=C-<C)+IKN<Z2;VN9NO@7'.@.,X=BJM.ABF8L-J/:.HJ.:V&O<+-
M-, :&V9T#*#>5U-0[PMVYF$3*#<$.K15 *+D&I17T!&/15EAQ2L*QG/-W'<_
M%ZK!\>P.,8U[*C(EU@Y@/9)%QF)O&G^5Y'$\)QN%=EJLK,,#X@XSX$- O,S/
MTA9>ATJ2.4A?C@H).1GMW))40/$C/?.NLRI3J@%M1L'0YA,3_'<M%PJLD.;<
M&\@S/+^(LIHR0"0X"1DCV?%J22TP 71:>??-Y0 FY+@3L#"\'(R?NV/R@/YL
M?S:J:A%XDSIEGU[7S@>2G)^<^I_93QX#Q\!X]SX>L^LZN#(!TD3$1KW7CPE2
MHZE$T1-$31$T1-$31$T1-$6.W)][1/XPB_T@T17YKWI_*5^O1%C]S)<5 /(
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M,*XJ(A)IJ H%U41U#G)Z+9R4JO\ Z/PQCQUF(IB"TB[IUVFJ9F(G+K-K2M#
M=-/M1?3!J<#IXFD'.%2JX88N:PP7 ##A@+J;)<UH876$YIOV9PI\37'MN)N=
M2[8W\X>*3MQML_1:])J]VP*!<=.FP9M-HZ784)AV96I[3:YE2)Z:S'<5@#D
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M89,4S=IEPUZXLOBGV3OF! DTS<JVVWIC++HAR)R(\]E:B4AAUA03S**DG !
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MNF]%*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*P.?MB_\
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M54Y',59Y\%1RGEP%=_:#ZQWR.VH#Z=4/IECC!<QV8. ,&"0=P=B#?5,KYD.
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M6!PCW18R,^8R<>O'E;G?'LT4;CP/Z?L5<Y)!:D$$$&(]@@Y![*]8T4JR6_\
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M)@3A.V/V.O8_;Y%415*3[NT59;/*W=$"))7 Z.<EI]*2>5P^)3R$#'<]]:&
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MZ##IK*7%NIC0(L>(P2HG(<;CH;05JR5%03W425*)YE$I7*O$>,;L\"PQR_\
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M#N(3^1_Q:_W)Z2.8]0DCO]#^R@>.+8D#)IW$)CM__2!Q: =SC))V3  []R2
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MQ!J2H!25#A XM2%)(R"#^PGW!!!!]FHD<QZA1([_ $/[*/V\.Q/P=Q"?R/\
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MF NB6]!J%2=F.-RTRGWH\%#+#D<N.U8<[RV(@Q.OF;6%QSW4Q:?+W\X\%V)
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MB?\  4SZ9G3-^5WHB>>)_P !3/IF=,WY7>B)YXG_  %,^F9TS?E=Z(GGB?\
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>)HB:(FB*! /B ?E /Z]$0      >  P!\@&B+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g418853g00a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a05.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[16$4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $6   "80    8 9P P
M #  80 P #4    !                          $              F$
M  $6                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $6     %)G:'1L;VYG   "80    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$1  (1 0,1 ?_$ !X  0  !P$! 0             ! @,$!@<(!0D*_\0
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MGY?J7?5\_.GM'T1/#[#\J'?JXW[M2#J?I[(GAY_MMCT^@89?_M7^[2.)/3[
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M([ON7(Y'M1JH_9RKLW?2&Z#H$5ZP0.1-V0#.148J*D,&RH_;EV7N.OGU_?I
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M$P'D ..&2X$!P#&@L,"-TD-(,-! ;S\!VT[<P-VEH:]GR/+(:)I!%7&H!)D
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MH]X=N@ _NFH(_M<KD!6ML D5415*@VZ_^=;[O]_S:V3O.;$Y>JNT?Y#^(/\
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MNO>MWVW_ !>G4D'7Z#ONZ^<_:U]!#QRXK\;.SOE%CZ1_C+E8;\L3%[/(>),
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MKF0KZJQ;!*-#&4N&T=1%9-;'815E54@,.BC[Q((36AU\2%QL;(Z/:='N[O\
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M^SY]!B8Q_P#ZW\:#Z4J=%G<PZSB $?\ ,>G[J*59(6KRH]>J=-W.55]_EO\
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M57'=)\9?K7[VB*W=LBJGPMT=M^.]$V1?:B.VZHFVWY_FT17#94<Y&HBIOO\
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M2W6KK9FV%FE9-'"A\==WTXX;R#VBS1".B=^,.%LXV@X6^]V'ON:US2W>> 7
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M3F;\9OUI^_1$1S5WV<U=MM]E3INNR;]?:O1/>NB*951/-=OIT12\[/CM]O\
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M$6!?\1[@A6R^(4<>95=O%3V%?XJ3G>5V[##+."V!FR6]K;6U+K<BRZ &[LA
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g418853g00a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a06.jpg
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MH8J7MGZ;C1M&]3ZY[*:_@&.EB^U^)EHX+L7@2L0H
M
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M-HN<)LFE2U1I*T@VN%FCK%&.X*KN(E/TTLA/RB#@[.*6BD?^])I/5D3QZ/\
MW7A42?T@@Y,I,7SAQ+5Y9Y699FV7?QA7L+,G:8EF&,+H%<LWAF973/Z\T53,
M0^4R/&QE4C^5-=(V2GQ 9 X6.)W%[X:M.;DWW=]=5*R;A?+QD-'HY1J$4[FU
MK=)UB'KM=9S<_*R,Q)N\MF9E").UULK+J*X0;M2Y\S4U!M*-V/C(TJE%)MI1
M-+TG;FKMDL[!(4#8-0N#&J/E(ZR/*_/1TFVA':;;#S)))9LN=-JFHSSAXW<J
MF*V<M/*Y;+*H8RIC3!K%0*FGAV&;U^(I:>XL-,:RHE\J5CUW=M8[5MD]%Q4<
MFO+E>58U-Q5YU.?5>K?7*U/)STH:%>Q3!K&21HE[EO*2Q452M+"YQ5\4K^^/
MA>(WW.Z$?3MCR-%,=QZKD[,I38_8%5=VDK26?I0:$NT._>M*^MEO8%XM+"GD
MERP#C&6T[B+,\-#.<?5Y(K5;^@$'C"X17IZ=N3D>)$;STW8&,=)P6T*-,QTO
M:U*)%OHNRQ3YI(W5%LJ\6J3)=LY43<V-%H@NY6ADC&?I((+JJ(%(BH8J#D\(
M]T^P14UC#OEVEJB%                              ,J[C];R^R67YCH
M9:&#[?,C#3]L^[P1?]&]3ZY[*:_@&.EB^U^)EHX+L7@2L0H
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MCH9:&#[?,C#3]L^[P1?]&]3ZY[*:_@&.EB^U^)EHX+L7@2L0H
M                              %+1FFL-]K2VT9W8FP+>F9R9]3*#8'\
M.:BZWD74"6N2<G5(Z.A6$B:1?Q2DDR*YF924^HM)R=19$1/+/5EK&Z$%V[WV
M^FY2)"^.7 ND0H             4MJS36-<R,_/3.Q-@;4L\X==HA8MBOX=X
M]K]:S*/99K5*^W@H6"CV,4D[>F6=N#-%I254;QZ;]\JQAX1C&5N.Y+L]/3O9
M$N,?3T[2Z1"@                                       &5=Q^MY?9
M++\QT,M#!]OF1AI^V?=X(O\ HWJ?7/937\ QTL7VOQ,M'!=B\"5B%
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M/&JJSJN:OPX^G& CP>7&']>SN-A2<<A+1[N-<JOT$'B)D%%HR2D(>02*?_\
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MG(<E,L__ &%<+K2,FHZF'\B\<ZJ22A"4>;QXFFBXQC-KP-IC2:@
M         RKN/UO+[)9?F.AEH8/M\R,-/VS[O!%_T;U/KGLIK^ 8Z6+[7XF6
MC@NQ>!*Q"@                8LW1KO8=IXL>%38\)07T[0-0QF\F-VE^6*
M:WP8VTJC7H.$Y,AY:QLY.128/8=;,UZ1DWRBW534CRR1\&2QJ34*2C>X0QW&
MEQC1<(PC+?VLDW%SJ:Z[,UO5#ZQBZO.W+5FS:=M2 I%OR@VJ=[3K"<I&RM'E
MG*R#AI'(SD!.RB#!ZX;':-91-@=<S5'!WC=1:3<=ZA'>N)6HPX.**#VQK3<6
MU^&3;5<A.&:J:CN-Y2HD3!Z[@[/K9S,K*5^WL+)-S]NM\.M#54D5AJT*RKT7
M'O9B2263</7B:.9;+.)L4FKVX1O<98;WWZ$OQA!W7*$7#C&]9;RTMXU/=<=N
M#2W$CJ&@EOSZKTV[ZUV)J&3M5:JMC=5.^/*M/H2==GY*17IR<Y6[!5&1Y1HX
MF3-99EDK9@_QDN7)8H0:;WIIWPX\BN,4TII^;NYD1WIKK?EP?:)WHRU/0K_;
MM;2>PVEHX=YFQP1FC^@[,CZVR.SBKQ86"=7<7RKO*A"SIWCMJSA5%W\W"QTF
MZ9-6CZ5)I146D]]^[@G@[^0OQQ<KN7IO?!'\7[6FU[7 </C^)T9 TIQ6>*6D
M;DLU#ILW04<5"E5BN3$([),2^)"MP]INK]W($D#$@$7,<V8G+#EEGN8A"0EK
M%1I1;?XK2;C>_-Z3)?<X;^&$&HN?HB'[4X>]P["9?2,1$;3\QN.(6O:_1U4_
ME;!5BM)U[2M;1%3?,GQ&$V_>0:DC+19S1:TJU;M3,ETEY!>.5PJW)(K\2_!W
MXS3$'^-QN64#D'K)Y:R4MD6ZU3%7?R\4HUF:DXEV$\HP0<I*-E(]])Q/EC'+
MA1J;R.\1KAXS244.DV?O$R%<'TFKT](&/.&VF;BX4J?G0#G6%AVYK6HS=A5U
M/L:C637+63)3)^<?V!I7-AU[8%THKQG8:^ZE'C$DK7#V&*EH\C0^4XM=$R"N
MIP=\8/>G'E"-QI5RA"*W8<9P]'#=$E.\J7MR]3/#',-:6G*J:_XB(W:5M:0D
MY746]9I[&C7JII1Q7EAF81>Q3N'-L92#DT<Q39Y*E)MVZABM6!Y**%]^ZZ[&
M]/S3*XW7;[\FO.4_8=<<3<1/\6%FUS3)!BKM'=FD;=#H(W.F0=AN&KJE5J)3
M=F5^MSR-A=%H]OG(^MRQ8&;E#QBC"/>IO64E%6$C;ZG;KHO<YW/=X[I2)!J-
MT8N-\N>']BNKCP[;SDZOQZ0-<TO'PC'B/IVN6^NF+7854=NDIF-HS*K2[>RJ
MO';,A91)XF\E[5+KR3XKF17SB(D;@9RXEBV*_%OP=]W'TA=D(>VAO4Y*'I'-
MQNTG+UFW,N)*D;HLE,6A-65'A8V!0[O/6&PT9%C 2<Q8Z5;US2[9"SOG"D''
M1-/E$)F3:-WK9!1=N=$KME]9<H3_ ,88OK>: :O3W),RYH^/O-$@.'>5V9PV
M;5SKS63Y*0UY)QNU=-6JBZX7VB8];AY>)JYEZYM^<AH")MZT!7(^S*V>T0T-
M(G]+&2=@9LU&VIWMI-1WW0C#CANW002FH0P]%?%[U%QO[[2T_IW<FKY^;U'*
M<.^JKK42;&MMEI?$Q)2U+.Z84VWW"3N6&MKIKV,7O$M?:OB7=QD6=CA.!E%V
M\8DYF(UDU6D7$;BH]9IPOHWXYPAZ<!?<H)J-W!+#'?V<C:._H2P6C2&VZG5(
M1Q8;);M;W:IP<6W>Q,=Z>5LE;DX5@=P]FI",8-62+IZDJ]7.Y,JFV*J=NW=+
M8(@II6*X./IB5X/BH>F!E/\ Z9;<\WZ/XW_3*8\_A_,D39Q,V37_ /\ EXSH
MV8U<H>,-BWYQ-)DFY@L@7ZG_ -P\0T75]&5\9!@K;OQK\<,;[X^8D(NBY1YK
MM[OZ$\84;9VI.)K=^TH"E26SZ#O^N:W=N6]?G:C%6&BWK6$ ZJ2;)XRNECK#
M)Y5+/!JLWJ<E$2$A)1LTV=(+P7U1R5^9%-)1A".,;X]A;TYQ[H0US[2F]:<,
MFR-1V/@ACFM>S8X?3?\ \AYO:$_#S-?0B(6>WJ1])$C(!E-2T1.2\3 SLJ\9
MY<MX9%0\*V:/DVJC]PXCD*VFJ7&$%V<B)-0X1YN.'=SN(_;-$[OF^'+C4UVR
MUE(EM>[M_P!LOU 9.+1K]-L[K%DDJ0Z:/)-\G;EF\6X:(U5]E\R5,HX*9U'E
M:%>>D=Y91-)T;[DN.^.I;[Y[LDEX>F)R<N))\E"&E4J_*NI##$CHM:2<01)@
MS@Y"FS&Y<KS*5?*[2,;*:JO+F6'G$.9%ZL3S#'TE.+S6.G-XU[@&;\)=AX>S
M3%Y=4F]4M>2L]SU@;5S%Y;[#99.-LCB1B[9/V]4E;+.,Y1)./I7*>9:,P1@L
MT-AO)$UMKK=:-UTXW+##?VFF^$(8QWJZ+?;N>Z)/T=*;_IS32FI7D?C=FIZK
MPX)Z[F7+BZ,JI%I[E9*-61+3L".DCGFK=0<5Y!..KT2@PMQHITDM(2-7>2.(
MV28R*<7@XMKLQ2X.._F(-04(JY8YQX0W>B@E=X:KC,:!X;M8;=T;:4K)J763
MJ'A=AZAVC3X7;6IK[$)0L8QE*[8U[=58_DVULFSUR[9,I.Q1R2D7 <M,'2CA
M4L&C>X.YS3@^'HIWHB3@DY=Z=[_ICR=WG+Z<XEZ1<=6[7LVK:+Q83\WH"BZD
MW;7Y&:IE>G86ZTF8L<]&WZL2UW9H5Z2CWN+?+Q-G8M>3'CYV@A,LVZA#89IV
M*O2;HWQ6.'<_[39;TXXW7]J?]7P? NBQZRV8XVOP9VEIKB%:0NJ9?;\WL%G2
M)&KQ]<IJ>QZ)/5J&A(-K)/ZZ_L.85_,H$F)9A L,2J+5Y.(1J+U\6%2D5"E?
MC"$=\/3^I;XIXXK-K2_P*.V#H?=]BT[QUTR,UH_/.[ZW:RNFNDEK10$6SVO8
MB=7Q"SN3<YMF2Q2R!J')NCM'!<KG1?19$2J+*/4V*ZZ_<T[G=&.I+[[O_)-*
M.*4-"T]MZ.O^X=X; >JUB6K%!V3P37KAZ6MSN5J#AQ7[A=; I,$4=0D=:'DH
MZ8QS!<[=TY9(.45I)/#9'*T<IF2*327%4H[[UD5QOAO4(RQXQWR/<\-5;W(R
M7J<7M'AFU3JB7H,6>-G]IUJ9I,_G8SMM#.(%)]1(ROQ3:Q5=M.JK8G)AQ:EX
MYVQ:I*5]"+E<2R[^)-K=2;CNONSQ"W78=G9=>_1EA;\B-QRE[TWFG5=>\ZD2
M<71';51B[A&4J3>2#R.BD:#)RKZ1=QZDW18MUB?YV5>/=K+RF'<<LY@K,U9F
MB5"A?%P=T'",)]Y'&*A>KXWP[#(=4X>=^U;1/#W5S:QACV+0W&5/[><U:%O-
M;P2PT"8M6ZGV'E<?/"Q4*R(R8[-B%F,;*NHV2<M(V0(O&Q;O#5@O8J+<<:,,
M,'QRW!12PWNZ.YN-QRLM3.3M6QWJ*+=X=!$SMNW<'=MT')DRY710=*-F:CE%
M)7)R).#M&IUB%*H9L@8V4BZ#48.I'!_F/VOQ7GM:R3[2NYD; O2ZLF=N?,9)
M[OKT(TX@G:Y,^>=%:8F:;774-DR2:;)-[+&:^520?G5U.E<IKS8919$KWVW7
M+?C?C?Z7$)K_  D;:SP*S>D9^RPKW>DBI59DD],E(\K3Z7T[8*:754/+%;X=
M^?!/*;JRD0E@-DCM159[-23M!R\=.B+.M^,G"Z7;&/-O^A(7-8]M[?ANRG<C
MSY;3VV=]:4VA3IGA\UGPM6J<H9X2)79R]+N#BPW=G-P-EB5U)"D1>4HS7"<E
M6TF\@SDU'\U+IRQ55X-EB!)B;L8-7NEGV;]Y;VH817:X^$/2XE5,@]Q6.BW<
MMFX3M?:5M&-:VFL91J-BUQ-R]]M4[%\EMLU:0B,QK.MTHIS.9%[BUS;:;4.I
M&LRLE"L73EZBHK\9N].^-R\[[.(4=Z45'?CRN3[2 \)FG-\\,RFM:VWI4Q-:
MTNNKZ6VW%7WEOIKV0U5NVE5"M4M]:Z<\=6M0]AI%\CH-L:2KS98RT">+:2,,
MBV*Y7K6#:<;[UAC>I88J?]R)0W/CABE#GVLV?MK25>W"K5',S:-D51]3'DJ_
M@Y'6][FZ+()NIA@6+>*.7<*JDJX-R?EPS0,8V#H-GTB@F;"3YR132G"-R<9H
MU>;T].UE"<)'#78M&6OB&G;%8M@2:%WW#.RE/0M&QI"XLYJF.:S0T65NF63A
MVX)SW=2L1+1;R9DBDG5(=BR9K8PS*V\ZTG&$(87W;Y=B-*4(QF^]-QCV\X&W
MQI-0                  95W'ZWE]DLOS'0RT,'V^9&&G[9]W@B_P"C>I]<
M]E-?P#'2Q?:_$RT<%V+P)6(4
M#PI*-CYB.?Q$NP9RD5*LG4;)QDBV1>Q\C'OD%&SU@^9N2*MW;-VV55;NFSA-
M1%=!0Z2I#IG,7(%*4;ADT;K>29RE-H3:*6C%?3PK->:LLS!UU?&#837J]<G)
MJ2K]861(<Z3=:OQD:HV1.H@@9-$YR9K;?HH][Q?>(%\"
M                                             RKN/UO+[)9?F.AE
MH8/M\R,-/VS[O!%_T;U/KGLIK^ 8Z6+[7XF6C@NQ>!*Q"@
M
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M6HY8L_4\_?T9_ (*:YZ"+D^6HY8L_4\_?T9_ (*:YZ"+D^6HY8L_4\_?T9_
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M]+7J-*DU12BZ$%%M7NXY,N6+/U//W]&?P'6\%-<]#E<7)\M1RQ9^IY^_HS^
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M];^E_P"7ZG?\]V@/5'D3_-*V?/UL^P[,.F?*%[MU'S;4?:+6<,@[@."@
M            3+77]H-$_OE6/WVQ&SVC[GV[Y':OJ*9N+)^5V7Y14_643Z&P
M\!GI@   /G7\4_ZSO$;_ (\;>_\ 8-A'F?:WNKM/YPMOVFM/Z.?)/^BWR:_L
M!T-_V[LTH<?/.?@                <O?T'OZ^=:_PVV1^Z6XYIT!_.*J^2
MVK_0CQWZNC] .T_VFZ-?:ZT[IH[T/Q+                       #*NX_6
M\OLEE^8Z&6A@^WS(PT_;/N\$7_1O4^N>RFOX!CI8OM?B9:."[%X$K$*
M                       '4R^G/_6_I?\ E^IW_/=H#U1Y$_S2MGS];/L.
MS#IGRA>[=1\VU'VBUG#(.X#@H                $RUU_:#1/[Y5C]]L1L]
MH^Y]N^1VKZBF;BR?E=E^45/UE$^AL/ 9Z8   #YU_%/^L[Q&_P"/&WO_ &#8
M1YGVM[J[3^<+;]IK3^CGR3_HM\FO[ =#?]N[-*''SSGX
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M-A'F?:WNKM/YPMOVFM/Z.?)/^BWR:_L!T-_V[LTH<?/.?@
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M!"E+C&,>9MK>ZNT_G"V_::T_HZ\E'Z+?)K^P'0[_ &[LXHL?/.?@
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M>(W_ !XV]_[!L(\S[6]U=I_.%M^TUI_1SY)_T6^37]@.AO\ MW9I0X^><_
M               Y>_H/?U\ZU_AMLC]TMQS3H#^<55\EM7^A'COU='Z =I_M
M-T:^UUIW31WH?B6                       &5=Q^MY?9++\QT,M#!]OF1
MAI^V?=X(O^C>I]<]E-?P#'2Q?:_$RT<%V+P)6(4
M       .IE].?^M_2_\ +]3O^>[0'JCR)_FE;/GZV?8=F'3/E"]VZCYMJ/M%
MK.&0=P'!0                )EKK^T&B?WRK'[[8C9[1]S[=\CM7U%,W%D_
M*[+\HJ?K*)]#8> STP   'SK^*?]9WB-_P >-O?^P;"/,^UO=7:?SA;?M-:?
MT<^2?]%ODU_8#H;_ +=V:4./GG/P                .7OZ#W]?.M?X;;(_
M=+<<TZ _G%5?);5_H1X[]71^@':?[3=&OM=:=TT=Z'XE@
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M/Y /L?\ Z-G]CN?]X]L?S^'K&Z-_!U/Z7;OX@?AI>J,_7VS?NET,_D ^Q_\
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M6NO[0:)_?*L?OMB-GM'W/MWR.U?44S<63\KLORBI^LHGT-AX#/3
M                                         !E7<?K>7V2R_,=#+0P?
M;YD8:?MGW>"+_HWJ?7/937\ QTL7VOQ,M'!=B\"5B%
M          #J9?3G_K?TO_+]3O\ GNT!ZH\B?YI6SY^MGV'9ATSY0O=NH^;:
MC[1:SAD'<!P4                "9:Z_M!HG]\JQ^^V(V>T?<^W?([5]13-
MQ9/RNR_**GZRB?0V'@,],
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M:)_?*L?OMB-GM'W/MWR.U?44S<63\KLORBI^LHGT-AX#/3
M                                    !E7<?K>7V2R_,=#+0P?;YD8:
M?MGW>"+_ *-ZGUSV4U_ ,=+%]K\3+1P78O E8A0
M       ZF7TY_P"M_2_\OU._Y[M >J/(G^:5L^?K9]AV8=,^4+W;J/FVH^T6
MLX9!W <%                 F6NO[0:)_?*L?OMB-GM'W/MWR.U?44S<63\
MKLORBI^LHGT-AX#/3
M       !E7<?K>7V2R_,=#+0P?;YD8:?MGW>"+_HWJ?7/937\ QTL7VOQ,M'
M!=B\"5B%                            #J9?3G_K?TO_ "_4[_GNT!ZH
M\B?YI6SY^MGV'9ATSY0O=NH^;:C[1:SAD'<!P4                "9:Z_M
M!HG]\JQ^^V(V>T?<^W?([5]13-Q9/RNR_**GZRB?0V'@,],
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M,>9Y3>I_(G#UI6R'P];,7'_T=F\$=->4'W;J/FVHW0_]FU\6<.@[@."@
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MWRK'[[8C9[1]S[=\CM7U%,W%D_*[+\HJ?K*)]#8> STP
M                                  95W'ZWE]DLOS'0RT,'V^9&&G[9
M]W@B_P"C>I]<]E-?P#'2Q?:_$RT<%V+P)6(4
M    .IE].?\ K?TO_+]3O^>[0'JCR)_FE;/GZV?8=F'3/E"]VZCYMJ/M%K.&
M0=P'!0                )EKK^T&B?WRK'[[8C9[1]S[=\CM7U%,W%D_*[+
M\HJ?K*)]#8> STP
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MZ7_E^IW_ #W: ]4>1/\ -*V?/UL^P[,.F?*%[MU'S;4?:+6<,@[@."@
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M@O\ 1\N,>7.<Y]3^11M]$[9'X>MGV'9ITUY0?=NH^;:CC_[%KF<.@[?."@
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M.?\ K?TO_+]3O^>[0'JCR)_FE;/GZV?8=F'3/E"]VZCYMJ/M%K.&0=P'!0
M              )EKK^T&B?WRK'[[8C9[1]S[=\CM7U%,W%D_*[+\HJ?K*)]
M#8> STP                                                  95W
M'ZWE]DLOS'0RT,'V^9&&G[9]W@B_Z-ZGUSV4U_ ,=+%]K\3+1P78O E8A0
M                          XU^+_Z,O5W&/L^*VE==@WZJRT32HND(QU7
M)731RK"*F;#-(O%<RT2^<_6U5[$Y14P18J/HD$/-3*?TAC]B]$O*1M/HALVM
MV98[!8+555MMK;:ZRTNT*L5.MJ;/4N@O\*MH4>HE9Z+4:,8TJ47"!Q7;?1.Q
M[<M="V5]IM-33H6>A9U1J?\ "ZKHT*RMK%2?7H4GUFZUIWP@E=B95^P;X?\
M]LVXO]*E?RZ.4>SCM[X'V1G;?X@^/['6S??]NRL_W0^P;X?_ -LVXO\ 2I7\
MNA[..WO@?9&=M_B!['6S??\ ;LK/]T/L&^'_ /;-N+_2I7\NA[..WO@?9&=M
M_B!['6S??]NRL_W0^P;X?_VS;B_TJ5_+H>SCM[X'V1G;?X@>QULWW_;LK/\
M=#[!OA__ &S;B_TJ5_+H>SCM[X'V1G;?X@>QULWW_;LK/]T/L&^'_P#;-N+_
M $J5_+H>SCM[X'V1G;?X@>QULWW_ &[*S_=#[!OA_P#VS;B_TJ5_+H>SCM[X
M'V1G;?X@>QULWW_;LK/]T/L&^'_]LVXO]*E?RZ'LX[>^!]D9VW^('L=;-]_V
M[*S_ '0^P;X?_P!LVXO]*E?RZ'LX[>^!]D9VW^('L=;-]_V[*S_=#[!OA_\
MVS;B_P!*E?RZ'LX[>^!]D9VW^('L=;-]_P!NRL_W0^P;X?\ ]LVXO]*E?RZ'
MLX[>^!]D9VW^('L=;-]_V[*S_='M8+Z##0L#-P\XWW%MY9Q#2L?+((K)4ST*
MJT<[1>))*^97BG]&H=$I5/,,4WFYSYIL9\F1BK_+9MVOJ:ZHI;(V2J-=55E5
M2=%VSK*C64'0;4;0U%)Q44U'%&NJ\GVSJJLJZU6ZVMU=.A32:J(-T*2I).%4
MG!M7P9S>CI<Y^
M   95W'ZWE]DLOS'0RT,'V^9&&G[9]W@B_Z-ZGUSV4U_ ,=+%]K\3+1P78O
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M9(K1BBDRCTXEPCPGS37+=WS$/-XQ?"_^NY&G1"@
M
M             &5=Q^MY?9++\QT,M#!]OF1AI^V?=X(O^C>I]<]E-?P#'2Q?
M:_$RT<%V+P)6(4
M                                                       #*NX_
M6\OLEE^8Z&6A@^WS(PT_;/N\$7_1O4^N>RFOX!CI8OM?B9:."[%X$K$*
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M\6H/<2>R;X6JRM,82NK[SB:NVT'&IHN'2=TS"N; C1YO8",J5\YM+:+7K,C
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MEH8/M\R,-/VS[O!%_P!&]3ZY[*:_@&.EB^U^)EHX+L7@2L0H
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MNNQ9Q+URZS*.Y!LUTMX;X*$;[\Y%6_CYO&?>7:(4
M                  ,J[C];R^R67YCH9:&#[?,C#3]L^[P1?]&]3ZY[*:_@
M&.EB^U^)EHX+L7@2L0H
M
M&5=Q^MY?9++\QT,M#!]OF1AI^V?=X(O^C>I]<]E-?P#'2Q?:_$RT<%V+P)6(
M4
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A4\TOE\A?/4,8WFX\N?)CR^3'ESY,?I%@E@H$BWBXG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g418853g00a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a08.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1>R4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M         %)S;'15;G1&(U!X;$!8            "G9E8W1O<D1A=&%B;V]L
M 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M                5&]P(%5N=$8C4FQT                4V-L(%5N=$8C
M4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!2
M96-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -
M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $;   "2     8 9P P
M #  80 P #@    !                          $              D@
M  $;                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $;     %)G:'1L;VYG   "2     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M!     0X0DE-! P     #1D    !    H    $X   '@  "20   #/T &  !
M_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)
M"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,
M# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $X H ,!(@ "
M$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!
M  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS
M 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1
M R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /54DDDE,&M!:#KQXE/M
M'G]Y29]$?!224QVCS^\I;1Y_>5)))3'://[REM'G]Y4EA]>^L^/TLG&I:,C-
M(GTYAM8(]KKW?^BF_I/^+^FC&)D:B+*"0!9=K:WG7[U3MZOT>DEMN;2QPY:;
M6S_F[EP-V7UGK=YK>ZW+=SZ%0(K:.TUL_1L_KW_YZNT?4OKCVR6T8_\ )>\D
M_P#@++6_]-3_ '>,?GR 'L&/W"?EC;V5/5>DWD-IS*;''AK;6D_YNY6]H\_O
M*X._ZE];8V0VC(_DL>0?_!F5L_Z:IT9W6^AWBIKK<9W/V>X%U;@.=K'G9M_X
M3'>E]WC+Y)B1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( 1L"2 ,!$0 "$0$#$0'_Q  ?  $   8# 0$
M     @,$!@@)!0<* 0O_Q !G$  !! $# @(#!@P,$0L#! ,! @,$!08 !Q$(
M$A,A"10Q%2(R05&3(U-55F%Q<I:ST]76%C,V=8&7H;&RM-'2%Q@9.#E46&)S
M='B#D;;!PN$*)#5"69*4HJ.WU"5#4B8T1?!D@J3_Q  = 0$  04! 0$
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M5(_TEKYEG\7HB>J1_I+7S+/XO1$]4C_26OF6?Q>B)ZI'^DM?,L_B]$3U2/\
M26OF6?Q>B)ZI'^DM?,L_B]$3U2/]):^99_%Z(GJD?Z2U\RS^+T1/5(_TEKYE
MG\7HB>J1_I+7S+/XO1$]4C_26OF6?Q>B)ZI'^DM?,L_B]$3U2/\ 26OF6?Q>
MB)ZI'^DM?,L_B]$3U2/]):^99_%Z(GJD?Z2U\RS^+T1/5(_TEKYEG\7HB>J1
M_I+7S+/XO1$]4C_26OF6?Q>B)ZI'^DM?,L_B]$3U2/\ 26OF6?Q>B)ZI'^DM
M?,L_B]$3U2/]):^99_%Z(GJD?Z2U\RS^+T1/5(_TEKYEG\7HB>J1_I+7S+/X
MO1$]4C_26OF6?Q>B)ZI'^DM?,L_B]$3U2/\ 26OF6?Q>B)ZI'^DM?,L_B]$3
MU2/]):^99_%Z(GJD?Z2U\RS^+T1/5(_TEKYEG\7HB>J1_I+7S+/XO1$]4C_2
M6OF6?Q>B)ZI'^DM?,L_B]$3U2/\ 26OF6?Q>B)ZI'^DM?,L_B]$3U2/]):^9
M9_%Z(GJD?Z2U\RS^+T1/5(_TEKYEG\7HB>J1_I+7S+/XO1$]4C_26OF6?Q>B
M)ZI'^DM?,L_B]$3U2/\ 26OF6?Q>B)ZI'^DM?,L_B]$3U2/]):^99_%Z(GJD
M?Z2U\RS^+T1/5(_TEKYEG\7HB>J1_I+7S+/XO1%\]7925 --#GPO_LLCCE9!
M]C8Y\OEYX^+@Z(N BI'Z(KE*?H?_ #"G'+:4I(_Y[9#D>]X*C\9(/.B*YFQV
MIXY*N%+\U<<GWZO;P /W-$4>B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*W)GZH(
MOZR6/X>+HBN!OX)^[<_"*T11Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HBA)(/D4C[9\]0<VZ.^?L10%2Q[%- ?9)]NHZ6_+]**2I]:5<
M<M'XSYGGCDCD>>A>QIAQ.8B0!&F@L3.JG(\B6Y8TO.O<(4#LM3:.[M1QSQW+
M+B$>?L'<EIT=WV"1\7V]1F)]EI)[)]RG*X>T6SU'LUF#QTE0)L6N0E92A12"
M>XA \R1RD/%IU:?D<2T6U$\)42E0%36UG7#.CI,.L>!B8]X.L*T^HQCLKG-F
M";.;Q(XSJ#N4'NFSY\N-C@\?!<^0?'P!\?Q<C[.JQ2JG4#N#Y[I \?H4&O0'
MSG?])]Q\E\]UHW=P'F3Y>P*45<^?Q >S@'X^=5\S4_)/@[R5(Q%$F,^_=EOW
MYH]ZB19,K*@'&P D'E06CSY//Z9V)(X'EPKGV\@ <FWS=6]A;J?_ &8[+W51
MK4=SCWN;YJ),]+GDWVD@^^402UQSYCQFE.MI7_>*5W\$$IX4DFVX56^TR+VZ
M+A;<;]A^V)"K8]E0$M<+$B,S2; 3I;>+$@Z]JJ?&403V]G!X^B I!\@2I)Y]
M\DGV*(3SP?+RY+.T>V'"W4+]YTU53@19L$V/&W7&\;_>OJ72KGX)X/M'/'Q?
M'S[?]FIS9KLB-#FUGNM$0HAP]J)-[3IUSO7TK7P2"V/NB0>?]/\ _?/4B=\=
MWWJ#.Z._[E$VI2DDJ[>>>/><\<<#Y?C]O[FI03OCN^]3-%*:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*6KX1_S7X0Z(K;B?JDN?\1I_P".
MV6B*YD^P_=+_ (:M$46B)HB:(FB)HB:(FB)HB:(FB)HB:(FB*W)GZH(OZR6/
MX>+HBN!OX)^[<_"*T11Z(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB*2XXI"@ ![ ?/GY3\A'R:(N.DSBR3W>$GR0$>(HM!:EESWH<<*6RKWG
M/8A2W>"5>'P$]]/-U7NAGLALGVK7N20" !(G4]2H>]K/:/J_&!NT!GJA=);J
M]2VR.R4#U[=?<W#<)"D\QX5I=0#<3E\J2&ZJA:E+OKEUQ:5MM1ZRKD2%K2I*
M6SVG7KX+8&U<> <-A,56G?2HUG4YZ,CG.;R2,P,2#!"\[$;7PF%GG:M)I$@M
M<YA<")L6\X'3T3N$&QA:S]U/33;(XVY*A[7X!F6Y,N/RWZ]<(C;>5"U=RQW(
M1?*>RH#M#;J4NXLRA:74^&^I8<2C=ME_!AM;&,Y[$ T(J9,M3#XDU"P-INS
MNPH $O(!Z0EKC"US'\M,/1>&4&%X-.<S7T\H>7/;<,KD3T03+@0"-5@!G_ID
M.J3)7'F\1Q_;G;>*X>8,F)1VV0W[+)4OM*K')IRZB2!R4>(QC3314A92KDE#
M>\[.^"3!B#BC6<"1(-4LCV)]G T_^;4F(ZEKV(Y;XUUJ8 &ABFXG?K.)?N@V
MB^[CBCE/7QUE9<IY5KU!9W&\?R4G'ET^,(;2"HA#0QVHK.SM*E .<E\I[$*=
M4AMI*-PPWP:[%HT\HP]$D.)#G,P[W1#?GOP1?J)UBYXE>54Y28W$DN?6KTP
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M!B-&C)0I/':TT@?&H%143S3%8W$8][JU>M6J5'F75*CW&H3&]SG.._C;00
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M:>%QV&8^D]I<6,!:'4R6DL;T7%KW$N),Q%YF;0N]8JE*0X5%)/C.#E!Y3R"
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MC,("/!+2W7?%0XE+<DU,.T\XYO--;=SBXF(N2796R&M)), DZA6F/<]V4M@
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MIP=QY5PKM////M2 >?8"2>X@ *)XUKH8+DR\R3+X)$F8!C0;O>2O9-0F!E8
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M4I8LJ>!*@]V^#3DE2JX5VU,4W-4=B13P[7-$-I!N%K<ZW/1<":N9I:2)8UL
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M8*?6I2$1V=L\T>D+5]#2@IC(A*?4@NN)1WA)!)[1[X'BANQJCS%,N=QLXG4
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M/W+<(]R)XX) 3YR(@Y[4I Y'Q'CGXO,>6H<T Q>()[;'7JM]/9%+;GA:+=9
M.LF]O *X&&$K0HE2OTQSCR1P 5$\#WG/'))\R3Y^W1VO;/O(^Q7&:>'N"G>K
M(^57_D_F:I52>K(^57_D_F:(GJR/E5_Y/YFB)ZLCY5?^3^9HB>K(^57_ )/Y
MFB*E?92E39"E>\4E0'O>"5*"3SPD>0'LXX//M)\M5"S9ZXZB+'[%;=[7]4^Y
MRP1D N>D5K@I2^T=*TYOM2HI!"MSIA[CV\$J1P0@\\ +7R"2"#@ ?'WD;HX
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M%,.8<KM'?CFO:1SEB##"(,ELCHD-6H)EIMI3B6BM3:EH4$$A2&PVRRPEIO@
MA"4-)X"RI7)5RK@@#NKG#GJ=)A&446")UAQ;T@+:0--  N=EKW4ZCV-^>\F
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M*$(0D)X!/M!41QQZO**MS]?#ORY",+1;&7+(#ZYS1)F9UG=   6F?!E4PU3
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MW(^,^ZJ<@P%UY#W?,PK)$B93<O.);1(<H7G7L:MGFFFT/V5--?0E >3KZVY
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M:'DNEH%-P&5P!=T@28!87!T'+,&.-;ZF=K7X+,IC)H;\B7D,C"H]+&K;.3F
MS:-3.9'(QA6!(;1F*;J+C#$G+I5-,J:ZU;Q5MF^3%74R43TUG /_ "1W@@C?
M<9/=/4K#>4>#=$5F.)>:0:QS34-1KLKFBF*V<9=3G:P@%L@S;M_%,KI,WQZ+
MDN.S6[&FL1(,&<TAU#4EMAYR.IQ"7VVG@DN-+'*FTI)!+*WV"U)>QW474:Y8
MX0<DQ!%BZ-" =W#R7K4\53Q>$%:D\/87D!P(()#3,03H9$3J#$B">2MO^C9?
MZWN?Q=_2E\N/SZ?[T*K$_P 7U/T=3]P5K ]%'^I[J_\ \N'?G^([?ZV+E/\
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M:&G>[WE=4=J>T^]3]2H4"D)5[?DX^+_:#\NH(DS)[ ;=Z* ,(![@5!7''<"
M0/M]NI4@QN![1*U"];"(^+^DN]$SN3D,Z-0X7 3UO[;/Y1=2O<VD9SS<C:/
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M^<?JE</;?]&R_P!;W/XN_JY2^7'Y]/\ >A6<3_%]3]'4_<%:P/11_J>ZO_\
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M2@S8K8C48+]*-^DSOB_@NY^G66B)O=M\XHA(]U7V1W^0+LJJLHS(]HY"G%@
M>14?('DC7=?\GO'LPW+_ &2&@$'$X.[P#TW;7V,T"SVB# ZQOMIHWP@X=N)Y
M.8Q["Z6TW2"6SEIT,15=8 Z-!WV.[CO'B>+V-]H3X92A:5$*Y(6$N<\CWI^&
M>./D^/CD_LA0>VKL_!/!'2P^&J6(B]$&US:XW]Z^00'-K5<P@%U0:&;ODQNX
MCM"Y9HDI//'DHCR^P!K(&@[![E68W3US&O<IFI4)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB*0YR5*'EP&BH?+W<GV_8_=U ,O#8L0#/?$3]RDV
M87;P3V:2J!]0#2TJ*@"A2UE Y4$H3POMY!'/"_($>?[!U#7.96#&@',1K,R7
MQ:(X6MJHR\Y2<YTMR@@1;1I(F0=;@FR\CGI9+9NPZTLWAH4%.8_C&"5,C@A2
M4O/X[%OPD$'V!F[9\OB//M]I^H_@EPS#R9J5CG!=M7$$"1!#<-@F@CHS'0XW
MN;:#DG*L@[5@&<N'IMUD_*53!@G2?#="UM]Y^0?N_P NNKBP(XMR]WFM6=3:
M[4G6;1Y+CU__ +\.%*5!MA)*0/HBRM3ZBE))'EZNS)X'!^BELGE(4A?B\H0V
MEL+&NDSEQ)N1%L'6/4=;:[S<%7L%3:W&T2))S4]8CY9A&X:D>$KW^8/7*J</
MQZK<(*ZNEJZ_D>Q7J5=&CI)\ARI0;!40$@J)*4I! 'Q9M$MKX_$59,/Q-6H"
M( AU5[M+P+Z38;UW'  MP=%N]M*F.\4F#WJZHY)2OGC],4/+GV<)]O/QZQ7&
M3V6'8%E,T/YQ^Q3]0JTT1-$7%6?Z6[_@/]\Z,^5;_5^L$/R=;]#5^H5J+Z2_
M[(KZ13[?3W_J#.ULF._@+>[ZCURSDO\ [7;8_2G_ +JFMP4?X!^[5_LUK0T[
MW>\KJCM3VGWKBKQ]$>*^ZMJ2\&84M];,5*U/266FBZ]"8+/+R)<QMM28WAH\
M1Q32FV76EJ),J%I?]&)A.+=:O1W@W6/U+1T;G[R=2UON+F$G(;*YOUL[,TW]
M%+-,8Q/;38::'(,S:6IP*DJ:_%V)N!RJ>ZRJZ8G9/<6DV3=+;2U2/7#K'BLF
ML!W6R[:<Y-T;[%X\[OOF?1YT\;4VV5Y5NIN';4UIF5QE<7,X.V^WGN['H,\F
M3\]R:DVUL;3+LLR>761J$Y#BMS$ILIAV=Y&Q6-/OOW6O]O;=!Z]%6U@'I+*W
M<*QVNNX&V2:;:'?CHMR/JWV8SJ[RN6SD.37F!S,9&XVPUSA<;$9,6#GN'U&5
MUUNN5B>69VU>18MM(I*R7!A(F2)G[NOL2ZY7,^O/<C''<FJ,9Z9\LW/S/:#*
M]H,$WWPK;>/NAEMG1YAN-B>V^X>55.W=Y2[.SL+R=K;;;O=7%LNLY&:Y/MO,
MNVV;FIJZL3F*U=J3?]WW^<:]O,T'6-OKF>?=4./85TQX]DV-]+&Y^8;7Y)+A
M[[P(><9Y=U^PF%;U;=1L#Q>XV^J\21.S"USFHP+*6\SW)Q.OP%^4QDS-EEU.
MU/3"*+]WKK^SS774STCM=BE)U:Y3D6WD*YLNG#$.G#*7F<&S)VZQ?)H74$]9
M1<<#N62,7CQZ^BPK(HE]#SO/,=A9OC#&,8O>Y37J<LX%GAM64_:KOG]>^4X3
MD._&+[B[.U=?+VFWDV/V+PJSQ;,,PR6%NYG74/$Q&[PIV!!C;3^ZF/TF.4.6
M^Z&;^Y;.=Y$PBFG-XYCM_83*2JM'KU]/AWHLC.G7?G/=X86Y"<\V6R?:BRP+
M.I&-TDNV@YA#H=T<3>QVEOZ/.\'&?85MWDS34V3;2\4ML>R+':F549-CMT8-
MAD&/.TE];D6.%YZ0_P!R=KK;J1A[;5USTT8QU*2^GS*<TC9G(:S6#2TN^*NF
MO*-Z:K"F\6FLVN)XYO$Q,;F8W*O*BYF;81)&Y-)8VTH0\*L"*_.G;JJWGW^W
M+W:HD[&8;B>V>S.]^[&Q>4YJYNS>W.3V-WM]58);T>1X_A!VGIFY-'DT;,%(
M=BV&15MK728CP:8G5#==>W\7X>O+Z>I/7K[I6<1=4\VM:@V/?2$H+2PXA32'
MG4,K"TD@J6TE"UI'Z6X5-GS02:F?*'\S_P @J:OR1_./U2N/MO\ HV7^M[G\
M7?U<I?+C\^G^]"LXG^+ZGZ.I^X*U@>BC_4]U?_Y<._/\1V_UL7*?Y? ?T=A_
MKUESGX,_X)MS^GL?^[P:[IZG/ZZSH<_7C>G_ %<Q'6L+IRSW;^"?NW/PBM$6
M'/5=U5RM@;S8[:[",1A[A;Y]3&?2MN]G<-M+I>,XTAZBH+/,\_S[/LI1"LG<
M>P+;C":2PN[CW,J+W)<@FOUM)CM/(E//NLDMQ\_77N7*5>:]4^,[J8%C&?8I
MM/F.UF60,L.2;G;?LYUBEGM]D='7M6E91VN&WC^;5EECMI%B7[+&>N9U1AZ?
M @5TG$*FSN*V!+)Z]:]R[!J^I+8N\BW<FEWEVHMF<9Q5&<9#*@Y]C$F%2X1(
M;?>A9];O1+:4:K!)[,24J)E4Q*:)YQI33-F\I)427]6GW_:J'%.I;8'<>QO:
M7;_>W9_.;['<48S2_J<3W+Q"YDU&(S [ZCDEN:6UM)<?%9+H4RUD*6$U;I8E
M.-/..+BQ9!%:>X'43@U?@XR?;_=KI_BNQ<^VRQ2PN-R,Y@4^)P8V96U!8>XZ
M+*IL%/JS/-,%FSYFT=6X\XWDM[>8K)2)E=)+,TBZEZW^L*CZ5]M,_P XQ^QV
MVN]S]OL7HK>)MUD^2"MLWJG*LWQ;&F9+T>,EJZ;79IFV0QJ([#=9R.WA2HL2
MQ8=A3&B]>O7DG'Z/MGA]*R?R#>C:;&<LIL$O-Q, I\UR:Q@T^/89;Y-15>4W
MUY<UZ[>HH:G'K*<Q+DVUS$C3+.NAO(9DR$US[:!ZLE4V.]>OO3UZ]>&JM"/U
M7=+\N_L,7A]0NR;V1UD7,;&ZKHNZN$R;*!7;=N0F,^GV+#-[&E0(>%SK2MAY
M7WI:]PK%Z3#G1HRHDUZ.2#P]'1<-N)UA=/.V&%U6<Y)N5BD?'['>?!MAF)U3
M9-7,>+NGN%;8_1X]CUV_"Y%$&SE%%DE[+M ':C$7E7,V,VVI"4D7.XWOA"F9
MKOS%LMR-A++#=KH>,7J8^+YVU.S3 <?EXY.GWECO6R)4FKQ:'-E5C]KCECVU
M\2-BPG6%R5"K]9L2*XG.I#8N/CV:97*WGVJB8QMQ)0QN%D4S-**%48%ZXT9=
M;^C>7)LD,8J)5>%6,1^[?A1K2K3&N(;J*RRBOI(N5P#?/:C=6?E55MEN7M[N
M)8X!)@0<^AX1F./95.Q"QM82+:GKKV%CUG:)KI=S4J$VO:DRT/.L+;>2PM)4
MD$];OLE=HNK*VU<]I"9 2E23R%)"A[1R2A:"2VM*CSWH4KA(4$@BP/D_V1B#
M_DNRO_<NPU&\]@][D6?2/@)^Y3^\-2BBT1-$31%1/E7C#S/;X0/Q]O=WGS^3
MGC]GC5B'?&9^9S$;_:YR>S3O[E6T VBX,GLX?=HN.L2V\VN,GGO?B/QR4%/D
MJ0@H[E  J*NY*0#QR"KS"B0-8NTZ;<9LW:>"9TG8C XVB0V"1SF'J4C9H<9E
MXGHGL)LJJ3Q2Q#'F 0]I;( DBHT@3(L8M&L=2TF[C;6;@3]T\^CX]A&57$-S
M+K>4W,KZ:P7 =]T9'NBZ&;1<1FG;#;\MQMIAZP$EN.EE3K:DK0\]^2_PG?!'
MRUJ<N-K?@?9.T<1AL9CL=B'OH;/VM5HBKB-KX\N!J8;9QIAXI&D2QP>\-<"7
MN:6S]1<E>6>Q\'L6E1Q>(HMJ-%,-YRMA><<UN$P[ 7<YB:9)):22&@$R  1"
MYJ@Z6=WKGA4C&!1I4/>N7MJTRA(][[YSW-@V[Q4.22D,!/O2/$Y) N;"_P F
M;EUMAK#B=EXZAG#234PFUJ+02*1=)J["J1 J.N9TWP9M;1^$W8-%SFMQ+"1F
MM3YAU@7@>SC )W:[N&G;N*]-$3;2_P >SO.]U,*Q1G'[BMM0;*<U"KWGZZ4A
M],/W1N'::/Q(2MYE:"MM\<(5V)25!7T-\&'^2YM_DUM;"[8KT7AV%Q.'KD<U
MC'.%.CB<!B@7%VP<, TNPU07KL'1,EHZ;>>\I/A3V;C<!B,%1K-YNLVI3<:M
M6E3.:K1KT7-;_KKKAKP1^+<)M)T6T& L+BQBA:%(+38;6AU#J%MA(2VYWMDH
M*7$!+@[2>$*'/!Y ^YL)0=A\)A\,\$.H4*5$YIF:=-K">DUIF0?FCA"Y(7TZ
MP=486D.)>"TM(,]*Q!=+3((,W5?%*B'N[SXD. >WC@!/''/Q?)K)N !>P$3P
MW*PWYWYQ^Q5.BJ31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4AT$
M$J]@*"G[9Y)X_P"&C0<X.Z /I]R.(R$;Y)^CWKC9BBAIY25<%,<E*0!YN!7D
M"?(]J@3X@Y!(2GM4GS[K;.GBH,P'$'C:H--;7*.);AGD#I971.\&F?M B^\]
MWBEZYLQ1G75]U"7C2PZU'W"EXPT\"5)?3A-968:7D**E=R5KH5<*"BE1!* E
M!2D?87P=8;XKR;H,RY"^JVJ6Q$.J8/!N<"..:>S3<N)[8K_&-H8ATY@VI5I@
M@S(;6JD'VG18\1Q@+%+6]+RU=VUN.*S'>3:W$$)2IS+<YP_%&4D<^(YD61P:
MM94/? AAEYQ:24E*$K=*TN A*=;Y85^:Y/8T21-/$'=_,L3I) OOUW;XG)P#
M<V.H#_FI]EJS)'"XM/V3/O;KT^#%C-@]P#3')/GR0TV@D<<#S"?C'MY^+7Q?
M6=-9W R[Q>>L^MZ[CAV!M!FM@QOA3:.'4N3;' 5Y<=RRH>7'D>.-4&-TZ7GC
MY*Z!$]9)4S4*4T1-$7%6?Z6[_@/]\Z,^5;_5^L$/R=;]#5^H5J+Z2_[(KZ13
M[?3W_J#.ULF._@+>[ZCURSDO_M=MC]*?^ZIK<%'^ ?NU?[-:T-.]WO*ZH[4]
MI]ZIYC*'B4J+B>]AUHK:=<9< =0MOO2ZTI#B'6TK<\!Q*@IE3BUH(60H2H6#
MFW'1/&V+LLW@]/\ O?NAM)M9N%F>49]:[0UM5MWD^*X9E6<6!M\OG;16&5X/
M<7F"1,FNU*M96-R;:_Q6GL7I,O&**A,Q]*XCP]3?T45SV'2)11-T+G>' ]SM
MS-MMP,XV@H=C]Q;JJLJ2ZD9UCF'3,DL=O\HMF\GILC8C;H[?3,TS1[$\NK4P
MH[$;+K.!94MK ;KHE?*+Y;]"O3_/Q3I.P6NQN;CF*=%^7XGEVR%916CD)5*K
M$,'ML!@TUW(>1,>R&AM*>YERLEA3%A626T>'.MY$IQJ2F2CR]<45N7O1)7G?
M?<;>C;[?S>_:&!O><,?WZVMVYF[?-87NE)P?&FL+K+E$K(MN<ESG;[)KO$*^
MHQ#*\FVES/!,@L*'&\;>AV=5=5$.V014=[T%81D6$]<.WEYN3NA(H.NNQN;?
M<,Q)^-0)F"S+C:['=H"K;=V'BK+%;6Q<,P_&X_N9E,?,6;";7OHN_=:GL9M2
MZ*"WW6LL7]^.DW<7;K"^H_-L*W&ZD=[,JWYV]Z?=H]U6*"KZ=6;V%MY@V;7T
M/,]Q,&Q"9M?C&'W>2T>UN1Y%72-O'8R*#)*UQ4"#C=U8R*^'"'UI;KO]_8BJ
M=J^D;+=W]F,JVBW"W!WMI]LO7MN<^V?RZ1LKLQTL;U;1;N[=W$7)*'.MMZ#:
M/!,/H(JX-G54PDT^XNVC;T]-=8UKT*3AUNMBY(MDFS6U.0;=X_)CYOO%N/OC
MF5F_%<N<\W$8PFFL'X\1MU4&JK<1VWQ'",!QF!#,V:OFDQEBVE.3'5V%S,:9
MK6*XBQ]9Z"=JX5=FNWL;)LR_H+;A;[U?4KD^S4AZAF8T[N-#R^KW&MZ^MF.X
M\;ZKV\R_=*@JMRLHPZ-;):F9)[LTD*?7[=9#<X+,>O4(NU>G[IOI=@)N^5A4
M9?E66?T=-[<KWZR%&7*Q]\8YE^75./4MA3XNBGQ^C$;'H\#&:LQTW N;MV0N
M0[.NIRG$J03AZ]=\K(@I*&0#SR6N2"  . 4CM0D)0@$)![4)2GN*E<<J),L^
M4/YG_D%35^2/YQ^J5QUM_P!&R_UO<_B[^KE+Y<?GT_WH5G$_Q?4_1U/W!6L#
MT4?ZGNK_ /RX=^?XCM_K8N4_R^ _H[#_ %ZRYS\&?\$VY_3V/_=X-=T]3G]=
M9T.?KQO3_JYB.M873EGNW\$_=N?A%:(M8_7GT^[HY/OAT2=8NRM UN%GG19F
M^[3]UM(J\Q_%;/<':+J$V^1MGN<QA>3Y5/J<7K=R*&-!H[["X>4WV+8]=/P+
M&OG953I7S()Y<)X>N)\5>F_)W2ZI>G#J)V4Q#;_.-F;3=+83=/ *O<;=27C^
M$MT^4Y7M_D--5,5M9BU_E^;V2(%S-81D5RF'6X_!I$2;7%LIS-Z*[&F0;BUO
M7=ZU3MZ]_KUXK%[--D]Y][+GIMW,E[+7NV.5]/72!U/[=[DXLM_"7YF29INO
MMAAV$0]A\&E0KA^+?XI$O\?5E-1FR+*HQ)IBIQ&2FT>F9+>5D.4LNG=M.E_>
M.BK.DBIS7IGRJ\H,$]#1NATD;U84WDV%P(<[=&[7L,3LRBTA9@8TB5<.;79M
M5L9U0A6,+3:PKZVRJD=L(+S,1:.J!O\ '[_M3QL0;6D<)\KC6T*NW(Z<>KP=
M+>[NQL:-N'U*8]4;[=$N1].&3;EMX!C_ %$G"]I>IG;[=;=?'MR<W?O<>H\U
M.VU1BEO+V_W'LXU=DN5V<R[,QO):EZMNKI]/E-O!-_\ A'AZ%E9O4;L?U5VF
M%^DIV*HNGG+-VK+JIW5QW?O8S<V@NMJHN)2\:>Q3IRH).*9;$SG<"FL*3,-L
MGMK'ZZMEQZ:_B64:SI+2GM%V(O4!Q/W^,:]W8.*=GTV^@Z=\<3P7=,;8K<.R
MWQW^P;>KI0W3WCQG<[J:Q/J;V4W7A[XL4&R&()J<>VEL\>C;MX1'WCH+&KS;
MI\S7;YJ!43\3VOSE.0U]9BZ:N:Q+%L^Y*+C8&SV^>*],WI%VJSI6K=P-QMT>
MM;<[=C;G;C/ZS;JWC;F;4Y?N!M>AS)Z2NM,L]Q[:ZH\ Q&PR_#L/S%S'''\G
MQ7$D6]2\B;";<C7Z.K@4B(CUU>&FX6X+JC,-@^IBSN>IK+1T][LV35EZ1OT?
M?5WCT/*LBV.LLSSW =K:#I=HMX8=:W0;B2,?A9ICC.U>X+TW&&W<8Q^7B+5+
M'J8CD2Y:JXK6?7#U?W(K\WUZ7^I7>#+O29VV&[5V-!)WDB>CZRW:)6;7^&QL
M>WAF]*^00,TW)VCOI]+DN1FC;R5VFD;?.R\ACP*$.7[\V3=/XPO)G(D^O7K[
M4_P]3[_N4KKCZ8-\^I6!U>[H[8[3Y+!M=T_1P5W2MC&V]_)P.DRS<+<_(<^O
M,X@.7S?Z(9.*U53M/%O[2E]VW;ZRI["SSK(OT+S)E)50+NS@]^_C]D'PU2UO
ML/H7ZP8W+-+:+;G/8'7MU#[I.;<7N*;3;@]*'2O@6&Y!*DX5!B2\HVQS3J)R
M+)<=134N2VN3QI>.TNZV("+8*H)%.XE1AMV<ERO<CQY]7]6];T6Q-!*HJ24I
M2?'!5V)4E"G5*"Y*D!Q1=[?6E/#Z*AEP$$%OM"5K(L%9/]D8@_Y+LK_W+L-1
MO/8/>Y%GTCX"?N4_O#4HHM$31$T10+;2OCGD<$'D< ^7/D20?+S]FBD$@R%P
M\B"$2"^AQU)('OBH*2.U,I\@)[0!PI#8'GY)6H'D]I39I464JM2J"YQJAP<U
MY#F /<'&&P(((@238D&5;>P5"'$N!!!$&-"2!<&URM#?I*>N'J9Z<=\1MOMU
M/PO',6M<-H<SQ[(5X=$N,EFQ9XMJ^U:E2KUZRIG7F,@K2AD1Z1A3<%Q@/>(^
MHR#TOX/O@_Y+\HF8C%;5V?2KXAVTJ@%04Z >!EP50@.-!SK.K5' DDYCKQU/
ME/M_:FRW,IX.IEIC"M><W..&><0)AM1K0<M,;@)D6D+4%FO6OU99VY*3?[_[
MF(9><=:>B4612<5KEMAQSM:%=C J("6^P@$"."1[SGPDMH1W["<@^2>R&4FX
M?9.#+1D8.=P>SWNN&ZO^*,<?DQJXGP$<Y?MW:FT&/J5L;B6.ETMI8C$M:!ED
M]%U9P !<0# B!O$G&&PE2[VY=M;>SE2+9,5;AO9LN2_8)D.IEB+)>G..*DN-
MPY!=DR2M:G"I]"@XGD\^OM'D]L6KL?$T*6 PE(&E6=-#"X.F\.^+5&]%S:!@
MC-( ;(<&]B\["X[%U,4RE4Q6(>PUF])]6L]Q'.L80"YY;[)+HC7J(!]RO3)N
M(UNUL)M-N,TZ7'\MPC';.T2IQ;BHUY[FQHN0P/?K<<;56WL>PKU-N+6XAR*H
M.J4YW*/QMRCP[]G[9QV%8T<W2QM:DW,#:F:U1S/9#6YA3+;@!O!H$+N^QG-.
MSJ$/<\FBPESG9G$BE3:9/:._4W)7?[ "4KX^-Q1/VR!KSI+@"> 6< !,;R2>
MTJ=HI31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4AXD^]^()[N?L
MCD<<^SCCXO;J02)C>(41+@#[-C/7,1PT77.Z&95NW>WN;9[<+2BJPW%,@R>R
M)("O4<?J9MO*#?*D@NK9AJ;:'M4M03P20!>V7A'8O:E"@)#:]:E3S $EKWXA
MC2;6(#7$D6(B22-,;:F(^*X&L]L33I5'MG0Q2? L1J6@"-Y$+P8R;6=?V-K>
MVKZY-I=V]C:V3RR2MR9/E.2'G5%94OQ'ROUAXK4HJ?>=6"$J2E/VGL&@S![/
MP="GFROPV'K/SQF%1]&BQP&5K &@-$ M)&]Q7"L14)KUB(,U:A/::CI OH-P
MX+X4 <GSX _9Y_T:V$M:&@F;CJB8GP5G.>KZ?-9F>CFP)W<#K<V0A^KF3"QN
MUL,WL/>\B-$Q>DNIC$KGM6E#HOW,=BL+4 D/2T@<K4A3?,?A)VF<+L+%TVY'
M9Z99O)!KT\3AQ(#P8!,N@'2^Y>]R=PPQ6TZ#79@&N:Z61!YNK2<02X.!!$P(
MG0WT7L\82$MH 45@)2E*DD$'M0D)(XYX"D@+XY)Y5R"1QKY1!-2J\DZ3-]!F
M!(^G>NT%K:5-K6R?9B8DG+&Z)$B%R2/@I^Y'/V^![?LZJ.ICBJ1H)X*+4*4T
M1-$7%6?Z6[_@/]\Z,^5;_5^L$/R=;]#5^H5J+Z2_[(KZ13[?3W_J#.ULF._@
M+>[ZCURSDO\ [7;8_2G_ +JFMP4?X!^[5_LUK0T[W>\KJCM3VGWJ7(]O/(2
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M= (IG',Z8S&9<YNX28Z1B%O?(K#A]6K7()%.J:9)$W<<*YL6D:$]AT&J](#
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M(#5.AT-J4!.6H>]0L'W>36.&!VW@*KG\VP8BB:KI@<V:U/,7',T!C"!4<20
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MI1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7$6+PCJ6X5H1S$<X[TJ4
M$$E2NU)3W'E:&T(2KO6ISWH(20:2SG8I3=Y L1F =T9 UU,3$ D=A5*K:=!Q
M.H<77$B TFXD$@D7 O8<9'D,])QU"HWSZE[RFIY:9.';0)E;<5"V'"Y!LK>#
M8O/YO/;^BNMN=^1H;H'I#'A-R48=7/,!+2G52?ISX*-@'!;.^-565&N>):7-
MBQH[/J,DNHMD -=HZ+N@;QQ_E'M&KB\56I!K.:87M!:'$V=6:7DYW-F'F#$0
M1(W+72!VE9*EK4MYUU2U\$J*W%*2D\ #AI!0PT..4L--I45*"EJZD:I:7Y,I
MBLZD-2(!M,'73R6KL8VE3>YI)+GND.(.K1,0 =1O)U*D^M>#, 7X(CM-)EK=
M>2XI,9]L2?!>66W$$L$!Q*D#A:G WVK2 H*G: I,V;7Q3WEM2GAJCP"Y@87L
MH/J%L&':DVS Y01(,N&1A*/QIP:_,"3D:&1[)+ "0X.N9() C3A!]DOHUMBE
M;)]).W5+9PU5N396P_G^2Q^$!^/9Y<S$FP6Y0<:4OW3@8\BD@6'B%;?NA$DE
MMMII264?'W+/:];:VV<2:HIAN'YS!4^:#@.;I5Z\'I/>"\E[LSK D  90T+K
MG)G9M/ 8 934+JU8XAW.9207,I!HLQI RL:<IF"3H96?#<5ML!*5.<)*2D$I
MX 2E*>T<)'D>WN//)*E*//! &HTVBFTM;<$DDF)N #$ 6M.FI)6R/Z;@XZCA
MI8D]9W\=+*>E(2"!SYDGS^4ZD")ZS*DF8ZA"BU*A-$31%Q5G^EN_X#_?.C/E
M6_U?K!#\G6_0U?J%:B^DO^R*^D4^WT]_Z@SM;)COX"WN^H]<LY+_ .UVV/TI
M_P"ZIK<"P0$'D@>_5\>M:&G>[WE=4=J>T^]?7&FW%!164D(4@%*DCCE;;B5^
M8/*VUMI*.>4CE7*5 ZE0I:HS2S[Y:RDN>*I"G.]"B0Z%(X<"NQM8=*5H;* M
M"0VKEM3B%D4/J4<A()6>T)"B7/?NE *4+?6.%O*2A2VU!Q2D/H<6F0EX$<$7
M4&Z73GL3O=,QFQW=VJP/<BSPN;*L,1M,RQJHR"SQI^<\T].12S[.))DU\2>&
M([-A!C.-PK"/&BLSF)"8D7P2+L:BQ'&L7H:W%\8J*W',;IHS<*IH:2#"KJ>M
MB,NK?9C0JR,PB#'9:>7XB&T,!/<D$\][H<(N3?AMN*![W5=J7D$+67T%,N0E
MYY"FWP\TM/B-L^%WH48S;268I994ZVY(C?.[3Z?N5)S3:--\]?!<%'9*KZV2
M%K"TPZA05R%J04RK)+(;\1*PREE'#:6VDMMN@K7)0^\Z\XXM.^-W'7R^E3TN
MK3KX>Z?H7/""PX$]Y4E#8+3; [/ 2UXC;BT>$M"@M*W6&E<N=ZT=G8RIIMQU
M#@QNGO[?*.]!,7CNTA5*8[2>/HCIX"T\^*I)[% I0CZ&4<I802AGGS2275%4
MA2GE0I7PQFE @J)2>WN02@I(3QW )*>&TN%*%.):\-*E("N 5+*R*,M(/=W+
M*NXI5SRA)"T#A*P4)3RK@)')Y\DI'' XT129('"RCCN4DD_(?>E/Q>?/ 2/M
M#4L^4/YG_D%35GFSPS=\Y2N(N.15R^."H5RR1]MA\<<>WGGY?B^SJ[1$XEH-
MAG9/[01U*QB\PV?4@3%.I:#/R)FWA]*U@>BC_4_U@>W^OAWY]O\ B.WY\OL:
MV#E,2:V G_AV'^M6.]<Y^#+-\4VYFB?P]C])TYO!QKU+NGJ<_KK.AS]>-Z?]
M7,1UK*Z>L]V_@G[MS\(K1%'HB:(FB)HB:(K<F?J@B_K)8_AXNB*X&_@G[MS\
M(K1%'HB:(FB)HB:(J>3^EI_PC?\ "T18%R?[(Q!_R797_N78:C>>P>]R+/I'
MP$_<I_>&I11:(FB)HB:(FB+B;)I3J@$("U%EP@$$@J1R$]W'Q)2ZZ4@>?>4J
M'FD:H8YS,2UPF#3#3$_RC9C=,$Z]4RJ:K0ZD1P+C&_V"/>5XW?2)=/[FP'4_
MFL*N@,U>%[@29FXV(MI;*8_J5S(<:NX412$LLH]Q,IX:>92V?"@9!2M@]Z'7
MW_J7X.^4AQN"P^'JU2][0RC4EQ/38W!TC9U4W=F)@- $FUPT\BY1[.^*UJM0
M-ALN>TP "USJ[P)#1, 1<S:#=8,)<)4KN3PI(2D_&"2A#G</[U06"GS)XX\S
M[==7K/92IAX@!W2M DD.,ZC<-96IA_.47BQA[F=D,B#<VO,6MN4DL-.2$O..
M%DE*&'%!*%ER I3BYZ&D%M9#J%"&^5J[T?0T)+9074N8V)ITMHX"M1.5X?2J
MM@ACNFZB6BY#P/;X3J(,J]L^M\7JM=$%KFP08T<P@@2))(L;6F+3'K%]%MU9
M(WQV0B[>9;<(7NKM+7Q:>Z3+7WR+S%TLL1L:RYHJDA<B+V-JJK-2??>O1DN%
M4=+Z4'Y,Y?<G';+VO4JTV.%#$R\0T@-JNK8AIIP*3 7/;2-01?VLURTNZ_R;
MVK3Q.$YM[FE].H6 $R[(&TH,N>3#2[+)%K:F0-J+2U*'<?(E(4$\\E/*4GA1
M!()\^>1P."..?A'GD97@'\H::Q,;XO;@.Q;2X@LS- [1%[$[MW?UZ0JIDDI)
M/_Y']X:R'1:/R1]NO6K322#/$]VEE-U2JDT1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31%3OO.-\]C1<X#?()"$J+JRD$.DD?0@E2G4]A(2I"@0 02+7SZ13J
MB8Z<-C;F936 ;W%SV#-Q#;N/"<;=FQ[6<S(CR,O9964DMX?XJ9L8K2Y%D7+U
M/ >2YZ^A(V[D;R?J;<VM0ACG4*-6CSY+"^F6_&*'0=^*J@$AQ-P06AT@6)US
ME#M$8*B6!P#ZE)T N@@%M09Q#FD%I: V"+N)&;*0/'' 0A#)[7%R M:5B4XX
MIU<ISP6D/O..N?1'5F2AY#LI?"I[B%6!"3+[1]>8##T-D8"AA6M:PBC386 4
MVN+Q193G*!3UYH"[9FQ%H'',5C<^)>)!+W/N#,AU1P@=+KL(CA.IK0"2>2"/
M-7D?>\_9_P!OQ\:JPU*:[L]Q4S8AK?SGMRF".T2)X!Q5MSAT6@GI $CA-C;C
MW+*/HGV)G]0W5#MQ@@KT2<5@38V9[AR5H\2,WAN*S$2Y,*2.U:6V[JR?K<<0
MIQ"DF3>1GB/"B2$.:%\(O* [)P%6A3?E=5IO:&@Q>K2QM*"&UJ9@<V)@'*!<
M:1LO)[!C$8JFW*2);PME?1+MQ@P?G6O8&"O;55QT1H;3+:4)0D)2E+8"4!"$
M(;;[4@#M'AH1PCCWHX3Y<<#Y4JU#4>7DDDDF2<Q,DG7?),SOU78*-,4J88
M !8" ( $1 B(T7(:MJZFB)HB:(FB+BK/]+=_P'^^=&?*M_J_6"'Y.M^AJ_4*
MU'=)2"?2)^D3((\U]/B>#\OZ IG\[Y/B^/SXV3''_46]Q_Z'KEG)?_:[;/54
M)_\ ^IGK?V 76WA(/'M^,_\ 72GVGGV'S_9UK8!C0FYT'$S]JZFXB3<"YUMO
MZU%P?E_]5'\NI@\#X%1(XCQ"<'Y?_51_+I!X'P*2.(\0G!^7_P!5'\ND'@?
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MYV((Z$\)Z0MQ/9$=:A[@*6H/2XC\DZ=:XFW5_P#39B_+A4%SX^0!X$A7Q<<
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M_-C1$_IG^J?^X<R/]MS'OS8T1/Z9_JG_ +AS(_VW,>_-C1$_IG^J?^X<R/\
M;<Q[\V-$7$O]2W5 Y;L.JZ)\B:?34V20P=UZ%?>V'H)"PM.,A()*E)[3R1V\
MD<:(N85U-]4[1*?Z1S)#[YP\G=S'AS]%6.1_^F!Y>7^GGGSY (H?Z9_JG_N'
M,C_;<Q[\V-$3^F?ZI_[AS(_VW,>_-C1$_IG^J?\ N',C_;<Q[\V-$3^F?ZI_
M[AS(_P!MS'OS8T1/Z9_JG_N',C_;<Q[\V-$174QU4OI\NAS*.T*!Y;W7QQP<
MIX/!4K'V^/:.1VGRX/=Y\ BMK:F-O7GO5E_1CW!V.N=HJ>)LC:8.TBTR6MR-
MJ39,Y4+YF0'J^%"\-M]$]4<1B%.H,5;I<*74A$;YXV/5$^:+8XT5%![D]I2M
MQ ^RA#BDH5[3\) !/LY/)  XU**9HB:(FB)HB:(J1WGQ^ 5 %I)/;[3V.*][
MY@CA040H>T@#@CC3?._CO429RZB"8/$V[%K']*/TSN;[=/L_)L9K7+#<3:-R
M9F&/1(L(2K*^H0PZ[EF)14I['I+MC'BP+JNKX[B'YMYC=1 2L":K6[\A=M/V
M9MC#TRYHH8FM0I59,!A%>B14]MH!RAS23:X+K-$:SREV=3Q6!J/Z8?394>"T
MM$@LJ")--UFET@[A,$3?R,0W'W&29)96YXSK85&!\+EE994A"E+47&F'6W&&
MW_>)E---R6VT-O(2/JYU9N.HX7F*@?3?AZ!>YKP\A[F=)H+"YH.5X.4RYI,$
MN$$\A^+TL.:E%SJ@FJ^ITG-G7)%VMMT3N@Z@P8%8$CN#B1VN(3VAT#WZ4']-
M0D'E'#R>$N<I*BE( *>.=9V&I?%Z1:"7 DR'F8):T'0-B WN,]U!I4@9:]YG
M27-(!.AL+ <?>NZNF[?')NF_>G$=U<5<E/KII$>%=XZP^66<JQ><^ZNTQ24I
M9"2+,,(E0GRH(IUU<FV>3(8C.17].Y7<F\%M?9^+JN%4U^9JTV9.;+6N92Q%
M:F\ 4GOS,JN!$&_1 &:Y]?9.T:F!Q%)K7@#G&OAQ=#@7TPXF'-,%K<NAD'+8
M2O:?L[NUAN\NWF,;D8);1[7%<I@"= E-H=#K*POP["NGL*4I<&SK;!,JNGQG
ME'P9D9T)Y;4WS\C[5P&*V=CJN'KL+31>6.+F/!<&/>!4;+6C(YK9:3IH0(@=
MFP&+9B\/3>".DUI !%CE:,IN?9)BPN '"Q7;S'P5'RX[SV_+V]J?;]GGGV>7
M''Q\ZQ \/ ((,"+&8C<8)O>X686AI($WN9X[XL+*?J5":(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB*G<=6AP) 3V]@/)!Y[NXCCD$#C@?;U#B TGYPF.!M8<9
ME "3U;^(OKPB%8&XN=8WMYB.0YOF5Q78_CF,TMK9VUO8O"/&KZ^/&+SLM;CG
M>D*0&>QOL:?==><;C1X[[\AMER_LS"8O:.)IX9M/,ZK5%.FVDUY><SF!MC()
MREQ-P!&8D-:XK&QN*I8.B^J7-.0%T.(@@!QBT$$D =\ $P%XR>L#J?R+JUWE
MOMQ;@3X.+Q'/<' <4F.!"J#$H1<;#$AJ,O\ YO.R5Y2[R[:0\N77S)$:O:GN
M2*9JP=^KN0/)C#;!V:YWXU^(JX@UYKBF2#4H8,CFP:%)X:'T8:)=<NDN)$<:
MY0[=Q6.Q@Z% ,;0%/H-J"0*M:/\ ?/:70[@ >$66+2&UI[RM;CJUK4XM:TMI
M)6K@J(2TVTT@$\J[&VT-HY*4)0@)2G=,5AJF)JTZA+V<V6EK&.<&N#7.< X$
M/+@<T&]P -RUEE$/J\ZXO#@9B>C.8.^<"=3&NG7)4(<>+Z6&F_%#@#? '9V2
M'V)9A^(\I7AI9=>C'Q5E/T%IITJ)+K91=KU3@\+4QKPUM2A1?3:'6INITJ9J
MAS@2QV;,PAQ#@TM-@T@E9M.FZMBJ30WHQ3:2T$'Y0 G0@N@^,39>J+T3/2TW
MM/LJG=K**]YG/MY8L>W8:EQ!%ETVW*_"EXI52&76C+CRKQI:<EM&B_PE$RIA
M%AB16R'9/RM\(?*6MMK:E2B>9;2PQ?2(I AM2JVKB>E)K5LV1M5S1E+#F+VN
M:XM;'6N3FR:6$I#$#G2^LUIZ9!:&.%-Q  IM@/<V9),L:TM(DSMWA)6EDI6H
MK4E9!60D*6>U!*U!"4([EJ)60A"$ DA*$) 2.<M#@"';B8UN+7,[R9GKX:#;
MB[-!M8 6WP($]<6[@=55ZJ4)HB:(FB)HBX6V\;L4EKP^7&5)3WA9X*&Y#A)[
M2/+N0T!QY\%8]I20I_+LS69#23OD/N!-M(CK-]RHJ\X*-0TPTDM>PY@X@!S'
M">C&^-_TPM&$U_JZZ=>L_JPW,VWZ2,@WGQ?>23M2FGNH^>46*U\6)A>',P+=
M]8L8+KKBS)G/MM-H45*4PEO@$+5K;RW XG",8_$%KLH)#:E(&<A!$.TAQ(&L
MWN-W&W'E!L+;N/VA@ME#%BN]QRU6XPTV@5N<#N<P^&>TAS6M$$C)FDEU@NX!
MUL=?10A2O1N91ROQ%IYWCQIKELO.!E02BL?![V0VX5%23RHCL  *O/I[/V?#
MA\8Q%G'_ 'N''#B!]O:=5ZXY4\KJDN?R>P],DF &[4@MF0>E@YT,:D&)WP']
M.QU\_P#9N9/^W/CGY&U7^#]G?SG$?M</Y*?\Y>5?_ :'ZNTO[FG].QU\_P#9
MN9/^W/CGY&T_!^SOYSB/VN'\D_SEY5_\!H?J[2_N:?T['7S_ -FYD_[<^.?D
M;3\'[._G.(_:X?R3_.7E7_P&A^KM+^YI_3L=?/\ V;F3_MSXY^1M/P?L[^<X
MC]KA_)/\Y>5?_ :'ZNTO[FG].QU\_P#9N9/^W/CGY&T_!^SOYSB/VN'\D_SE
MY5_\!H?J[2_N:A/6OU]*5P/1M9.1P#W#>?&N003Y<*I?LCX^/L?+(V?LZ_\
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M!J!K& %L!KG1+@X2UPEKB+==YU"EK8"GFY <=0MM*NSM#1 <4AQL. K:6O\
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M$*Y4"!QY'CX^?DT1/#'!!4L\_*>?]F@L0>"&X(XJ$- >Q:Q]I7'[PU)))DJ
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M9>^:ASULE9],U7.IP7D,:(<&P7#IE@ZOL38E/ 4FU'L'/$ N<6MZ RLE@=D
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M;=8E-/!;+K,EE:"Q):<966W&GVW&W&^$.)4GD&BFU]"HW$TZ^(#Z9&5O.N#
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M5CK*7$+>1&OUWBT^.KN61X?9R_;'PC[;VDYPI8AV&:2[^#5J[W&34LYS\0\
M14B&L:\6((LMVV?R9PN':TUFBH0!\HQC6Z,W<W)-B#+H-Y;&NS&IQFBHJ^+5
M4U7$JJV"TU&A0*V)'@08,9E!;;8@08C3,.O;"206X3$=*@>% CC6DU<7BL47
MU*U2HZH]QS/>^J:CQJ"][WN>\R;%SG&P$P M@9A,/1 :QC0T $!H8&APX!K0
M #O@ F;KF&XS#7)0A8Y)/':GM X' 2 !V\'E0[>"%*4>?,ZQC2#G%SRXN/\
MS$B!?>.,SVG>5= #= !U "+=6BKF0 C@ @ D $J/EP./A$G]@>7R#5P  0!
M4J;J431$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$4M7PC_FOPAT16
MW$_5)<_XC3_QVRT17,GV'[I?\-6B*+1$T1-$31$T1-$31$T1-$31$T1-$31%
M;DS]4$7]9+'\/%T17 W\$_=N?A%:(H]$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$4"FTJ4%'GD<>7EQY'GS\M01)F3W?:I!@$0.]%-A7_66/L
M\#_1QJH&!$ ]HE4D3O([#"EJCI4I*N]P=H X"@ >#SYCM\R?CU:=3#C.9[?^
M5ARM-R;B.[L "E?%QFUD*(/>D )7PA2T\'GE)4E7:?,^:0#]GD#BH, XGM@]
M^FME(,;@>V?L(UWJ'U1GDJX4%$ %8(2M7'_Y+2 I7V>21R ?;JH6TMV6]RF1
M^0P[KM!]ZDKK8RR5$>^4>2L-L!9)'!Y4&>X\\DDDE7)]OL I(>1'/5FC@UY
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>HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g418853g00a09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a09.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1<@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %P2^6)(X0DE-! 0      "<< 5H  QLE1QP"   "   < E  $T1E97!A
M:R!086YE97)S96QV86T .$))300E       03VU_L"E!NVXS#Z"992D'2CA"
M24T$.@      Y0   !     !       +<')I;G1/=71P=70    %     %!S
M=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13
M:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              %V   "+0    8 9P P
M #  80 P #D    !                          $              BT
M  %V                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  %V     %)G:'1L;VYG   "+0    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M0-U#3!=!XC=XG9^]^_[%79@Y3V-^TY+RZ!L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M=\JY'4ZZ::U2HT56N;4 <UPAPB 1P,0K,_3@L]V#(UOXRK9NT6UI6^W#92H
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MG80?V$T13;Z>WX#\U$3?3V_ ?FHB;Z>WX#\U$3?3V_ :(I ^T2 %I)/8I)^
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M7K\_7/Y,2I13S_Y06C^R7G]MMJI^)O\ R]$63U9$HBLY2MPMJZM=Y.]U)&\
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MJFZYW")B"&^^PG>.0L";F-39:;M#5-'8^-():]^&KED&'%PH5@W=$$EQ,!I
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M\_7/Y,2B*:=_']I_LMZ^5;:(LHHB416<P)*$[R-\ DC3DH$#4:*!WD[Q\4D
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M[IT5HH<CKIH>?(Z\M#Y:(H[R=2-1J--1J-1KKIJ/)KH=.W0T1-1VCW11%$D
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MMP2X*:6H 'FB4_&W=?(5'77=!XSM ?:8BA2&E=@(X7$V%]1?FMQ@9%'$._\
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M$HB41*(I'/O%_P#A/;S'E T(.I'($'4$ZU5WPGK5%HMDF0](>#M@QO9]%S_
M(3.96//<FA*.S>;.%J;QR=;V[1;I4EK,8B[@I3-U9%RG&*UPBT7&02%[V'GW
M=_04D'E!R,B\9F2?LOI*Z4F#8U<;Q;[[-VBWR^-;2<<V33;+&P2ZB#!SV]VA
MAZ):+"ZJU6^>BQWQYP2[==<@F26)"9+;<24_"YHNS/+3J>7\(<LQ,]W\]PBT
M:2OJ6GI?;*Y;D W-G,L:AW%S,X9O.46)%IML"[[.X,JZ9C8);S5RE2'+I8X%
MMGRVQ%8N-N6B+(5'N;R6'.'EF%"R78OTG-EG2'<R2+LUO(N,W&F;>_/C.2K3
M*+<.Y$JA7*/)QZ]W>$MM0!+K#TB'>8[H5&EQ(SI*1A?.]X"/MY]< /SZZYWT
M"U2=Z5V>VO/E8<,WV>Y[D<3;Y*V9779C8<9EVS-K9A* XI>;O.)R2\.P8]KC
M.=U3;K-ML6SN1$K95*0ZI*$5]+_37K[NN'HMAT=,'9*R$/W)S*[3;;K8;WD^
M(WR[V$1K3GMHQYU#5XDXG-B3'DO(@\9I4>/>H]KDNPWDW",'8A3(.<$P#8R/
M,_2XX)UKUKU"C*Z3JSE.R;&[3LWSR7'VEW*[0A<)4>Q0C#C6ZS,7D7!A[PE=
MCW6(ZR\ )EMN#T-M+,AEB7,<:0V[-QGG\OY"C/J/L>2VM,AI#BDN.M-D)*E!
M3K>BD #18*BETC3FI;H<"E:E*^NBE:V]*':-G6S?#L-OVSZ[V&!-O>T[9_A<
MOOY9'K]#?MV;Y-;\==F,IC7RR%EZV-S'9T=1>>1)D--, (44E1%Y]+V_93LB
MVOW#9MMLN^-W3%9VS:][4,7SS'[-*L$EJ%BDQN#DEHNUBDS[XR7V1<;>Y;)+
M$U+DYV5W,E*EM*%$60JZ7FS9BX&QS;3FEIS%<S%HUOPVYV2!;KY>V<S8?=QZ
MZ0 _>6[/+M4Z/;9Q6X_=69D23&$!Z,Q/3W)4@V G6\CON.N8-RL+OB.7D.&O
M'Q2_],W8IBF;V#9_D-[N%GRB\IQ@/VB<+;$N6/R<Q;;788E\LDZ[1\CXTX.H
M$AZ!9;O&MZE 7"9 WB1,BQL0#D<^/EPTY9JLF^=^=K:<3U?19AM+S"_.Y]@V
MRW%+ZC'KOE%MR#*[G>H\=$N5%QG'C :?;A,/K$=<NZ7B;%B+EE27(MN#[392
M^XU7G9\7=/4_4?<KT&?3/A_62\*V [=;YM3V<6#"K[D61VS:YE%ESNZVK/#B
MMK8LES.)YG<[+*9MD)LOIX-K#42$^S(MS+3K#SJK5<'7R7&O21[L\1W$&UQK
MR/@>$.NNOHMH]@NT&1M*P&UY)/88AWONB]6?)H49TNPXF28[=Y-BO3-N*W'U
MIMAN,"0]!2)+Z P\C19!233H(O;:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HBQ6P?A+U^?KG\F)1%-._C^T_V6]?*MM1(D#CEX(LHJ42B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*D^E2F7$H2%+*"$I5R!/
MDYZC3UCJ-#H?)4.$@A/DO ,@V-7J];9\6VNL9I+MZ<4QZYV%C%&['9Y$*X1[
MP6USUOWA]1N+,I:X<0LR&VP6!J$D@JTQ;CN'#A]_+@B\@O/0_NUWS/(,N1M;
MO-O[];7\7VRIM[.)XZZW&O\ AL:/!LUL2\IYMU^UN1HK0GH?U=E#7><2HZ5=
MC2)F?E]#Y(;_ #^?7W7RY_0A9O)M<?(=IU]O5G@9/M(R&99UXUCT5BZ1]JEM
MN-HRVS..-NK6S!=@7.2U;%)^Z6\;I0%*U(OK/])PY>?G_:V,V8[,,CP''(F.
M7K:!><XCVJWQ;39WKM;;5#=B6RVA*;>W)3$/#GW%E#;*!<G>&7$-)XK*5^-6
M-S23(X<L\HZ_A%9;-]CL_!F<^8N^62,Q8SS)[SD\AF=9[;:>]KU]:$>X0FS
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-"5$D,'R(3U_/J1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g418853g00a10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a10.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1I<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              %&   "7P    8 9P P
M #  80 Q #     !                          $              E\
M  %&                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  %&     %)G:'1L;VYG   "7P    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M\:PO#":2XML<#.W?[7,.^KW#Z"LXM#!=DMET![(]SNU5;?'^2DI-Z-W;(?\
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MEX/V5^/8'T?I?4!(:YGJ_HSM;[;'LV/25J__T.]%'3K[NJ,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6(:3E=35)2<S.$=58G)WE+(T-5-VL[2VPBA#9H>BX38W1$969W.#P\;B_\0
M'0$!  ,! 0$! 0$           $" P0%!@<("?_$ & 1  $" P0$!@P(!PP)
M! ,! 0$"$0 #(00%,4$&$E%A$R)Q@9'P!Q05%A<C,E.AL<'10E)4DI.4TN$D
M,T-58M/Q"!@E-$16@J*CPM3B)C5%8W)S@X2R-D9D=+/#Q*2T_]H # ,!  (1
M Q$ /P#]^_47GCJ#GOVY#GMY]OJ^.D(X')N6ZW0<H&\(_2/4/ ")1X$1)R<
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M=3"*^(F(%$#@8#"/3TF#OQSSQP(<\<#S]&D10NQZ#AZ:10!*)P[CSWX 1Y^
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M#CMPHW030,HLJG:#++&$B?)U%P2*98PB)C& !X'SU)M]X3$B1,2> 2VJ\U)
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MC^.3$44M3E^H01    /(*/>0 "EX Q1 ! 1#N81&>'!Q2YPI]X&/[8LF[ @
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M"IVPHPJ"(^?L.G%QVNT&1+M4W62HC6F6:T(0=4ZI92Y02Y.'&KBP8/)(NZ7
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MA)>.5#J3<E.7SZBE.(#^ 0+P/XM5X&9\7TI]_3LB1:I"L%/R ]>N^.=-\V5
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MS"(F$! H![PCW 0, _EUP3+5-6:K<$,<69@ ,<FYGRCV9=DL\I 2B6D .P!
M-222P2,SG[HZ#C%E#>]7K-2KBQ1 Q0\6(CS^Z;CJ*)?52AP8//WA[ZA-I6D-
MAL;T[.OIQ789"U%10"2V(&TYMLIGS1C;K;[A]T3A;&]+4$!$W)H!@41'@?\
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MQ!LA'Q3R!^OW1?NK9_C <H(Z_MCT6FY? []UZJVRO0CNP$ ,T/;()!V01 !
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M3F'OWYX'@ ^/(CW_ "<_E\W!S#B2.3VX;.M(@K0,5"*@Z2$.>1X^G@P\A](
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MM?>&;%;R8]+,2G24%XA^PI&4<E 3=2!1*(:M$,-_2K><CNCC<YFQ\U3?+.;
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MC4%,LM_7;'3DL\X8C/;3V0R# M$X2Q1=1F55#+G*TG9L0",B3 1LH*Z[H1
M40(9!,# *KE/WN!"RPX50&# )PV5!Z3N#Q5*$)7PFJZGQ-&+CGRI'9D\_P"&
MH,UA1D;Y!-5:E-1%>L1#JO%#1,O.I>)$LEP*BJ0RKHG!BJ-A7;D Q?$43$!
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M,A&!%5BL8EH*;)H"R@(I%Y+THR-5%69=^<OZ#A&G\?I$)NSW&G*4O4..<,G
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M' ]](14&Z8 (!U>8& >H1$!#R'D>1$0#MR;J'@>!$0XX0BH-T@$>"% !\R\
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M;88YRNNKJT-"X#U;GPYC@[TCVU&3<5/$%!+J^D2)B ]Q,/8P" <B;D1  ,/
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M\\?041U4E3LE!51Z$#9M.^GLQBJE)0'4H#I]S>F!'A#$ YB] " #P8Y.0Y^
M@ _#D/R_#4)*SC+((!)!4"P#O4;&K%G24A6L&+,2"!7#*N-?;%_K2?TA^^+^
MO4NKXO\ 6$2PVCT^Z'K*8_$/WY0_2.I!.8;G!B"PS'I]H$5]9)])?\X3]>IB
M'&T=(AZR3Z2_YPGZ](.-HZ1%?6"_5^_)^O522]$OO<"+!C5QZ?8#%/6"?27]
M^3]>K15QM'3%?6"A]'[\OZ]5=7Q?ZPBS#:/3[HM]:3^D/WQ?UZ.KXO\ 6$&&
MT>GW0!TF/D)?WY?UZ OET$'U1!89CT^T"*^LD^DO^<)^O5HAQM'2(>LD^DO^
M<)^O2#C:.D0]92_PTP__ +A?UZKK#J4^^)AZP3Z2C^[)^O5LL.;V1#AV<;,8
M&<D* F'C@./VY?B/ ?'Z1U0J(#E-!C4>UO7$E@')&6W,MF ,XH9TF4!'DH\#
MQV.7Z.>?/CCZ_IU*5!63%GR;IZB(7Q "K M7#%]K;.BHBH."CSV#CX#UE[]N
M?I^&I!.8;H,3D#B^X[MV^*BN4/NND!__ *A/UA^34\SPZYGU F*@N4>_N_YP
MG\[2$/&*'^#_ )Q/^=I"+/62B8   $!#D#>(3CX_7S\/CQ^+3 MGLB0"I.N,
M.?8^0(SVQ=XY//J)Q\1ZR\!HQ&(:*!0(?T9] AZPG_A$_?ETB7&_H/NBH+D'
MR,3]^72)=_V$>N*^*7Z2?YPOZ](@ELB>0/%OK!.1#W>WT'(/\O/Y0U4DC+I+
M=>=MT3%?&+W[!V_Z11#\H"/ZM055 U37;3KTQ(!/[#UI#QR?$2!^%0@?RZO$
M&GW ^ZG/#QRAS]SV^/B$X_*(\:A]QZ]?=$\X]/NAXY/@8@\?0H3R_+J8J"^W
MG!'LBWUDGTE_SA/UZ@$G$-$D@9CKRM#UDGTE_P X3]>IB'&T=(AZR3Z2_P"<
M)^O2#C:.D0]8)])?WY/UZ@OD']$2"#F.GW/%1<$#SZ0_"<GZ] 2<0W.\"PS'
MJ]8$4]92^)R!^%0GZ]"0/VCVD0<' O#UE/X&(/U@H3]>@+]1["8AP,2!SP]9
M)])?\X3]>I@XVCI$5\<OU?OR_KU5U?%_K"+,-H]/NAZP0//@/W9/UZD$YI;G
M!B"P^$/3[0(IZR3Z2_YPGZ]3$.-HZ1#UDGTE_P X3]>D'&T=(BGK ?  $/I\
M0GZ]44H@L$$[PT6&J1Y0Y@3%/6TP[")0'XAUD'C\^FM,RDK(VNCVJB#J_'3S
MN/9% =D,7K  $G)NHW64 *!1X$1Y'R[#]7;S^.M"""QQ+85QB$J2I*E!09..
M._-F&&9$"O$C 82B B7[H ,';_![CP ]0=PXY[?3JI+*"30G?3/'HZYP%I*5
M*!<)+'I;J[1S$5 X%'I$.KZ?,/A_;ZOR:L0W7;$@O7KUPZX\G/<0^CC\^H@"
MY(V%HKI$PTA#2$-(0TA#2$-(0TA#2$-(0TA#2$8G:T73B GDFDBA$/31<B1I
M)N.D&S 1;]W3GK Z?A)B'B',<AP H"82B <#RS6KSL7:K@$<Y+;=E8T0:@[&
M?$D8@$88=##E$0=V:5^1@9*[IO<RXRR<XEE$Y65B\9OJT+6$DE'I&Q'#V-K\
M/&+MG:K5(@O7<H(.'K@>01 H&/KILY\4K#%7I &=']^ H8YIM)XY!0855CZ7
MRW4B368<*-LP,X.!EK$K&U5G)HR4U"MX*(>.)A=D[CW<:=C,O$SOZTX9J,CI
M^O0PI/%F[QRD*Q , ZQF#64*MJMSX?LSC7KUZYQ@."]I]6P3'VV,966;LC"=
MBHVH0B3E!G!.:GCN%;/6=?J$?)P(-)1TM#A*RJB-F7>$FS&=I=*R)VJ:AN@*
M)0E-&%:;P!['YX1JS;IB^JXCW'[C:G3E+8K#C1,1R0#<L@7W),N#EVC:P6#Y
M19%LMJL'JP F0$67M,&;8 $K9ND4PAJQ6I2$(.KJR];59" KCD$ZRPD+744U
MU*U:A+ D1TS;9.G6:RV-8D\#8S/5(*++994XFTK2N;P]IE246FU *EIX(6J=
M.$A.LB0)2%*2KYZ>E;WO[@]N&=*C3L3V:.A(&4QBUL#YF\@H^5%:6-999D+H
MJSLAE$^6C-)$4RCTB =7'4 #K[G1:Z+->$D&:D%1FK2Y)%&+#$8ZIIZWXO\
M,W9K[(MZZ&VN3)L*EI0JR2Y[IEH4-=4T(KK N:BCBAV1\N"^EJWL"BD'V080
M X#W?D="B "(AQW%+D1#S#XC\=?H"M"KM 0>#0G7IK:TQPY"7J=[LVQZ1_/R
MOW1.D8LLL\+-"CJ@'@9#JJS&K# 5&.QXK\[3O6'SR'#B'Q#Y&PH?_P"/6IT!
MNX_E$<RA[XR'[H72D?E)GT,GW1<7TM&]/GMD*& 1^FGPP!^#NGJIT N_*8GY
M_P!YC67^Z&THUN-,6 Q_(R!6F;".3YVC>K]\.#'\-0A?Y"!J.\"P>=3])]T;
M']T)I(<9JCRRY$4^=HWJ_?#A _R0A?Y2#IW@6#SJ?I/NB?WPND@PFJ'_ $Y$
M/G:-ZOWPX3^"$)_1Z=X%@\ZGZ3[HC]\)I'YT_1R(?.T;U?OAPG\$(3^CT[P+
M!YU/TGW1/[X723SJOHY$4-Z6C>J "/V1(0/P4^$$?R>'WY\M2- +O?\ &)^?
M^R**_=":2:JFF*=BS2I#OE''\[3O6^^'#_P,A?Z/5N\&[C^43S* /2YCF_?"
MZ4^<F?0R?=%Q/2T[U>1_WPH7R^-.A2_H('/GJIT N[*:.=8]G7VZR_W0NDY)
MUYBF:CR9 ]@CD'TM&]7[X<&'^2$+_*0=1X/[!YQ/S_NC?]\+I(,)JA_TY$4^
M=HWJ_?#A/X(0G]'IW@6#SJ?I/NA^^%TD\\KZ.3#YVC>K]\.$_@A"?T>G>!8/
M.I^D^Z(_?":1^</T<B'SM&]7[X<)_!"$_H].\"P>=3])]T3^^%TD\ZKZ.1%B
MGI:=[!2"*>0X,5!$I4P-3X82BH<P$( @5/D0$Q@ >-:2NQ_=IF)"YJ=4N_'_
M $2WI:.>T_NA]*)<E:Y*EKF HU4IE2"HDK2"  #5B3A&PE/2.^D3<8S4RNG8
M6"M ;V="HN9PM-A!(G.+QYGR#/U8J1ERE=%*HW1<J 5L5P4$E% .<H#X]LT5
MN:RVG@.&EA8&L/&ARD*U2IB>,':HP=]P^L'9AT]MES(O&19;5P/#(D*FBRI4
MD3ERYDU*=42U$$H2HA1!!8@%XV+C3>#Z4S+M;2LN/I:K3T.M8/DJBY.UH$6H
M$^9 7I&!V$K),WH^(U W@+MTG":ZS=V4H%!,O5R6O1^Y+,J5KS4@J0I98E0U
M4E"2RDNDJ!55*5%0!"BD)+GV[G[('9)O6Q3)TBS35\'.1(3K)DRE\),3-6'E
MS$!80H(($TI$HJ2I 65)4!'][Z5'?S&2#V-D;E#-'D>[79NVRM.AB'27:J"B
MZ2*?I,53PE2*E%<@&; 4$U!5$J@<=<C1BYYJ01.EUP.NDXU ?6)Y:$Q\7;.S
M#V1K-:5R39[51:DG\")+I4H%OP<N'!K@P?,/DM7])=Z0:W.W3&"NM<<+1\1)
M3C[UF JD8DE&Q"8+/W""\HLU3>]"?49)%D9RZ6+TG30,4Y>=%:)7*DEYDO%O
M+!J<V2HT%7- PW1V6?LO]D*8@#@9^L$+6=>SHE@I0"H@&9*0%*9@B6EUK+)0
ME2B <8^=;WX#P!;K&G X<%,6@L03$Q $RA0.=J03**E$"MD@( G.105%$PX
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M%)(8,$FC4+9<=GT^T+$Q6M8#.0J3-E!:+&H)452]5!2E5F!ED*)UE,5)4DJ
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M#E?*O[7_ #PX*;\AG=?Z,.D?[ ;^;IP<KY5_:_YX<%-^0SNO]&*=)O@4QOP
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MT7)BF*0H#J+HO!VX!8&-02P<C(.#R,^V.<Z=Z%!SWQ6 ZH=A/LQ>A+?C0Y-
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MAW_Z$_SCNZF/X5(H^'Y3.*#OBVF]^=PN+@ # 0>;?7P #B)P HB9YP!A%-0
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M;\-YAV+XZQ@8D="DJ5/+N]>@KE7S3-@"SM@26V/@\4/8]T&Q&C-E+D.\N3K
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M([MXFYL;RN1<[4,J2D%3'5P.DO;5:Q&J5PA6(61V@W<RJ0KG3452 Z ( /0
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MCU8J,?1$@?A45DET5G*)7!EPL=')H^$*OY*GKO=.\TIG6M,U=E6Z !J*"25
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M$AMVH,:4R.!R@.RO=#56E\6$F:U!@Y62'/PB"P<!,;(J>^/T;=4Q[?L:%O\
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M'+ 7+<A_V=9JM^3'K;[MYC/D:?M\63;*D@<6'2>.SLFRJ;>LJ)+NB#TF:(J
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M=#*,_&W.P6B13LLBWA2/(ILZ9S981N_9MWJX@R*86W)0ZM^U%;"&9_1MW5P
MWLT8]MW?F0'8_!?%J<4$DLR6J3A&][%Z..V33'(L!$2L;5(Z=P)CR@4JQJ9"
MN5BND%8Z9;$[!.Q2\])(>M-8RVPX+U*6L449*97B'$@D*:;-RHS.[34& !Q
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M'R$RNP;LC1ZC5^DX5;N"JJV7?EVJ UKNE/BXF3 :"I+3AM!%:Y$1578UO]8
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MJ6%\R,NT=M3'06.P>KM'953E4*X<-G"#943D %$S\"&LC?\ 8 L@6*6VPK6
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MI['&,,=711 4UW#8S?(=EM[]0K@72APEDUI5Y*+KMA?Q0.%-=%'P%58XX5Z
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M=-=%AC?EVC_O+-[)L/MVMIG)B_;!XGZB\"8H7FN&,4!#D!,!)$P@ _ 1#O\
M#3N1;\I0/),1[5##V1'?OHI^?;M^N6;];%P;V-IA@ P;A,3B E$P<7BNB(D
M>!-P$@(\ /(=P >P]M1W(M_F1])+W_I;NM8D::Z*D.+\NW%OX[9OUO5Q%/MV
M=IG^,'B?\=XKH?F&0 ?P=NX=]2+HMY_(CZ1'VHGOTT6_/EV_7;-^MBOV[&TW
M_&"Q1_#BN_[0T[CV_P R/I$?:BO?MHJ/]NW;]<LWZV'V[&T[_&"Q1_#BN_[0
MT[CV_P R/I$?:AW[Z*?GV[?KEG_6P^W8VG?XP6*/X<5W_:&G<>W^9'TB/M0[
M]]%/S[=OURS_ *V'V[&T[_&"Q1_#BN_[0T[CV_S(^D1]J'?OHI^?;M^N6?\
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M2D9!HV>N(^ B8QL_7,1NU63(LY20%("=9]7MUXVI29)5,)5J)X0.SJ(<EG8
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M0"$EF!(IF7)%:^G#$U/8_P!"&)-Q2:LQ8L#4YI&=6IEF[2PN^W+T<N.*1$9
MMV-<9Q=1FTF!Z](HU63FG,^E*-ROF1H:%A8R4L,L8[ YGZH,8IP=NQ25>NP0
M:)*+DHN]K8SJF!CN.9PQH_[:17P>Z$?F*SM3X)?>?Q=:C(4PC&Y'$OHO8BQ,
M*K*U#$<=+R4.E.M3.JQ(I0H,5XXDLV0=6<\66M,)MU&*%?M*N]EF]F=LQ!TU
MB%FX^(%47Q:JZLU@^PBO3%T=C[0D/JW'(R?523D_Q-GNV1A<=$^B'EG[2-CV
MN#G#E\\A&390D!(FCU#V)-V>%=C+$B31:4/)"Q<I,Y]=VE N'**C1*2,Z(=
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M.!!]"H/6C<"HJJ'*@=RHSCNM::DS#K8!G;!J@G!L"[-$^#_0AC_ 4K @'5-
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M_)3=11^6]\Z@'CCS^4?(AQ\!Y#ZM.[UX?'1@WXM&&SR?V90\%6ACOVA:G_\
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MS'4=V;=\:7\V7[HKX*="_D%J^O7G_B8M^:#V%#W^P\^[]_\ ]-[Y_6/5A?\
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M/EP 72]B'8>>_-E'J#X#VX$.>V@OJVI+@H!=_)EYYCB]12+2>QCHE(?4LEL
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MD_>LP7_&K;_ZH:0A\I=Y/WK,%_QJV_\ JAI"*#9MY)0$PXMP4 % 1$1RM;@
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MA^7W<XIS.379$X](F&D(:0AI"&D(:0AI"&D(:0AI"&D(M$Q0 1$Q0 .>1$0
M X\^1$>W'QY\M,<*Y<^R$5 Q1X$# (#Y" @//X.//3#&F7/LA' ZX\ _/' "
M43<AU%X P<]91^Z)_A%_;%Y#2$?,.^Y9S:AO[IN.&"K5GBAG4X=!6LL()X-M
MM[FU)6-[)W@UD6A'T6I0ZH\@8N#F8AA(1SUC.R<;*2#PK:28I.9!8[.CEIL]
M>Q\\9P)2&V^P_L?)]\?3*.$X%4\3L'("0!+T@4HF/TD 3]*@F*D"0'ZB 4!
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,2$-(0TA#2$-(1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g418853g00a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a11.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1524&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              &5   "7     8 9P P
M #  80 Q #$    !                          $              EP
M  &5                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  &5     %)G:'1L;VYG   "7     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !E0    !29VAT;&]N
M9P   EP    #=7)L5$585     $       !N=6QL5$585     $       !-
M<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT
M27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG
M;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L
M:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O
M;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET
M;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T
M=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-
M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M)C7"TD235*,79$55-G1EXO*SA,,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQ_O4 \"NGI)7T6/]Z@'@5T])*^BQ_O4 \"NGI)7T6/\ >H!X%=/22OHL?[U
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MY85(S4?E!>ANMQ#2M>\>C+6CC3X=;LB@(*1VGK9N/QVO-M[?MV'G%1[+Q_\
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M;4:<9/J;]&V]=4TN+;L$Z:]*?'DI\1ZVXWDZ$;D,Y;@B(SSJ4<T)=N%FNJ.
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MM)W/+EGT>Z1)OT.V:*7^;#UGE?EZ9W=O?;M+';G1]QW:NQ*C>3WJ6(A#G?\
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M==*?[[NDS_C>E/\ IE:J$6LNWP1L;0HH!0"@% * 4 H!0"@% * 4 H!0"@%
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MJA%K+M\$;&T** 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0%"-]N8^, _P"=1I/5$=^#MW7+> =YJ."X9/GGE\2F*F(L**NOW!)Y=4!V
MG?MXO-^NIZ&BM*;3O>^^]<\].OF-ZK>^^K<MQ:<%>YS*9XN'RO:G?FD*Y[>;
MB)V[3V=Y[ZNZU[#<>>KNN*S?4OH+)^VE*VEENV]S,=^ EX[E8_WV6G-N_;B'
M+?O3LKS$FL94,/4SK4*=5VM>:5^[)VSS+OUHY4ZLJ:RNEFG;GGFNIY9&@6LW
MY/;!-:,\NV>WG/LTL]PNW@R%P;6;.Y"BMQD!MM$5$J [(0C<=8&E2%MI=)7P
MJ[*_'.DWV.[$Z1;3_$GBG@JGI74<*>$A64F]VZ<W7I975UZME?1O-_K70_[7
M]N]$-G2V;0PU+&TI0<+UL14I;L7*<O5C"G))^OZUV[V6AZ+;>A+H[;,=LUGB
MQKM#O%HML6W',K/.DX]DUP5%:+:9T^98WH#3TM1_K"KJ0V'-E<!  'U>%Z#;
M/P^#IX2G6G&5*W[Y4LY633O#TFZK]O;?A\ICNFFT,=CZV.KT83C6;_L\Y[T(
M+)I*7H]YVMFTDY7M9+(P'^CMJOB!2K3?I%9HAEG?J[1J#:X&:6HHY<#"W4+M
M=UX"0 7W);ZT@>U)WKFQ'1K:^%=]G;=KTDN'W:4TK9<,0N"UMQSRLCNPO2'8
M6(@H[3Z.4*\KN\J>-="Z=U=7P\G=7NDYN_%Z&)&SKI;8(HIR;2W#]5;<W_5F
M;IW?UXU=T):W2'7++D[KL5SK$#B*&+@TD.GJVT$!-:\/B^EV ;6+V3][I0>Z
ML4L55A+$*-UZ=T_NDO1NJDIN&_.,=[=4Y92:K@>A^.O]SVM5P563<_NE3"TZ
MD*";;5%8AXJ/I?0Y4W4<*<I[N\Z<6VE/6_ICX7"<$;47#=1]+9FR0X,MQ"\+
MMC)"BDE5_M$2?9NKV\KC5+0GA(/(;[>O1Z748^KC,)/"R5DFZN\F^-MZE3]G
MCF>7/HGB&][!XNCBXM.3]&FK<LE*=VU;CQLCVK'-;=,LP;2O%,WQ._+6-PS
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MN*]YEZW)>]_]H2KBW]KR[E!7^0&U12BW9.[6I;26JM[_ !2+ZR H!0$+<O\
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MQ!)OUER-08&FUK<;FIN5CD28JA)ZPI+2W0ZWU(XFT @J$Y^?/#GJ;?4** 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
MA+E[HVC].9^ZKJ/6/;X,$G5!&0O=6Y^J)^R70$NXYP;<M]]_/MV;? >^M=3A
MW^!4E9MOEPOK?K7(U#Z8%X_H_@-ER-V\X_;8UJS/'9[MMR"\0;$W?A"EI>%M
MA7:X6R\-1)*T![93$./*W5NU.A\(?K7XZ>?+&CR\_3N9W7HS7!ZZZ38K=I-W
MQ^]2;J]=YKTO& @V=I4JZW"6FWL24PX N+UM0Z(DJZ&%&>N,AI<IUM)64GKE
M'=Z_AX_7CI8Y:>:US=UG?E[M..7#5HV+[_@^P'^-:HRWKY6L=(K("@-<M*?[
M[NDS_C>E/^F5JH1:R[?!&QM"B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"$N7NC:/TY
MG[JNH]8]O@P2=4$9"]U;GZHG[)= 3*D)7MQ;\M]N??M]E:ZG#O\  >?/O/FS
MTMM/]5%YY"SZW9U;\8T_BQX$&/-F9'J/;CBES%KN;$ZZNQL-0\S'8NKKT.$B
M2EM#W6I)D++"U Z[=O;YRX?,&R7185?%Z/XRYD,V7<[H_-R)Y=VF^.B]=H2\
MCNZK9<4_TC:8OH9EVWP*4R+F%S$MR$]?Y1!';.]M'[\L[:KC\LSEHVOR>\^?
MZ?17Y:^MZBYQ$T^Q6[Y+*COSUP(DI^%:H@!FW::Q'5(:M\7B!0E4@-+2MY8#
M<=&[KBDH237-#CW>/R69U&OS?2?<DVF!?HV/P_%5HPK!<YU&6_<W6W\<MF<E
M0AQ+9P6]R)<;A 9;D3YQER[=%,./M&<<<<23G?S[L^//RLP;4KN+#4)RXN26
MFX;<;PQ<AU3;33<3JR^9#JW%(0V@,I)4I2@E(\HU0:YZ*W:V7G67I-2[3<8%
MUB#(-+V1,MLZ)<(RW&=-K8TXD/PW7$<25(/$E24*&_($=@B^?T1L_0HH!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * A+E[HVC].9^ZKJ/6/;X,$G5!&0O=6Y^J)^R70$W
M0&I/2.P[7K*5);TYS)VS8:+;P7>Q8FS M&?S[B74\3L+*;NBX0X\%<4%I3,.
M)!N*5<V9>Y"Q.[SYT[].(]4T5M%JL.#6FTV:!EL&'"DW1OJLW?FRLC5)5<)3
MDU^?,GN.R9'7OER2PHNK:+,IL-D<)2FD22T2)34S3*RZEVX0;K(OD&0Q N\.
MW7"R9!?;*N(N\1#$DKD-66Z6T7!GJT(*XLPN,/ =4>#B*J%/"[?T58MGL<'%
M[?E,Y5DFXCA&'9VBXL2KK,RFW8--,NVO19\V[NR;9)>2Z_!=3)<N<5%M68K<
M5"0':$S\_P!#:N1;(TB ];7XC,J$]%,-V));;>CR(:HZXRHK[3B5MN-K;5PN
M-K0IM220H$;[BFMNA.,X[B>K_29M>,6*S8[;!D6F#R;=8[=%MD1+CNFUL4MS
MP>&RPQQ.;@\24DGF5'<T(N.F3>GO]^>9M30HH!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M=TF?\;TI_P!,K50BUEV^"-C:%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M.MMN0TAQ*W8[CJ ZVW(;22MAQ;9#B4.I0HH\H#AYT!EI4E8XDD$;D;CO!V-
M8BI#;:BDE?(@<DK',G8<^'S]@^$[=M3T4G9N<5R;:2]Z=EIVY=AJ](D[*+?8
MGX1?)YZ9%B+C!6ZXRB0PJ0VA#KK =27FVW5%+3BVP2M"'5)4$$I 64GAWVY:
M56I3G*G&O3E."3DE))I.ZSS5EEWLW^BJQ@JCHU(PDVE+<>ZW'-I.RNTGFM5R
M6KO5(:)5_6 E.Y4$H6O;A',>2D\_,.9*B"!N0:W*,VO5FGHM8\>>;?G/4U.4
M(^W%K)O.+6F?Y7?N[-<@_<8,5IQ^3+8C,,[!Y^0XEAAK= <'6.NE+;8*"#NI
M0',#?<@5<UD]5KV\3/4M5=;:EUAA4Z*EZ4A3D5HO(#DEM !6Y'23N\TD*3Q.
M-!2!Q)!5NH;@5D7.WQ&R[+EL16@IM!<DK#".L>4VVTWQN\*>L=<=;:;;WXUN
MJ#2$E9X: Y_"6.0ZP<SRY*\KVG-/+FG=:4\0\GC/!OQ B@*B0R>Q?FW]JL<M
MDD]J?-Q)XOS20%;$[4!$W!253[1PG?9^23\ 3$=W^3<>O?E3Q!G<"N[]8^V@
M,*%[JW/U1/V2Z FZ 4 H!0"@% :Y:4_WW=)G_&]*?],K50BUEV^"-C:%% *
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M>((5OC!:FVNL=>6X\^\Z_(DR'W5*7)E27G%//R7#USBE\*^2$T!V2@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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( "- 9- ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g418853g00a13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a13.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1:D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              'U   "7     8 9P P
M #  80 Q #,    !                          $              EP
M  'U                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  'U     %)G:'1L;VYG   "7     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M_D$?HBCW1#JG
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@!FP'P P$1  (1 0,1 ?_$ !X  0  !P$! 0
M       ! @,%!@<(! D*_\0 8Q   0,# @(%! L*"0@'! L  0(#!  %$08'
M$B$($S%!410B5*$5,C5A<9&3E='3X@D76'-U@9>QL]86&",X0I*RP=(D4F)V
MHK?A\"4G,U-R@K0F2&.4-#=#1$579<+#U?'_Q  < 0$  @,! 0$
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M]LL>OU\J$E5/2?D!*>/HX])X+P.()VYLJTA6/."5IUEA8!R L<E#F.1H"/\
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M(.4Y/BK^T:$DU * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"P.^[R?R9(_;1
M* DB9]FKCX=1;?ZW\MZ_;>_V^_4?S/L7W_0&15(% * AQ)SCB&>7+(SS[.7O
M]WC0$.-&,\2<<N?$,<SPCGG'-7(>)Y=M 1!!["#\!S0'*F]O\X#H>_Z];K?[
MEM8T(XKL?UB=4M^T'PJ_M&A)/0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M5TUXVY\'GP#:32=\W;)-_-)HGH2* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MDM4UR?++JZ^'C4=-NG5A[S;BFUG=M6YVMX(NM6,@H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0%@=]WD_DR1^VB4 BDB\W'\5;A^8^6 _K-57Q2_+] 7^K 4 H
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M=9KK>U=MU_#;7KO\M"M4DB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M.7/M^$$@]QKH53]FMU2WD_>3NW=/3-W9Y?M%4O+=W;/=:M;-9-VLO7+1>JI
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M+EQL]U_,]E6NN:\42*D"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MT^APF!&'-,J_!:Y9JZ3OPN\^]^9J;\K)9WUR3T2R=UIU:<ER.I>CUN+>=Q=
MS[G?7$R+YIK6>L]#W*7&"FX]UEZ2U%-LR[LTR<(C)N3+3,PQ$_R,0N!IH)0D
M '\\[Z:]WKK?#-2;=[KAK9Z<,WZR1H;<3=_0.K.EAT6] V"_^7ZKTOKG>!=[
MM:K?=V%P&HFR^L83JTSIEM8@RUK>F1R$193Y4$*6,A"B(,QWPUD-H!&"$A)
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M(Y'B/C% 1H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MNDY)YGX"<_W#PJ5%W7O-^/F%*]LFK^K]_ GJY84 H!0"@% * 4 H!0"@% *
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MYSDYYCB!)PK! ]MV]@'/ERP:DDJ4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MR&;8WJJ-8;TXI+:[%JEB3IB[-NK6&T(,2\HC./*XR$\#)62HX3DD"O<PG3+
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M0GC;M^5O,ZG9&&FT]Z4)0??*!PDCWB1R]Z@*E * 4 H!0"@% * 4 H!0"@%
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MDMI*L!7G<0!R H*(4 2!V'/TGM(DJ4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MW^<!T/?]>MUO]RVL:$<5V/ZQ.J6_:#X5?VC0DGH!0"@% * 4 H!0"@% * 4
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M+45I2E#@2I2B !FEUSZ^[F#"]%[HZ6U];+Y=M.^S#L33UZO&GKB)UDN-L?\
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MOTBQJW3\ZQS9]TA,2@PXN399\JTW$+BR$26RU+@O,NM*=4@HDJ;4DN)6<%)
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M;;'?F$(O#DU<AN78K>@\04TVRMZT'CY?;+U<^C\-AR-.@1GE]:\Q8E,NN_\
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M'/- 1#: .$ @<@!Q*Y '( \[D!W <@.0&.5 .K1GBP2?.P2I1QQ  A.2>$8
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MV/ZQ.J6_:#X5?VC0DGH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M??LZ0OX'&M_TP;(_OA0#[]G2%_ XUO\ I@V1_?"@'W[.D+^!QK?],&R/[X4
M^_9TA?P.-;_I@V1_?"@'W[.D+^!QK?\ 3!LC^^% /OV=(7\#C6_Z8-D?WPH!
M]^SI"_@<:W_3!LC^^% /OV=(7\#C6_Z8-D?WPH!]^SI"_@<:W_3!LC^^% /O
MV=(7\#C6_P"F#9']\* B-[.D'_2Z'>MD#D I6[VRBD\14  0WJY:P#GM"%8[
M\#*@!A,7I5[Q3->7C;=CH@:^_A38]*V/6,Z(YNILVE@6345QO=IM;[,U&JG(
M4A;T_3]R9<:8D..QPTA4EMDNMI4%_/Q,T&]O2$(!'0XUN00#G[[^R8[0#V+U
M<E7(G'9SQD<J C]^SI"_@<:W_3!LC^^% /OV=(7\#C6_Z8-D?WPH!]^SI"_@
M<:W_ $P;(_OA0#[]G2%_ XUO^F#9']\* ??LZ0OX'&M_TP;(_OA0#[]G2%_
MXUO^F#9']\* ??LZ0OX'&M_TP;(_OA0#[]G2%_ XUO\ I@V1_?"@'W[.D+^!
MQK?],&R/[X4 ^_9TA?P.-;_I@V1_?"@('>[I H!4YT.M;H0 25???V0/8"0
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ML3D=P.2<\\I YJ&.>4@C )SR. "GVD J6L(2,DJ5E(2$YR5$@!*1@^<K )&
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M% * 4 H!0"@+ [[O)_)DC]M$H"$7W8N/XNV_KEU5?%+\OT!D%6 H!0"@% *
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M"@% * 4 H!0%@=]WD_DR1^VB4!"+[L7'\7;?URZJOBE^7Z R"K 4 H!0"@%
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M^K5$67D-6]QM:PAQ"0IQQE0PIU"$JQU1!X5'M]XU/KUP]=A)?\ J([@5# )
MP",9 P#C)[<]M 1X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT
MX$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/
MTT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^
M'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT
MX$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/
MTT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^
M'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT
MX$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/
MTT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^'K/TT X$^
>'K/TT X$^'K/TT!(L # SA0(())!'A@DX_-B@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g418853g00a14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a14.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1C.4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M         %)S;'15;G1&(U!X;$!@0           "G9E8W1O<D1A=&%B;V]L
M 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M                5&]P(%5N=$8C4FQT                4V-L(%5N=$8C
M4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!2
M96-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -
M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              '%   "7     8 9P P
M #  80 Q #0    !                          $              EP
M  '%                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  '%     %)G:'1L;VYG   "7     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M/?O)LDF=+'@?<')*3II54P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %/ ;X# 1$  A$! Q$!_\0
M'@ !  $$ P$!              @#!08' 0($"0K_Q !?$  ! P," P,'! T(
M!@4)"0 ! @,$  4&!Q$($B$3%#$5(D%15933%S-A<0D6,C57='6!D9>RL]4C
M-T*AL;;!T1@D)2=V\"92=X?A&4-&1U9B@I+Q-E-G<H63E:;%_\0 ' $!  $%
M 0$               $" P0%!@<(_\0 1!$  0," P0(! 4# P,#! ,  0 "
M$0,A! 4Q!A)!41-A<8&1H='P!R*QP10R@K+A(T+Q%3-2"&)R%B22%U-48W.B
MTO_:  P# 0 "$0,1 #\ _>H79\JZ2H;4I$9J,Q$>1M%0Z3WD/[GF4\%=5,.#
M;8;;=1L4[Q?J\/YX7Y:]2CO(\/N./V\?9W&Y>U4^X(^/2_,>!]4@\SY>B=QN
M7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,
M>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W
M&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+
M\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7H
MG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/C
MTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY
M>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(
M^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S
M/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[
M@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(
M/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5
M/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]
M4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>
MU4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX
M'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;
ME[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS
M'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=
MQN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ)W&Y>U4^X(^/2
M_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX]+\QX'U2#S/EZ
M)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^7HG<;E[53[@CX
M]+\QX'U2#S/EZ)W&Y>U4^X(^/2_,>!]4@\SY>B=QN7M5/N"/CTOS'@?5(/,^
M7HG<;E[53[@CX]+\QX'U2#S/EZ*A;%R'4RVY;B7'HLU^.%MMEE*FQR.)/*AU
M0\%I\>O]8$^_ D'S!0?3T'NRZP_O]<OQ"T?M76BE9#1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*Q6[Y^Z_E-_P#<Q:#0?J_>
MY0-7=OV"IP_O]<OQ"T?M76BE9#1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B*Q6[Y^Z_E-_P#<Q:#0?J_>Y0-7=OV"IP_O]<OQ
M"T?M76BE9#1$HBZK6E W4=AN!UZ#J=NI/0>O<D#Z:(O*Y/CM-EQQ:4@<P/G)
M.RDG8H\U1W61L4H&ZB".F]$1$YA90 K;M$\S>^P[0;!0Y-]BH%)!W'0'S20O
MS:(O0AQ*SL ?#?KM]'J)]=$52B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$5BMWS]U_*;_[F+0:#]7[W*!J[M^P5.']_KE^(6C]JZT4K(:(E$7G
MDJ"6MRHI)4E((\02=B4C8[J">8@<JM]ON3X41?,C(K?>7L3UXMUMM^>,,?Z2
M-LNMM?FX]G%PM;5E+=DF2I<NU+:3=\DPMR:Q=&ID+&>]I:2XPMMM"6EDCUR/
MN.KJZ_\ *CP_GC]E9<%L.HL=W3YB5CFH4&\HC:3C!7+FS?),>RVNV7ZZ#4DW
MVY.-LH@-SX:T/MV^_J8F&URK4AI@S&G& 2??A]SQO*G/KMDVI^%:>7K*]+8V
M RKSCL"[7RY1M0WK_&MDBS6:T3KE*CP#CZ')9N;[D9E$93P$8(+RG1T204^_
M?L+8^#9!(RO#<5R:5':B2,AQRQ7Q^(RM3C45Z[VJ)<78S3BP"XW'<DJ90X22
MM* I6RB4@@T'WU[UE=$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB416
M*W?/W7\IO_N8M!H/U?O<H&KNW[!4X?W^N7XA:/VKK12LAHB41/'QHBXY4]/-
M'0[CH.A]8]1^GQHBX"4CP2D==^@ Z]>OAX]3U\>IHBU?K>$IT9U:V"4[Z99]
MOT W_P"B5X(_SHB]ND00-+=.>0)&^!883R@#<_:Q:1N=O3L-NOJVHBV+1$HB
M41*(E$2B)1$HB41*(E$5)^0Q%9=DRGFH\=A"G7GWW$-,M-H!4MQQUPI0A"4@
ME2E*"4@$D@4%]+WCOF/JFNB\%OOEENJW&[7=K;<7&4)<=1!G1I:FT+)"5K##
MKA2E1! 4K8$] =ZJ+7 26N .A((![RI+7#4$=H(^JNE4J$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(K%;
MOG[K^4W_ -S%H-!^K][E U=V_8*G#^_UR_$+1^U=:*5D-$2B)1$HB41:MUQ'
M-HQJT-]O]V6?G_\ J-YHB]ND2>72W3CKXX%A?]V+51%L6B)1$HB41*(E$2B)
M1$HB41*(L-U#@.W3!LMMS+C33LS'[M';<?)#*%.0G@%.E/4('](CJ!4TS#FD
M_P#(_N*J:8<.WM44^$Q03=<Q27V7/]1M90AOG.R"Z\7%)6H;+2VM'(=O$D$=
M =MAC/\ :I_^7 ]1CO\ H05?K1N-[;=D6Y=_\7FZD\P!VVWZ@>/3T5KEC+FB
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HBL5N^?NOY3?_<Q:#0?J_>Y0-7=OV"IP_O\ 7+\0M'[5UHI60T1*
M(J3RBA 4"!YR020" %*"=R"I/0$CP4#1%&:?Q.8[9<>U'O\ ?K)>+8K3_.UZ
M?M6A*6+E<\EO;T>%*M+=I8MRGA_M1B<AQ(=7SQF6G'7D<J5$$5HM'%59KO(L
MIBV1$JURV\6&0WFV7RW7:WXS)S:XRK=C,53D-(\KO2WHZ431!6GR8MX"0D\B
M@"+9>O\ ?+=:=%=5';G/M\!M[3K/(S:[A.C6]IUY>(WCLV6U2EH[5;I4$MMM
MDNJ/5*2 K8A]_P +(](%%>E>G!)&_P!H>&[@ IY3]K5K\W8DG9/@"3YP .YW
M-$6QZ(E$2B)1$HB41*(E$2B)1$HBUOJG=C:=/\PF]H.9NQW)EM(Z*+TELQ6!
MN-R//> ) ]._B*88%]2'$6>8CD"3;CJ./T5;1<6.D@S;0=7/_"C=@L$8!E>E
M,U32H\7-L1:MT]:00SY5=*Y+:5$*(+BC(:(Z#9.^QV)K8/(K,J-UZ,ES>T0.
M/:9Y'M"K>Z6AIT:=.LB9^GGWS53YJ#UW(.QW]!&R2/J&W3]-:T$[Q'")'DK*
MJ54B41<'P/U&B*D%GTJ)_P#@V_M-#U#N)] J8(U<.\>A"Y"U;^&_T#T_VFJ"
M7CA/O2P'T4R.8\0N.T5S <J@"0/#Z=M]SZ*G>,@$1.DG^/K"F#K(CEQ'5<C[
MWGL5:JD2B)1$HB41*(E$2B+@D#QJ"0!)1<<Z?7_4?\JIWQR/EZHG.GU_U'_*
MF^.1\O5%R% ^!_MJ0X$P)1<U4B41=5$C;;?KOX#?]/JHJ28BQ,^_?>NA41XD
M_P#RC_.H+@)N+<.* N/]L=IC[*AVSO\ ]VY_^TK_ "JO=_[F^*M]+_V.]]R[
MI=60KF"D;;;<R"D'??\ ZVWT>'AO4$1Q![#*J#W/F!NQ$SQF=+=5^Y5DG=()
M4"2?$;>OP\?^=ZA5"1^8CN]]8X+O15)1$HB41*(E$2B)1%8K=\_=?RF_^YBT
M&@_5^]R@:N[?L%3A_?ZY?B%H_:NM%*R&H) U***>O&L9PVZM8C U+TQTPN\N
MVINBK]GR)-^E,0W7W8L9=KP^).L9N#2GV'Q+DS+Y;XK?*A(=<42D1O"0)Y<#
MQB/?T3Z>^ _SY3D^AV:Y%F]D<DW#*\)U$ML5:VX>=X)&FV2VW62PI/;0I6-S
M9EX;@S6?,=[2)?KC"6TM*$J:4"DU0=>'-4A[7:&=.?&(X=?N"L==X;EK5F4K
M[>KVFZ9'J?;-6+'<V+9:6W<3R*V0(MM1%CQBVY'NUM7#BAAQFX#E=;=4DMI4
MD.DJH]^_?@K7CO"3B^.RK08&07UJT,2+'<LGLBTPG(F7WO'KY,R&U76:LMAV
MTKBWB<_+,>T*:9>:*(KH+20D!9%G_$EA^,YAH?J?"RO&;#DL2#@&:W2%$O\
M;(5RC0KC%Q.]"/,C-RX\I#4J.E2PU(0V'4)=6E#B0M0)%F^D*0G2O3=( 2!@
M.&;!/1"1]K-KV2AL>8TA(V2EMM*$ #<)!)HBV+1$HB41*(E$2B)1$HB41*(E
M$4>N(B6I&!.6EL;/7Z^6>W('7SM[BU(6-QT(W9:!&XWYMO &KV': YSK6!))
MYFXU[#].,JMKA-SH  /?9[A>+6:R2(. X]>(#1[U@,^Q7%GD&ZDLP.[1G4J.
M^P2%J2M9!4"&_2*FC4'2U02(>PQ/_D#'ASM:+(2"#',GC?6(Y6MIRY+?5DN#
M-VLMOND=:7&+A#BS6E(WY2F4RT]TW /BL^@>K8> QG#=>9D ?+?G/5]?X5"O
M%5(E$5"4\F/&D2%[E###SRP!S'E:;4M6R=QS'9)V&XW/3<59Q-9N&P]?$/\
MRT*-6LZQ/RTF.>;"YLTV%SP5=.FZJ]E)OYJCVTVW ^9Y#1<V%R+FP4+7^-G1
MUIQQHOW]2D+=0I2K*YLXM#CC:@DB2"I*N0E*"D* VY^50Y:\6S'XX;/X &:K
MF[LW_"8MUP"2!#".RXT)!7?83X9;18J-W#,.];YL5A6@6$7-7UT BZL\+CDT
MI>D242;?D<-J.LIC25VQ+HDIVWYFV693BV$@] EXMJ/H /6M#A?^HK9RNYS3
M7J-:';N\<%C+DAIN.BUOJ2=+%;.M\(,_HAD4Z#JC@7;@Q%$0V3^5YJQI.K1Q
M/-9]8^)S$\XQ_.)N .R9-ZQ+%[AD26+U;GX\-Q42+*>C)?2Q+#ZVG'8X0ZE*
MVE\A^<0=BGTC9WXC9;M)4HT\$35Z5])H<ZA6IP*KF-F:@!$!V\#%H(.BX_.=
MD<RR.'8ZFVE=Q %:E4_VP7$?TW&20($"#UZK5VG_ !8YU)R"S0M2-/IUIQ[(
MK2Y+Q^\VK$\BLT^[2'KGAEI@256#++DQ<X=G<N63/V9,MYM:ILJ.S,A.&W.J
M>KT5<VMH_P"E1A+[-M>B6;-0JZMS!&+]H@.,Q)MO;6)\*:@WUA#ER@..L,W*
MWL2!*C%U4ET-Q&'WVDZ=:+F7Q78!;L.N&<R8>73L:LMOM;TW(+;C?9VB?*EQ
M6[A+CPY#US[-B5:X+R)D^%<9<=<:,H.17YZ@=WOWR43SB>WWQ5JO^O>4,Z;9
M)F=EB6D.V?5B!@L,N67)<B5+LEQO%OMT*Z-V*S2X=YG753-WAR9$"$Y(0MMF
M1LAY)02]^^7?"2.?LZ:=H7K'%#CN)HM]NU'C7JVW:3B4W-EW.+B-RL%H=QV$
M[)"Y1M>3W).06^X6V.F$W=[-)CO3+=<9\=ESG#R 2F??OP7./\76G63268EK
MLVH3K\AVS,QTKQ8LOR)V0.7E,.'$85<E/S7&V<>O,Q]R'&?@*CVY;S,A94PA
MTB\LGC"TUL\20]?DY-%4U"F2T*^UX0Q*D-9 [CL6QPF)%U#\V\O7&,N.V6%B
M('2"](CDAHQ[]/)/>BE%B>36S+L;LN2V@R/)U\@L3X8EQ'X,M+4A <2W)B2$
M(>COH!Y76W$@I6"-R-B91=,OR6V8A8)V0WA3J+;;@VN4IAHO/!#KB6$]DV".
M916XD>(V25&JV4C6<*;0"3) )C0$ZJIK2XPT2??^%HN3Q.:;-,2'(Z[Y-=:
M#<1JVI:6X=^0<CKLA#0V ZE1 "M]B=@!?&75B8+6@<]^>?7K95=%4X-\QROQ
MY:KRP^*+3U]A:IK.0VI2'E(*'X3,@K0EKM"I*VI3C205>: 5#;Q'F]:DY=5&
MC0?U1%^T_P =EU/0U-0TD=HYQS]51S'B$AL8=#RO T*GH1GV#XC=6[AC=]O3
MXB97?85GD2+5:,<>-UN$V(U+,N/&B,RW'G&0RF,I2TJ%FKAW4-W? !=,0Z;
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MRG$QV0Q$>W=VW"U(2G92TK1K\PV4S+*Z8JU:)<QP>7.%:@=P4]TDD"I)D.X
MFVEUOMG_ (R;*;48^G@,LQ=0XDO8QK'X+&T@]U9Q#1OU:+6@#<,G>!Y F(D%
MC?$S<A?IMDS!FTP)^/&[1KE9K):[B]>\AEOYC]KF#/XL9U[$>0QD;,V*E^/,
M"T0+U#NT5^=':;;VYP"'.;J6@[P'"TSU\^K5>MUVU&TL/7>-UM4C=_+!.\&_
MVF6W@$N FTCBKQ(XS]-&67YJ;#J%+M49YB,]<XV-15Q&I;EHG7Z1#(>O;<Q3
MT.#;+B)O^J=BSW!X)<4E;"G:4GUZ_#5=KKQ>80(O=+)&O:,EN,++O(42^V=<
M:*;OBELFW1R'=2Q.5(C=_BL(?B+C..E;3S3+[;#J5))%?OEARZ]7_3[%<9M^
M-P;_ )/I8K5.\R<C3<$V5B EVW0&+/;N[/QYK<R7/G*0J0^9:+:Q#;YV)2E!
M+A%0NG%A@%@FM6:Z0<F?O*YAM 9L-G%UM5PNS$T6J]L6>X/3(0D1+->@BURW
M934,AU]EQ#3K2E/MO?N46*2.+:R3,JAQK%!NDK"Y5EA/.9*<>EEY-^GY'C=D
M;MK,==[@-N-1/MCC,7!Y8CKMTI;:BN;&+Q;@SPC6\\O5.:N5IXN\/DV=V[WB
MQ9595]PC7-G'3:8DZZ)M:6+Q(F75M^'=784NTPX%EG3IDAON<N,AM<=N$^^$
M!R?Y]WA1[]W5U1Q;Z;\\A*[?FI4U=56MA;UB8CL2^RO<NQ/RV9DBZ]S1!BS(
MBEE^:[&?6S*C]T9DK4XAN 9[U/O_ #["EC'<#K25C^EU\22=^NYW0V=^O4%"
M2/2*E%:+=\_=?RF_^YBT&@_5^]R@:N[?L%3A_?ZY?B%H_:NM%*R&K=3AW_9%
M%;BNO$O&].?*MJFJM-SFY+CUE5=8TW#;/.CPY\I]IQMF_P"<,OX_94K4L+[]
M/8F)0I/9IC;KYQ0.$Z*#H>H'V9\.2]O"Q<+A<=/5R+I=I5YE&_7)LSIN383E
MDA[LD-)Y3>=/X<#&)!2$DE$.,EQOJ'EJ(&V1P&NIOX:??NX66-2[OS#MX>_%
M2<J%E)1%J[6_^9G5K_LRS_\ NE>*(O=I)_-;IQ_P%AG]V+51%L.B)1$HB41*
M(E$2B)1$HB41*(HWZR)\J9KI-C23NB7E*+E);'G$LPUH<6M2>GFI"5'<]!Z=
M_3D4;,J.' =7 3]_KUHMTY5:&[SCUXLRP%)N=OFQ DC<%;S#_9$C<=4K[,@C
M;SD)K%88JSRB>SY93EUK66@-Y>G:=Q;9*3RSL:G3<>>;)/.#!6%,I<W2.509
M6E'7??D!\#L+N* #@1HX-/5,$&.H:)[NMZ50B41='$!QMQM0!2M"T$$ @A22
MD@@]""#U!Z'PJBHQM1CZ;P',>QS'M.A:X%K@9M!!(*EI+7!P,%I!!&H(,@]Q
M6KG-'--E[J^TO&>92E+)\C6_J5DE1/,R3S$D\RMQN3OOMX\E7V%V5Q5JV689
MP.O].D>TP6'O[2MPW:3/J7^UF.);_P"-5X=8SP([AK?LBVP]"=*83LAZ/@F-
MM/2W"Y)7Y,C.]HH@#=*5MJ0V-P.B$@=/#K6&SX:[%4FN#,HPLN=O$]%0'+_]
M4\.8U-QHKQVLVCJ%N_FF+^41/2O$BY']PTGAQ\K^WI=@C%MNMHBXQ9X<2^P7
M;7=VX<-,!<^!)0MN1&>D0%19*6W6W'$D-.H4GG)0M)"2.@RS9_)<HM@L%1I&
MQ:64V#=+9W2-UHT=UB(LM=C<SS#'D'%8NM6 )_.]Q,$_,)F\BQG7C*L=VT&T
MPO*+#W_&8LE[%;7%M.-.O2;F1:8<"X1+M":0VW/:1*;C72W6V>E,SMU+D06"
MXM0!!WG8L%6]CA_P"396+5DUFMV1.MWJZY(]+6Q*MR';]>7G7IMQ;APIZ66G
M.9Y?8)/:=W4$/-*0^D.441K?Z2/?"?-<*X;=&%6>1CYP6U*LLH0B_:G'KF[
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M&T*M1@BP:X@_+W:F^O$R%SN*V4V<QE9]?'93@L75>[>=4K4*;W.F!\Q<QTV
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M\IGW?7K12$=!5LE/4[[[;[=/S]*QQ!@^!1:!S64K&=8,#OCF[43(+5(Q.6X
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MS7.RP+S&,*ZP(=QB*<2Z8\UEJ2SSI4%I):>;6@E*AN#MND]4D'K5--U5AG>
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MR/'0M3:3<)EF"BIMY6V^;GF#V.V;S'/<T!-(4JQ8]H8XA@95J.(#W4VR UH
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MT:W)=3,$=K>K36%M7.\MM.#XI?LKO<AN):K':9MVN$E\;,1H4*.MZ4M:E;)
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ME76:9,UY:!NJ0^7BZ2.:OG/9)V*V\VSS?:_-*1.&HXW%MRK#/)Q%-F%.+?\
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MBU*+2G(?.D\I0E36Q22K972N(%/;;;GI#7K/R/!U9._A-U]1M.2T.#*M RX
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M _("^H^09WN#K$6T6^,8X@-+,T8MZ8F2VZ-.N"DH1;+FXS"N#$@IZL.QW^T
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MMIQ#B [YKN)B8WK@S<@$ ">8[5[RE)Z[=>@W Z[#T=!OM]%26@Z2.X_0J5R
M  !O^?Q_PJ6C=$3-Y1<U4B414"E6ZO$I)\-C_;_S]'KJU%0.)#I!)(!&@[9'
M<=1Y(0" "+CC;G.A![%XID?M6>3D225C;F0I6Y*5@#[H;>/570 #KXU15HX?
M%L-'%414I'@;P;@.%K&"1WE :P_VJFZX7N0 8FVK1,P1%Y'&;05U:X04YUJ
MSEM@O+>-1'FF572.U;EN/,S&"ZIN5;DLJ99*W5*;#H4-TJ"G0I2E;5\Y[7?
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MNBCKID$1;1F.L^4AUER^=\N(+K#KLB'C<$+<C]FVE*WU!QM#*D,L)4M?8-A
M4H[',KM<^KA\+1 <##238S\Y)F1>.$>JL8G&TL/@L5B,1\E+!M>Y[FM))8UH
M=,"23\QL-8$"5\:\@XU-</LA><7SANX8X@TZPIR\W9&;ZJ252HN0Q=.V9#-M
M6]#B(>*H=TGAUUI$5Q428^W*8W3#3&E)<[JED^ R7#T,QQ;G5G-;2J/HU=S<
M)AKG0&!KY$0R7PUL[Q=O6^;/_7V<?$/-,7L_L[2ITLK;6Q-#%9BP5J==K&O=
M28W>>_<;+6U2\=&XU"6@!MPZ86):#X7HY;[!POZ'1'$S;TS'NFK^?OA#^1SH
MJ=O*#]VNS:4+>E30 IN(M;S4=*NS9"%!2J^4?BGM=G.W>U>&V=RBN/\ 1*;V
MC'#"EPZ)K&O.X'/D#=+F;QW2"XS$KZ[^%&P.2;![.5L^KTW''Q_1K8C<-7$X
MBH6R\D $!Y!;28-UK=T[Q,V^H^(8A9L3QZS6*Q-]UMUKB,,QVV@A(=0A"//<
MV0"I3B@7%J.RU*42HDUZCD.28#9[ 4\OR^G%%C&L#Z@::C@UH:"XM:QN] DD
M-$GAP6KS3,,3G&-JX_%57OJUJCJIO8AQW@((L.H1J>:RM#00L*"E'9*D@';;
M92@KU;[C8 ?1O6V8W<!$DRXNOPG@.J]OJ=3A'YG!VA (@:7B]Y,_*.,:V56J
MD2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+C;KON?JWZ?V51N"9D
MZS[LBZK1S\OG*3L=_-VZ]"-CN#Z_K_-O54#B-Z-)X=8B/>J@SP)'9%^HR#;P
M/6NA8!5OS*V]0"?[>7?_ .IJD-<V8J/B]OE@=P:#Y]JGY3JUI.DWGZ]?HM/Z
MJ:1XSJC:>Z79I46ZPU]XM%]A\K5SMTM (96U) +A0E125-!2>?E"=P>HXG;+
M8W+]JL"YE=KZ6)IOWZ>)PY8RLV&O80'/94!'S:%LR ;Q!Z+(-H<;D>*%2@YK
MZ+@6U,-5WG4:C20Z[0YI!D3((U,FZ^8NN^B=BUEM\71[B*4_B><6/G?T>U\L
M38@7!N:PH/P4OW?SW&U=NT4R8:G(X<YWFE/I=6VZ>9V"^)>9; YA3V;VM:'9
M'6>RG@\;5;5?B2^'-JBI48[H0 UE,L?T+9<XM=($,UOQ*^&>1?$++F9UD?2X
M3.\/OU'4<%T;&TB US6O:^F^H^C+G;],.<[^^FYMYA+ICQ7/:)ZWO\,G&T^9
M-XLMP>LT76RT3I8,QE<6W)Q>ZWEEQ3B1#EQ.S<E7OL%%M3C1F-I[&3+7]78G
M+L/G66TLYV;KT<3EU2@VN0]S#5:7M#]US6AD:/T:;B)/'Y4V7^)V8;!;55ME
MMN:#*9IX@T*.+#<54%:DU[&T7/<:CF_E>USWD-^4@[K PS]ML;S',,+ML&[V
M&Z-ZMZ<2>5V/<K=+;GW:! < 4T\EV,XZF8PVW]VYS+94KE(=0#7GM3#L; W:
MH>=9<PLWKS!W1 @2!/._%?3&!Q."SEK:N5XJB^F]N\#4JL<'6D[CV0UP$VN3
M )*D/B6HN-9K&[Q8;C'D.I0E4B X2S/B*.X4U)CN%*DK2I)2%(#C2BE7(L['
M;%?3<S7F?*->6JN.@/?3N74S#S'RW) +3>02T\5G+:BI(4=AOZ!T._JZGQ^C
M_#QMF>$:WGEZJF]Y$?Y\=(UCN52I4I1$HB41*(E$2B)1%8K=\_=?RF_^YBT&
M@_5^]R@:N[?L%3A_?ZY?B-I/YRJZ[GZSZ312LAHBB?Q>C'5Z42SDT!BX6J/?
M[&]+3,E6R):(;2I+C3DZ^O7F+.MJ8+;"G^R[S#6WY0$+LW$2.R(Q7M<=V&FQ
M!T/.> /+3EQ%I@Z'L/O3W]?)P;M8JSIG/:PQX3+ UFF5L0[G%AVJ!9;JW&G"
M.S<<=9LD2):WK+)CM-&),C(6)*VWGU.*4\HJR^!MQ%^[3S\EC4N%]"/ D>[>
MJEV0"-B 1ZCU%0LI<<J?^JG] HBU;KEO\C&K6V_\V>?>'_"-Y]5$7MTAW^2W
M3G??_P"P6%^._P#[,6KUT1;&HB41*(J;IV0>I&Y )!((&_4@C;;ZZI>8;/6/
M,@??A=%''6"Y2<FN^-Z4VQYPOY(ZF=?2V2H1;)%W>*'E-GG4EY;*NTY@$E"=
MU=#O6529NTW5G1;\LVFQDB]P3 ^A07F+QK%X[8T[U$_[(OQ%R^'G0IC ]-HY
MG:J:KR+;IKI=:82BY+9DW!UAB;=Q$9"Y!39[:F2^'$M)Y+D]"2XI*74;[?(,
M.RMCJ56NX!C7/=+R UP:QQG><8+=09L(B\PO,/BIM6S)LEIY7A6.K8_.WLP=
M%N'!?59TE2*KRQK7/&Y2%B;!SF&03)LF@&C>&\ /#5:[=%A1KQJ]FD*W/9+=
MNS2N]9-G=PBI<E;K6%2E0(,Z4ZZU';46R0X4-I=DK*O._C)\1CEK!@<+4Z2O
MBGNP6#P].J.F+*D4/Q0HM#GD4]]KBX !H+02-Z5U7P2^&& R'!T,/T 96Q@9
MF&9XI]'=(>6]*^ET@;\HWGN:W??.]ON!W@ )=Z :82L.M$G)<F:=N&<9LZN\
M7ZX.M*6N(N3_ "[=N#S@4Z&8P)2EM12.=9V3T._(_#;9(Y/AZ^98T&KBLQ+J
MY=6I_.T5',<&CI-YW]HO$:A>J[6YX<35I93A#N8##'<;T9+:;G-!WGNW8;^:
M0V8)!)_N ,FXJ0B.PA*5(2EI"0E8(4D!( "@0""/2-AU]%>IKC]T,^0&0WY0
M09! M(/$'AY*O1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B*B4^<3R;C?U>/]7@:H:3$$&>PF?)#H>"UQJ5IYC.H%B?LV0VYM]I>ZHL
MEN,E<Z%)04K:D07DI#K#B%MI)4TH$CS=]CUYC:/9;*MH\#7P6,PM+I*M)XPV
M)-!CGX:J!OM>U[FS3.\ "6N:7?EDS?<Y/GF,R3$C%X<N?NQOTI<6U6D[K@Y@
M)+K$D6M F5\9-2]/M/K=JTQC.MVF^/ZML8_:)^'L7W(K(DY([AEY<2^PVU=U
M*7,=>M"'GGH3ZU$Q$..M17&BM15\Y95\3-NO@]FF*V<Q#\RS7(F5W4J56F[&
M&BR@RJ[=#3.(I!H95@?,T -W= -WN,X^"^P'Q/RIFV68-R>EG@HU'C+JU'!.
MQ8<07.#6.=3Q +GTVEG](R7R&FTX';M$L_T NC^7<!7$3'O6/-%^;=.&35*_
MNI@W)MS^6,#$GYLE"X\SL4JCH,=*$)" V%C?I]3Y'\:=@]IJ5+"8S&Y'EV*J
M!K0,5F& PM7?(%PRKT+R7&1'S<3%C'R_G7P-^(NPV(?F>RE3-ZN6X=W25L",
M%C*^&=2.\2&NIU.A! ( >:;*@,WO?;>FW'/I-J#ET3 ]7K'=N#WB)MZXT:1'
MR_L[#CF1W9YT,)$6[R4PV7XLR2EM3?;R$IEA: U+E=HIE?9-RRCB/Z^68JAF
M]&N-YOX"HS&=$T_,T/-!]1HWP_Y3 WMTQ.[:SEWQ1I/Q&'R?:+!XC9?,J%04
MFOSFD[+J>:5"YE*HW!U,:S#OQ'05& U&T^GZ(8BD7. JMF=EKUXR^R9;!QK*
M)5CFV>%,AQ[MDMN9=DHD0Y$(36IS#D9QN. X'F"XXB.VA""0IH$<E8&(P3</
M3WZ@=2<\$4V59IESIW0UH?=SMZP )DV!DA>KTZF'Q-"G5HU*51U0[H%-[7[S
M][= ;NN.\YQ @ $DF1<B9AVJ^6J[1FI<"Z0)T=Y"%M/Q93+K3J5[\I24GHOH
M0I )((((!&PUI! )(( U)$ =I.BH<YK'ECB&O&K'$!XXW:8(MU*\!:%;\JTJ
MV)!V4#L0-R#L?$ @D>H[U2"")!!',7'BJB"TP002) -C$Q-^$V[;+M21I(GE
M*A*E$HB41*(E$5BMWS]U_*;_ .YBT&@_5^]R@:N[?L%3A_?ZY?B%H_:NM%*R
M&B+YR<:R=,47NP>7=3-1<<SVXV.3!L^G6 Y7D%H9U M34F6XE%^MUDN=G989
MBRGY;+5^GW&*U!2^\5J<#;:"4.T/8>_BM]<*-HCVC2^VLMQKM;I+TV=(FVF]
M9\-1YUJDN!KG@JR1$B0TXVTE+2FH*%'N"'>QYU@%:YX1UG[>^OCH%C4A'/4#
MS!Y]ESW:E28DRV(B5.2%=FTA(6MU71M">NY6L[)2$A)*BH@ =3T%0LI>=-TB
MJ,=)4$+E<W9-J<9"U% 05[#M?/".<;J;YT[%*@>5QM2B+7FM[B3HSJUX@G3+
M/^AVWV^U.[IWZ$C;<CKO_91%<=)/YK=./HP/#1^C&;4/\*"X!YHMAT1*(E$5
MJN]QB6RW3)\YP1XD)A4F0^XI*4-(0.8\Q)Z=.GY_JIN;Y#=9(MSB_P!E+209
M$3!U[#Y\NM1LTP<5(<S#6?)UMQ?*K[[=K7*4A#=NQ^V$E3B%NH"667?Y1+JT
MKY2&W5*4$C<Y5-KZ[V89LD[Q; OH+1,3![-8NK5?$4L#@J]:JX-: ][W$EH#
M1O$29 '.-#$<%\I]$9DKB\XH-4.-'*$H>T6T#1=\)T"A79 1;+I>X3,F-.RY
ME#J&VUAJ3<"MAV4TM:;A+CN!WM+=$1!S-M<XP6Q^QF-Q%+=_U6A0<X<=U[BU
MK&_,2)<7@!I:9O)LO&]@\FQ?Q)^(9S+$T^DR? 8TT,M:02T@8<.=6:ULR:8J
M5:CG$R'AK@ 0T"5?#^O.===5&,KU+CR[M8\6C/S[$X_%3!M$*Y/RSW5$5IEI
MMB<MEH$!94I2$H;+B$DA-?$'PUJ;2?$K:G$9OM)3<<-@\16=A35#:;0PXESJ
M6ZV@QK2-VDVQX:S-ON';7#Y)LGD&&P64%E+'$4J%8T]YSW_TFLK.+GN)#CN_
MF&AT@BWU&83R)2V/N4@)&W0;@>.WHWV/KK[&;3;0HTJ;8 8T,M> ('7R)XWY
MKP5SC5J.>X<21WQ';:/*=;^X=0/J%5J5S1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1%Y9(4>3E4$]5;[@'T#;^B=OIVV)\/#>EC(
M,P1P4'>D%IB+GZ<CS6+S,/QNX7%%ZG62SOW9N.N.BXNPVW)B67$CG:1(+:7$
MM+.Y4WS$'?H4;[#19AL_L_CG])CLOH5WDDEU8/FXO):\3(CA866;A\RS+#LZ
M.EB:S66^6F\M (((T XW'G*UGE?#YI5FC3J[SA]K%Q6E03<(# MDX<PV.[MO
M7&#B1N3_ "@4">B@I)*3H,U^'6S6;LW_ /2L/@*S0 RM0Z1C@6SNN^6INR9M
M\I)U-ULL%M3G67 LIYE7Q5-Q.]3K!M1CFF!!#Q,VX.B_'10]UF^QUXCJC938
M9UW-\MK27!;H64QQ<7K&I8[)+EHO20+K:EI;5RI[K(#8"$#LBG=-<WA-E-K]
MF\91J;/;0U:N%%1IQ&&JD$,ITGCH0POP[_[34! ,PUHWK*G/7;*[5Y;B<)G>
MS6#_ !]6A69@LT8:K:^#K5J;FOJ-:RJULN?T53>@P:<!MROD+B&D'''PAZWZ
MD6S3;&IVK^FV'Q;7;8N%Y7*G7RUWG'Y<&-<4HQ^;<8TN1:)EN===90];G6P&
M@EE452&TQA[-@=N\$_"T,IS_  ]2MF;ZC:#<33# 6U:M0"F]Q:]C=T%["Z:9
M^6\$@1\ROV#^(NPN:U<;LMF3=H,LK5&U:&#Q#@YN'!(.XTU<,'MW7/)M5@;@
ML!92:P;[(QIS9[T+5J'B^I/"9G;2PF7%R*T3+[IY<'"M(2!-8;2[':6X4K45
MV\! 2K=93S5OQ0P6(,-<UX,<7,/:""6DR>, <."ZG"?%JGE-08+;?):V Q3A
MNOQ+&LJTFU/S --!U)]V& ',=<7=(D_4_3+BIQ_);5&N<^X6&^V22M26LTPR
MZP[Y9GG TT5(D,Q%.N05$*3S,.)2XDK2%-)W23BXO*7,?.&ES"V2#/YI=(!(
M&@#?&R[K*]HL@SC#'%8/,&OIN>6MWW-<6D-82UPIN?N$!S3#B'C>DM ()W[C
M>K^!97=XMDL5V[U<9(=4PP(LID*2PAUQS9;[3: 0VP\M*"0M26U<J20!6LJ8
M2O2!?480T1/Y2-0!I)L3SLMRQ]%XFG7I/&H#7$DS, "/+06T$+:E8ZJ2B)1$
MHB416*W?/W7\IO\ [F+0:#]7[W*!J[M^P5.']_KE^(6C]JZT4K(:(L7N>%8K
M>KCY6NU@M-QN/=40A,FV^'*D)B-..NMQDNOL.+2REU]YWLTJ"%K=47 L; $-
MP1S7NL^/67'VG6;+;8EL9??<E/,P8[45EV0ZE*7'ELQT-MJ<6$I!64<QY1UJ
M9\E0*;6W$\.,Z:>"U]K.YC\?#)K^18Z_E<1+D?L;"S;Y]T;G3.T*(?E"!;VW
MW9%LCO.]XEI<CR&TM-J46'% )J%6H)6_33)+6[A]JL=ORZ_F%;].HFFN03;9
M=H36-^1\WGS]0#+3<7&Y=E@R[0M<6$JY)YKA:D1()!"6N1W^_+WQ4$>/#JXW
MF>.EC%K64N.)\9^K0W4EO 9>)1+BG \Q3<7\N@WB?$<M*<4O F-PT6F=;EHN
M*U%!CO.ONQT!*PXPYN"@I6R-'E.'2O3H.C9:<%PY*AR<AYDXW:TJ)3SN  J"
MBC99\PI"O.!J!;LX=B+9%2B41<*) W&WT[^JJ7$C3OM,:(HVZX7>9>C8]+[*
MZ#=,N?Y[B1S;Q;*PKM)#ZT@@]5MI00>O(2=O 5LL"UC15KU2!N4J@I@G6JZF
MYK9%R0'$"QF]E>;NTV=(X.,PQL6A]3Y&DV,M#G GF ;MU$!?LCNKMXB8UI_P
M4:.R.RU/U]=:QQ;T(!MS%=/6EAK(+U)4#RQ^_P %+[*7UK;Y$=\D)*>S!1G9
M$,-E^&QN?Y[4%*AAA4.'#'"F'U0]Q;)<*A+0QDNW;R3)$0?'/B;GU;$8K+M@
M\F<*V?9YN]*QC75!0P3H8][]PMW":M1C?F<) ( ,K*='-(K==[%B'#S@"GHN
MB&DS$:)D=Z92IE[-+^R%R+F77P$J?7)N"Y#\E6W=U=X7_)J[..6?FK.,US#X
MI[48UH@9*S$BI1.%:ZF*M*G3:[YW5'.#_P"IO  ,;( F\E?1&Q^S> ^$^RF5
MX+".=4SJCA74:PQ);5+*E5S^D<=P,(>YKR\DU"&[S6AH  7U#LEAM5B@P;5;
M&$PXD",W&CQ6-DM):80EML$;'=24I^Z)YE$E2E*/6O8\IRO"91@J&"PU&G2#
M*=-LL;#G=&T-.\X?FDCYB9D\>"YS&XRMF&*JXO$5G5:M5SW/D_*7/=O.(9H!
M), 0 #$*_=FGZ?T_7]'TULBT%P=)D3 X7D7\5C\(TM%O?4NP&P 'H 'Z*J3W
MXKFB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+JI
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MXK)Z^897BQ1#&X?!UZ=/!/+7O=OU*/0E[GOW]QSA6 W*=,%ORR?F]@N6\6/
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M8]WJX22(]NM$985.F27&PIMI*026VR"%%92?'<'8]+^'P]2L\P"&2"7$$M
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M-\BD*;:SBQK#3PU(O+6.#B\G1Q!_11@.!V7 ,;MV/6.$8T. TA&Y2#(D.)2
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M*-6NC>2G)-#G<>A9'*[IJI'?R-S'XT^1'C8YY!O<62;SW-?9)MBK@;*E:Y*
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M_P#ST'@.NVV]  +@0>?OZIPC@5WV &VPVV V]&P\*E(C1<T16*W?/W7\IO\
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;EK0_LT6HR>I:W0#S)\/'Q.YWI[\Y]]:E?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g418853g00a15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a15.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1IH4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $,   "9P    8 9P P
M #  80 Q #4    !                          $              F<
M  $,                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $,     %)G:'1L;VYG   "9P    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MZI]OF_\ .1_E_@.'_P ^.H?]Q*?\]_\ Y%3J^N75+G%M>'02(YM+>3$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MA)2CPF3#U>)%Q+7%X__:  P# 0 "$0,1 #\ ^_4*T)!!/$Z:<3SXQ;X;Q!%
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M%TSB$N$.H<$$.<,5%@J/KWL=]D>5NKDR++-6$VR0)*9CE 3."$V=,Q24B=,
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M>6ZU&I>\Q+1(84?)Z@]<+Y6H4*4YNJ5R:2[2IA,!9# &]X_E[(HL"U3$I(0
MFZ0&8J$H!)%Q+O>)"B23B:DO]M;@-V\K=A9I4T*(GH,T34E0NJ%ZTI"T^Z3:
M*5(42@%T,+O ,8>]6O@OS\O<H($9"5.U#-!Z*PE2TM(Y:5:=5;0K?6]'2A06
MK>"U. !0WB%@%)[O<Q.1*4J\ 22EG:C":,2=)<\NDEM'[,TB=.LDA,E2DEYI
M-V\'%^QT-T'$C#/GI&B2^LC<Q<NX9J-WVX8\)=;=MSEJ;)I%2:16%4^+6HT5
M8I;SCS"W*3-CN!#K#IU<U4I.I5CTX92LR[,4,@EP3[V[!2B7X3YM&C&ICY=G
M[FLJ6>SS)JM]2;TD WIQ<3$I4EE $%TK20'%": @@6N, E2DI@2G5A2FG$MP
MU!*'&R-Z(-YN/I*CD%I\H<2\5Z<%'&+MN14W0V?O"^?2=="*F.)*R)E)3 S)
MKU^%.V427(SN:/%PAE#>;5K1;R>HK:J!,HAK<>0B9!ZY>IR)[E*/6\-,XRNN
M6ZF$MN-NCEU)2I&NFHQ>7;;,%*("'"64 $.+P# A\,YY2\<FTY%RE99,F:HS
M@F=.")2R9Q"F5<402D US. YH"SBV\J"^TG=?ITPJ+;DEXII[J2AMQ#YZY?8
M#SC[$=Q14TP0@,)#2D]KKH;R]XFI6L(2&"B2$I-""2'#MB*.VT1QLJY%RA9M
MYM-^:+V]D.N: ]XD7290!+!\^ .(>/JRZD)VFR329!"!^RNZU-I;4 EU*ZDX
MMS>4H@AU7;N$+4=Y2=2->V3Y#NJ*.W[H  )4D,P+F8L#5RL'=P": _9?88WU
M&Y26N<5*4D2TNHE1)%CLJC56+M33'JMNO;WMG9BM]VVJ&N'7LV[A@S/*[;;C
MN]%IT;<E,JN"YUQ7D*AT^$2E3$5)8>JTTQ827XS3CTR+3(>YV9;IR)UTW I)
M-"0]Z6HA($M9<7G!<:S0@\[=[V0Y&YZRS[/+*5VPREA,M-UI5Z7: A4[W9&>
M65;VDA18$E*3'RD7E>%QW[><^^KVK$ZO7%7ZI%J]?JU3U=D27$ZRHTB,TF)(
M0U#;C%76$&.Q&3%9+;[;$*-,A"1ZP,C?R%%GDINK0E)40EBI(DA!J$.74VAZ
M:8^09VZ>;;LLBTVR:J8@VHSP%+?W3ME1+WYJD@@**2H4-4@D)4WTP63U6W9.
MMFSK:I<^M7.Q,A42D1)3#-EUYYM$B/38T8A+[<4-+0E<9T)Y/@22H :D'S7*
M>Y:W&TS27(4M5TI$P&Z5K57W(G$MR-R#Z>R'V6]SF3\D6*SS24+DV:SREI*K
M,U^7(E()!-H%#=.8'4[OZKSY+9#TU\GKIY]#^PFX><=.D;3O8XOM,MUQ*@%,
M:53,?!\\IB.G#7':CLS[FKH42IB6!OV9C0'/:^?DB'GR6R%]WKI^)%Q?1L5]
MIMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^
MDLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7
M%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&
MYCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>
MNGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_
M90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?)
M;(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[
M0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_
M>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;
M#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,
MKZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B
M1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#N
MT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?
M=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%
M7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY
M\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;
M;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8XROI+
M+][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI^)%Q?
M1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4.[1N8
MXROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R%]WKI
M^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*\5?V4
M.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN'GR6R
M%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]IMNT*
M\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^DLOWN
M'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7%]&P]
MIMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&YCC*^
MDLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>NGXD7
M%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_90[M&
MYCC*^DLOWN'GR6R%]WKI^)%Q?1L/:;;M"O%7]E#NT;F.,KZ2R_>X>?);(7W>
MNGXD7%]&P]IMNT*\5?V4.[1N8XROI++][AY\ELA?=ZZ?B1<7T;#VFV[0KQ5_
M90[M&YCC*^DLOWN'GR&R&OM?)ZZ3KPT\I%Q<?_\ &Q9&XRWJ6E("G)847MI*
MS1"NS3N82"J\JGQ[*>CMO_3&,:=KGJF^S#G7L^9DY8VA5;CEW%=UO2:32XM3
MM&LQH3TQYUA:$NOR(R66D)Y)2M]Q02DI3QYL<_)6Y:VV:WI2L*=Q@%T(4<QE
M!J"M.G#5MVW94R#NAW.6_)E@6HVFT2#+E@*L[I44IJ=[M,Q0 P<!PY.-(TCY
M+YVYA[.M[4W,C+>J+I-1IX::J,).B*1<-,0I)DPJGR:DK4T^@J05*"U-KW'$
M:+;2<;QE/(<V99-YFHO!20UY*B00S*<R\6>K4K6KQ\^;C=UV4MR64@E,^:)<
MV:J\"N:4D*5,5=4C?Y22*X$&N%0#'UQ['6UW9.U78<&Y;?FI8K<=MF/=-LOO
M#R0H%6#9+L=;3R^N'H;J@7(4Q+>Z^T07#OZA/DN5\E*L<Q08Z06HU-0P<@C6
M^#1]I[C-U]GW1V1$V6HB: !.EE22I"B5L4D3%/+64DH-2W!60H1FPGCN>MO:
M^WKIKCI$ETCUSQO1[Y//Y(J8M%H^%?:A:85M+;0Q+3>_YNF;FF\VDZDY@7!J
M3J.(X=T]S'T+D123DC):2 6R=81@"?YK+ 9S1L](_./=>@>W7=4M*0YW39??
M@BI&4[7JQ>I+O5X]AE7G58]H9<S+*NZBTZ\+>FNW54)5%=H28];HU?J#,:)3
MJA9UTH ZV8J4V,VBY:?4E.19\6F)C0TU%,@Q,<3*%D7-7?D3%2SP:H4JH26(
M4$C,"H)(.)+G1W>1\O6*Q24V>W6.1:)*=^4E$VSV<[U,4C@+0HS H.4H,X%)
M!2E%'J+B5G:/RK@M7Z;<H%%*JU5+5GV; GY:6>VJWJ#%J\>HW%;#LA5-J?+2
M':6F13/)%QXN<L\@<LVK1:>N59K00A[1-)3><WY@O&Z0^( (-6P(#1SE;J\F
M)7:"C)%FWM:DF6.UK&=[1OZ5D%RHEY23+=!"B2":.([JN;3.1DV)>K-$RZLN
M+*JDBEJM&7(RT@/]9T3D5-5*@2FV*K]5JL204OL5>,V$+Y,;[;J%;BK"SVF@
MW^<"4U9:^_.>@<9QBW*1"5NGR4DK;)-E W]*D;Y9[,;LEB"A8,PL,&*0HDAR
M$@M'9U3:>V?YK:"BRJ2TM<2X*8@P[&MZ*@P:@Y;\BD&6AF T'.0>I-32[OJ!
MWI7:*65J+?'&3K:+H[:GT(*O=I]15QFQS8"E32O8S]U>1%VJ8$9+L@OI*)8[
M7L00A15*95U"BS,H&Z_!4&Q(%P[3SWV;[RGU29Y!V+;[M-G39[$JO6%1XK$R
MGS;P15[>@MQ8$&<HT^F49,FG5Q[R-4KK9Y*5RD! 4+^QMN'?3[0M+B^G?UC@
M_#8K(36K/08LV'-M>6LB35RU]I9/L[I!2I5BD+E[Z)E]*5RY*5J*2AP01=(<
M5#/K$NU#(KU>CH?A2T&N5,QW8#2(\"1'7+<T73FGNLE=:;DA "5,%W<2E*4*
M4$HQL5E3@E*B$FC EB!=!!9GIB:EJ8QX_EF=OMO*Y2+DG? ;J 4RP#,6H$(2
M"D<$70Z0 "Q+.(EM*XZ[8UQ46Z+6JT^V[@H%2:J=*K-+WDS:?-:<0X9#+:"C
MKA2RVD/QUDMS6P8\A+C2U)-;=DV5:$*0J6A8FI*%.A*Z+"P272:<+1GUQV&3
M\L6G):[+:;'.FV8V:;9YZA99JI%],A2)A3,WM: H\ 7@JA"4N:"-F.TOMRT;
M:HV3+;MFYHL*F9LVSF!;KM?I24\HS6H7E>K+;E<H3RE+4XPU(FM&HM.C]3ZO
M-IT*AKI\G($ZPY1&]*4B22DLA2DA+34W4,$@$%*:4H$L7X,>M;KNR%9\N;C;
M&F<+UNORU3)A2@[Z%9.M.^+*A,44KWU8O)5B5 I2S@:L]QAL$!AD!0W0E*6V
MSQ[J5*0L ]W4H5J!IH<;^I:$RI$B8KO[B+SAWN,74:YLX?/B\>+*DF;(1:TR
M4K((F'W,&ER]PBWQJ@ES2L96939]6+EU9%IV_4K2?DUJ@WF]<%7JM/H5)EKK
M-"<FPY+3+,^9/ARH=6ITFEO'>6RH)BR'$(2EMQ6O1V[)*IZEF7:%A*DA@)JQ
M7A8LDCA N0[N&8O3;\BY?L5EE65,RP68S9,Y2IBU6>SD*2HR5 !2E!0*"@W0
M $LHNH5$7.A;7&6L1->H[EE7#4[6N:M9A7/*74*?0Y$]BIW<F##IZ8,'KB52
M6H<)AA3CSJYZ9H><WRVDGCUTG<[/04SDVF:5((-)LTDAF(2;H.?2&&,=_:=V
MMA5*M,@Y/LRI:U3EH>19RTQ93=4I"E%)8"I!))-#"O;6V59IU>39MD5NBW)+
ML.9:]$K=1HMH*\AY3=RFX&JE,0F1+CJ:8IGZ@9<1%==9;2ME"0RE  V"W)62
MJ?/I=(]UG,P2 S&[G#US#&(7NOR',L9L\K)-D"U(F(2I=BL5XK5,2I*B4E50
ME+'$DD58/%AL\KZB7.JRZ2V*).KEOVY$AWA<M#<;72[FKD5I%.8JL5R.AF*B
M2J! B]>168K.DXSI"BIU2UK[>QA@9,U6^A:KWNCJ9S>()6[L:@$<&@S1H^5,
MI2;4H2)=BD6=80B05R)<D)F&2RA-098!3>EA"5J=5]7")X48_E 4>U"0E1*B
M@#1"CJ%:E"1H3O +)/'? 5SC':% NW$. ,PX(Q<4H!5S01TBD%1X3J2'<*=0
M#@9B^+!WQ8:(]IE_?UUY6W91+YL6LS+=N6VWS,I=2IQ6EYE24J+L<M-J0),:
M4VIQB3"7JS+:=<9=0M+A2>NM>2Y-LDS)2Y4M86 &6A*N](< W21@X88@-@([
MK)&Z*W[GK3)MECMEILR9"WNR9ZY2"5WT K0%IEJ ,U1(6"*J)!!(.R+:YVV[
M0VI\@<E9\MMBD9@69?\ !J=[T#0.;J$4*<X:W1RMP*?IE04"8*7%A]E17#D)
M"]Q*M.LFY^99+:M+G>R04BH2'0>"S9J&H K2KB/:=VW9 LF5<DY.N@&U&9-3
M,10DA,V2+]Z^W"4 E@2QO'O0#%O:MMLV15:^_-K%D7&_3O)UZX68LA%&8GTZ
M0JRJ?:C5-#3,I$2H&4_3>N:I45O,SX[!2U!ELI2K3OYV15I4B6)BTGW11(*D
MEBLK9P"[!5T';HC5)NZZS),J>NS29J%(0E,LI1, ,N4B0%%"E!"@Z$S'("DJ
M ND!WG5MO9>IN"IU)>5JGX4RHU&;3RAN%%EVV*S3XL:I2H/6DIF-5'E5%I,J
MF&7%ZXC.K=<Z^4M]+::C)11P3/F AG)6H@C# BF)#T<5PPXR]UTB8I2TY,LE
MPO=3VO*!25#A.I*N$;P*@XQ-7 $=% VRK5:@LLS[4N"=/C4^'">EIA42,5.P
M+V3>?*\@W*2T@OPFN0)82@OJ><W]=\@U7DA01,7+G+)4 X"UE3!)%2*D85&
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M8J*4@&@>H%8ZJ=3':7.E4N?&:9F0)3T*8VI+2U-R8KJF'V=]"0E2DN(6-X)
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MLZ''CL-SI]3K+=+96[R=+8Y>#3GU.-HF3VE)<46R0,<B;:UR@M14DD!0O!1
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M9*RBB1*5.40$H8DEL5*"=+XG37-JUVSY)GY4M<O)LE)7-M!4$I%YS<EJFL
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M:3K-K%IO+J"JK.ER% N5>-,2I*E*>=@B6$I6&PBIR;;IJ[X4LZC>8AP:MGH
M#F#8XFN0]TV3T)FR56>S@K4DNA" D 2)LLA-XK4 I2PM0O,5@E+42*>T'G19
M]V4NW+3MU3]>ZPDV=<-3N!"HP:933[/IE%G4.CA*RX ]/1)=<,A+ 6^DN$'=
M#@A.2K>FJBL]]0E9 !62"[L[,S5Q%<W-RINDR7OZI<F5+K,DS+]R6%"[9T2U
M(##O"HDGO4WDNSEQW4G;$:J%]7'45T^N.637+:IU)HU +5(74+>N&EQZ8$W
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M*-MNI0HI)&\#IP(QWLB4982#1D 8US.]?4Y].C95M]EGJ*@ Y)(("0Q)7HQ
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MNTII+-+J*XM&4]30%EQQ43?;.XXM:EK4\G=<4M2UE14HDS[<1X"4,1WB#P<
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MVQCFIZBO314V:R=HG,T5F.D(8JJ4014V&PCDPVS.U$IM.YHC=0Z$[G::;O#
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MVR3*G!$Z6B8DU92%H"TJNA?P@H$.,#B7BNCJ5&UVM2CY5:.#W4^6>.-.)_\
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M:&&B(>=1[7/ >5.BZ $ >6>-P"FRTH#]3< II1;/2V2@]J2,/;;9O"2]H]&
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M$:45?X+3>))X\_/J3CC*MUO(94U5<0]">1_7E<QGEY$R7=0GM601+  >6E6
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M?4UE*61EW96JD*6;5MQ;B]WM5\I1H2M=.<;W/IW\>?Y76M5KG%-ZLU>?XZ\
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M3KH2G74)5INGM<@*F2K<@E1<%ZG74XGD&H:#&G=D"1*G[F+> E/"D*&&D Z
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M;XX1,8>5+:'19&?-1RZNI;;=MU*+3GZ;4"?JU*F/(6"U..\E'6KY&B5'>XJ
MXZ\$(RZCNM/AM]IQIUAQ*%QRR1R99=0%H=!'!6\-.*>UXCCA".=A$.-(VPPB
M880AA"&$(80AA"(*YC[!^3"$=9*_:4G_ +-S\2O%Q[Y*Y$_O)C&KWJT?[N;^
M['PX;8G^,YM"?Y\\Q?\ Q/7<>Z;E/YE_P%_P+-'YY;O_ -,-T/RG*?\ _)6J
M-_\ U$C_ !7KK_SP71_X>L/'G&[+^DE?M3/XTZ/J3L&?HJG]N7_D<G1N=3SC
MV1\N--5\']H>>/:4]^KG\HBOBT9(80AA"&$(80AA"&$(QFVNOK(7!_*-#_\
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M#>OB]/XPB1? *5NA8*"T&CZ-3CBD[KS2M.T6PD$ZZ\=0.C090 PYL7V.:,=
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M*CRD3$@D !G56G'%2ELW*#GS@5UMYWI$@$L-GEQQBT>3VT[?>:.868.7Z(]
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M7.AR3KW$<:A1-#KP_=!ONXI)E&;,"!-$E52%J4E #!VO+8!\-,2+]1+!*C0
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M;B_TAKY^)WM?$7XIZH;])QWV6VG?$]<!-AGFEQCW>#[1X=/H\-[F>#7XJNJ
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MZH;]*\++\=/7#KZ%]N1?Z0U\_#>YG@U^*KJAOTKPLOQT]<03,B;H_54;N_\
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M[%#]:M/C'T8=B+_E ;3?^M"1^9,.W5:)?1#V*'ZU:?&/HP[$;3_^(#:;'_\
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MZ.+T:<,V>.IJ3*9S#J"ZI+4AE44JW4R$)#R6RU)0TL:%T+<Y! 21J'RX3]3
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M\<P:6_14WO0W&I%D9DT6U;*@W#(JB*354U]V.FGKDL=<B.3USU=^2FG8C=)
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M^A (HQ',U*QM/8UGRY79&LJ%EBN0I+.U591LB:C54Z=1K&-N\T/^%3_?V\?
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M R"IKLN8H]Y+4<):@6(Y2QC5=T^Z*R9*R7;!OJ$E*9+%2T@DF=))'?H)+*-
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M1DRXD02),-B/)4^RH*;7$<D(.H05!P[@P'>GX+72Y%'(2';H T9\[Q(&5B2
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MYTPF9U1KE7S#R\MZ+:TJ.P*A4J9*IY8;836W(R7#%6)V.<.KS:HFY-=WKB0
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M%W<I]-GL/M.=<*1O*<0Z2-W<W$A1T[=GV0LD[DEV>S6ZVHD;_9E3T@R9\R\
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M'S]V1MU@W+Y8L2K;.7)EK4I0WM*IW ";R73+0HU!8@D5CTW<GD-&6[//LTM
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M^QHFFZ$JED@$,04I)8AVQJ,]W%W>/'\H;M9UFM\V2)4P[U-EI!!-U29A2'!
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M.N?;[GL8R#\GNSBH-B*L[(DFF<OVD"[T<O$+[,.4%AE2YUUW83YA8L0" 9Y
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M$PV%YWJXC^O^LZO!K).F+)_)_D!W583\V46T_P!C'DB#V8<J'!,T?\Q./_[
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+EL?7"L<G"+Q__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g418853g00a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a16.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1/>4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          3A"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))301$       0     @   D    )      #A"24T$'@
M!      X0DE-!!H      T$    &              $8   "5P    8 9P P
M #  80 Q #8    !                          $              E<
M  $8                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  $8     %)G:'1L;VYG   "5P    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M 0 "$0,$(1(Q!4%181,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( /<"$ ,!$0 "$0$#$0'_Q  >  $
M 04! 0$!            !@$" P4'! @)"O_$ %L0  $#!  # P0)#P@(! 4%
M  $" P0 !081!Q(A$Q0Q"")!414R4F%Q@;31U D6(S0U4U15=9&2DY2AL20E
M0F)TA)7!%S-R@J+AY?!$1632A:.RL\(8)T-E<__$ !D! 0 # 0$
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MX>Y] =NV*W]@L7:VL39MM,ML/]NAE4N _'F(8!TVMI+P#C)6TK;:U W^>/\
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MM @G1'3T[W4JE)I[=.?+Y8%W9IYDJT>9 *4G9\#Z/4:L"^@% * 4 H!0"@%
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MKB36[B@E"E$(<+2TN-EIQMP **'&SI2%<I2H GJE25#H:D'AN( N%A \!<7
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M/E%C7(=M-]M\>YVYR2P8KRXDI <94[&>0'6'"D@J;<2E:=@* - 2'E5ZC_\
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M7>5 /=XN=QN+$&*'''_8JS,SGGQ:+-WIYV8;7 4Q$,E:BEM"2 D#J@Z  ]2
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ML]OM:C%6=\/"=W-^!:Z_.AT!)YD@].H!Z>'6MCF*T H!0"@% * 4 H!0"@%
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M2GE#:5YLUO\ ;,RQ5-#C.Z49Y/+^3Y[X;\L;&^'#R!V:+3=LCQ22CNAE2EL
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M3U-1A.75=Z<TW>6GX6M$VS![:W H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M]@J0VR\I(6V02XRTHKYO-(T33!R=DOY??;G-HN;-S31&26[>BWA_$=$K<J*
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(W=/NE8ORD[\EE4!\:_5
M$K5=KYY(?&2V67%T9?->M5L4JURK??[FTF&SD-M>ESHT'%6W,FD3+;;D/W"W
MFS1)$M$EAOL>=WDWABYT[6<VM?7YX3#VPK\2UAVEWGP76^^<'S1]3$EY?;,
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MTN&B-MHT6EMMCK5=!44 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M04X7:V>\VSS+]!'4[/H_[_-4.=([_P!B]-,.>41GYPO0Q//%O1'+H[.R"KE
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M4D*!\2!K7-S'^D>I!Z5AVFC\B3LDI6F4:WRU??J:X-3XY3:O;>\PO&/X.?\
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M7CI>RU<NVFI7CPE_:[*<X[K3?I:WA5./9@I]YU[-7W&7),=3+$>S6QL166D
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MW&CGH].<>$26H*2HZ3H@$;Z^&QT]7[_@H%5+:B-?BA;F6A84 H!0"@% * 4
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MQ)52_*J:VU97F)6:JA[<VB7VIX*^E0_RU/BFG.7%,)I56_+LE,Y6.CM)"$!
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MS[JO1D/+OI]42 ^U<_\ ]!_%%02:+&/M!S^UROE#E 2.@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@(]D'VI_?;?\ +(E 2&@(
M]#Z7VXCW-OMP^'4NXU"S?<_&WV!(:D'D<4$(4LC82E2M=/Z*2KJ3T'M>A]!U
M657ZUU7H15D^C]#YGM^=6+#LZXR+O4QN TS=L15':Y5O2I<ZZX^"Q$MT1D*D
M3)LIQD-M,1FW%*6-D!(4H>C50J\.BTPG$[-)I*5;/+G#E'D_6>#BXT/AXJE.
M<NTJTJ7G&:M$FTC8YEG%P][S9$S$\'#B'(N#Q);C-XR8-*VTYFUUCO+>;M6P
MEQ.,VIV*W*5TO4F6PHP$92L.(Y==W\[LF;T<>,IQ+*(X7>=FYE+?[*37W>V0
M^$.>V_(;>U%MN&9D86-Y+ C,M1+=;;\([S>/9*IM"$LQ$S0TSB\TH#;2I$ZU
MJ4M;SA4;7Q/SW;:AK^?2=W"4G/BJKL^.JTHPW2E4EDJHA50N3AKG9S"/H!-X
M@,15/.R&V&F&5NO.NK2TTRTTA"EJ><<*4MA"5)V7%@D#?72B,JL.I.R;OMKW
M6CIZ*3T</&HK5ZE&MGWS,OG&<9G%GN)U^S"2];.%EK%RC]HMF7FMW1);Q:WE
M)6-PTH<1)O;H"2M+=N'8E20%OI20NKJE*+77)9Z]>MNAQO&Q:ZVJ%^7B:=3F
M$OS97>TRK6W)'C7"&W6ZX'(\DN4O-,M?20[?+XAE3,!!ZJBX]9@TY;;%"4HG
M8BM=^=2E(FSYBDA0HZTIY:Z?%WR:T=E3:=?YGFVTO!2GFN_G>7T5W&+(^4E^
MVP7U(&@7(D?8V-$>8TE.M=/:;UTW5?KYW5\[57ZF_P!"AJZ3?11'<E/D1VY<
M+\#N2DJFX?C,PI4%!4BS0W' H!0Y@OL2I*@#H$'?6K4XUVD]-$]UO8H^RX6F
M'2W-_P J7G,S)'IO _AS<$=D]B\-EG9/9P)%QMNCZ"E=ME0E)UX#FY]=-:Z@
MW^L_BSRTE[:1YE/PM+_M2Y3/@Y3^:GD7P1QIII+%KN666)M" EL6G+\CBJ1X
M@J!7/>*EZT.<GJD!.M)%3]9:ISY<M='T=E<RK[#54TZ<3$HME1B.E-RW+4M-
MWS>>LF&+P@N%O1RV_BEQ-C*!44N/Y(W>2.915HM9#;KQ$(!.@.[:Y0 0>NWU
MJ7_;ULG]UX>9G^ QDY7:<9:+_><HSU>OEO-[7#WB'#4XJ-QHR"X!2U%#.28U
MA4UEI))(0E6/6'$Y*@D'E"G9#CA VM:E$J-77AO.E]530GKEGYOQ+_A.U?\
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M'VI_?;?\LB4!(: C\3[OW/\ L-O^5W&HU?1>M0)!4@4 H!0&-384KFYE!6M
M@CH/'H"" ?BH &T@$ GJ=J(Y05;\02$CH: R    > &A\ H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@(W=/NE8ORD[\EE4!)* C5W Y;=^48BOC[!X;
M_,3T\*?/$?/ D2/%?^V?X)H"^@% 4Y1O>NO_ &/@H#S.08KJN=QE*E>/-M05
ML^G:5 []^K<3M?+*R]C)X.'5=TIOJUZ,S!E   "M :'V1SP'^]5<S5*%&UAV
M2/4K]-?_ +J!J;,*:;4-*!(_VE;'P'FV#Z0000>H.Z$IQE;]OMRR(E<^'F"W
MJX2+M=\1QZZ727:'[!*N-PM4.7.DV24095ID2GVG'GK?*T!)BN+4S(3YKR%I
M)%0DDY2O$3[[EZL7$KI5%53="J=2IM";46A64:*RT1KFN$W#)B*83>!XJ(9Q
M[ZTC&598*V3B_.ISZW^S6TI/L0%K*Q UW8*""&P6V^6?MD9D91Y/? J)%E0V
MN$G#UNWRV($:=!1BEH,67'MA4;>U,BF*IB4S$6IQUIM]MQ';//O*2IU]Y;@$
M(MODK<&K9D]UR-&+0);5S@MVDV.=:+"G&H5N3$8AM08D2/8XLU5M;CM,"):Y
M-SE6J#);1(@Q(TAMM3;]]7J/D:'3KEP4X1WNV6*T7GAMAESM>-M+;L%NN&/V
MV5#LJ'6PVXFW1GF'&8FT#L],I2$HVA.DD@Q'Q6] 0S)O)SX-Y%9;I8D858<<
M5=+9$M4F=CMELD"ZMVR!,B3V8#0D6R=">@+D0HVX4F#+A.H0&'XST93K#B.O
MB_GW[P;S'>!_#"T6#$L:>Q*SWF!AEP>O.-*OUHMLA^T7YYT/O7:TMH@PXELG
MJY#MVU0800V7$(0AIUQ"Y!L+_P !^"V4W*=>,DX58#?;M<P@7"YW7%K/-GS
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MPV_Y7<:C5]%ZU D%2!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g418853g00a17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a17.jpg
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MD9/2)#A6(R<R0=$E1W<F*#,W0D-586)E9I33_\0 '0$!  $% 0$!
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M(KW1^QH_7G6#I><J@5"EUW)GF#CGA6H0Q,]'B 6RU\D<1HYHC'79G8CFH&/
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MQX1LO"R[,ZC[DTR^!]US[U62'&PVI;RQ*DLL4E6ZVCQ+J[)DD:EB5['POD?
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MFM5..Y;A7I)C@E@G,QD@@JV3'*\A LWZP2Q%SN,3+U"]G6.=A6K&]JWRP$O
M4DH8B7'-<'[['0S+B ;0;'S/LF=R:.X26&HYM9*<;D@@1T-;B9H%A@<D:+"Q
M8K$S7-C5J*KT>J<-D;F4BZ.TZYBQOI/?&^^N5GC?<NN9:O\ C56XEJXQ;"MM
MRML4JKVOL)(K6Q+$W:*6=DH7I6Z0 +18;MXAA7Y0ISEIZ=9D>3+6?5Q&>?GB
M0>60WJ>;<'J?'QM\/A9%,D%N$:&U)1\AXO0*0&ZECT=J+,.@CK^-HV.-*"-<
MRO59-OB]_$'+9;"EA7UD79CEEX2IS.5R;G@S0NE66YKODU7S6'9GC&27\C+4
M5-0HB9F-M%]MU)L>0V1TT;:Z,1WY4:,5$VMX#IXX)I=<XGAP=SB('BZSQMGX
MM7.\M<@S?BZ2&KTA68".#DY^XG$S-<CJ]+%@050-)/K(K#O?@XG3ZW'G/&;,
MWYY;DTCX$?D(706UCITXDE8^5D\CN#' QK)I)6-<^PQ&SNVV616[(E75TGA:
M=?%588KBPX2TRYC4GRN4LOKR15Y:D,?&6+DLDE6&O*^*&G*Y]2-%W;"CMW+M
M)H/ANUW+E>F3RW9"0MW%T/#\E-&W*117BZ,^1>(1FOLQVK.AB"*'2Y;7)MV#
MB8DA#$FDF4D7'RANREBNV84J\4]K%IV%M5G-AAX<<[EC<LBOXOAR+O#%LV5S
MVMX"(UJ)S%RL8BA:7(^,12RIE:3,??8^U;XF:FUEAB0,A2=(JZ*VU8X;ZS(9
M)%E<Y[W.V5.(I/HQZ-3("-H\O7$/PL)Q<9T]1T.=S/R:I\/C(^RP]G)X_P!/
MO<A>,E,[GHR"4PIXA<R(*)'0@AC$0AB/RYMU-FV3/L-ML;-)?;E'O2E03A7V
M1/@;95OBW!1_%R2(K4:C'.>Z1S%D57F.R>#[2,M6&E+C9GUH,._3\,3\OF5X
M&'DLQ7'44>N1XQ8UG@A5KU>LS(XF0,D; U(TYUY#X[X=YHH\=QW=T1EEK!4A
M$'5UL:U'A3#$_2RAY6&F:S9H67$L8MBKI83)K<K%2J)-A3;NRGULODH=MU/(
M6Z%GQNK*D4ZME8Y>+C?')'.US)HI(7L=#)%(URM=&YBLVVV1%1%2_93"8S-4
M$QF1KK8J-?7EC1)YXIX9ZDC9*UB"U#+':AL0R,:YD\<S945%W<J.<BZ"T\*\
M%VB) I-VVY.>*K_4^44MS7)%J19W[[2VF9>J3TG+-6<6?/W$#P#1X4284[!:
M"B-+W%J#"WIOTARUZO*Z:"2.%[ZL])6LK5N+2K91Z3Q-B=$Z-O&(]_">UJ2?
ME.7A[JJE/9TUA[M:.I<@GM1Q9&IED?+?OK8=D:"QNJ6);+;+9Y%@6*)60OD=
M71&,18E1J(<=N=*/2''1\%%/0PH0--;YA)AV'^7K^SN*9ZAXF4>Y9(=>>O>G
MWV[K$.2YVWI!U],4.DR2KBHK;*R$52ZBS"NE>MIBNG\G\:OB=+\KR4K74$V\
M6V:E=6-V1J(DB(B3<8G,6YNA-+-CK0ICI>!2\M^+-\J9;]ZY2,?'FMU\?X3_
M !YLC]^,5_$.>Y]7B7+PC6"])71E+ 6:G1T&"3HZ'XAXTE!Q.5[Z],137!,7
M&RO#T?!2"KL[)URRT2,F(R1B9FOD 61QB6;?E) Y,B[W_P"DU+FDDCE\;:KX
MI[]AN]2GP729/_U_&L2NC)H[7_\ )#*CXDV3@,;P6[?#M :3=7GJ^39$BGIX
M:BY4R65XV.OIY$3"^+S+=66K-CT_Z-FNZ*R[A/XV63AOX7-(O$_#%7Y#@>2-
MJ4'R-4>/B^/Q;#,<A6@J7(HDC/-S3X=I;E[,^W:T.60K4DU,6P>7D69<Y1 Y
M[91.E;H7Y.Y)5EI.D9XK-9;<= VO78QMAD?$MDAX$35@_>D2-60+&Q6(C5:J
M)L7B+3^)@R-;+,AF\I5,?)BX[;[UZ662A).ME\-KC++VW=["NG26XV>5LKG2
M-D1RJIN9.H\1R\5R=%SZX>=K_)*4(Y*A[#:"IN D&92O"5A [\5+RY<7 "24
M!%B!Z$B1XH8W0FB]-.&:<)5Y,NV8WU)(Y>*DH[+5DB9'%)$J2NG1>,C8U\CD
ME>YR.D<]R;JU%1O,5$N)QT\64@L0>,09A')DJ]F:>Q7L-?6CJ.;Q$TKXH&.K
M11QN979$QW!1ZHK]W+ E\%=/L)?#;YN&<:MLW7Z7Q99XL"X6GQ3;X85I=>I0
M=]H M@16+>3!Q<F8W&2]H@).1C8?PDIHK3,>PX+4KF,@M9E19FK%'8EM0JL$
M"S5YIG(^9:UA8^/KME>UKI&0R,8YR;JWG=O0-TK@VY"3)MJ2-M3T:^.M(VY=
M;5O5*D;X:K,A1;82E>?6BEDCAFMP32QM=LUZ<%BMD0NFWI4@*[QYQ<*Z2.%1
MKCJS<5@N<S<@EV>E35,AI52@*5/D7<BT5RO5VL2DJ 56HN2$K@4+).CEQZ?"
MVU.>[]0922Q9LOFA66Y ^O;VI4FQVF2.8^1UB%M=(9I7R1LD69[%EX;6N1Z;
M%)%HG3L%&ACHZUM*V+N0W<8JY;+/L8Z:NR6.%E*V^ZZU6K1PS30-J13-J\5(
M]G%+PMS.D>%>F: X(KO2FU679/AJ_$.4R*H$3>;,89(@S,E+6^7>18EW%BW[
MA1R8^:FY<B.GG%#ACG,,,+%2H//)<WDW91,TMAOE)KVR-L>+UN9[(TB8[B>)
MXA5;&B-15B7S(Y=W<Y[MTCI]FG7:3;1?Y ?$^%U#QV_NZ*6PMF1GC7C7CJ-=
M.YSW(VPB;.5B;1KP#RG=-'2XW9WN4S89+ME8Y$JO+SDZYRA?'DN\A\5TR9H-
M:G]A+NBHL@F IH<[ /Q2Q%Q9HX1ZIB/,+">?9^TSV52OXHEEB5_%+-#BTJTT
MVJ6[#;5B%'>+\-$DL-;+PT=QC')LQ[6\QYKHW3;KWE)U&5UWRG1S''NR.4<J
MY+&47XZE96-;JQ.=!2>^OQ2QK#*U56:*1^SDZW"M].?(W,O&]YG=RAO*U2C[
M=5*M883D>W5-VBLS0%0<LD!,1]?ND $/)SNKA2XW8I,5(RCDA,0X?_#N+8WJ
MGKY2[5IV*$,D:5+4D4MB&2K5G222'=8G*Z>&1Z<!556HUR-W5>;G4K;VG<1D
M<G1S-N"P[)8V&Q7I6H<CDJCJ\-M&MLL;'4MP0NXY$:CEDC<Y>"W94V3:4L73
M1THRMLGJ19Z!/S\S/\4 <;394Y?.0Y[4Q1N2>2;ER B+>*E+P9)%V)WD"LV6
M\OVY0ZK1$$AM2+%D'0RPTS5QZBS$2Q\5:9%Q5N.]&D52E$UEF*LE)CFMCKM1
M(TJM2!:Z)XNZ/=KHEW7>V3Z%TM:\82SCI+"V<5-AK#K&2RD[Y<?9R$F5EC>Z
M:[(YT[LD]UU+KE6ZR?@N98;P6HW,K7 /2X5,72+B(B7<FAN5ZS?Y2[R')UQE
M9DWF1%('A@Y>NVR0NTE.#6D:CRH$//B@*CV9"+FQ1#QI-LI6D?#\]E'\!'31
M<7'4?0;"VI4C@\3?-XPZNZ&.!L;XTG1)6<-KG,>B.8YJHAZ1Z+T[$DRMJV5F
MGR469?:ER>3FN>5(:JTF78[4UN2:*=:BNKR\4YC)HG*V9CT4JH/IFZ8Z58:9
M=:I @4F2XTIX'#\._5[_ &BL1*ZG %+EXNF7&+B;.%#W341(+?EF1[L+.2"#
M7B#GUN.N+<W$N=REB&S7L64L1V[3[LO'P5Y7MM2MX$DT$DD3I*SGL1&.2NZ)
MO!1&HB(FQ]UM&Z<I6Z%VE0=2GQN/BQ5;Q.[?JQ/Q\$BRP5;<$%ED-^.*572M
M6\RP[C'.>YSG+N<8U_HKZ)55N<HL747VH.V0,%Q;*5XKF'E7PJ7KO'%^L5MJ
ML((DGD)<FD6(ML-89. )C7F7UQ@!X SRH(<H%%4_56=?/%8=<CXZ&Q/:B>E&
M@BMGLUTJV)-DJ\%5EA:C7HY%:KDXS;C/RRVQ^#?1L52Q1;BYTJ6Z53'3PNS&
M:<DE.A==D*4'#=D5D8E>VY9(EC>U[6+Q"+Q'[T<C-],W2S'V=OEE4*#J:;Y0
MM/*GVQG\F7(J'>Y+MM/;X^M$L2$?<7JV6N2IP*:\1 D@O0HX33VAXIAY;[JJ
M9<]E75UJ+::D'B<-#@-K5&N2I7L+:AB;(V!)6\"PJRI(UZ2J[;A/5$1$N3=&
MZ;9?3)I0>MU,I:S/&OR&2D8N2NTVXZU8? ^XZN])J3&UE@?$ZNV-%1D+5<Y5
MK..*%P1TT4<J ILNS3Z*)'KF1@9_DFQV",K]<4Z66.Q6=VZRS"J[51G3RU1<
M97U!1#*R-I#'[XI&LIK^2MY.;QBX^.2?;\J1E>O Z5VS462;B(HTFE<C6\.6
M5'/=LF[E*_"X'%Z>J+1Q44\%1%_>X);UZVRO'PGN;!52Y8G6K78Z1ZQP5UCB
M8KEX+$4F1N,.G'A[CZS</1L,L2@<S6J[Q5X@W[S89AIV5Y(KEIL-]D)F;LMO
M?EJV%+0D38CCW8N3"6,YI;\8,T_OOB/N?+Y"S;JWYIVNMTVUFUI6P5H^+;35
MJUDXN*%D3TBX+=N,8_=$1'<).8\*>F,%0Q>0PU6F^/&Y5]]]^N^Y>GX]^3:]
M+[N.L699XEL(]ZNXF6-&N57,X#N<T".C[I-J=5M#>ZP4%7P[%QI>K')$\I<G
M&GPUIX&AHH7CNPMSI%V*FX*;J4'$Q(Z7XTX(R1!'$:E=2#>VD[JGZDS$DC)'
M68^$R&]71$ITFQK!D7ODN0OB;72*2.9\CW*U['(QSE5B-52W1:"TK#!+7CH3
MI'+;Q%Y[G97+OF;<P,4,.*LQV'WG3PS5(8(HT?%(QTK&-2=9$.TWINZ39&(Y
MFCY8%,97>=G#9;F"G/\ +MV@*Y(R\\:,'.SA%5C[T'#5.T6&0A&H^Q3T$)#S
MDJ4&='2)KKA$J.1\-U!E6.Q\C;$?&XMK&4IW5*;YX8X^&D42S/KNDEAAX;N*
MBF<^./=%:U%:Q6^LFB--21YN%U&=*VHGR2Y>FS)Y2*G9GG6-;-EM2*ZR"M9M
M+%'XS9JQPSSHCDDD<CY$?>U"K\*\,*F)GCJ)D7FN<^0HIRSS$!:YNYMR=N)C
MXRFB3"U2]IDR0F1(^,C )'=285J+ CWIV4#%BXB6EP:.WD;=U*K;,C9&TXE@
MK(D,$:1Q+*^96*D43.,199'O_?.&N[E3?9=BZXW!8O#OR$F/@D@?E;+;=YSK
M5RPL]EL$=9LJ+8GFXEW$0Q1_O/%-5(V*J*Y.$2EOJG3%%>/N-KE%Z'8%X+.X
MYM,W*V6R(E(W@R9!L\R? 3-X>L2;H)5W@Z9/N.SBY+0@;X:(S<V/(EC!/>C,
MMD(YFSLG1KVWF9)K4A@2%MZ/F982OQ7BZ/3U<5P%]+5V/"736$EK/J2TU?')
MB)<"][K-Q;;L/.N\M!;WC'CO%/5/.ECC&HFS'MV./4]+?2%94\,MZXUM[K1-
M(I5*XTTWR)R@"J-H/!DFOD7C=<J*SR&P8ABM2O@[L)*SXQ-ECR942O3;T?X<
MY'96MU-FF+.K;<>]JQ<M3JM*B[ASWX>(N/YZR\!)XOR7L9P8U5$<C4>B.2TO
M\'^DY?$D?C9]J%'%XVFB9;,-XJEA;7CN+C7@Y!%D6E9W=#--PYVHY8ED6-RL
M7F$?IHZ>KEQ1R326ZF9)<9]2,^?RGR+&;NM\3]N$[=E1$U)3*)1NT)F()J7W
M&Q3KT;6Y&(BDM,:'9";'=>;=IV9O)QVJ%UEAJ6<97BJT9?%ZJ\1!"U[8F<!8
M5CE5B2/V?,R1^Z[JY51%2ODTAIZ7'9K$R47NQ^H;UC(YBNM_(_\ Q=RT^*2Q
M-QJ6^/KI*Z")5BJRP0HC."V-&JY%P#^BSIS.7)$(IDW%'2?*8W-BI. Y(Y-@
M).,Y49C7(8NZUL^(N 9-5EYV*>="M*JVY%#VM#FW[$Q)EH:(1ZMU%EV\!%L1
MR-927'<":G2E8^CPTD;7F9)7<V>.)Z(Z#CD>Z#;:%6-546FDT+IAZRN2C/#)
M+EVYY9:V4RM:6++I$L+[U:2&ZQU2:Q$Y66UJK"VYOPK397HCDY8JW#/'-*OE
MMY+K,&5%W*]0=2KMNDDV&RDBSL=10'(JJN'0ALN3!+E8F,<5'-3J8U,V^%_P
MY4@^VI:54,^0MV:T%.:5KZ]:6Q+ SBH6NB?:>DDZ-D;&V5&2/3AK%PUC1W.U
MB*7>I@\90R-S*U*[X;V0KTJMV5+-I[+,6/C6&FLD$D[ZZS01*L3;"1)8='^0
M^5R<QRAE$7<8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# .(+EQ&+;]/NZL,G 'ER9CY!\$TT$ZF)-A).$=C14-K2ELU#
MIX=G;FRMFEJN%?K4N0T0#78.'CA"IO\ -S^CU>KZOTHB^@E.3N$B;C(34M%S
MD@+)V)0S""M/M#N5E\:DV^EQLH,3W#CYL17&[A-6:,JS#8CA%T/5*/S+8"R
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M=;:3I;KB&D;6VWI3BTH3MQYQ+32-*5O6N[==6AIM/;W2W%I0G6U*UK8'?@#
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MW1\^WL!Z 6#%6"G5G0'?FS]R;\K*2MZK[4,.%%E,2'?W$(*23ID=\-_TIO\
MJ^\RE<G<?H=TRNVPJ%JT4I'=E:0AU ,L' G.,.*UIM]H*;/%B3'65K;%D5K#
M?6V0P^VT&Z?'QS_/ZC>0=HKMF\8_:_-1TQXI+;!DM $MD;#*?"%DQD/:1O>T
MI+C3@I$)[7:R: 6,:*X\,^TZH2?+Q]D)_P";;E7];AOJ*.SI?P<?P2QW]+>_
MOLY^?_AW_C-SO]7P_P#A%(]+,SDT^, 8 P!@# & , 8 P!@# & , 8 P!@#
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M/_A%(]+,SDT^, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@'[C?8;_Q+J&_6
MN+/W/(6:5\+W_/I__MRGZ\>=9_\ #!_T];?]^G?_ &YP_76Q<>Q=B:D$*E;#
M#O2DY%SQID)(M"EO$0T</'QP6W"1#$)BQE"LR38"6]-(E]+DD;20ZXI6F3JS
M;??Y_CF^/.>!7%]6=LH-N*1('3P#@SK)IQRRMK7&+NNZ_LA#J-I?U6F.0[:)
M#)<[4H9DF7#M'%Q402 &WY^??\_^G^OGYSCN[]+O$W(981MF G"'@1N\M;%L
M,B#MUYQ+23) MP9Q#Y<A(['8>/??=6D@M+Q_>TG'2))@;)Z4W^GG^/CYSV(P
M2, 8 P!@# & , 8 P!@# & , 8 P!@# /7LGIZX,O\G.6B[<2T&U6(Z?FFC)
MN=K,7)29384D2((A\LD=QYQ(XK+0[.E*WIMIM"$]B4ZUEWJ9_-T(&5J65OU:
M\:N5D,%F6.-JO<KWJUC7(B*YSE<NR<ZJJF,9+16D<S<DR&5TWALC>F2-LMNY
M0KSV)&Q1MBC1\LC%<Y&1L:QJ*O,UJ(G,AX_)(Z8/,'Q3ZE0G\IE3RKU+T[E/
M;)OQE!\FV@.IVG>RJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJ
MG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=CR2.F#S!\4^I4)_
M*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\F
MV@.IVG>RJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=FCL/2=
MTS#QS3C'!'%C+FYFN,[6W3(5*MM$V&+'?;WO0FM]P\PZXRXG\"FUJ3OMUO>L
M<J]2].Y3VR;\8^3;0'4[3O953NS>>21TP>8/BGU*A/Y3'*O4O3N4]LF_&/DV
MT!U.T[V54[L>21TP>8/BGU*A/Y3'*O4O3N4]LF_&/DVT!U.T[V54[L>21TP>
M8/BGU*A/Y3'*O4O3N4]LF_&/DVT!U.T[V54[L>21TP>8/BGU*A/Y3'*O4O3N
M4]LF_&/DVT!U.T[V54[L>21TP>8/BGU*A/Y3'*O4O3N4]LF_&/DVT!U.T[V5
M4[L>21TP>8/BGU*A/Y3'*O4O3N4]LF_&/DVT!U.T[V54[L>21TP>8/BGU*A/
MY3'*O4O3N4]LF_&/DVT!U.T[V54[LT<5TG=,SLC96W.".+%MC2XK(Z%4R%4E
MEI5?A2%-MZV)V(0I]]YW:==FMN.+5O[ZMXY5ZEZ=RGMDWXQ\FV@.IVG>RJG=
MF\\DCI@\P?%/J5"?RF.5>I>G<I[9-^,?)MH#J=IWLJIW8\DCI@\P?%/J5"?R
MF.5>I>G<I[9-^,?)MH#J=IWLJIW8\DCI@\P?%/J5"?RF.5>I>G<I[9-^,?)M
MH#J=IWLJIW8\DCI@\P?%/J5"?RF.5>I>G<I[9-^,?)MH#J=IWLJIW8\DCI@\
MP?%/J5"?RF.5>I>G<I[9-^,?)MH#J=IWLJIW8\DCI@\P?%/J5"?RF.5>I>G<
MI[9-^,?)MH#J=IWLJIW9HK/TG],PM;GB1^".+&"!X>1>8>;ID*AQIUL1U;;B
M%:$UM*T*UI2=Z^_K>M;QRKU+T[E/;)OQCY-M =3M.]E5.[-[Y)'3!Y@^*?4J
M$_E,<J]2].Y3VR;\8^3;0'4[3O953NQY)'3!Y@^*?4J$_E,<J]2].Y3VR;\8
M^3;0'4[3O953NQY)'3!Y@^*?4J$_E,<J]2].Y3VR;\8^3;0'4[3O953NQY)'
M3!Y@^*?4J$_E,<J]2].Y3VR;\8^3;0'4[3O953NQY)'3!Y@^*?4J$_E,<J]2
M].Y3VR;\8^3;0'4[3O953NQY)'3!Y@^*?4J$_E,<J]2].Y3VR;\8^3;0'4[3
MO953NQY)'3!Y@^*?4J$_E,<J]2].Y3VR;\8^3;0'4[3O953NS1L])W3,JRR(
MV^".+-CMP<,^VSNF0O>T//'SK;KJ4>"=SI;B!V4+5K7:I+2-;WV)UCE7J7IW
M*>V3?C'R;: ZG:=[*J=V;SR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>
MRJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=CR2.F#S!\4^I4
M)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ
M\FV@.IVG>RJG=CR2.F#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=CR2.
MF#S!\4^I4)_*8Y5ZEZ=RGMDWXQ\FV@.IVG>RJG=G3?21TP]F_P#N#XI_!O\
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M^.Q*6UB6TE"K%6\86#C.)XWBFMX?%<=+P.%OP>,?MMPE.0\MY>Q@# & , 8
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M]X78?8A(IIYEWE"DMNLNM@L(<:=;7-Z6VXVO6TK0K6E)5K:5:UO6]8Y-ZBZ
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M/].9CM.[WXY#Z+ZH:7[ Q/NAHZOT]\!/UFO/O\'\0///0<4Z\\[QI2W'777
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M52@\*&_Q#'^LW_NQLOJ7ZE(XR/\ E&?VF_>/"AO\0Q_K-_[L;+ZE^I1QD?\
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M<M+Q)*JE+T>48C=1:A9>M3)8!I A#9\::L4D=T%;89D>X(MD>1D4.(>=4"\
M'Y_7\?3_ *G%4OTM5.6)E2=W.^@^.94N7.8">J&F'"";GRQ?$-Z253RE=Y$G
M^8+"H;3BG'-"Q=?0ZXZ4(<7(AM^;Z-OS^CT_5Z?/SDE"]*R$EU4FQ20C_9Q]
M+42\ZC7F$[-C]3$)*UX&#TY6A])'96--:D)M_85G1LT%(DDO0 RAA"MWVY_0
MJ+S>??\ 5\^W/Z-SD$'IGH X\#'G&3\[#P=7@ZJJ(EWXI0<L+7ZC?*,*7([
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MU66 @'CCB)C<1(2+!LH8<L60%#;XYO6B^KYOI]/GV-?#=+5+A6HUA%FNI[(
ML0 XU(%U[:#0(6'X:B!!WD@UL'3+O<\%4DO9X?@\@T2]/;%*'0<$B,#;YU_1
M\WS?-\<QR7Q9Q5"<2PA$# RDW*!D(K"-KG%Q3A#>JI0JEQV IM43$Q+7=$PE
M-BB3MK97WR4=.?'T,*\R&.")M\?,B?Y'S4?9"?\ FVY5_6X;ZBCLZ7\''\$L
M=_2WO[[.< >'?^,W._U?#_X12/2S,Y-/C & , 8 P!@# & , 8 P!@# & ,
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M , Q#_Q$W]4)_<KP##K_ ,0PGHB-^A,X!M\ 8 P!@# & , 8 P!@# & , 8
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MWM_62< H< 8 P!@# & 8A_XB;^J$_N5X!AU_XAA/1$;]"9P#;X P!@# & ,
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M;\72;+C3>W%+CRB=,H4UM_O>GF>[#?X^GS&R2I*NWN5)5W*MI5W.];[E2?\
MQ)WV;WV*U_YZW]_7_GK /F'Z];W>(/JIY1C86Y6N'CF38I3($78I>/":4]#
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MH([^REM3L*Z0(A"B8]J5CW)!H5!;*E@6^ , 8!/0WQI;/38?\,P& 4. , 8
MP!@# )VW_)6R>@Y3Z$]@%%@# & , 8 P!@$\Q\JY3YO0/UE8\ H< 8 P!@#
M& =%?@W^C?[, GZC\E:UZ A_J\? *' & , 8 P!@$]^5>OF]OZR3@%#@# &
M, 8 P#$/_$3?U0G]RO ,.O\ Q#">B(WZ$S@&WP!@# & , 8 P!@# & , 8 P
M!@'3?;V;[G>M*[-]F]ZWO6M]GWM[UK:=[UK?X=:5K>]?>[=?AP#U53TM0QP_
M&K%HGQK*WQ;$"URO"%U<3441 .VFIVJRL2T<7)2*3I&QDT:K K,6^D*-  (;
M$B5.21KC@^4:FVWG1/-O\?3ZN9=E(M_I@LD$;2A*_)5:R0D6;";E/MEAI 9
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M.A)Y< 8!/0WQI;/38?\ #,!@%#@# & , 8 P"=M_R5LGH.4^A/8!18 P!@#
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M"-TC & , 8 P">AOC2V>FP_X9@, H< 8 P!@# & 3MO^2MD]!RGT)[ *+ &
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MT:2%+CR&"$M/LG!FB.-I(#);: W. , 8 P!@# )Z&^-+9Z;#_AF P"AP!@#
M& , 8!.V_P"2MD]!RGT)[ *+ & , 8 P!@# )YCY5RGS>@?K*QX!0X P!@#
M& , Z*_!O]&_V8!/U'Y*UKT!#_5X^ 4. , 8 P!@# )[\J]?-[?UDG *' &
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M9/KHW *+ & , 8 P!@$]9_BMGT[5?XHA\ H< 8 P!@# & , GH;XTMGIL/\
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M 3.F0VB9":)D0V_-]'QM^CTJOG4YOP2, GK/\5L^G:K_ !1#X!0X P!@# &
M, 8!/0WQI;/38?\ #,!@%#@# & , 8 P"=M_R5LGH.4^A/8!18 P!@# & ,
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M , 8 P!@# )VW_)6R>@Y3Z$]@%%@# & , 8 P!@$\Q\JY3YO0/UE8\ H< 8
MP!@# & =%?@W^C?[, GZC\E:UZ A_J\? *' & , 8 P!@$]^5>OF]OZR3@%#
M@# & , 8 P#$/_$3?U0G]RO ,.O_ !#">B(WZ$S@&WP!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & 3M:_%)'YQ63ZZ-P"BP!@# & , 8!/6?XK9].U7
M^*(? *' & , 8 P!@# )Z&^-+9Z;#_AF P"AP!@# & , 8!.V_Y*V3T'*?0G
ML HL 8 P!@# & , GF/E7*?-Z!^LK'@%#@# & , 8 P#HK\&_P!&_P!F 3]1
M^2M:] 0_U>/@%#@# & , 8 P">_*O7S>W]9)P"AP!@# & , 8!B'_B)OZH3^
MY7@&'7_B&$]$1OT)G -O@# & , 8 P!@# & , 8!.$VVN"6<*FDRPK-FD*_+
M6D6)7M>GUP$(=%1TE)K<[CO###!DR RG3[K;I'=D+&;>;"-6.'Q\?6=7[=6!
MQ5&*GHIYK3<@XVD0X<T@K<6T6](,@BB./$G$BH -[Z*(T\2E0A".]=VTM*0/
M!"72N3X0L@#(M(%/2*N/6=O0"ST%P8%B;4(R5MIU_O<5(L/$)0CNQE();>2A
M0[O<@B[^8(NU4?E!X82>BY"3?0&_L./.%-?&#D!9LH"0+;'=<4-'FHKLPV,8
MYK3#SX3K2%[4G?8!M&)V$*=%8%F8HE\YKOX3+$B(\Z8SV$[[\*VV\I9#78&7
MOOC6EH[!2=]O_8.]R!(B<ITHY<CX-*/*&B967A9"4>CI$2$&D*],24!86539
M@P\4KQ%,0\F%+Z06I8'@OA3Z$ D!E$"-_P#7X^[S>DH-6ZM.0YDZ+,@GQ8$*
MW8B7XQ[4FXB%?!=DA9! H'A!3K)H3+I />F5K-0C>A4NJ^]@D\43=JG.!Q1T
M=/QBVYH*+D(Y@@EL&0>&FAD&1?=QANQY$9\P=Q"VA"162NWND*92XA:4@>*+
MO=/F&5NAV.'[XRH%HP-^1#'/CBI&$"L8@,B&Z\E\,YR#D0I3P1]*7M!$-D=S
MWI6EX!YH>YU>?%9.B9N-,CRR QHV0:,'4#,+D(B/G0UPQ6G=LR;1$;)#/-K$
M4[I6^^IUK>VE]@&Z!DHZ4941&'A2+"5]Z4^"4P6RESO;;W>U.#N.(TOO+S3O
M<;5I7>W6U]G<K3O8'R[?9 I64%ZL>4V1I(\=E!<1M++!A#+2=JA(]2MI;;<2
MA/=*WM2NS6NU6][W]_>\Z3\'443M)X]SHXW.66]NKF-55VNSHFZJBJNR<WT'
M GAUGG9X2\XUDTK&I7P^S6R/:U-\125=D1R(FZJJKS>=54]T?L/AYQLUSWHP
MTLO3<7QUMO1)+S^F]J+N?=;1IU:^YVKN4]UW/9V]FNWM[-9BWA;C8R'!<!C&
M;RY#?@M1N^S*>V^R)OL;(_X9999+.LN,DDDV@P6W#>Y^V\F6WVX2KMOLF^WG
MV0_<%+S*G'&4NMJ>92VIUI*T[<:2[W?>E.(UO:D)<[VOO>U:UI?<+[G>^YWV
M:5.LS"'F(DOO7@LI'$]^'?+9\'-&>[Z**]H<DEKO;JN^#CD*2P^\GM;9>5II
MQ25[TG -@E25I2M"M*2K6E)4G>E)4E6NW2D[UVZWK>MZWK>M[UO6^W6 =< 8
M!/6?XK9].U7^*(? *' & , 8 P!@# )Z&^-+9Z;#_AF P"AP!@# & , 8!.V
M_P"2MD]!RGT)[ *+ & , 8 P!@# )YCY5RGS>@?K*QX!0X P!@# & , Z*_!
MO]&_V8!/U'Y*UKT!#_5X^ 4. , 8 P!@# )[\J]?-[?UDG *' & , 8 P!@&
M(?\ B)OZH3^Y7@&'7_B&$]$1OT)G -O@# & , 8 P!@# & , 8!P=>^&&;=*
MKM;<T6S:P3RBH1UUXE$6F((I<S3WZ<>%WTL-V#D4S\O)E&;C2) 63D%GB(VX
M(&VT'Q\?ZG#==Z2V!)$)^8(@&QRJQ1R+ 1""Z;-:O])U2V8]VM-N18R(RN*8
MHD,N5>V4DZPNDSC)$;&,2RM"CYX/HYMMN?\ 1Z]]DV3U_IYRS:Z8(=A,JVS<
M9AMJ<@G8*3'=@JI)B*0FDT>FQLH&'/1$N,#,QVZ''R^BVFE-'$R$B.>,0RU$
M;BA.WH]&VWYMD3_(PBND^NG#R(QEUMCJ99%D2<^E,6DU*K0YSVN0("-<#>)8
M+93U!VE(;Y;A^^[BH5PU)W8>DP-OG7]'S_-\;?3O50O3U!PU\&Y$;FB79U,X
M-8SD:CA&@R91&N8-&>"-Z6MZ-".^&:P+>%:?=4I^,BBGWR2G)9^2#;]>_I^/
M\E/#+].-<FK+-V<B7*".GY9B2E]0\;'129G8Q,NL(B?:&1H&9L$1%2OVL0UH
M>!:F&*T&-&R3TLO6R<!4W]/QZ/J7S;\WK15YS:4[@F,J 5I$;L!<L[9*ZNO(
MDI&$KB9>+&+C!PY%MJ8"C19<Z->.'\:A1$@>^)%NO.AC[4$S',@!MS*F_G3]
M?G^_Z=_S2@?2[70Y&+E$SY+AD497367'(:._[5ZMD< DB;=VE6G-Z(7T]5I)
M6T.)6I$]8]-+:VY';CQ.QX8OI9A8D>MA"W:RH!KIM!/T*@*!1X<1Q\#PO'QG
M?B/%ZBFV#!N#:ML\)+R@'"3Y8O0FB&H)R%$;;[;JO-]'W?G^GZ$.^$Z6*W"L
MQHWVTSQPX0\*"^T2/'-I-#@X;A&+#4KP1D?P630[P)3BVI47O9 _C&QMLH2^
M3#F0@;?/O\)ZMN?U+Z/S')W$7$\7Q! $UZ(D7Y$,C57[%D""B.(55N/Z?QV.
MYM(FDM+<-BZ7&GF+[VGNI(DY;>D#+8''$I\?Z>H^;'[(3_S;<J_K<-]11V=+
M^#C^"6._I;W]]G/S_P##O_&;G?ZOA_\ "*1[J_8<OCKG[T7QQ]+NF8KX7?\
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M & , Q#_ ,1-_5"?W*\ PZ_\0PGHB-^A,X!M\ 8 P!@# & , 8 P!@# & ,
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MP2QW]+>_OLY^?_AW_C-SO]7P_P#A%(_4_P"Q$_\ +U??_C--?P10<UQX6/\
M]_H_^'A_OM\WS_PU_P "<Q_]4V_\)PQ[S6'B$ZP0W)L"]90FX[DNV)LIS:J^
M4M0@HM:J$('!/[18VD28!)508<L'=H#3,PDG(0;+,8XI$KFKSH94WYE7ZN9?
MF]?QZC2.\"K%AWVH"SJB;/X:5)"VG0)#Q[;QUL'EW(U3JY+9J(F-J ,?QS I
M;.\, KT?#/E$2)M9K2HL-OK^-_3Z?N]2'L""R0.$&.46L\I@4=DDYQIIA9I#
M32$/%K88TEEE9+B5/*:93IIO:]H;UI&M:P296 , GK/\5L^G:K_%$/@%#@#
M& , 8 P!@$]#?&EL]-A_PS 8!0X P!@# & , G;?\E;)Z#E/H3V 46 , 8 P
M!@# & 3S'RKE/F] _65CP"AP!@# & , 8!T5^#?Z-_LP"?J/R5K7H"'^KQ\
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M!6JL2+BZL:HU8W.1ZO57JBHUO/66(S$8 P!@# )ZS_%;/IVJ_P 40^ 4. ,
M8 P!@# & 3T-\:6STV'_  S 8!0X P!@# & , G;?\E;)Z#E/H3V 46 , 8
MP!@# & 3S'RKE/F] _65CP"AP!@# & , 8!T5^#?Z-_LP"?J/R5K7H"'^KQ\
M H< 8 P!@# & 3WY5Z^;V_K). 4. , 8 P!@# ,0_P#$3?U0G]RO ,.O_$,)
/Z(C?H3. ;? & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g418853g00a18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g00a18.jpg
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MV<#&>[!SZQ5.PO[J\TA=080)-)%-*J".0QKRFE4*V9MS;M@)(9<9/0U9(%V
MK^,12NTKPN*EH=8TP@X^8KAGLI"U^F^;+B?BQ-['XW+Y>3.J!12.CK5P_P!W
M[Y/5)DX=N%6VNJB2,9C8LVQ'90Q4'!;TX )  R?5]-74NX8XX?&KFVCFDB64
MJ9$AR"NYBB22LVU>N3N(P"21Z)$A-NU39</7L.NK,@$\@+;)##J;0^81^21-
MKL(2]L5U=2$.0>"6VPQ'T+$=5G:>S)+.%'.$M,XSS5D=6VLK*W]%E(;KW="
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MRRI"8BJOE3^QZS0CIY>9+B#<;E\2L4JQ:2$:/BFB9<8L;DS=1<CHNML$<MW
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MN-Y"W(MC4KB@PRX6U!;2@L%U+&\-$%MGIT ^':-/?4&^$6Y!NM=B F07"EU
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M)&G+3=$\I#(DJ'<M=]Y>^BZ.S@$*%O&Y/V.[5TR]BGJFOI" QLT'<?& <MW
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M,7<E[(-ZQRRH%=(GD,A0D,VYB2JELJ"D<:JB[3FTO(JOTXI7DZ?\*6L)4SM
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MI#^!3SRE7RV/_P"&(_NG'\8WC3Y)X7_5-6_?-/R:L?A;OVD/X%//*5?+8_\
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MK9PCA(DOG3&?NV5SNS3QMMC^_.NN,XUSG_LXWW]'_:SS\I?PE;B7G\)6F\B
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M[7V.GCKA84GG2WE:>!)I%@F>/E/-"KL(Y6BWORVD0*[1[WV$E=[8R;0S@;@
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M2G%*<4JMM\_]]C?_ *4C_P"\TY^2_P"$K_TAPG_4]6_X]C7K^&/Y.\_[</\
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M>2$-<7EW%"DKFV@AD6%XM?%B5B225I(X6C==RKS'>(@H9''1@" 2%1"V.TS
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MRIKC&RNJ6V<XY^*N-? 7Q+I6HW$_#%HVMZ+-*\EM'#-$+^R1V++;7$$TD;W
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MRRW_ '+CR)QU\^K+_"%K^]Z<^P^(/^N/^%3X3+OQ>U_RRW_<N/(G'7SZLO\
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M67^$+7][TY]A\0?]<?\ "I\)EWXO:_Y9;_N7'D3CKY]67^$+7][TY]A\0?\
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MA!\*?'6GZK=\+ZSIO#R-I.L:;J,$]O9ZE'XTNF7]MJNFW"F35I5-M=B"!ID
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M/0Y)SW"!D_M.%\5^OJ]BETU4RL")^&:SB!U4]#%C0R2NF%]H;ZCVL)8VJ!D
M [EJW9R)%KK,"ZB8M%[A9@X;/6Y ?VCXM+X,KZ_N=)U)[&Y\(;74 AO%ADMU
M?1&&][Q],G@GAW,T!;Q2(&4IM=61HWA&1J*1K+&'6P"ME-P;$WH42*0>F[&\
M]G.<C!%D95X>C0E4L*B42MEU&+8BO;IGW>*VV2@[*2L9C>RQ\Z8D;DY7Z<A
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MMNO-G#-;QD.QF<S#4683Q41R;5M7=\,FYI&D#!RQ#( 6WNQPN-QR!@;3E/\
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M'AEU&6,'M);6<3R&.1L;=]Z8%CSS!'/MY;4+O7[.%"+=O&9<$*%#+&I]!=V
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MK*GD'3/@&]M-]^MQCEW/TUTT),S0<M-]L:[/F">472&,YQC*BC?U]D7&FO\
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MT<<TZ'!+A88WY*V$TJ3" 6?(=D696AES$=SJF'V/LVY ()"GK@5-5NQFA(X
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MQF#5(F :22YNE2,+EY&9$"!!C+$/@Y&>6>TQ4#-=N>_:>#!K<ZO3B*3.*V>
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MC'J37=TLBQR%$@ADE;ER!8R8W"U/'K;#G>X6-S%(YAG")(" 5=S$$0@D9+,
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MS)L3)CDF"E&4HH5U0A6["MTS@$@C?:V$SXEXJ?;QKBZ;%P) =<.MA0%%WK:
MDHH/1DQF[=-8^F/6A*95M'A)1K@\AD,=#R8L2<.-9)*#3+5DU94]1EL8_!KP
MJWDBPYL^O\11372-?1W3FVBT4\\N+PQ-/+&_(;G02V\4:J;>VA?>S[1ASJ%S
M[J^!! 0I"%1N:;LXV9V@]1A@Q/OF88 A(=V"[E2GPUYOV5C-K$RMR4A=%\D9
M:B#@-7IZV33=,7[+(S*XNR"E(89'A3@ZJ(X1>Q8@*0P07.C6R)E0WN^55YV)
M-"X3MO"%9\/7&F)%I.L:3HD=J9K[4F.GZMK&A6ES:W+S1W<4DT+ZI<1I<QR-
MRU@D8Q"$(!41FNFL6G60F6&28MMCC',BBG=64 HP#")3M(!8D '<3FK3VIVT
M>1RO;Q[55Q+7TXH^BNJ;6QQT9091?[/6=9DQAREG11)\<UCF):%T#P%Y 3);
M02:0%NF%H#'6H]-<"Z;/?-:9PNMQ?Z-PS?VJV>LZUQ,=/DN&>X\8T[3K6[&F
MW+)#S_%9C+?)?11F2(R*^FR)O(G5DL27!6.:XC;?%%;<P# VR2,AD7)V[QA#
M&20=I$@.,J:[M;O>Z>EXTL<6)R.8=>YE#I,A=R=J?Z.87:-R?< V-UY+J&TI
M=T]DA ,:,:/@9^-3PW)-F$;7$E6!<B50*/5M+].$3HVKPB.WM-=M+JV;1CIA
MU^;QBVY[0W]KK9U=$MTEAB,<T%Q906V^X66.2)(C%&N8_&N=$<LT#(_-Y@@&
M&V@QM#RLL06[++(QPI!&6R:D#M5>TF@UE]4.O4$+XB<P[5VC*XOM/LCQ91Q"
M8-6%>';,G+^/L#K,F <S,TV$BXI%LGQ)<,P='G!EZ(+?"DA;RCPUHMO>Z=Q-
MKM[%XU:<,Z;:W/B/,DC6\O-1OX-.LHYWA>.=;2)I9;JYY$L4SK L*2Q<TRIM
M<3,LEO C;&N)'7?@$HD<;2.5# C><!5W*RC=D@X -)JQ'61 >Y_BU*,+5*2"
M8!>N74J10Z=RR+0]T8$:LH?V *CV9<1&0T3BIS88];O&[)SJ"'95&[L$RR15
M^U>$"7L-2DT^]X1\%X?3(X+677^*8+NRM;F[6*7?=Z%&[Q2W,MU<P\Q&0NO.
MDQ()#$8D9(XZT8D2YU$\PLP@MF1V5<@!;@@$*J*<$''0=,9R<DR!7%_7C8/7
M;PYID>NAO'B=ZT]K+K=2A43CYCL+;$S=5>",@F-00A2NI?!&$<:R H2/6F?(
M (\#AXAO']MCH(6^?[[4+_0]&L->X^M(=(>>/1=6:TTHWEU/%H6F6::G/#,^
MK7HO[6]>X:"*.#38(YYYKN5I_<9I43&Z32O#8L90IFB#2[5!GE<Q*1RDY;(%
M#$M(Q550;>H!J,(AW:["+](:2LV5E_<9&<[MN>LEY74YC<0:NJPJ$+?$\KHG
M;A\2P:$JQ!G\,(W%XF9.*#'M=@Y#*59-@4J(:HL>=*ZX/T(<8ZSIUM%OMX.#
MTXBT;2%N+IUU'5)M#L=0CTJ"5WCU&>#F7-S<PPB5+^:WMA;\T3,7J-;J;Q2&
M1CAFNC!-*0@Y<0GDC,C  QJV%52Q!C5FW8V]*VA6[>TVBOB<O8I>VLGK'J_6
M*9N@[)?US7!Y$Q.W-/$;.ET:?R&-B@$:D[RJS(M@ >)("=\)#9>Q92/5U(P[
METZK#1^&BO@Z2YT;Q?4>(]1,.N:?'?W\+162ZM'IUK<)!<2SW%LFIPRR3H3*
M,R6CO;E+>941SK@>4")=T=O'NAD,<9#/R3(R[E"JQC8 $8[F 8[@:5?>/: '
M9?A=&IY>6]B13NW5IUK9=>+US7\; 1N2ANL^MT@IG#BX(&VF:9UX5$/1\O;%
MY,1BI3)=R\C<5B#5 >(98U'1N')M/\(\5EHPL+G@_4H'TZ_&H7UQ//;3<1>1
MYK2[BFF:S:%8IDDM6BMHKF+E*EQ=7;,\KYBEN-^GL\V];J(B2,QQJ XMS,KH
M54."2I#@L4.[*HF M8E3M/V'L_H?;OB&U=9V\97K\U>D]A]#D8I!"%<$JEZ^
MV++8J0A]@/7D77LW,OFT/@9:2O#\=L"/:A9";$MQ0O4,P=,2TXX:T'3N-=*X
M#U+3A<+?1:+8W>MQW5ZFH1ZIKVGVMU'=V*+<KIPM;.[OHK=(+BPN#-;PRM+)
MSI%>''C$TEG)>QR;=AF=82B&,QP2.I60[>9N=$+%ED4*S# P"#]O+O),HW)1
MI6>S:S^IM.732E0RGK/>J=>0N:4.TL>=@7I@S$>QDJ+P*:F((:T,$X\'9:J*
M1< K&6Q PD18D$U'FV-&X-M+BWDCL;/3N*-6TC6-5MN(M%\?O+36WT^RF2**
MZT"UBO;.*^A,,<\SX%S<"Y:.(QO&0@2W;!@7>2VBEBC:WFV(T.]U+%;AF1RC
M;BJ_S5VY8D>^JT#BXKJ;^(A+Z0%RH7(:S4Z+*7E"8*L#"#&J-EJ6_F#LG#^7
MHH+GWHYV/'Z)^KL01'-]2KUQABHHDS50\V-*TAN [76)+:2#41QEY'N[T332
M,=/&E"\94M2RP(Z/(3G89&Y2+O +AK'-E\=:(,#&;3FJF /=.;LR7P6P1]..
MI."0*B?H_P!K)%<5IC*WM2TK+A=_1*G#2]\=2KPK>$P20#["W.0/1E9E,&8S
M!@F)C4+++:?"&#QK-9CJ["GH:4)IMR&%R#[J<8\,V^DZ;)J&FZ=IUWH=UJT*
MZ)Q/HVH7E[!)8B&]+Z=J\-Q>S>*:JX:QF=&L[0I-!=Q1%H]J)%:7+32!)))$
MF2(\ZVEC1&#[DQ)$51=\?OP#O;*E"0#U-@^R-[2B.]B^H?5F&G5X24[+/[I/
M'K 9#@A4X!AE%P1G*"06),Y0,-1O$EE9P_'6>Q(P#/-A488R91$5J6<B"8[A
M\/Z+;7&@\5<27<(O(^'DTB"&P>2:*&>[UJ]>VCFNGMI(;CQ>UA@G?EPS0/+<
MO; R\I98Y)IYF6>VMU)0W!E)D !*K"@8A0RLNYBR]2" H;IDJ17'6U;G(S3Q
M ^G,^LR2%EZCIB,W'5%X" %=BI\0KVR8O*MB$(G#!*$+5XH6!2**E C$^'A0
ME^:B9#+K&@N1CM32W>.F:3'9\#<66.GV\0U35KK2M3T:6>_DL4O].N+41WEG
M(;P7XBGM[J*9X);R1(;N/:#);R<E8>9*6O;9W8\N)98I0J!]DBME'&SEY5E*
M@J@+(2>C#-39X6P(H'Z!=27!"9R25(F>N]-DAS \UA[9I$V:L""YT  -XO%(
MV^<B6_IQ[%:4O9*=V]77W@TOG.V=N1X2)HY>..*5CM+>V,6OZO'(\#7;-=.+
M^?,\XN;FX196_G"V2W@_HPK4NG@BSMLLS9AC(#;>R-HPHVJIP/1N+'Z:A%&'
MRA?QDI*JE;M@M6Z/0:"RO4:F-JU4?N(4[.3M+>O%,.*V6?XAJFS/*RKYN_;V
M+ONZ7T^WVJ*3!)EV3=6R^":W!TNQ9CQQ>VO,,FI"02CARR(OQMU )XV-^ C(
MU@ JDV)8N7AVMY4;W1P/$T;&(\8\8D['6/.WIWYW]??]V*D=E[9MRU?#B\3%
ME:4Q:3,Q4G>]G2\*)ZQH-&FK&#PF\NLRL:&+#@*#;WK+=R7(.G;YZY>E':SM
M;&[_ -@FT0;>GX>TS2]-X^\'CZ;:-:1:IP4^KWD?C$MPSWEWH_$0N)!).6V[
MEAC5$14B0(,1[BQ:O<22R6-^)&#&*[Y2$*% 198"H( ZD;CDG)/KQ@"YZ\T[
M;4;W7IBDI]?K"Z*S[@06\-HNX<U+#(:4H*S:=C0R9*.HXG&O9+22O#@8KN.8
M!YT3DY]@3:,\OY8^RHMDMY(6?"^L\'ZOK%CHDFD:CPK>Z-XR%U2[O(]<T[5K
MB6T"SFXRMO?P31"1YK**V@DB=]EJF%Y5HO<0W<43S"6.Z2;;[FB&&2)0^5V]
M6C8' #EV! R_7K4^ONW/;F#^'BU\0FT;Z$6"Y>0R3U^-IIS4<+ 0S:SY5V<T
MJ"N;4/RZ/:B)1HSB2#C?$AB8]8:",1O5HT14:R5@YDQ_TU_PMPM><>-P)INB
MRV"K>6U[)JZZI>3W8TVUX<;5=0TR"UN.;;;[IES;W4BR30W.YB'MI%MH(([F
MY6R%Y),K]ADY7*15,C7'*CD+C#X0'M("%*_]<;FNQ9=EWMUL[-=3:^*6R;N*
ML^U+^P*D.;36(5VPD-;6E&X(]G$/G40WKN)09,A&#>H@R,ED5DWQ?X<@B/)B
M#;;9-ZV>>0T_3]%X@X=XGOH],ATG4>&H['5(/$[J_>WU#3;B^2RN[.[%_=7I
MCN83-#):W-ORN83)'+"V49++R307%LAE,L=P7C.Y(PT;JA=73EHF5;!#!]V!
M@@]"*HVIV<[IL.C;CN&KV.1?2>J^V1FL2D WJ.LVT'M""Y[C:=?\BYHJD"WE
M8QT/ E6;@(0@,BASENB-V3-J2$J\R;;^Q7AWA"3C,<*#0&2VU/AB'48K[RIJ
M+7FFWOY(^7N99@SBVD22>-UFCOK>[5FDS +>).2U4SW8M/&C."T=P8S'RHPD
MB>-\C#G;O! (VLC(<+AMQ)-76C4J[&@>\4ZZJ27L2;F$<L;IT3O^(2I2MZJ!
MFJ;GX>VAM;O&,(9C8IE@;A;II(V9)D&LO$\-LUA&B#J4$LNW;E;R5Q:Z#-P9
M9<36^@PVMQI_%D>A75L-0U*:'5[&72Y-01[UI+G?#=JUN\;S:<;&%Q,2MM'L
M15LJ\PO'MVF++):F9&V1@Q.)1&0F%P5PX($G,(V]6.3F/Z [&WS9M/Q.C9?9
MY03W4C':DU1%YGAL7KA/(@)6I5U8TTFHB,.H0O'D(#.J';!TH!(%8XKEO,[!
MB+=P3)[).4WEW7-!T33M6N=9M=-CEX0N>&H=:T6"2YOSS9M0B73[2SEN5O%G
M:]LM;:8W\ N!NM+"[*QQ@H4TAGFDB6%Y"+M;@PS,%086-B[.%*;0CP8V-LQO
M=>I].G]F^T'8BH$K6L$!<*4I<5QV]I> -X%6\.B)VEHQ2TVF=301S"[KFLL@
MHV4)WH94FALV<!5I894K$57\'<JA <9=D'#NUP[PYH.JG3+&?2C;+?\ "NL7
MS7VH7=U#J]SJ]E9ZK>K=Z/9VM[):G1HA9PPP3:CI\<5T([U1--<I&J:W%Q-$
M)9!(&Y=S$FR-%:)86:)2DKN@83'<Q812%EW)T5229[QONGXPIK=)+*ZNGAFA
M-TT<;:Z96WU[0R7.B6-]\XTTRIMC&F-M\XUUSGT[9QC&><4@'P50@G /A#G!
M/4X'Y.6V3@=3COZ=:E__ .F?Z@/_ !#54N)]L.T]H5STPE41N-03>U]=F)%4
MG8+KNG JW-*4=$6#VQ59J]2BKF.-+&CJU%MH?'FY4O-I(]:'6DCRZ)YV<R")
M8;>GNN&.&]-O^+K:ZTD2Z+HG#UOJFA:\;W4(5UFZD33Q9J;E;AK"X76FNYVC
MBL[=&A>W"Q86"[W5UN;F2.U9),337#130[(SR4!D,AVE1(#"$&XR,<ALGWR5
M:;6];]:=D_$=KC2S:\1"TIUPIJR*-WLL4,B-;5U*IU'KJ>O2MD2@0U5D;Z(M
MR40C[N3DWK]?5B$'NU13 >HHY]X\T=&T1N'^ +\Z=?F;6-?UC3]9&G2R76H7
M]M97&BHD>G6TK"W2[,=W<);1J@WS2()9) %VV.;,)[Y.9'B*"*2'F +'&SK,
M29&':*912Y)Z*#@#KG7>NG86XG_<N"TA(K%FMGUG8'2HG=F)'/J^A<&]]LR&
MV/7\/+R"LT@,(KF78KB2,9J[W;-9Y%4U7.P\47C#U82\76=V->T+24X2O=8M
M["ST[4;#C"+1S;V5]>7FS3KO3[^[B@U$SWE_:'4+>2S0,]C<D+OEAN465%"8
M@FE-RD32-)&]H9=SHJ9D1XU+1[5C;8PD/1T] *G!.?6+GS*NA3BE.*4XI3BE
M.*4XI3BE3Q1"F^"I]+&<^SW'M5-M?[L[I.=]=,_[]=5E,8_^UGGZ5_@V2N-9
MXFA#$1R:992NOH+PW<B1L?I59Y0/^V?77F.)P.1:MCJ)9 #]#("1_:5']U68
MY^NZ\=3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI5.K7!K")>^<YTV
MPT,Y^(M5?1_9WW4QKAXGZ<?=[1-UZ^VVO_:PFJCMM_V\9S^"_#7PY<:%QSJ-
MV8V%CK[>5K.;!V/)*%%_$6][S8KSF.R Y6&>W<@"05] T.Y6XL(TR.9;^XNN
M>H R8VQW[63 ![BRL![TU&G/D==BG%*<4IQ2G%*<4IQ2N%RFHLW711<*-%E4
M54TG2.B*BK93?3;71PDFX26;[J([9PIIHNBJCMMKC55)33.VF<J0&4E0P!!*
MDD!@#DJ2I# $="00>O0@]:557K'U, ]725W$(U9ME3G2_+DF5]35A/L0!1JT
MLB>?"4Y$2C^\0@D1=L!R[8(.:MP[IR_9-$D/71TU7W45W]-Q%Q1/Q)'HT=SI
MVG69T/2;31+.2Q\>#OI]ES3;QSB[OKM'D5II&:55C=BV"=H"BO!;K;F4J\C<
MZ5IG#[,"1\;BNU$(!  P20,=.N:[=G=60$WNZ&=DH?-I74UW0^%E:Q<RZ)MX
MX483BL#!1,\K I[')2&,#S0@5(D\22..V&X<R$-[*KI$EF3AT/7TT[B2>ST>
M[X?NK.UU/1KN\BU);6Z:>-[/4H8C +ZQN+:6*2&:6W/B]PL@FAFA 4QJZK(J
M2W5Y4G5FCE1#'N7:0\9.=CJP((#=I<8(;TX)!Q([J&#B8.)-*WL^QH)*H];L
MUO*23IIB&&#-M6%8PZ0#9PZM8<6B:P T&D"<AW4^#1H9$4X_\#BK6(+QQA&Q
MC1&23BB:ZFNGO].L+VVGTJTT:WLW\<BBTNPL)+>2S73)(KI9X9H#;@<VYDN^
M?SKE[M;B2XD=@ME4*(Y)$82O,SC86D=]V_F@IM8-N[E5=NU0FT* (\DWAYUK
M):SWKC2PK(C&2W9AKVXF<IB:-=L3,RNIE+14T9DW[$K C<=%@&9@$$20"@PP
MY9P.$M4BY(H^7*D25^WXZU&WU#Q\V.GW/+X=?A:TMKHW[PVFCO:RV;Q1O#?0
M7$D[0SS$S3S2!9)7,4<2+%'%HUE&4V;Y%S<"Z9EV!FF#!\D&,J%! P H.% )
M)R3*RO54*EV3)]G0EFV;&I;)ZQB]93J*AG,-UA4Z;05](B4)D!UL0AS^1,R\
M>?2DJX]UC<D! C.NK1@>$DA/Q$<3Y@XEF/#\7#LVGZ=<6MMJ-SJ-E<S+=^.6
M37L=O'>00-'=I;O%<);1#=<6\\T)W/!+'+RY(Y.0.>;@/(&:-8W0%=CA"Q1F
M!4L&4N?>LH/0$$;@V2ZT=8HQUDK$S4X.7S*PXN:F,_FKG:QTX:[?:$;-DI>7
M2]AC[)Q&)#G(A^=.E'*31\.=*-T76S+1?+/1)'2/B'B*YXBU&+5)K6TL+F*T
ML;-1IYNT0QZ=;16EJ_\ I5W=2+*D$$2ETD4,4#[0Y).8(%@C,:L[J6=O=-A.
M9&+L.RB @LQ/4$]<9QBL?3_3JD*:ZU/>IP2/KG:<+AYU'#P63/%2#P_'; <%
M]2X8J23RW=N&C0&5TB@C;51-<9&Q0<<T523'-LZ2:KQ7K&K\0IQ//.L.K136
M5Q#-;H(TAN+%8N5-%&=RJ[31>-2]"LEQ)+(P)D;.L5M%% ;95)B(=2&.2RR$
MY4D8)&T[1Z0H '<*CCK-T7'];7P!'/8CL3<D*KMLZ'TQ7-NRV/&8O5#!R.=
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MX@>)9@GI(B9)?<NK+576[=ZHTV]**375O;/$DIX9CX7.G:?XI'JDFLB\!O\
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MV =  #TW!B3WUSM/NKS5+.2_BE6 2O.ME!RT>,)$[1HURS R.[NI+<IX55<
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M2;H:)#'ZK F0VPT3=["UESCL@\TPX)/OMN\'NQM*]01Z^X5&VO6*H9 )V06
MU'*HG^KF;Q<C!D!YJ2Y#(0,;3@GH#DK=\2VBZ6+ST;*X?<#QE5\)IVR9](@$
M:BK\)'('=YYA&(C)%O>9PP,$$VA\DU'&PX802DB.<KO184N,:.GJ.$MI'"X*
M LSJH)8$L@)8>]([@<$D#T$@UM<:W:6S2B2.Y8016T\SHD95(;IQ''(<RJS
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M(U&&Q68R2)1QN](),$Q $8J:P8D,A)BPX0<_<N%/81QQ-+NVX[ #-G/<3CN
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MVU^H(#'<1@':<$G'3H.ZHK?34MKJ:XAGF5)^498&Y;HTD,8B63F,AE4LJJ9
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MJ@&';)A)XXODFQ=J1>+CEAP_IBSV2.DF1D9()VD$9QM;O#="*N>66%TUJUL
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M'MX.7/IZI!TB1XH422CB3Q1DW3DCEJ.W2%523=AF:U,P&T$)D]G#9)W8ZG
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M-S/\UY91V/SK:12*.S=XY,1.>NJS=[C)$PVC"8R+OMX\U:QE5;>5+MI$\W1
MLM4BC*0N"2SW"H R K@$=& 8=.N3UZ]W3OJ6XU"\%QJ-NR1K':Z0UT>3.Z2[
MW20EHY3 =KKL"QG8 A)D[9(01[)?$_EU'5C%41M+;6&+A/A]=;>WIZ2SV\GZ
MLZ,1NQ)''ZY)1TF_0J5PA*9^V=+JF'DL=;Q\=)'6[D@X&AU5-1ZFPM0[GMA=
MT\L0"Q]D%0S @;^B], =2.[)[ZA?79+6! MMSEATBRU%WFNF,K),Z0E&86Y$
MDP)W&0E!(<L0IZ5=3KY:CB9]U.]D"56GWN];@^IKYBU.V1O)8"BTL*O)H;24
M@5>;Q01BLR"VH[&9MLG)Y<G,2FK$GKL%PQ]T7@D3;# W9[1E!PN&RK =IMQW
M]_9Z+@=.M=.SN#+J>K1>[8A73V >??#B:"1ARH>6O(;"CFXDD$C8;LXP?-DH
M1[H6?VB[X5WUQGEK;RVJ.RW5WR[,GK94S3U30([#E)':+"70>53!3$JCDE;8
M<^PCH.%2E^B^PV^'; T$<;[61R5AMWD5,.DP<!!O<@@+M8#LD>LD=_I/=Q6;
M4Y[_ %:&REN.9;WMAR6>X_T:WA>/?.LD4DAYB2#/82*0@XVE0!5S^S\VG /Q
M+?#1KX'.9L$@=I#>V:UB0T-+Y&*B\Q4KJHVTEAFYT&P)MQKW(0VNH^2]=MCW
MO.=4"'O;731'6&-5-M<,54LIB"L0"1N?!P<9ZC_[5TK^65-<T2!)94AN!J!F
MB61U24P6XDBW*& .UNO=U[CD5&[SQ8]VE ]AKE\EVNLOZZS:L83.:',S@I%[
M3CI>Q;9>5MJ/E# O LM6&[4:M')5'SHK<S&)=@D7!HE SZ./55-O%,R1('.)
M0Q60*"I"INR,,.\Y!!((Z''6H3Q 1:7ESXLO,LY8(I;1I6CG1I[@P8D#18&%
M*2(Z[HY-S(&4H35]Y<:M0QUKN<K9$;:5/.&4/MI42WKFRBY]<<."CCBT/DHZ
M:L <(*#C3MHU8%%VK5DCL-=9RVV<+ZY42U@4()4"G>I9,[E SDC(*DL,?VG-
M=>1KAK&Y:=!;RB.XVB&=G*JJN8W655B8,0 Q  VGIDUXLD.QO8^%]1N^W5*4
MVG8F>R?31U9\B4O!8N20GI^A51;BPJ8G"<NSG"N)/*"1('&7+77?=SI!DB>J
M+E-ZU]NC<Y<9E@F"H8YM@Y>.R)"=KC;ZEZG/=N]&*\P;V]CT_5]/DN)O'=,-
MQ)XUN/->TVF:VDYG?S)&*QD#KR@W7(Z7/KSO))8?$.O=2@JUL*^K*3Z<=<>P
M5E.FKR72>:'A]HF8W#BJP;= #)UBTA8Z9F-@F7DH+@0VR D3%V+WWJ1[/(W$
MUN"TK%UC032QKG  V!B,]1T. H"@GJ3C Z]2'5'BCM+9()KN8:;97<Y!DDE=
M9WCB8J=DA>0#FS,79%.U8P<N2D53[N98UR7SU4?UYJ5KNJ&?B'V+UC+*"["/
MIE;3'5O#3B<@4F4(:!V$>UC):2,E'8%J],%RC)J':.'"2*AUTS&;+"B1R[L.
M_BZRC*C"%CTVL3G('?T .?HJM+J<]S=V!A#06XUF:P8B9MTX@B;?S(@H3ELX
M)3+LP" D#>0MR?$;MZS:SZ\2UC1$ICT6N\E'9!,(@\/$&;)38%6&HZ42MH";
M/EVR1N127&0\!"A$5<O'#R9ZD$45FXIYZD-M&KR#>"4!"MC/0OD DCJ%'5B?
M^K]-=/6KF>"SD6TD2.Z9'DB+D#*P;9)%4$@,\G9A1<Y)DR =IJ,K!\3>*Q7K
M3U@[-A(<B2KKL,W]@:F9HL8'0"H)/F./-VL:L20QZ,2UZ#T(V,S6K921JAU0
MH%\U)&"2BK=DDT>;+;$R2Q%L-'W* "SC/>H)4'"G=C()[A5>;78X[&QOECW0
MW@P\K%EAMI-APDSHDC)NF')W[2J$%FZ#!Y97XFD4@%E]DH).81]G<]?:XDEL
MLACTV]1EUM5T#@864CYQ6""L>TALLCD@D#\O$%-Q<S<$8TJ%:FB;%R.*&,P\
MML66-E;/,8*2!V48D@JQSN! P>J@'.!W#=F37$AGO8I83'XG#)<*K.1)<PI$
MLBRP=CE21NY:,E92R%0Q4AFY> U\4)D(>.H3,JQ:![0?&NFH:)CV$P</H4_W
M[FMTEHZN<DSF,,7P5*ME&TAUE.V ;O!YF)&O0WN:YUP- 9\6SV@Q* 3$]GM8
MA.#@9P2V1CJ,=<YP,Z>70I,4D 6X+:8D:B0M$QU, IN<QAE$&'YG8.]54K@O
MA?0>O[ E*U6MIO?42#43(&2QU"6!"4[ 'XZ$;"I&1"BCJ<T:[L161$J&-ADC
M')O=61 8@;;B"J"15HYTY791OVQL9 <8.T@G(R05ZG(.0<9!QD'%=B&:3Q<2
MW<:VC@N)%:5'10KLJOS00NV10KKG:RA@K ,"*HEX=LVG$PMSQ$QTPG,WEXRN
M>XDNK^!,)7+Y')&,2AP\>T>LP %J:)OD&#-!P[5VURCIA?*>4T=E=D$D4]+%
MRJJMOM55W0HS8 !+$#)) ZURM&EEEN=9626618-2DAA621W$<0&0B!F( !)[
MNN,#.  )<\0V&3*5=>Y0YKVWKJK.QQ8HHC4 2D94G$#MAW6720:UA&S+YNUV
M+E8^J>3PV-!420L$G'B!^1293#( W)AH[=@)!N1&4D;RXW!4&2Q /3..XX)R
M !U.#8UB*22SD,-S<P3*K"V6UDY;S73 "!&(&YD+]&0,J;&=Y.B!E\M.V_:C
MM'4:W8+5U8Q;:==1.J72"7#UHH0>BXC/;@G-ZQ2/W+)"X$;LT%2P3,442,(3
M"G1[\8%'X(?!F HNZ>.=K4443[.R-LTLXZCM*BQL4 )S@CHV1@D]Y(K@ZC?W
M]N;S,S<W3M/TN0&,D1S7,MW&EP[(N%D64;H@CAE49*JK$UMR?;R]/]([[2+R
MN1,&&WBS2?IDO"GI,AB#LJ'&T.R506<1/9VD"T(,I'G>T%I=[LE(=W&56:AO
M$;VV&8QR8^7C /\ HHFW #<7W^AB,XQV<=WT9ZU(-1NC>[S(ZC\H'TSE%CRU
MM!:#OCSLR)/=S)@/G(W!.S6/\/\ [1]CI;;6L,G\BD4TG;3K%=4^@J)F82A6
MK.\K_6U_;UU:]5DY4,T"TR'#,V[Z)/!;,,+]L#DHTMF-:A@39H,7$483<H 7
MFHK8 WP#9AE;!RY/>,Y((.3DDG72+^]DN>7,\DDHL+J:'?)(;;53XQF&> R+
MMME09C*JHRCJVS8@ N7VQM.]8^9\,\FZ+R*FSMM]H:JAEVU)&).%.1[;!J'2
M"22"'DI:-#MB4D9"38G45NL.)LXZ=9)K;NA3S19%1.&)4(N0 '"QL4<@@]&
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MU6D-G#N1JS$#Y?CF::,:4!FQZK59P4?+J.2!PX[(Y$\H96#8*;MN%4#MG+Y
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M9QZJD\1M>?XSRAS2YE/5MG-:+D&7EYY?-,(Y9?;N*=,^FM3C?2OK=$QBX4-
M%TA?E9+J1$LW4NFA#2)5/.WJQ&5P:$*OI"NYAH@L[5TSNK'%AQ)JU9"!K%^V
M%@PS)ADSRD@ENH<29VKU=>YFZ=HCZ<CUC).8DTNRC!583M\7DM5!DE;EV\I)
MDBBW.3&K$_S"" %4$*J@9(KU"H W'J$BQ.'F%PG6)[%B=(-$+$LL;F%E(6)P
M"C1/9<5+V*\C?C1/KL,.96H<4<-UG&CO*^'"_M'.D!D8,,R@ASM4Y#=XZ@X!
M^C%;-IUFR6D;1L4L3&UJ!-.O*:)=J-V9%WLJY&9-V03G.36>(=9J1*6BG<;^
M#M7$[TDX&<[O=B1G40ZGD6B1>!1J=OHOH1UC+Z9@86=)QH7)'8E8JU%JM$]'
M/M10A5A@2N%V!NS@KW#.TL&*YQG:6 )&<9_.<[FQM6G%R8@9@Z2YW/M,L<;0
MI*4W;#(D3% Y4L%QURJD1F%Z8U=I3-F=9)>/4E77>;3.72P/!VYV4Q%Z%&6'
M+"-@2J!NBT/,@R;R,L9T5,%X\HW*,]L!B[:,D1ZVL<2+G-C,V])%Z2*H4M@-
MG:H4-@@]2HP<YZC(/7 @33(/%I[&4<RSEEED6(/)&46:1II(2T3(QC$K,R88
M=E@C [ S;H=ZYQV1SR@3)!;?[$=:M29VN(JX>ECCUS/7\8>P03(3YLZ\?/W;
M:%0XF=:@V[ER1?$#4AP9>OVBL<8I$<"0A9!_.EP&. !MSN(   !9L9Q@ #&#
MGI*]DDDUF[$\JQW/!'EF)E,9B5W9R21%&SA 2Q+/N+#8 V0C?5ZE(E56U)Q^
M*.V=:*S?-A.(XO*)63R[DJEC-[6<J/"I8T_,NQ;Z9MM'9$$X(*!B W=R">,E
M@KMTQ6P97+[R<MMVYP.[;L[L8SM].,@]>^LQV%K';^*I&1!S><4,DC9?GBX)
M+,Q8J91ED)VE<H05)!E"20.,2XY Y#(&"C\E6DD?2^';;/'B+49)'\3D<(6+
M*L4%TVA!PE&I;(A[3!%%TDRV)JO&J:3U)NX1U#%0P!P&&UOI&0V/[U%3O#'(
M\+N-S02&6+J<*YC>+<0#AB$D<#(.-V1@@$8VTZK@5TP<O7-E@$I+$#:HIR]&
M[/2(QPD_!%V)\$5&E@SP>8#EPAP8.+B2PI^S(#R#)NY:N$U$\9X1V1@RG!&>
MO0]XP1@Y!!!Q@BL7%O#=1-#.@>-BI*Y93E&#HRLI#*RNJLK*000"#43I=/NO
MJ<BC\P4A3MU+H[;JU[MY2ZETQ5.D[56BVT*Q*)$_^/:J2/5M%\IA!P,SAY'!
M8YNW:#1#1NGE+;?G28(W="G+Q@8"9S@=.G7O(ZGTDFJXTVS#I)RB9$N3=B0R
M2EVN#'RN8YW]O"=E4;**  J@=*LUR*KU.*4XI3BE.*4XI3BE.*4XI5:)IV:C
MD;NM;KZ C[^:VFPJA*Z7\2'G(N#,/H.Z/FHTR1AS63%Q*<KD[LG'B^=A>C@8
M(%-&R#@_(P^Q0.B1E6(F/F$[4+[ Q!(W8!.2 <  CKU)[@#@XHRWR)=>)HAE
MG%OXRT8=$8Q%F0"(.R\R1F1NSE54#+NN5#3&'GT:)MX=J[),@!Z< F9X'$#S
M]@/E:[=P-T)N6V@15SAZX="T=E-">C1)?1INW7]IOC5/;;&A4C=@$A3@L <#
MK@9/<,^BK*S(PBRP1Y4#I&[ 2'*[B I.25&=V,XP:S0V2QPR0,"1!\(5*QY9
M%N?&#2K%\0!N''MLMT##-JNJY&++X;K^Q2>IH;J^P6]37;V>_JX(( )! /<2
M.A_-ZZV61&9E5T9D(#JK LA/<& )*D^C.*ZN\QBFLB^QNLGC>9ELQ5(I1+8Z
M-TD:C)+1-3=Y@+[QL4]RTU61V4=ZL]D4]%4]]MO1OKZS!QNP=N<9P<9]6>[-
M.;'OY>].;C=R]Z[R/7MSNQ].,5 '7SMQ5G8"JHY:[-SFNQLIEL\A88%8A>-!
MSI W7DM+0XXDP2;&GK0CHH0$+.FFK%TNXRQ<-57*#9539'222)HW*^^P%8E0
M2,, 1GH,=_IJG9ZC!>6\=P#R1))-$B3-&KLT,C1N  Q#=5)&TD[2"0.ZK"(2
MN+.9"\B3:2@'$K'M-'[^,H&1RLA8L5,-]DWKP*FYV)-FBFKMKG1RLVT1VPY;
MYUWSA9/UH\'&<'!Z X."?5GNJX)(RYC#H9%&6C#*7 .,$KG<!U'4C'4>NN#:
M6AG45(2^/OA\I$M!Q=\V<@23!^S);AL.]';1H1;KJL-EM'C)P/5SE?U&SM)5
M%QE/=%375@Y .0<CO!Z9].._N.:QS%,;2(5D4*Q!1@0Q7.0&!(SD%3ZB"#W&
MH HKN#2UZT.%[ L)(-@\4?0?:Q#XF<GXR-D,"BFKDFAJ6F[5B:(M 3)9,2[=
M(/5WF62[;7UTG&^==]=9'A=)#'@L=VT%0<,>G1>G7OJI:ZC;75HEX'6*-HN<
MZRN@>*/+ -* Q"@[202<$=QKMQSN-UME3BH60>V8BJ2O"!K67 1;@P/9D7$,
M;#QKYP5,-7+I-0%LEN5:#,L"?L""A?0@/1:JK!C'N PRC?E#A&VMT/?UZ#IU
M[L]/1@^D5E-2LI#;A;B,M=0F>)2ZAC$ I+,,]C!8+AL'<&4#*MB:0]BU](52
M" "=0XXL*&HF2B(>3A":HT0YU5V;E2";)\ONS&KZH+;(OG&$VJNJ*N=%=L)[
M^C0JPQE6&>@R",GU#(JRLT+YV2Q/M4,VV16PI[F."<*<'!/3Z:_;"P(&5:""
M N;1$DPD!3X(!>L)(&>-#9KW15_\($.6[U1$D4]Q;KO?<&>ZSOW1%5S[+V*>
M^^HJPSE6&!DY!&!ZSZA^>LB:%@I66-@[;4(=2';&=JD'#-CK@9..O=47'^P<
M; NYJVW$DG6L,M>M*;5<:N&#=$K+K":0DT]W8;.%M/\ YH@T6G0^42P@I_9:
MC!,DP@FJY"N4L[",D+U':1GQUZ!=P_O8J0!ZR/75=[R-#*"K'E7$%L2",-),
M(F.,GWL22K)(Q[E5_P"B:D5O:-9N_=_=;$@KGWP>_+-/=Y< 6]Z%"_>_B9-O
M[,AM[<>.^'O_ ']ZEZS9G[D[]X43]V6]378X[U;H<'LGO/<.[O/JJ87$!QB>
M$[@67$B'*KG<P[74+@Y(Z#!SW&OFMIUCOG;72QH'MMH3;A=\:R^/[9T,/,+9
M:"=L8(9SJ3=8;N,MV&?0Z7P@ME)+;"6_JMC_ -%N[/O3W>ON[OIIXQ!\/#T8
M*?=$]\W<OOO?'T#O/H%?5;1K-!5V@O8D%178-W+M\BK+H^FJR:LGVXQXY=I[
MD-=V[=H234'N5EL:)H/D]VBNVB^NR>&QSW*W?CWI[\9QW=^.OYJ&X@!(,\((
M!)!D0$ ':21NZ ,"I)Z C!ZUL(F1QX]E7 (Z&-90;CW:V!)1B1RBT+-_?!3I
M7W-=;V;<FTQET/6W]";QO_T[;91+^US!!'>"._O&.[O_ +O3ZJD5T?.QU; 4
MG:P; 894G!. PZJ?2.HJNU\]M*QHFO=;(<+9L,(WM""5.:;5X8C1DC'Y'/Y$
M/C WXLFN9:-FN!Y$JP4*LE7*9-!BMLY19N-M,);R1PO(VWWI*E@6! (49Z=/
M2.[T52N]1@M(>>3SE$\5NXA9&9'F<1KNRP PS#<"=P'4 ]U3?FQZ\Q&5)KF>
M0S$-267;*RW,H!XC*;ALY49.4%#V7WPK19N\25:+I;.\;I.4E$%-=5=-M,:;
M6SC:V?5@Y_N[ZM<Z'9S>=%R\D<SF)LR#@C?G;D$$$9Z$8K\%K+KD"W0=G)_"
M0K1T&3D35T6E0(<W<Q]7;35(Z@L\?HIK!E-E$]4R:>VS+?;?3&J^<[:^D%8]
MRL>N.@)Z^KN[_H[Z-/"@!>:)05W@M(B@I_3!)&5ZCM=W7OKG-6# HVJ-1D4W
MB !8RVW>ATC4E#"E2K-/V7M'8U-\]0W?-D_;H>NNUPJEK[9+UM\>TT](*QSA
M6.._ )Q^?'=66FA0J'EC0L,J&=5+#UKDC(^D9KG7G$+:OG8MS+XNW)L FTE?
M#ESXE%\RCFF-,[GW;11WJX;!-,*)YV*K)Z,=<*:9ROC&^OIQM;&=IQG&<'&?
M5GU_1WT,L0)4R1A@N\@NN0G3MD9R%ZCM=W4=:XPD]@LF4)(QR:1.0*AFK)\8
M2"2,.54$LB3;9Z.>$M&#QQLQ:D&>F[MDX=821=-M=ET-U$M<[XR588RK#)P,
M@C)'>!GTBB3129V2QOM +;'5L!AD$X)P".H)Z$=147V+V$B,-@XV<Q1%.WF)
M*P8I7FC2NI3!WBB1.1GV(9^XW?EY*)$*8C#5VH8,CD'ZA5-BU5WU9X2U6<(;
M+&S,5/8(4MV@W< 3Z 3U[LXQ4$UY'%$LL>+@--'#B&2(X9W"$Y9U7W/.YU!+
M #N]4EH6)7[HRWCC6=0YS(79 H):@D).$6,N2H1#5T:&-Q:;[9\L0$-=]')1
MDFALY8(;:K.TTD]L;9UVL!DJP& <X.,'N.<8P?0?3Z*F$T)8()8BY9E""12Q
M91EE"YR64=6&,@=3TK5)5;*48MNJ*GUBALTO:#&=OUI..(1E(/"484(:%$-I
M(/(G&4E<Z2E1=P-!JQT(:33>L'>Q39@T3V<XR$RCOD#9MZ$'+;CCH0".G><D
M=.[-1R7 CN+>WY;L;@2G>ICVQ")0WNBEQ(>9U5"B,,@[BHZUV)G<4)B5=V'8
M[0LPEPVMQ9UT9&Q,H++DES85ELXTA[?1N[V12E)5WNS%#A+M5!PH1(,D-]=/
M;ZYR",652"I8C!8$#!/OO^R.I)]0-;2W,4<,TP82+ KEEC968L@SRQ@XYC'"
MJI()9@/36U;S>(MG1,:0E$9'F0 G0Y)!#B0B=7T>%Y215W(EV^[E-=@,3U72
MS\2>(MVFVBB2F%,:J:>G7:W0@$@G .#U/J'T_0*WYL0+*TD:NB[W4NN47IVF
M&00O4=H@#J/77* FD.E:[]M%Y9&9(Y%HC'!-N /"S"XYN::Y?!UWZ0YTY4:(
MEF6,O!BKC5/1^UQEPUV51QZ_!5E[U(SG&01G'?W^KT^JB2Q2$B.2.0J%+!'5
MB PRI(4G 8=5)[QU&16B:V\UVN\I3&T8,:)AZL;6<^L'8E%_LHVV<218#F'N
M66#N98UD"+1-*1*.G,=2C_P=RCGXQ[YNFUWVV'EA\CJ^P+@Y/3.>[&/1WYSZ
M*B\9'C;6NQNS;BX,VZ/EC,FSED;^8' PY)0)M([62!79E=Q0Z/1$',A1!A,Q
M<EFT-@@)6+%A9)L1+2^8C8ANNW((.E6*C*-8>/S\D42644' P!MSE+=1ELED
M$8L5(*D*S'<"#A5)QCORV %]9(_/69+F)(UD5A*KRQ0KRV5@6DD6/WP)&$R7
MD/\ -1&.,C%;.!L. 2E_\*C$YA\C)_#MC'PX#)@I=_\ "-7J@W8I[F/>N''P
M[4BBL/V?>S]VP]24:Y5]OILGC!5@,E6 SC)! SC..OIQU_-UK=)H9&VQRQ.V
MW=M216;;N*[L*2=NX%<]VX$9S4<6;V!AD#JZQ++C:C.V-ZY1TT)1& 2F&N#K
MHPLNV1;Q_5R7D P*.+K:NM7&C(L29N5D--M6B#IUNW;+[)&6=5/8W=Q8-C'K
MZ DC/3(]/?4-Q>10V\TZ8N.3C='#)$7+$C"99U56P<X9@2.X$X!W[2S*_P /
M&@IY-(D-/.WH@5B.OY1'DCJ)P\U4>"0"@](FLIN:?MT'"C)@WRNJ_3;.%F/O
M*"6RO-=C=^UL8)S@XP.\]W</2?1Z:EY\.0IEC5R5789$#AW&50C<>VP[E&2>
M\9'6M<N^V4J5K]U.U(H;FZB!R+ VT7C;^,CC9):2R,8"W68K2TY'0ZFH=J^<
M'7R*A--QN,&/=FZ:F^F?1F-.8P7(7()R02.@)] )ZXQ6MU<"UA,W+:7#1J(T
M:-78R2*G0R.B]D,7(W9(4XZUM>+$K_)I&-XG4.S(G)1V$;@<28)DTN:8-\NW
MPA$7A][\J49-==G+MAHAL[;-]<K+):)XSMS&UL9VMC&<X.,>O/J^FM^=#NV<
MZ+>6*!.8FXN!DKMSG<!U*XR!U(J-+?["PZK:^GTU$Z(6@8KU5@T+5[!I3"-9
M@H1>FV(7<9LG(Y("$C'[+9XJ]<M3),>OELQ=)-DW#[V#1;9(V9E![(;.&8-M
MQ@G/0$D>CH#4-S>1P0S2KB=H<!H8I(N86+A-O;=%4@G)#LO0$=^!4FO;!@@P
MVG&"DTB0R3JZ--TXV0DH5H>VU?[X38^J)6?:OM\.U<^R:[)H;ZN5/["&RF?1
MZ=0K$9"L1ZP"1_?W5.9HE8(TL:N0"$9U#]>@[).>IZ# ZGNJ"NNO;BKNQ<4-
M2,*X^QC^/R>R8V4B4R,QEK)D4*LE+V(R>4ZL!QHAG:):EF"^&YS?9)#5+U??
M=6:^=D-=Y(6C(![0(4AE!QV@"!DCOP1TJI9ZC!>QLZGE,DDZ-'(Z"0"WD,3R
M;58^Y[E.&[L=^#TK<Z_[*419T*%6)#K4@Y"&G9 ?C ,ZM)0[%F8+QTL1$NVX
MW=V]2RZR[R,6*"]4\95(@G#$PW2V8O$%=L-%(K%2K;@ 2,$X!_\ S!]1!'>*
MEAOK2>)9H[B(QN[QJQ=5#,C,I"Y(SG;N7TLA5P,$&HONSN3":.F\<AIR)RR0
M)R&V>OU*9.QW(51@*GG8<K+F,<8$$B1,>M["-#XR./RK9M[=XV$3&,+#6))1
MR[T:;)"T@)! PLCX.>JQXSW#TDX'T@YQZ:]UJ<5I*D;QR.'N+.VWIL(66\:0
M("&8'"",/)Z0LD94-DXLBO8< :BGIUS.8>W!C2>X4B97DP5$4P,I[8T4$O2*
MCW5FU)I[[:Z;L%UDW6NV<:[)8SG&.1[6)P%8DC(&#DCUX]57C-"%+F6,(K;6
M8R+M#=VTMG ;/3!.?HK]+V! VKDPR<S:(MWD>3;+'VB\D#(N0:3Q5N@T5,(*
M/=51B;I9VT1;;O=$-5U73=-+.VZR>-FUL [6P>XX.#^;IU_LK!FA!<&:(% "
MX,B H#@ N,Y4$D8)QG(QWBLJ:D<>C:+5S(CH8 W?/41K)<T48BD79%SC?+=@
MU5?+H:.'KC":F46J6VZZN--\II[8UV]& ">X$],]!GH.\]/16[ND8!=U0$A0
M78*"Q[@"2,D^@#J:PN+'KS,6S.<3V%YA.-U4\S#$I!YBV-T7&[-;3,@]^^$^
MND[25:JZ^]^E-PGNAOC"NFVN,[6SMVMN]6#G^[&:TYT.SF\Z+E=W,YB;,YQC
M?G;W]._OK0S5Y@0]H0FO,"G! -,*\E=D+V8U/P[2$QH)&]Q.6F3&SJ1-SBB,
MB;$'3P45&B'HC+<8Z65>X12>+,LB,E&;."K!=N#N).>[ICIZB0?_ #A>[1;B
M*#;E9(9)S.'CY<:IMQORX;#AB58*5PIR>\B2 $VADJ<O6<7ET8DCL8W&O"+4
M ?%&'(]H90V="'3U <[<*M&Y5KINY&KKZII/D-=EFNRJ>N=L:E6'>I'>.H(Z
MCO'7U>FITEBD)$<D;D!20CJQ 894D*20&'52>A'45V"\KBT??!1AZ2@ A*2.
M\L(\/+F1PU\>?8V1TRR"M'KE%P4=XW<-],MF*:ZV-ET=<Z>E73&P G) ) ZD
M@$X'K/JK+21H55W16<X1695+GH,*"06.2!@9/4>NN'29P]0L8 :2N-;G8ZR^
M)2 +H=%[%@8[V2*_OY@=AUEX,9>P<(+>]/44$/9+HJ>T]173;9M; .#@] <'
M!/J![C6.;%N9.9'O0;G3>NY5P#EESE1@@Y( P0?37 #GL%D[IPQC4TB<A>M!
M[8LZ9@Y&'+.FPIYNJDT)N&[!XX61'NE4%TVSU335LONBKHDIMLGOC JR]ZD>
MCJ".OJZT2:*0D)+&Y"AB$=6(4]S$ GLG!P>XXJGLB[]UF-F5[P:+1PW9!:CZ
MBCEO[/H5(J_>1Z>C9.<(QH?&XH>>RQDQUDZ!T4^8/V);9BDFJCA%FN^?*I,M
MYQ;N5C8D+O<IA@V5(&<D8[L=V/[<5S7U>!9;N*.-YFM;9+G,3PE)E=S&J1N9
M -X92&#8 Q@$GI6_S3N-4D50M(0-?)RZT:EJ^-V=)J?"R"'H3/5O+T"ZL<C&
MC@G(FD<Q*7OP9?=<;J95V:LW@9_C*[8^!V)ZK"YV$C"NY0.0<9&,G &<=>AQ
MUP?4:EEU.WC%PJD27%O;I/);*\8DQ(&*1Y9Q'S#M.1N. 5/<Z;I\'3Z+NU(N
M.?&1 *3RT(T.B8:6. M)2LV<L\O%=$!C0D[R1RQU3<I.W(A4@/QNT<[H/%T$
M_;9C*GJ<$A3@L =O?COQTSZ,X/T5<6:,F-2RI)(@=8F=!)@C/10QW8P<E<CH
M<$@9K]#[$K\L60 "IU#B9UTH41;!1\F"/"SA8'A+)I) <V?*/%E!&'"&2B::
M.VP_"R67>$<*:>L*L!DJP'3J0<=>[K]/H]=96:%F"K+&S$L JR*6)3WX !R2
MN1N&.SZ<5JLPNN!Q>OK!L :;%S9M7@HDZ)AH>:#F"SPVTU70'1%OHW>[H-Y(
M?,I)Q\2P?*MLJEW"393*><*9TRJ,65<%2V,%@0,?TOS =2?4*CDNHHX9IE99
M1"K%EC968NN<1C!P'9AL53@[B!52#'B(Q+%D3.OX#4LZM1O6]IQ^FI_*(G)Z
ML'#HU.#F(6X_MC9C.8T:+QY!G+"221<(Q(.%R\'F#1P+8"F#8\[F%L=H9G52
MREU!#Y*C/>0I /3N/3!!!)Z#FMK4?.DBAMY;@0SI;321R6X6.5^4?>R2HSIB
M1AN0$EHI 5"@,9UI3M=6MURVW(&.W4BLPJ*Z9I2+V/R@K'6Y67G8*$CI\T>A
M0YH7=$2\;3'R9CMERJS:/FNR;CWY@UTU3W4C>)D"-WJZ!P0#T#$@!NF <@^D
M@^@FKEKJ$-U)<1#,4EM<R6I21DW2/$B.SQ ,2R;9%ZD!A_.45-C6Q:^?*[(L
MIU#7BVC4R^W2:R<(X5T91W9MI('FR:+[?;5J"W>,]#+C.,)#-G3;5[NAE=+&
M^FUOZ+>CT'T]WH]/H]?HJR)H6.!+$2 Q($BDX3 <]#W(2 Q_FY&<9K\IV-7J
MPH2=2GD,5"'GV18,PG* FXHT3U441V'"2&K[+0B^U6152RT9K+.,*)*:93];
M3;&&ULD;6R.\8.1^<>BG.A*JXEBV.=J-S%VLV2-JMG#'((P"3D&N$?:%:%LL
M-15B04GL5#$)&+P/EH![DE'A"ZS4J=88;$%,O PQTW7;$"C?VC%DN@LBY724
M3WUU%6'>K#J!U![SW#N[SZ!Z:+<0-C;-$VY6==LB'**<,XPQRJGHS#H#T)KO
M#YY!BR3-<5,XH30(MB;T>L/D0=XD^9A=M=##MFHV>*:.FPG??34FNAG=)AMO
MKJZW2SMC&15AWJPQ@'((P3W#N]/H]=96:)P"LL;!@Q4JZD$+T8C!.0I]\1T'
MIQ4$75VTK*FH; I[JIO9$9GMU0*BVI"N2\;/)"I98)S$?'.2+C8PV99'BB&V
MFIQ%J[6*LTU-=DASG?UM-=TB9RR^]*HTG:!&0HSTZ>D=WH^FJEUJ$%K%#-_+
MI-=0VH,+(X629MBECN VJV X!+#/13UQ,Y&SZ\&ORH9>;Q#,A#(KJOXUB51U
M ^ANW8Y)9;KC7A1JJT6W9>JXU]^RU1U04T<K*I-LY6QIM8X.UL'N.#CU>K_Y
M5:,\*EE,L>]<Y3F)O! S@J6!!QUZXZ=>ZM)K:^8G-JQK>QY5HC42]EM$E \.
ML22P]G($B*KW9AH%T6%'R88J256RWRBV#DGRV</&J*Z3=[NHT2V:,JS*,OL/
M4J#C\_=D#\]0P7D<L$$TF+<S@%8II(P^2<;>R[*Q/3 5CW@=#TJ<>1U;IQ2G
M%*<4IQ2O+_O/T^9]IS)=4S31A]+(7 1COKAV$JVP ,"M6O+2V=RIP^'F7Y(_
M'G.8./>)P\NQWU3E6VBY&4J#@8XJ@S(.[,$O*'1QAC[I&ZEE9>F,8![1&0<X
M]'4C('"U73A?LVZV8R10J;*\@F2&XAN,R95B70\H'EL.DG4R$(&"DQ;#>G/8
MECV92DMW*.[OB4DAW2L^M:0"QAL+4A=T]5P+MC(WYP \&?; S'I?*2TIGH89
M%=DQ!,E)R8"7L6PXX1(B]S-'RL1XC8&==I4ME)3D8.=H( 523U &1W#->+3;
MT7V^ZS=1O%IC^,),(C%=6"%7+H0)&CDD:295C[):0I(,.Q60/#PZK6M0^K?%
MZ1Q^XL:NXY9U7LK;;V4,-QBUH9-+F(6T//,8.+9(%61EV4(OR<A)V"I]HQQE
MZ_U"KOV$H,)"=;B59/>'LL5<IM(*,J!,%CT(P !MZ''7J 3-HUA<6@'C:'G0
M)/ +@3*T=Q%+<FX5Q$HW*Y8L7:7MJQ.PLKL%BHOU0[/ON[L,NMI7</!U9"NX
M<TM3?("S-7+Z2PN;T"QK!]83T+(D711O,'[P4Q&R>/CCP6-H"QL?91N&;K:R
M.7F=Q+%R"F\ES$J]4[BLA;;D>CKD$@GJ<L.BU7;3[\ZK%=""-;>+49;CL3@F
M2*6S$!F*2982Y4*Z*Z1X"!(B=\K0C"^@/:B+U1124=$O(1>%7V'=>Z[O,M@,
MHJ.55;<_84?8$F@=NQ!Z9V5+1HA%$A<@9F8CH^E,>F,233:!W;S[,R(+N9XB
MTF2&1E3'1@X9(RH9&Q@'/3#="I[QV@U:+2+]+>T"*T5U;S774R0R6TD%U>":
M2*XB+]I#'M<-'F1)8QM4GENL^USTH["1SL;")*5(M](Y"N[W:?M"8M+!]@LY
MF5=777HV-1&NFXA-WO(]#B"JJ4;D[(H+818: B3=V$+$=LAAFNC3QF-@,Y:"
M*()C&UD8DG(Z;?YPZDEC@@5;@TN\CO8G8C9%JFH7SS[P3+!=0K'%"%W&3>.B
M.&58U6,%6;LBKW=>8(<AG6)G"W%#0?K\>1'6/HE2M924=)(D#<EY)*7@_(F1
M:L0 U=>5:/6TA>Y509H,"!IPT<*I:M=\IUY&#2[N8T@RO;8$$X SD=3T[O[.
ME=:SA:*Q$1M(K-P)O]&@<21H6>0C:^U 3)D.<@ ,Q!/2O(.A?#@[$PN*H1,S
M XE&%"OA37?U#/DDI)%EQJUZSJUY%+XT2*:!7+M^1!X#NVJZTFPQ=/&CEUJW
MRT]=-QLE;>YC+;@Q;%TDH&#GEJ@! SW'(QCNKSEIHMY'&L30QQ[M NM.<B2,
MJ;N:X:1&8(267:<E\$@D],U8VL^I]U0:>](K(D%=1MF+I3HB>ZW6FR3E$;<$
M(U-1HB%:(2K'NVJK8X+*[QHTH.5!."9)-9TPP63%:.WR[#1ID83*&)+SB1#@
MX*DMT]8QD=^!U/\ ;<AT^ZBETN9X$"VNDO97 YD9:.55BQ)TR'#<MBI0LV2N
M[;DD4<Z,]3)M>?6SJ_-F%<:"ZS$]%>T].37<3,8W%#?8 G=,N*MPL/&$1:SL
MF$;A=F3\H\DDZ&L68J4*M,L6)\?AR0S--*(Y)5+Y8SQ.N5)Y80#+'. <C PN
M>S_=7+TO3Y;NRL)5@VP)I5];2;9(T>\:ZD8+&I4ED"8+EY0H63;@.,M7I!1?
M7>^H'"Z:CEOU?#.QA6$]KRLIC]DV>8B$>MJM:C'PO2.PNU91M&=9/'YU=(O0
M<F!75$GG#HL%^S;XF]2--WST+7>2-F<H[1AHL%5!*LY8DH,@%4.<]0,=<=.A
M[5K97<,5LEQ!'>M%J#2)/.\:7$%N(MD<\FS>DUTH4)V7.Y=C,0P8K8FLJ;GZ
M):B2$Z$MF>@)W=5_V/KJ3&OE&?8"VGCAD%BB"C1TYW,A8+#++M2+($M<JC<-
M L-PQ<KX12]WC=U]T"GO"1KTQF-!U/=T+,JMZ^IS5R"UEW6IF4#8;J\F[2MB
M\N"0D?0G<L44\\8;&W"1X/JH+'O"_LV'3F$%(M-6 R)5CVKMY""1_1;7(P/T
M:[!QHV8M>N$6GKZY^TCF9RLH&";*I;9$:"Q<A;:*+))J\G-TK*P9>TT2$GTF
M>,@*V?0-HST[^XUR4T*>*6)DE41P:A<\I,]%TN\C=KB #^F99"J9'9VAQW U
MM?;/PX;(M:RNT4[J:4L8NRLZ!4O;]?B=76@Y9IW8H(N8:P>7:KZ_]7% R$#1
M9QX^LLWW2(E3R9QU[5U'6RFF(KE46)7&=K.C'&<P2 %A])#=1Z@,#H34FH:+
M-<3W\UNX03PVMS"N=N-4LV812Y'15,6$<D88ON/5 :F?L#T(>6S.^LQ]@<:M
MF82(VQ2':=\VTP,?6O2UN1$F?F#=777?9=1X<MP:S(821<87'KSL\=QNOLPW
M34CCGV+*".\H\7>0CHP ]/\ 0./I"@59O-)-Q+8NK !8[BUOV]ZUQ:W$;/*#
MCJ2URH.,]DS._HK&4S0?;.I>M%==:%=HY(3TRK2X:XM+L E,/@A2H-(Q6^:Y
MZV%XG&46#TE,=U@@:*)G<HEV3D*7;E3><[;/\MTLO)"TK2=0%9&6/&=^6W2@
MGN7J3CH0>@K%K::C;V,-B>6[R07,,]X)2C6W+AY-DT<85FE)18]^'4HP9O3B
MJS%>DMW2SI-%*G?=:H-$KU$E^G$+LPP,L6*F!EOPOJH;9M&<H5U76:"FHQ6%
M#E4A0TEEM(G90^[#E1#<4+:%%Y1.@G+\TM&1,R@J04,O4KW9/7O(R, 8/HJB
MVEW3Z7';FRBCNU?38YV6:-EN([!P!)U(4+REPJMAR7*LH"ACEAW3;LV !30+
M'JLA>N\D\2GL#V$C))Y8K &[KVE;6@Y:,!S<89B=C<:T,.FQ8K')-'C\;E:0
MJ/G"B@"-O3CAB< #-$2I+GI;1QGLD[I$;<<YP<= 000<@9..AR--OD654MXL
MOK=W>(QF5##:W$;(K1A=Z;R&9'1T<*C'8I<ATBI+P]NRSVH>IL+DE9QLP:IC
MHYW"H62)NY=#"C5A8]MQ5U':QW&KOW^FJK+11HCLX*L]=L F1%IC7;970@W9
M9-Q%OE97(#S0N.RP.U#E^X?3_;@_1F :1?&WT^*2W1FM=+U*T?,D3 37,>R#
M;N8=!CJP]Z&'IW 1)<-=:5XFQJ^W:K[&2IC%N@G1F(=H#-',ZULY6%:4--BD
MT6T$OC]DP]>N<+OJU<.533-C8*<Q$FEB0\#%#P7WR02(V[+(T8)N)VB#EESS
M%V]0%;=@-W=G!'>0>E:YAY.(+FWO)%CTC2H[]K807'*\4E:8[2\\9AR8<E@)
MA(KEE2-U#/<9AUBLH'+.V%CV+%BAZ$E)5?G9>C+3;3X> :@X_;/7+6N75<RV
MMMQJ$X<G(M'1HZ*,Q)I7:%(!6C=^W4'&HT,9%(N:A$*JP# 1Q2(5)R4D#;PW
M1<,26R.UG .021TEL9U?4)IHV>)I+N^M+@3! J7%ER3#)!MYI9$ C"O[D%ZC
M:T:AJM=6NJEPVCUYJVT8'4L+Q&G7A5F^OC>+RN7(1X)V$GMA2;64#FYM6 &V
M$E%Q,6QT=NRQ<Z3ATC5DYEP,%N$1N[N68WEE1)&5G.1="3(&3&JK@XW @L<
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MKTW*/5D J.DI%)F6'<AKI1VAHPPZ<.EP^K2'D/O!RTIDA?& =^]9.F<!>A(
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M1'-F^+FGUT%)U&UR*L>=KF'\?>1W"+0A)4&;M^-W*8339**-U_92O<Q,<Y+
M7,<H!!Z(L:J<9P,YS@=W=5*VT._CB6/8D#'0[O3WD62/'C,URTJ%BA+%"F 7
M )&<8Z5LA_HOVAET.[,-FM) (0_MCP^J$ZT1D%K.Z_6]K9M7KMQIQP27$%%!
M[2/X9IZJ@BV[IR[7CXX;HY9CRJFP ?@3Q*8^V6"3R2$[6'9<'& 1G.3U'=G/
M7'6MWTJ_EBO@+58FN-'M+&-.="?=X" ^XJ^T)@95LDE ,@-V!)UF=(^PAI/O
M\F"K\ 2W[5=2>NM<0%UO*XLQ7 3VM8*<ADL R'5TZURW55(EV95,L.7>!78=
MF\5U)K%DF0A[HL\8Y&6/N4LC-T/56;<"/6,#N/4''3'43SZ5>-Y8V0HWE#3[
M*&$\R,%)H8FBE1\GH<L&W*2C*#VMV%/$?Z(=F#$VDRK15!BC8]C^';8@N>*2
M8-[>F0_56*JB['B2C)$CN5<E]BC5Z\A.L19E8^;<3-_L<+!<:E7CD)X@HSUV
MK<+MP<.96!4]1W'N;.",# /=1])OFEDQ@">;1IEE+IFV6P3;/'@,6+;@3%RP
MR/S3N9>T3U*YZ*WW&>R<2MA[7 1B/:^)!V^[&G)"TDT/U->2=W5\A%(2FNLS
M*ZEG+[!)V^<%HXANML,:Z/%D-G+E=%%R>>,Q% QSXO#& 0<;T8EO1C&, $]_
MYJQ#I5VE['<&% !K6I7K.)(]PM;J#EQ D-N)W$ET!.T9(R2!4G]4.H'8*K,M
MZREB)#?KXWL^D95%Q<Z/0J1V=7\-J4+.+(2J]>;1<B\6GM?1F^MJU;U@Z+(L
M3J$31FR!<("9*BT'NLLT;99?Y0I(I*@A6+E5W;2!M9H]^\#(SC!))(GT_3;R
M#$$F?$Q/:/&LKQ//#%;++.+?FQL>;#'=F$0%P'Y?-#(@V@QO9W23L+(A?;AJ
M!KL<HYMWOS1W82#[9E,+:8=UK7SN%.9 X>;J&M-AQ7.8F1V8B7&-57*A9AMM
MNEE0EEALLT8Y66]Y \;=&]\V<>CJ!GO^CNJ&?2[QUU ) ,W.KVMY%[I$,P0F
M$N3V^C9C8A3W[AW$G&6_T#[P+6P:?JQP)&FQ7Q5 _>!K:C<['UW;"F8G%-@V
M8-LBT=;2O$PEQ =EGH%T&N8HVCTI<O2QM,@@^!;8$Z!!U)(M6AV8/5V;.<XQ
MM ZDYSD8 ZYK8Z3=/<,Q18PVOIJHG#H2+:*/9RL F3FR%<;=IC".2SY!2L$X
M\-RQI-U5[QQ+>"P>)]B+J['W38M93<BYC;TZ1J&<VQ";'Q6KB;B<E2D7"SP-
M%7D9DD>U<HA47Y59T_0>LW+]POMXRHEA(9C&D:*X ( <*R[L'&2N[(/?@=.H
M%:>1)WT_5(^5%'>W-Y=302L4+-;2W$4W(,B[VC69(RDB A<MEL@MG+6#TA[
M3F1$I>M$6#B.33Q1*"[6N*G-2"(+XB5-U=$6L5F[\NEH8?11]+IPJURX5C(,
MD8:NAR [)$IJ\</6C/59XU &[JMK)#N ;M,Q)4#H#M7UD#!S@=U;3:7=RNTG
M+&R77K/4#;N\1Y=M!&(Y2W;,9DEQDQHS@KC)R2!JU&](+II^W.MMHR>OHQ$X
MI4':#OK;UEG4I)!DLCJEO>%O1=?Y5]Q*[*OVXW#KUCPC7.Z0)F-<J-]76FK3
M5QN\Z.DBAB2\<"J,-[^-B6ZGN]&#Z?3W5':Z5=6US8SO#''';7VK7$[AXNEO
M=QE8<X;)"@D.O\P#IGI6]4YUCD&_5?N-!Z>3K.^:ADZUIC.CL:(R$R$@KJI+
M\#P^V91%'$NBY0*1^RN)T9WCK/4>;$O$G<*>-'!L/DBZ<,]'E'-A9]R.-IF.
M 6WQED!VD$9P,]0??#OQUFMK!O$-2BMN1=VTAN!I<;.R1&WNTBN'0RQLK!.:
MYC&UT/N1!9=Q(BS;HWV]=!+)0.Q$>6*S#O?U1[.HK^8L-?K.8K7$:C&EC;NU
M=&<0':21J^C^1^K5N)9MR;S=MADY>C4-C6^W/ARN"1B"6/JK=[$[1_.Z#)ZY
M[O[JK^2M1*3AXE+2ZM87P(FB.8X4CYV>D:[P4(P% 8XP2!N.ITHTB*'9 !\3
MJ7LLX$B.SG?T10TW1CM>2:K)=8MSD)")D2<JM5&Q=Y(?&Y;5H6?1U!W6T:3A
M9=VU8S"4'T(AB6O=GW&(X>+K% 9!E@P5,$;4VX![0![1R =J@MM$=J(Q>INM
M[[:M_JZV<H2!X))KHNKB2<3<QUQ S)F%.62!+(XCYK:Q+?#L[FE^HM;4"$K&
M!L)*#Z9R2GI3*MK69M"SR;I]@@UFAH2JT5^.Q1Q"EA8-O)!9X0/"2Q26[M!Q
M>8@(PP(A))D7$(E9RS8,P<#;T"\LJ6]!W9."#D8!P"2"(Y-&U-M.ALT@A5UT
MQ[:23Q@!FE\<6=8<=J,Q%5$BNH23F$*TBQAD?^DP)E]D,(R4;Y:$LC&&2+7+
MC1WEL^RU2][;Y=I?]&YRBX]HGEPG_86]7VFG]G;'.<<9..[)QZ.E>V3.Q=PP
MVU=PSG!P,C/IP?3Z:R?,5M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5PN6S=XW<
M,WC=%TT=(JMG35RDFNW<MU]-DEV[A!77=)9%9+;9-5)379-33;;3?7.N<XR[
MNZL$ @@@$$$$$9!!Z$$'H01WBN@% @XV/2$QT,* BT=U%$1H4<S%CTMUM\J+
M;I,V**#=/=53;*BFVB>,[[YSMMG.V<YYDDDY))/K)R?[S6%1$&U%5%ZG:JA1
MD]2<  =3U/KK*\Q6U.*4XI3BE.*4XI3BE.*4XI6OE(G%39$:8-1F/ERX;;&X
M@H4##GY$5OC?VF-QKYVV5<L=L*?])C9JJEG&_P#;]/K??S() (!(![P"<'\]
M:-'&[*SQHS+[UF569>N>R2"1UZ],=:R[UDS),W0\BT:OV#U!5J]8O6Z3IF[:
MKZ;)KMG39?11%P@LGMLFJBKINFIIMMKOKG7.<<QW=U;$!@58 @C!! ((/>"#
MT(/J-=80&#Q\>@) BAH04UQOAJ,$,6HT>VPIOLJIA!FS21;(XW4WW4WPFGKZ
MV^VV^WIVVSG.223DDDGO).2?[36%54 5%55'<J@*!GJ<  #J>M9+F*VIQ2G%
M*<4IQ2G%*<4K\J)Z*Z;I*Z:*)J:;)J)J:XWT4TWQG7?3?3;&==M-M<YUVUVQ
MG&V,YQG&<9XIW]]8@%'(]%V.1D9 AHZ-RNHYR/!"V(ACERKC355QEH/0;H97
M5U33U45RG[3?">F-MLXUU]&22>I))[LDD]/5UK5$2,;4147.<(H49]>  ,]!
M_=69YBMJ<4IQ2G%*<4K7]HE%=C^LKVC,?VE.B/NVDEV##LG]6_L\H^[ZF<MO
MB.J/L<Y2]EASA/V><I^KZN?1S.3C&3CU9./[NZM.7'OYG+3F8QOVKOQW8W8W
M8QT[ZV#F*WIQ2G%*<4KHH"QC5\_)M1S%L2*X:8*$$&C=%\2PP2V08X?NTT]5
MWF&:.^Z+3#A13#=+?9-'U--LXSG)P!DX'</0,]^/SU@*H+,% 9L;F  +;>@W
M'O.!T&>[T5TSL;CLH:HLI* "R)DW<IO4&AT4Q+-4'B6N^B3M%N_0<))N4]%5
M-$U]--5=-5-]==\8WVQD"1U!(/=D$CIZNE8=$D #HK@'(#J& /=D @C./369
MUUUTUUTTUQKKKC&NNNN,:ZZZZX]&-=<8]&,8QC&,8QC&,8QCT8YBMJ^\4IQ2
MG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OFVNNVN==L8VUVQG7;7;&,Z[:YQZ
M,XSC/W9QG'W9QG[LX^[/%*Z8T8-#,6HL0/8BAC%+"#(<-:(,6+1#7.<ZHM6C
M5-)NW2USG.<)I)Z:8SG.<8^_@DGJ3D^LUA550%50J@8"J  !Z@!@ ?FKN\5F
MM?:1**L#;V2L8S'V4C):93(GV@8<V-OT\YUSG1Z51;:/G6F<Z:9SJNNIKG.F
MOW?V<>C.21@DX'<,G _LK01QARX1 Y&"X50Y'J+ 9(Z#O/HK8.8K>G%*<4IQ
#2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g418853g11q22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418853g11q22.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1K\4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M         %)S;'15;G1&(U!X;$!8V^>         "G9E8W1O<D1A=&%B;V]L
M 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M                5&]P(%5N=$8C4FQT                4V-L(%5N=$8C
M4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!2
M96-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -
M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M       _@   .$))30/R       *  #_______\  #A"24T$#0      !
M %HX0DE-!!D       0    >.$))30/S       )           ! #A"24TG
M$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$1       $     (
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M           !.0   G,    & &< ,0 Q '$ ,@ R     0
M           !              )S   !.0                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   !.0    !29VAT;&]N9P   G,    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3D     4F=H=&QO;F<   )S     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    $.$))300,     !!.     0
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M3SQ(KV8_H_Y3]R49?YG^J\2<N@'^G=0</
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M ?_$ !\  0 !! ,! 0$            &!0<("0(#! H!"__$ %T0   & @$
M PH("0<(!@H# 0$" P0%!@ '"!$2$PD4%1895UB5EM88(5:2E]'3U!<B(U)3
M5932U3$X=G>UMK<D,C4V.4%XDS,T-T)1= H:)6%Q<W61L]=#@:&T_\0 '0$!
M   ' 0$               $" P0%!@<("?_$ %X1  $# P$"! \+!0L, P$
M P$" P0 !1$&$B$'$S&5"!05%A<8(D%155:4T]355%=A<8&1EM'2UO C,E.A
ML3,U4F9U=I.TM<'A)#0V-SA"<Y*RMN+Q<G>S=$-B)?_:  P# 0 "$0,1 #\
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MK'[Q4\J?SV\_[[V U1[B8[*FO?'Z^;[3ZA3M0.AS][>/])-8_>*K[\7>Z/\
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MV&%*A**9"4+;*76%#8<2ZMM:]EP["'$,/*0M6$J2TX03LU?-\,/!NX2$ZIA
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MNF"*]#5A],]A^.0E2*QGME9E:79[!49Q--*8K4S(P<FFBH"R(/8QTJT<"@L
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M=EE2TIV$J+;:4%24C\T'&0.\*STF_P#9@43_ (TKC_A!#YT*1_JNMW\])O\
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ME*8I4TH^P;5KE_+RE1D314C-UB?J+QXD7_*20]E8GCI0K-8!*HS=G;',"#Q
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M=;MJ4NI-LIZ-DGZRUO56/8H5E/IK%O!D#3[=5*3*N4[17O=(K1N/Y-B0!*V
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M4N,OL.J4VXVX@E*DJ200?#@UL7XX<AE;@".NMAND$-@,&_\ [*E3"5!M>8U
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MG0$@)$N, D  <>WN & /SN\*S";#=D)2A%JFI0A(2A*8KH2E*0 E*0$8
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M:"I2UJ) 2D DDU,FR7,$J?B/1&$)4X_*EH,:+'90DK<>??="6VFFT J6M:@
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MW3UJGD^.*OFSC?G'^O'4*R>)K5S=$]#3KWUIY7:FY]NGK5/)\<5?-G&_./\
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M;+L:5=[A(8=3G.RXR[(6VL9 .%)(R <;JRP(0J92D(4I"$*!2E*  4I0#H
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M[0GDJ[I:XL%DG<<L=L]9N)!)&',R,[3,@!'*#,6-=AFJC9%8.T$KMLS.H'6
M 6'H$U52FR\VL*24AQPKVDE1(<3&V5+3Q:$*2VM+P("02,J"-IP@ZY$8OZ!)
M;4S);#L9UJ,M<T/!EQ+SBFW'1(N4YY#KK.RG++KR4$I&4 '9K*EJI35D0JT=
M S4HHX$CAPSKK./9"Q.J;L !-S IK$6:(CTK*-$V;A<Q2$!PL4!$0<;'%!2$
MK42T'W E*6SL@%Q;: @* R"-D!&T22H8W&R%GOSCRRW*N,&*EG:9:>NC\A\2
M$H_*;2FYZD%+[GY@=4\VV"H[#9Q7>E8]>E?2!7#6(5:NUP[T53@&2B#-!-@H
M!2KI%JD:ZZ%'704H,A2737,BJZ=/VQ%B'BVML$A>QO>"BHH"D\6'(AV0$M).
M2VE\#"&T@[6TA>VE1IN6S4RF(Y:>FH=::P\E5Q>2MYU4@Y+:C>)37<M$%1?X
MQ"FPM++4=XMJ3T+36M33[I^NBU.Q5C$HQ-K'P"2C<JKB1>"XDB(BQKJ";AO%
M%;H@Y)')N6ZZZ9T$I%9NJ[- %@I<2K\YYIIHK2,\4KI<H==0=EO9/&H:6%MH
M2HJ4\ VA*@HU40=4I@,L-./!]$IR6MV5<5!U26X[ :BJ6)%Q<4TY*4\OBE25
M-+;:(<<C(=2PFVDS-)OVD?'),V:2<6"B1'C=,Q#O"]80*KU3D(HD54O0JHFH
M*AS*B!A$G1U HK<4[Q:EI""AI+92G&,C!.TH ;1!W))Y!GE))K:H,!49Z3)4
M^^M4LI6675!09. 2@J2HI66SE"%("$I1D *SM5'<EK)TQ2J[2^;RU<CG]+@]
M*VNV(4::D:P\GFMHID4T>R*)DI-R+5G*2J#TJ*)91)'KJI%ZYTSB4 #X@P9U
MF_'>DPX]BDRT07U1E/B9#92XL(;>44MNK"PD!U(!(WX)K&WC@-1=GX]]F:XL
M]I5?H;%S8@/6J^2WF(Y+D-'&O1(;C!6M<-Q>RA1V4E()SOJ7_#PL/HY7+VZU
MW_&\CU[SO)J3SE;_ $E8GL 0/?*L?,.I?4*?#PL/HY7+VZUW_&\=>\[R:D\Y
M6_TE.P! ]\JQ\PZE]0I\/"P^CE<O;K7?\;QU[SO)J3SE;_24[ $#WRK'S#J7
MU"GP\+#Z.5R]NM=_QO'7O.\FI/.5O])3L 0/?*L?,.I?4*?#PL/HY7+VZUW_
M !O'7O.\FI/.5O\ 24[ $#WRK'S#J7U"GP\+#Z.5R]NM=_QO'7O.\FI/.5O]
M)3L 0/?*L?,.I?4*?#PL/HY7+VZUW_&\=>\[R:D\Y6_TE.P! ]\JQ\PZE]0I
M\/"P^CE<O;K7?\;QU[SO)J3SE;_24[ $#WRK'S#J7U"GP\+#Z.5R]NM=_P ;
MQU[SO)J3SE;_ $E.P! ]\JQ\PZE]0I\/"P^CE<O;K7?\;QU[SO)J3SE;_24[
M $#WRK'S#J7U"GP\+#Z.5R]NM=_QO'7O.\FI/.5O])3L 0/?*L?,.I?4*?#P
ML/HY7+VZUW_&\=>\[R:D\Y6_TE.P! ]\JQ\PZE]0I\/"P^CE<O;K7?\ &\=>
M\[R:D\Y6_P!)3L 0/?*L?,.I?4*?#PL/HY7+VZUW_&\=>\[R:D\Y6_TE.P!
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MQO'7O.\FI/.5O])3L 0/?*L?,.I?4*?#PL/HY7+VZUW_ !O'7O.\FI/.5O\
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MH&,NNAV0*H% 3%*9-0H*D$W28G5 1QQ1XQ+>T-I2=KD. "X&D[6[=M+4!O\
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M'8Q*</I864H<V-Z2M&XA0-1=1,Z2ATE2&(HD<R:A#!T&(<AA*<A@'XP,4P"
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MK)&NP4+"TJ/HCENQB[7JNQD;DG8EB=U*HH'3;EEGSR1C46"YTS),?"?GIM$
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MMF@$]"ZVLMFJ^XM+M:]9Y:OJPFRTI-38\+,W5(&T>=]%R0ZD4$3O',.PF&A
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MQ2F*4Q2F*4Q2F*5K MW^M=G_ *0S7]I.<UM[]U=_XB_^HUZFLW[SVK^38/\
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MG 4VL'&R<3IO4%R1'C,=,R526(\E#L:'*D1D,2E.H8<?DM-*982X6'<<:M&
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MP$K_ -U1P%=XFJJ>/N::2?6;6/LG;4CI,I22)R*LR'4ZBIBDZP=D0Y%#%ZX
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M#L0K@5S'2J[LZ .3D.V=K.B(])@ZZY#)F63 .H;I[0    1Z>@,D(5E>0<I
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M.1<L$)!K'J& 6#OW_%^/V[_A&,TR-V!R'/P]_O\ [-WQ\F_Z42@(%* _R@4
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MUM+>7@@D@;)?7@I 5C<5$$YF;L\YI<I2=%<(V):I*UH5IQ!2A4IUQQPM'\]
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MI^JO9V&FWNX]!]>&<]^$;L]B&13<.2"DH0YP<(.DT>LL@B*G>Z:9.H!@!(P
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MQ2JY5;7::#9XN[4>97@+5"F,+&01#M$7#=00[XBY5F801DXEZ4 *Y8N0,01
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M>;62_3TRHS?O'#BCV-=563&'@3Q)E$6Z$=7T6A%(GOIL]!4ZA !@^'XAWO\
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M&TZKI.2TUQ\EUA*XZD)+4AU3R5H5ME0PM5M\LZV.F*4Q2F*4Q2F*5^@ B/0
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M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5\WFU?\ M0V1_3VX?WAD<YM*_P YD?\
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M;1%D^;CTH+HILF+<H=D/^8F("B4/B!/H^+(<>[ML.;6%QE!3"@E*>+4 TD$
M) W)8: R" $)')G-6'I+3L!<QR+;4-N7",Y#FN*?EO+D1G00XTXMY]Q7=A1V
ME A9)R59WUQC=H7V(;2;..LKQLVF) \K))@DS4[YD%!2%1T)EFRATSG%!'K
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M'?42:MD!+VUTUE9.\;!=O8FJM6CNN1KQY"KKH."I2Y4(V&_E^4#O\G(?E_\
M=1PG'*.]W_A(.-WQ'D.*H>E-N]U-N^AN6%^V1JG:-7VRVW=J]MI:HN:$]J)Y
M77T>DGXQR,'4'$I/.&4:]Z>I8&R4]))BLFJH@^*54O4#.-_+^/ 33N<@#Y2?
M!X3R<F_YJO@TW%W3FR:%G)F?HZE$VC [HTFJV&M:5E99W+ZFGY=F.R8UK37U
MM7=2CJN,5%2OI9G(MUC(IK=FQ:J "I63X._CY/#^WX_EH0!W^]G/*,^#X*Q[
MIG(/NP.NU:E2GNE)B^P,O9EYEUL*S:BM$C-0D0]M]W23HUA;Q%D*L5!Y$L(:
M0+=T60>*$>\C8]>M38NTWPM_Z_G&[]?+C]>>6IL)\(!\ (QN^?<?"?VUDMRO
MY,]T:U[OFYT?0N@Y*\:P33H1JU>VNF[+:8J&2>,&#BW'?R+:V0R]MDCR;KP>
M@PK\81A Q@O)-[+.Y&+6AE1)'(,_C\?%R[ZE2$GE..7OCX*C>ZN5G=)ZQ;YJ
M+H^@IIS&-U*ZA&&AN/MZV'&K(N*:SF%I0ED96J!0<!,7)9S4)&+48M7-%8MR
MV&1/)$.9D1O\'_KYL9^#]=,)P=YR,^#E[WAW<N=]1'<O)WNL<)8+$QK''P0I
M<M*R==92M9TY:;Q8:-&H,ZYWO;FR4=;6IKN:4D9I_&-V;1E%$BF\4\L!UWZ+
M!PP%OW[A\&_EY?F_7X/AJ(".^3N W>'P_5\_>WUMHXHFV0?C)H VXBS9-K#J
M#7WX1B65 S6PEN@5B-"QA-MS 4Z,J$H#GO\ 3.'7(Y[0#])ND1C\=2G&3CDS
MN^*L@,5"F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5_.ZY0?SEN0_]>>VO[_6
M#/'E]_?R\_RK<?ZV]7WEX./]7F@_YF:7_L.#5$TMK5AMJ]LJ4_MK&G _9/W#
M21>MV[H7K]JD"C6%8HO)2%9J24F<129$=2C-)54O9%4%91),\MJMPN3[K'&J
M0M#'&,M-H0X_*=+[#(CQT..LI6\4O*>#>WMN)96VTE;JT)-QK/4KVD[*J\-6
MIZ[(:DLM26VG5L(B1G$N%V?)<;C3'418Y0D/*;C.EL.!Q02VA:DWVAN#.WY>
M(-959"H058.]CVS"1GI-\A(2B+E1,DPZCH.-C)60=(TDRI$KZX2*:/JKDQ4)
M!^':MSK9JV:/N%P=@)6_&BLW"?9H;+BP\XM;=\8A2(<UME#0VH2D3V6>F77&
M&#.VH'&B5ALZ5<.&O2,&4];TLW6=<(T6=)DLPHS*H\=40S!&C/39$F,PB1>Q
M!D.6%C)D76.GCX[);"RB@67A[LFO2'>A)NCR;=UL67UU#.T)Q=L>97B)UQ6U
MK$U:.X])7Q?---7,<=4HJOT'+9P95B#),KQ3$1;)-E)LY0N)F] *C%+RU-I:
M4[<VFI*W"R@]*2%6B<MAY*"HMH;+[3#C[3:K^'PM:<E1I4A<2]1S;[)&O5Q0
MN"EP1#)A1;AU,6ZT^I!N3<.9&D%L[+"VWFPA]3VTTC]L/$>W4>>H["]7.AQ%
M?N=E0KJEIB)9::8P0KM3O22$@DZ;PB1FJJ"2PH"5Z0IU$5"+*MR@!QN18'6Y
ML&+*F1&&9S;SC<U*^,CIXJ,F4E"BLL86\AUGBP2E)XU.5 @@(O"G;;M;[U(L
M=EO<VX6B!T\+5+C(@OS0)28CC+*FUS5I<9=4"Z%,%024EM#F=U>I_"^[7?;&
MQ=:0K^259Z\K4C8W%E2JCF7&43+#.I>N-&T76Y6;02&TIM%18//#2[))HFJZ
M%9=4J+-Q(U8I+C>HG%AYH:?;N6V@QEK<?EV^!<[DF*Z$**8G3$>TRFP^I;K;
M<M<6,.,5);55E=^&"S673FE[]*88+FIKG"MS<+JDW&3#0]/B0+A+<DSXT-;J
M+2]-C],L]*M/GC,E#;:'76X^^XW";43#;M)MJME9MXV*0LS2/BG@*1%HD$F#
M^5B3*G*T%)E6(US(IV!XD,@"#J.:K)]JQEW"D'<3;$(L*%<HLLR8<Z+:$.N-
MH6D1)=T7-C2H\DD)RPW(BB(PX$\3,?=DQVWEKM\D&^C\(8ZYW]+7FU"V2NF;
MH[!,B2T>F+7 ==CPIB4I+H4]=GDQG8+2NER&I*VW>+D1XZ+C,+3Q!C8:,924
M=LD7:GX2*IK.;CU*VBX<1,K8XAJ[4DR!&6!T_7C6LBLHS2%_$Q'?:0$.U6<+
M =(+AS3*"[ :C3"YT[?+K8E*4RE7$R+6NX,J>4F.\\M+3[MO<V4/(9=::=2Z
M4K:;6X<+:^%Q^:Y(:?TYQ91I69JV&ZFXJ;;F0(\K8;C?Y1!;;1+7%4AY:8\B
M8EMP*;=#04E50GD#QD=:&CDE7=L;V.197&3HUA1;1;B/:,IV-A8B>.$<NX65
M-),>\YEJF#TI4TU5B*]F0"EZ,QEYM0M3C+:7^F,KF1WUE'%!,J%)4RXAMLE2
MN+V-A06X4J422$!)23GM!<(S6N75<3;%P([]F@Z@MRUR42''[9.ES(+*I*$(
M0(TDOP7RN,2I32"@*45$XQ7S#5TRKK0_^BV/_P D?_R'S69O^=/?_(?]*:R4
M?]Q;_P#C_>:J66M5J8I5_P#CC<*A2+O8YB[MV[^!<:IVU"&B'3V0CDIU_/:_
MGHJ,@@D(LAWS%27?ND&";M'J"@=<JAE4RE$X;1IN?;X$?48N#:)")=C5&8B*
M=>8Z:?-QM[P:2ZR"M!#;+CF<@$((SD@'GG"59KS?;-9XEB<<CSV=9:,N!FM,
M1I*K?%MVH[=,EW QY:DL/IA1V7)"F5[7&);*4H42 <F*]/\ 'M?CY<"K3M9A
M9>::RCR"U,_6.^4@+*C)QI8A<9A:JN+/)@=B1X<)%:VHM$T%UFZD2H8B9LSZ
MW]/IT[%0B1"?E+=M[[5M>.$0GC<WC-:>6B(F04&$&FWY+DI\NLJ_)LH<22>7
MS[?PBHX1;6M%NNLF)#<CQKAJZ,D-"YVM4&49 $)-U;M,129*FDB*W:"Z7&T.
MB8 M0$J<[/J41:+*%7VYKN%>7OCU*5I5-BS(^H=1GFUFBG3"J,9=6B-95PFZ
M@F<B9LK(P[YXD\>)-W4LMV:#A"I<+G#2-5Q85WB*5=['$"5E"#&+T:<VMZV1
MGD0FRM72/&M1751V5J44I<>#C:7SBH^E;K)MEA5==':DFLZ=X1V+@A;SRV+_
M '6VOV6<U(O,J$F_NQ&E-W-V(EY$6:VRIMI;C,1"7'6G,3=16RKP5'VG#6&6
M9(/)ZS:@<L&JZ2JJ<FS@+@^?3JR92MS)"@T9*E<+$6!,3I* 4B9S=) Q>E+A
M;(C5O;N#K"&V^$'1=TD-/H+K9M=NM6LX\]]U&PM*V6'+E":=00I2^F$[*%I"
MRGJNM++=[AJ;2EPML.0Y'M^G->Q7WVUH0J++NEOL[=L:)+B5AU]V.ZEM2-H)
M6T2I2=Q.9]"V7HBU6S<]BV;?JBQJ[V[6B'AZ2VKL-#1\YKE)6==5KP:1"F2$
MFX0%T[162092E<D$ESIJN7BR?511RUGN%C=M,B1>YL9;KSDX/6I+++9*&$PT
MVLMH;BAU8:07VXVS,82T&L/I?+A(XS?]+:^M-KT9;=*:>O#MUC6"T3I-_>ND
MZ:_#U,\F"B\)EEV]1XC:@E@I<6]$N4=QO;0PTTH%;EN6>P=:US=%2GY>U:]L
MVG&=6N#.%K=31D8:Q0<!)4QRQ+3K Z)7V:[:1D7RZJ"+COV<,D^<*+F?$0$"
MEJQ+O:8]]N3]UDVV=:9%HG1XS5O;<:5TD]=(3D:WOI2S')ELPVSLH45H5Q*F
MW)"MK)V5_3FJ+GH>XP(%IU#:=;.WBR2+A<[RJ-.MTVZ1+PAU5[@LFY/MO1([
M3:'%MAF!MQD);$<N FL0=WOJ_);(FWE3EHJ7JRR46-=5B(KP*V8PP1;,(^&6
MCNH7L'\*V!.+D3=HY[9ZU76%VZ%05S\^NZRNZ7!1DQYB3+?XJ5$:XB.^QMGB
M7&H^RCI=);V?R.#Q9!3MKQM'LVAF+A&TS;V;M#EP;HA4OJDW-E]///3C+?,J
M8F5M'C6)SVU+C;FPAAYM 99">*3:7,=6W4Q2F*4Q2F*5D/Q[XQ[6Y)6UG5]>
M5UZ^(HLD#^7,@JG%QC8Y^J=T]?"F9!L@7H$!54$>DP&!%)PH0R69JQZ?NFH9
MC<.VQ7'UJ4 M8!#3*"<%QYS!2V@=]1R3OV4J(Q7.>$3A0TGP:6AZZ:BN+#"D
MH48\0+2J5)="<I:98"N,=<4<=PD#<05J;2H*K["N%W%L_%'5"%#<72:MSYVN
M21D"O'2QX6*=F2*15K7F:ZBIF;0PAUE?RG0LH 'ZA.CX_76B-*+TE:S"=GO3
M77EAUQ*E*Z687LX*(K:B2A).]1R-M6_%?'7AHX4QPL:K7?T66%9V6D*CL%AI
MM,V6R%DH>N#S:4!Y[&Y(V>X3NVCWLO\ -TKC],4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE1NY6R#H-0M=ZL[L6%:I=;G+987P)G6%G!UR+=3
M$L[!),!.J+=@S<+ F0!.<2=4H"(ABE:UH7NP'$F7=ST>X0VE7)&MK5=*896F
MIPT(+,MRF*K"UYRL]<6L8MNR?*W.OO1>NGZ#5O&NS.W"J0(G($-H>'\8S^RI
MMA7X_&?F_;4>D.['<=W5<>3=!UUN_8;^*(Q6G86&K-;0-74'MO;4L!F9<]M<
M0Y5?"SM 6Q(QW*)/$%DE$5P(8YDXU I(Y?Q_<?!N.:NI5NZA<<KIL2(U?683
M;TM:IZ_CKB(*VHB)HM[/-Q6+,+IRHSH-$XRNK-'Z,VJN=)XV.P<J-V+IOV"R
MT,_^^]RX_'@[],'X/G_'+WO#RC=OJ"\A^ZIZXU#>XO4=&UGL?9NR9G=]5TA'
M SC(N-I[N<?7JI4B\NF$TZFTWCX^OI&XPK*6:+1T:5U)R+1-@\=-"N'*;._'
M?_'[?GJ(3D9/)\Y^/XAW_BJ);\[J;8=$;AV5J)SQK<W%Q4)6MQ5:M<!M-B6K
M3#R?@;=;%(2URJ],%E2KDQJ517LAZD=S,NPCY2)%R[:@]0649[WQ?KS]5 G/
M]WZL_(/#^PX%5>Y=TULT&]DC5SC['6*NI\=8+D*PL3O<;*':,(Z=:,W3&HW0
MJ=&E$JM:)D[LS*I1A74J[LSM$ ;-VY%BF+&H8Y?BR/"?DSWM_P U;(]07Q]M
M#5M V+)525HS^ZU.$LKNGSAA/+UM>78HO%(B0.+=J)G+,5124,9LW,82])D4
MC")"J$8/>/Q5<?%0IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE?SNN4'\Y;D/_7GMK^_U@SQY??W\O/\ *MQ_K;U?>7@X_P!7F@_Y
MF:7_ +#@U$=6RNRX6W(2.I9&?BKBTC9=Z@_K3HS*3;1D7'KR\NX*Z*=+L4&K
M"/6=K&%0O25 "DZR@D(:A >N$=;S]O=?86W'6J0\RLM<5&"V]I3KN4I;;+O$
MH!4I(4\IIM.7%H2K):GA:;GVP1M51H$NU.RXC(CW%H/1W)DMX0HC?%$*VW'7
M9(92-D@!Q17A 4H7/G]T\EZI7H'7TQ/[%I,:TKLN[;Q+I*:KKJ;K^Q7CVROY
M=\F[2;.92,LJ<THX0?F!1D^CETCMU%$%"F-D'+Q?;<XB#Q\VUOVV/;(3D4%^
M*\T+?->OEJ,IEPAQ+[$F?T[$6XE*DH5&+6&FF G6X.CN#FZSYNHHT*P7N1+N
M;"S/0Y$N+4:X66-%M#<>,ZVXZTP] ZF(:6P@I<9DH>XQ*7>,J+R&Y=_65J]>
MR5\V+,LF-A/;)!VO(RSMJQLTF[3,:==./QTFLF_? D/?:ITU7#H2]!C*F^.S
M7<;JIJ(M<N86(<QXPEE;G%,3IG5"4\EA7YB9$CIBYOJ;2=M:7)C@24\:1D6-
M':"@K$>/8]/Q7)<%%N#*&(K:Y-OBLH;1$#>0IZ,PPVA ; 4EMI"0<)2,>ZJ3
M?)38\NT;4<^W+Y.4XQ+$T9U6.LUID:YWF@NW),@SB&C]>-2;-UW"7?ITDDDD
ME%"BH!1')XSUZ=V9,0SW1:D;8>80\ZF V60UMJ6A*DQT<0QL;2RD<6T1G"#B
MC=HG!S8HSAOATK98E\"H"UW67;K:S="X\W(7$#DMYE,I:WDMNJ:0I:U+"5%)
M.*HDEN7>#R8/-R>P+\I.(.)=5607EY5-^FYDVJD9-BLJ!R* =TT.JR>E4_\
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MXTN1<EJ?$3I'IUB7'CQ&3XM;"A(%L^F']>8VB2V!,:YA-?E5F9&Q34W79AO
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ME,4IBE,4IBE,4IBE,4IBE,4IBE,4K^8WRW_G6\F_^(3='^)%ESS/=OWUN?\
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MR+1QL-#TA,IR]2(;8DMQSTY:9P2%QT!TXN<F]%5O1%CK<#7+UX]IR\"E(OI
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M9YW%-WK]XYCHQ>1.QBUG*RD<@U,<1&1C1ERC,0(T>_-,LVZ-#B1DMVAE*BQ
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M_P!RY-V,U^.4\WGURJG;:,>0;OTE1["KZ)>&''-7B3QEU5QW7MZ=\5UK'3K
M]M2@C5I.9&:MM@M *E@SR\Z9AWN6<!D)!EGG:BV%QUTP6[%+H5FMQM-LBVXO
M!\QDN)XX-\4%[;SCN=C;<V<;>S^>K.,]_ \P:\U2G6FK;SJ=,(VX79V.Z(2I
M EECB(4:)LF0&(P<VNE^,SQ+>SM[.#L[1R@S*5J-,4IBE,4IBE,4IBE,4IBE
M,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE
J,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
